<SEC-DOCUMENT>0001193125-26-216791.txt : 20260511
<SEC-HEADER>0001193125-26-216791.hdr.sgml : 20260511
<ACCEPTANCE-DATETIME>20260511161350
ACCESSION NUMBER:		0001193125-26-216791
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260511
DATE AS OF CHANGE:		20260511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eikon Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001861123
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				842807586
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-43085
		FILM NUMBER:		26963357

	BUSINESS ADDRESS:	
		STREET 1:		230 HARRIET TUBMAN WAY
		CITY:			MILLBRAE
		STATE:			CA
		ZIP:			94030
		BUSINESS PHONE:		341-777-0566

	MAIL ADDRESS:	
		STREET 1:		230 HARRIET TUBMAN WAY
		CITY:			MILLBRAE
		STATE:			CA
		ZIP:			94030
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>eikn-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-11T16:11:45.5469+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:eikn="http://www.eikontx.com/20260331">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e9d4c374-3c57-454f-9c1b-4e04018b2483" name="dei:EntityCentralIndexKey" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24">0001861123</ix:nonNumeric><ix:nonNumeric id="F_73e76b8d-0092-49a4-8dee-9b25ac5251cf" name="dei:DocumentFiscalPeriodFocus" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24">Q1</ix:nonNumeric><ix:nonNumeric id="F_f6e8d3dc-888a-4fdc-90c5-0f2ebc9fad8b" name="dei:CurrentFiscalYearEndDate" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24">--12-31</ix:nonNumeric><ix:nonNumeric id="F_3680dffe-fb9e-4e37-962a-89878e0aac8c" name="dei:AmendmentFlag" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_406021d1-f696-4dc5-823b-2dbb02101b41" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d5172da2-0e18-422f-9dd6-381742ad61d9" name="us-gaap:CommitmentsAndContingencies" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d7440967-f56a-48a1-8724-4db9ad3811ca" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_a0702cde-f66e-4486-b5d3-9b3aee1b98c2" unitRef="U_pure" decimals="6" scale="0" format="ixt:num-dot-decimal">0.134088</ix:nonFraction><ix:nonNumeric id="F_a1712c5d-8279-47e4-b1b8-8c2d8242df25" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_2513182e-84c1-42c0-8135-b3838edee5c8" name="us-gaap:LeaseExpirationDate1" contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194" format="ixt:date-year-month-day">2040-01-31</ix:nonNumeric><ix:nonNumeric id="F_4891b7a9-ea44-4065-bf6f-ac1774d7b202" name="us-gaap:LeaseExpirationDate1" contextRef="C_e8020709-4b5b-468b-8ef7-0060d74c84ab" format="ixt:date-year-month-day">2026-10-31</ix:nonNumeric><ix:nonNumeric id="F_fea5efb2-ee1e-4e93-a542-9a2bbd4553aa" name="us-gaap:LeaseExpirationDate1" contextRef="C_aa0ce56e-57e3-4af8-a0ed-914475550a24" format="ixt:date-year-month-day">2029-07-31</ix:nonNumeric><ix:nonFraction id="F_85997c2d-5760-46fb-bcd0-7b83f0349464" name="us-gaap:NumberOfOperatingSegments" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_2ea580d6-5cea-4c6a-9652-7b14b693ba76" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eikn-20260331.xsd"/></ix:references><ix:resources><xbrli:context id="C_82c0918f-98b5-404a-874a-7e2868a58706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83013968-b516-4963-8f78-e02e28e21aac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:FurnitureFittingsOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_855d3fb8-6bf1-4d46-a30f-cd01135bf333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88eddc74-25a3-4aa5-b892-0c78cef4f38f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ad16874-961a-4ba2-b824-435ee9b04091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c7f8085-733f-4767-ac3a-7065758bbd4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-19</xbrli:startDate><xbrli:endDate>2019-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f4e15ac-2c2d-4f6b-9d70-e69adc4f166c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f9cf841-a084-4a0b-8321-a9f82ffed0e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_908c61c4-64bd-4c85-a9dd-94e0cd397a73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_912863b5-d421-42f1-b393-0c8022fb4cc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-19</xbrli:startDate><xbrli:endDate>2019-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92846805-1608-4137-b50d-75f45165732b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92fa46f0-fe5c-4ebc-817d-ec6bec9a5f5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eikn:StockOptionOwnershipPercentageMoreThanTenPercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-19</xbrli:startDate><xbrli:endDate>2019-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95010d63-09ef-4c23-8c49-40323fc46cd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9552213d-49d0-4396-a5da-0277b129dc28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95fce60b-f21c-4670-9602-3e7e50701ea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9608e9ac-9845-4074-830c-41f067773cfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_968ee666-b8c6-47b0-97be-66417cf66128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98a5f90f-67ce-444b-b813-16c9b0700876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b34b095-baf1-4e92-bd9f-785cb99e7d43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b60e528-d867-4710-996d-aa10971fdb80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9beb9422-a6eb-4bf6-9cb2-1645d1189e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c0f0b76-fafb-4f29-bcdb-edfbcba2d100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9de7842e-b8a1-481e-8377-402c9062d31e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0702cde-f66e-4486-b5d3-9b3aee1b98c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-27</xbrli:startDate><xbrli:endDate>2026-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a147cd78-029b-4abc-9fd4-bc8f281f4101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a58a5eaf-b724-4201-9cb2-92d031377e5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-19</xbrli:startDate><xbrli:endDate>2019-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a72dfdfc-a580-488a-9676-5c50bffd695e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-06</xbrli:startDate><xbrli:endDate>2026-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a949f785-fff1-46ba-9714-cd224ef31489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa0ce56e-57e3-4af8-a0ed-914475550a24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa54d368-814e-495c-b6b0-69aa5b033eff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa9bb9d8-99cd-44a2-b558-5d96aab73df6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b66b40a9-6ffa-4592-8e55-0cc8d9219267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9805475-e76d-41e7-932c-783895704433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc59c656-e863-43bb-acfa-25a6bfeba2a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0a37a53-ff96-4abe-8394-e87fa5432b98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1976207-b5cc-489d-b211-526e50ce39ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1981874-bd18-46b8-8717-745097f2f3bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3beda52-07b7-41e0-a055-08c63663c5d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesC-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7bcc98d-42fc-40a6-991f-28a29433e55e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca062afd-ce86-4311-8424-bd51f8222d31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca978d31-a9a9-4f8f-b576-a32d51689a78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2fe5e36-b89d-4ab6-a220-01ee0d375971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3834c7d-2fa8-4b3f-9745-5b403f6177a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d432863b-75bb-40d5-bacc-9c6f3baca062"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsAvailableForFutureIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5e0b4aa-c652-4259-90d9-48a14221845b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eikn:EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d632d010-5232-471e-abf6-d727c87dd4b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eikn:StockOptionOwnershipPercentageLessThanTenPercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-19</xbrli:startDate><xbrli:endDate>2019-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6aef30d-4b1d-4072-adb3-7c8d3cb1b224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d927b95d-37fc-4c9d-8791-5738a05cbc4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd617b4e-2a11-46a2-ae77-d0760c22bfc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e170b844-9352-4f6f-8503-8d06a7499836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e647b2ed-2de8-4ede-8766-0746071aee38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6ef9b81-32b1-4c49-9fa3-1c3d269aece2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7df204e-01a6-433d-b71b-99e1e283b5e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8020709-4b5b-468b-8ef7-0060d74c84ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8403787-14b9-4395-a9bd-4273c59b3ebf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:EngineeringEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8fb40c9-0eca-4b95-9025-0360ea439706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea08a515-6580-47df-bab8-c50e516fc3e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb9e9cc2-9255-4256-ac03-f2e532a2ed46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebfe9b65-c71c-4702-a2c5-feb06a82af91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed86a544-6aee-4ee9-acce-d3e07fcb1c78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eea5e544-8a36-4e39-9071-f9fe1d484521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1a8eeb5-1e5a-4045-acdc-0cfce87caf9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SharesReservedForEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4769796-b48a-4a61-bcef-e175508ab0bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6befb00-d49d-441c-b08f-36fbaa09ea83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SharesReservedForEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb91cb81-7c4b-448a-988e-9ead42c05b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesC-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_020258b1-9d04-4044-a458-aad5f3a473ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0395c051-54e6-4697-8ef1-dbef23445ddb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06851da8-c034-45e1-a93f-8136cb20bbc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09ce6087-ad99-4411-9be3-549230506f74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0eb6f30c-2652-4bc8-8657-bc2aac3eb2ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ec3c10e-a93c-4886-a100-9f5b244f7eee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10b77abe-4227-414e-a522-1ea2c59579c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15155790-267d-4a2b-aaa0-e438238b971c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16c203e7-dbb4-4d54-a213-cd806db24194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_170bbbfc-0868-43ef-95ca-29607794121a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_187793de-c269-4ef7-bb05-41fa5133f848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18d67718-9b0e-4fc6-9a9c-711cd4ddf402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1946717c-8e31-4a84-ab14-fa2fc8fe3174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eikn:SuperbWisdomLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19ce2956-fe58-4b8f-9894-55d51e63a6f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesC-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a50a933-7364-4862-966f-2cce973d2edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c487c21-7dd9-4244-95e3-68a278433e25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c77db10-7d9d-4dcb-8c50-adc69f65d083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e8500d8-0dbe-4c15-adb9-cf43d49e2d09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-07</xbrli:startDate><xbrli:endDate>2024-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ea189f6-3a9d-423b-a06b-980dd823d3d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsAvailableForFutureIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fef2348-70de-4794-94d6-9e3dca9ad9dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21e45ff9-b261-46ab-ac86-9eca533d24f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28287679-ce3c-40bb-abd2-c8b78786196d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2eca1e62-aa09-48af-834d-34f067e0bf98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eikn:EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3076528d-17ef-41ea-9093-a57058ff97ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_307b49d7-4a22-4c20-90d0-a57dab4d74f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31e76bc3-5aba-4a5f-9818-f4b753bd92ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32e58006-0bc0-440a-94eb-1e6e99c57dfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:ConversionOfRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_346f6ee4-54e2-4fbe-b3f1-de86b076b6d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3989eb12-e5ab-4eaa-81f3-cfefea545c70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cf22cef-9013-42e6-8cf3-e35b755febc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3deb9837-54c7-4413-864c-a18fd9e51818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43059c80-0146-49ba-8b0b-010e3648880e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43ceca5b-74f1-4f99-8520-dba39c9a9772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_480832dd-e171-4ca4-b482-a03140d73654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a28407e-c2fe-49ab-87fd-4c1824a42626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b9ef807-4b9c-4eeb-b8bc-e8285f9f168c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c693a1f-4ca1-464c-90fa-56debb4e78a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d578cb3-2d47-417a-989d-844acb9f3cbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4db66fff-bc05-4074-8e36-aeef64b327a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f7b2433-ea8a-4286-bb00-c2633ee0aa88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fc1b14d-49f9-46f4-b17e-b2678287a627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eikn:SevenAndEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50271040-0f62-455e-8383-928757d00db6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesB-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60427b0d-3053-455a-a653-545c63de803d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-19</xbrli:startDate><xbrli:endDate>2019-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6244dd7b-fa8c-4429-a004-33462cc5b476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62648b45-b0dd-4b75-99ea-21268ea1e65d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_645f2052-193d-45d6-894c-a8d3a45a5203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:ConversionOfRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64e1594b-40d8-45fe-8a5b-61465fc568f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_654d525f-1b50-489a-916a-b5b3453bca96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_660ec3d2-b609-4bfb-b1b1-c4305903c960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:EngineeringEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_662558f3-ac07-4fe3-b87b-689c90cf7fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b6e3025-7be7-4cf5-a556-aecb955a9d7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6efa0e52-ace6-4c24-8d0d-270fe66c03b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f295888-378b-4391-a021-9bca631286e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:FurnitureFittingsOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f92e515-198c-41f2-9ae2-33fc324dbf18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesB-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72c9554b-3432-4aba-ad4e-feadbc19e644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_734a9e98-beab-4d4c-b47e-a15b69419607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_760222b0-6d13-4c82-a9ee-2f2a276df9e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-07</xbrli:startDate><xbrli:endDate>2024-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76484ee6-c514-405c-9fcf-875c160c471b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesA-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7756d92c-fabb-4333-b946-71468f2cd618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7793f816-84ea-4007-b84f-955f26f60859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eikn:SuperbWisdomLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7930da5b-8c34-4bde-9df0-f3a4e63faa1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79517728-0638-49d0-b5e2-18ddacc50546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a831092-b41d-417e-82e2-51595df304eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c4a7bfd-264d-45e7-bcf8-d63ea24ce46b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cfa5dbb-75bd-4c08-84f9-248de234217e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d79440a-32b9-4e44-9930-5f1dcba2901b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f0bc01b-6dce-402c-b6f6-7f08c14a5096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861123</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesB-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>eikn:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, DC 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62d03e34-735e-4655-a913-9c56822f6ae3" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:0.30000000000000004in;box-sizing:content-box;"/>
     <td style="width:7.199999999999999in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_070ce654-3687-4335-aa1a-8007629f98c9" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_395cc1c3-2d7d-4245-92b9-b0be8ca60ff5" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31,</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45a71b4c-8a13-42eb-9c95-f9c8ad964d24" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2026</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p>
   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:0.30000000000000004in;box-sizing:content-box;"/>
     <td style="width:7.199999999999999in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4f131e03-916c-4d8e-b680-a5d07ab27c08" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from                    to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                    </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a721c450-0993-4143-9cb5-c8e4c65086cc" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-43085</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c46e4a3-30ef-4dd1-9065-be575fe61b41" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EIKON THERAPEUTICS, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3.75in;box-sizing:content-box;"/>
     <td style="width:3.75in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_06603eee-4a38-4602-96dd-63d2f959cdbc" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_655b1079-4e75-4e8e-aa21-c9f761df01aa" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84-2807586</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fab902e2-f8f3-49bd-be72-0a03c46adcd7" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">230 Harriet Tubman Way</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_de19529a-4ec7-42aa-a4eb-197d650e72ed" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Millbrae</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_bcec27ee-b3ba-4b6e-945b-b248c448481e" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e363c8ea-d251-4c5d-a444-51425a7fc44a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94030</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6884df5-151e-4676-927e-34c5b43a4577" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">341</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00bbf200-61c6-476f-ab5b-60b61ad1ce76" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">777-0566</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3.0923611111111113in;box-sizing:content-box;"/>
     <td style="width:0.07708333333333334in;box-sizing:content-box;"/>
     <td style="width:1.1597222222222223in;box-sizing:content-box;"/>
     <td style="width:0.07777777777777778in;box-sizing:content-box;"/>
     <td style="width:3.0930555555555554in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_84954921-f3c2-4dbd-a2e3-56d838678763" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_83684347-9ccc-4ad0-bf5d-eb3af0cfa87d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EIKN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5a4f8a3a-bc8a-486a-a2ea-028c2d1ae41a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="text-indent:5.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c9d0789-7b65-4025-b63d-b74dac1b6fac" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eab8712e-b19c-4a8a-ab19-35eb12f051dd" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:1.4472222222222222in;box-sizing:content-box;"/>
     <td style="width:0.04513888888888889in;box-sizing:content-box;"/>
     <td style="width:4.188194444444445in;box-sizing:content-box;"/>
     <td style="width:0.07916666666666666in;box-sizing:content-box;"/>
     <td style="width:1.5375in;box-sizing:content-box;"/>
     <td style="width:0.04513888888888889in;box-sizing:content-box;"/>
     <td style="width:0.15763888888888888in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e6a68baf-a0f3-468f-a00a-54d0380b9cd4" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_11898d60-5719-4949-8511-015b41cdfd9d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntitySmallBusiness" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a186863d-910c-46a7-8f4a-857d9444815b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ab1322a1-8532-453d-af26-2b9151504100" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_81b7b36d-5f03-47f9-92d9-c261f4f75e1b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of May 1, 2026, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caca63f8-fe30-41c9-9f66-78f46ec9edde" contextRef="C_9beb9422-a6eb-4bf6-9cb2-1645d1189e95" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">54,138,628</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, par value $0.0001 per share, outstanding.</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:0.7569444444444444in;box-sizing:content-box;"/>
     <td style="width:6.211805555555555in;box-sizing:content-box;"/>
     <td style="width:0.53125in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i_financial_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Financial Statements (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Balance Sheets</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations_and_comp_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_stockholders_def"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_condensed_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Condensed Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales_of_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) contains forward-looking statements about us and our industry within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, plans for and results of preclinical studies and clinical trials, research and development costs, manufacturing plans, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; or the negatives of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strategy, initiation, cost, timing, progress, and results of our preclinical studies, including our EIK1006 program, and clinical trials for our product candidates, including EIK1001, EIK1003, EIK1004, and EIK1005;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the characteristics, safety, and efficacy of our product candidates and the potential differentiators of our product candidates compared to alternative therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop or progress our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to leverage our technology platform to enable more informed drug research and development;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates of the number of patients with certain diseases and conditions we intend to treat, the number of patients that we plan to enroll in our clinical trials, and the size and nature of the market opportunity for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to meet current or future regulatory standards with respect to our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans relating to the further development and manufacturing of our product candidates, including for additional indications that we may pursue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance and therapeutic benefits of our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">anticipated developments related to our competitors and our industry;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitive position and the success of competing therapies that are or may become available;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the implementation of our strategic plans for our business, product candidates, and technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to enforce such rights and defend intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain our current license agreements and collaborations, including our ability to comply with our financial obligations pursuant to the terms of such agreements, and our ability to identify and enter into future license agreements and collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory, manufacturing, or commercialization expertise;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on third parties to conduct clinical trials of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on third parties for the manufacture of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the impact of general economic conditions, including the impact of tariffs and import/export regulations, and geopolitical events;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans relating to manufacturing and commercializing our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">anticipated regulatory developments in the United States and foreign countries in which we may seek regulatory approval for our product candidates in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our views regarding the restatement of our financial statements as of and for the nine months ended September 30, 2025 and our plans to remediate a material weakness in our internal control of financial reporting;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act or a smaller reporting company; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our anticipated use of our existing resources, estimates of our expenses, capital requirements, and needs for additional financing.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We caution you that the forward-looking statements highlighted above do not encompass all of the forward-looking statements made in this Quarterly Report.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have based the forward-looking statements contained in this Quarterly Report primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in the section of this Quarterly Report titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and elsewhere in this Quarterly Report. Moreover, we operate in a very competitive and challenging environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. We cannot assure you that the results, events, and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The forward-looking statements made in this Quarterly Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report to reflect events or circumstances after the date of this Quarterly Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Quarterly Report with these cautionary statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY OF RISK FACTORS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Listed below are some of the more significant risks relating to an investment in our common stock.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late clinical-stage biotechnology company with a limited operating history and a history of incurring substantial net losses, have no products approved for commercial sale, have never generated revenue from product sales, and may never achieve or maintain profitability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial additional capital to finance our operations and achieve our business objectives. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, or eliminate one or more of our research and product development programs or future commercialization efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business depends entirely on the success of our product candidates and development programs, including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006, and we cannot guarantee that any or all of our current or future product candidates will successfully complete clinical development, receive regulatory approval or be successfully commercialized. If we are unable to develop, receive regulatory approval for, and successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in applying our technology platform to identify or develop safe, effective, or commercially viable product candidates.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on the services of our key leaders, and our future success depends on our ability to retain these individuals and to attract and retain qualified personnel.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have identified a material weakness in our internal control over financial reporting. If we are unable to implement and maintain the effectiveness of our internal control over financial reporting, our investors may lose confidence in the accuracy and completeness of our financial reports, which could adversely affect our stock price.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in U.S. government policies, including those with respect to China, increased tariffs, and reductions in federal research funding, could adversely affect our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our product candidates/programs are still in preclinical or early-stage clinical development. We have not yet completed any pivotal clinical trials with our product candidates, and we may be unable to do so for any product candidates we are currently developing or may develop in the future. If we are unable to advance our product candidates through clinical development, obtain regulatory approval, and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical and clinical development is a lengthy and expensive process, with uncertain timelines and uncertain outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our current product candidates or any of our future product candidates on a timely basis, or at all.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing similar drugs before or more successfully than we do.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates and any future product candidates we may develop, or enforce such intellectual property rights, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates. We may infringe, misappropriate, or otherwise violate the intellectual property rights of others, and be subject to legal proceedings alleging the same, which may prevent or delay our drug development efforts and prevent us from commercializing, or increase the costs of commercializing, our products.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on license, collaboration, and other similar agreements to provide rights to the core intellectual property relating to most of our current product candidates, including our most advanced product candidate, EIK1001. These agreements impose significant milestone payments and other obligations on us. If we fail to comply with the obligations of our current or any future license, collaboration, or other similar agreements for our product candidates, or otherwise experience disruptions to our business relationships with our current or future licensors or collaborators, we could lose license or other rights that are important to our business, and hence lose the ability to continue the development and commercialization of our product candidates, if approved.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently enacted legislation, future legislation, and other healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for, and/or to commercialize, our product candidates, and may affect the prices we may set.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have relied upon, and expect to continue to rely upon, third parties to assist us as we conduct aspects of our preclinical studies and clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines, or terminate their relationship with us, our development programs could be delayed, made more costly, or fail to yield interpretable results, and we may never be able to seek or obtain regulatory approval for, or to commercialize, our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers and suppliers to supply our product candidates. The loss of our third-party manufacturers or suppliers, or their failure to comply with applicable regulatory requirements or to supply sufficient quantities of materials at acceptable quality levels or prices, within acceptable timeframes, or at all, would materially and adversely affect our business, financial condition, results of operations, and prospects.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price may be volatile, and investors in our common stock could incur substantial losses.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iv</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i_financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I&#8212;FIN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANCIAL INFORMATION</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 1. Condensed Financial Statements (Unaudited).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Ba</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1298ade4-c379-44b9-bc04-082e559bbc77" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c646c2b-9cb6-438a-9cb6-63a041fb259c" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,901</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_430b1ae1-ca5a-45fb-bd88-ed5eb54455cf" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,028</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a0e3e9c-02b9-4c3b-b180-84e799e23c2d" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">231,074</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6588e086-03ef-46c7-be43-ef30ffb50b2f" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,919</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ca7b8b4-57ed-43d0-adc2-de561d617f64" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,542</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f8233f5-7063-436a-a25d-ba5d17e42f58" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e97eba3-03e7-40c5-88c2-b4d685f8318b" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b89eed7d-cb69-4957-bb9e-0630574fdbe9" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529,501</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00771179-853f-482b-8267-8579a87bc79b" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348,917</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79405566-5ee4-4905-81ea-bc9b535b59c8" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,067</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc116891-ec80-42fe-9ba7-9af5cee39770" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,898</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d279727-2106-4eb5-8eec-96e8b3dbbf93" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,066</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54e74ead-e02d-477f-ac2c-524c5feb3a65" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,965</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15a8942d-5a64-40dd-8d17-da1b2e994f26" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,828</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash, non-current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_269906fe-6c43-4dee-856b-6e7fe83ca644" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,808</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5461bbdb-e376-4dbd-8ea3-910d575ddf80" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,771</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ae67b7e-37e2-43ec-ac60-5dedaacf8bc5" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">556</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b620e04-d456-4f4e-bd52-f16ffc173798" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,183</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a506e2f-a09a-42bd-8e70-75a581a85a9a" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">850,826</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b773e6d4-ef16-401e-973a-2d7453b81e8d" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594,734</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities, Redeemable Convertible Preferred Stock and<br/>&#160;&#160;&#160;Stockholders&#8217; Equity (Deficit)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5671e417-e2b7-48e9-b602-23f5d41e2416" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,005</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c0c51fb-c871-4959-97c5-dc34a6a9747b" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">681</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1de2385-d9c4-4a5b-b933-9c241df104a6" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,319</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_350160c5-9848-43fb-9f46-cd46c76be10e" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,298</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_396215bc-73d6-4754-9553-ba2d88fde0d9" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,740</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2eaadf4-f598-4bb6-9507-b39ba1e632d3" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,028</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_644f4356-a49f-453a-af9a-71727ed1417e" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,064</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f421ef1a-c1bc-45dd-a4d8-7442859a225a" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,007</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, non-current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b30610bc-4685-4089-945e-ebf4e4ab6090" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,091</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6663b200-2173-4f0c-8e56-87ccf17aecb1" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d57ef116-8bcb-425e-83ee-0285f55829a1" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6b060f4-d3c6-4c61-bd8f-070da36e8f60" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4347ef0b-b530-43d5-b732-e4d5d924ce4e" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300,155</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd58afc1-a5b5-4b89-8190-5958179b49e4" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312,298</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_406021d1-f696-4dc5-823b-2dbb02101b41;"><span style="-sec-ix-hidden:F_d5172da2-0e18-422f-9dd6-381742ad61d9;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (see Note 7)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Redeemable convertible preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06bb60a7-e6ec-4003-9ea1-ec40c5774995" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_78397c62-8fc7-4ac3-8ad6-8bd6bfe804ae" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4530fe1f-48ff-4c51-8c1c-0d0036d74b5a" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c467e3a1-e09b-4c2c-99bb-677fa0a2c56a" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_10757568-7fe7-4f56-a7d4-45f81b59599d" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;authorized, issued and outstanding as of March 31, 2026 and<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9f58b6f-3fec-496d-b0ef-8f3d750b7cf7" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">262,597,889</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92d9bbf5-baaf-493f-979a-dcd0e4b34336" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_46112bcb-ff52-4aa7-86fd-f5970eee8f04" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,658,133</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and<br/>&#160;&#160;&#160;outstanding, and aggregate liquidation preference of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d51f3553-f894-47aa-8733-c7a63f6d257f" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,159,762</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;as<br/>&#160;&#160;&#160;of December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d54b30d8-f810-4df0-b7cf-06a153c4100e" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b06870aa-5a19-460a-9aba-b853b1818afd" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity (deficit):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d566b202-01c3-4a06-94c7-b5ba2fba2bec" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_18471c44-3030-45d9-9178-d1beba0168c8" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb3c2758-5fb1-4f1b-96a1-cf99ba233935" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized and<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b040ab7-05b9-4da7-90b2-d62f485955c1" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d1e26192-1f23-4b8a-9dc7-be8ac104488d" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of March 31, 2026 and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4cdca40-e3a3-4d53-afdf-1909e726136f" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7b0bdbd2-2bd7-4b4d-a127-e7cf5e603478" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_35854f55-5aed-4c2f-94a1-02156e7b8fd6" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;&#160;shares authorized, issued and outstanding as of December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ac40109-661c-4915-a097-4505716a1735" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8026e45-1b60-4990-ae60-40dd11977fb9" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7465953d-8c16-4d7a-9a0d-492844b8bf11" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3da991f0-b552-4839-b1a7-19fd085c5343" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4a8d0b4-102c-4ae1-be4a-255299d8af0f" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized and<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23c53375-aab6-4798-adee-de9283fa59d0" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2f34306b-0235-4e45-9ab8-f89051bf7e2b" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">54,138,555</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of March 31, 2026 and<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b693cd6-8a1c-46ff-8d87-d7a4eda453ef" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">340,650,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb96cfa5-65a8-4b29-8d51-c55144ffe45d" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_53ec40f6-8a6e-4f6c-8570-6d8e6c226b46" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,068,490</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and<br/>&#160;&#160;&#160;outstanding as of December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5e3d8fe-66c1-4e68-98a9-b45eaca9d0f1" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74cd5f75-7290-4368-93b0-12f41ce4d605" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,554,133</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b930e43-d639-4e65-8ac1-bac41ec27b0c" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,475</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e91b8b8d-6148-46bd-87a5-37a5cead01b4" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,003,467</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f9e5a9e-8d89-466a-a89f-4c67acffd38b" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">920,509</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity (deficit)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b137ad9-bbed-432d-9244-30eb9f62ad68" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,671</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46de2d73-1a60-448d-b358-9f4eaaaf4876" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">879,034</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities, redeemable convertible preferred stock, and<br/>&#160;&#160;&#160;stockholders&#8217; equity (deficit)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77cfc14-db57-4ce0-ba63-b4db6aa2d3a5" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">850,826</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab3011be-573c-4966-8887-3b86e86cef2c" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594,734</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations_and_comp_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Statements of Opera</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tions and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83407a55-df4a-4a2f-8842-13dbd614d2fd" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,047</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a4abc7a-92da-42bf-bc62-a1bafb6ca942" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,587</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea5591b-a798-4d1c-9880-953ad9a3c063" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,290</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c438408-c9b6-45e2-ade9-48d24e45f100" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,796</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b583b4b-213a-48e6-9506-fd9df4ef9ab6" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,337</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd598f64-33e7-4047-9942-03ebffdd97b5" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,383</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84d1b3a9-6e68-4495-8da4-068ccdd0aba6" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">87,337</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80132ec7-e68e-40aa-954e-c23a2642f8d1" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,383</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income (expense), net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_552fce07-6981-462c-ba19-f56de6b3ea43" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,380</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d7528e7-dc04-47d9-b49c-b3dd84de96ae" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,160</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7760b2a5-24a0-4a61-ade7-3f201839fd75" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd5f5c9e-ae8b-4bee-b01f-748fffef244f" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2214ca20-9d5e-4842-8390-b0c38132610f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40b611ff-f23c-46ef-b5ca-644f7c43e5b8" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,243</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impact of preferred stock extinguishments and modifications</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08d221ed-c51f-40fc-8efc-b2483da98eb8" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:ImpactOfPreferredStockExtinguishmentsAndModifications" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,300</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1947356-4961-418a-bc1a-ce92a7ad32d3" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14f9dd25-6d1b-4f40-9c02-c5daa2eba0e5" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">74,543</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eff186fd-7588-4b18-b2dd-0e9619ea1b1b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8c85716a-6121-4142-a8c2-b53aff4c0e62" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.46</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ec17b47-3d9a-4eb8-987a-189df24feb8b" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d38b5162-a020-4e83-ac3b-9268cfe3c2e1" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">26.91</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares of common stock outstanding used in computing<br/>&#160;&#160;&#160;net loss per share attributable to common stockholders, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4f88036-c0bc-4e47-9150-dada906bc48d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6592170b-fcf3-4d91-8dc3-ecc7bc838bb3" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,700,550</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_733b5a2e-e1d4-47e4-a558-dc1103a36842" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1b4829ec-93cf-4db7-a033-17fcb0e2db4d" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,770,352</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_stockholders_def"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Statements of Redeemable Conve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rtible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:28.474%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.979%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:4.819%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.039%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.619%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.718%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Redeemable Convertible<br/>Preferred Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity (Deficit)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a04c6218-b778-4328-9e87-40ea12ec4e0e" contextRef="C_9c0f0b76-fafb-4f29-bcdb-edfbcba2d100" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,658,133</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cacf51e-6289-4047-a9e5-5524cf360cdf" contextRef="C_9c0f0b76-fafb-4f29-bcdb-edfbcba2d100" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d37fc30-5f1a-4e82-8bf7-89addb33598f" contextRef="C_43ceca5b-74f1-4f99-8520-dba39c9a9772" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,068,490</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1ace71a-7a0c-4c30-bd5e-e5c3b12894f2" contextRef="C_c0a37a53-ff96-4abe-8394-e87fa5432b98" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,475</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2cdb35c-1cd9-46de-9fd0-af6336548577" contextRef="C_09ce6087-ad99-4411-9be3-549230506f74" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">920,509</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5396c6c8-5056-4cd4-ad17-1f16d569be31" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">879,034</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">Issuance of common stock in initial public<br/>&#160;&#160;&#160;offering, net of issuance costs of<br/>&#160;&#160;&#160;$</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed07b523-6a39-4fd9-b242-3cef3fdb657e" contextRef="C_7a831092-b41d-417e-82e2-51595df304eb" name="eikn:AdjustmentNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,093</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3899dbe7-0dc0-4fb2-8269-f2672b1b0fe9" contextRef="C_7a831092-b41d-417e-82e2-51595df304eb" name="eikn:StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,177,600</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00c64cc7-fb7b-4134-b910-5dc0da11a162" contextRef="C_7a831092-b41d-417e-82e2-51595df304eb" name="eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa5027e3-b01e-4c3d-8fd1-b3a3209259fc" contextRef="C_92846805-1608-4137-b50d-75f45165732b" name="eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348,102</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee540309-bfff-4941-83b8-2d56f448bbb0" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348,104</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of redeemable convertible<br/>&#160;&#160;&#160;preferred stock to common stock upon<br/>&#160;&#160;&#160;initial public offering</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4950bfc-43b0-4abc-bdbe-77ddecf8919b" contextRef="C_62648b45-b0dd-4b75-99ea-21268ea1e65d" name="eikn:TemporaryEquitySharesRedeemedUponConversionShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,658,133</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b27afcde-0318-4a28-8d52-109039ffc215" contextRef="C_62648b45-b0dd-4b75-99ea-21268ea1e65d" name="eikn:TemporaryEquitySharesRedeemedUponConversionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f958e87-2770-49da-a3bb-6a70b1e8ef5c" contextRef="C_7a831092-b41d-417e-82e2-51595df304eb" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,855,741</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a4955cb-52a3-4ba5-aa54-f7abf5cc3929" contextRef="C_7a831092-b41d-417e-82e2-51595df304eb" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91537f2b-f72b-4e1c-83e6-55adf8afac52" contextRef="C_92846805-1608-4137-b50d-75f45165732b" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,467</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34cd23b6-b1b0-4b35-9cb2-6ec3970a076b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise<br/>&#160;&#160;&#160;of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d585c9b-5494-4b1b-a1c6-c073c24d6b81" contextRef="C_7a831092-b41d-417e-82e2-51595df304eb" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82784b26-9e2e-42b3-9265-8c9997504a9b" contextRef="C_92846805-1608-4137-b50d-75f45165732b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc4fe2cf-c3d4-4597-9ac9-defd9b0f059e" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of early exercised stock options<br/>&#160;&#160;&#160;and restricted common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80bc589f-3b96-47ec-93f9-34496edbfe20" contextRef="C_92846805-1608-4137-b50d-75f45165732b" name="eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e38b1e1-08e2-43c0-99b9-837683e61848" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fbaf4dc-64fe-4a52-9558-5ffc7651dd58" contextRef="C_92846805-1608-4137-b50d-75f45165732b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,777</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0303193-f35c-41f1-8ee1-23ee1ed95ef1" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,777</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98558b5c-63d6-45a9-b978-785fdde94b1a" contextRef="C_8ad16874-961a-4ba2-b824-435ee9b04091" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6759add-a193-4d67-b961-dc0fae273cfd" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of March 31, 2026</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77ff738b-2c4c-41f4-acbf-3c2345c138bd" contextRef="C_9b34b095-baf1-4e92-bd9f-785cb99e7d43" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f61e54d8-75d7-4f39-814c-65181054ad9e" contextRef="C_9b34b095-baf1-4e92-bd9f-785cb99e7d43" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4fd9b9b-5069-42d5-bf42-fc34dd5f7c13" contextRef="C_4b9ef807-4b9c-4eeb-b8bc-e8285f9f168c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">54,138,555</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37caa142-f522-4c01-8a65-f102fd8e81e7" contextRef="C_4b9ef807-4b9c-4eeb-b8bc-e8285f9f168c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41833894-3f3d-4719-a823-08e6612a41af" contextRef="C_4f7b2433-ea8a-4286-bb00-c2633ee0aa88" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,554,133</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccc81f08-4d0d-4fa4-8c4e-e197dd27e774" contextRef="C_7930da5b-8c34-4bde-9df0-f3a4e63faa1e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,003,467</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c1f0a8d-93c8-4ce0-87f4-fc7403b734d6" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,671</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:28.474%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.979%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:4.819%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.039%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.619%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.718%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Redeemable Convertible<br/>Preferred Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cec1854-c8b1-4a44-886c-cb3b0437fa4d" contextRef="C_6efa0e52-ace6-4c24-8d0d-270fe66c03b8" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,087,291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73fe79f6-9753-4c72-a81f-980d5b0e5e58" contextRef="C_6efa0e52-ace6-4c24-8d0d-270fe66c03b8" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">808,221</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acc95c7e-1f24-4b44-997e-b354759feeda" contextRef="C_43059c80-0146-49ba-8b0b-010e3648880e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,869,760</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2b4f83e-1c20-4670-a7a7-f67c75c416e6" contextRef="C_1a50a933-7364-4862-966f-2cce973d2edd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,011</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_739c440d-a7ad-4dfc-aae8-aa75b4398a09" contextRef="C_654d525f-1b50-489a-916a-b5b3453bca96" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">604,941</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_362218dd-08f1-46e9-bb55-f88b9bd05b2f" contextRef="C_170bbbfc-0868-43ef-95ca-29607794121a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">571,930</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">Issuance of Series D redeemable<br/>&#160;&#160;&#160;convertible preferred stock, net of<br/>&#160;&#160;&#160;issuance costs of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_668f27c4-5ca1-4072-b380-0c38de02f74f" contextRef="C_82c0918f-98b5-404a-874a-7e2868a58706" name="eikn:AdjustmentNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">547</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c730454e-0a44-4016-9aa1-377d679f6f10" contextRef="C_82c0918f-98b5-404a-874a-7e2868a58706" name="eikn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,005,669</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a290fbd-a8d7-427a-ade8-fd8e3e009ae9" contextRef="C_82c0918f-98b5-404a-874a-7e2868a58706" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,153</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of Series B-1 and C-1 redeemable<br/>&#160;&#160;&#160;convertible preferred stock and common<br/>&#160;&#160;&#160;stock warrants in exchange for<br/>&#160;&#160;&#160;extinguished Series B and C redeemable<br/>&#160;&#160;&#160;convertible preferred stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f33f83b-2b14-403c-854d-a246738345a6" contextRef="C_8f4e15ac-2c2d-4f6b-9d70-e69adc4f166c" name="eikn:TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,977,824</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b700dc6-6b68-4512-b863-3fb0569aecdd" contextRef="C_8f4e15ac-2c2d-4f6b-9d70-e69adc4f166c" name="eikn:TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,566</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd7be9a6-6b6f-418a-aa43-9cca842f308f" contextRef="C_ca978d31-a9a9-4f8f-b576-a32d51689a78" name="eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6227bcfc-604d-4fce-8367-1b6765b8eefa" contextRef="C_187793de-c269-4ef7-bb05-41fa5133f848" name="eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,680</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_280fb900-231b-4aaa-a4cb-5be74103f20a" contextRef="C_1fef2348-70de-4794-94d6-9e3dca9ad9dd" name="eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,566</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of Series B-1 and C-1 redeemable<br/>&#160;&#160;&#160;convertible preferred stock in exchange<br/>&#160;&#160;&#160;for modified Series B and C redeemable<br/>&#160;&#160;&#160;convertible preferred stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17339fb8-e1af-47c8-8377-494e455e20e6" contextRef="C_d2fe5e36-b89d-4ab6-a220-01ee0d375971" name="eikn:TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,587,349</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05bc3a11-6c3f-4c4e-a4be-56a406cb38b5" contextRef="C_d2fe5e36-b89d-4ab6-a220-01ee0d375971" name="eikn:TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcdeb78c-9cda-451c-ae71-fbb5d4aeaecc" contextRef="C_6244dd7b-fa8c-4429-a004-33462cc5b476" name="eikn:StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1de83c1-3a30-4457-8ec4-b90c6fe48aaa" contextRef="C_eb9e9cc2-9255-4256-ac03-f2e532a2ed46" name="eikn:StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise<br/>&#160;&#160;&#160;of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2588e1b-743c-4db0-ae53-86239b244a6e" contextRef="C_b66b40a9-6ffa-4592-8e55-0cc8d9219267" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,197</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f96ce468-8ef2-4dd0-a98b-de8ddead8d84" contextRef="C_3deb9837-54c7-4413-864c-a18fd9e51818" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bdab32d-74ec-40e4-8111-9306997c2633" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7ae7c4-11bc-40c0-83a0-d90b4f6b8b02" contextRef="C_b66b40a9-6ffa-4592-8e55-0cc8d9219267" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">201</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of early exercised stock options<br/>&#160;&#160;&#160;and restricted common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1231c48a-01a6-44b5-ba37-626ef92bdbba" contextRef="C_3deb9837-54c7-4413-864c-a18fd9e51818" name="eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70fc7320-2c79-4ffe-b1ee-07bc159fa05b" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4fb5ddc-f535-48e1-b3a1-ecdf66d1e058" contextRef="C_3deb9837-54c7-4413-864c-a18fd9e51818" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,970</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4114263f-6445-4e06-a2e4-3404e4969699" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,970</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98ed9f51-fd2a-4660-926d-87165f474523" contextRef="C_95fce60b-f21c-4670-9602-3e7e50701ea5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,243</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e36337ec-ad08-4d3c-86ae-37419bf15aec" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,243</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances as of March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d2e0308-ea65-4a73-8126-eb8727e66026" contextRef="C_9552213d-49d0-4396-a5da-0277b129dc28" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,658,133</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400e1dd9-68a4-43dc-9bfa-6ab59836c933" contextRef="C_9552213d-49d0-4396-a5da-0277b129dc28" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_762f1d72-67d4-420a-8cbf-4cd4f04f7f0e" contextRef="C_aa54d368-814e-495c-b6b0-69aa5b033eff" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,870,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_250ffd97-5db8-4ef1-b8ec-383a3eb3a0fa" contextRef="C_4d578cb3-2d47-417a-989d-844acb9f3cbd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,367</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_418b58d9-8a1f-45e2-a109-5ad2fa850107" contextRef="C_a147cd78-029b-4abc-9fd4-bc8f281f4101" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">664,504</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e4f69c6-d54e-4ddc-9862-457698f95211" contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">640,137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.967%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.037%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.037%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46f32449-1268-48bb-872b-d5b338f75429" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b34b96d-a978-4ce2-b8ce-f8f989a51c8b" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,243</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bbde1e5-f207-47ad-806a-91fc67154c38" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,214</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eb53223-0233-4344-877d-7fdafd89bace" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,789</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f65128b5-9b1c-4ea1-beb2-63bc73f204fa" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,777</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c3d34cc-0b73-48a2-98d3-d1792218e341" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,970</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of operating lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c72f2a38-8d5a-45b1-b8f7-763f8e155273" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19d02bd1-0519-4d64-93b2-ed3c06c49309" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,677</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of premiums and accretion of discounts on marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bbc899f-02fd-4f48-9df9-70d7904e9514" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">827</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ad1324c-ee47-4923-a975-e4f2227bcd68" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,234</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c132468-6df7-4344-add0-e4fbb5851e6a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,377</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86b9fbb1-5051-4dd5-b86a-1cb52d9c85bb" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,686</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38ac9cb4-a00e-4529-9f17-7696fd29dd24" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:IncreaseDecreaseInOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c6babbe-b013-4599-9179-8667deaccab9" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:IncreaseDecreaseInOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">399</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18c2ab90-f16c-4f0b-9b5b-26108aac5f8f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,324</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5491d9c5-6608-4b57-b1d1-25852f07d162" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f472f9cb-4624-4707-b614-8a3fafb6cbac" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,065</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f22c6139-0049-4234-82a1-7923bed35700" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,384</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a593c996-de0e-4da6-a7fb-83e6a10bb598" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,488</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94c952b9-03ce-47a8-a586-dc9228cc0533" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,023</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dae9165e-d7ad-4622-95f8-59735dd939ba" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cf7310e-d497-42a5-a53b-f5de80a738a2" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,801</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be6f2f92-9a69-48b3-bc2a-499f1e357478" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,521</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing Activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dee2f25-9371-457b-b4d7-80f5bff79234" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e51e37d-ee15-4b91-95bc-d0829b4c04bc" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,358</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30716680-d5e6-4c2f-923f-d05b00e0fbbe" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,955</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46d3e51e-3282-4421-a9d9-4d8aeda5819f" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,496</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c86d80b-bd72-4598-9a98-109c0944dc00" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e6f3655-90cd-4206-8f9d-496541adfb2d" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb304823-72be-441c-ac99-841ccbe0d80c" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">203,217</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd8aa235-f670-4891-93a2-4ea43efdb808" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">213,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing Activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock under stock plans</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad298e01-7069-4024-a1ab-912384bc912d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e6e8f78-9597-46cf-9ad7-e5deebfbcc9b" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of redeemable convertible preferred stock, net of issuance<br/>&#160;&#160;&#160;costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ac74a33-fe41-418f-84ce-31ed7cc5ad7d" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,213</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from initial public offering, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d6df483-0ac5-4c22-b201-7933b17c2817" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">349,031</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d40d52fe-5332-4bfe-8293-a8b73b5355a1" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">349,308</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e163e53a-4cac-4db0-8d7a-aa2e689c3fab" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,234</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d9e1eb-bce5-4770-8f7a-1307627cef60" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,290</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53c22f54-903a-420d-93f9-e055584ad34d" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,859</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e99376ff-953e-4b25-a1c6-f6086f0394e4" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,072</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ca606a7-4627-4892-95ee-31455ffde629" contextRef="C_170bbbfc-0868-43ef-95ca-29607794121a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,878</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4164670e-d82e-41cf-8452-8802d6e418f7" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,362</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_202473ca-dc29-4756-8acd-f25f193bf37a" contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212,737</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a514a15-9045-43e3-8c38-61c140c265b1" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad5c5857-f0fb-463d-9e8e-63cc087e200a" contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,582</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a1c4e57-4c18-4e69-b205-340e4e4bb489" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,208</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c21c4ace-6f08-4d72-8b23-54b74040ec1d" contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,155</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e552fa0-a93f-4571-be4f-9221940228ef" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,362</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f7579e-3867-4222-bfa1-88a0a4a6e866" contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212,737</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dd9882c-d859-4a1a-8f98-602245da2525" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaad2668-b186-4a75-b118-981e072fb28b" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_360c08eb-5817-4759-8ebe-91a2fa13668d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:CashPaidForOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,483</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5349d9f9-c9c1-4503-b365-83b6d9c56709" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:CashPaidForOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,555</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash financing and investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment included in accounts payable and accrued<br/>&#160;&#160;&#160;expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35b7f864-d1f7-45fd-95b9-708612149f8f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4947f691-31c7-46b1-ad96-639e2db7df04" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,346</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of early exercised stock options and restricted common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfac1ae0-0496-4f2f-a47b-50839f7fda41" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cca946f-5eb4-4e4c-b84d-c7d21ee33de2" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_condensed_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Condense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Financial Statements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3490e21c-dfa3-430f-a4bc-43a14c245ee4" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1. Organization and Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc. (the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important innovative medicines to address serious unmet medical needs. The Company&#8217;s technology platform integrates custom-engineered super-resolution microscopy systems, bespoke automation, data science machine learning and artificial intelligence tools, and software engineering capable of processing petabyte-scale datasets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was incorporated in the state of Delaware on July 9, 2019. The Company is headquartered in California. It also has operations in New York and New Jersey.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2026, the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8edf35b-cf9c-479f-939c-234e68696c22" contextRef="C_7a831092-b41d-417e-82e2-51595df304eb" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d7440967-f56a-48a1-8724-4db9ad3811ca;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1-for-7.4578</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which also resulted in a proportional adjustment to the conversion price for each series of its redeemable convertible preferred stock and warrants, and to the exercise prices and number of outstanding stock options. Accordingly, all shares of common stock, stock options, warrants, and per share information presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split for all periods presented. The per share par value and authorized numbers of shares of the Company&#8217;s common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 6, 2026, the Company closed its initial public offering (&#8220;IPO&#8221;) and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e4019c1-5da1-4260-8523-3a51da064b3a" contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,177,600</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c306c4e-7a8e-4e85-b65b-a865980c1f72" contextRef="C_f4769796-b48a-4a61-bcef-e175508ab0bb" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">18.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for approximate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8693ecac-95e0-4dc1-9d8d-eb797eb89b89" contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">348.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fb3f51e-d221-4464-9c94-9f4da6536bc1" contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2" name="eikn:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_474633bb-ff42-4ae4-aff3-b3bee5ecec02" contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In connection with the IPO, all shares of Series A, A-1, B, B-1, C, C-1 and D redeemable convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e864d6b3-4ee8-4b39-abbb-fbd2d79a315a" contextRef="C_f4769796-b48a-4a61-bcef-e175508ab0bb" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,855,741</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern Assessment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced net operating losses and negative cash flows from operations since its inception. As of March 31, 2026, the Company has an accumulated deficit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c978ca01-d3dd-42ef-a3c6-8aa21da05b68" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="9" decimals="-8" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically financed its operations primarily through private placements of its redeemable convertible preferred stock, and most recently, through its IPO. The Company may seek to raise capital through private or public equity financings, debt financings, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes its cash, cash equivalents, and marketable securities balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f69cc32-ee13-4641-8eb3-48ec69954326" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">596.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2026 will be sufficient for the Company to continue as a going concern for at least one year from the date these condensed financial statements are issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Even if the Company is able to acquire additional financing, the financial terms may not be satisfactory to support its operations. Failure to generate sufficient cash flows from operations, raise additional capital, and reduce discretionary spending, should additional capital not become available, could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3ac895b-0ea5-4f82-971d-f6fe6e7b7c7b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules and regulations of the Securities and Exchange Commission regarding interim reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These condensed financial statements include all adjustments necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative GAAP included in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;) issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58c1c101-9a45-4809-b2ff-43edb628bca7" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to, useful lives of long-lived assets, the incremental borrowing rates for leases, accruals for research and development costs, the fair value of redeemable convertible preferred stock, common stock warrants, common stock and various other inputs used in estimating stock-based compensation expense, and accounting for income tax uncertainties, including a valuation allowance for deferred tax assets, in the accompanying financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9925596a-3355-4f65-bfbc-3d5956632d0a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and marketable securities, which may exceed federally insured limits. The Company has no financial instruments with off balance sheet risk of loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future in-process research and development of its technology, its reliance on third parties to assist in conducting its clinical trials, the need to obtain regulatory and marketing approvals, competitors advancing medicine in a field that the Company intends to enter that constrains its ability to compete effectively for market share, competitors developing technological innovations that reduce the value of the inventions that enable the Company to discover and develop new medicines, protection of its proprietary technology, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize its clinical assets, it will be unable to generate product revenue or achieve profitability.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b7bbfb9-3fc6-4a9d-9ca4-2821380e5bff" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts held in money market funds and commercial paper, which are held at amortized cost.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8794a30-1361-4646-a8b6-f65102ba413b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s marketable securities consist of United States treasury securities and commercial paper, which are held-to-maturity and reported at amortized cost. The amortization of premiums and accretion of discounts from the purchase of the securities are recognized as a component of interest income in the statements of operations and comprehensive loss. Marketable securities are classified as either current or non-current assets based on their contractual maturity dates. Marketable securities are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. As of March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there had been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ada991b-2683-436a-8739-5fec29a8f28c" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:ImpairmentOnMarketableSecurities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment or credit losses on the Company&#8217;s marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_1" continuedAt="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a4604f6-ffd7-4b15-9e0d-12910307b148" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f95f1bcf-d351-4e1b-bb62-bf7ba1cbc89b" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_425276d3-9166-4318-a6b3-e6d9c94f4538" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included in long-term assets as of March 31, 2026 and December 31, 2025, restricted from withdrawal and held by a bank in the form of collateral for irrevocable standby letters of credit held as security for the Company&#8217;s leases. In addition, the Company had deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc638199-801f-4f94-99ba-40ff4a2b7534" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1f6e9302-314d-46ff-9242-205fe3cefb0e" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included in current assets as of March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, pledged for corporate credit cards.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f448283f-4a12-4669-9765-d13769a52784" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are presented at cost, net of accumulated depreciation. Depreciation begins the first day of the month after the asset is placed in service. Depreciation is computed using the straight-line method over the estimated useful lives of five years for lab and engineering equipment, seven years for motor vehicles (used in the transportation of materials between sites) and furniture, fittings and office equipment, four years for computer equipment, and three years for software. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated once placed into service. Upon the sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations and comprehensive loss. Maintenance and repairs are charged to expense as incurred and costs of major replacement or improvement are capitalized.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fceb6ff9-8d8a-4c29-aa89-87198f403348" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the carrying amounts of its long-lived assets, including property and equipment and right-of-use leased assets, for potential impairment whenever events or changes in circumstances indicate that the assets may not be recoverable. Factors that the Company considers in an impairment review include, but are not limited to, significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount, and the impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined using discounted cash flows. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20c1b660-b57d-42b7-bdf0-1cb08efb1e59" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8ff70eac-1809-4497-8576-2834e9685029" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment of long-lived assets during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e2351cf5-b8e3-4664-8dd7-95a2501ffc0d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_e2351cf5-b8e3-4664-8dd7-95a2501ffc0d_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of a contract, the Company assesses whether the contract is a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is determined to exist, the commencement date of such lease is assessed based on the date on which the Company gains control over the use of the underlying assets. The Company&#8217;s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options that the Company is reasonably certain of exercising. At lease commencement, the Company also determines lease classification based on whether the arrangement is effectively a financed purchase of the underlying asset (finance lease) or not (operating lease), which governs the pattern of expense recognition and the presentation reflected in the statements of operations and comprehensive loss and statements of cash flows over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For leases with a term exceeding 12 months, a lease liability is recorded on the Company&#8217;s balance sheet at lease commencement reflecting the present value of its minimum payment obligations over the lease term. A corresponding right-of-use (&#8220;ROU&#8221;) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. Variable lease payments are included in the present value of its minimum lease payment obligations when the contingency is resolved. The lease liability is remeasured at the date the contingency is resolved and the corresponding ROU asset is adjusted. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company&#8217;s incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Company&#8217;s operating leases, fixed lease payments are recognized as lease expense on a straight-line basis over the lease term. For leases with a term of 12 months or less, any fixed lease payments are recognized on a straight-line basis over the lease term and are not recognized on the Company&#8217;s balance sheet as an accounting policy election. Leases qualifying for the short-term lease exemption were insignificant. Variable lease costs are expensed in the statements of operations and comprehensive loss as incurred.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_2" continuedAt="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e2351cf5-b8e3-4664-8dd7-95a2501ffc0d_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9baf0df5-5f55-4d94-a94b-7a54f1740c85" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_26e15826-8d2b-4cea-8e81-470360d62c08" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any finance leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c9e18c9-cf18-4156-8b90-ff8509618434" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Holders of the redeemable convertible preferred stock can cause redemption for cash upon the occurrence of a deemed liquidation event, which is outside the Company&#8217;s control. Therefore, redeemable convertible preferred stock is classified outside of stockholders&#8217; equity (deficit) on the balance sheet. The carrying values of the redeemable convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because the stock is not mandatorily redeemable and the occurrence of a deemed liquidation event is currently not probable.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d194dd37-d7f9-417b-b19a-6ea9713225f0" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are charged to expense as incurred. These expenses consist of compensation expenses, direct research and development expenses such as software development costs related to research and development activities, laboratory supplies, costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation, other miscellaneous expenses, and allocations of facility and information technology expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of its research and development activities conducted by third-party service providers. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with the third-party service agreements. If the Company does not identify costs that have begun to be incurred or if the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from the estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed and classified as current or non-current prepaid expenses and other assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company makes payments in connection with clinical trials to contract manufacturing organizations that manufacture the materials for its product candidates and to clinical research organizations and clinical trial sites that conduct and manage the Company&#8217;s clinical trials. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in payments that do not match the periods over which materials or services are provided. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. The Company makes estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05dc25c5-7f9e-4bf3-85f1-53e422887a38" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:InProcessResearchAndDevelopmentPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Asset Acquisitions and In-Process Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company evaluates acquisitions of assets and related liabilities and other similar transactions to assess whether or not a transaction should be accounted for as an asset acquisition or business combination by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If the screen test is met, a transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs that would meet the requirements of a business. The Company accounts for an asset acquisition by recognizing net assets based on their cost on a relative fair value basis. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-monetary identifiable assets and liabilities assumed based on relative fair values. In-process research and development (&#8220;IPR&amp;D&#8221;) acquired in an asset acquisition is expensed provided there is no alternative future use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for future payments such as those upon the achievement of certain regulatory, development, or sales milestones in an asset acquisition when achievement of the underlying milestones is deemed probable. Milestone payments made to third parties subsequent to regulatory approval may be capitalized as intangible assets, if deemed to have alternative future use, and amortized over the estimated remaining useful life of the related product. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_3" continuedAt="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b40f6945-c960-480f-883a-a32f59359a8a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:PatentAndTrademarkCostsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent and Trademark Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related and trademark costs incurred in connection with filing and prosecuting patent and trademark applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses on the statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ae67fe6-c0df-4b69-be86-f805ee181348" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Initial Public Offering Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred IPO costs, consisting primarily of legal and accounting fees relating to the IPO, are capitalized and offset against offering proceeds following the completion of the offering. Deferred IPO costs for terminated or delayed offerings are expensed immediately as a charge to general and administrative expenses in the statement of operations and comprehensive loss. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_192de495-12e8-4ff5-8c9c-5d40bfe5edea" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred IPO costs capitalized as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026. The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_058bdab3-350f-4bd8-971a-ab972f3f26ac" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of deferred IPO costs capitalized as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, included in other non-current assets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78a11302-01da-4c6b-bb47-012406d136ac" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards issued to employees and nonemployees, the Company measures the estimated fair value of the stock-based awards on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective awards. The Company records the expense for awards with service-based vesting using the straight-line, ratable attribution method and accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#8217; vesting terms and contractual terms, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s cash compensation costs are classified.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_1149f673-112a-4a12-871e-87aa17d0ab6f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock" escape="true" continuedAt="F_1149f673-112a-4a12-871e-87aa17d0ab6f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of the common stock underlying stock options on the date of grant. This has historically been determined by management with assistance from external appraisers and approved by the Board. Due to the absence of an active market for the Company&#8217;s common stock prior to its IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s common stock valuations prior to May 31, 2025 were performed using the Option Pricing Method (&#8220;OPM&#8221;) as it is deemed the most appropriate method based on the Company&#8217;s stage of development and other relevant factors. Within the OPM framework, the backsolve method for inferring the total equity value implied by a recent financing transaction involves the construction of an allocation model that takes into account the entity&#8217;s capital structure and the rights, preferences and privileges of each class of stock, then assumes reasonable inputs for the other OPM variables (inclusive of discount for lack of marketability, volatility, the expected time to liquidity, and risk-free rate). The total equity value is then iterated in the model until the model output value for the equity class sold in a recent financing round equals the price paid in that round. The OPM is generally utilized when specific future liquidity events are difficult to forecast (i.e., the enterprise has many choices and options available), and the enterprise&#8217;s value depends on how well it follows an uncharted path through the various possible opportunities and challenges. Among other factors considered are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s common stock, common stock warrants and redeemable convertible preferred stock valuations from May 31, 2025 through the IPO date were performed using a hybrid method that combines the OPM and the probability-weighted expected return method (&#8220;PWERM&#8221;). The PWERM employs additional information not used in the OPM, including various market approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_4" continuedAt="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1149f673-112a-4a12-871e-87aa17d0ab6f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an IPO or sale of the enterprise, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#8217;s common stock and redeemable convertible preferred stock is then applied to arrive at an indication of value for the common stock and redeemable convertible preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the IPO, the fair value of the common stock underlying stock options is based on the closing market price of the common stock on the date of grant.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afe52031-2a8d-4c36-be63-b33e3de35d5b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:CommonStockWarrantsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa63750e-5e35-4ffd-ac94-b804108a0cbb" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:4.537%;border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:8%;box-sizing:content-box;"/>
         <td style="width:92%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets or liabilities.</span></p></td>
        </tr>
        <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td>
        </tr>
        <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></p></td>
        </tr>
       </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3674bc5a-4eba-431c-accd-f4504189e8f4" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There are currently no components of other comprehensive loss for the Company. Thus, comprehensive loss is the same as the net loss for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2daacb96-8692-481e-9c4d-98afedfba62a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The functional currency of the Company&#8217;s operation is U.S. dollars. All monetary assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Non-monetary assets and liabilities are translated using the exchange rate that was in effect when the asset or liability was initially recognized. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the statements of operations and comprehensive loss and recorded in other income (expense), net. Foreign currency transaction losses were immaterial for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f3fe3dca-88fa-430a-96df-e7e38d8ae5a3" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_f3fe3dca-88fa-430a-96df-e7e38d8ae5a3_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099_5"><div><ix:continuation id="F_f3fe3dca-88fa-430a-96df-e7e38d8ae5a3_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax credits are presented on a gross basis in the effective tax rate reconciliation, and the tax effect of changes in unrecognized tax benefits related to such credits is presented separately within changes in uncertain tax positions.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ca3f7ab-8ff5-4fdb-abff-28d5cab5d069" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker, its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a1712c5d-8279-47e4-b1b8-8c2d8242df25;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57ab0668-5514-4e68-9c30-d07c9adcc96c" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options and warrants to purchase common stock, unvested common stock subject to repurchase and redeemable convertible preferred stock are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be antidilutive for all periods presented.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock and legally outstanding unvested common stock subject to repurchase are considered participating securities. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f5fa97c-7fd3-43ab-bd50-855fdf3ebb66" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daa1fb42-e46e-4b51-828d-ba1c581d5dcb" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:EmergingGrowthCompanyStatusPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, (the "JOBS Act"), and may take advantage of reduced reporting requirements. These reporting requirement exemptions may not be applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59956d62-9874-4c0d-ab6c-81ad831e9a24" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s financial position or results of operations upon adoption.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2024-03 will require public business entities to disclose in the notes to the financial statements, at each interim and annual reporting period, specific information about certain costs and expenses, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each expense caption presented on the face of the income statement, and the total amount of an entity&#8217;s selling expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_8fc0a420-1eae-4c5c-ac50-1c81ae3e30ad" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3. Net Loss Per Share Attributable to Common Stockholders</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbb1e6eb-1283-421f-92bc-f75fb1b8330a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025 (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6be1261e-7be5-43c3-add2-c0b43ac73cf6" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6366e6b3-db33-477a-bea8-1e2aeac696b7" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,243</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impact of preferred stock extinguishments and<br/>&#160;&#160;&#160;modifications</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1785d068-686e-452d-8aa6-ddd0afde5f29" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:ImpactOfPreferredStockExtinguishmentsAndModifications" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff9e005d-9c75-40b6-aee3-a9f9349fea1b" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61269d8f-039a-425c-8c0d-42230ca6a50f" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">74,543</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_163e8263-00e8-4d9f-b3a4-529eb637a79f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:WeightedAverageCommonSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,701,800</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae288793-b1e7-447a-a30e-3906063975db" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:WeightedAverageCommonSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,869,926</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Weighted-average common shares subject to<br/>&#160;&#160;&#160;repurchase</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_987ab7cd-0d12-4c7f-90ca-2d215d00a77e" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,250</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e5aaedc-d572-4a81-a313-709b91dc2de6" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">99,574</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and<br/>&#160;&#160;&#160;diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a92b610-2d09-4a3d-bbdf-0b55ebdf7603" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ae763516-31fc-4b9b-ad80-a0d8037f5b68" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,700,550</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_945f6c4c-c909-4d70-96d1-3c8b6cf44a52" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d11ac3bc-643a-42f1-a27e-96aa54d5fe97" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,770,352</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic<br/>&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_836f822e-411a-4d5c-a58e-e1fbd4c6e85c" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_49da7903-5528-44d7-8980-d30d6d9c9103" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.46</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc2fbf50-7975-4ede-951e-d2029af60a18" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2951e757-a569-4043-a629-c5b44ce4cb73" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">26.91</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9995c632-9cc5-4f82-a61f-4ade0388cb71" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_9995c632-9cc5-4f82-a61f-4ade0388cb71_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding common stock equivalents have been excluded from diluted net loss per share attributable to common stockholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025 because their inclusion would be anti-dilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_606b4898-d69a-4b7c-b7b7-304f84412a36" contextRef="C_6b6e3025-7be7-4cf5-a556-aecb955a9d7b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,522,330</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20a295b7-6b22-43f5-8048-6feb6c6e8786" contextRef="C_64e1594b-40d8-45fe-8a5b-61465fc568f9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,904,399</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercised stock options and unvested restricted<br/>&#160;&#160;&#160;common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffd87672-2458-4614-978e-35a17469f3e4" contextRef="C_2eca1e62-aa09-48af-834d-34f067e0bf98" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">862</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dacf49c8-0a6c-449a-a07f-e030e939e933" contextRef="C_d5e0b4aa-c652-4259-90d9-48a14221845b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">63,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71e53620-7967-4de1-b424-bdb8ff6c8ae4" contextRef="C_c1976207-b5cc-489d-b211-526e50ce39ae" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">739,559</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_417934e3-df0e-4caf-83b6-e0d37cce4317" contextRef="C_855d3fb8-6bf1-4d46-a30f-cd01135bf333" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">739,559</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Redeemable convertible preferred stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa98b5f7-a866-462a-b820-1909340818d5" contextRef="C_62648b45-b0dd-4b75-99ea-21268ea1e65d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9267e3d8-2376-41ce-b57f-810dd8195ae7" contextRef="C_0ec3c10e-a93c-4886-a100-9f5b244f7eee" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">29,855,741</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bbce7cb-5b44-4d0e-864b-b31422eefaf8" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,262,751</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68c1f9da-847b-45a9-bc71-091aec381fa4" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">33,563,186</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_9995c632-9cc5-4f82-a61f-4ade0388cb71_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_5350677d-4114-468f-9e6a-7b2498f654a2" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_5350677d-4114-468f-9e6a-7b2498f654a2_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4. Fair Value Measurements</span></p><div><ix:nonNumeric id="F_b12ad585-066b-4c7a-a994-36d6abcf1f81" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_b12ad585-066b-4c7a-a994-36d6abcf1f81_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets, which consist of cash equivalents and marketable securities, presented at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.628%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:11.91%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58ec3791-72c2-4ce1-a182-0cf27d88e4df" contextRef="C_d3834c7d-2fa8-4b3f-9745-5b403f6177a1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,094</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4162694c-4570-408a-9f7a-cadbb149e8c1" contextRef="C_d3834c7d-2fa8-4b3f-9745-5b403f6177a1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,094</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd5c4688-1150-4f25-a02c-1b0b74c3b8d4" contextRef="C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,094</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7823aaec-52e6-4c74-86ab-feb07634fa16" contextRef="C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,094</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25ab3cfa-691b-479e-9f42-3524482ebd6b" contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,234</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_244a0f34-3aab-40ed-992d-7b116b07b3e6" contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bae92fb2-b57f-4567-a4c6-db4c1c75211a" contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">381</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_528d8e03-226b-42fe-af4f-1c05bbffa223" contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,856</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bc3e12b-83d7-493a-9981-108d90e5c953" contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,794</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00f8c655-ad58-4eed-bc9c-2fe74a5d598a" contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f636b164-545f-4c72-a347-a894584216b9" contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14b880bc-6f73-4e50-84e2-ef692fd95b18" contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,753</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ca03030-f48c-4c78-8957-991fce813da2" contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bb2c494-e701-45dc-aa38-1bb5e5ddff68" contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1f7357f-ed0d-4a73-a324-6592fbea51e6" contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f1b6507-f223-4443-830e-4d758d407d06" contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,609</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dd6b255-4950-4cbb-adb7-96fdcc4a3e7a" contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,925</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31d8b2e6-2a9c-415f-a350-8330251e69e2" contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc" name="eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a9f1d29-b1f7-40e7-871e-dfe4d210c76f" contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,747</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6c48ba4-1df4-4081-a2b5-8e5c8c799023" contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,903</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fed17eeb-84a9-47d4-8a7c-9cc2c97fbbfe" contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e" name="eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b55c6294-b336-4e35-b045-b36e46677fb2" contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,829</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, non-current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_012f4d07-5aae-43df-bdf9-eaef869207a1" contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,828</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e77954f-1a53-45a9-aada-98d3d8e7ac02" contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8" name="eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c43da301-c5b5-4a80-80bb-a9d18a76a9f6" contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,576</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5350677d-4114-468f-9e6a-7b2498f654a2_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b12ad585-066b-4c7a-a994-36d6abcf1f81_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.628%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:11.91%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.181%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.889999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2776fc47-297d-4dd5-9be8-b70c4598918c" contextRef="C_ca062afd-ce86-4311-8424-bd51f8222d31" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,960</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_907d93ef-e897-4268-873b-b40fd30b76bd" contextRef="C_ca062afd-ce86-4311-8424-bd51f8222d31" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,960</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b265e74b-eb98-4515-8e81-cd9bd5a012be" contextRef="C_21e45ff9-b261-46ab-ac86-9eca533d24f1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,960</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dff485d-552a-4557-9996-0db14bd6f48e" contextRef="C_21e45ff9-b261-46ab-ac86-9eca533d24f1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,960</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c465c0f-81ea-4322-a507-d5b950d915a7" contextRef="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,870</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a68dc31-6949-4c35-a513-bb90223f5528" contextRef="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc6228a4-f839-4d85-a3ff-0f1e7497a069" contextRef="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,935</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1642487e-5883-4730-bea0-9d7d6ae632fa" contextRef="C_968ee666-b8c6-47b0-97be-66417cf66128" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,204</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44a17d6-8615-4905-9d62-a0b050642368" contextRef="C_968ee666-b8c6-47b0-97be-66417cf66128" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fd70016-2ea7-4f0d-b8b9-1b79211a64d7" contextRef="C_968ee666-b8c6-47b0-97be-66417cf66128" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,358</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6563ff5b-3f5b-48d0-a4c8-130eeff798fc" contextRef="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">231,074</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_948976a5-5f5d-4ddc-9304-3767254a4f44" contextRef="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154" name="eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7771ecf2-a7f4-4695-abde-5e9246b0785f" contextRef="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">231,293</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae4a63f6-2eec-427a-9a43-791e399df5dc" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_11a67bfa-8331-4aab-b06d-a34c6b27e6eb" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t hold any financial assets that would be classified as Level 3 in the fair value hierarchy during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair values due to their liquid or short-term nature, such as cash, prepaid expenses, accounts payable, and accrued expenses.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bc83aab-3af3-4067-8474-6f4c2a3fcccb" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5. Balance Sheet Components</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f7cb1e3-38dc-42bf-b8d6-bb42527c47bf" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82ad0d92-6f74-4c3a-bb40-8c430aafa486" contextRef="C_ea08a515-6580-47df-bab8-c50e516fc3e4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,909</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce1e303b-5fca-42c5-bb01-0ed5af45a0d1" contextRef="C_1c77db10-7d9d-4dcb-8c50-adc69f65d083" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,909</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Engineering equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b705c853-67ea-487b-b7bd-2afcbe2e3acc" contextRef="C_e8403787-14b9-4395-a9bd-4273c59b3ebf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,843</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1979b5d9-e358-41d4-8f68-23c7f02ad0d4" contextRef="C_660ec3d2-b609-4bfb-b1b1-c4305903c960" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,843</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4721da35-79f6-4dda-90c6-7398e34f85a5" contextRef="C_dd617b4e-2a11-46a2-ae77-d0760c22bfc1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,588</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_670cc9b0-de7c-46f0-989a-cc33d4d42bda" contextRef="C_1c487c21-7dd9-4244-95e3-68a278433e25" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,588</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432ae07a-60f4-406c-92d6-2ca35720daa8" contextRef="C_15155790-267d-4a2b-aaa0-e438238b971c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87f718a0-f634-495d-bd3f-201eef6a9008" contextRef="C_020258b1-9d04-4044-a458-aad5f3a473ac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture, fittings &amp; office equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4638bb5f-abac-4db9-811f-51dfd760049a" contextRef="C_6f295888-378b-4391-a021-9bca631286e6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_964050a4-145d-42b7-84fe-e43efccaa94a" contextRef="C_83013968-b516-4963-8f78-e02e28e21aac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5ee6359-8ad3-4309-8d73-fa6cf85bd3c2" contextRef="C_aa9bb9d8-99cd-44a2-b558-5d96aab73df6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,062</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee94a6b6-52bc-4159-ac1c-3a583dd4d629" contextRef="C_95010d63-09ef-4c23-8c49-40323fc46cd9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,970</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_050a9d6d-abdc-4930-baf7-4496d81105e9" contextRef="C_e647b2ed-2de8-4ede-8766-0746071aee38" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,627</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b0e1acb-11e1-48d5-bcdc-c273dde208ba" contextRef="C_7c4a7bfd-264d-45e7-bcf8-d63ea24ce46b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,627</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e55d2cd-cc55-457c-95a6-882012da7031" contextRef="C_06851da8-c034-45e1-a93f-8136cb20bbc9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">963</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b95c6c8-0e53-4c9a-838c-a88657a217cb" contextRef="C_7756d92c-fabb-4333-b946-71468f2cd618" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">624</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38208a10-dbec-489a-8a5c-3eded675db91" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,161</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_506eb8ce-7144-4a7f-bf4c-e176c7502e3b" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,812</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20f2ce54-973d-436c-8b5f-fd24aff17704" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,094</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_599e89e7-974b-4cf2-ad18-fffd7469f033" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,914</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4d9f723-bf6d-4c8f-bc51-17609de61d6f" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,067</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9275a90-cf55-4710-bab8-eb9a37068599" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,898</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f043000-296d-4662-b142-e2827ec25beb" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26dbea41-de40-403b-bffd-45f685431a01" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2026 and 2025, respectively. Disposals of property and equipment during the three months ended March 31, 2026 and 2025 were not material.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ff4a6dc-7993-4c84-b1f7-5e536aae80da" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_415a400c-ab10-49a2-bc84-8c5593f45913" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa575ebe-5d06-49cc-9c92-1efb492bcf48" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,868</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7b6c620-cb9b-4f98-a838-00fabefe42a8" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:AccruedClinicalExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,128</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3642aa8f-2fd4-4731-87ea-d014cbe8f656" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="eikn:AccruedClinicalExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,518</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses related to purchase of IPR&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_561b3eea-0732-472f-b4ca-3e95c4ac130e" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:AccruedInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_596bd91d-11a4-4723-ad53-255f0db97e92" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="eikn:AccruedInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued vendor expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b83478d7-6df1-46ac-bb3f-37a28a749177" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:AccruedVendorExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecb1f5cb-d632-4087-bf79-f8b7e6699098" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="eikn:AccruedVendorExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of early exercised options and<br/>&#160;&#160;&#160;restricted common stock liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f67846e-dd07-48e7-9d25-e24105246109" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73193497-b5c0-4084-8e22-c9b72b739fcb" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="eikn:CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd87776f-90ee-45fc-935c-649f87f511b7" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_965ea90e-b7a2-4172-9477-264194e9116b" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b7bc364-3a2a-45a5-8f06-058851dcde3b" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,319</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce1e87e-4cb2-44ae-acb1-8272c9f0dddc" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="eikn:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,298</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de02886e-20bd-4bee-b6ee-76a63173ebd3" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6. Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company entered into an operating lease of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f70a7d48-ab1b-40a4-bbbc-1c8ac330e62b" contextRef="C_7cfa5dbb-75bd-4c08-84f9-248de234217e" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">285,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and laboratory space that now serves as its corporate headquarters located in Millbrae, California. The lease commenced in February 2024 and expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2513182e-84c1-42c0-8135-b3838edee5c8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2040</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lessor provided the Company a tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c24c43a-ed2f-479d-b37c-30bcb02dcbc9" contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the Company constructed leasehold improvements, which were concluded to be lessee assets, in the space. The lease liability at lease commencement was calculated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_450737af-cb21-41b4-9d3f-65ae4d400865" contextRef="C_7cfa5dbb-75bd-4c08-84f9-248de234217e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">159.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is equal to the present value of the future lease payments, discounted at an incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b714af14-5023-4ea6-9752-0149fd244c4c" contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194" name="eikn:PercentageOfIncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The lease agreement also includes a renewal option allowing the Company to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e73ed994-3094-4696-8bcf-61623f970edf" contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend this lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd463777-8822-4d47-946b-b0ee2580a743" contextRef="C_7cfa5dbb-75bd-4c08-84f9-248de234217e" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at the prevailing rental rate, which the Company is not reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the lease agreement provides for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_120252e0-9cd8-4d13-ba2b-b465c8a6a0c2" contextRef="C_7d79440a-32b9-4e44-9930-5f1dcba2901b" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">57.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional tenant improvement allowances that may be utilized by the Company and is repayable over the term of the lease with interest. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aad7f8f-bd64-4e03-b88c-92fb708afd62" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of additional tenant improvement allowances had been drawn down as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company constructed leasehold improvements, which were concluded to be lessee assets, in the space. The Company is accounting for the repayment obligation related to these additional tenant improvement allowances as part of the lease with the amounts included in operating lease liability, current and non-current. The Company has an irrevocable standby letter of credit for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d4802a1-1e0d-48c2-be5d-f2a6d6f9c0f8" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LeaseDepositLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million held as security for the Millbrae lease deposit.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had leases for other office and laboratory facilities of between approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aba3036f-edb4-4b33-aab6-a9c82ff4f217" contextRef="C_6f92e515-198c-41f2-9ae2-33fc324dbf18" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84b9f22a-7715-4950-9daf-f5c49ef2d607" contextRef="C_734a9e98-beab-4d4c-b47e-a15b69419607" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">72,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet in Hayward, California, New York, New York and Jersey City, New Jersey as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The leases will expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4891b7a9-ea44-4065-bf6f-ac1774d7b202;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2026</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fea5efb2-ee1e-4e93-a542-9a2bbd4553aa;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2029</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless their terms are extended where allowed under the leases. In January 2026, the Company notified the landlord of one of its Hayward properties of its </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecb1b47f-b825-442e-8606-522aa1b491fa" contextRef="C_c7bcc98d-42fc-40a6-991f-28a29433e55e" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intention to early terminate</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44f844c8-fc05-46bd-81e1-930bc0a3e310" contextRef="C_c7bcc98d-42fc-40a6-991f-28a29433e55e" name="eikn:OperatingLeaseTerminationDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company remeasured the operating lease liabilities, which resulted in a reduction of the carrying value of the operating lease liability and a corresponding reduction in the operating lease right-of-use assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59f237cd-b911-49ea-85e0-918ad9900df0" contextRef="C_346f6ee4-54e2-4fbe-b3f1-de86b076b6d1" name="eikn:DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_45a9a613-867f-4e51-ac42-65d7ce3943bf" contextRef="C_346f6ee4-54e2-4fbe-b3f1-de86b076b6d1" name="eikn:DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases had weighted average remaining lease terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5ce9d3f-2a83-4653-9f26-271b2b1a52f7" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d39f021-ac95-47b6-9296-447004df3384" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and weighted average discount rates of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_666c822d-549b-4233-b083-0f1dcad4f43d" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88a5c077-681f-48f5-b0bd-d2ee5b0bcd01" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2026 and December 31, 2025, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_786ac81f-3164-407b-8dd8-1435110c9c6c" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments under non-cancellable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2026 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"/>
         <td style="width:1.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.823%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026 (remainder of year)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a4090b8-e912-4918-b22f-7f017ec110a8" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,988</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fae49951-72d1-4f3e-aa33-d90865bb951c" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,310</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d122dba-0b7d-44c9-85fb-a6e8970e7635" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,286</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8cce0b3-0225-4525-9dde-e3a1a4ca0a4b" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00881499-ede0-44c5-87f3-16f4e1cddc84" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,913</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe384188-2ea6-4bda-ade8-ed3279da385a" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370,302</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1444d22-38cd-4a61-8468-3da203039a78" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">551,576</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08c4b917-5230-4e6a-9fa0-28ab3f71697d" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,745</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of future lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fafb6262-6ebc-4b95-84ba-8b75d03a0cb4" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254,831</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Operating lease liability, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_380b6625-3496-44a1-be54-ea83f12e3413" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,740</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3bcb1e4-c6aa-4bdb-a3ee-c1734446ea56" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,091</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense for operating leases was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_052e5827-5fc4-4215-a7e1-457ab02b570f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0be76cb2-a6d5-45f0-8773-71a14d038d1b" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ca9e2f9-f363-4a4f-ac1b-081ae5b57258" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:VariableLeaseCost" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b1331756-1a08-4994-8916-cb2666e949c4" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:VariableLeaseCost" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1d772fa2-956e-401c-ba23-2ebbe8880691" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8154e847-a40f-458d-9107-4e432f7bc547" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> variable lease costs and short-term lease costs were not material for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_7e4d6168-6238-439f-9451-6bb25921bc84" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_7e4d6168-6238-439f-9451-6bb25921bc84_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into various agreements in the ordinary course of business, such as those with suppliers, clinical research organizations, contract manufacturing organizations, and clinical trial sites. These agreements provide for termination at the request of either party, generally with less than one-year notice and are, therefore, cancellable contracts and, if cancelled, are not anticipated to have a material effect on the Company&#8217;s financial condition, results of operations, or cash flows.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7e4d6168-6238-439f-9451-6bb25921bc84_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Milestone and Royalty Payments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into license agreements in the normal course of business in order to obtain rights to promising product candidates, advance product development and obtain technologies and services related to its business. The Company could be required to make development and regulatory milestones and sales milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2470e713-0a42-435e-8d9f-e7a1922c78e0" contextRef="C_4a28407e-c2fe-49ab-87fd-4c1824a42626" name="eikn:DevelopmentAndRegulatoryMilestones" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">630.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a1afa0-300a-47f7-a45f-8be07249a219" contextRef="C_4a28407e-c2fe-49ab-87fd-4c1824a42626" name="eikn:SalesMilestones" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, and tiered royalty payments to licensors based on the net sales of the licensed products. Contingent milestones are recorded when probable to be achieved. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has incurred and recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_490a4fbe-56af-45a0-b59e-3d5d4d6bdfdd" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:UpfrontsAndMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">93.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in upfront and milestone payments under these agreements (see Notes 10 and 11).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations, or cash flows. The Company may pursue or be subject to litigation and other legal actions from time to time arising in the ordinary course of business, including intellectual property, products liability, breach of contract, commercial, employment, and other similar claims which could have an adverse impact on its reputation, business and financial condition and divert the attention of its management from the operation of its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0f088e1-2b98-4c24-8525-65d76329561a" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d4588876-512f-4da8-b09c-96db494d05b1" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> legal contingencies requiring accrual or disclosures as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification claims. Accordingly, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a736155a-d983-4883-a106-ca38f5929597" contextRef="C_e7df204e-01a6-433d-b71b-99e1e283b5e3" name="us-gaap:Liabilities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_678eafaf-f6c9-42ec-a1a7-728f2f6a7d26" contextRef="C_662558f3-ac07-4fe3-b87b-689c90cf7fae" name="us-gaap:Liabilities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any liabilities for these indemnification rights and agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_1fdda789-7e13-41eb-8f75-9233130c7454" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_1fdda789-7e13-41eb-8f75-9233130c7454_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8. Capital Structure</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Redeemable Convertible Preferred Stock</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1543c30b-0262-4be9-99ee-22a405751153" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:TemporaryEquityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issued and outstanding redeemable convertible preferred stock consisted of the following (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.634%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.818%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.098%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.618%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.618%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.618%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Series</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares<br/>Authorized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares<br/>Issued and<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Original<br/>Issue Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Liquidation<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3e9110c-8f14-4b97-9d0b-6f31070379c2" contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">48,000,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29c77500-5f55-4a9b-aa9f-cc44d11070fa" contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9459b305-c44f-44f7-ace2-6f2a84018467" contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">48,000,000</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c74d6c7d-0cdd-4c99-8cfc-7594cb14a61e" contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5000920-7805-4f68-81c6-2ec7bb7353b7" contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5434ca69-7218-44f8-915c-2c269133c8fb" contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,916</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a8d63d-ae45-4512-9c35-5cad7212df88" contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,268,891</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_171f5e71-2703-4482-88d5-c713622e10c4" contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_06bde316-d35c-4fc0-99e8-a684b4981001" contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,268,891</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99b86313-e7be-436b-8bdc-b9b926f6895d" contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8137126-41c5-4b87-b017-44eba4b49500" contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,538</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0afb69a7-4e68-4ab5-8668-14f4f952923f" contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,472</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c96681f-4297-448e-845e-9982a1cc2e97" contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,271,143</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba66a150-5ea2-4620-a842-11b6c163aa6a" contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f01550be-bff8-4a48-a3ce-0ed9603bbeb1" contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,456,768</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfd33ffa-8d6d-4cdc-9675-dbf83d093097" contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">17.69</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c4ae21c-6207-4754-b05e-def72524f836" contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f96d98e-f236-4bda-9bf4-ccb0409e7ae6" contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">297,294</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecd7e70e-bb0d-4107-8fde-70890f18adcb" contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,756,908</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d4ad982-c624-4767-ba59-a7838dd39177" contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0d0e02fd-e7c4-463c-a71b-d98ab280107a" contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,756,908</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9de91909-3ff0-4b8a-884c-e0041c74c8e8" contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.84</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_343df225-df62-4ecc-bd6b-3c19120cccef" contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,979</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de2651ec-57ab-4025-b223-1745ee99147c" contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,200</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4f48db6-1fc5-4980-a598-a784325defff" contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">24,884,830</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31db0da3-e961-4c4b-8639-a228ff35ec2a" contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9798746d-5c97-42bf-a23f-63dc94e40323" contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,194,787</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb99fea5-06df-4671-a194-eab0245e6342" contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">21.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f3257f4-1079-4ed4-a1ff-c782e5841a0a" contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,682</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b47432e6-b01c-4797-b985-0c474c767811" contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,629</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07fd8da0-737a-4444-b1de-391fee2a29b6" contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,975,110</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffb4f73a-a1f0-4fd9-ab4c-3b99466a93fe" contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d961901e-4fef-45a3-aeeb-348e31bc4886" contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,975,110</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a23e6899-0a38-405f-b42c-3165b0ee0322" contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.84</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_421015ae-981f-4514-8a05-3bfbe2cf43a7" contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,077</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e87777ab-2bc7-4bff-9f69-c993989a23fa" contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,806</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e33e22c9-8630-4d3b-a761-e862836f35e2" contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,441,007</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1acfa50-8095-44f0-9700-3ca0ef36b314" contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a2732424-ee99-4db1-a432-3a72d6c7bbf3" contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,005,669</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_578c8491-2b6b-4f07-bfd6-80be6c2ffa7b" contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.84</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c529fe55-77e8-4b2b-9183-ae2f630d8646" contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d61460af-69ae-4e67-8140-26ba0196d572" contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,153</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee7e153d-9b2b-45e6-afa7-d1c1adbc1377" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">262,597,889</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_899d1660-7c50-4175-8aa9-2de7ea78bdf2" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b14084d7-1b4f-4558-963b-2261d2461738" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,658,133</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f92c9658-9f28-4916-8577-c7cce8fe4d5b" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,159,762</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_156691eb-7cec-44e0-bb69-d383dd68bee1" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,161,470</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, the Company entered into a Series D preferred stock purchase and exchange agreement which provided for the issuance of Series D redeemable convertible preferred stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d871e0fc-8682-4f57-9176-9dcbbfbd9f3e" contextRef="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The transaction provided returning investors the ability to exchange their Series B and Series C redeemable convertible preferred stock for Series B-1 and Series C-1 redeemable convertible preferred stock, respectively, if their participation in the Series D financing exceeded certain qualifying amounts. Further, investors that invested more in the Series D financing than their aggregate investment in Series B and Series C received common stock warrants based on the excess investment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the transaction, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc016e64-d0a1-4c4e-a51e-8904eb0f3f29" contextRef="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">60,005,669</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series D redeemable convertible preferred stock in cash purchases at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76436e43-d23a-4b9d-919b-b9746e28dc4f" contextRef="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46e53835-8031-472e-99f9-8a8e4b16a361" contextRef="C_79517728-0638-49d0-b5e2-18ddacc50546" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">350.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company also issued (i) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f06a1542-cfb7-4182-b0ab-c7c8526705b2" contextRef="C_7f0bc01b-6dce-402c-b6f6-7f08c14a5096" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">35,756,908</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series B-1 redeemable convertible preferred stock as a result of the exchange of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01c36811-ee1a-46ce-bb6f-5ea059d97f49" contextRef="C_4db66fff-bc05-4074-8e36-aeef64b327a4" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,814,375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of its Series B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_1fdda789-7e13-41eb-8f75-9233130c7454_1" continuedAt="F_1fdda789-7e13-41eb-8f75-9233130c7454_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">redeemable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">convertible preferred stock, (ii) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2d02f0a-ada1-4df9-b974-1dca5fb2b92f" contextRef="C_fb91cb81-7c4b-448a-988e-9ead42c05b5a" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,975,110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series C-1 redeemable convertible preferred stock as a result of the exchange of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c763650-c97d-4bda-a6ce-8a77a2dd9eb1" contextRef="C_8f9cf841-a084-4a0b-8321-a9f82ffed0e1" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,352,470</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series C redeemable convertible preferred stock, and (iii) warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01565543-0004-4a98-8ab8-c6cb367683ee" contextRef="C_e170b844-9352-4f6f-8503-8d06a7499836" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">739,559</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_606b9a69-6839-4c25-b233-9aedafb75788" contextRef="C_c1981874-bd18-46b8-8717-745097f2f3bd" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">43.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants shall be exercisable in whole or in part, at any time up to and including the first to occur of the consummation of a liquidation event and the fifth anniversary of the date of issue and thereafter shall terminate and be void. The warrants can be exercised either in cash or net issued. As the contract allows for physical settlement or net physical settlement, the Company concluded that the common stock warrants should be equity- classified and recorded in additional paid-in capital at their fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ecca716-be5d-4aa8-b797-49314c323abe" contextRef="C_72c9554b-3432-4aba-ad4e-feadbc19e644" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assessed the impact of the transaction, on an investor-by-investor basis, using a quantitative analysis in order to determine whether it represented an extinguishment or a modification of the Series B and Series C redeemable convertible preferred stock held by each investor which were exchanged.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extinguishment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The quantitative analysis indicated the fair value before and after the transaction was substantially different for some investors. Specifically, these represented investors that participated at a level which enabled them to exchange all or nearly all of their Series B and Series C redeemable convertible preferred stock, including the investors whose participation also entitled them to common stock warrants. For each of these investors, the transaction represented an extinguishment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The extinguishments resulted in the following impacts:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derecognition of the existing carrying amount of the extinguished Series B and Series C redeemable convertible preferred stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a750ac-69d0-4bd4-8154-401b005e1040" contextRef="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">172.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11f93170-c946-4c71-8d0b-50137b2f7aef" contextRef="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting for the new issuance of the Series B, Series B-1, Series C and Series C-1 redeemable convertible preferred stock, and common stock warrants at fair values of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6fd6ab3-0dc5-4f31-b534-1580e523c080" contextRef="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74a7e0c3-a88c-422b-b327-57def106976b" contextRef="C_50271040-0f62-455e-8383-928757d00db6" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">149.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fe8ee84-24ef-4e37-af0e-e583e068a1a1" contextRef="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d46bc6f3-cae9-4652-933f-f8725a43db0e" contextRef="C_19ce2956-fe58-4b8f-9894-55d51e63a6f4" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_679d40b6-8c45-4fc7-bbde-1fe3302b13dc" contextRef="C_b9805475-e76d-41e7-932c-783895704433" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offset for each investor was recorded to either additional paid-in capital (investors for which fair value exceeded carrying value, aggregating to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f534f93-ef4d-4a1e-b2e6-51274a7aa06d" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:TemporaryEquityOffsetFairValueExceededCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) or accumulated deficit (investors for which carrying value exceeded fair value, aggregating to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e182d18-db93-4013-b3ee-a339d443852c" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:TemporaryEquityOffsetCarryingValueExceededFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), as appropriate.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate difference between the fair value of the consideration transferred and the carrying value of the extinguished shares was reflected as an adjustment to the numerator in the computation of basic earnings per share for the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Specifically, the extinguishments resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a71bd741-23cc-43fb-9bde-18559f17f459" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net reduction to the net loss available to common shareholders.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modification</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The quantitative analysis indicated the fair value before and after the transaction was not substantially different for some investors. Specifically, these represented investors that participated but only at a level which enabled them to exchange a portion of their Series B and Series C redeemable convertible preferred stock. For each of these investors, the transaction represented a modification.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The modifications resulted in the following impacts:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The existing carrying amount of the modified preferred stock was adjusted by the increase in fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0330dd1-fb73-4ff1-ade3-4105173fe4b5" contextRef="C_b9805475-e76d-41e7-932c-783895704433" name="eikn:ModifiedAdjustedPreferredStockIncreaseInFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million comprised of a net decrease to the carrying amount of Series B and Series C redeemable convertible preferred stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56d81b63-e16e-4e3e-a4e4-e5931d68ef9e" contextRef="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0" name="eikn:DecreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3fc673a-3691-4a3f-9d24-fbc377a71567" contextRef="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44" name="eikn:DecreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and an increase to the carrying amount of Series B-1 and Series C-1 redeemable convertible preferred stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fa45286-9b85-477d-8a8e-a81a91154a27" contextRef="C_50271040-0f62-455e-8383-928757d00db6" name="us-gaap:IncreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">74.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0635fc8-9e69-44d0-bcba-fb6a0a710382" contextRef="C_19ce2956-fe58-4b8f-9894-55d51e63a6f4" name="us-gaap:IncreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offset for each investor was recorded to additional paid-in capital (all represented increases in fair value).</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in fair value of the modified shares was reflected as an adjustment to the numerator in the computation of basic earnings per share for the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Specifically, the modifications resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_420849d7-a12d-4046-8612-118bb99db5cd" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million increase to the net loss available to common shareholders. See Note 3 for the net impact of the extinguishments and modifications on the net loss per share attributable to common shareholders.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1fdda789-7e13-41eb-8f75-9233130c7454_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the IPO, all shares of Series A, A-1, B, B-1, C, C-1 and D redeemable convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc406e7d-31cb-47f7-ac27-2470d293c89c" contextRef="C_f4769796-b48a-4a61-bcef-e175508ab0bb" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,855,741</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec6132da-41ab-4c33-906c-371adc3fa80e" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance, on an as if-converted basis, consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of redeemable convertible preferred stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75b5f648-dfb5-42f4-8816-45a3882fdbae" contextRef="C_32e58006-0bc0-440a-94eb-1e6e99c57dfe" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84eed224-61e1-43e9-a99f-4b07de7ed10b" contextRef="C_645f2052-193d-45d6-894c-a8d3a45a5203" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,855,741</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d131f769-b6ec-40b0-b8de-c7d82cf6c4ae" contextRef="C_31e76bc3-5aba-4a5f-9818-f4b753bd92ef" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">739,559</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eaeb219-d218-4a96-996d-efb7ce6b5c3c" contextRef="C_908c61c4-64bd-4c85-a9dd-94e0cd397a73" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">739,559</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37cdcaf0-4bb8-4587-8fcf-50ab72a144d4" contextRef="C_d927b95d-37fc-4c9d-8791-5738a05cbc4b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,522,330</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_019cf032-2cfd-4466-98dc-41558dcf4d6d" contextRef="C_18d67718-9b0e-4fc6-9a9c-711cd4ddf402" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,513,142</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options available for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_744584f6-2d34-4e6c-b66e-db5ff498b3cc" contextRef="C_1ea189f6-3a9d-423b-a06b-980dd823d3d7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,269,981</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4f81a17-3f71-41e3-8c40-2814bb3e104c" contextRef="C_d432863b-75bb-40d5-bacc-9c6f3baca062" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,449,522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dca71211-df37-44e4-aa25-e27b5aea0de8" contextRef="C_f1a8eeb5-1e5a-4045-acdc-0cfce87caf9b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">539,582</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c845e3d-29a2-431f-b52c-07d80f07f4bf" contextRef="C_f6befb00-d49d-441c-b08f-36fbaa09ea83" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf546f1c-3d25-4acc-a6fc-de49f3464dce" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,071,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af1780e3-8afc-42d7-a128-071264b1966f" contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,557,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stockholders are entitled to dividends if and when declared by the Board and after any dividends on redeemable convertible preferred stock are fully paid. The holder of each share of common stock is entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_683fb320-69e6-4920-9e21-cc5fbcdf678f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f00b02f8-46ae-4274-b88a-90f36f1f92ac" contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec" name="eikn:DividendsDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends have been declared.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_9c6c8d27-c8b4-4405-9428-7134374c59e6" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_9c6c8d27-c8b4-4405-9428-7134374c59e6_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9. Equity Incentive Plans and Stock-Based Compensation Expense</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2026 Long-Term Incentive Plan (the &#8220;2026 LTIP&#8221;), which became effective on February 3, 2026 and replaced the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted on September 19, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfd67a62-9806-4680-8fca-a7550f9ef87e" contextRef="C_480832dd-e171-4ca4-b482-a03140d73654" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,137,117</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock have been reserved for issuance under the 2026 LTIP, in addition to any shares of common stock outstanding under the 2019 Plan or shares of common stock issuable in connection with the stock option awards granted to the Company&#8217;s Chief Executive Officer on April 2, 2025 that expire, are withheld by the Company for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to the Company due to failure to vest. The number of shares of common stock reserved for future issuance under the 2026 LTIP will also be increased pursuant to provisions for annual automatic evergreen increases, subject to any action by the Board of Directors that reduces the increase to a lesser number of shares for a given year.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2026 LTIP and 2019 Plan provide for the granting of restricted stock, incentive stock options (&#8220;ISOs&#8221;), or nonqualified stock options (&#8220;NQSOs&#8221;). Restricted stock and NQSOs may be granted to Company employees, officers, directors, and consultants. ISOs may only be granted to Company employees (including directors who are also considered employees).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options under the 2026 LTIP and 2019 Plan may be granted for terms of up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8212e674-2f49-455f-89ed-be00a10e794a" contextRef="C_912863b5-d421-42f1-b393-0c8022fb4cc5" name="eikn:ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant, provided however, that with respect to an ISO granted to a person who owns stock representing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2709b48-ff95-4ac2-9e38-db6e52d0af8d" contextRef="C_8c7f8085-733f-4767-ac3a-7065758bbd4a" name="eikn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total combined voting power of all classes of stock of the Company, the term shall be for no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2775d9b2-60db-4954-bf47-6d11363a8f34" contextRef="C_912863b5-d421-42f1-b393-0c8022fb4cc5" name="eikn:ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise price of options granted under the 2026 LTIP and 2019 Plan must be at a price no less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1550a6db-120d-4b4a-8c87-963753f34258" contextRef="C_d632d010-5232-471e-abf6-d727c87dd4b4" name="eikn:ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the shares on the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to an employee who at the time of grant of such option owns stock representing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6163863e-d104-47f0-b7da-2f9dab66159e" contextRef="C_8c7f8085-733f-4767-ac3a-7065758bbd4a" name="eikn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total combined voting power of all classes of stock of the Company, the exercise price shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4046894-b97e-49d6-a8b8-e86f576ab025" contextRef="C_92fa46f0-fe5c-4ebc-817d-ec6bec9a5f5a" name="eikn:ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the shares on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted under the 2026 LTIP and 2019 Plan generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68b1550a-1032-4e68-ab46-b07cbac3ce75" contextRef="C_a58a5eaf-b724-4201-9cb2-92d031377e5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, generally </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_490ee96a-8b14-4bd2-a341-4b8bde79a27b" contextRef="C_60427b0d-3053-455a-a653-545c63de803d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% after one year and monthly thereafter. Annual refresher options granted to employees generally vest monthly over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e64dcd16-9ac1-4289-b1d3-ecf293455008" contextRef="C_a58a5eaf-b724-4201-9cb2-92d031377e5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2026 Employee Stock Purchase Plan (the &#8220;2026 ESPP&#8221;), which became effective on February 4, 2026. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ac5cf92-db93-4df2-81e3-e70fc01f2d4d" contextRef="C_e6ef9b81-32b1-4c49-9fa3-1c3d269aece2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">539,582</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock have been reserved for issuance under the 2026 ESPP. In addition, the number of shares reserved for future issuance under the 2026 ESPP will be increased for annual automatic evergreen increases, subject to any action by the Board of Director that reduces the increase to a lesser number of shares or provides that there will be no increase in the share reserve for a given year.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9c6c8d27-c8b4-4405-9428-7134374c59e6_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6658163-7733-4606-8b6c-949b55ab5ba8" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense includes options granted to employees and nonemployees and has been reported in the condensed statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35fd9c95-eca4-4f42-90ba-83d6adaaa8f1" contextRef="C_88eddc74-25a3-4aa5-b892-0c78cef4f38f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,162</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed879f1a-4ec8-4ec5-8a34-e4c0414737c4" contextRef="C_ed86a544-6aee-4ee9-acce-d3e07fcb1c78" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,151</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a828569d-e3d1-4134-ac03-42d3e975d9f7" contextRef="C_9b60e528-d867-4710-996d-aa10971fdb80" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,615</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ca56ffc-c230-4659-9030-9ae348225831" contextRef="C_bc59c656-e863-43bb-acfa-25a6bfeba2a7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,819</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b60487a-0b3e-46cd-931a-6ceb9423ebd5" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4642d0b7-e1a8-4f25-bae0-cefaf07c6e47" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,970</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_a1e82350-035f-490e-8cfd-e8f848c36e6a" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true" continuedAt="F_a1e82350-035f-490e-8cfd-e8f848c36e6a_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10. Acquisitions of IPR&amp;D</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seven and Eight Collaboration Agreement and SW License and Development Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 29, 2023, the Company entered into an Exclusive Collaboration Agreement (the &#8220;Seven and Eight Collaboration Agreement&#8221;), with Seven and Eight Biotherapeutics Corp. and related entities (collectively &#8220;Seven and Eight&#8221;), and an Exclusive License and Development Agreement (the &#8220;SW License Agreement&#8221;) with Seven and Eight and Superb Wisdom Limited (&#8220;SW&#8221;). Under each agreement, Seven and Eight and SW granted the Company a worldwide, exclusive license under certain of their patents, know-how, and other intellectual property rights to develop and commercialize certain toll-like receptor 7 and 8 agonist product candidates, including the Company&#8217;s product candidate, EIK1001. The license from SW is exclusive in the field of oncology, and the license from Seven and Eight is exclusive in all fields. The Company has the sole right and responsibility to conduct clinical development, perform regulatory activities and commercialize the compounds and products licensed under the agreements, and must use commercially reasonable efforts with respect to its development activities. Under the Seven and Eight Collaboration Agreement, following a transition period during which Seven and Eight transferred certain contracts, regulatory documentation, biological materials, research tools, rights and other information related to the product candidates to the Company, Seven and Eight agreed to wind down its research efforts with respect to toll-like receptor activity, including its development of the compounds licensed under the agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid Seven and Eight and SW aggregate upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc79dcba-202a-4986-bf17-23ebeda4193d" contextRef="C_4c693a1f-4ca1-464c-90fa-56debb4e78a7" name="eikn:UpfrontFeePaidInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ddc2e53-e135-40c9-bacb-bbaa39e79d51" contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627" name="eikn:UpfrontFeePaidInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Seven and Eight and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9e571df-7f10-4df8-9427-d32abd93faae" contextRef="C_7793f816-84ea-4007-b84f-955f26f60859" name="eikn:UpfrontFeePaidInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to SW), and issued two Simple Agreements for Future Equity (&#8220;SAFEs&#8221;), equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5bb753a-292a-4711-974c-1423ac3a83d6" contextRef="C_4c693a1f-4ca1-464c-90fa-56debb4e78a7" name="eikn:SimpleAgreementsForFutureEquityIssuedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0126f086-2810-4fff-bfcc-6a344c7a1536" contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627" name="eikn:SimpleAgreementsForFutureEquityIssuedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Seven and Eight and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_703e011e-faf5-4b03-96d0-da3279ac5b09" contextRef="C_7793f816-84ea-4007-b84f-955f26f60859" name="eikn:SimpleAgreementsForFutureEquityIssuedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to SW) upon entering into the applicable agreement. The SAFEs automatically converted into Series C redeemable convertible preferred stock upon the initial closing of the Series C financing round in May 2023, which then converted into common stock upon the closing of the IPO. The Company has also agreed to pay Seven and Eight additional milestone payments in the amount of up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2405276a-87e7-493f-847e-32df627d4ac9" contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627" name="eikn:AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">369.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d261dba-d9d9-4230-888a-3af3c3edf597" contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627" name="eikn:AdditionalMilestonePayableForACompoundThatIsNotAConjugate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">219.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are payable for a compound that is not a conjugate and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea1853e-b5f8-4a6f-b08b-7e7f9cd84929" contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627" name="eikn:AdditionalMilestonePayableForACompoundThatIsAConjugate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for a compound that is a conjugate, in each case upon the achievement of certain development and regulatory milestones. EIK1001 is a compound that is not a conjugate. The Company has also agreed to pay SW additional milestone payments in the amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f7379cb-ed94-464b-b42a-ead1b02db7e0" contextRef="C_1946717c-8e31-4a84-ab14-fa2fc8fe3174" name="eikn:AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9b3f71f-dcc6-4a02-a82e-05cbe3daf9d3" contextRef="C_1946717c-8e31-4a84-ab14-fa2fc8fe3174" name="eikn:AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">350.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain regulatory and commercial milestones, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Seven and Eight Collaboration Agreement, the Company owns and retains all rights in intellectual property and other information discovered, developed, or otherwise made in connection with the Seven and Eight Collaboration Agreement, whether made by the Company or Seven and Eight, either solely or jointly. Under the SW License Agreement, the Company owns any improvements, enhancements, updates, or equivalents of the intellectual property developed, created, or otherwise made in relation to the compounds and products licensed under both agreements. The Company also has the right to prepare, file, prosecute, enforce, and maintain patents related to the compounds and products licensed under each agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Seven and Eight Collaboration Agreement expires upon the latest of (i) the expiration, invalidation, or abandonment of the last patent licensed thereunder, (ii) the expiration of any data or market exclusivity program related to the product candidates, and (iii) ten years after the first commercial sale of a product candidate. If the Company notifies Seven and Eight that it is permanently discontinuing its efforts to develop and commercialize the licensed products under the agreement and does not intend to pay Seven and Eight any milestone payments contemplated thereunder, Seven and Eight may terminate the Seven and Eight Collaboration Agreement. Either party may terminate the Seven and Eight Collaboration Agreement if there has been a material breach of contract, but such termination can only be invoked if the breach cannot be reasonably remedied by the payment of money damages. The Company may also terminate the Seven and Eight Collaboration Agreement upon prior written notice for any reason.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the SW License Agreement expires upon the earliest of (i) the expiration, invalidation, or abandonment of the last patent licensed thereunder in the applicable country (and if no patent application was filed or no patent was issued in such country, ten years from the first commercial sale of the first product licensed thereunder in such country), or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a1e82350-035f-490e-8cfd-e8f848c36e6a_1" continuedAt="F_a1e82350-035f-490e-8cfd-e8f848c36e6a_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) payment of the last commercial milestone payment. The SW License Agreement automatically terminates upon any termination of the Seven and Eight Collaboration Agreement. The SW License Agreement may also be terminated, without terminating the Seven and Eight Collaboration Agreement, by either party if there has been a material breach (including if the Company fails to make any milestone payment due thereunder). The Company may also terminate the SW License Agreement, without terminating the Seven and Eight Collaboration Agreement, upon prior written notice for any reason.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized the upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2584b476-924e-4708-8122-2ab1891a59c9" contextRef="C_0395c051-54e6-4697-8ef1-dbef23445ddb" name="eikn:UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as in-process research and development expenses within the statement of operations and comprehensive loss in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the transaction was accounted for as an in-process research and development asset acquisition and the acquired technology did not have an alternative use. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63b57687-cecb-47d0-a0e4-27474d5c4489" contextRef="C_c3beda52-07b7-41e0-a055-08c63663c5d6" name="eikn:FutureMilestonesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_51b52b3f-3184-4ecc-8dab-e5492508e0f6" contextRef="C_d6aef30d-4b1d-4072-adb3-7c8d3cb1b224" name="eikn:FutureMilestonesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> future milestones were accrued on the Company&#8217;s condensed balance sheets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025 as such milestones were not achieved or probable of being achieved at each date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impact Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 10, 2023, the Company entered into a Collaboration Agreement, which was amended and restated on November 22, 2023, and further amended on December 12, 2024 (collectively, the &#8220;Impact Agreement&#8221;) with Impact Therapeutics (Shanghai) Inc. (&#8220;Impact&#8221;). Pursuant to the Impact Agreement, the Company received an exclusive license under certain of Impact&#8217;s patents, know-how, and regulatory information to develop and commercialize any selective PARP1 inhibitors owned or controlled by Impact or its affiliates, including the Company&#8217;s product candidates EIK1003 and EIK1004, and any pharmaceutical products comprised of or containing such inhibitors, on a worldwide basis excluding China, Hong Kong, Taiwan, and Macau, such excluded territories collectively known as the Impact territory. The Company also received a co-exclusive, royalty-free license under certain of Impact&#8217;s patents and know-how to develop and manufacture such product candidates within the Impact territory solely for the purposes of supporting the development or commercialization thereof outside of the Impact territory. Additionally, the Company granted to Impact a co-exclusive, royalty-free license under certain of its patents, know-how, and regulatory information for the sole purposes of Impact fulfilling its obligations related to the Impact Agreement and to develop, manufacture and make regulatory filings related to the product candidates. In addition, the Company granted an exclusive, royalty-free license under certain of its patents and know-how to Impact solely for purposes of commercialization of the product candidates in the Impact territory. The Impact Agreement further prohibits either party or their sublicensees or affiliates, as applicable, from developing, manufacturing, or commercializing any selective PARP1 inhibitors during the term of the Impact Agreement except as provided under the foregoing licenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Impact Agreement established a joint steering committee (&#8220;JSC&#8221;) to manage the collaboration. Under the Impact Agreement, Impact retains responsibility for all preclinical development activities for the product candidates. Impact is responsible for clinical development, including preparing and maintaining regulatory approvals, and commercialization of the product candidates, in the Impact territory, and the Company is responsible for these activities in all other jurisdictions worldwide. The Company also has the right to propose global clinical studies and global development plans that include clinical sites in the Impact territory for the JSC&#8217;s approval. The Company would be responsible for the conduct of any global clinical study in all territories except the Impact territory, in which Impact would be responsible for such conduct. Under a global development plan, the Company and Impact could each also propose the development of a combination product in their respective territories. Further, under the Impact Agreement, the Company must use commercially reasonable efforts to achieve regulatory approval of a product candidate for one indication in the United States, subject to Impact&#8217;s performance of its preclinical development activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The JSC consists of three Eikon representatives and three Impact representatives; the chair of the JSC is an Eikon representative. In the event that the JSC cannot reach unanimous agreement on any issue, then the Company&#8217;s Chief Medical Officer must discuss the issue with Impact&#8217;s Chief Executive Officer. If they are unable to reach agreement, then the Company has final decision-making authority over any matter related to the development and commercialization of the product candidates, including Impact&#8217;s preclinical development plan, and any Impact, global, or combination development plan. Impact has final decision-making authority over the day-to-day implementation of any development plan, manufacturing, and commercialization of the product candidates in the Impact territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a8f1d37-451f-45b2-8078-adf13011c4a9" contextRef="C_307b49d7-4a22-4c20-90d0-a57dab4d74f7" name="eikn:UpfrontFeePaidInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash to Impact. The Company is also required to make payments to Impact of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8c6659c-91b3-4d56-b8be-f1b9249eebf6" contextRef="C_28287679-ce3c-40bb-abd2-c8b78786196d" name="eikn:MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">181.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce30ea08-3352-4e1e-8dda-da0c34d3e2cf" contextRef="C_307b49d7-4a22-4c20-90d0-a57dab4d74f7" name="eikn:MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">775.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development and regulatory milestones and commercial milestones, respectively. In addition, tiered royalties of high single-digit to low-teen percentages of net sales per calendar year, subject to certain reductions, are also payable by the Company to Impact post-commercialization.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and Impact each own and retain all interests in any information or invention individually developed under the Impact Agreement, and they each own an equal and undivided interest in any jointly developed intellectual property. Subject to the licenses granted under the Impact Agreement and the respective exclusivity obligations therein, the Company and Impact each have the right to exploit such joint intellectual property rights and grant licenses to affiliates or other persons under such joint intellectual property rights.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a1e82350-035f-490e-8cfd-e8f848c36e6a_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impact has the right to prosecute and maintain its own and joint patents in the Impact Territory; the Company has the right to prosecute and maintain its own patents worldwide, and to prosecute and maintain Impact&#8217;s and any joint patents in any jurisdictions except for the Impact Territory. The Company and Impact each have the sole right to enforce patents in their own respective territories and have agreed to cooperate fully where the enforcing party requires documentation or other assistance from the other party.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Impact Agreement expires upon the expiration of the last royalty term for the last product candidate for which the Company is actively pursuing research, development and commercialization. The royalty term for a product candidate in a country expires upon the latest to occur of: (i) the expiration of the last-to-expire patent held by Impact or joint patent in such country that contains a valid claim that covers such product candidate or corresponding licensed compound, (ii) the tenth anniversary of the first commercial sale of such product candidate in such country, and (iii) the expiration of regulatory exclusivity for such product candidate in such country. Upon such expiration of the royalty term for a product candidate in a country, the exclusive licenses the Company received under the Impact Agreement will become non-exclusive, perpetual, fully-paid, royalty-free, irrevocable licenses for such product candidate in such country. Either party may terminate the Impact Agreement if there has been material breach, but such termination can only be invoked if the breach cannot be reasonably remedied by the payment of money damages. In addition, either party may terminate the agreement if the other party becomes insolvent. The Company has the sole right to terminate the Impact Agreement immediately upon written notice to Impact if the Company receives a clinical hold or a withdrawal notice from a regulatory authority regarding safety concerns related to the development or commercialization of a product candidate, in each case that has no reasonable likelihood of resolution. The Company also has the sole right to terminate for any or no reason upon prior written notice to Impact.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f1f3939-73ad-454d-abf3-dc4a93735a4d" contextRef="C_ebfe9b65-c71c-4702-a2c5-feb06a82af91" name="eikn:UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as in-process research and development expenses within the statement of operations and comprehensive loss in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023 as the transaction was accounted for as an in-process research and development asset acquisition and the acquired technology did not have an alternative use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934a7605-bfbf-4fa5-8902-ec021adb75ac" contextRef="C_3cf22cef-9013-42e6-8cf3-e35b755febc6" name="eikn:DevelopmentAndRegulatoryMilestonesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development and regulatory milestones, which were recorded as research and development expenses in the condensed statement of operations and comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c567530-278a-473d-b181-369e7178607f" contextRef="C_3989eb12-e5ab-4eaa-81f3-cfefea545c70" name="eikn:DevelopmentAndRegulatoryMilestonesPaid" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestone payments were made in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4fdda17-278c-4307-806a-d963652a6de9" contextRef="C_a72dfdfc-a580-488a-9676-5c50bffd695e" name="eikn:FutureMilestonesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_adf52e64-0bad-4f5d-b541-f66b4c639d71" contextRef="C_9608e9ac-9845-4074-830c-41f067773cfa" name="eikn:FutureMilestonesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> future milestones were accrued on the Company&#8217;s condensed balance sheets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as such milestones were not achieved or probable of being achieved at each date.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_2f71c769-bbf6-42f9-87e6-cd6cd477d174" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_2f71c769-bbf6-42f9-87e6-cd6cd477d174_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11. Research and Development Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Column Group and Catalyst4 Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 7, 2024, the Company entered into a collaboration agreement with The Column Group-Neuro, LP (&#8220;TCG&#8221;), an investor in the Company, and Catalyst4, Inc. (&#8220;Catalyst4&#8221;), a limited partner in TCG&#8217;s neuroscience fund.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, Catalyst4 will pay the Company an aggregate payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50423364-8d68-4b44-9b20-bd3aacdbe316" contextRef="C_1e8500d8-0dbe-4c15-adb9-cf43d49e2d09" name="eikn:AggregatePaymentToPerformResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million over the next five years to perform upfront research and development on drug discovery or drug development programs for Parkinson&#8217;s Disease. In addition, the Company is required to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4464876-74b1-432d-83c5-2e05448ae82d" contextRef="C_760222b0-6d13-4c82-a9ee-2f2a276df9e9" name="eikn:PaymentForAchievementOfCertainRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Catalyst4 upon the achievement of a certain regulatory milestone. In the event Eikon sells or licenses programs to a third party to develop, the Company is required to pay Catalyst4 a mid-double digit percentage of all payments received, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_665311ce-feec-4093-82b3-0313cdb79c70" contextRef="C_0eb6f30c-2652-4bc8-8657-bc2aac3eb2ba" name="eikn:SalesRoyaltyPayable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate across all such programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f0e8ee3-54d7-4dbd-8db9-a34d1ea50467" contextRef="C_a949f785-fff1-46ba-9714-cd224ef31489" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Catalyst4 for future services, which was recorded in other non-current liabilities on its condensed balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with MSD</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into a clinical trial collaboration and supply agreement (the &#8220;MSD Agreement&#8221;) with MSD International Business GmbH (&#8220;MSD&#8221;), for three separate studies: (i) the Phase 2/3 registrational study of EIK1001 in patients with advanced melanoma (dated August 1, 2024); (ii) the Phase 1/2 clinical trial of EIK1005 in patients with advanced solid tumors (dated December 3, 2025); and (iii) the Phase 2/3 registrational study of EIK1001 in patients with non-small cell lung cancer (dated December 5, 2025). Pursuant to the MSD Agreements, the Company and MSD agreed to collaborate on these clinical trials evaluating the safety and efficacy of its compounds in combination with MSD&#8217;s compound, pembrolizumab. Under the MSD Agreements, the Company acts as the sponsor of the clinical trials at its own costs and MSD has agreed to supply to the Company, at its own cost, pembrolizumab for use in such trials. Pursuant to the MSD Agreements, the Company and MSD must each use commercially reasonable efforts to supply the Company&#8217;s applicable compounds for use in the portions of the clinical trials in which patients are intended to receive pembrolizumab either alone or in combination with one or more treatments, in accordance with the applicable study protocol. The Company recognizes costs incurred for the EIK clinical trial as research and development expenses within the statement of operations and comprehensive loss.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2f71c769-bbf6-42f9-87e6-cd6cd477d174_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and MSD will jointly own all clinical data and results generated from the portion of the clinical trials involving the combination of the Company&#8217;s compound and pembrolizumab. The Company owns all clinical data and results generated from all portions of these clinical trials that involve its compound alone or in combination with other treatments that are not pembrolizumab, and MSD owns all clinical data and results generated from the portions of the clinical trial involving pembrolizumab alone or in combination with other treatments that are not the Company&#8217;s compound (the &#8220;MSD clinical data&#8221;). The Company may use MSD clinical data solely to evaluate the safety or performance of the combination or to register its compound in the combination.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MSD Agreements will each expire upon the delivery of a results memorandum and final report of the portions of the respective trial where patients receive pembrolizumab to MSD, unless earlier terminated, or, in the case of the Phase 2/3 trials, if the Phase 3 portion of the clinical trial is not initiated. MSD may terminate the supply agreement for a particular clinical trial if the Company does not initiate the trial for the combination within one year from the effective date of the respective MSD Agreement. Further, MSD may terminate an MSD agreement and the supply of pembrolizumab immediately if (i) MSD notifies the Company that it believes that pembrolizumab is being used unsafely in the trial and (ii) either MSD believes such matter is not reasonably capable of being remedied, or if the Company fails to remedy promptly such issue to MSD&#8217;s reasonable satisfaction. Either the Company or MSD may terminate an MSD agreement for a breach of the agreement, for patient safety, or due to regulatory authority objections or actions. Further, either party may also terminate an MSD agreement if such party determines, in its sole discretion, to withdraw any applicable regulatory approval for its respective compound, or to discontinue development of its respective compound for medical, scientific, or legal reasons.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31a18fb9-bb8d-4258-94d9-627312994c9f" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 12. Employee 401(k) Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sponsors a 401(k) defined contribution plan covering all employees. Employer contributions to the plan were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8d26ed-bb08-4455-a6dd-83269463c2a8" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40868b8f-ee37-4fe3-9a90-66417531d5ab" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b41a36a-6f62-47b3-8436-99bff7cc4a81" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 13. Segment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_85997c2d-5760-46fb-bcd0-7b83f0349464;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment that is managed on an entity-wide basis. The Company&#8217;s chief operating decision maker is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2ea580d6-5cea-4c6a-9652-7b14b693ba76;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3d90123-3c0a-4821-98e1-e3517a335ca7" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s chief operating decision maker uses net loss to evaluate the performance of its segment, analyze financial trends, compare the budget to the actual operating results, and make resource allocation decisions. Segment net loss represents the Company&#8217;s total net loss. All corporate costs, including allocated facilities and information technology costs, and depreciation, are included within this segment. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0020ed7-3597-4fb6-8b5d-707be655d8a5" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and engineering expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a26e6f6-b859-4668-9908-9dea892d43ef" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:ResearchAndEngineeringExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,483</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99ae0e13-687c-4dd2-82a7-c898e49bc003" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:ResearchAndEngineeringExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,627</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1acd802b-fba3-40b2-a2a0-cb0e34634c27" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:ClinicalExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,564</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e5b78ad-a4fa-4e86-946d-dae88328da65" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:ClinicalExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,960</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54a400ae-870f-48d3-b8a8-54032a8d7622" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="eikn:InProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa3a3942-ac0d-48d4-b346-07419b497e96" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="eikn:InProcessResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a2ae4bf-efcb-4fd7-b289-46f65920cd2d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,047</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c050f910-6ba1-4fc7-8a4a-3282eec1bf6b" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,587</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b72b47e-d0c7-4bbf-ac3d-6f5644f05c2e" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,290</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77fe08d-98db-4314-b9a6-548d0a7b4134" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,796</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c8d2b99-3618-4142-adf5-5d3859cd4030" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,379</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c32b717-1aee-4b5f-b5bd-099d83a63d8f" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,140</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b9fcf24-7306-4670-bfa4-7348ca146e25" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,958</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a0ebe72-9544-425b-97bf-e18d1733774e" contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,243</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items is comprised of interest income (expense), net and other income (expense), net.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-lived assets as of March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were located in the United States.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of financial condition and results of operations should be read together with the unaudited condensed financial statements and the related notes included elsewhere in this Quarterly Report, and with our audited financial statements and the related notes included in our Annual Report on Form 10-K for the year ended December 31, 2025. This discussion and analysis contains certain forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth herein under the heading "Special Note Regarding Forward-Looking Statements" and in the section titled "Risk Factors" in Part II, Item 1A of this Quarterly Report, and in the other documents we file with the Securities and Exchange Commission, or the SEC. Historical results are not necessarily indicative of future results.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world&#8217;s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes&#8217; track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated and have begun dosing in a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our pipeline is set forth below:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img119830300_0.jpg" alt="img119830300_0.jpg" style="width:720px;height:307px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0e2841;white-space:pre-wrap;font-size:6pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#0e2841;white-space:pre-wrap;vertical-align:super;font-size:4.0200000000000005pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1</span><span style="color:#0e2841;white-space:pre-wrap;font-size:6pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration; </span><span style="color:#0e2841;white-space:pre-wrap;vertical-align:super;font-size:4.0200000000000005pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2</span><span style="color:#0e2841;white-space:pre-wrap;font-size:6pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 safety and efficacy study nearing completion; United States Food and Drug Administration, or FDA, has allowed us to proceed with the Phase 2/3 registrational trial; </span><span style="color:#0e2841;white-space:pre-wrap;vertical-align:super;font-size:4.0200000000000005pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3</span><span style="color:#0e2841;white-space:pre-wrap;font-size:6pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">NSQ = Non-squamous cohort, SQ = Squamous cohort, Phase 2 readout for NSQ cohort expected to be presented at ASCO 2026; </span><span style="color:#0e2841;white-space:pre-wrap;vertical-align:super;font-size:4.0200000000000005pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4</span><span style="color:#0e2841;white-space:pre-wrap;font-size:6pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Greater China: China, Hong Kong, Macau, Taiwan; </span><span style="color:#0e2841;white-space:pre-wrap;vertical-align:super;font-size:4.0200000000000005pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5</span><span style="color:#0e2841;white-space:pre-wrap;font-size:6pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone achieved February, 2026; Note: Readouts are contingent on acceptance for presentation at one of several major medical conferences</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the product candidates and programs described above, we are also actively pursuing discovery research in oncology and neurodegeneration.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception in 2019, we have devoted substantially all of our resources to research and clinical development activities, the development of our technology platform, recruiting management and technical staff, business planning, producing materials for preclinical studies and clinical trials, establishing our intellectual property portfolio, entering into collaboration and license agreements, and building our infrastructure to support such activities, and raising capital. We do not have any products approved for sale and have not generated any revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses and negative cash flows since our inception, consistent with our operating plan. Our net losses were $83.0 million and $68.2 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of $1.0 billion and cash, cash equivalents, and marketable securities of $596.0 million. Since our inception, we have financed our operations primarily through the sale of shares of our redeemable convertible preferred stock and more recently, through our initial public offering.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we estimate that our existing cash, cash equivalents, and marketable securities as of the date of this Quarterly Report will be sufficient to fund our operating expenses and capital expenditures into the second half of 2027. We have based this estimate and our forecast of cash resources and planned operations on our current assumptions, which may prove to be wrong, and we may exhaust our available capital resources sooner than we expect. Additional funds will be necessary after that date to maintain current operations and to continue our research and development activities. We plan to monitor expenses and raise additional capital opportunistically through any combination of public and private equity and debt financings, strategic alliances, and licensing or collaboration arrangements. Our ability to access capital when needed is not assured, and if capital is not available to us when, and in the amounts, needed, and on acceptable terms, we may need to delay, scale back, or abandon some or all of our development programs and other operations, which could materially affect our business, financial condition, and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability, if ever, will depend upon the successful development, approval, and commercialization of our product candidates and upon the receipt of sufficient revenues to support our cost structure. We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates and commercialize any such products or enter into license or collaboration agreements with third parties that generate substantial revenue for us. Because of the numerous risks and uncertainties associated with product development, we may never achieve or sustain profitability, and unless we are able to do so, we will need to continue to raise additional capital.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our expenses will increase substantially in connection with our ongoing and planned activities, as we:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to progress the development of our clinical-stage product candidates, including EIK1001, EIK1003, EIK1004, and EIK1005; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to progress the internal development of our preclinical assets, including EIK1006;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">invest in our target selection programs and develop any additional product candidates, including the cost of acquiring any necessary rights from third parties to develop those product candidates or entering into partnering relationships to further the development of any such product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and expand the manufacturing of preclinical and clinical supply of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct clinical development, and if that development is successful in producing sufficient evidence of safety and efficacy, then seek regulatory approvals for any of our current product candidates or any future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing, manufacturing, and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire, and retain qualified clinical, scientific, operations, commercial, and management personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add and maintain operational, financial, and information management systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create, prosecute, protect, maintain, enforce, and expand our rights in our intellectual property portfolio or acquire or in-license intellectual property and technologies from third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">navigate any delays in our preclinical studies or clinical trials and regulatory approval negotiations for our product candidates, including as a result of macroeconomic conditions, geopolitical conflicts, or other factors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting, or other expenses in operating our business, including the costs associated with operating as a public company.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently own or operate any manufacturing facilities. We rely on clinical manufacturing organizations, or CMOs, to produce our product candidates in accordance with the United States Food and Drug Administration's, or FDA's, current good manufacturing practices, or cGMPs, as well as such cGMPs as may be required in other jurisdictions in which we conduct our clinical trials, for use in our clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given our stage of development, we do not yet have a marketing or sales organization or commercial infrastructure. Accordingly, if we obtain regulatory approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Highlights</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EIK1001</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For EIK1001, we expect to present updated data on our fully enrolled Phase 2 trial evaluating EIK1001 in combination with standard-of-care therapy in the first-line stage 4 NSCLC setting at the upcoming annual meeting of the American Society of Clinical Oncology, or ASCO, beginning at the end of May, including a full interim data readout of the non-squamous cohort and a partial interim data readout of the squamous cohort. In addition, we expect to make a Trial-in-Progress presentation to highlight an ongoing Phase 2/3 trial of EIK1001 in combination with pembrolizumab in first-line advanced melanoma, as well as the initiation of a Phase 2/3 trial in combination with standard of care in first-line NSCLC settings.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EIK1003</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the ASCO annual meeting, we expect to present updated data on our ongoing Phase 1/2 trial in patients with breast, ovarian, prostate or pancreatic cancer for Cohort 1A evaluating EIK1003 as a monotherapy and Cohort 1C evaluating EIK1003 in patients with breast cancer and ovarian cancer in combination with paclitaxel. Dose escalation has completed for Cohorts 1A, 1B (in prostate cancer patients in combination with the novel hormonal agent, abiraterone, and prednisone), and 1C with backfill nearing completion, and dosing has commenced in a Phase 2 dose optimization trial. Finally, we have initiated site selection for Cohort 1D evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapeutic agents in patients with breast or ovarian cancer.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">EIK1005</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For EIK1005, we expect to present two abstracts at the ASCO annual meeting, including data on pharmacokinetics and pharmacodynamics from the healthy volunteer portion of the trial and resulting dose modeling, as well as a Trial-in-Progress presentation for the ongoing Phase 1/2 trial.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="text-indent:4.547%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses include expenses incurred in drug discovery, development of future technology, and the conduct of clinical trials. These expenses consist of compensation expenses, including stock- based compensation expenses, direct research, and development expenses such as software development costs related to research and development activities, laboratory supplies, costs associated with conducting clinical trials at domestic and international sites, fees paid to CMOs and contract research organizations, or CROs, professional fees for consulting and related services, depreciation, facility and information technology expenses, and other miscellaneous expenses. We expense all research and development costs in the periods in which they are incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where possible, we do not outsource primary responsibility for the conduct of our clinical trials to CROs. While we still rely on CROs for certain support, we believe that conducting our clinical trials ourselves offers significant advantages relating to quality, efficiency, and continuity. As of March 31, 2026, we had 155 employees primarily engaged in clinical development activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to continue to invest in our research and development programs and new and ongoing clinical trials on our product candidates. As a result, we expect that research and development expenses will increase in absolute dollars for the foreseeable future as we continue to invest to support these activities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses include compensation expenses, including stock-based compensation expenses, for personnel in executive, finance, human resources, legal, information technology, and other corporate administrative functions, professional fees for legal and audit services, depreciation, facility and information technology expenses, and other miscellaneous expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will increase in absolute dollars for the foreseeable future, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, and regulatory functions as well as costs associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Income (Expense), Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income (expense), net consists of interest earned on our cash, cash equivalents, and marketable securities, net of investment management fees and interest on additional tenant improvement allowances drawn on our operating leases.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Income (Expense), Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense), net consists of realized and unrealized gains and losses on foreign currency transactions.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of the three months ended March 31, 2026 and 2025</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.37%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.182%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.182%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.942%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.662%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,047</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,587</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,460</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,290</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,796</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,494</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,337</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,383</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,954</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(87,337</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(71,383</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,954</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income (expense), net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,380</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,160</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,220</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(95</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(82,958</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(68,243</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,715</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.37%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.182%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.182%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.942%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.662%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and engineering</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,483</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,627</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,144</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,564</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,960</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,604</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N.M.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,047</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,587</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,460</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $70.0 million for the three months ended March 31, 2026 compared to $56.6 million for the three months ended March 31, 2025, an increase of $13.5 million, or 24%. Direct research and development expenses increased $8.7 million as we advanced our clinical trial activity, and a $5.0 million milestone payment related to our collaboration agreement with Impact was recognized and paid during the quarter ended March 31, 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not allocate our internal research and development expenses by individual projects. With respect to our external programs, we allocate some project-specific research and development expenses by vendor, but we do not allocate such expenses to each project specifically where it relates to more than one project. As a result, we do not provide a project-by-project breakdown of research and development expenses, as the majority of such expenses have not been allocated by individual projects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.38%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.944%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.645%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,290</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,796</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,494</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $17.3 million for the three months ended March 31, 2026, compared to $14.8 million for the three months ended March 31, 2025, an increase of $2.5 million, or 17%. This increase was primarily due to $1.6 million higher depreciation expense following the occupation of our Millbrae headquarters in April 2025, and $0.8 million higher professional fees, mainly from recruiting and professional service fees and insurance expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Income (Expense), Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income (expense), net was $4.4 million for the three months ended March 31, 2026 compared to $3.2 million for the three months ended March 31, 2025, an increase of $1.2 million, or 39%. This increase was primarily due to higher average investment balances following our initial public offering in February 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have primarily funded our operations through the sale of shares of our redeemable convertible preferred stock and more recently, through our initial public offering. We have not generated any revenue from product sales and have incurred significant annual operating losses and negative cash flows from our operations.</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2026, we had $596.0 million in cash, cash equivalents, and marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 6, 2026, we closed our initial public offering and issued 21,177,600 shares of our common stock at a price of $18.00 per share for net proceeds of approximately $348.1 million, after deducting underwriting discounts and commissions of $26.7 million and expenses of $6.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Funding Requirements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that we will continue to incur significant and increasing expenses for the foreseeable future as we continue to advance our product candidates, expand our corporate infrastructure (including the costs associated with being a public company), further our research and development initiatives for our product candidates, incur costs associated with our efforts to discover new targets and product candidates both organically and inorganically, engage in future collaborations, and support the potential commercialization of our product candidates, if approved. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional financing to fund our continuing operations, which consist primarily of research, engineering, and development expenditures related to our discovery and clinical programs, and general and administrative expenditures. Cash used to fund operating expenses is affected by the time at which we recognize these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses, and prepaid expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant annual operating losses and negative cash flows since our inception. As of March 31, 2026, we had an accumulated deficit of $1.0 billion. Based on our current operating plan, we estimate that our existing cash, cash equivalents, and marketable securities as of the date of this Quarterly Report will be sufficient to fund our operating expenses and capital expenditures for at least the next 12 months from the issuance of the unaudited condensed financial statements included elsewhere in this Quarterly Report and into the second half of 2027. We have based this estimate on our current assumptions, which may prove to be wrong, and we may exhaust our available capital resources sooner than we expect.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our forecast of cash resources and planned operations involves risks and uncertainties, and the actual amount of expenses could vary materially as a result of a number of factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results, and costs of drug discovery, engineering, preclinical development, laboratory testing, and planned clinical trials for our current or future product candidates, including additional expenses attributable to adjusting our development plans;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, prioritization, and number of our research and development programs and clinical trials required for regulatory approval of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing, and outcome of regulatory review of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing clinical and commercial supplies of our current or future product candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish or maintain collaboration or license agreements and the achievement of milestones or occurrence of other developments that trigger payments under any existing or additional collaboration or license agreements, and our ability to identify and enter into future license agreements and collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with acquiring or licensing additional product candidates, technologies, or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our licenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of continuing to invest in our drug discovery efforts and tools designed to identify novel targets and drugs, including our technology platform;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential increase in the number of our employees and expansion of our physical facilities to support preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company, including expenses related to legal, accounting, and regulatory activities, as well as costs associated with director and officer insurance premiums, investor relations support, and maintaining compliance with exchange listing and SEC requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of securing manufacturing arrangements for clinical and commercial production and establishing or contracting for sales and marketing capabilities, if we obtain regulatory clearances to market our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of competing technological and market developments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and fulfillment, for any of our product candidates for which we receive marketing approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve sufficient market acceptance, adequate coverage, and reimbursement from third-party payors, and sufficient market share and revenue for any approved products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of inflation and tariffs, as well as other factors, including economic uncertainty and geopolitical tensions, which may exacerbate the magnitude of the factors discussed above.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through public or private equity or debt financings, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements with third parties, or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing to support our business plans when needed on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional capital through collaboration or licensing arrangements with third parties or other strategic transactions, we may have to relinquish rights to our intellectual property, discovery tools, future revenue streams, research programs, or product candidates, or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise capital as and when needed, or on attractive terms, we may have to significantly delay, reduce, or discontinue the development and commercialization of our product candidates, scale back or terminate our pursuit of new in-licenses, or a combination of the above, any of which may have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of the three months ended March 31, 2026 and 2025</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our primary sources and uses of cash for the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:46.54%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.040000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.040000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.52%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands except percentages)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(89,801</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54,521</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35,280</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(203,217</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(213,854</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,637</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">349,308</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,234</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(926</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in cash, cash equivalents<br/>&#160;&#160;&#160;and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,290</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,859</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25,569</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(31</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the three months ended March 31, 2026 was $89.8 million, which resulted from a net loss of $83.0 million and a net increase in our operating assets and liabilities of $13.9 million, partially offset by non-cash charges of $7.1 million. The net increase in our operating assets and liabilities was primarily the result of a $15.1 million decrease in accrued expenses and other current liabilities from the payment of our 2025 corporate bonuses. Non-cash charges primarily consisted of $5.2 million of depreciation and $2.8 million of stock-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the three months ended March 31, 2025 was $54.5 million, which resulted from a net loss of $68.2 million, partially offset by non-cash charges of $8.2 million and a net decrease in our operating assets and liabilities of $5.5 million. Non-cash charges primarily consisted of $3.8 million of depreciation and $3.0 million of stock-based compensation and the net decrease in our operating assets and liabilities was primarily the result of a $16.0 million increase in operating lease liabilities, partially offset by a $9.4 million decrease in accrued expenses and other current liabilities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for the three months ended March 31, 2026 was $203.2 million, which primarily consisted of $307.0 million of purchases of marketable securities and $0.3 million of payments for property and equipment purchases, partially offset by $104.0 million of proceeds from the maturities of our marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for the three months ended March 31, 2025 was $213.9 million, which primarily consisted of $252.5 million of purchases of marketable securities and $22.4 million of payments for property and equipment purchases, partially offset by $61.0 million of proceeds from the maturities of our marketable securities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the three months ended March 31, 2026 was $349.3 million, from net proceeds of $349.0 million from our initial public offering of common stock and $0.3 million from stock option exercises.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the three months ended March 31, 2025 was $350.2 million, primarily related to the net proceeds from the issuance of redeemable convertible preferred stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Collaboration Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below is a summary of the key terms for certain of our license and collaboration agreements. For a more detailed description of these agreements, see the section of our Annual Report on Form 10-K for the year ended December 31, 2025 titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration and License and Development Agreements with Seven and Eight and SW</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 29, 2023, we entered into an Exclusive Collaboration Agreement, or the Seven and Eight Collaboration Agreement, with Seven and Eight Biotherapeutics Corp. and related entities, collectively known as Seven and Eight, and an Exclusive License and Development Agreement, or the SW License Agreement, with Seven and Eight and Superb Wisdom Limited, or SW. Under each agreement, Seven and Eight and SW granted us a worldwide, exclusive license under certain of their patents, know-how, and other intellectual property rights to develop and commercialize certain toll-like receptor 7 and 8 agonist product candidates, including our product candidate, EIK1001.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We paid Seven and Eight and SW aggregate upfront payments of $11.0 million in cash ($10.5 million to Seven and Eight and $0.5 million to SW), and issued two Simple Agreements for Future Equity, or SAFEs, equal to $35.0 million ($31.5 million to Seven and Eight and $3.5 million to SW) upon entering into the applicable agreement. The SAFEs automatically converted into Series C redeemable convertible preferred stock upon the initial closing of the Series C financing round in May 2023, which then converted into common stock upon the closing of our initial public offering. We have also agreed to pay Seven and Eight additional milestone payments in the amount of up to approximately $369.6 million, of which $219.6 million are payable for a compound that is not a conjugate and $150.0 million for a compound that is a conjugate, in each case upon the achievement of certain development and regulatory milestones. EIK1001 is a compound that is not a conjugate. We have also agreed to pay SW additional milestone payments in the amount of up to $29.4 million and up to $350.0 million upon the achievement of certain regulatory and commercial milestones, respectively. No future milestones were accrued as of March 31, 2026 as such milestones were not achieved or probable of being achieved at that date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Agreement with Impact</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 10, 2023, we entered into a Collaboration Agreement, which was amended and restated on November 22, 2023, and further amended on December 12, 2024, or, collectively, the Impact Agreement, with Impact Therapeutics (Shanghai) Inc., or Impact. Pursuant to the Impact Agreement, we received an exclusive license under certain of Impact&#8217;s patents, know-how, and regulatory information to develop and commercialize any selective PARP1 inhibitors owned or controlled by Impact or its affiliates, including our product candidates EIK1003 and EIK1004, and any pharmaceutical products comprised of or containing such inhibitors, on a worldwide basis excluding China, Hong Kong, Taiwan, and Macau.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We paid an upfront fee of $31.5 million in cash to Impact. We are also required to make payments to Impact of up to $181.0 million and up to $775.0 million upon the achievement of certain development and regulatory milestones and commercial milestones, respectively. In addition, tiered royalties of high single-digit to low-teen percentages of net sales per calendar year, subject to certain reductions, are also payable by us to Impact post-commercialization. We have paid Impact $13.5 million in development and regulatory milestones as of March 31, 2026, including $5.0 million in the three months then ended.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement with MSD</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into Clinical Trial Collaboration and Supply Agreements, or the MSD Agreements, with MSD International Business GmbH, or MSD, for three separate studies: (i) the Phase 2/3 registrational study of EIK1001 in patients with advanced melanoma (dated August 1, 2024); (ii) the Phase 1/2 clinical trial of EIK1005 in patients with advanced solid tumors (dated December 3, 2025); and (iii) the Phase 2/3 registrational study of EIK1001 in patients with NSCLC (dated December 5, 2025). Pursuant to the MSD Agreements, we and MSD agreed to collaborate on these clinical trials evaluating the safety and efficacy of our compounds in combination with MSD&#8217;s compound, pembrolizumab. Under the MSD Agreements, we act as the sponsor of the clinical trials at our own costs and MSD has agreed to supply to us, at its own cost, pembrolizumab for use in such trials. Pursuant to the MSD Agreements, we and MSD must each use commercially reasonable efforts to supply our applicable compounds for use in the portions of the clinical trials in which patients are intended to receive pembrolizumab either alone or in combination with one or more treatments, in accordance with the applicable study protocol.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, we entered into an operating lease agreement for our corporate headquarters located in Millbrae, California, expiring in 2040. We are also party to several operating leases for office and lab space in Hayward, California, New York, New York, and Jersey City, New Jersey. As of March 31, 2026, our non-cancellable lease obligations were $551.6 million under our operating leases, of which $31.0 million are due in the remainder of 2026. Refer to Note 6 to our unaudited condensed financial statements included elsewhere in this Quarterly Report for more information on our lease obligations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and Collaboration Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into license and collaboration agreements in the normal course of business in order to obtain rights to promising product candidates, advance product development, and obtain technologies and services related to our business. For example, our product candidates, EIK1001, EIK1003, and EIK1004, were in-licensed pursuant to license and collaboration agreements with third parties. We could be required to make payments related to development and regulatory milestones of up to $630.0 million, and sales milestones of at most $1.1 billion, alongside tiered royalty payments to licensors based on the net sales of the licensed products of high single-digit to low-teen percentages. We cannot estimate when such payments will be due. To date, we have incurred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$93.0 million in upfront and milestone payments under these agreements. See Notes 10 and 11 to our unaudited condensed financial statements included elsewhere in this Quarterly Report for additional details on our material agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Estimates and Policies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates and assumptions could occur in the future. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they became known. Actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our significant accounting policies are described in more detail in Note 2 to our unaudited condensed financial statements included elsewhere in this Quarterly Report, we believe that the following accounting estimates are those most critical to the judgments and estimates used in the preparation of our financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are charged to expense as incurred. These expenses consist of compensation expenses, direct research and development expenses, such as software development costs related to research and development activities, laboratory supplies, costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation, other miscellaneous expenses, and allocations of facilities and information technology expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record accrued liabilities for estimated costs of our research and development activities conducted by third-party service providers. We accrue these costs based on factors such as estimates of the work completed and in accordance with the third-party service agreements. If we do not identify costs that have begun to be incurred or if we underestimate or overestimate the level of services performed or the costs of these services, actual expenses could differ from the estimates. To date, we have not experienced any material differences between accrued costs and actual costs incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, and are classified as current or non-current prepaid expenses and other assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We make payments in connection with clinical trials to contract manufacturing organizations that manufacture the materials for our product candidates, and to clinical research organizations and clinical trial sites that help to conduct and manage our clinical trials. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in payments that do not match the periods over which materials or services are provided. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time-and-materials basis. We make estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. We confirm the accuracy of our estimates with the service provider, and make adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards issued to employees and nonemployees, we measure the estimated fair value of the stock-based awards on the date of grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective awards. We record the expense for awards with service-based vesting using the straight-line, ratable attribution method and account for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. We estimate our expected stock volatility based on the historical volatility of a publicly traded set of peer companies, and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded stock price. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#8217; vesting terms and contractual terms, as we do not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify stock-based compensation expense in our statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s cash compensation costs are classified.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate the fair value of our common stock underlying stock options on the date of grant. This has historically been determined by management with assistance from external appraisers and approved by our Board. Due to the absence of an active market for our common stock prior to our initial public offering, we utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock valuations prior to May 31, 2025 were performed using the Option Pricing Method, or OPM, as it was deemed the most appropriate method based on our stage of development and other relevant factors. Within the OPM framework, the backsolve method for inferring the total equity value implied by a recent financing transaction involves the construction of an allocation model that takes into account the entity&#8217;s capital structure and the rights, preferences, and privileges of each class of stock, then assumes reasonable inputs for the other OPM variables (inclusive of discount for lack of marketability, volatility, the expected time to liquidity, and risk-free rate). The total equity value is then iterated in the model until the model output value for the equity class sold in a recent financing round equals the price paid in that round. The OPM is generally utilized when specific future liquidity events are difficult to forecast (i.e., the enterprise has many choices and options available), and the enterprise&#8217;s value depends on how well it follows an uncharted path through the various possible opportunities and challenges. Among other factors considered are the entity&#8217;s financial position and historical financial performance, the status of technological developments within the entity&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the entity&#8217;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock, common stock warrants and redeemable convertible preferred stock valuations from May 31, 2025 through the date of our initial public offering were performed using a hybrid method that combines the OPM and the probability-weighted expected return method, or PWERM. The PWERM employs additional information not used in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an initial public offering or sale of the enterprise, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of our common stock and redeemable convertible preferred stock is then applied to arrive at an indication of value for the common stock and redeemable convertible preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the initial public offering, the fair value of our common stock underlying stock options is based on the closing market price of our common stock on the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: (i) being permitted to present only two years of audited financial statements in our periodic reports and proxy statements, in addition to any required unaudited condensed financial statements, with correspondingly reduced &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; disclosure in this Quarterly Report, (ii) reduced disclosure about our executive compensation arrangements, (iii) not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden parachute arrangements not previously approved, (iv) an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, and (v) being permitted to take advantage of an extended transition period for complying with new or revised accounting standards, which allows us to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may take advantage of these exemptions until we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years, or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these exemptions. We have elected not to &#8220;opt out&#8221; of the extended transition period for new or revised accounting standards described above and have elected to avail ourselves of the exemption from the requirement to communicate critical audit matters, or CAMs. As a result of these decisions, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates, and include a discussion of their CAMs. We may choose to adopt any new or revised accounting standards whenever early adoption is permitted for private companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company,&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company if either (i) the market value of our common stock held by non-affiliates is less than $250.0 million, or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Reports on Form 10-K, and we have reduced disclosure obligations regarding executive compensation.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is provided in Note 2 to our unaudited condensed financial statements included elsewhere in this Quarterly Report.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 3. Quantitative and Qualitative Disclosures About Market Risk.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Rate Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary objectives of our investment activities are to ensure liquidity and to preserve capital. As of March 31, 2026, we had $148.1 million in cash equivalents, comprising interest bearing money market accounts, and $434.9 million in marketable securities. Our exposure to interest rate sensitivity is affected by changes in the underlying bank interest rates. We have not entered into investments for trading or speculative purposes, and our marketable securities are held to maturity. Although an immediate, one percentage point change in interest rates would have a material effect on the fair market value of our portfolio due to the size of our portfolio, because held-to-maturity investments are reported at amortized cost, we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates. As of March 31, 2026, we had no debt outstanding that is subject to interest rate variability. Therefore, we are not subject to interest rate risk related to debt.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency Exchange Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees and our operations are currently predominantly located in the United States and our expenses are generally denominated in U.S. dollars. However, we do use research and development vendors outside of the United States. As such, our expenses are denominated in both U.S. dollars and foreign currencies. All monetary assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Non-monetary assets and liabilities are translated using the exchange rate that was in effect when the asset or liability was initially recognized. Expenses are translated at the average exchange rates prevailing during the applicable period. Our operations are, and will continue to be subject to fluctuations in foreign currency exchange rates. Foreign currency transaction gains and losses are included in other income (expense), net in the condensed statements of operations and comprehensive loss as incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. We do not believe that a hypothetical 10% increase or decrease in exchange rates during any of the periods presented would have had a material effect on our condensed financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also exposed to inflation risk and inflationary factors, such as increases in service, material, and overhead costs, which could impair our operating results. Although we do not believe that inflation has had a material impact on our financial position or operating results to date, a high rate of inflation in the future may have an adverse effect on our business, results of operations, or financial condition, or on our financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 4. Controls and Procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain "disclosure controls and procedures," as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management is required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2026, our disclosure controls and procedures were not effective because of the material weakness described below.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Weakness in Internal Control over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. We did not design and maintain effective controls related to the evaluation of the accounting considerations for complex terms in lease arrangements. The material weakness resulted in the restatement of our condensed balance sheet and condensed statement of cash flows as of and for the nine months ended September 30, 2025. Additionally, this material weakness could result in misstatements to lease-related accounts or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remediation Plan for Material Weakness in Internal Control over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are taking steps to remediate the material weakness and to strengthen our internal control over financial reporting. The material weakness will not be considered remediated until management completes the design and implementation of the controls and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II&#8212;OTHE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R INFORMATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 1. Legal Proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 1A. Risk Factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An investment in our common stock involves a high degree of risk. In deciding whether to invest, you should carefully consider and read the following risk factors, as well as the financial and other information contained herein and in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, or SEC, on March 30, 2026, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. Any of the following risks could have a material adverse effect on our business, financial condition, results of operations, or prospects and cause the value of our stock to decline, which could cause you to lose all or part of your investment. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business, Limited Operating History, and Financial Position</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a late clinical-stage biotechnology company with a limited operating history and a history of incurring substantial net losses, have no products approved for commercial sale, have never generated revenue from product sales, and may never achieve or maintain profitability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late clinical-stage biotechnology company with a limited operating history. Consequently, it may be more difficult to evaluate our business, and predictions about our future may not be as accurate as they could be if we had a longer operating history. We were formed in July 2019 and have devoted substantially all of our resources since that time to research, engineering, and development activities, including the clinical development of our clinical-stage product candidates EIK1001, EIK1003, and EIK1004, which were in-licensed, and EIK1005, and other preclinical programs, the development of our technology platform, including the engineering of the hardware, software, reagents, and processes that we use to conduct single molecule tracking and other techniques, recruiting management and technical staff, developing and establishing our intellectual property portfolio, entering into collaboration agreements to further our development programs, building our facilities, including our site in Millbrae, California, infrastructure to support such activities, and raising capital. We are currently conducting a Phase 2/3 registrational trial for EIK1001 in combination with pembrolizumab for the treatment of patients with advanced melanoma. For patients with non-small cell lung cancer, or NSCLC, we are conducting a Phase 2 trial, and recently initiated site selection for a Phase 2/3 registrational trial, for EIK1001 in combination with pembrolizumab and chemotherapy. For EIK1003, we are conducting a Phase 1/2 trial in ovarian, breast, prostate, and pancreatic cancers. We have also recently initiated Phase 1/2 trials for EIK1004 and for EIK1005. The rest of our programs remain in preclinical development.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to incur significant research, development, and other expenses related to our ongoing operations. The success of our business depends primarily upon our ability to identify, develop, and commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any products approved for sale and have not generated any revenue from product sales to date. We do not know whether we will be able to develop any product candidates of commercial value. We do not expect to generate product revenues unless and until we obtain marketing approval for a product candidate. We have not yet submitted an application for marketing approval for a product candidate in any jurisdiction. Investing in biotechnology product development is highly speculative because of the significant risk that, despite significant investment, any potential product candidate may fail to demonstrate adequate effectiveness or an acceptable safety profile, gain regulatory approval, or become commercially viable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses since our inception. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. For the three months ended March 31, 2026 and 2025, we reported a net loss of $83.0 million and $68.2 million, respectively. As of March 31, 2026, we had an accumulated deficit of $1.0 billion. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue research and development efforts for our product candidates, advance our product candidates through preclinical studies and clinical trials, and seek regulatory approvals.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that our expenses will increase substantially as we:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to progress the clinical development of our product candidates, including our four most advanced product candidates: EIK1001, EIK1003, EIK1004, and EIK1005, and our preclinical development of EIK1006;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">invest in our target selection and drug screening programs and develop any additional product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and expand the manufacturing of preclinical and clinical supply of our current and future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approvals for any of our current product candidates or any future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing, manufacturing, and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attract, hire, and retain qualified clinical, scientific, operations, commercial, and management personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add and maintain operational, financial, and information management systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain, protect, maintain, enforce, defend, and expand our intellectual property and other proprietary rights, or acquire or in-license intellectual property, and other proprietary rights and technologies, from third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience any delays in our preclinical studies or clinical trials, or regulatory approval for our product candidates, including as a result of delays in patient enrollment as well as macroeconomic conditions, geopolitical conflicts, or other factors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional legal, accounting, or other expenses in operating our business, including the costs associated with operating as a public company.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing, and selling products if we obtain marketing approval, obtaining market acceptance for such products, and satisfying any post-marketing requirements from the United States Food and Drug Administration, or FDA, and/or foreign regulatory authorities. We may not succeed in any or all of these activities and, even if we do, we may not generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company, and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We also may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business, financial condition, results of operations, and prospects. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require substantial additional capital to finance our operations and achieve our business objectives. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce, or eliminate one or more of our research and product development programs or future commercialization efforts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive, and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since our inception. We expect to continue to incur substantial expenditures to advance our current and future preclinical and clinical development programs, and seek regulatory approval for our product candidates. In addition, even if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution. Furthermore, we will incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional capital in connection with our continuing operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because the design and outcome of our planned and anticipated preclinical studies and clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements will depend on, and could increase significantly as a result of, many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results, and costs of drug discovery, preclinical development, and planned clinical trials for our current or future product candidates, including additional expenses attributable to adjusting our development plans;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, prioritization, and number of our research and development programs and clinical trials required for regulatory approval of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing, and outcome of regulatory review of our current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish or maintain collaboration, license, or other similar agreements, and the achievement of milestones or occurrence of other developments that trigger payments or other obligations under any existing or additional collaboration, license, or similar agreements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with acquiring or licensing additional product candidates, technologies, or assets, including the timing and amount of any milestones, royalties, or other payments due in connection with acquisitions and licenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing, and prosecuting patent applications, obtaining, maintaining, and enforcing our intellectual property and other proprietary rights, and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of continuing to invest in our technology platform, including our proprietary single molecule tracking, or SMT, system, and our drug discovery efforts to identify novel targets and drug candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company, including our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of securing manufacturing arrangements for clinical and commercial production and establishing or contracting for sales and marketing capabilities, if we obtain regulatory clearances to market our current or future product candidates, including the cost of any third-party products used as combination agents in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of future commercialization activities, including marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage, and adequate reimbursement from third-party payors, and adequate market share and revenue for any approved products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage or adequate reimbursement from third-party payors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of inflation, as well as other factors, including economic uncertainty and geopolitical tensions, which may exacerbate the magnitude of the factors discussed above.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time as we can generate significant revenue from sales of our product candidates, if ever, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other sources. Our ability to raise additional funds will be dependent on financial, economic and market conditions, geopolitical issues, and other factors, over which we may have limited or no control. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy. As a result, we may have to delay, reduce the scope of, suspend, or eliminate one or more of our research-stage programs, clinical trials, or future commercialization efforts.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or current or future product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we believe that we will have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if there are specific strategic considerations for doing so. To the extent that we raise such additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring and distributing dividends, and may be secured by all or a portion of our assets.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise funds by entering into collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms, including royalties, that may not be favorable to us, any of which may harm our business, financial condition, results of operations, and prospects. See the risk factors in this Quarterly Report titled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on license, collaboration, and other similar agreements to provide rights to the core intellectual property relating to most of our current product candidates, including our most advanced product candidate, EIK1001. These agreements impose significant milestone payments and other obligations on us. If we fail to comply with the obligations of our current or any future license, collaboration, or other similar agreements for our product candidates, or otherwise experience disruptions to our business relationships with our current or future licensors or collaborators, we could lose license or other rights that are important to our business, and hence lose the ability to continue the development and commercialization of our product candidates, if approved</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have entered, and may in the future enter, into additional collaboration arrangements, which are important to our business. If we are unable to enter into new collaborations, or if we fail to realize the benefits of any current or future collaboration arrangements, our business, financial condition, results of operations, and prospects could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our research, product development, or future commercialization efforts, or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business depends entirely on the success of our product candidates and development programs, including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006, and we cannot guarantee that any or all of our current or future product candidates will successfully complete clinical development, receive regulatory approval, or be successfully commercialized. If we are unable to develop, receive regulatory approval for, and successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no products approved for commercial sale or for which regulatory approval to market has been sought. We have invested the majority of our efforts and financial resources in the identification of our product candidates and their development programs, each of which is still in preclinical or clinical development, and expect that we will continue to invest heavily in the development of these product candidates, as well as in any future product candidates we may develop. Our business and our ability to generate revenue are substantially dependent on our ability to develop, obtain regulatory approval for and, if approved, successfully commercialize our product candidates, which may never occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and development programs will require substantial additional preclinical and clinical development time, regulatory approval, commercial manufacturing arrangements, the establishment of a commercial organization, significant marketing efforts, and further investment before we may generate any revenue from product sales. We cannot assure you that we will meet our timelines for our current or future clinical trials, which may be delayed or not completed for a number of reasons. Our product candidates are susceptible to the risks of failure inherent at any stage of preclinical and clinical development, including the appearance of unexpected adverse events or failure to achieve the designated endpoints of our clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our product candidates are successful in clinical trials, we will not be permitted to market or promote any of our product candidates until we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval to allow us to successfully commercialize any product candidates. If we do not receive FDA or comparable foreign regulatory approval with the necessary conditions to allow commercialization, we will not be able to generate revenue from those product candidates in the United States or elsewhere in the foreseeable future, or at all. Any significant delays in obtaining approval for and commercializing our product candidates could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or comparable foreign regulatory authorities may also consider their approvals of competing products concurrently with their review of our new drug applications, or NDAs, investigational new drug applications, or INDs, or other submissions. That review may lead to changes in the review requirements that had been previously communicated to us and our interpretation thereof, including changes to requirements for clinical data or clinical trial design. Such changes could delay approval or necessitate the withdrawal of our NDAs, INDs, or other submissions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are approved for marketing by applicable regulatory authorities, our ability to generate revenue from any approved products will depend on our ability to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receive regulatory approval for the targeted patient populations, and the ability to make claims that are necessary or desirable for successful marketing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture products ourselves or through contract manufacturing organizations, or CMOs, in sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price our products competitively such that third-party and government reimbursement supports broad product adoption;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrate the superiority of our products compared to the standard of care, as well as other therapies in development;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create market demand for our products through our own marketing and sales activities, and any other arrangements to promote these products that we may otherwise establish;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish and maintain agreements with wholesalers, distributors, pharmacies, and group purchasing organizations on commercially reasonable terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain, maintain, protect, enforce, and defend patent and other intellectual property and proprietary rights and regulatory exclusivity for our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain compliance with applicable laws, regulations, and guidance specific to commercialization, including interactions with healthcare professionals, patient advocacy groups, and communication of healthcare economic information to payors and formularies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieve market acceptance of our products by patients, the medical community, and third-party payors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain a distribution and logistics network capable of product storage within our specifications and regulatory guidelines, and further capable of timely product delivery to commercial clinical sites; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ensure that our product will be used as directed and that additional unexpected safety risks will not arise.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in applying our technology platform to identify or develop safe, effective, or commercially viable product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our technology platform is central to our belief that by quantitating the dynamics of proteins in their full, living, cellular context, we can improve the speed and probability of success of drug development, as well as the identification of clinically relevant biomarkers. Our technology platform is centered around our proprietary SMT system, integrating tools such as custom-engineered super-resolution microscopy, bespoke automation, advanced data science, and software packages capable of processing petabyte-scale datasets. While we believe that we can generate important scientific insights by understanding protein behavior at a molecular level inside intact living cells from human cell lines, thereby accelerating the identification of novel agents that would prove clinically valuable, EIK1005 is the only product candidate in clinical development that has leveraged our technology platform. Rights related to all other clinical-stage products candidates are in-licensed. EIK1006, which also leveraged our technology platform, is still in preclinical studies and it is possible that it may not advance to clinical trials. There can be no certainty that our technology platform will lead to the identification of clinically relevant biomarkers or additional clinical product candidates, or improve the speed and probability of success of drug development in the manner which we expect, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our technology platform depends upon the continuous, effective, and reliable operation of our software, hardware, databases, and related tools and functions, as well as the integrity of our data. Our ability to develop drug candidates depends in large part on our ability to enhance and improve our platform. The success of any enhancement to our platform depends on several factors, including (i) innovation in hardware solutions, (ii) increased computational storage and processing capacity, (iii) development of more advanced algorithms, and (iv) generation of additional biological and chemical data, such as that which underpins our ability to identify important and emerging use cases, and to quickly develop new and effective innovations that address those use cases.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested, and expect to continue to invest, in research and development efforts that further enhance our technology platform. These investments may involve significant time, risks, and uncertainties, including the risks that any new software, biological, chemical, or hardware enhancement, or the integration of software or hardware from third-party licensors, may not be introduced in a timely or cost-effective manner, may not keep pace with technological developments, or may not achieve the functionality necessary to generate significant insights to improve the speed or probability of drug discovery or development. Moreover, similar technologies may be developed that provide significant advantages over ours, which could adversely affect the return from the investment in our technology platform.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our proprietary software tools, hardware, and datasets are inherently complex. We have from time to time found defects, vulnerabilities, or other errors in our software and hardware that produce the datasets we use to discover new drug candidates, and new errors with our software and hardware may be detected in the future. The risk of errors is particularly significant when new software or hardware is first introduced, or when new versions or enhancements of existing software or hardware are implemented. Errors may also result from the interface of our proprietary software and hardware tools with our data or with third-party systems and data. Any errors, defects, disruptions, or other performance problems with our software, hardware, or datasets could hurt our ability to gather valuable insights that we intend to use to assist in developing our current and future product candidates and hence accelerate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our discovery of new drugs. We have experienced and expect that in the future we may again experience interruptions, delays, and outages in service and availability from time to time due to a variety of factors, including infrastructure changes, human or software errors, website hosting disruptions, and capacity constraints. See the risk factor in this Quarterly Report titled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems, or those used by our CROs, CMOs, clinical sites, or other contractors, consultants, or third parties with whom we work, or our data are or were compromised, including by system failures, security incidents, or loss or leakage of data, or otherwise disrupted, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or action, litigation, fines and penalties, disruptions of our business operations, reputational harm, and other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully enhance our technology platform, or if there are any defects or disruptions in our technology platform that are not timely resolved, our ability to identify and develop new product candidates could be materially and adversely impacted, and our reputation, business, operating results, and prospects could be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our technology platform performs its intended functions, we may be unable to use the discoveries resulting from the platform to produce new therapies. If we are unable to use our platform to develop and market new drugs or therapies, our business may fail or we may never become profitable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent on the services of our key leaders, and our future success depends on our ability to retain these individuals and to attract and retain qualified personnel.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent upon Roger M. Perlmutter, M.D., Ph.D., our Chief Executive Officer, and Roy Baynes, M.D., Ph.D., our Chief Medical Officer, and losing the services of either of these individuals could delay or prevent the successful development of our product candidates, the initiation or completion of our preclinical studies and clinical trials, or the commercialization of our product candidates. The employment agreements of both officers with us are terminable by them at will and, therefore, we may not be able to retain their services as expected. We currently do not maintain &#8220;key person&#8221; insurance for any of our executives or employees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success also depends in part on our continued ability to attract, retain, and motivate highly qualified management and clinical and scientific personnel. We may not be successful in continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biopharmaceutical, biotechnology, and other businesses and academic institutions. If we are not able to attract, integrate, retain, and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of such objectives, our ability to raise additional capital, and our ability to implement our business strategy.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We use AI/ML to enable our analysis of the internal data generated from our technology platform, and for certain other uses in connection with our business. Defects in, or loss of access to, our data may impair our ability to discover or develop targets or product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use artificial intelligence, or AI, and machine learning, or ML, to enable our analysis of the data generated through our technology platform. We also use, and may in the future use, AI/ML to perform other tasks in connection with our business. If access to this data is lost or limited, it may delay or otherwise adversely affect our ability to develop our product candidates. Our competitors may render our approach obsolete, by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The occurrence of any of these events could prevent us from leveraging our AI/ML capability and software to help us identify potential product candidates through our technology platform and have a material adverse effect on our business, financial condition, results of operations, or prospects. See the risk factor in this Quarterly Report titled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems, or those used by our CROs, CMOs, clinical sites, or other contractors, consultants, or third parties with whom we work, or our data are or were compromised, including by system failures, security incidents, or loss or leakage of data, or otherwise disrupted, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or action, litigation, fines and penalties, disruptions of our business operations, reputational harm, and other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While not directly related to our AI/ML capabilities, other uses of AI systems have additional risks, including around generative AI. Although AI systems may help provide more tailored experiences, if the content, analyses, or recommendations that AI systems assist in producing in our technology platform are, or are perceived to be, deficient, inaccurate, biased, unethical, or otherwise flawed, our reputation, competitive position, and business may be materially and adversely affected. To the extent that we do not have sufficient rights to use the data or other material or content used in or produced by the AI tools used in our business, or if we experience cybersecurity incidents in connection with our use of AI, it could adversely affect our reputation and expose us to legal liability or regulatory risk, including with respect to third-party intellectual property, privacy, data protection and cybersecurity,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publicity, contractual, or other rights. In addition, the regulatory framework for AI and similar technologies, and automated decision making, is changing rapidly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the utilization of AI/ML becomes more prevalent, we anticipate that it will continue to present new or unanticipated ethical, reputational, technical, operational, legal, competitive, and regulatory issues, among others. Because these technologies are themselves highly complex and rapidly developing, it is not possible to predict all of the legal or regulatory risks that may arise relating to our use of such technologies. We expect that the continued incorporation of AI/ML in our business will require additional resources, including the accumulation of additional costs, to develop and maintain our technology and features to minimize potentially harmful or unintended consequences, to comply with applicable and emerging laws and regulations, to maintain or extend our competitive position, and to address any ethical, reputational, technical, operational, legal, competitive, or regulatory issues which may arise as a result of any of the foregoing. As a result, the challenges presented with our use of AI/ML could adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any product candidates, which could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we conduct clinical trials of our current or future product candidates, we are exposed to significant product liability risks inherent in the development, testing, manufacturing, and marketing of new treatments, and we face an even greater risk if we commercialize any products we may develop. Product liability claims could delay or prevent completion of our development programs. Regardless of the merits or eventual outcome, product liability claims may result in decreased demand for our product candidates, termination of clinical trial sites or entire trial programs, withdrawal of clinical trial participants, initiation of investigations by regulators, injury to our reputation and significant negative media attention, significant time and costs to defend the related litigation, a diversion of management&#8217;s time and our resources from our business operations, substantial monetary awards to trial participants or patients, loss of revenue, the inability to commercialize products that we may develop, and a decline in our stock price. While we currently hold product liability insurance coverage, we may need to obtain higher levels of product liability insurance for later stages of clinical development or marketing any of our product candidates. Any insurance we may obtain to cover product liability or other claims may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability or other claims that could adversely affect our business, financial condition, results of operations, and prospects. A successful product liability claim or series of claims brought against us could decrease our cash and could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, contract research organizations, or CROs, consultants, commercial partners, and vendors. Misconduct by these parties could include failures to comply with FDA regulations or comparable foreign regulations, to provide accurate information to the FDA or comparable foreign regulatory authorities, to comply with federal, state, or foreign healthcare fraud and abuse laws and regulations, to comply with manufacturing standards we have established, to report financial information or data on time, completely or accurately, to disclose unauthorized activities to us, or to comply with comparable foreign requirements. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid or comparable foreign equivalents, additional integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have entered, and may in the future enter, into additional collaboration arrangements, which are important to our business. If we are unable to enter into new collaborations, or if we fail to realize the benefits of any current or future collaboration arrangements, our business, financial condition, results of operations, and prospects could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key part of our strategy is to strategically evaluate and, as we deem appropriate, enter into collaborations or partnerships, including with major biotechnology or pharmaceutical companies, to advance our current or future product candidates. We have entered into collaborations with Seven and Eight Biotherapeutics Corp. and related entities, collectively known as Seven and Eight,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Superb Wisdom Limited, or SW, Impact Therapeutics (Shanghai) Inc., or Impact, and MSD International Business GmbH, or MSD, to conduct various research and development activities. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may in the future continue to enter into collaborations with other companies to partner with and/or provide us with funding for our programs and technology. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. Further, any of our existing or future collaborations that we enter into may not be successful. The success of our collaboration arrangements now or in the future will depend heavily on the efforts and activities of our collaborators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current collaborations and any future collaborations we enter into pose a number of other risks, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may have significant discretion in determining the efforts and resources that they will apply;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not perform their obligations as expected;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial or test results, changes in the collaborators&#8217; strategic focus, or available funding or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may own or co-own intellectual property covering our product candidates that results from our collaboration with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution, or marketing of a product candidate or product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators with marketing, manufacturing, and distribution rights to one or more of our product candidates that achieve regulatory approval, if any, may not commit sufficient resources to or otherwise may not perform satisfactorily in carrying out the marketing and distribution of such product or products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws, resulting in civil or criminal proceedings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to invest resources and attention into such collaborations, which could distract from other business objectives;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreements with collaborators, including disagreements over intellectual property and other proprietary rights, contract interpretation, or the preferred course of development, might cause delays or terminations of the research, development, or future commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may seek to amend or modify the terms of, or terminate, any collaboration;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in such a way as to invite actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may infringe the intellectual property or other proprietary rights of third parties, which may expose us to litigation and potential liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or future commercialization of any product candidate licensed to it by us; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates, if approved.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates, if approved, in the most efficient manner, or at all. If our collaborations do not result in the successful discovery, development, and future commercialization of product candidates, if approved, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or royalty or other payments we are owed under such collaboration, and could be required to raise additional capital to pursue further development or future commercialization of the applicable product candidates. Additionally, if one of our collaborators terminates its agreement with us, we may lose rights that are important to our business, or find it more difficult to attract new collaborators, and our perception in the business and financial communities could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate partners for our product candidates, and the negotiation process is time-consuming and complex. To successfully partner our product candidates, potential partners must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking, and as compared with other products available for licensing by other companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborations are complex, expensive, and time-consuming to negotiate and document. We may also be restricted under existing collaboration agreements from entering into future collaboration agreements on certain terms with potential collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Moreover, we face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or applicable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, and the existence of uncertainty with respect to its ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for its product candidates. Additionally, our collaboration agreements may contain non-competition provisions that could limit our ability to enter into strategic collaborations with future collaborators or restrict our ability to commercialize product candidates on our own, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, if approved, or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or future commercialization activities at our own expense. If we elect to increase our expenditures to fund development or future commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations or do not have sufficient funds or expertise to undertake the necessary development and future commercialization activities, we may not be able to develop our product candidates, bring them to the market, if approved, and generate revenue from sales of drugs, or continue to develop our technology, and our business, financial condition, results of operations, and prospects could be adversely affected. Even if we are successful in our efforts to establish new strategic partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic partnerships if, for example, development or approval of a product candidate is delayed, or sales of any approved product are disappointing. Any delay in entering into new strategic partnership agreements related to our product candidates could delay the development and future commercialization of our product candidates, if approved, and reduce their competitiveness even if they reach the market. See the section of our Annual Report on Form 10-K for the year ended December 31, 2025 titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;License and Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for more information on our collaboration agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, which could result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. We did not design and maintain effective controls related to the evaluation of the accounting considerations for complex terms in lease arrangements. The material weakness resulted in the restatement of the condensed balance sheet and condensed statement of cash flows as of and for the nine months ended September 30, 2025. Additionally, this material weakness could result in misstatements to lease-related accounts or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are taking steps to remediate the material weakness and to strengthen our internal control over financial reporting. The material weakness will not be considered remediated until management completes the design and implementation of the controls and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective. The measures we will take may not be sufficient to remediate the material weakness we have identified or avoid potential future material weaknesses. If the steps we take do not remediate the material weakness in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management will not be required to evaluate the effectiveness of our internal control over financial reporting until our second Annual Report on Form 10-K after our initial public offering. As part of that evaluation, we may identify additional control deficiencies that are determined to constitute one or more material weaknesses. In addition, there can be no assurance that our remediation efforts will be successful, that our internal control over financial reporting will be effective as a result of these efforts, or that any future control deficiencies identified may not be material weaknesses that would be required to be reported in future periods.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to litigation, which could result in substantial costs and divert management&#8217;s attention and resources from our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings relating to claims arising in the ordinary course of business or otherwise, including claims related to employment matters, security of patient, employee, and other personal data, product liability, intellectual property and other proprietary rights, or contractual relations with current or past collaborators or licensors. Any litigation we become party to could be costly and time-consuming and we cannot assure you that we would ultimately prevail. If we receive an adverse judgment in any litigation, we could be required to pay substantial damages that may not be covered by our insurance in full or at all. Expenses and damages relating to litigation can be difficult to predict. Regardless of its merit, litigation can be complex, extend for a protracted period of time, divert management&#8217;s attention and resources, and be expensive. Litigation initiated by us could also result in counterclaims against us, which could increase the costs associated with the litigation and result in our payment of damages or other judgments against us.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by natural or manmade disasters.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current operations are concentrated predominantly in Millbrae, California, New York, New York, and Jersey City, New Jersey. Any unplanned event, such as a flood, explosion, extreme weather condition, epidemic or pandemic, power outage, telecommunications failure, or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and may have significant negative consequences on our financial condition, results of operations, and prospects. Any similar impacts of natural or manmade disasters on our third-party CMOs, CROs, or other third parties on whom we rely could cause delays in our clinical trials, and may have a material and adverse effect on our ability to operate our business and have significant negative consequences on our financial condition, results of operations, and prospects. If any such natural or manmade accidents or incidents occurred and prevented us from using our clinical sites, prevented or limited patient enrollment, affected clinical supply or the conduct of our clinical trials, damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs or CROs, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we and our CMOs and CROs have in place may prove inadequate in the event of a serious disaster or similar event. In the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance we currently carry will be sufficient to satisfy any damages and losses. If our facilities, or the facilities of our CMOs or CROs, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our development programs may be harmed. Any business interruption could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions, including any adverse macroeconomic conditions or geopolitical events, could adversely affect our business, financial condition, results of operations, or prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, rising inflation and monetary supply shifts, rising interest rates, labor shortages, declines in consumer confidence, declines in economic growth, increases in unemployment rates, recession risks, and uncertainty about economic and geopolitical stability. A severe or prolonged economic downturn, global financial or political crises, or geopolitical events including the ongoing conflict between Russia and Ukraine and hostilities in Iran, could result in a variety of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks to our business, including delayed clinical trials or preclinical studies, delayed approval of our product candidates, delayed ability to obtain patents and other intellectual property protection, weakened demand for our product candidates, if approved, or weakened ability to raise additional capital when needed on acceptable terms, if at all. The extent of the impact of these conditions on our operational and financial performance, including our ability to execute on our business strategies and initiatives in the expected timeframe, as well as that of third parties upon whom we rely, will depend on future developments, which are uncertain and cannot be predicted. A weak or declining economy also could strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business, and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely affect our business. Furthermore, continued market volatility or a general economic downturn could cause our stock price to decline as a result of factors unrelated to our performance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. government policies, including those with respect to China, increased tariffs, and reductions in federal research funding, could adversely affect our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant political, trade, or regulatory developments in the jurisdictions in which we may sell our products, if approved, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on us. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. For example, policy actions by the current presidential administration, including the imposition of new tariffs on imported materials and goods from certain foreign countries, including Canada, Mexico, and China, and the temporary freeze on federal grants and loans, may have an adverse impact on our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, the current presidential administration imposed a baseline ten percent tariff on imports from all nations importing goods to the United States, with that baseline supplemented in certain cases by additional tariffs that vary by nation, product, or industry. Retaliatory tariffs on U.S. goods have been imposed by, among others, China, Canada, and the European Union, or the EU, which could impact inflation rate, increase the cost of goods, and adversely affect our business. On February 20, 2026, the U.S. Supreme Court ruled against the current presidential administration&#8217;s use of tariffs under the International Emergency Economic Powers Act, or IEEPA. However, in response to the U.S. Supreme Court ruling, the current presidential administration imposed a new worldwide tariff under other legal authority, effective for 150 days from February 24, 2026. While the baseline tariff has been temporarily reduced, the underlying trade tensions and the potential reimposition of elevated tariffs may continue to pose risks to global supply chains and economic relations. It is unknown whether and to what extent new tariffs, export controls, or other new laws or regulations will be adopted, or the effect that any such actions would have on us or our industry. Historically, tariffs have led to increased political tensions, between not only the United States and China, but also between the United States and other countries in the international community. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange, and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including, but not limited to, U.S. and China trade policies, could have a material adverse effect on our financial condition or results of operations. In addition, increased tariffs on critical raw materials, components, and finished goods could raise our production costs and disrupt our supply chain, which could adversely affect our clinical development activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, reduction in or suspension of certain federal research grants may negatively affect our industry. Any prolonged reductions in such funding could slow innovation, delay collaborations, and limit the adoption of new technologies that contribute to our business growth. If these or similar policy changes continue or expand, we may face increased costs. Although we cannot predict the full extent of these impacts, any prolonged disruption could adversely affect our business, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Research, Development, and Commercialization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Many of our product candidates/programs are still in preclinical or early-stage clinical development. We have not yet completed any pivotal clinical trials with our product candidates, and we may be unable to do so for any product candidates we are currently developing or may develop in the future. If we are unable to advance our product candidates through clinical development, obtain regulatory approval, and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our product candidates/programs are in preclinical or early-stage clinical development. We have not yet completed any pivotal clinical trials, obtained regulatory approvals, manufactured a commercial scale product (or arranged for a third party to do so on our behalf), or conducted sales and marketing activities necessary for successful commercialization of any of our product candidates. Aside from EIK1001, which is our most advanced product candidate currently being evaluated in a Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma, as well as a Phase 2 trial and Phase 2/3 registrational trial (for which we recently initiated site selection) in combination with pembrolizumab and chemotherapy for the treatment of patients with NSCLC, all of our other development programs are either in early-stage clinical development, or will need</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to progress through IND-enabling studies and receive authorization from the FDA or a comparable foreign regulatory authority to proceed under an IND or other submission prior to initiating clinical development. We may not be able to file INDs or other submissions for any of our preclinical product candidates on the timelines we expect, or at all. Even if we submit an IND or other submission for a product candidate, the FDA or a comparable foreign regulatory authority may not clear the IND or other submission and allow us to begin clinical trials in a timely manner, or at all. The timing of submissions of INDs or other submissions for our product candidates will be dependent on further preclinical and manufacturing success. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and comparable foreign regulatory authorities. Any guidance we receive from the FDA or comparable foreign regulatory authorities is subject to change. These regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect. Furthermore, the recent turnover at the FDA under the current presidential administration could lead to further delays and unpredictability in FDA&#8217;s clinical development and/or regulatory approval processes, which could adversely affect our ability to advance the development of our product candidates/programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates/programs beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, or if there are safety concerns, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not obtain marketing approval at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to post-marketing requirements to conduct additional clinical trials; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to have the product removed from the market after obtaining marketing approval.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical and clinical development is a lengthy and expensive process, with uncertain timelines and uncertain outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore may be unable to commercialize our product candidates or any of our future product candidates on a timely basis, or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our product candidates are either in preclinical or early clinical development, except for EIK1001, which is currently being evaluated in a Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma, as well as a Phase 2/3 trial in which we recently initiated site selection, in combination with pembrolizumab and chemotherapy for the treatment of patients with NSCLC. The risk that our product candidates fail to proceed successfully through clinical development is high. We expect it could be many years before we commercialize any product candidate, if ever. The product candidates we are developing are novel and unproven, which makes it difficult to accurately predict the challenges we may face with respect to our product candidates as they proceed through development. It is also impossible to predict whether our clinical trials will proceed through registrational trials, and when or if any of our product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and lengthy, complex, and expensive clinical trials that our product candidates are safe and effective in humans. Clinical testing can take many years to complete, and its outcome is inherently uncertain. Commencing any future clinical trials is subject to finalizing the trial design and submitting an IND and/or protocols to the FDA or a comparable foreign regulatory authority. Even after we make our submission, the FDA or comparable foreign regulatory authority could disagree that we have satisfied their requirements to commence our clinical trials or disagree with our trial design, which may require us to complete additional studies or trials, amend our protocols, or impose stricter conditions on the commencement of clinical trials. Furthermore, the recent turnover at the FDA under the current presidential administration could lead to further delays and unpredictability in FDA&#8217;s regulatory approval process, which could adversely affect our ability to advance the development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where possible, we are conducting our own clinical trials rather than outsourcing them to CROs. Although we believe that this strategic decision has benefits, as an organization, we have not completed any clinical trials. Accordingly, our decision to conduct our own clinical trials may enhance the risks described in this risk factor.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to rely in part on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, including the participant enrollment process, and we have limited influence over their performance. We may experience delays in initiating or completing clinical trials due to unforeseen events or otherwise, that could delay or prevent our ability to receive marketing approval or commercialize our current and any future product candidates, including:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, such as the FDA or comparable foreign regulatory authorities, Institutional Review Boards, or IRBs, or Ethics Committees, or ECs, may impose additional requirements before permitting us to initiate a clinical trial, may not authorize us or our investigators to commence or conduct a clinical trial at a prospective trial site, may not allow us to amend trial protocols, or may require that we modify or amend our clinical trial protocols;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching, or failing to reach, agreement on acceptable terms with trial sites and CROs, the terms of which can be subject to extensive negotiation and may vary significantly;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of participants required for clinical trials may be larger than we anticipate, enrollment in clinical trials may be slower than we anticipate, or participants may drop out or fail to return for post- treatment follow-up at a higher rate than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials may be greater than we anticipate, or we may have insufficient funds for a clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the quality or quantity of data relating to our product candidates or other materials necessary to conduct our clinical trials may be inadequate to initiate or complete a given clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">supply or quality of product candidates, or of components of product candidates, or materials or other supplies necessary for the conduct of preclinical studies or clinical trials may be inadequate to complete such study or trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen adverse events during the conduct of clinical trials and/or occurrence of adverse events at greater frequency or severity than we anticipate, which could lead the FDA or comparable foreign regulatory authorities to place our clinical trials on clinical hold, cause an IRB to terminate its approval of our clinical trials, or cause us to decide to terminate our trials due to safety concerns;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reports from clinical testing of other therapies may raise safety, tolerability, or efficacy concerns about our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates may fail to show appropriate safety, tolerability, or efficacy, may produce negative or inconclusive results, or may otherwise fail to improve on the existing standard of care, and we may decide, or regulators may require us, to conduct additional clinical trials, or we may decide to abandon product development programs.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have and may in the future experience participant withdrawals or discontinuations from our trials. Withdrawal of participants from our clinical trials may compromise the quality of our data. Even if we are able to enroll a sufficient number of participants in our clinical trials, delays in enrollment or small population size may result in increased costs or may affect the timing or outcome of our clinical trials. Any of these conditions may have a negative impact on our ability to complete such trials or include results from such trials in regulatory submissions, which could adversely affect our ability to advance the development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended, put on clinical hold by the FDA, or terminated by us, the IRBs of the institutions where such trials are being conducted, the FDA or comparable foreign regulatory authorities, or if a clinical trial is recommended for suspension or termination by a data safety monitoring board or data monitoring committee, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, failure by us or our CROs to perform in accordance with good clinical practices, or GCPs, or applicable regulatory guidelines in other countries, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Even if our clinical trials are completed successfully, the FDA or comparable foreign regulatory authorities may determine that they do not adequately establish the safety and effectiveness of our products required for approval, or permit delineation of practices required for the safe use of our products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also conduct preclinical and clinical research in collaboration with academic, pharmaceutical, and biotechnology entities in which we combine our development efforts with those of our collaborators. Such collaborations may be subject to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional delays because of the management of the trials, contract negotiations, or the need to obtain agreement from multiple parties, and may increase our future costs and expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates. Any delays or increase in costs in our clinical development programs may harm our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, or if regulatory approval we do obtain is limited, our business will be substantially harmed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our current product candidates and any future product candidates will be subject to extensive governmental regulations relating to research, testing, development, manufacturing, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, post-approval monitoring, marketing, sale, and the distribution of products. Rigorous preclinical studies, clinical trials, and an extensive regulatory approval process are required to be completed successfully in the United States and in many foreign jurisdictions before a new product may be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and subject to unanticipated delays. It is possible that none of our product candidates will obtain the regulatory approvals necessary for us to begin selling them, and any delay or failure in obtaining required approvals could adversely affect our ability to generate revenue from the particular product candidate for which we are seeking approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the discretion of the regulatory authorities. We have not obtained regulatory approval for any product candidate, and it is possible that any product candidates we may seek to develop in the future will never obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States or elsewhere until we receive regulatory approval of our product candidates through an NDA or biologics license application, or BLA, from the FDA, or similar marketing application in another jurisdiction. The FDA and other comparable foreign regulatory authorities may delay, limit, or deny approval of our product candidates for many reasons, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to demonstrate to the satisfaction of the FDA or other comparable foreign regulatory authorities that a proposed product candidate is safe and effective for any indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the number, design, size, conduct, or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the benefits of any of our product candidates outweigh their safety risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials, or may not accept data generated at our clinical trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable regulatory authorities may conclude that our studies were not conducted in accordance with GCP requirements or may otherwise question the integrity of the data generated from those clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from preclinical studies and clinical trials of any of our product candidates may not be sufficient to support the submission of applications for regulatory approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may have difficulty scheduling an advisory committee meeting in a timely manner, or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution, and use restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may require development of a risk evaluation and mitigation strategy, or REMS, and foreign regulatory authorities may require a risk management plan, or RMP, as a condition of approval for new products, among other additional requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial supplies;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may change their approval policies or adopt new regulations; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may require simultaneous approval for both adults and for children and adolescents, which may delay approval, or we may have successful clinical trial results for adults but not for children and adolescents, or vice versa.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these regulatory authorities may also change the requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a clinical trial. The FDA or comparable foreign regulatory authorities may require that we conduct additional clinical, preclinical, manufacturing validation, or drug product quality studies and submit those data before considering or reconsidering the application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA or comparable foreign regulatory authorities for granting approval. Furthermore, the recent turnover at the FDA under the current presidential administration could lead to further delays and unpredictability in FDA&#8217;s regulatory approval process, which could adversely affect our ability to advance the development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA or comparable foreign regulatory authorities may approve a product candidate for fewer or more limited indications than we request, may impose significant limitations related to use restrictions for certain age groups, warnings, precautions, or contraindications or may grant approval contingent on the performance of costly post-marketing clinical trials, or may impose risk mitigation requirements, such as the implementation of a REMS, RMP, or comparable foreign risk management approaches, which may include significant limitations on distribution or use of our product candidates, if approved. The FDA or comparable foreign regulatory authorities may not accept the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the FDA or comparable foreign regulatory authorities may respond to any BLA, NDA, or comparable marketing application that we may submit by defining requirements that we do not anticipate. Such responses could delay clinical development of any of our product candidates or any future product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing authorizations, pricing and third-party reimbursement, and may in the future become subject to additional requirements. The regulatory approval process varies among countries and may include all of the risks associated with the FDA approval process described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval in foreign jurisdictions may differ from that required to obtain FDA approval. FDA approval does not ensure approval by regulatory authorities outside the United States, and vice versa. Any delay or failure to obtain U.S. or foreign regulatory approval for a product candidate could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter delays or difficulties enrolling or retaining patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected, which could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in a trial until its conclusion. We may not be able to initiate, continue, or complete clinical trials that may be required by the FDA or comparable foreign regulatory authorities to obtain regulatory approval for any of our product candidates if we are unable to locate, enroll, and retain a sufficient number of eligible patients to participate in these clinical trials. Patient enrollment, a significant factor in the time required to conduct and complete clinical trials, is affected by many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility criteria for the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to clinical sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the clinical protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to obtain and maintain patient consents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of a combination study with another product, the ability of such product to be used as a combination therapy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or before trial completion;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of competing clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of new drugs approved for the indication the clinical trial is investigating;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the emergence of adverse events or other safety issues that are unanticipated;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other factors outside of our control, such as public health factors, including pandemics and other health crises, the effects of global economic conditions and volatility in the credit and financial markets, inflationary pressures, the ongoing conflict between Russia and Ukraine, the hostilities in Iran, and other geopolitical conditions.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for ongoing or future clinical trials. In addition, the process of finding and diagnosing patients may prove costly. Other pharmaceutical companies with more resources and greater experience in drug development and commercialization are targeting similar treatments, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. In addition, some of the diseases our product candidates are designed to address have existing approved treatments, which may make it more difficult to recruit patients. Because the number of qualified clinical investigators and clinical trial sites is also limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites, and may delay or make it more difficult to fully enroll our clinical trials. We also rely on CROs and clinical trial sites to enroll subjects in our clinical trials and, while we have agreements governing their services, we will have limited influence over their actual performance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors may make it difficult for us to enroll and retain enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process, and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Positive results from preclinical studies and early clinical trials of our current or future product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our current or future product candidates. If we cannot replicate the positive results from preclinical studies and early-stage clinical trials of our current or future product candidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for, and commercialize our current or future product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and results in one indication may not be predictive of results to be expected for the same product candidate in another indication. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unfavorable safety profiles, notwithstanding promising results in earlier trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of such product candidates. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful. Even if our clinical trials satisfy clinical endpoints that regulatory authorities deem clinically meaningful, such regulatory authorities may still conclude that our product candidates have not met the required threshold to establish safety and effectiveness. There is typically a high rate of failure of product candidates proceeding through clinical trials, and failure can occur at any time during the clinical trial process. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support the approval of our current or any future product candidates. If we fail to produce positive results in our planned preclinical studies or clinical trials of any of our current or future product candidates, the development timeline and regulatory approval and commercialization prospects for our current or future product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Phase 2 trial evaluating the effect of EIK1001 in combination with pembrolizumab and chemotherapy for the treatment of the NSCLC, as well as our Phase 1/2 trials evaluating EIK1003 and EIK1004, utilize an &#8220;open-label&#8221; trial design, and we may utilize this for future clinical trials for this or future product candidates. An &#8220;open-label&#8221; clinical trial is one where both the patient and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients and physicians in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results of a product candidate when studied in a controlled environment with a placebo or active control.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, top-line, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or top-line data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations, and may draw preliminary conclusions as part of our analyses of then- available data, which may change when more complete data analyses are available. As a result, the top-line or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses, or may interpret or weigh the importance of data differently, which could affect the value of the particular program, the approvability or commercialization of the particular product candidate or product, and our business in general. In addition, the information we choose to disclose publicly regarding a particular study or clinical trial is based on what is typically a significant volume of data and other information. You or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities, or otherwise regarding a particular product candidate or our business. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could adversely affect our business, financial condition, results of operations, or prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may experience delays in commencing and completing, or ultimately be unable to complete, the development and/or commercialization of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before we can initiate clinical trials of a product candidate in any indication, we must submit the results of preclinical studies to the FDA or to comparable foreign authorities, along with other information, including information about the product candidate&#8217;s chemistry, manufacturing and controls, and our proposed clinical trial protocol, as part of an IND or comparable foreign regulatory filings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may require us to conduct additional preclinical studies for any product candidate before it allows us to initiate clinical trials under any IND, which may lead to additional delays and increase the costs of our preclinical development programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delays in the commencement or completion of preclinical studies or clinical trials could significantly affect our development costs. We may experience numerous unforeseen events during, or as a result of, preclinical studies or clinical trials that could delay or prevent our ability to obtain marketing approval or commercialize our product candidates, including, but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, IRBs, or ECs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may disagree as to the design or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable preclinical studies or clinical trial contracts or clinical trial protocols with prospective CROs and prospective trial sites;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of our preclinical studies and clinical trials may be greater than we anticipate, and we may lack adequate funding to continue preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply with regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may have to suspend or terminate clinical trials for various reasons, including a finding by us or by a Data Monitoring Committee that the participants are being exposed to unacceptable health risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our product candidates may produce negative or inconclusive results, or have undesirable side effects or other unexpected characteristics, and we may decide, or our investigators, regulators, or IRBs/ECs may require us, to conduct additional preclinical studies or clinical trials, or delay, halt, or abandon our development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct of our clinical trials may be negatively affected or delayed by changes to clinical trial protocols;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate and result in delays or suspension of our clinical trials; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">global health crises or geopolitical conflict may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting, or completing our planned clinical trials.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays, including delays caused by the above factors and other factors described in this section of this Quarterly Report titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#8221; can be costly and could negatively affect our ability to complete preclinical studies or clinical trials or obtain timely marketing approvals. We do not know whether any of our planned preclinical studies or clinical trials will begin on or be completed on a timely basis, or at all. For example, the FDA or comparable foreign regulatory authorities may place a partial or full clinical hold on any of our clinical trials for a variety of reasons, including safety concerns or failure to comply with regulatory requirements. If we are not able to complete successful clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which may impair our ability to successfully commercialize our product candidates and harm our business and results of operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate in specific indications and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given our broad approach seeking to advance new important medicines in a wide variety of indications, we will need to carefully allocate our limited financial and managerial resources among our selected product candidates in certain selected indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates, or other indications for our existing product candidates that later prove to have greater commercial potential. If we are unable to discover and develop additional product candidates, our ability to commercialize product candidates or partner product candidates may be negatively impacted. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements, or experience unanticipated problems with our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidate for which we, or any partners obtain marketing approval, as well as the manufacturing processes, post-approval clinical data, labeling, and advertising and promotional activities for such product candidate, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, but are not limited to, restrictions governing advertising and promotion of an approved product, requirements to report adverse events and other post-marketing information and reports, registration and listing requirements, the FDA&#8217;s current good manufacturing practices, or cGMPs, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, and requirements regarding drug distribution and the distribution of samples to physicians and recordkeeping.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For instance, even if marketing approval of a product candidate is granted, the FDA may impose requirements for costly post-marketing studies or clinical trials, and may require surveillance to monitor the safety or efficacy of a product, including the adoption and implementation of a REMS.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, or any of our partners, must also comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product candidate&#8217;s approved labeling. Thus, we, and any partners, will not be able to promote any product candidates we develop for indications or uses for which they are not approved, or otherwise engage in any promotion that the FDA or comparable regulatory authorities would deem false or misleading.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to ensure that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our third-party manufacturers, and any partners and their third-party manufacturers, and our CMOs will be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a condition of approval of our product candidates, we may also be subject to requirements to conduct post-approval clinical trials, registrational studies, observational studies, or other post-approval studies. These studies must be conducted in accordance with protocols submitted to the FDA or comparable foreign regulatory authorities, and in accordance with time schedules agreed to with regulatory authorities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, assuming we, or any partners, obtain marketing approval for one or more of our product candidates, we, our partners, and our CMOs will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities, and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. As a result, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA as well as other federal and state agencies, including the Department of Justice, or DOJ, enforce and closely regulate compliance with all requirements governing drug products, including those requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling, and manufacturing of products in accordance with cGMP requirements. For example, the FDA and other agencies actively enforce the laws and regulations prohibiting false or misleading promotion, or promotion that otherwise establishes intended uses for which there are not adequate instructions in the FDA-approved label, and a company that is found to have improperly promoted its products may be subject to significant liability. Violations of such requirements may lead to investigations alleging violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the civil False Claims Act, or FCA, and other federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. Our failure to comply with all regulatory requirements, or later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes, may yield various adverse outcomes, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation involving patients using our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on such products, their manufacturers, or the manufacturing processes that were employed;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modifications to the labeling or restrictions on the marketing of a product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on distribution or use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning or untitled letters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal or recall of the product from the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications, or supplements to approved applications, that we submit;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution, or disgorgement of profits or revenues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to relationships with any potential partners;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable press coverage and damage to our reputation;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-compliance by us or any future partner with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of our products, can also result in significant financial penalties.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if our product candidates are approved, if they do not achieve broad market acceptance, the revenue that we generate from their sales will be limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently developing and may in the future develop product candidates across a number of indications in oncology and neurologic disease. However, we have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidate for which we obtain regulatory approval does not gain an adequate level of market acceptance, we may not generate sufficient product revenue or become profitable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of market acceptance of any of our product candidates will depend on a number of factors, some of which are beyond our control, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety, side effect profile, efficacy, tolerability, cost, and ease of administration of our product candidates, and any approved products we use as part of a combination treatment, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of our product candidates together with other medications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which the products are approved and the approved claims that we may make for the products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the product&#8217;s labeling as approved by the FDA or comparable foreign regulatory authorities, including potential limitations or warnings for such products that may be more restrictive than other competitive products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to such product candidates or to which we agree as part of a mandatory REMS or RMP or voluntary risk management plan;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the standard of care for the targeted indications for such product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of adequate coverage and reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to offer our product candidates for sale at competitive prices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent and strength of our marketing and distribution of such product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the safety, efficacy, and other potential advantages of, and availability of, alternative treatments already used or that may later be approved for any of our intended indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of such product candidates, as well as competitive products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of target populations to try new product candidates and of physicians to switch their patients&#8217; current standard of care;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent and strength of our third-party manufacturer and supplier support;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity about our product or favorable publicity about competitive products; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product liability claims.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts to educate the medical community and third-party payors as to the benefits of our product candidates may require significant resources and may never be successful. Even if the medical community accepts that our product candidates are safe and effective for their approved indications, physicians and patients may not immediately be receptive to such product candidates and may be slow to adopt them as an accepted treatment of the approved indications. If our current or future product candidates are approved but do not achieve an adequate level of acceptance among physicians, patients, and third-party payors, we may not generate meaningful revenue from our product candidates and may never become profitable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market opportunities for our product candidates and forecasts of market growth are subject to numerous uncertainties and may not be accurate, and the actual market for our product candidates may be smaller than we estimate. Even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our estimates of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including sales of our competitors&#8217; products, scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect in general, or as to their applicability to our business. Further, new trials may change the estimated incidence or prevalence of these diseases. The estimates of our market opportunities included herein should not be taken as indicative of our ability to grow our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the eligibility criteria included in the final label for each of our product candidates approved for sale for these indications, the ability of our product candidates to improve on the safety, convenience, cost, and efficacy of competing therapies or therapies in development, acceptance by the medical community and patients, and drug pricing and reimbursement criteria.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of patients in the United States, other major markets, and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition, results of operations, and prospects. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very small, we may never achieve profitability.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing, or commercializing similar drugs before or more successfully than we do.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of new drugs is highly competitive. We face and will continue to face competition from third parties, including larger and better-funded pharmaceutical, biopharmaceutical, and biotechnological companies, developing treatments for the indications that we have decided to pursue. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization of new drugs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, manufacturing, supply, marketing, and sales resources or experience than we have. Such competitors could also recruit our employees, which could reduce our level of expertise and degrade our ability to execute our business plan. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These third parties compete with us in recruiting and retaining qualified management and other personnel, establishing clinical trial sites, and enrolling participants in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other foreign regulatory approval for their product candidates more rapidly than we do, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if our product candidates achieve regulatory approval, they may be priced at a significant premium over competitive product candidates if any have been approved by then, resulting in reduced competitiveness. Moreover, technological advances or product candidates developed by our competitors may render our technologies, or product candidates we may develop in the future, obsolete, less competitive, or uneconomical.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our programs may be delayed and our expenses may increase.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory, and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, as well as the submission of regulatory filings. Also from time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our programs may be delayed or never achieved and, as a result, our stock price may decline. Additionally, delays relative to our projected timelines are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of our product candidates could be associated with side effects, adverse events, or safety risks, which could cause us to suspend or discontinue clinical trials, cause us to abandon a product candidate, delay or preclude approval, prevent market acceptance, require us to conduct product recalls, limit the commercial profile of an approved label, cause regulatory authorities to withdraw product approvals, or result in other significant negative consequences that could severely harm our business, results of operations, financial condition, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials that our current product candidates, including EIK1001, EIK1003, EIK1004, EIK1005, EIK1006, and any future product candidates, are both safe and effective for use in such product candidate&#8217;s target indication. Product candidates in later stages of clinical trials may fail to generate desired safety and efficacy data despite having progressed through preclinical studies and initial clinical trials. It is not uncommon in the biopharmaceutical and biotechnology industries to suffer significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of our clinical trials could reveal a high and unacceptable prevalence or severity of side effects, or other unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label, or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial, or result in potential product liability claims. Any of these occurrences may materially harm our business, results of operations, financial condition, and prospects and may cause us to interrupt, delay, or abandon the development of any such product candidate, or limit development to more narrow uses or subpopulation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials, or experience known side effects with greater severity or frequency than anticipated. For example, serious treatment-related adverse events such as diarrhea, irregular heartbeat, hypotension, tachycardia, and vomiting have been observed in our Phase 1/2 trial for EIK1003. We will continue to learn more about our product candidates and potential side effects as they advance through clinical development. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing other medical treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still deleteriously affect the success of our clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, the FDA, other comparable foreign regulatory authorities, or an IRB or EC may suspend clinical trials of a product candidate at any time for various reasons, including a belief that patients in such trials are being exposed to unacceptable health risks or adverse side effects. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance. Any of these developments could materially harm our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA or comparable foreign regulatory authorities could require us to adopt a REMS or RMP, as applicable, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to healthcare practitioners, patient education, extensive patient monitoring, or implementation of distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Other potentially significant negative consequences include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be forced to suspend marketing of that product, or recall it, or decide to remove the product from the marketplace, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw or change their approvals of that product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way the product is administered;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to conduct additional studies or clinical trials to assess safety;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused to subjects or patients; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive, and our reputation may suffer.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates, and could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in product candidate manufacturing, formulation, or analytical methods may result in additional costs or delay, which could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates are developed through preclinical studies to later-stage clinical trials toward approval and future commercialization, it is common that various aspects of the development program, such as manufacturing methods, formulation or analytical methods, are adjusted to optimize processes and results. Any of these changes could cause our product candidates to perform differently, and thus affect the results of planned clinical trials or other future clinical trials conducted with the altered materials or utilizing different analytical methods. Such changes also may require additional testing, or notification to, or authorization by, the FDA or a comparable foreign regulatory authority. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, or jeopardize our ability to commence product sales and generate revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we are also subject to risks associated with large-scale manufacturing for clinical trials, including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and the availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that our third-party manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product, or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations, and growth prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A variety of risks associated with collaborating with third parties overseas, including in China, conducting research and clinical trials abroad, and seeking to market our product candidates internationally, could materially adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are collaborating with third parties and developing our product candidates globally. In addition, our enrollment timelines for our product candidates depend on initiating clinical trial sites outside of the United States. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing regulatory requirements in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing standards with respect to data integrity;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing standards and privacy requirements for the conduct of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates to the patient at the relevant trial site abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the imposition of new laws and regulations, including those relating to labor conditions, quality and safety standards, imports, duties, taxes, and other charges on imports, as well as trade restrictions, tariffs, and restrictions on currency exchange or the transfer of funds;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in staffing, workforce uncertainty, and managing foreign operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing payor reimbursement regimes, governmental payors, or patient self-pay systems and price controls;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977, or the FCPA, or comparable foreign regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges obtaining, maintaining, defending, and enforcing our contractual and intellectual property, especially in those foreign countries that do not respect and protect intellectual property, and other proprietary rights to the same extent as the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges with obtaining any local supply of drugs or agents used with our product candidates, which are required by certain local clinical trial sites before conducting any study;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from health epidemics or pandemics, or natural or man-made disasters, including earthquakes, tsunamis, fires, medical epidemics, or geo-political developments, including war and terrorism;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to observe local or international GCP regulations, including data integrity rules, leading to rejection of safety or effectiveness data by drug regulatory authorities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to observe local privacy or cybersecurity rules leading to prohibitions on data transfer.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EIK1001 was in-licensed from a Cayman Islands entity with significant operations in China. In addition, under the collaboration agreement, or the Impact Agreement, with Impact, a Chinese entity, we received an exclusive license under certain of Impact&#8217;s patents, know-how, and regulatory information to develop and commercialize any selective PARP1 inhibitors owned or controlled by Impact or its affiliates, including our product candidates EIK1003 and EIK1004, and any pharmaceutical products comprised of or containing such inhibitors, on a worldwide basis excluding China, Hong Kong, Taiwan, and Macau. Pursuant to the Impact Agreement, Impact conducts clinical trials for EIK1003 and EIK1004 in these regions. The U.S. government has recently made statements and taken certain actions that may lead to potential changes to U.S. and international trade policies, including imposing several rounds of tariffs and export control restrictions affecting certain products manufactured in China, and most recently, proposing legislation that, if enacted, would restrict trade with certain Chinese companies that provide biopharmaceutical research, development, and manufacturing services. Recently, both China and the United States have each imposed tariffs indicating the potential for further trade barriers, including the U.S. Commerce Department adding numerous Chinese entities to its &#8220;unverified list,&#8221; which requires U.S. exporters to go through more procedures before exporting goods to such entities. On February 20, 2026, the U.S. Supreme Court ruled against the current presidential administration&#8217;s use of tariffs under the IEEPA. However, in response to the U.S. Supreme Court ruling, the current presidential administration imposed a new worldwide tariff under other legal authority, effective for 150 days from February 24, 2026. It is unknown whether and to what extent new tariffs, export controls, or other new laws or regulations will be adopted, or the effect that any such actions would have on us or our industry. Sustained uncertainty about, or the further escalation of, trade and political tensions between the United States and China could result in a disadvantageous research environment in China, particularly for U.S. based companies, including retaliatory restrictions that could hinder or potentially inhibit Impact&#8217;s ability to conduct clinical trials in China pursuant to the Impact Agreement or our ability to continue to collaborate with these Chinese or China-related entities to develop EIK1001, EIK1003, and EIK1004. If we are unable to continue to develop these product candidates due to new laws or regulations as a result of ongoing tension between the United States and China, it could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in September 2024 during the 118th Congress, the U.S. House of Representatives passed the BIOSECURE Act (H.R. 8333). This bill names certain Chinese companies as biotechnology companies of concern. The Senate advanced a substantially similar bill (S. 3558) but it did not pass. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies like ours to contract with certain Chinese biotechnology companies without losing the ability to contract with, or otherwise receive funding from, the U.S. government, and it is possible that some of our contractual counterparties could be impacted as well. Specifically, we and Impact contracted with Wuxi AppTec Co., Ltd., a Chinese entity named among the &#8220;biotechnology companies of concern&#8221; in certain drafts of the BIOSECURE Act, for certain manufacturing and development activities, including select in vivo pharmacology studies, chemistry, manufacturing, and controls activities, and nonclinical testing. Further, we continue to utilize EIK1001, EIK1003, EIK1004, and EIK1005 clinical supply for their respective clinical studies, components of which include manufacturing, packaging, labeling, storage, and/or distribution services performed by Wuxi AppTec Co., Ltd. or its affiliates. As a result, if these bills become law, or similar laws are passed, we may need to seek alternative relationships for such activities. Such disruptions could have adverse effects on the development of our product candidates and our business operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such unfavorable government policies on international trade, including export controls, capital controls, or tariffs, may affect the cost of manufacturing our product candidates, the demand for our product candidates (if and once approved), the competitive position of our product candidates, and import or export of raw materials and finished product candidate used in our and our collaborators&#8217; preclinical studies and clinical trials.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are conducting and intend to conduct certain of our clinical trials globally. However, the FDA and comparable foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting several clinical trials, and intend to conduct other future clinical trials, in a number of countries around the world. The acceptance of data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authorities may be subject to certain conditions or may not be accepted at all, including as a basis for later-stage clinical trials. In cases where data from foreign clinical trials is intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (among other prerequisites) (i) the data are applicable to the U.S. population and U.S. medical practice, (ii) the trials were performed by clinical investigators of recognized competence in accordance with applicable GCPs, and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical power, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, we would need to conduct additional trials, which could be costly and time-consuming.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacturing process for any products that we may develop is subject to the FDA or comparable foreign regulatory authority approval process, and we must therefore contract with manufacturers who can meet our and all applicable FDA or comparable foreign regulatory authority requirements on an ongoing basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process for any products that we may develop is subject to the FDA or comparable foreign authority approval process, and any CMOs with whom we forge contracts must meet all applicable FDA or comparable foreign regulatory authority requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products in accordance with GMPs and to specifications acceptable to the FDA or comparable foreign regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product in accordance with requirements from the FDA or comparable foreign regulatory authorities to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. Our manufacturing activities are subject to ongoing, unannounced inspections by the FDA and comparable regulatory authorities. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, result in sanctions being imposed on us (including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production or recalls of the product candidates, operating restrictions, and criminal prosecutions), delay approval of our product candidates, impair commercialization efforts, or increase our cost of goods, any of which would have an adverse effect on our business, financial condition, results of operations, and prospects. Our future success depends on our ability to manufacture our products on a timely basis with acceptable manufacturing costs, while at the same time maintaining good quality and complying with applicable regulatory requirements. An inability to do so could have a material adverse effect on our business, financial condition, results of operations, and prospects. In addition, we could incur higher manufacturing costs if manufacturing processes or standards change, and we could need to replace, modify, design, build, or install equipment, all of which would require additional capital expenditures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party CMOs to manufacture and supply drug substance and drug product for our clinical trials for EIK1001, EIK1003, EIK1004, and EIK1005, and we expect to rely on third-party CMOs for our future clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third-party manufacturers entails exposure to risks to which we would not be subject if we manufactured our product candidates ourselves, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to negotiate manufacturing and quality agreements with third parties under commercially reasonable terms;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory issues experienced by third-party manufacturers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced day-to-day control over the manufacturing process for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced control over the protection of our trade secrets and know-how from misappropriation or inadvertent disclosure;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that may be costly or damaging to us or result in delays in the development or commercialization of our product candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">international or multi-national activities that are related to business activities outside of our scope, but may have an impact on a CMO&#8217;s ability to conduct business in a manner consistent with governmental or our regulatory and ethical standards; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to synchronize operations and standards to ensure that all aspects of manufacturing are consistent without deviations across facilities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should we continue to use CMOs, we may not succeed in maintaining our relationships with our current CMOs or establishing relationships with additional or alternative CMOs. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. If our CMOs were to cease manufacturing for us, we would experience delays in obtaining sufficient quantities of our product candidates for clinical trials and, if approved, commercial supply. Further, our CMOs may breach, terminate, or not renew these agreements. If we were to need to find alternative manufacturing facilities, it would significantly reduce our ability to develop, obtain regulatory approval for, or market our product candidates, if approved. The commercial terms of any new arrangement could be less favorable than our existing arrangements and the expenses relating to the transfer of necessary technology and processes could be significant, as would be the time required to effect a satisfactory, compliant transfer of the manufacturing process to a new CMO.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if we are unable to manufacture or contract for a sufficient supply of our product candidates on acceptable terms, or if we encounter delays or difficulties in the scale-up of our manufacturing processes, our preclinical and human clinical testing schedule would be delayed. This in turn would delay the submission of product candidates for regulatory approval and thereby delay the market introduction and subsequent sales of any products that receive regulatory approval, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. In addition, if any of our product candidates are approved for sale, our inability to manufacture or contract for a sufficient supply of such potential future products on acceptable terms would have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even to the extent we use and continue to use CMOs, we are ultimately responsible for the manufacture of our products and product candidates. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines, injunctions, and other civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product, refusal to permit the import or export of the product, product seizure, detention, recall, operating restrictions, suits under the FCA, corporate integrity agreements, consent decrees, or withdrawal of product approval.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to pursue the development of certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exploring and may in the future continue to explore the use of certain of our product candidates in combination with other therapies. For example, we are evaluating in a Phase 2/3 registrational trial the effect of EIK1001 in combination with pembrolizumab for the treatment of patients with advanced melanoma, and in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection, of EIK1001 in combination with pembrolizumab and chemotherapy for the treatment of patients with NSCLC. As such, we are subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of, or that safety, efficacy, manufacturing, or supply issues could arise with, the therapy used in combination with our product candidate. If the therapies we use in combination with our product candidates are replaced as the standard of care, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials, or we may not be able to obtain adequate reimbursement from payors. The occurrence of any of these risks could result in our product candidates, if approved, being removed from the market or being less successful commercially. If we are unable to use pembrolizumab in our current combination trials for EIK1001, we may be required to enroll additional patients at existing sites or identify new trial sites. As a result, our clinical development activities could be delayed or otherwise adversely affected, which could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our ability to develop and ultimately commercialize our product candidates in combination with other therapies will depend on our ability to access such therapies on commercially reasonable terms for the clinical trials, and their availability for use with the commercialized product, if approved. We cannot be certain that our contractual relationship with MSD or any potential future commercial relationships will provide us with a steady supply of such therapies on commercially reasonable terms or at all. In the event that MSD or any other collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing such products. Additionally, should the supply of pembrolizumab be interrupted, delayed, or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">supply, or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price, and prospects may be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities do not approve or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain regulatory approval of, or to commercialize such product candidates in combination with, these therapies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates and any future product candidates we may develop, or enforce such intellectual property rights, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to seek, obtain, and maintain patent and other intellectual property protection in the United States and other countries for our product candidates and their uses, as well as our ability to operate without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business, and in-licensing similar rights. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. The risks associated with patent rights generally apply to patent rights that we in-license now or in the future, as well as patent rights that we may own now or in the future. While we in-licensed certain issued patents related to EIK1001 from Seven and Eight, none of the patent applications we own or in-license in connection with EIK1003, EIK1004, EIK1005, or EIK1006 have issued yet, and there is no assurance that any such patent applications will issue at all or in a manner that provides us with any competitive advantage. In addition, the chemical structure of EIK1001 is in the public domain. Accordingly, we are unable to obtain any composition of matter patents claiming the composition of matter of EIK1001 as a sole active ingredient. We in-licensed patent applications relating to methods of using EIK1001 to treat certain indications, crystal forms of EIK1001, and a Patent Cooperation Treaty, or PCT, application relating to dosing of EIK1001, however, there is no assurance that these applications will issue or, even if they are issued, will be sufficient to prevent others from developing products that compete with EIK1001. Moreover, we or our licensors have also filed PCT and provisional patent applications related to EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006, and none of our owned or in-licensed provisional or PCT patent applications are eligible to become an issued patent until, among other things, we or our licensors, as applicable, file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application, or file national stage applications based on the applicable PCT applications. Any failure to file a non-provisional patent application or a national stage application based on a PCT application could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent application or PCT application. Moreover, we cannot assure you that our owned and in-licensed pending patent applications will issue, or that any future issued patents will afford sufficient protection of our product candidates (including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006) or their intended uses against competitors, nor can we assure you that the patents issued will not be infringed, designed around, or invalidated by third parties, or that we can effectively prevent others from commercializing competitive technologies, products, or product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining, maintaining, and enforcing intellectual property, particularly patents, is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications, or maintain or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. Public disclosures by us or third parties may preclude our ability to obtain or maintain patent applications and patents. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In these instances, we may not be able to prevent third parties from using our technology that has appeared in the public domain to compete with our technologies or product candidates. We may also depend on current or future collaborators or licensors to take necessary action to comply with patent protection requirements with respect to any licensed intellectual property. Noncompliance with such requirements could result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any specific method-of-use. In particular, composition of matter patent claims covering the active pharmaceutical ingredient, or API, in pharmaceutical drug products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are generally considered to be the favored form of intellectual property protection for drug products, because such patents provide protection without regard to any particular method of use or manufacture or formulation or dosing of the API used. However, we only have issued patents directed to the composition of matter of EIK1001 in combination with one or more other substances. Further, we cannot be certain that the claims in our pending or future owned or in-licensed patent applications directed to the composition of matter of our other product candidates will be considered patentable by the United States Patent and Trademark Office, or the USPTO, or by patent offices in foreign countries, or that the claims in any of our current or future owned or in-licensed issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method-of-use patent claims protect the use of a product in the methods claimed in the patents, and dosing patent claims cover dosing regimens of the API or a formulation thereof. These types of patent claims do not prevent a competitor or other third party from making and marketing a product, including an API, that is identical to our product candidates for an indication that is outside the scope of the method-of-use claims, or from developing an identical product with a different dosing regimen that is outside the scope of the dosing claim. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, clinicians may prescribe these products &#8220;off-label,&#8221; or patients may acquire them and use them in such manner themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation, resulting in court decisions, including U.S. Supreme Court decisions, which have increased uncertainty as to the ability to enforce patent rights in the future. As a result, the issuance, scope, validity, enforceability, and commercial value of any patent rights are highly uncertain. Our pending and future owned or in-licensed patent applications may not result in patents being issued that protect our technologies or product candidates, effectively prevent others from commercializing our technologies or product candidates, or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. The coverage claimed in a patent application can also be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we (or any collaborators or licensors) will be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patent applications may not issue as patents and even if issued, may be challenged and invalidated or rendered unenforceable. As a result, the issuance, inventorship, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability and our pending patent applications, and those of any collaborators or licensors, may be challenged in the courts, the USPTO or patent offices abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our pending patent applications may be subject to third-party submissions of prior art to the USPTO. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one or more of our owned or licensed pending patent applications. In addition, our issued patents may be subject to post-grant review, or PGR, proceedings, oppositions, derivations, reexaminations, interferences, inter partes review, or IPR, proceedings or other similar proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and product candidates, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could adversely affect our business, financial condition, results of operations, and prospects. For example, our European patent EP 3166976 B2, which is directed to pharmaceutical combinations relating to EIK1001, was opposed before the European Patent Office. The opposition, which was filed in November 2022, has concluded without the need for an oral hearing. The Opposition Division issued its Interlocutory Decision in October 2025 maintaining our patent in amended form.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A third party may also claim that our current or future owned or licensed patent rights are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse result in any legal proceeding could put one or more of our current or future owned or in-licensed patents at risk of being invalidated or interpreted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">narrowly and could allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize our product candidates, if approved, without infringing third-party patent rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if they are unchallenged, our current or future owned or licensed patent rights may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patent rights by developing similar or alternative technologies in a non-infringing manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but falls outside the scope of our patent protection. If the patent protection provided by our owned or licensed patent rights is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates, if approved, could be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely upon a combination of trade secrets, know-how, and confidentiality agreements to protect the intellectual property related to our product candidates and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market. See the risk factor in this Quarterly Report titled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot ensure that patent rights relating to inventions described and claimed in our or our licensors&#8217; pending patent applications will issue, or that patents that issue in the future will not be challenged and rendered invalid or unenforceable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. We have many patent applications in our portfolio; however, we cannot predict:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and when patents may issue based on our patent applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection of any patent issuing based on our patent applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the claims of any issued patent will provide protection against competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether or not third parties will find ways to invalidate or circumvent our patent rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights, which will be costly whether we win or lose; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the patent applications will result in issued patents with claims that cover each of our product candidates, or uses thereof, in the United States or in other foreign countries.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to, or otherwise involved in, various priority, validity, inventorship, ownership, and enforceability disputes, including third-party pre-issuance submissions of prior art to the USPTO or PGR procedures, oppositions, derivations, revocation, reexaminations, IPR, or derivation proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenge may result in loss of exclusivity or in our patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could require us to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects. Furthermore, if the breadth or strength of protection provided by our current or future owned or licensed patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may rely on more than one patent to provide multiple layers of patent protection for our product candidates. If the latest-expiring patent is invalidated or held unenforceable, in whole or in part, the overall protection for the product candidate may be adversely affected. For example, if the latest-expiring patent is invalidated, the overall patent term for our product candidate could be adversely affected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates. Further, in cases where a particular compound of interest is in the public domain, third parties may be able to obtain patents on improvements or other inventions relating to such compound if they were to discover the same patentable inventions relating to such compounds after us but manage to file a patent application before we do. In addition, we may enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, including any polymorphs and variants, such as our employees, collaborators, consultants, advisors, and other third parties; however, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to obtain patent protection. Furthermore, if third parties have filed patent applications related to our product candidates or technology, a derivation proceeding in the United States can be initiated by a third party to determine who invented any of the subject matter covered by the claims of our patent applications. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our current and future owned and licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing, and regulatory review of new product candidates, our patent rights protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Our competitors and other third parties may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors or other third parties may seek to market generic or biosimilar versions of any approved products and, in so doing, claim that any current or future patents owned or licensed by us are invalid, unenforceable, or not infringed. In these circumstances, we may need to defend or assert our patent rights, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find such patents invalid or unenforceable, or may find that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, some of our patent rights may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to develop current and any future product candidates on acceptable terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because some of our programs may involve additional product candidates that may require the use of intellectual property or proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these intellectual property or proprietary rights. Our product candidates also may require specific formulations to work effectively, and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and expenses and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology, or we may have to abandon development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may have limited control over the maintenance and prosecution of any current or future in-licensed intellectual property. A licensor may not successfully prosecute any patent applications to which we are licensed in a manner consistent with the best interests of our business. We may also have limited control over the manner in which any licensor initiates an infringement proceeding against a third-party infringer or defends any intellectual property that is licensed to us. It is possible that a licensor&#8217;s infringement proceeding or defense activities may be less vigorous than those we would have conducted ourselves. We may also enter into future license agreements under which we are a sub-licensee. If any sub-licensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which could terminate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sub-license. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may collaborate with academic institutions and governmental authorities to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program, and our business, financial condition, results of operations, and prospects could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a highly competitive area, and companies, which may be more established or have greater resources than we do, also may be pursuing strategies to license or acquire third-party intellectual property rights that we consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire, including on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property or maintain the existing intellectual property rights we have licensed, we may be required to expend significant time and resources to redesign our product candidates or technology, or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis, and we may have to abandon development of our product candidates or technology. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidates licensed from third parties may be subject to retained rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties who have collaborated with us by contributing intellectual property or whom we may collaborate with, or license intellectual property from in the future, may retain certain rights under the relevant agreements with us, including the right to use the underlying product candidates for academic and research use, to publish general scientific findings from research related to the product candidates, to make customary scientific and scholarly disclosures of information relating to the product candidates, or to develop or commercialize the licensed product candidates in certain regions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also at times choose to collaborate with academic institutions to accelerate our preclinical research or development. The United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh- Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates. We may infringe, misappropriate, or otherwise violate the intellectual property rights of others, and be subject to legal proceedings alleging the same, which may prevent or delay our drug development efforts and prevent us from commercializing, or increase the costs of commercializing, our products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe, misappropriate, or otherwise violate existing or future third-party patents or other intellectual property rights. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are absolutely comprehensive, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to our research and other operations, or necessary for the commercialization of our product candidates in any jurisdiction. If a patent holder believes the manufacture, use, sale, or importation of our product candidates, if approved, infringes its patent, the patent holder may sue us even if we have licensed other patent protection for our technology. Moreover, we may face patent infringement claims from nonpracticing entities that have no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relevant product revenue and against whom our current, or future, patent portfolio, whether owned or licensed, may therefore have no deterrent effect.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S. and foreign patents and pending patent applications exist in our market, and markets we may enter in the future, that are owned by third parties. For example, we are aware of third-party patents and patent applications that relate to selective PARP1 inhibitors. A third party may seek to assert such patents against us. While we believe we would have valid defenses in connection with any such assertion, in the event our defenses were unsuccessful, we could lose our ability to develop and commercialize our product candidates, even if approved; be required to obtain a license; lose our competitive position; and/or be subject to significant liability for damages. Defense of any such claims, regardless of their merit, would also likely impose substantial litigation expenses and business interruption arising from the diversion of employee resources from our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained, or may in the future apply for and obtain, patents that will prevent, limit, or otherwise interfere with our ability to make, use, and sell our product candidates. We do not always conduct independent reviews of pending patent applications and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, product candidates or the use of our product candidates. As such, there may be applications of others now pending, or recently revived patents, of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that may be infringed by the manufacture, use, or sale of our technologies or product candidates, or will prevent, limit, or otherwise interfere with our ability to make, use, or sell our technologies and product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope of a patent claim in the United States is determined by an interpretation of the law, the written disclosure in a patent, and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent, or a pending application, may be incorrect. For example, we may incorrectly determine that our product candidates are not covered by a third-party patent, or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. In addition, we may be unaware of one or more issued patents or patent applications that would be infringed by the manufacture, sale, or use of our product candidates, if approved, or we may incorrectly conclude that a third-party patent is invalid, unenforceable, or not infringed by our activities. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends significantly on our ability, and the ability of our current and future collaborators, to operate without infringing, misappropriating, or otherwise violating the patents and other intellectual property rights of third parties. For example, there could be issued patents of which we are not aware that our current or potential future product candidates infringe. There also could be patents that we believe we do not infringe but that we may ultimately be found to infringe. Competitors may file continuing patent applications claiming priority to already issued patents in the form of continuation, divisional, or continuation-in-part applications, in order to maintain the pendency of a patent family and attempt to cover our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. Third parties may assert that we are employing their proprietary technology without authorization, and may sue us for patent or other intellectual property infringement, misappropriation, or other violations, or subject us to other adversarial proceedings or litigation, regardless of merit. These lawsuits are costly and could adversely affect our business, financial condition, results of operations, and prospects, and divert the attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate that our product candidates, potential products, or methods either do not infringe the claims of the relevant patent, or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable, and cover our products or their use, the holders of any of these patents may be able to block our ability to commercialize our products unless we acquire or obtain a license under the applicable patents or until the patents expire.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot provide any assurances that third-party patents and other intellectual property rights do not exist which might be enforced against our current technology, including our research programs, product candidates, their respective methods of use,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture, and formulations thereof, and could result in either an injunction prohibiting our manufacture, or future sales, or, with respect to our future sales, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant. We may not be able to consummate licensing arrangements, or to make other arrangements at a reasonable cost, or on reasonable terms, or at all. Any inability to secure licenses or alternative technology could result in delays in the introduction of our products or lead to prohibition of the manufacture or sale of products by us. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product candidate, if approved. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates, or force us to cease some of our business operations, which could materially and adversely affect our business, financial condition, results of operations, and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could adversely affect the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar material and adverse effect on our business, financial condition, results of operations, and prospects. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming. Competitors or other third parties may infringe, misappropriate, or otherwise violate our patents, trademarks, or other intellectual property, or those of our collaborators or licensing partners, or we may be required to defend against claims of infringement, misappropriation, or other violations. In addition, our owned and licensed patent rights also may in the future become involved in inventorship, priority, ownership, or validity disputes. To counter infringement or unauthorized use claims (which may require us to file infringement claims) and to defend against claims that our or our licensor&#8217;s intellectual property are invalid or unenforceable can be expensive and time consuming, and divert the time and attention of our management and scientific personnel. Our owned and licensed pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we, or one of our licensors, assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement, insufficient written description, or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Any future patent-related proceedings could result in the revocation or cancellation of, or amendment to, our owned and licensed patent rights, in such a way that they no longer cover our product candidates, or prevent third parties from competing with our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours or that we otherwise rely on is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly, or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1) or is otherwise exempted. In addition, the U.S. Supreme Court has in the past changed some legal principles that affect patent applications, granted patents, and assessment of the eligibility or validity of these patents. As a consequence, issued patents may be found to contain invalid claims according to the newly revised eligibility and validity standards. Our future owned or in-licensed patents may be subject to challenge and subsequent invalidation, or significant narrowing of claim scope, in proceedings before the USPTO, or during litigation, under the revised criteria, which also could make it more difficult to obtain patents. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive position, and our business, financial condition, results of operations, and prospects. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could adversely affect the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to detect infringement against our current or future owned or in-licensed, patents, as the case may be, which may be especially difficult for manufacturing processes or formulation patents. Even if we detect infringement by a third party of our current or future owned or in-licensed patents, we may choose not to pursue litigation against or settlement with, the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce our current or future owned or in-licensed patents against such third party.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If another party questions the patentability of any of our claims in our current or future owned or in-licensed U.S. patents, the third party can request that the USPTO review the patent claims such as in an IPR, ex parte re-exam, or PGR proceeding. These proceedings are expensive and may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential USPTO proceedings, we may become a party to patent opposition proceedings at the European Patent Office, or similar proceedings in other foreign patent offices, where either our current or future owned or in-licensed foreign patents are challenged and may be revoked or cancelled.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may be involved in similar proceedings challenging the patent rights of others, and the outcome of such proceedings is highly uncertain. An adverse determination in any such proceeding may result in our inability to manufacture or commercialize products without infringing third-party patent rights. The costs of these oppositions or similar proceedings could be substantial, and we may nevertheless fail in avoiding patent rights of others or having such rights revoked. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources, and more mature intellectual property portfolios. Even if we ultimately prevail in any such claims or proceedings, the monetary cost of such litigation, and the diversion of the attention of our management and scientific personnel, could outweigh any benefit we receive as a result of the claims or proceedings.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to claims challenging the inventorship or ownership of our owned or licensed patent rights and other intellectual property, or claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our patent rights or other intellectual property, or those of our collaborators or licensors, as inventors or co-inventors, or other ownership rights. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being invalid or unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates, or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship or ownership, and the outcome of such litigation is uncertain. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, which may in turn result in our inability to develop, manufacture, or commercialize, if approved, our product candidates and proprietary technology without infringing third-party patent rights. Such an outcome could adversely affect our business, financial condition, results of operations, and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and could become a distraction to management and other employees. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. However, such agreements may be insufficient to provide us with all the rights we require to maintain our operations, and develop, manufacture, and sell our products and/or services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our employees, consultants, or advisors have in the past and may in the future be employed at universities, academic partners, or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals, or we ourselves, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer without authorization. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. An inability to incorporate such technologies or features would harm our business and may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevent us from successfully commercializing our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. In addition, we may lose personnel as a result of such claims, and any such litigation, or the threat thereof, may adversely affect our ability to hire employees, or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which would have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we or our licensors may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we or our licensors regard as our own. Moreover, any assignment of intellectual property rights may not be sufficient or self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could adversely affect our business, financial condition, results of operations, and prospects. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property that we may own may have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In light of the advent of AI-assisted inventions, it is possible third parties could challenge our future patents as invalid for lack of a human inventor. The law regarding AI-assisted inventions and inventorship is evolving rapidly, and allegations of improper inventorship of our AI-assisted inventions could pose a challenge to the enforceability of our future patents throughout the world. See the risk factor in this Quarterly Report titled &#8220;&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We use AI/ML to enable our analysis of the internal data generated from our technology platform, and for certain other uses in connection with our business. Defects in, or loss of access to, our data may impair our ability to discover or develop targets or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. If we do not obtain patent term extension, or the foreign equivalent, for our product candidates, our business may be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are paid on time, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional or international patent application filing date. Various extensions may be available, but in all cases, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of products or new product candidates, patents protecting such products or candidates might expire before or shortly after such products or product candidates are commercialized. As a result, any patents we may own or license may not provide us with sufficient and continuing rights to exclude others from commercializing products similar or identical to ours.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any of our product candidates, any issued U.S. patents that we may own or license may be eligible for limited patent term restoration, or patent term extension, under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process based on the first regulatory approval for a particular drug or biologic. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended, and only those claims covering the approved drug, an approved method for using it, or a method for manufacturing it, may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as with supplemental protection certificates in Europe. Although all countries in the EU make available supplementary protection certificates if certain conditions are satisfied, there is no centralized EU procedure for obtaining them. Hence supplementary protection certificates must be applied for and granted on a EU member state-by-EU member state basis. This can lead to substantial costs in applying for and obtaining these certificates, which may vary among countries, or may not be provided at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, we may not be granted any extensions for which we apply because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. In addition, to the extent we wish to pursue patent term extension or a supplementary protection certificate based on a patent that we in-license from a third party, we would need the cooperation and consent of that third party. Moreover, the applicable time period of any term extension, or the scope of patent protection afforded, could be less than we request.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain patent term extension, or the foreign equivalent, or if the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection is dependent on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will have to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of our current, and future owned and licensed, patents and patent applications to retain them pending or in force. We rely on our outside counsel and/or other annuity service providers to pay these fees due to the USPTO and non-U.S. governmental patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to certain of our licensed intellectual property. We employ reputable law firms and/or other service providers to help us comply, and in many cases an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, and this circumstance could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property and other proprietary rights, particularly patents. Obtaining, defending, maintaining, protecting, and enforcing intellectual property and other proprietary rights, including patent rights, in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time consuming, and inherently uncertain. Changes in either the patent laws, or interpretation of the patent laws, in the United States and other countries could increase the uncertainties and costs surrounding the prosecution of patent applications, and the enforcement or defense of issued patents, and may diminish our ability to protect our inventions, obtain, maintain, enforce, and protect our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our future owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the AIA, signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future issued patents. The AIA includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution, and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including PGR, IPR, and derivation proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the patent positions of companies engaged in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances, or weakening the rights of patent owners in certain situations. Depending on future actions by Congress, the U.S. courts, the USPTO, and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain, protect, and enforce new patents and patents that we might obtain or license in the future. For example, in the case, Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that claims to certain DNA molecules are not patentable. In Amgen Inc. v. Sanofi, the Federal Circuit held that claims with functional language may pose high hurdles in fulfilling the enablement requirement. Recent decisions raise questions regarding the award of patent term adjustment, or PTA, for patents where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will or will not be viewed in future, and whether patent expiration dates may be affected. We cannot predict how future decisions by the courts, Congress, or the USPTO may alter the value of our patents. Any similar adverse change in the patent laws of other jurisdictions could also adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, changes in patent law and regulations in other countries or jurisdictions, or changes in the governmental bodies that enforce them, or changes in how the relevant governmental authority enforces patent laws or regulations, may separately or together weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have both increased in recent years. In Europe, in June 2023, a new Unitary Patent system was introduced, which significantly affects European patents, including those granted before the introduction of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">system. Under the Unitary Patent system, after a European patent is granted, the default is that the patent will be a part of the Unitary Patent system, thereby resulting in a Unitary Patent having unitary effect; the patent proprietor, however, can, in some instances, opt out of the Unitary Patent system and opt for the traditional state-by-state national validation instead. Each Unitary Patent is subject to the jurisdiction of the Unitary Patent Court, or UPC. As the UPC is a new court system, there is little precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be potentially vulnerable to a single, UPC-based, revocation challenge which, if successful, could invalidate the patent in all countries that are signatories to the UPC. We cannot predict with certainty the long-term effects of the new Unitary Patent system.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know-how. Competitors or third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, or develop their own competitive technologies that fall outside the scope of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. Any independent development by others of our trade secrets, or knowledge of them by others through other means, would also likely result in such information losing trade secret status. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future and we may require a license from the competitor to use our own know-how. If the license is not available on commercially viable terms, then we may not be able to launch our product candidate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed, or that competitors will not otherwise gain access to our trade secrets. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, and consultants who are parties to these agreements breach or violate the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we could lose our trade secrets, and third parties could use our trade secrets to compete with our product candidates and technology. If our trade secrets are not adequately protected, our business, financial condition, results of operations, and prospects could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that we have entered into such agreements with each party that may have, or has had, access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. However, such systems and security measures may be breached, and we may not have adequate remedies for any breach.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build brand and name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current or future registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared merely descriptive or generic, or determined to be infringing on other marks. The use of registered and unregistered marks may also be limited by certain agreements with third parties. Our current and future trademark applications in the United States and in foreign jurisdictions may not be allowed or may subsequently be opposed. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to such rejections, we may be unable to overcome them. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. In the USPTO, cancellation proceedings may be filed against our trademarks, once registered, which may not survive such proceedings. In foreign jurisdictions, opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any name we have proposed to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to protect our rights to these trademarks and trade names, which we need to enhance brand and name recognition among potential partners or future customers in our markets of interest. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties, or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks, or trademarks that incorporate variations of our current or future registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish brand and name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names, social media handles, or other intellectual property may be ineffective, could result in substantial costs and diversion of resources, and could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to develop products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of patent applications that we own or license, or any issued patents that we may own or license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our current or future licensors or collaborators might not be the first to make the inventions covered by the issued patents or patent application that we may own or license;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our current or future licensors or collaborators might not be the first to file patent applications covering certain of our or their inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may circumvent our regulatory exclusivities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that the current or future pending patent applications we own or license will not lead to issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may have access to the same intellectual property rights licensed to us in the future on a nonexclusive basis;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we may own or license may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent or other intellectual property rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents or other intellectual property rights of others may have an adverse effect on our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may fail to adequately protect and police our trademarks and trade secrets; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, financial condition, results of operations, and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain, maintain and protect our intellectual property rights throughout the world.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While filing patent applications in foreign jurisdictions remains possible for our provisional applications and patent applications filed under PCT, the filing, prosecuting, and defending of patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than those in the United States. In some cases, we or our licensors may not be able to obtain patent protection at all for certain product candidates and technology outside the United States. Moreover, obtaining such protection in a timely manner, or at all, may be affected by factors or events beyond our control, such as a prolonged economic downturn or global financial or political crises. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our or our licensors&#8217; inventions in all countries outside the United States, even in jurisdictions where we or our licensors do pursue patent protection, or from selling or importing products made using our inventions in, and into, the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our product candidates in jurisdictions where we or our licensors do not have any issued patents, and our patent claims or other intellectual property rights may not be sufficient to prevent them from competing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost, and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs, divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. In addition, certain countries outside of the United States have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government authorities or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on license, collaboration, and other similar agreements to provide rights to the core intellectual property relating to most of our current product candidates, including our most advanced product candidate, EIK1001. These agreements impose significant milestone payments and other obligations on us. If we fail to comply with the obligations of our current or any future license, collaboration, or other agreements for our product candidates, or otherwise experience disruptions to our business relationships with our current or future licensors or collaborators, we could lose license or other rights that are important to our business, and hence lose the ability to continue the development and commercialization of our product candidates, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The growth of our business depends substantially on the intellectual property and other proprietary rights we in-license from third parties. For example, we have entered into license and collaboration agreements with Seven and Eight and Impact to license certain intellectual property and other proprietary rights relating to our product candidates EIK1001, EIK1003, and EIK1004. Our programs may involve additional product candidates that may require the use of other intellectual property and proprietary rights held by third parties, as may further development and commercialization of our existing product candidates, if approved. For example, we may develop products containing other pre-existing compounds. These compounds may be covered by intellectual property rights held by others. Thus, we may in the future enter into additional license, collaboration, and other similar agreements with third parties under which we receive rights to other intellectual property and proprietary rights that are important to our business, or we may otherwise acquire such rights. We may fail to obtain any of these licenses or rights on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Alternatively, our current and future licenses may not provide us with exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates, if approved. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee, or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation, or for other reasons. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses. Our success will depend in part</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on the ability of our licensors to obtain, maintain, and enforce patent protection for their intellectual property, in particular, those patents to which we have secured exclusive rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current license and collaboration agreements also impose on us various development, regulatory and/or commercial diligence obligations, payment of milestones, and other obligations. In particular, some of the milestone payments are payable upon our product candidates reaching development milestones before we have commercialized, or received any revenue from, sales of such product candidate, and we cannot guarantee that we will have sufficient resources to make such milestone payments. Any uncured, material breach under the license and collaboration agreements could result in our loss of exclusive rights, and may lead to a complete termination of our rights to the applicable product candidate. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also in the future enter into license, collaboration, and similar agreements with third parties under which we are a sublicensee. If our sublicensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we were able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impair our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some circumstances, we may not have the right to control the maintenance, prosecution, preparation, filing, enforcement, defense, or litigation of patents and patent applications (including designating one or more patents for extended terms, where such extensions are available) that we license from, or license to, third parties, and are reliant on our licensors or licensees to do so. We thus cannot be certain that activities such as patent maintenance and prosecution by our licensors or licensees have been or will be conducted consistent with our best interests, or in compliance with applicable laws and regulations, or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#8217; or licensees&#8217; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves, or may not be conducted in accordance with our best interests. If our licensors or licensees fail to maintain such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize our product candidates or any of our product candidates that are the subject of such licensed rights, in each case if approved, and our right to exclude third parties from commercializing competing products could be adversely affected. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In spite of our efforts, our current and future licensors might conclude that we have materially breached our obligations under our license and collaboration agreements and might therefore terminate such agreements, thereby removing or limiting our ability to develop and commercialize product candidates, if approved, and technology covered by these license and collaboration agreements. Our license and collaboration agreements are, and future license and collaboration agreements are likely to be, complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, any or all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Disputes may arise with respect to our current or future licensing and collaboration agreements and include disputes relating to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license or collaboration agreement and other interpretation-related issues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial or other obligations under the license or collaboration agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our technology and product candidates infringe on intellectual property of the licensor that is not subject to the licensing arrangement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sublicensing of patent and other rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license or collaboration agreements and what activities satisfy those diligence obligations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we are currently engaged in a payment-related dispute with Seven and Eight. Seven and Eight has alleged that it did not receive a payment we made to Seven and Eight as required by our collaboration agreement and thus such payment is still owed. Although we believe our payment was made in good faith, if we are unable to reach a mutually agreeable resolution to this matter with Seven and Eight, arbitration may be necessary. If this dispute or other disputes involving our license and collaboration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agreements, including disputes over intellectual property or other proprietary rights that we license now or in the future, prevent or impair our ability to maintain our licensing arrangements on commercially reasonable terms, we may not be able to successfully develop and commercialize the affected product candidates, if approved, which would have a material adverse effect on our business. If our licenses are terminated, we may lose our rights to develop and market our technology and product candidates, lose patent protection for our product candidates and technology, experience significant delays in the development and commercialization of our product candidates, if approved, or incur liability for damages.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may jointly own intellectual property with third parties. Under some circumstances, it may be difficult to determine who owns a particular invention or whether it is jointly owned, and disputes could arise regarding ownership, use, prosecution, maintenance, and enforcement. Such disputes with any third-party co-owners of our intellectual property may result in direct financial harm or distract our management from our operations or strategic goals, harming our business, prospects, financial condition, and results of operation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours, and we may be required to cease our development and commercialization of certain of our product candidates, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our agreements with third parties may limit or delay our ability to consummate certain transactions, may reduce the value of those transactions, or may limit our ability to pursue certain activities. For example, we may be a party to license, collaboration, or other similar agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we commercialize any product candidates, such product may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which could harm our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulations that govern marketing approvals, pricing, and reimbursement for new drug products and biologics vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or limit our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenue we generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our product candidates, if approved, depends in part on the availability of coverage and adequate reimbursement from third-party payors, such as government authorities, private health insurers, and other organizations. We cannot be certain that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will continue to be made available for any product that we may develop that initially receives coverage and adequate reimbursement from one or more third-party payors. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Accordingly, coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. These groups have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective, and medically necessary;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors, which may result in significant variations in coverage and reimbursement from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical, and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability, or may require co-payments that patients find unacceptably high. Further, even if favorable coverage and reimbursement status is attained for one or more drug products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, at the federal level, the Inflation Reduction Act, or the IRA, was signed into law in 2022 and set forth meaningful changes to drug product reimbursement by Medicare. The IRA, among other things, directs the Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax for failure to comply with or participate in the program. This program applies to drug products that have been approved for at least seven years and biologics that have been licensed for 11 years, with exceptions such as for certain orphan-designated drugs for which the only approved indication (or indications) is for the orphan disease or condition. Should our product candidates be approved and covered by Medicare Part B or Part D, and fail to fall within a statutory exception such as that for an orphan drug, those products could, after a period of time, be selected for negotiation and become subject to &#8220;maximum fair prices&#8221; under the program. This could heighten the risk that we would not be able to achieve the expected return on our investment in drug products, or full value of our patents protecting our products, if prices are set under the program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IRA also establishes a rebate obligation for drug manufacturers that increase prices of Medicare Part B and Part D covered drugs at a rate greater than the rate of inflation. The inflation rebates may require us to pay rebates if we increase the cost of a product reimbursed by Medicare Part B or Part D faster than the rate of inflation. In addition, the law redesigned the Part D benefit, and our cost-sharing responsibility for any approved product covered by Medicare Part D could be significantly greater compared to the pre-IRA benefit design. Additionally, manufacturers that fail to comply with certain provisions of the IRA may be subject to penalties, including civil monetary penalties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The negotiation provisions of the IRA are currently the subject of several legal challenges, and the outcome of that litigation is difficult to predict. In any event, the IRA is likely to have a significant impact on the pharmaceutical industry and may reduce the prices we can charge, and the reimbursement we can receive, for our products, among other effects. If healthcare policies or reforms intended to curb healthcare costs are adopted, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited, and/or our revenues from sales of our products may be reduced.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, there may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including costs related to research and development, manufacturing, and sale and distribution efforts. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, and may be incorporated into existing payments for other services.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to experience pricing pressures in connection with the sale of all of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives, and additional legislative changes. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or third-party payors, and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and future relationships with healthcare providers and physicians and third-party payors may be subject to applicable anti-kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians, and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Any arrangements we may have with healthcare providers, third-party payors, and customers can expose us to broadly applicable healthcare fraud and abuse laws and regulations. Such laws and regulations may constrain the business or financial arrangements and relationships through which we research and, if approved, sell, market, and distribute our product candidates. In particular, the research of our product candidates, as well as the promotion, sales, marketing, and business arrangements of our product candidates, is subject to extensive laws designed to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commissions practices, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The applicable federal, state, and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, or recommendation of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal civil and criminal false claims laws, including the FCA, which prohibit individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by, Medicare, Medicaid or other federal healthcare programs, knowingly making, using, or causing to be made, or used, a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government healthcare programs if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA, and to share in any monetary recovery;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating the healthcare fraud statute under HIPAA without actual knowledge of the statute, or specific intent to violate it;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">furthermore, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, also imposes obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; and their respective subcontractors that create, receive, maintain, or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the civil monetary penalties statute, which, subject to certain exceptions, prohibits, among other things, the offer or transfer of remuneration, including waivers of copayments and deductible amounts (or any part thereof), to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare, or a state healthcare program;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs that may be used in the calculation of reimbursement or discounts on approved products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payments Sunshine Act and its implementing regulations, which require some manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to HHS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain non-physician practitioners (such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and may be broader in scope than their federal equivalents, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and local laws that require the registration of pharmaceutical sales representatives.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal, state, and foreign enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, significant fines, penalties, and settlements in the healthcare industry. Ensuring that business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and may divert our management&#8217;s attention from the operation of our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages, and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses, and divert management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future marketed products could adversely affect our business, financial condition, results of operations, and prospects. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil, and administrative sanctions, including exclusions from government funded healthcare programs, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may attempt to seek approval from the FDA for one or more of our product candidates through the use of the accelerated approval pathway. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future seek approval for one or more of our product candidates under the FDA&#8217;s accelerated approval pathway. Under the accelerated approval pathway, the FDA may approve a product candidate for a serious or life-threatening disease or condition, which candidate has shown that it provides a meaningful therapeutic benefit to patients over existing treatments, based on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval are subject to certain additional post-marketing requirements. These typically include a requirement to conduct one or more post-approval studies to confirm the clinical benefit of the product, submission to the FDA during the pre-approval period of all promotional materials intended to be used within 120 days following marketing approval, and submission of promotional materials for use after that period at least 30 days prior to their dissemination. There can be no assurance that we will be able to use the accelerated approval pathway or any other form of expedited development, review, or approval for any of our product candidates. For example, the FDA may not agree with our conclusion that a surrogate endpoint we select is reasonably likely to predict clinical benefit, and thus the FDA may not agree that accelerated approval is appropriate based on that endpoint (even if the results on that endpoint are statistically significant). Also, for any one of our product candidates, if any of our competitors were to receive full approval for an indication for which we are seeking accelerated approval before we receive accelerated approval, our drug candidate may no longer provide meaningful therapeutic benefit over existing treatments, and our product candidate may become ineligible for accelerated approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A failure to obtain accelerated approval would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate, and could harm our competitive position in the marketplace. Even if we are able to obtain accelerated approval, if we do not complete the required post-approval studies, or if the FDA determines that the completed post-approval studies do not confirm clinical benefit, then FDA may withdraw approval of our product using expedited procedures.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek a Breakthrough Therapy or Fast Track designation or priority review voucher for current or future product candidates, but we might not receive such designation, and even if we do, we may not maintain such designation. Such designation may not lead to faster development, regulatory review, or approval, and will not increase the likelihood that the product candidate will receive marketing approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek a Breakthrough Therapy or Fast Track designation for our current or future product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, where preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biologics that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs or biologics designated as Breakthrough Therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA or BLA is submitted to the FDA. The FDA also has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria. New drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition, and preclinical or clinical data demonstrate the potential to address unmet medical needs for that disease or condition. Fast Track and Breakthrough Therapy designations apply to the combination of the product and the specific indication for which it is being studied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also recently announced the Commissioner&#8217;s National Priority Voucher program, designed to accelerate the development and review of certain drugs and biological products that are aligned with U.S. national health priorities and to enhance the health interests of Americans. Companies selected for the program will be issued a priority review voucher entitling the company to benefits including enhanced communications and rolling review to allow for a shortened review time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has broad discretion whether or not to grant Breakthrough Therapy or Fast Track designation or a priority review voucher to any product candidate. Accordingly, even if we believe that a product candidate meets the criteria for a Breakthrough Therapy or a Fast Track designation or a priority review voucher, the FDA may disagree and instead determine not to make such a designation. Even if we receive a Breakthrough Therapy or Fast Track designation or a priority review voucher, the receipt of such designation or voucher may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures, and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a Breakthrough Therapy or for the Fast Track program or for a priority review voucher, the FDA may later decide that it no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shortened. The failure to obtain a Breakthrough Therapy or Fast Track designation or a priority review voucher for any product candidates we may develop, or the inability to maintain that designation for the duration of the applicable period, could reduce our ability to accrue sufficient sales of the applicable product candidate to balance the expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently enacted legislation, future legislation, and other healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or, collectively, the ACA, was enacted in the United States, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States and significantly affected the pharmaceutical industry. The ACA subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program, or MDRP, are calculated for drugs and biologics that are inhaled, infused, instilled, implanted, or injected, increased the minimum Medicaid rebates owed by manufacturers under the MDRP, extended manufacturer Medicaid rebate obligations to utilization by individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and biologics, and established a new Medicare Part D coverage gap discount program. Since its enactment, there have been judicial, congressional, and executive branch challenges to the ACA, which have resulted in delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the IRA includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap, impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay until January 1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Various industry stakeholders, including certain pharmaceutical companies and industry groups, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access, marketing cost disclosure, transparency measures and other measures designed to encourage importation from other countries, and bulk purchasing. In January 2024, the FDA authorized Florida&#8217;s Agency for Health Care Administration&#8217;s drug importation program, which is the first step toward Florida facilitating importation of certain prescription drugs from Canada. Authorization of other state programs may follow. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations, and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products, and which suppliers, will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 was signed into law, which resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2032.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the ACA, the IRA, and any other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies, and additional downward pressure on the price that we receive for any approved product. We cannot predict the likelihood, nature, or extent of healthcare reform initiatives that may arise from future legislation or administrative action. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates, if approved.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive marketing approval for our current or future product candidates in the United States, we may never receive regulatory approval to market outside of the United States.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to seek regulatory approval of our current or future product candidates outside of the United States in the future. In order to market any product outside of the United States, however, we must establish and comply with the numerous and varying safety, efficacy, and other regulatory requirements of other applicable countries. Approval procedures vary among countries and can involve additional product candidate testing and additional administrative review periods. The time required to obtain approvals in other countries might differ substantially from that required to obtain FDA approval. The marketing approval processes in other countries generally implicate all of the risks detailed above regarding FDA approval in the United States, as well as other risks. In particular, in many countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of any of our product candidates in certain countries. Regulatory and marketing approval in one country does not ensure regulatory and marketing approval in another, but a failure or delay in obtaining regulatory and marketing approval in one country may have a negative effect on the regulatory process in others, and would impair our ability to market our current or future product candidates in such foreign markets. Any such impairment would reduce the size of our potential market, which could adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws. Anti-corruption laws generally prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments, or anything else of value to or from recipients in the public or private sector.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our ex-U.S. activities to increase over time, including the engagement of third parties for clinical trials or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with Trade Laws may result in substantial civil and criminal fines and penalties, imprisonment, the loss of trade privileges, suspension or debarment from government contracting, breach of contract and fraud litigation, reputational harm, and other consequences.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing, and selling certain product candidates we may identify outside of the United States, and require us to develop and implement costly compliance programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate in the future. The creation, implementation, and maintenance of international business practices compliance programs is costly, and such programs are difficult to enforce, particularly where reliance on third parties is required.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FCPA prohibits any U.S. persons, as well as their employees, agents and other collaborators, from paying, offering, authorizing payment, or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate, and other related parties, for the purpose of influencing any act or decision of the foreign entity, or to obtain, retain, or direct business. The FCPA also obligates companies whose securities are publicly listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all of the company&#8217;s transactions, including those of its international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with the FCPA is expensive and can be difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Export control and economic sanctions laws may restrict, or even prohibit, the provision of certain items, technology, and services to countries, governments, and persons targeted by sanctions programs. Governmental regulation of the import or export of our product candidates, or our failure to obtain any required import or export authorization for our product candidates, when applicable, could harm our operations. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our research and development costs. Violations of the FCPA can result in significant civil and criminal penalties. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could adversely affect our business, financial condition, and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our future commercialization, research, engineering, and development efforts, and business operations, and/or environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures used by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not be the case, and we may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state, federal, or other applicable authorities may curtail our use of certain materials or interrupt our business operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain insurance to cover us for costs and expenses that we may incur due to injuries to our employees resulting from the use of hazardous materials and insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials, these insurance plans may not provide adequate coverage against potential liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes or our future compliance. In addition, we may incur substantial costs to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could adversely affect our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel, the ability to accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also extend the time necessary for new drug development and for those new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business, financial condition, results of operations, and prospects. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, or there are other changes which limit the FDA&#8217;s ability to perform its necessary activities in a timely manner, it could significantly reduce the ability of the FDA to review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the current presidential administration has expressed an intention of, and undertaken efforts to, reduce the size and spending of the federal government. As part of this initiative, the current presidential administration established the Department of Government Efficiency, or DOGE, which is tasked with reducing government spending and increasing efficiency of the federal government and its component agencies. Since its establishment, DOGE has taken action aimed at reducing the workforce of the federal government and eliminating other expenditures, such as facility leases, used by the federal government and its component</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agencies. While these and other actions taken by the current presidential administration could be viewed as a part of a larger goal of de-regulation, a consequence of these developments and other actions taken by DOGE or the current presidential administration generally could be reduced resources, employees, and contractors at the FDA, which could significantly reduce the ability of the FDA to complete their review responsibilities, and hence could materially affect our ability to achieve timely registration of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Social media is increasingly being used to communicate about clinical development programs and the diseases our product candidates are being developed to treat. We may utilize appropriate social media in connection with communicating about our development programs. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to report an alleged adverse event during a clinical trial. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations, or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website, or a risk that a post on a social networking website by any of our employees may be construed as inappropriate promotion. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Data Privacy, Information Technology, and Cybersecurity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems, or those used by our CROs, CMOs, clinical sites, or other contractors, consultants, or third parties with whom we work, or our data are or were compromised, including by system failures, security incidents, or loss or leakage of data, or otherwise disrupted, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or action, litigation, fines and penalties, disruptions of our business operations, reputational harm, and other adverse consequences.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of our business, we, and the third parties with whom we work, collect, receive, store, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, share, and otherwise process, which we collectively refer to as process, personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions and financial information, and other proprietary information, which we collectively refer to as sensitive data. We also generate a substantial amount of sensitive data through our technology platform in the ordinary course of our business. As a result we, and the third parties with whom we work, face a variety of evolving threats which could cause security incidents or other disruptions. Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties with whom we work. Therefore, it is critical that we and third parties with whom we work process sensitive data in a secure manner to maintain the confidentiality and integrity of such sensitive data and otherwise safeguard our information technology systems.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, given the size and complexity of our information technology systems and those of our CROs, CMOs, clinical sites, and other contractors, consultants, and third parties with whom we work, and the increasing amounts of sensitive data that they maintain, such information technology systems are potentially vulnerable to cyberattacks, computer viruses, bugs, worms or other malicious codes, malware (including as a result of advanced persistent threat intrusions) and other attacks by computer hackers, brute force attacks, application security attacks, social engineering (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), infiltration by unauthorized persons, fraud, supply chain attacks and vulnerabilities through our third-party service providers or otherwise, denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, supply-chain attacks, software bugs, breakdown or other damage or interruption from service interruptions, system or server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks facilitated or enhanced by AI, telecommunications and electrical failures, earthquakes, fires, floods, other natural disasters, terrorism, war, and other similar threats. Such information technology systems are additionally vulnerable to security incidents or other disruptions from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners, and other third parties. The increase in remote work has increased these risks to our information technology systems and sensitive data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit, and in public locations. Any of the foregoing may compromise or disable our system infrastructure, or that of our third-party vendors and other contractors and consultants, or lead to data leakage.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors, for geopolitical reasons and in conjunction with military conflicts and defense activities. In particular, ransomware attacks, including those from organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent, sophisticated, and severe, and can lead to significant interruptions, delays, or outages in our operations, loss of sensitive data, loss of income, significant extra expenses to restore data or systems, reputational loss, and the diversion of funds.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of attacks for geopolitical reasons, including retaliatory cyberattacks, that could materially disrupt our systems and operations, including our supply chains, thereby degrading our ability to continue our research, engineering, and development efforts, or to produce, sell, and distribute our product candidates, if approved. In addition to experiencing a security incident or other disruption, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveal competitively sensitive details about our organization. These data could be used by third parties to undermine our competitive advantage or market position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, future business transactions (such as acquisitions) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in the systems and technologies of any acquired entities. Additionally, we may discover security or other issues that were not found during due diligence of such acquired entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It may be difficult or costly to detect, investigate, mitigate, contain, and remediate a security incident or other disruption. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident or other disruption could result in outages, data losses, and disruptions of our business. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we use a combination of in-house and third-party cloud services to store and manage the data we generate using our technology platform. If either cloud service is disrupted, it could result in the loss of proprietary data, which would require additional cost and time to recreate and have an adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our reliance on third-party partners could introduce new cybersecurity risks and vulnerabilities. We rely on third-party partners and technologies to operate critical business systems and to process sensitive data in a variety of contexts, including encryption and authentication technology, employee email, and other functions. We also rely on third-party partners to assist with our clinical trials, provide other products or services, or otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party partners experience a security incident, breach, or other incident or failure, we could experience adverse consequences. Further, in such a circumstance, we may not receive timely notice of, or sufficient information about, the security incident, breach, or other incident or failure, or be able to exert any meaningful control of or influence over how and when such security incident or failure is addressed. While we may be entitled to damages if our third-party service partners fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of, or disruption to, our information technology systems (including our services) or the third-party information technology systems that support us and our services.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively implement measures designed to identify, protect, detect, respond to, and recover from vulnerabilities within our information systems, including those related to hardware, software, and third-party providers. However, despite our efforts, not all vulnerabilities may be detected or resolved promptly. In some cases, there may be delays in developing and deploying necessary remediation measures and security patches. These undetected or unaddressed vulnerabilities could be exploited, potentially leading to security incidents or other disruptions, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. We have experienced certain immaterial security incidents in the past, and may experience security incidents in the future. Such an event, or other threats in the future, could cause another security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, or disclosure of, or access to, our sensitive data or our information technology systems, or those of the third parties with whom we work. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our services, including clinical trials, or continue our target discovery programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have expended significant resources and modified our business activities (including our clinical trial activities) to try to protect against security incidents and other disruptions, and will continue to do so. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The costs related to security breaches or disruptions could be material, and might cause us to incur significant expenses. If the information technology systems of our CROs, CMOs, clinical sites, and other contractors and consultants become subject to disruptions or security incidents, we may have insufficient recourse against such third parties, and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any such incidents were to occur and cause interruptions in our operations, including to the extent that any disruption or security incident were to result in a loss or interruption of, or damage to, our data or applications, or those of our contractors, consultants, and other third parties with whom we work, or inappropriate disclosure of sensitive data, it could result in a disruption of our business, operations, and development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in the loss of, or damage to, our sensitive data or applications, or inappropriate disclosure of sensitive data, we could incur liability and reputational damage, and the further development of any product candidates could be delayed. Applicable privacy and cybersecurity obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, future customers, regulators, and investors, of security incidents or other disruptions, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure, or the failure to comply with applicable requirements, could have material adverse effects on our business. Any such event could also result in adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections), additional reporting requirements or oversight, restrictions on processing sensitive data, litigation, indemnification obligations, negative publicity, reputational harm, monetary fund diversions, diversion of management attention, financial loss, and other similar harms. Security incidents, other disruptions, and their attendant consequences may negatively impact our ability to grow and operate our business, and may result in a loss of confidence in us and in our ability to conduct clinical trials, which could delay the clinical development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the information technology systems of our contractors, consultants, and other third parties with whom we work become subject to disruptions or security incidents, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. Our contracts may not always contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and cybersecurity obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from, or to mitigate liabilities arising as a result of, our privacy and cybersecurity practices, or that such coverage will continue to be available on commercially reasonable terms, or at all, or that such coverage will pay future claims. Additionally, our sensitive data could be leaked, disclosed, or revealed as a result of, or in connection with, our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our data protection efforts and our investment in information technology will prevent breakdowns, data leakages, breaches in our systems, or those of our contractors, consultants, and other third parties with whom we work, or other security incidents or other disruptions that could have a material adverse effect upon our reputation, business, operations, or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our contractors, consultants, and other third parties with whom we work, it could result in a material disruption or delay of the development of our product candidates. Furthermore, significant disruptions of our internal information technology systems, or those of our contractors,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consultants, and other third parties with whom we work, or security incidents, could result in the loss, misappropriation, or unauthorized access, use, or disclosure of, or the prevention of access to, sensitive data, which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of sensitive data, including sensitive data regarding our customers or employees, could harm our reputation directly, compel us to comply with federal or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of sensitive data, which could result in significant legal and financial exposure, and reputational damages that could potentially have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies, and other obligations related to privacy and cybersecurity. Any actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation (including class claims), negative publicity, or other adverse consequences that could negatively affect our operating results and business, as could changes in such laws, regulations, and other obligations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we and our partners process personal data, including sensitive personal data, as well as proprietary and confidential business information and other personal data. As a result, we and our partners are subject to numerous privacy and cybersecurity obligations, which may include various federal, state, local, and foreign laws and regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to privacy and cybersecurity. These laws, rules, and regulations may be subject to differing interpretations, which adds to the complexity of processing personal data. Guidance on implementation and compliance practices are often updated or otherwise revised. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions, or to collect, store, transfer, use, share, or otherwise process personal data, necessitate the acceptance of more onerous obligations in our contracts, result in liability, or impose additional costs on us. If we fail or are perceived to have failed, to comply with these laws, rules, and regulations, we may be subject to litigation, regulatory investigations, enforcement notices, enforcement actions, fines, imprisonment of company officials, public censure, claims for damages by affected individuals, and criminal or civil penalties, as well as negative publicity, reputational harm, loss of goodwill, and a potential loss of business, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, numerous federal, state, and local governments have enacted laws, rules, and regulations, including state data breach notification laws, state health information privacy laws, federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act, or the FTCA), and other similar regulations (e.g., wiretapping) that govern the processing of personal data, including health-related information. Each of these laws, rules, and regulations is subject to varying interpretations and constantly evolving.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, HIPAA, as amended by HITECH, and regulations promulgated thereunder, impose specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information on &#8220;covered entities,&#8221; and their respective &#8220;business associates,&#8221; as well as their covered subcontractors, that perform services for them. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. For example, while we are not a &#8220;covered entity&#8221; under HIPAA, if we enter into a business associate agreement, we could potentially face substantial criminal or civil penalties if we knowingly receive protected health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of such protected health information, or otherwise violate applicable HIPAA requirements related to the protection of such information. Moreover, determining whether protected health information has been handled in compliance with applicable privacy standards, as well as our contractual obligations with third parties can be complex and may be subject to changing interpretation. If we are unable to protect the privacy and security of health information, we could be found to have breached our contracts. HHS has the discretion to impose penalties without attempting to first resolve violations. HHS enforcement activity can result in financial liability and reputational harm.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even when HIPAA does not apply, according to the Federal Trade Commission, or the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce, in violation of the FTCA. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered personal data that merits stronger safeguards.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on April 8, 2025, the DOJ implemented the Data Security Program Rule, or DSP, under Executive Order 14117 and the International Emergency Economic Powers Act. The DSP imposes restrictions on certain data-related transactions involving U.S. persons and entities, particularly those that may result in access to U.S. government-related data or bulk sensitive personal data of U.S. persons by foreign adversaries or entities under their control. The rule effectively imposes export control-like restrictions on the transfer, sale, or sharing of sensitive data-including genomic, geolocation, biometric, health, financial, and other personal data-to or with entities in countries of concern, including but not limited to China, as well as entities and persons associated with those countries. The DSP also creates additional obligations for U.S. companies concerning personal data they collect, store, or transmit. Compliance may require us to stop or restrict certain data transfers, alter the geographic scope of our operations, cease doing business with certain third parties or using certain tools or vendors, or change how data flows throughout our business. Failure to comply with the DSP could result in civil or criminal penalties and restrictions on our ability to engage in certain business activities. Additionally, the scope and interpretation of the rule may evolve, and future guidance or enforcement actions could impose further obligations or restrictions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may affect our business. Certain states also impose stricter requirements for processing certain personal data, including sensitive data, such as conducting data privacy impact assessments. Failure to comply with these laws, where applicable, can result in significant statutory fines. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act of 2020, collectively the CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices, and honor requests of such individuals to exercise certain privacy rights, including allowing customers to opt out of certain data sharing with third parties. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants to recover significant statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. The CCPA and other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties with whom we work. Several other states have passed comprehensive privacy laws similar to the CCPA. Like the CCPA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data. Some of the provisions of these laws may apply to our business activities. A number of similar privacy laws are also being considered in several other states as well as at the federal level, which may add additional complexity, variation in requirements, restrictions, and potential legal risk, and require additional investment of resources in compliance programs, alter data handling strategies, and restrict the availability of previously useful data, and could result in increased compliance costs or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly, and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, all 50 U.S. states and the District of Columbia have enacted breach notification laws that may require us to notify patients, employees, or regulators in the event of unauthorized access to or disclosure of personal or confidential information experienced by us or our collaborators or third-party service providers. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states frequently amend existing laws, requiring attention to changing regulatory requirements. We also may be contractually required to notify patients or other counterparties of a security breach. In addition to government regulation, privacy advocates and industry groups have in the past, and may in the future propose, self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws and regulations, including Australia&#8217;s Privacy Act 1988, the European Union&#8217;s General Data Protection Regulation, or the EU GDPR, the United Kingdom&#8217;s General Data Protection Regulation, or UK GDPR, together with the EU GDPR, the GDPR, and China&#8217;s Personal Information Protection Law, or the PIPL, may also apply to our processing of personal data, including health-related and other sensitive personal data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR, together with national legislation, regulations, and guidelines of the European Economic Area, or the EEA, EU member states, and the United Kingdom governing the processing of personal data, imposes strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including processing health data from clinical trials, adverse event reporting, and engaging in other activities associated with clinical trials. In particular, these obligations and restrictions concern the legal basis, such as consent, upon which personal data may be lawfully processed, the information provided to individuals whose data are processed, the transfer of personal data out of the EEA or the United Kingdom, security breach notifications, and the security and confidentiality of the personal data. The GDPR also provides that EEA member states and the United Kingdom make their own further laws, rules, and regulations to introduce specific requirements related to the processing of &#8220;special categories of personal data,&#8221; including personal data related to health, biometric data used for unique identification purposes, genetic information, as well as personal data related to criminal offences or convictions. This fact may lead to greater divergence on the law that applies to the processing of such data types</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">across the EEA and the United Kingdom, compliance with which, as and where applicable, may increase our costs and could increase our overall compliance risk. Such member state-specific regulations could limit our ability to collect, use, and share data in the context of any future EEA or United Kingdom establishments (regardless of where any processing in question occurs). The GDPR also imposes substantial potential fines for breaches of such data protection obligations. Companies that must comply with the GDPR face increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements by national authorities, temporary or definitive bans on data processing, private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized under law to represent their interests, and potential administrative fines for noncompliance of up to &#8364;20 million (&#163;17.5 million) or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition to administrative fines, a wide variety of other potential enforcement powers are available to competent supervisory authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by non-compliant companies. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Further, the exit of the United Kingdom from the EU, often referred to as Brexit, and ongoing developments in the United Kingdom have created uncertainty regarding data protection regulation in the United Kingdom. While the EU GDPR and the UK GDPR remain substantially similar for the time being, the government of the United Kingdom has adopted reforms to its data privacy and cybersecurity legal framework in its Data Use and Access Act 2025, which became law on June 19, 2025 (phasing in between June 2025 and June 2026) and will introduce significant changes from the EU GDPR. This may lead to additional compliance costs and could increase overall risk exposure as businesses may no longer be able to take a unified approach across the EEA and the United Kingdom, and such businesses may need to amend their processes and procedures to align with the new framework. Implementing mechanisms to endeavor to ensure compliance with the EU GDPR and the UK GDPR may be onerous and expose businesses to divergent parallel regimes that may be subject to potentially different interpretations and enforcement actions for certain violations and related uncertainty.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be unable to transfer personal data from the EEA and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws or imposed policy mandates requiring data to be localized, or limiting the transfer of personal data to other countries. In particular, the EEA and the United Kingdom have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and United Kingdom to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the United Kingdom&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework, or the Framework, and the United Kingdom extension thereto (which allows for transfers to U.S.-based organizations that self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges or may be challenged in the future, and there is no guarantee that we can satisfy or rely on these measures to lawfully transfer personal data to the United States or other jurisdictions. If there is no lawful manner for us to transfer personal data from the EEA, the United Kingdom, or other jurisdictions to the United States, or if the requirements for a legally compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors, and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and United Kingdom to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and civil society and privacy advocacy groups.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PIPL covers the processing of personal information of persons by organizations and individuals in China, and the processing of personal information of persons in China outside of China if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, persons in China. It imposes similar restrictions as the GDPR does, including restrictions on the ability to collect and process personal data, consent requirements and data subject rights, and data localization and limitations on cross-border data transfers. Companies that violate the PIPL are subject to fines of up to 50 million renminbi or 5% of the revenue of the noncompliant company in the prior year and other penalties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Implementing mechanisms to ensure our compliance with the GDPR, the PIPL, and relevant local legislation in EEA member states, the United Kingdom, China, and elsewhere we do business may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations, and prospects. In addition to the foregoing, a breach of the GDPR, the PIPL, or other applicable data privacy, data protection, and security laws and regulations could result in regulatory investigations, reputational damage and orders to cease or change our use of data, enforcement notices, or potential civil claims including class-action-type litigation.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are bound by other contractual obligations related to privacy and cybersecurity, and our efforts to comply with such obligations may not be successful.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding privacy and cybersecurity. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations related to privacy and cybersecurity (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices, and to those of any third parties that process personal data on our behalf.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our collaborators or our third-party processors fail to keep apprised of, and comply with, applicable international, federal, state, or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any of our collaborators&#8217; ability to seek to commercialize our product candidates, if approved. Any threatened or actual governmental enforcement action or litigation where private rights of action are available could also generate adverse publicity, damage our reputation, result in liabilities, fines, and loss of business, and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with U.S. and foreign privacy and cybersecurity laws, rules, and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use, and disclose sensitive data, or, in some cases, diminish our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. We may face challenges in addressing their requirements and making necessary changes to our policies and practices, and may incur significant costs and expenses in an effort to do so. Any actual or perceived failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, or adverse publicity, and could negatively affect our operating results and business. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, and could result in adverse publicity that could harm our business. Moreover, even if we take all necessary actions to comply with legal and regulatory requirements, we could be subject to data breaches or other unauthorized access of personal information or other sensitive or confidential information, which could subject us to fines and penalties, as well as litigation and reputational damage and other adverse consequences.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have relied and expect to continue to rely on third parties to assist us as we conduct aspects of our preclinical studies and clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines, or terminate their relationship with us, our development programs could be delayed, made more costly, or fail to yield interpretable results, and we may never be able to seek or obtain regulatory approval for, or commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and intend to rely in the future, on various flexible service providers with whom we contract to undertake specific tasks in the conduct of preclinical studies and clinical trials to support the evaluation of our current or future product candidates. Because we currently rely and intend to continue to rely on these third parties, we may have less control over the timing, quality, and other aspects of preclinical studies and clinical trials than we would have had we conducted all aspects of these studies independently. For example, under the collaboration agreement with Impact, Impact is responsible for the clinical development of EIK1003 and EIK1004 in certain jurisdictions, and we currently depend on Impact for our clinical drug substance supply for these product candidates. While we generally do not rely on CROs to supervise and conduct clinical trials in their entirety, we often employ CROs under flexible service provider contracts to represent us in jurisdictions where we do not currently have permanent employees, or to undertake specific tasks where our own employees cannot allocate sufficient time to complete the necessary work. These parties are not, and will not be, our employees, and we must supervise the amount of time and the resources that they dedicate to our programs. Additionally, such parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Large-scale clinical trials require significant financial and management resources, and reliance on third-party clinical investigators, CROs, partners, or consultants. Relying on third-party clinical investigators or CROs may force us to encounter delays and challenges that are outside of our control. We may not be able to demonstrate sufficient comparability between products manufactured at different facilities to allow for inclusion of the clinical results from participants treated with products from these different facilities, in our product registrations. Further, our third-party clinical manufacturers may not be able to manufacture our product candidates or otherwise fulfill their obligations to us because of interruptions to their business, including the loss of their key staff or interruptions to their raw material supply.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable trial protocol and legal, regulatory, and scientific standards, and our reliance on the CROs, clinical trial sites, and other third parties does not relieve us of these responsibilities. For example, we will remain responsible for ensuring that each of our preclinical studies is conducted in accordance with good laboratory practices, or GLPs, and clinical trials are conducted in accordance with GCPs. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections (including pre-approval inspections once an NDA or BLA is submitted to the FDA) of trial sponsors, clinical investigators, trial sites, and certain third parties, including CROs. If we, our CROs, clinical trial sites, or other third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCPs. Moreover, our business may be adversely affected if our CROs, clinical investigators, or other third parties violate federal or state healthcare fraud and abuse or false claims laws and regulations, or healthcare privacy and security laws.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event we need to repeat, extend, delay, or terminate our clinical trials because these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, our clinical trials may need to be repeated, extended, delayed, or terminated, and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, and we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates, or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our relationships with these third parties terminate, we may not be able to enter into alternative arrangements or do so on commercially reasonable terms. Switching or adding additional contractors involves additional cost and time and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. In addition, if an agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#8217;s technology or intellectual property, or require us to stop development of those product candidates completely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers and suppliers to supply our product candidates. The loss of our third-party manufacturers or suppliers, or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, within acceptable timeframes, or at all, would materially and adversely affect our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have any manufacturing facilities, and do not plan to establish manufacturing capabilities in the near future. We currently rely, and expect to continue to rely, on third-party contract manufacturers to provide bulk drug substances, drug products, raw materials, samples, components, and other materials for our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. There can be no assurance that our preclinical and clinical development supplies will not be limited, interrupted, or terminated, will be of satisfactory quality, or be available at acceptable prices, including as we expand the size and number of our clinical trials. Any deviations from their contractual obligations by our third-party manufacturers could delay, prevent, or impair our development or commercialization efforts. In addition, replacing a manufacturer could require significant effort and time because there may be a limited number of qualified replacements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process for our product candidates is subject to review by the FDA and other foreign regulatory authorities to the extent applicable. We and our suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA and foreign regulatory authorities. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their facilities for the manufacture of elements of our product candidates. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing, or otherwise, or if our projected manufacturing capacity or supply of materials becomes limited, delayed, interrupted, or more costly than anticipated, we may be forced to enter into an agreement with another third party, which we may not be able to do in a timely fashion, or on reasonable terms, or at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty transferring such to another third party. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with applicable quality standards and regulations and guidelines, and we may be required to repeat some of the development program. The delays and costs associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate; however, we do not have any agreements with third-party manufacturers for the long-term supply of any of our product candidates. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our product candidates will be subject to periodic review and inspection by the FDA and foreign regulatory authorities, including for continued compliance with cGMPs, quality control, quality assurance, and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our, or a third party&#8217;s, failure to execute on our manufacturing requirements, comply with cGMPs, or maintain a compliance status acceptable to the FDA or other applicable foreign regulatory authorities could adversely affect our business in a number of ways, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to initiate or continue preclinical studies or clinical trials of product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a loss of the cooperation of existing or future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension, or restrictions of production, injunctions, delay, or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product, refusal to permit the import or export of the products, requirements to cease distribution of the products, product seizure, detention or recall, operating restrictions, suits under the civil FCA, corporate integrity agreements, consent decrees, or withdrawal of product approval.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our CMOs may experience difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our CMOs were to encounter any of these difficulties, our ability to provide our product candidates to patients in clinical trials, or to provide product for treatment of patients if approved, would be jeopardized.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some of our suppliers are located outside of the United States, which subjects us to additional risks that are beyond our control and that could harm our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our suppliers are located outside of the United States, including China. As a result, we are subject to risks associated with doing business abroad, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">political unrest, terrorism, labor disputes, and economic instability resulting in the disruption of trade from foreign countries in which our products are manufactured;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the imposition of new laws and regulations, including those relating to labor conditions, quality and safety standards, imports, duties, taxes, and other charges on imports, as well as trade restrictions, and restrictions on currency exchange or the transfer of funds, particularly new or increased tariffs imposed on imports from countries where our suppliers operate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">greater challenges and increased costs with enforcing and periodically auditing or reviewing our suppliers&#8217; and manufacturers&#8217; compliance with cGMPs, and operating in a manner acceptable to the FDA or foreign regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property and other proprietary rights, including trademark protection, in some countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions in operations due to global, regional, or local public health crises or other emergencies or natural disasters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions or delays in shipments; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in local economic conditions in countries where our manufacturers or suppliers are located.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there is currently significant uncertainty about the future relationship between the United States and various other countries, including China, with respect to trade policies, treaties, government regulations, and tariffs. Increased tariffs could potentially disrupt our existing supply chains and impose additional costs on our business. Additionally, it is possible that further tariffs may be imposed that could affect imports of active pharmaceutical ingredients used in our product candidates, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to such raw materials used in our product candidates. Given the unpredictable regulatory environment in China and the United States and uncertainty regarding how the U.S. or foreign governments will act with respect to tariffs, international trade agreements, and policies, further governmental action related to tariffs, additional taxes, regulatory changes, or other retaliatory trade measures in the future could occur with a corresponding detrimental impact on our business and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other factors beyond our control could interrupt our suppliers&#8217; production, influence the ability of our suppliers to export our clinical supplies cost-effectively or at all, inhibit our suppliers&#8217; ability to procure certain materials, or delay or increase the cost of certain preclinical development programs, any of which could harm our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our stock price may be volatile, and investors in our common stock could incur substantial losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock may be volatile and could fluctuate widely in response to many factors, some of which are outside of our control. As a result of this volatility, you may not be able to sell your shares of common stock at or above the price you paid. The market price for our common stock may be influenced by many factors, including the other risks described in this section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of our preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments with respect to our pipeline, including the commencement, enrollment, or results of preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments with respect to drugs we are using as part of a combination treatment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delays in regulatory filings and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">volatility and instability in the financial and capital markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by competitors that impact our competitive outlook;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in market valuations of similar companies;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments with respect to our product candidates, or similar products or product candidates against which we compete, including unanticipated safety, tolerability, or efficacy concerns;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our efforts to discover, develop, or in-license additional current or future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any changes to our relationship with manufacturers or suppliers, or any manufacturing, supply, or distribution shortages;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments with respect to patents or other intellectual property and other proprietary rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of technological innovations, new product candidates, new products, or new contracts by us or our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements relating to strategic transactions, including acquisitions, dispositions, collaborations, licenses, or similar arrangements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated variations in our operating results due to the level of development expenses and other factors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry, positive or negative recommendations, withdrawal of research coverage by securities analysts, or changes in financial estimates by equity research analysts and whether our product development efforts or earnings (or losses) meet or exceed such estimates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement or expectation of additional financing efforts and receipt, or lack of receipt, of funding in support of conducting our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales or the perception of potential sales of our common stock by us, our insiders, or other stockholders, or issuances by us of shares of our common stock in connection with strategic transactions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expiration of lock-up agreements related to our initial public offering;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments within, and outside of, the United States, including changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation or arbitration;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pandemics, natural disasters, or major catastrophic events; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, political, and market conditions and other factors, such as the imposition of or changes to tariffs, including any such changes specific to the pharmaceutical and biotechnology sectors.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or our directors or officers may be subject to securities litigation, which is expensive and could divert management attention.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be the target of securities litigation in the future, including based on volatility in the market price of our stock. The stock market in general, and Nasdaq-listed and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies. The market price of our common stock is likely to be volatile. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. Our directors or officers may in the future also become involved in securities or other litigation in the context of any roles with other public companies. Securities litigation (including the cost to defend against, and any potential adverse outcome resulting from, any such proceeding) can be expensive and time-consuming, damage our reputation, and divert our management&#8217;s and board of directors&#8217; attention from other business concerns, which could seriously harm our business, financial condition, results of operations, and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance we may publicly provide, which may cause our stock price to fluctuate or decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our operating results to be subject to quarterly and annual fluctuations which may, in turn, cause the price of our common stock to fluctuate substantially. Our net loss and other operating results will be affected by numerous factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in the level of expense related to the ongoing development of our product candidates or future development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results and timing of preclinical studies and ongoing and future clinical trials, or the addition or termination of any such preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of payments we may make or receive under existing license and collaboration arrangements or the termination or modification thereof;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our execution of any strategic transactions, including acquisitions, dispositions, collaborations, licenses, or similar arrangements, and the timing and amount of payments we may make or receive in connection with such transactions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any infringement, misappropriation, or other violation of intellectual property or proprietary rights and any related lawsuit or opposition, inter partes review, post-grant review, derivation, or cancellation proceeding in which we may become involved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruitment and departures of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments affecting our product candidates or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in stock-based compensation expense;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impacts of inflation and rising interest rates on our business and operations; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in general market and economic conditions.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our quarterly or annual operating results fall below the expectations of investors or securities analysts or any forecasts or guidance we may provide to the market, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. Our financial results should not be relied upon as an indication of our future performance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared nor paid dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development, operation, and expansion of our business and we do not anticipate declaring or paying any dividends in the foreseeable future. As a result, capital appreciation of our common stock, which may never occur, will be your sole source of gain on your investment for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our board of directors is authorized to issue and designate shares of our preferred stock without stockholder approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Certificate of Incorporation authorizes our board of directors, without the approval of our stockholders, to issue shares of preferred stock, subject to limitations prescribed by applicable law, rules, and regulations and the provisions of our Certificate of Incorporation, and to establish from time to time the number of shares of preferred stock to be included in each such series, and to fix the designation, powers, preferences, and rights of the shares of each such series and the qualifications, limitations, or restrictions thereof. The powers, preferences, and rights of these additional series of convertible preferred stock may be senior to or on parity with our common stock, which may reduce our common stock&#8217;s value.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no internal sales, marketing, or distribution capabilities, nor have we commercialized a product. We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need to invest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant resources to develop these capabilities. To achieve commercial success for any product candidate for which we obtain marketing approval, we will need to establish sales, marketing, and distribution capabilities, either by ourselves or through collaboration or other arrangements with third parties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have incurred these commercialization expenses prematurely or unnecessarily. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As our development and commercialization plans and strategies mature, and as we transition into operating as a public company, we may expand our employee base for managerial, operational, financial, and other resources. In addition, as our product candidates enter and advance through preclinical studies and clinical trials, we may need to expand our development, regulatory, and manufacturing capabilities or contract with other organizations to provide these capabilities for us. We have to manage additional relationships with partners, suppliers, and other organizations as part of our ongoing and anticipated clinical trials, and we expect to have to manage additional relationships with partners, suppliers, and other organizations in the future. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, and management controls, reporting systems, and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. In addition, we may need to expand our facilities, including laboratory operations, and may be unable to do so on commercially reasonable terms, or at all. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may engage in a variety of strategic transactions, including acquisitions, dispositions, joint ventures, or making investments in other companies or technologies, that could negatively affect our operating results, dilute our stockholders&#8217; ownership, create or increase indebtedness, or cause us to incur significant expense.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our business strategy, from time to time, we may pursue acquisitions of assets or licenses of assets, including preclinical, clinical, or commercial stage products or product candidates, or businesses, dispose of certain of our product candidates or businesses and enter into strategic alliances, joint ventures, and collaborations, all in order to expand our existing technologies and operations or otherwise generate capital to advance our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any such potential transaction may entail numerous risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exposure to unknown liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption of indebtedness, contractual obligations, or contingent liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of our equity securities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">write-downs of assets or goodwill or impairment charges;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased amortization expenses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property, and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing a strategic transaction;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status, and their existing products or product candidates and marketing approvals; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to generate revenue or other benefits from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we may not be able to find suitable partners or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. We may not identify or complete these transactions in a timely manner, on a cost-effective basis or at all, and we may not realize the anticipated benefits of any acquisition, license, strategic alliance, or joint venture.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To finance certain transactions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, or acquire intangible assets that could result in significant amortization expense. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our common stock as consideration. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take certain actions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 21,177,600 shares of our common stock sold in our initial public offering (unless they were purchased by one of our affiliates) are freely tradable, without restriction, in the public market following our initial public offering.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our directors and executive officers and holders of substantially all of our outstanding securities have entered into lock-up agreements with the underwriters pursuant to which they may not, with certain exceptions, through August 3, 2026, offer, sell, or otherwise transfer or dispose of any of our securities, without the prior written consent of the representatives of the underwriters. However, the representatives may permit our officers, directors, and other security holders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements at any time in their sole discretion.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the lock-up agreements expire, an additional 32,924,231 shares of our common stock will be eligible for sale in the public market; however, shares held by directors, executive officers, and other affiliates will continue to be subject to volume limitations under Rule 144 under the Securities Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the 7,522,330 shares of our common stock that are subject to outstanding options and the 739,559 shares of our common stock issuable upon the exercise of our outstanding stock warrants, in each case as of March 31, 2026, are eligible for sale in the public market, to the extent permitted by the provisions of various vesting schedules, the lock-up agreements (and the exceptions thereto), and Rule 144 and Rule 701 under the Securities Act. If these additional shares of our common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of 29,855,741 shares of our outstanding common stock, or approximately 55% of our total outstanding common stock as of March 31, 2026, are entitled to rights with respect to the registration of their shares under the Securities Act, subject to the lock-up agreements described above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act. Any sales of securities by these stockholders, or if it is perceived that they will be sold, could adversely affect the trading price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our principal stockholders or their affiliates are venture capital funds or other investment vehicles that could invest in entities that directly or indirectly compete with us. As a result of these relationships, when conflicts arise between the interests of the principal stockholders or their affiliates and the interests of other stockholders, members of our board of directors that are representatives of the principal stockholders may not be disinterested.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our common stock and will be able to control matters subject to stockholder approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of May 1, 2026, our executive officers, directors, and holders of 5% or more of our capital stock beneficially owned approximately 52% of our voting stock. As a result, these stockholders, if acting together, will continue to have influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation, or sale of all or substantially all of our assets, and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent our change of control, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of us or of our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time and resources to public company compliance initiatives.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, or Nasdaq, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming, or costly, and increase demand on our systems and resources, particularly after we are no longer an emerging growth company or a smaller reporting company. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control over financial reporting on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could significantly harm our business, financial condition, results of operations, and prospects. We plan to hire additional financial reporting, internal control, and other finance personnel or consultants to develop and implement appropriate internal control and reporting procedures, which will increase our costs and expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business, financial condition, results of operations, and prospects may be significantly harmed.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss, or NOL, carryforwards and certain other tax attributes to offset taxable income or taxes may be limited.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. As of December 31, 2025, we had U.S. federal NOL carryforwards of approximately $423.6 million and research and development credits of approximately $23.3 million, and state NOL carryforwards of approximately $253.3 million and research and development credits of approximately $12.0 million. Under the Internal Revenue Code of 1986, as amended, or the Code, our U.S. federal NOL carryforwards will not expire and may be carried forward indefinitely but the deductibility of such NOL carryforwards is limited to no more than 80% of current year taxable income (with certain adjustments). In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation due to the complexity and cost associated with such a study; however, we have completed several fundraises in recent years including our initial public offering, increasing the likelihood that there have been changes in our ownership that would limit our ability to utilize our tax attribute carryforwards. Furthermore, there may be additional ownership changes in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future, or as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If we have undergone, or in the future undergo, an ownership change, and our ability to use our pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes is limited, it may harm our future results of operations by effectively increasing our future tax liability. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase our state taxes liability. As a result, even if we attain profitability, we may be unable to use all or a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future changes to tax laws could materially adversely affect us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax regimes we are subject to or operate under, including with respect to income and non-income taxes, are unsettled and may be subject to significant change. Changes in tax laws, regulations, or rulings, or changes in interpretations of existing laws and regulations, could materially adversely affect us. For example, the IRA includes provisions that impose a 15% minimum tax, or CAMT, on the adjusted financial statement income of certain large corporations. CAMT is effective for taxable years beginning after December 31, 2022 and generally applies to taxpayers with average annual financial statement income exceeding $1 billion over a three-year period. The impact of this law was not material to us for the three months ended March 31, 2026, though it is possible that CAMT may have a material impact on our financial position in future years. Likewise, on July 4, 2025, the One Big Beautiful Bill Act, or the Act, was enacted into law. The Act includes significant changes to the U.S. tax code, including restoration of immediate recognition of domestic research and development expenditures and reinstatement of 100% bonus depreciation for qualifying property. We do not currently anticipate the Act to have a material impact on our financial position.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and our election of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our Annual Report on Form 10-K and our other periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements in our Annual Report on Form 10-K. We could be an emerging growth company for up to five years following the completion of our initial public offering, although circumstances could cause us to lose that status earlier, including if we are deemed to be a &#8220;large accelerated filer,&#8221; which occurs when the market value of our common stock that is held by non-affiliates exceeds $700.0 million, measured on the last business day of our most recently completed second fiscal quarter, or if we have total annual gross revenue of $1.235 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the end of the fiscal year, or if we issue more than $1.0 billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. As a result of being an emerging growth company, the information we provide stockholders will be less than the information that is available with respect to other public companies. We have taken advantage of reduced reporting burdens in this Quarterly Report and our Annual Report on Form 10-K for the year ended December 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our common stock held by non-affiliates is less than $250.0 million measured on the last business day of our most recently completed second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value our common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. Even after we no longer qualify as an emerging growth company, we could still qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in our Annual Report on Form 10-K and our other periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement, or prevent future non-compliance with the listing requirements of Nasdaq. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us that may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our Certificate of Incorporation and our Bylaws contain provisions that could delay or prevent a change in control of Eikon. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our board of directors to issue one or more new series of preferred stock without stockholder approval and create, subject to applicable law, one or more series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eliminate the ability of our stockholders to fill vacancies on our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at our annual stockholder meetings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">permit our board of directors to establish the number of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that our board of directors is expressly authorized to make, alter, or repeal our Bylaws;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that stockholders can remove directors only upon the approval of not less than 66 2/3% of all outstanding shares of our capital stock entitled to vote generally in the election of directors, voting as a single class;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require the approval of not less than 66 2/3% of all outstanding shares of our capital stock entitled to vote generally in the election of directors, voting as a single class, for a stockholder amendment to our Bylaws absent approval of our board of directors, and to amend specific provisions of our Certificate of Incorporation absent approval of our board of directors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specify the jurisdictions in which certain stockholder litigation may be brought.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in the State of Delaware, we are governed by Section 203 of General Corporation Law of the State of Delaware, or the DGCL, which may discourage, delay, or prevent a change in control of us. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision of our Certificate of Incorporation, Bylaws, or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Certificate of Incorporation designates certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Certificate of Incorporation provides that, to the fullest extent permitted by law, derivative actions brought in our name or actions against directors, officers, and employees for breach of fiduciary duty, arising pursuant to any provision of the DGCL, our Certificate of Incorporation or Bylaws, or governed by the internal affairs doctrine, may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#8217;s counsel except any action (i) as to which the Court of Chancery in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within 10 days following such determination), (ii) which is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or (iii) for which the Court of Chancery does not have subject matter jurisdiction. In addition, our Certificate of Incorporation designates the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act; however, such exclusive forum provision does not apply to claims brought to enforce a duty or liability created by the Exchange Act. The validity and enforceability of such provision is uncertain in a number of courts other than the Delaware Supreme Court and certain other state courts. If a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may result in increased costs to stockholders to bring a claim for any such dispute and may have the effect of discouraging lawsuits against us or our directors and officers. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock should be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations promulgated thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports about our business, or if they publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock will be influenced in part by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over the industry or securities analysts, or the content and opinions included in their reports; we do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, or if analysts cease coverage of us, we could lose visibility in the financial markets, and the trading price for our common stock could be impacted negatively. If any of the analysts who cover us publish inaccurate or unfavorable research or opinions regarding us, our business model, our intellectual property, or our stock performance, or if our preclinical studies and clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to establish and maintain effective internal control over financial reporting could adversely affect our business, and if investors lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be negatively affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to comply with the SEC&#8217;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of internal control over financial reporting. Although we will be required to disclose changes made in our internal control over financial reporting on a quarterly basis, we will not be required to make our first annual assessment of the effectiveness of our internal control over financial reporting until our second Annual Report on Form 10-K. In addition, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To comply with the requirements of being a public company, we have undertaken various actions, and will need to take additional actions, such as implementing internal controls and procedures. Testing and maintaining internal controls can divert our management&#8217;s attention from other matters that are important to the operation of our business and failure to establish and maintain effective internal control over financial reporting could adversely affect our business, and if investors lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be negatively affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sales_of_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unregistered Sale of Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Initial Public Offering Proceeds</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 30, 2026, our Registration Statement on Form S-1, as amended (File No. 333-292633), or the Registration Statement, was declared effective in connection with our initial public offering, pursuant to which we sold an aggregate of 21,177,600 shares of our common stock at a price to the public of $18.00 per share. J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC acted as joint book-running managers. The initial public offering closed on February 6, 2026. The approximate aggregate net proceeds from the initial public offering were $348.1 million, after deducting underwriting discounts and commissions and other offering costs of $33.1 million. The offering terminated after the sale of all securities registered pursuant to the Registration Statement. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities, or (iii) any of our affiliates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds from our initial public offering have been invested according to our approved investment policy in a mix of money market funds and high-quality marketable securities that are being held to maturity. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus for our initial public offering filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February 5, 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 3. Defaults Upon Senior Securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 4. Mine Safety Disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 5. Other Information.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the quarter ended March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be18b8a3-5136-49c4-bfc1-3a9f4f3b59bd" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d1014c2e-2e9e-4a97-86f1-fbba77473d8d" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f33337d9-c342-413d-a45e-6c59b60ff873" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_751e0830-d438-4e35-b24c-3998741e1394" contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">none</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of our directors or officers (as defined in Section 16 of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Item 408(a) of Regulation S-K.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 6. Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:91%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526041201/d49647dex31.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-43085), filed with the SEC on February 6, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262dex34.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 9, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 9, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262dex42.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant to Purchase Stock (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 9, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3&#134;#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262dex43.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement, dated February 14, 2025, by and among Eikon Therapeutics, Inc. and the investors thereto (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 9, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526130395/eikn-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc. 2026 Long Term Incentive Plan, and forms of agreement thereunder (incorporated by reference to Exhibit 10.2 to the Annual Report on Form 10-K (File No. 001-43085), filed with the SEC on March 30, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262dex103.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc. 2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 28, 2026).</span></a></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:91%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262dex104.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement by and between Eikon Therapeutics, Inc. and its directors and executive officers (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 9, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526025565/d903262dex107.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated January 22, 2026, by and between Roger M. Perlmutter and Eikon Therapeutics, Inc (incorporated by reference to Exhibit 10.7 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 28, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526025565/d903262dex108.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated January 22, 2026, by and between Michael Klobuchar and Eikon Therapeutics, Inc (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 28, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1861123/000119312526025565/d903262dex109.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated January 25, 2026, by and between Roy Baynes and Eikon Therapeutics, Inc (incorporated by reference to Exhibit 10.9 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-292633), filed with the SEC on January 28, 2026).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eikn-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eikn-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eikn-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eikn-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Indicates management contract or compensatory plan or arrangement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit (indicated by [* * *]) have been omitted because the Registrant has determined that the information is both (i) not material and (ii) of the type that the Registrant treats as private and confidential.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Certain schedules or exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIG</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:3.2944444444444443in;box-sizing:content-box;"/>
     <td style="width:0.014583333333333334in;box-sizing:content-box;"/>
     <td style="width:0.5986111111111111in;box-sizing:content-box;"/>
     <td style="width:3.592361111111111in;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">EIKON THERAPEUTICS, INC.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 11, 2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Roger M. Perlmutter, M.D., Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger M. Perlmutter, M.D., Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 11, 2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alfred Bowie, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alfred Bowie, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>eikn-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-11T16:11:44.2687+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Roger M. Perlmutter, M.D., Ph.D., certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Eikon Therapeutics, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Omitted;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:4.04%;box-sizing:content-box;"></td>
     <td style="width:40.5%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 11, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Roger M. Perlmutter, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger M. Perlmutter, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, Chair and Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>eikn-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-11T16:11:44.2672+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Alfred Bowie, Ph.D., certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Eikon Therapeutics, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Omitted;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:4.04%;box-sizing:content-box;"></td>
     <td style="width:40.5%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 11, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alfred Bowie, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alfred Bowie, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>eikn-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-11T16:11:44.2618+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report on Form 10-Q of Eikon Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ending March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:41.54%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 11, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/  Roger M. Perlmutter, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="border-top:0.75pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger M. Perlmutter, M.D., Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, Chair and Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>eikn-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-05-11T16:11:44.2644+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report on Form 10-Q of Eikon Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ending March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:41.54%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 11, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alfred Bowie, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="border-top:0.75pt solid;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alfred Bowie, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img119830300_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img119830300_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 9V#Q\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,C7]?T/PIH.M^*/$^L:;X>\->&](U+7_$.OZU>V^FZ/
MH>AZ/9S:CJVL:MJ-Y)#::?INF6%M<7M_>W4L5O:VL$L\\B11LP_@2_X*,_\
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M;Z)K=Q?17N@Z]X@_;FOX0_\ @F#_ ,&^?_!3#_@GU_P5?M?VA/ASK7PI\/\
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M  7;_8=_X*FZE?\ @+X1:KXM^&/QVT?1YM>U#X'?%VPTG1_%>J:-9%5U/6O
MVK:+J^M^&_&^EZ:666_ATW4K?Q+IUDPU+5O#6FZ?FX'Z1_M5?M"^&OV3?V;O
MC=^TQXRT37?$GA3X%_#7Q5\3?$&@>&18'Q#K&D^$]+GU2\T_1AJMYI^FG4;F
M&!H[;[;>VMMYC+YL\:Y8>#BLHS/ X^.5XS!5\-CY3ITX86M#DJ3E6DHTN2[Y
M9QJ2:4*D9.G+I)I,TC.,H\T9)QWNO+>_:W5;GOU%?SR?L^?\'+?_  3X^,?[
M*OQC_:Z^(1\>_L[?#SX1^/=+^&=KX<^)4'AK5OB+\4?&FL>&SXFL= ^%WA'P
M/K_B*\\2Z@UG@789[.RT:$3:QX@OM'\/VMYJUO\ DSXI_P"#V'X)6GBDVG@K
M]@GXI^(/!/VJ[0>(?%/QN\)>#_%)LD4&QN#X.TGP%XXTD75RV5N[,>.3#9*
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M6C.+4J;I4IJHFG#F31G*O1C+E=1)[=6EZM)I?-GY_?\ !3__ (*)?MU?"_\
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MC2;R:W)N-.U"UGU'P]KEO'-<^']:U6V@FFC_ )-O^#I+_@L/\$=6\ _M3_\
M!(N'X7_%2/XT>&?$_P"SMKEW\3)1X2_X5?<6]QI_PO\ CXL-L4\1-XK\Y?#G
MB&VT9O-\/QI_;<$^'-CY=V_/PWPUC<TXEPN38G+\2UA\70GG&&E?#U\/@(8K
M#TL7.IS.%2"C&M%-PO.TXR@GHQU:L84G-26J?(]TY--JW1[>FFI_05_P0U_X
M*+?%3_@J'^R%XX_:@^+'A3PAX%U*;]HWXD> O"G@WP4NH2Z7X:\"^&?#G@&]
MT'3+S5=4GFOO$&MI-KNHSZOKTL6G1:A=SLUGI&D6,=MIUO\ LO7^:G_P0X_X
M.*/V9/\ @EM^Q;J/[,_Q<^!_QW^(?BN]^-7CKXFIK_PX7X?GP\FE>*M#\&:5
M9Z>Y\3>,-"U+^T+>;PU=27.+(VWEW%OY4\C>8J?Z4US<V]G;SW=W/#:VEK#+
M<W-S<RI!;VUO C2S3SS2LL<,,,:M)++(RI&BL[L%!(WXYX>Q&19YB[9?+ Y9
MBL7B5E-G%TZN'P_L5+V5ISJ6@JU*[J6E)S3;;N%"HJE./O<TE&//W3:Z^MGL
M345_*_\ ML?\':?_  3Y_9C\<ZQ\-/@AX7\=_MB^)O#E]<:=KGBGX:ZIH/A;
MX-17MI+Y%W9Z)\2]:_M.Z\8-#*L@CU?PEX0UGP??QJL^E>*;^&0./ECX-?\
M!Z1^RKXI\7:?H_QQ_9!^-'P@\*7U\;2;QEX,\>>%?C"=(MY;JXAM=4U;P[<Z
M%\,]1-C%;BSN]6CT6;6]3M$DO8=,T[7)K2U34HH\ \8XC"K&4LAQCH2A[2//
M*A2KRA:Z<<+5K0Q3NG>*5%N7V4P>(HI\KJ1OMU:_\"2M^/Y,_M'HKP_]G/\
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MZM_@%%%%? G0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEU!)IL8BD4;))497/[?5_E[?\'6NGWNK?\%@]8TO3K>2[U#4O@9\"M/L+2(
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M)_AI>WMW>7VKW.A6VD>/?%?PW$VI:A<:WJOA 6][?7K7]_)/7^A-_P %H/\
ME$Y_P4._[-+^,W_J'ZC7^9IX]_8V\1_\$_\ _@N7\%_V2_%_Q17XT>*?A?\
MM9?L37WB'XEIHM]H">)M8^)C_ [XM:@RZ=J>N>(M19=(N?'<F@KJ5]JLEUK@
MTL:W-9Z5)J#:39?Z9?\ P6@_Y1.?\%#O^S2_C-_ZA^HUV<;J$LS\-:RQ?]HR
MJX3+;YG*E.C4S"FL3@)T\5.G4;JP=?VLZ_LZC<X2K24O>;%A_@Q"Y>6TI>[>
M_+H_=OUMM?K8_P \3_@VV_X)A_#S_@IG^UCXPL?VB%UCQ%^S1^S+X6LOB9XL
M^'-IKFIZ5IWCKQ]XUU2#P_X-\,:G)IMQ:WFGZ%JUGX;UO5_%%YHUWI^KZI:^
M#]*T!KQ+.]DEMO\ 2AN_^"<?[ %[\+Y_@O<?L5?LM_\ "K;C3VTY_!D/P,^'
M%KI21M:?8A?6YM?#L-W:Z[%%B2W\26MS#XAMKU4U*WU.+4(TNE_C[_X,A_\
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MQ#U/4M#^&GA?5+..3_3E\'^&K$:YHUIL\BYU+XC+<3I/=Z3IDEGZA_P9#_\
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M<+.G?D^KSIMTX45%0IQY?9*#A!Q[94J;IN'*E'ELM%=66C]5O<_AQ_X,F?\
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M<:/)JO\ 87B2&PCT?Q'8ZEI$T]H_\4'PP_X* _\ !U=_P5:M)/'G[)>A:WX
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MGQ#I]SI=AXSUKPM<Z+XH\2>+[JPD\1:9>ZG_ ,(UH=YIVG6&H3:[^W_[:O\
MP2C_ &%_V\/A+XC^%OQG^ ?P^LK_ %/3KF+PQ\4_!'A#PUX4^*_P[ULV!L=-
M\0>$?&6F:5#J,4FFF.SDDT#5&U+PKK<5A:6/B#0]3L(([=/XOO@__P $:O\
M@YF\1?"3X6^(/A5_P4K\6Z-\+]=^'/@C6?AOH^A_\%$?VH='T32O 6J>&=,O
M?!^FZ/I.B::=&TO2K'P]/IUKI^G:03IEE:10VU@3:Q1&O1O^'*/_  =1_P#2
M3WX@_P#BR+]K3_Y65SYI@%CL[Q&;S\2\HH8Q8JI4H<E?%P>"C&I>GAZ*C)*G
M"C%*')%)2Y6Y\TI380ERP4/JLVK).ZB^9Z7;TU;>O^5M/G#_ (-Z_CW\8?\
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MBBB@ HHHH **** "BBB@ HHHH **** /X1_^#U__ )QH?]WE_P#OJ=?TM_\
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MX)'P_P#!7/5_$VI_M,?$OQ]IG[)7[(D-KX9\/> _!VI6^E:KXG\:_$[4]?\
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M/\!? ^A+=W/_  B=_P#$GPJVHV7QQ^/'C&PMC$-9C\"Q:=XUM-(FBDU#[)X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYK>XAD>*:)TDC=D96/\ FQ_\'-G[;?\ P3._X*%?\,U?'']CC]H6S^)_QO\
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M (,LO^26_M^_]C_^S]_ZCOQ4K]1O^#J'XM^(_A?_ ,$B/B7HOARZN+%OC/\
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M2P=K.?\ M#]5_P#@GQ_P;>?\$X/V O$VB?%"R\(^(_VC?C?H$T5]H?Q+^/\
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MK\LWW.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^$?_@]?_YQH?\ =Y?_
M +ZG7]+?_!#+_E$9^P-_V0#P]_Z<-6KP#_@M?_P10_X?#_\ #-'_ !DO_P ,
M[?\ #.W_  N7_FC7_"W/^$P_X6Y_PJG_ *JM\,?^$?\ ^$?_ .%8_P#4;_M;
M^V_^8;_9O_$P_2[]AG]F'_AB[]D7X!?LK_\ "<?\+)_X4=\/].\"_P#"=_\
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MJI-M:JW]?AZ %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K_ #*?^#F__E.+X;_[)_\ LP_^G*[K_36K_/$_
MX.(?V*/VROC9_P %C?#_ ,3_ (,_LD_M-_%SX:P^!_V=;2;XA_#'X"_%3Q[X
M&BN]$U"Y?6K:7Q;X5\*:MH$=QI",KZI"VH"33U8-=K$"#43V7K_F!_H=U^)?
M_!=K_@E?I'_!3W]C[5=#\):;I\7[3GP4CUCQY^SOX@N)8[-M1U9K6%O$_P +
M-2O9!Y2:'\2].TZUT^"2Y>"VTOQ?IWA36[F[@TW3]3AN_P!M**IJZ:[@?Y!'
MPC_X*/\ Q%^%'_!,O]O#_@E1\8;7Q)<>%?B1J'PU\2_!C3M5ANAJ7PB^+O@#
M]I7X2^,OBEX'OK&^\NXT3POXK\-^$O$NN7EA^[CT+X@Z!,8=+-]X[U^_A_KN
M_P"#-#_DQK]J7_LZ]_\ U4'PXKXP_P"#F?\ X(=_%'Q)\9K']NW]B/X+^._B
MO<_&76(M'_:(^#WP=\"Z_P".?%^G_$8V<TEC\8-#\'>#-(U/5[S0_&=G8M:?
M$*YM[%SIWC*&U\27TUV_C34IM,_3#_@TV_9X^/\ ^SE^QO\ M(^%_P!H7X&_
M&'X#^)==_:9?7M$\._&;X9^-?A?KNL:$?A9X!T\:UI6D>-]$T/4-0TDZA9WE
MC_:-I;S6?VRTN;;SO.@E1,TFI).^ETGY:_Y_+8#\DO\ @\]^$_B2Q^/7[%_Q
MR-M-+X/\3_"+QY\)TO(X]UO8^)/ GC./Q?);7<RD^1-JNE_$6.73XYEC^U)H
MVIM;&;['=B#^@;_@FM^P3_P2+_;&_81_9:_:&TK]AC]DCQ%J7CKX.>"AX\N8
MOA5X/U">P^*>@Z+:>'OBCHNHSF"ZN/[0TGQYIFO6D_VZ7[;,B17=PJM<C/Z"
M_P#!3W_@GA\+_P#@IQ^R9XR_9H^(U[_PC6JW%Y9^,?A7\1H-.AU34?AG\4-!
M@O8= \4VUC+);_;]/GL]1U3PYXGTJ.ZLYM6\+:YK-C:WVG7\MGJ5G_"K\&M.
M_P""^_\ P;N>/?%_@OP;\"->^,G[//B;Q-_:5_IVE^!O%_QT_9I\;ZDZPZ9!
MXRT#7/A_+IGBSX6>,=8TRQBLUM=9N/!.NZK'8:>?$OA+Q!9:/I*Q-Z2;:NG\
M[;;_ -=0/[A_^'-?_!*;_I'Q^RA_X9OPA_\ *^OR0_9__:%_X-N=5_;L\,_L
MQ_ []EOX0Z+^U?X%^/LW@SX:Z]X7_9:5M-7XM_"WQ+>W5MXG\$_$+PUI6J:;
M:V/A[6O"LNO:9XPN;C3+&WM]/BUA+B*WC,R?BE\;?^"^O_!;;_@H/X+U'X!?
MLE?L5^*OA(_Q L=0\*>(?%OP+^&'QD\=_%%8+N%(]6M] \?W\$.@?#FU72+^
M/^U-?31(=?T*&>+6+#Q;X>(CG'ZY_P#!O'_P0%\7?L%:Y-^V/^V)9Z/%^U!J
MGA_4/#WPO^&&E:I8>(+/X&^'?$>G_8O$VL:]X@TBYN]%U7XE^(],N+SPS)!H
M%YJ6A>&?#-SJUM%K.MWWB6YCT!JS:Y8JW5V]-O/^EW _J=^)WQ+\"?!KX=^-
M?BQ\4/%&D^"_AW\.O#.L>,/&?BO7+I+/2M!\.Z%92W^IZA=SR$?+#;POY<,8
M>>YG:*VMHI;B:*)_\T?7+OX__P#!T5_P5T_LO3+CQ1\.OV8? EO>PZ7=&SBO
M[?X#?LU>']2"OK%W:F7^QY?BW\7=8:WEDMY+G46?Q5KEMIZ3ZCX&\!(^G_LU
M_P '._Q=_P""A_[2VI:5^P/^R!^QU^V9XY^ 6C-H7BKX^?$[X>_LS?&W7O!G
MQ8\:1SP:UX3\ Z!XMT?P/=:)XB\"^!"FF>)-;U+2]3NM'U7QT]E9NR3^ _.N
MOV]_X(<?\$O-%_X)@_L:>'?!7B/3-)E_:2^+2Z=\0/VC_$]B8KN0^*I[>9M!
M^'5CJ22W"7'AWX6Z1>OX?M6L[AM,U3Q'-XJ\56,<*>)&AC'>3MT6_GY?UZ]@
M/XS_ /@G)^U+\:?^#=/_ (*D_$W]CG]JR_U _LV^./&&E>$/BO?I::BGA<Z'
M?2LOPI_:N\!Z?(MU<'2TT>^BF\66>EM=:A<^$[G7O#NIVNI>,O!.C:?IO^EY
MIFIZ;K>FZ?K.C:A8ZOH^KV-IJ>E:KIEW;W^FZGIM_;QW5CJ&GWUK)+:WMC>V
MLL5S:7=M++;W-O+'-#(\;JQ_FN_X.2O^"1=Q_P % /V;[?\ : ^!?A"36?VN
M/V;M'OKS0M)T+3;F^\2?&3X2B2?4O$OPLM++3HIKW6_%&D7,EQXK^&MC';WM
MW<:P=>\*Z7;K=>-C<0>??\&T?[0W[=FD?!NZ_86_;D_90_:Q^%:?!?07U+]G
MGXS?&']GSXQ>!?"NK_#F.]CCN_A'XD\9^,_"FF:1!XB\%W.H1R_#Z.ZOD.J>
M"6F\-VD5L/!6GQZJ+W7R]-T_T^_\?4#^?'_@Z?N[6P_X+0_"*^OKFWLK*R^
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M1=&\1>$]>F03/(T.I^(-+\?:1%(8HD#>'70;R"Q_K$K_ "A_^"5'P3_X*K?
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MQ]X'UOPSH^OW$<<%S*5T'5-2L]75H;>>9)+)7AADE54+BGRR76[7X(#^0?\
MX,L+NU?X;_\ !02Q2YMWO;;QO^SK=W%FLT;74%K>Z#\7X;.YFMPQFBM[N:PO
MHK:9T6.>2RNTB9VMI@GZD?\ !U-\)_$GQ,_X)$_$76_#EM->+\&OB[\(?BQX
M@M;:/SKAO#<&L:A\/M2N4B4^88=+D^(5KJ]_)&DGV73=/O;R8):V]Q-%_&M^
MS5-_P7(_X(<_&/XS^#?A!^S5\6= U;XD77AWP;XSCN_V>O$OQB^%?Q(NO!FH
M^(6\#:_X&\6Z+HEUH_B)K<:_XH30-0\,:^ZW-KKFJ6>I6+7T'V?3_P#1N_9&
MUCQA^VG_ ,$[/A#<_MF?"N;2O&7Q_P#V?D\-_M%?"OQCX'UWP%]LOO$>BWWA
M7QWINI>!O$L%IK6@6/B2'[9?VUG+%%&MAJEM=Z3*;&2QG9+5<CNG;];@?RI_
M\&N'[-W_  3B_;/_ &./BGX*^/?[+/[.GQ9_:(^"7QCU0ZWJWCSP%X:\2>-M
M2^%GCO1M(U7P+K5W=:HEQJ,NGP>(;+QUX:M_+BCLK.+1+.,,9[IL_P!.?_#F
MO_@E-_TCX_90_P##-^$/_E?7\4WQS_X)#_\ !6W_ ((=_M4:I^U)_P $V8_B
M!\</@]!)JT.B>)_AGX>'Q"\6+\.]1O(]2NOAE^T#\%+"VNM7\3:7:PV%O)J/
MB?P]H.I^%W?2=.\86^I^!/$T=A8:/[UJG_!T3_P5\\3^&)/AEX-_X)Y>#]*^
M/!T^VM[_ %_3?A#^T%XCELI;P0PC5M(^$EQJDNHV%Y,=2TN325UOQ'XATQ+N
MXM3=:?JUM>PV9$TE:4=5Y+7^OTW _6K]MWQ;_P &T7_!/7XYZ1^SW^TO^QU^
MS_H/Q U3P/I'C^=?"?[+VE^.M)T+1-=U'6M.TJW\03^&]/O=1TW6+PZ'<7\>
MF'2Y9_[*N],U$D6U_ YM?\'+7P%\/?$S_@AYX/U;X$^$ET/X6_LV^,OV<?C#
MX,\':/H5QX:A\+?"&T\(:W\&] TVS\)W$-C>Z+IOA/PS\6-*\_0Y;".?P]I6
MF7#7EG:0Z5<R6WY ?\$O_P#@@9^VM^V]^UN?V^O^"N>C>,/#?A.]\:0?%#7/
M 7Q;"6?QA^/OB_3YK*30]"\5>"5\F\^&/PLTK[%::=?^']=L/#^IMX;T73_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6DZ'HEC!INDZ99QDL8[6PL+:WM;="S%(HD4DXS6U115@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJIBBN(KFX4[[EP/MRA:)>B ****8!1110 4444 %%%% !1110 4444 %%%%
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M*XXR_*\-+%^UY+*I^[==U5",K\R4TZ2CVU;EYU0]RU_C7,XZ:J-NVMOTU?\
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MQBJ<]6\Z2BH>R5U^\C9X9S=**E#E2C'E?,GS*V]E\/3?OY!1117P!T!1110
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M_P 0/TCHHHI@%%%% !1110 4444 %?DQ_P %3O\ @KY\!?\ @EAX>^%(\?\
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M0Z1K\5U\1/#5J(C="";XCW,DS:?:Z9:V4MVEKL]O)_\ ! _MGHHHJ@"BBB@
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MC>3:'XC\1:;J<5K>1 R6MP]JL5Q&"\+NHS7O-?Y=7_!V-_RES\3?]D ^"?\
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M^+,MYX^^+WC:WN9/A7\ O"&H65KXS\9QVLOV:YU_5[^ZCNK7P5X#L+K-M?\
MBW5+.[:>Y2XL/#FC^(]5M;K3H1NVK _5VBO\V>?_ (+Q?\' G_!2/QQKF@_L
M+?#K6O!OAVSOD\_PW^S+\!K'X@GPWIOFQ2Z;%X\^+'Q)T#QQ'HMU(1;_ &O5
MTO\ P#I^J32-;Q:;;6-X=-:]K/QX_P"#N7]E6Q/Q'\7Z9^UEK?AFPMX=7UB+
M4_A-\)_V@-'@TE$FEN7U_2O#OA;QYJGA[3X;>"9]6N\:'<Z3!BYN;S3V:&>H
MYUV=O^&_S_+N!_I%45_%A_P2\_X.S/"GQ;\7^'?@?_P4<\'>%?@UXEUZ^LM
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M6DFFKH HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#_ "Q/^#MO_E+]XG_[-\^"'_INUVO](?\
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M<>+?$7CT:?+9?\)##IFL^'=%\,ZA+J7A^*W\03V<7B!O ?\ @K)_P0 \0?\
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MK]A[XJZWH<[M(&T[5)_C5^SIX<FO(0CJK2/HFOZQIY699(_*OI6""58I(_\
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M_%&I:IJ%OI-OJ&J:G?0:=#<)9PWFHW]S'"LUY</)[;_P=*?\H:?C_P#]C_\
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M_B#XCU'Q"\^@Z1=Q:7JFFP>//B:GA*VU2/1=6-LVMQZ7>K_:#_P0+_X(]/\
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MUFX/PS\0:C9>'KCQG;:;X5\6:G87$EC=:[XAO/%VM2M</JURZIWCKS7\F_\
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M0\7>&M6B,^F:_P"&?$>FW.D:YHVH0AD:2SU+3;RYL[A5=',4S;'1L,/Y]/\
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M19+FX_O0_P""RG_**;_@H/\ ]FH?&3_U$-0IINTDWJKZ_+_@ ?EU_P &X_\
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M.1"KHIE(0-2DFE#OK]^GZ@?L)XR_X+R?\%Q/^"B7BSQ;>_\ !*#]COQ-X)^
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M-\;?3X;>BST<97\F_2__  >MGWW#]QJ_DS_X+"_\'-?A;]C/XF^(/V4/V*?
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M4_Q/U[Q8D()166.&^\57\<,;O+Y<2HD;I"L4$-1NI.+=[*^OR_S C_X+2_\
M!P/\*_\ @ECJ^E_ [X?^ K?X[?M5>(O#=MXJD\(WNM2Z'X!^%OAS5'N(M"UG
MXC:KI\-UJM_K&N-;37FC> ]%%AJ=UHL8UK6==\-6&H^&Y?$'X2Z3_P %"O\
M@[7_ &GO#UO\5/@O^SMKWPZ\!Z_8V_B#0$\,_LS?#/PUI6H:']H@OX+WPS:_
MM&_\)/XMUW2=;L;ZVBTV]MKK5CK&CXU#0;J66.XU.OVF\>_\&W/PQ^+/_!4%
M?^"C_P 6OVEO$GQ-T^_^-\?QG\3?L_>+OA5I%YH>M+X=LE@^&W@2/QK:^-;,
MP^$_ TND>#+62TU;P9X@C\2^&_#$GAW4H(8]8GO;7]_/B+^T)\ _@^MTWQ:^
M.'P@^%RV,:2WK?$7XE^"_!*V<4D<,L<MT?$NM:8+>.2*YMY$>4HKQSPNI*RH
M6+2=[MQ5]$OU_K?\0_@=\)?\',?_  5Y_89^.&G?#+_@I1^SAI/B335FM[GQ
M1X1\8_"B]^ ?Q=;PW<:A+ WB/X?:[I":?X(UNQ5([I=-NYO"&M:#K[626MOX
M@T]FN=47^]K]G;X_?#+]J;X&_"[]HCX-ZU)X@^&7Q>\'Z5XT\(ZE<6S65]_9
M^IQ'SM.U:P9Y&T[7-%OHKO1M=TUY)'T[6+"^L6DD: NW\5G_  =1_MS?\$VO
MVL?V6OA-X$^!G[17PF^-W[3'PL^/MCK.AR_"RYO/'=MIWPRUCP;XOTCXCV2_
M$?P_8WWP]&BZGKL/P\U&:SM_$]QJ.IWV@Z3/I=M/96VISQ?M3_P:YWMW=?\
M!&3]G."YN9IX=-\:_M 66GQ2R,Z6=I)\<?'>HO;6ZDD10M?ZA>WC1IA3<74\
MI&Z1B2+=VKW5KW^X#SO_ (+A_P#!P3H/_!+_ ,1:'^SO\#_A[H/QE_:J\3>&
M;7Q7J-MXKOK^/X=_";0-7EFA\.7/BZPT"ZLM?\3^)O$8MKB\TSP?IVK>'6M]
M&^RZYJ6M0P:CI%CJGXLZ;^VK_P '?GQ3TVS^*_@SX$>-/"_@J\L_[8M/"<?[
M-'P,\.)>Z=K(6#36@\,_%/3;KXLS1VA@>^LXX+K[7Y%XM[JAN],GL&7X9_X+
M->(?%/["_P#P<;W7[5_QD^&,GQ*\!V_Q3_9R_:/\':%K9E-A\1_AOX/\&> O
M#<L&@:CJD,EG'JGA77/ NN^'=&>>*[TW0_$GA:P,MK<:7!%!-_9?^R]_P<-_
M\$G/VI;31H-)_:A\._!CQEJJV:3^ ?VB[2X^#^K:7?7JXATZ;Q7X@+?"[5+H
MS!K<#PYX_P!:3SO*1G1KFU$RO=N\FM;);=NO5_KY ?A/^P5_P=+?'GPM^T;I
MG[)W_!6;X'Z+\*M5G\76W@'7/BOHOA+Q-\+?%GPJ\3:A)9VVF_\ "Y_A3XGN
M;^,:*]Y=QR:SXB\/MX5D\/://;ZI_P (MK5K'/<G^XJOPY_;Z_X(=?L'?\%9
MOBU\-OVGOBGXT^(UM>:)\/5\&P:Q^S[XM^'.EZ%\3]!M]9NM3T&_\3>)+[P+
MXXN->70OMVKZ=IMUHVI:?,+.XAM3?&WT^&WK["_;_P#C?>?L'_\ !-G]HSXP
M^%-4U+4/$/P%_9RU;3OA[KOB6X@U35+KQU%H%KX%^&^M>)+CR;.#5;I_&.I>
M']1UTQP6O]I/]K6"&!IT1:5TG=W2V?E_7SW\@/PW_P""PO\ P<U^%OV,_B;X
M@_90_8I\!^'?C[^TCX:U*3PUX_\ &OBAM3U#X3_#3Q<THLV\#Z;HGAF_T[7_
M (E_$'3KMC:Z]IUCK&@:#X6U7[/HUQJ'B/7HM?\ #VA?F78_MR?\'>^O^';;
MXO:9^SO\0(/!<T=QJ,7A!_V4_A18:Q<V;E;^.(?#W6M(3XTM&EK87%K8I%:)
M?7D6H;!)>:A<Z1-'\>_\&OFF_L0:9^T[\=/VPOV[/VA_V>/ 7CCX2V?A>+X&
M6G[2WQD^''@S4-=^)?Q#U'Q)JOC+XN:1%\3/$.EWVO\ BCP78^'[.QM/$,$E
M])INI^/KK59'AURWTJ^M_P"]3_AZ5_P3(_Z2,?L(_P#B7?[/W_SPJE7EJY6U
MT2?I_6O5W\@/Y^O^"27_  <ZV_[2_P 8M!_9!_X*"?#CP[^S]\?=?UJ#P/X*
M^)'AZWUOPY\/_%OQ!-Z=)M_A]XZ\&>++O4-;^%_CK5K\0:?I=P^MZGX=U[Q+
M<3Z(]CX+NGT;3=4_KSK_ #?_ /@ZI7]@[XE_%7]GK]KW]C7]HC]FKXG?%?QH
MOB3P)\?++]GSXR?##Q[K=W=>$H-$U7X7_$CQ'8?#GQ)JM_9:TEG/XA\*WWBO
M5(5GO[+1_!FEK>C^Q;:,_P!O'_!*+]I+7?VNO^"<G['_ .T)XLO&U/QEX[^#
M6@6WCC57E>:36/'?@FXOOA_XXUJ5Y))9/.UCQ9X5UC4YDDED>*6[>)W=D+%Q
M;NXMWMJGY:?UU _0BO&OVBO@W8_M%? /XT_ '5?%'B+P5I'QL^%WCKX4:UXK
M\(G35\4:%H?Q \-ZCX5UJ_T"35['4M/@U:+2]5NQ8W5Q93FUG9+F$)/%%*GL
MM%6!^(__  20_P""(?P=_P""2'BKX]^*?AS\7/&GQ@O/CAH?PYT%+CQYX=T/
M2-5\&V'@;4?'&HZG;:??^'[B.TU.S\62^)M >]@N=*MIK"Y\(6\T-W<1ZG);
M67[<45^)?_!97_@M+\$_^"5GPDN+"UN?#_Q)_:T\<:/,WPA^!JZFLDE@ER)[
M:W^)7Q2AL+A-2\/?#C3+J&;[)$7LM7\>ZI9S^'?#$T$5KXB\1^%UI%=D!_,=
M_P 'G/Q>^'?B7]H+]B_X*Z%)8W/Q*^%'PR^+/C/X@SVK1RW-EH/Q;U[P%:>
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MXU\2I=KF<7.B6LWQ?ATLR0V\4I>WU#P]K41023%5"?*<\?/^OZ_#TN'Z3?\
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M1_9X^(6FQZWX!\8_M[?M,>(/'&@SNL=KXC\(?"WQ9\6/BUXE\-7KF2%_[/\
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MHIX)8YX)XTFAFA=9(IHI%#QRQ2(622.1&#HZ,5=2&4D$&O\ &9_;2\5_$/\
M;B^/W[=W[>ND:=>:K\.?^&A[:_UG5?L\X7PQX4^+7B+QMI7P3TZ\D$(BBCM_
M"_@.T\.Q&Y>*YN);2)@DC_:&C_U-_P#@C;^T<_[5O_!,/]C+XR7E[#?Z_>_!
MK1/ OC"YC<M+-XU^$=S>_"GQ7>7<3'S+>ZU36_!EYK#PN%4QZC%-;[K2:WD=
M1DVVOF@.[_;N_P""F/['_P#P3;T/X=>(?VM?B)J7@2Q^*NK>(-&\#PZ-X/\
M$_C74M8N_"UGIM]K\HTOPKINJ7UO8Z9#K.DK=7\\"6D=QJ5E;M*)KJ%']._X
M;/\ @*O['G_#=UQKWB"R_9O/P<_X7VOBB^\'>)K377^%SZ+_ ,)';>(D\&3Z
M:GBA_M^AM%JFG6*Z8;R]L[FVGMX72XB+?PE?\'&_B;Q'_P %!_\ @MK^S?\
M\$_/AU??:X?AY;_"/X%*+%VO(M'^(GQYUW2O&GQ \23R;&M8+?0? NM> SK@
M1+A=,7PCJ+W\WG0W%E8_V$?\%6_!?AOX;?\ !'#]M;X=>#-,AT7P?X!_8F^(
M?@OPIH]N,6^D^&_"WPZET/0M,@'&(;#2["UM8A@?)$M.[][:R7GO_7Z ;'P
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MGB+XZ?%;6-/CU@^ 8/$6GSP7G@KP'X%\+R>'FUBS\,II=YI^@:QX2\*>")]
MM5DU#1/[-O&'_! 7_@D'XQ^'D_PWE_8A^%?AS3FT>XTBQ\3^#Y/$OAWXAZ6T
ML$45OJT'C^SUW_A*-1UBQEMX+JWNO$.HZW%/.DJ:E;7]I?:C:WBO)ZJR72^_
M]?UV8'W[^S%^UO\ LU_MF_#>W^+?[+OQD\%_&;P#-<+8W.K^$[Z8WNAZHUM#
M>?V)XL\-ZG;Z=XH\&^(%L[BWNY/#_BS1M&UJ*UN(+B6P2&:)W[;XY?&CX?\
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M^_\ "<GQ=^(^H:87MR]]I^NZXGA_4B+K;<^'/AKI,EL;:6XN0[O:*ZMI)+Y
M?<WBW_@[A_;#^-7C_7/#7["?_!/'2?%ND6$-S)I=EXMMOBC\:?']U9;C!8:[
MKGACX.GPK;:!#+.4:YT>WU/78HV)LX?$TSD75>K?LU?\'>NL:'\4+7X9?\%%
M_P!CO4/@K97=Y86^I>._A6/%T6J>!H=0F40:AXI^#7Q!MY?%&H:'%9W$6H7V
MHZ!XKN-<BLK2=]&\'^(KF]MK.'^M_P#9'_9"^ 7[#WP/\(?L_?LY^ M)\#>
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M_#6:[@6>RLOB/\0'TOQ$;+Q)+!+#?CP=H'A_6]8@LFC;Q!/X9%]IDMY^I?\
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M-\$Z'8Z!H>G6\,4</F+:6$,2W-]<B)9=0U.\-QJ6IW1DO-1N[J[EEG?^"O\
MX/&/V3/A+\,_BC^RE^U)\//!_AWPCXU^.L/Q>\&_&6YT*RCTEO&VM>!'\!ZY
MX/\ %^J6-C;QV&H>)I+3Q?XITSQ%XDNBFM:G:6?ABUO)M0ATZ%K$?,E?FOW5
MM.G]=.H'^@VCI(BR1LKHZJZ.C!D=& 965E)#*P(*L"0000<&OQX_X*J?\%K_
M -D[_@E1X?TS3/B3)JGQ2^/GBW2VU?P-^S[X#O+*#Q/>Z1YLUM%XI\;:]>)<
M:9\/?!<U[;RV-KJVHVNI:WK5U%=CPMX7\0Q:1KTND^I?\$Q/C>FI_P#!)/\
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M5)Y--U.RN$C::,6NJ6?VC2M2T^\N=7]L#]K'X-_L0_L[?$S]I;X[>)]/\->
M_AOX>OM3,5W>P6NI>+/$(M9V\.>!/"T$Q+ZIXM\8:I'#HN@Z;;QRR2W=Q]HF
M6*QMKNY@_AHNO^#;O_@MK_P3X^(OB;Q'_P $R/VRM/USP;KDBR;_  A\5M?^
M 'C/Q%;V,[R:;8_$7X<Z\U[\+=?DLXY$6RN+GQEKUK)+]KD-CHZ2)#-);_\
M!N#_ ,%N?^"A/Q$\-^(?^"G'[9FGZ%X*T62.5O\ A+/BKKOQ[\7^'X+AU%[:
M?#SX:^'38?"K0KBZ@65+Z\M_&&@PB>2"<V>M9GC3Z%\)<(?7'C5QMEBR'VGM
MOJ_+6><_5^93^J_5.7VOM.2]+V_)S)_O'AKWIK/VU;EY70FZEK7TY+]^;;SM
M>W2Y\J_\&N?P?^(W[7W_  6/\??MO:_HR_V)\&;'XT_&GQ]KMOYD6C6OQ0_:
M0LO&W@KP_P"&[:,F1I;K5;7QG\0]<TV";,<%CX2O+F29+N&R2?TC_@[(_9N^
M(G[,'_!2GX)_\%"O 5C'!H/QIT;X>:Q9^*$L'D@TC]H#]G(Z-I<%AKIB/DR?
M:_ NC?#74M"DN;BVN=7ATGQ)8VT'D>&YKJ3^ZO\ X)^?\$]_V<?^":W[/FB?
ML\?LW^&[BQT6WN#K?C/QMK[V=]X^^*/C.XMX;?4/&?CO6K.SL(;_ %2>&"&S
ML+*RL['1=!TJWM=(T33K&PMTB/1_ME_LN?LP?MX_![QE^Q_^TG8:+XKT'QGI
M-EXA7P[::[I^F?$7PI>6T^I0>&?B7X)<FXU70M;T74++5ET?7ET^ZTN\^RZU
MH>JVNKZ)<Z[H]WUS\0J+XYCGM+"U99)2P*R1X7E3KRR=-RG4<'+D4_K$OK4:
M4I*/*H4)S3;J$K#/ZNZ;:YW+VE^BGHK7]%:_=W*?[!O[<WP*_P""A?[-W@']
MHWX$>*M)UC2_$^BZ8WC'PE!J=I=^)_A;XY>RBE\0_#WQOIL+_:](U_0;\SV\
M9N[>"WUS35LO$6BR7VA:IIU_<_!W_!>O_@I+\)?V ?V#/C7INJ^,=)C_ &@_
MCQ\,_&?PK^ GPYMKRVN/%VI:YXYT6_\ "EY\0&T82_:;7PA\/+/4;WQ'J>O7
M\46D3ZGING>&8IY]8UJPL;C^;'QM_P &B7[>WP)^(VL>)/\ @GY_P4%\%>'=
M$U&1[6SU?QMXG^,W[//Q&M/#\ZRRG2-8USX*>'?B/:>(Y+24Q6SW,2>'[+55
M,M^=(TAMNG'T73?^#8&+X"_ O]KC]MG_ (*9_M0R?M0_%KX9_LR?'?XA:!X:
MT?5O&>J^![3Q?X1^#OBG4]$\7_$'XE_$+[/X_P#B+'X8U*U@U#0O#PT+PE8?
M;](TR;6I?$&ESW?AEL</D7 F'S3#YC3XJ>/R_P"MTJN%R6EE^(695YRJP='
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M&[M[>'PW?+J+ZE/I,D4DMH+:*[629X/Z'?V8_AIKOP6_9L_9[^#GBF[TB_\
M$WPF^!WPG^&GB.^T">\NM"O==\"> M \+:O=Z)=:C8:5J%SI%SJ&E7$VFSWV
MEZ;>36;PR75A9SL]O'GGF9X#$\#<'9=0Q5*KCL!6S:6,PT6_:X=5\54G2=1-
M))5(-2C9O1CA"2Q%:;3491@D^CM&*?W6/<****^ .@**** "BBB@ HHHH **
M** "BBB@ HHHH _)#_@NO^S%\<?VR?\ @E7^U+^S=^S=X(_X6/\ &GXC_P#"
MD?\ A#/!G_"2^$/"']L_\(A^T;\(?'GB+_BHO'FO^%_"FG?V=X4\+Z[JO_$U
MUVQ^U_8?L-C]IU*YL[.X_/'_ (-@/^"=_P"V)_P3N_9__:=\$?MB_!__ (4_
MXH^(?QB\+>*O!^F?\+ ^%WQ _MC0=-\%1Z1>W_VWX6^-O&VGZ?Y.H*;?[+JE
MW97LF/-BMY(,2U_3[17T%#B3'8?AS&<,0I81X#&X^.85:TJ=9XR-:"PL5&G4
M5>-%4K82G>,L/.=Y3]]7CRYNE%U8U;OFC'E2NN6VNZM>_O/J>*_M'_ +X>?M
M3_ 7XN?LY?%BPN-1^'7QH\!>(_A]XKALIDMM3M]-\0Z?-9C5-'NY(ITLM=T6
MY>WUC0K]H)Q8ZO865V89?)V-_G<6/_!(;_@OE_P11_:=\7?%'_@GMI>N_&SP
M)?QZEHMIX[^$T/A#QEI/Q-^'\$TFKZ?H'Q8^ /BF^F\06_B&UMHE)6PT'6(]
M'U^2ZA^'WCJZNKJ.ZN?]+&BNGAWBW,.':6,PE+#X+,<MS!)8S+<RH/$82K**
MLJBBIP<:G*E%N\H32CSPDX4W!5*,:CC)N491^&47:2\O-?EK;=W_ (/;3XE?
M\'?'[?VFK\)(OAWIO[%/@KQ/8'2?%_Q5N_"'AC]GO4M.TF:673[J];7_ !#J
MGC3XV:)?22V\D_VCX0>'[/Q-%$T5S9FUTJ\CDF^/?V]_^#27]J[X6_#3]G6\
M_8OEUG]LOXTZ])\1+C]K#5]8\;_"[X3:7IFO77_")7_@B]\!6'Q5\<^&3J'A
MYI9?&VG:Q>7WB75_%.H:C!IVN7=C8VFKG2]!_P!(2BO:PWB/FN78BE4R;*\B
MRC"TYSG5P&#P,H4,=*5*I2A+'U56CBJ[H^T<Z*A7HPC.,'*,N6SS>&A)-3G4
MF^DI2NXZIOE332O:ST;WU/E[]B2T^+VF?L?_ +,NB?'_ ,!S?#+XV^&O@?\
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MUT2,^)[D7/@[Q?'J4>M^(/$%EHNF65R="2>.Q\07UK?WLNB3Z=+_ #9>&O\
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M]36[\6_LN?$GQ[\)-6M9BHOU\-:YJ\OQ0\#Z@Z*[;M-_LOQO=^%],GV0[O\
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MXL_;*_;&M-+TO]HSQ[X/N?!?PZ^%MKJMCXEOOA+X1U^_M=2\6Z]XUUVPEO\
M1I_B/XN?3=,T^VL_#NIZC!X7\+MK%IJ>LW^K^+-4T7PO.C:<5:V[V733]/\
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MC144!0!5RFE9)=E8 HHHI@%%%% !1110 4444 %%%% !1110 5_-I_P=<_\
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M7*:'KOD#$UUH.JVUU?>&/&.F0213ZCX6UK5$L9K36(=+U&Q3C[K2]5Z@=_\
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M6*_#GQ_\5O&'A]-&US5/".OW36&N?#[X6?#_ $74->UW5[[XAV#Q>&=3UCQ
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MM'WOQ3\4_$;Q[/XO\8>*+3P6?@-;>!)[_3+.UT+PGH-K9S^)?''V:?PSX/\
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M=W=:JTUU(OE75U\.M+<)!)+-!+)>A+'Y*_X+[?\ !$3]AC_@EG^P%\)?B!\
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M/AWPWX#\&V&NZ]!)J/B ?)T5WVN_Z_X/S _T5?\ @GM^R)\-OV$/V/\ X/\
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M40?@/_LM_P <?_4EMJ\__P"#NS_E%-H7_9U_P@_]1#XJUZ!_P:C?\H@_ ?\
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M&2/3RT5I>Q^'_$'B#QCXL32A/'#?QZ1=VHNC]K65R17Q)-\K5K^?X?U\@/\
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M_@]<2-%CC_X)G*B(JHB)^V2%1$4!5557]E,!54 !5     &!65TW>3VV6O\
M7^?H!_<QX1\(^%/ 'A?0/!/@;PUH/@WP;X4TFQT'PQX4\+Z38:#X=\/:)IL"
M6NGZ1HNC:7!:Z=IFFV-M&D%K96=O#;P1(J1QJH KHJ_A'_XC7_\ K&A_YN7_
M /DIU_9%^QK^T1_PUO\ LI?L^?M.?\(?_P *_P#^%[_"?P;\3_\ A"/^$@_X
M2O\ X17_ (2W2+?5?[#_ .$E_L3PW_;G]G^?Y']I_P!@:/\ :]GF_P!GVV[R
MUT4D]G^8'TM1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K_+J_X.QO^4N?B;_L@'P3_P#3?KE?ZBM?Y=7_  =C?\I<
M_$W_ &0#X)_^F_7*B>R]?T8'^HK1115@%%%% '^8U_P20_Y6G;;_ +.O_P""
MC/\ ZJ?]JJO].6O\QK_@DA_RM.VW_9U__!1G_P!5/^U57^G+40V?K^B _B&_
MX/3?^26_L!?]C_\ M _^H[\*Z_?+_@C9XT\.?#?_ ((J_L;_ !$\8Z@ND^$?
M 7[*W_":>*=5>.25-,\.>%H?$.N:YJ#11*TLBV6F6-U<M'&K2.(RJ*6(!_ W
M_@]-_P"26_L!?]C_ /M _P#J._"NOVY_X)>?"2T^/W_! K]GKX$7][_9MC\:
M_P!AWQ;\)+W4<2G[!:?$CPSXQ\'7-[B%DF/V6'67GQ$Z2GR\1LKX(%\<O3_(
M#^-#Q1^U)_P5(_X.3_VW/$?P#^!7Q&UKX1? FWM?$'BG2_A<GC+7O WP?^%O
MP:T?4K?1+;Q=\8E\(F_O?B1XZU$Z_IFF7$MU9^);JY\0^(;C2O"MCX?\'K=G
M3?UT^#__  9=_"^RAL;GX^_MQ^/?$UP[>9J6C?!_X3^'O T-LA,(-I8^)?&G
MB7XAO>L MPW]H3^$[ ,9X4_LQ?LKO>?@]_P2[_;/^)G_  ;[?\%%?BUX+_:U
M^"OBPZ-J6AW/P;^//@S2+>Q_X371;&UUO3O$GA/XE_#>;5KG2M(\7:>3:+>Z
M.C:UIWA[QGX/\22:G8ZJES'H]S'_ %U_$'_@[1_X)0^%/!DWB#P??_'WXH>)
MVL9I;'P%X?\ A)=>'M4_M'8XM+/5M<\;:OX=\-6-J\PC^VW^FZIKLEK:N\]M
M8ZC<1K92RN5W<M[];_I^0'\PO_!Q[_P2I_8Z_P""6NA_L,^$_P!ERR\;2^(O
MBC#^T?>_%/Q3\1O'L_B_QAXHM/!9^ UMX$GO],L[70O">@VMG/XE\<?9I_#/
M@_P^NKW%W?1W\NH+I-A%IO\ =]_P1K_Y13?\$^/^S4/@W_ZB&GU_G%?\%?/B
MS_P4$_X*%Q^'O^"HG[1GP)\1?!7]E/Q7XJTKX _LQZ+J+7</A[2])GT7Q7XW
ML;/PP^KVNE:UXT;7X?#GB77?$?Q0;0].T/Q1KL%SIOAU;;2/#]KH'A[_ $)?
M^"#7CO1?BA_P1^_89U.QO[?6[72O@P/ASJJ/':$6^H?#CQ'XA^'VJ:/>VL.Z
M,?8Y/#S6H6Y03WEE]GO+E7:[+NXVYG;:VGX?GN!U'[;?_!/[_@F3_P %1-9@
M^&_[0FC_  T\>?&[P;X;O;C0O$/P[^(FD^'OVAO!'A2RU33X[Z5;GPSJCZ[?
M^#].U7Q'91/I'C71O$7@S2]6\41746E6NLZQ;W4O\T7[2?\ P9B6[/?ZI^Q_
M^V5-$FVY.E^!_P!I/P8EPY?,KV:W_P 5/AA!; *1Y%M<M;_!PD$2WL2$,E@O
MY3?%'PC^TO\ \&SO_!76]^,GA'X<WWBW]GO7M:\:6OPWFOUU'3O!/QI_9O\
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MO#;F.-?\T?X<_"S]LK_@YV_X*;7_ ,8?&'AK4/ GP&T?4-!T+QQXKTR"[N/
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M3!\2O >E7"PS:D?#]SJ%EX3^/'P!U_6OL'A?QAI]_I\^HZ=,GVS2--\6Z?\
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MXE^)WAR^\,^.+E3*L\E]<?!:'7]/TLYFEA;QW.DR^7)/-&/W>5Z[6:_KS?\
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M %%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0:;I.IS1FY;2TUZRUG0-0@O8F37-$D >VDM(YG_A+_8#_:H^/G_!MC_P4?\
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M6,G1E"UN25.59QE"VBA).*6B5B%2IIW5."=[W48IW];?/UU"BBBO%+"BBB@
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M/H6HPM;ZAHOB'P[K=K?:1K6DW]N[P7NG:E9W-G=0LT4\,B,5/344 >$?!/\
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M_P#"?XC>+IM*TQ9$TW3)?$OC#PEK.LR:?IZ2RK8V3WIMK19)%@CC#L#]1T4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%?\ !4'_ */<^.W_ (4\7_R%7YJT4?ZN</?]"+)O_#7@?_E ?6<3_P!!%?\
M\&U/_DO)?<?I5_P^*_X*@_\ 1[GQV_\ "GB_^0J/^'Q7_!4'_H]SX[?^%/%_
M\A5^:M%'^KG#W_0BR;_PUX'_ .4!]9Q/_017_P#!M3_Y+R7W'Z5?\/BO^"H/
M_1[GQV_\*>+_ .0J/^'Q7_!4'_H]SX[?^%/%_P#(5?FK11_JYP]_T(LF_P##
M7@?_ )0'UG$_]!%?_P &U/\ Y+R7W'Z5?\/BO^"H/_1[GQV_\*>+_P"0J/\
MA\5_P5!_Z/<^.W_A3Q?_ "%7YJT4?ZN</?\ 0BR;_P ->!_^4!]9Q/\ T$5_
M_!M3_P"2\E]Q^E7_  ^*_P""H/\ T>Y\=O\ PIXO_D*C_A\5_P %0?\ H]SX
M[?\ A3Q?_(5?FK11_JYP]_T(LF_\->!_^4!]9Q/_ $$5_P#P;4_^2\E]Q^E7
M_#XK_@J#_P!'N?';_P *>+_Y"H_X?%?\%0?^CW/CM_X4\7_R%7YJT4?ZN</?
M]"+)O_#7@?\ Y0'UG$_]!%?_ ,&U/_DO)?<?I5_P^*_X*@_]'N?';_PIXO\
MY"H_X?%?\%0?^CW/CM_X4\7_ ,A5^:M%'^KG#W_0BR;_ ,->!_\ E ?6<3_T
M$5__  ;4_P#DO)?<?I5_P^*_X*@_]'N?';_PIXO_ )"K^VK_ (-T_P!H[XY_
MM0_L*^-_B)^T%\3_ !5\6?&^G_M+>/?"=EXF\87RZAJEMX<TWX>_"74['1XI
MUBA LK74-:U6[BCVDK-?7#;CN '^;77^A3_P:M?\HXOB'_V=O\2__57_  2K
M\N\8,GRG!<&U:^#RO+L)668X&*K8; X:A5492J<T54I4H349?:5[/JCU<FK5
MIXU1G5J3C[*H^6524E=<MG9MK0_I7HHHK^43ZT^!O^"I?C3QA\.?^"=W[8/C
MGX?^*O$7@CQKX6^!_B_5_#7B[PEK.H^'?$OA_5K6WC:VU/1=<TFXM-2TN_MV
M),-Y97,-Q$22DBFO\U3_ (>7_P#!1;_H_']L3_Q)/XP__-A7^D+_ ,%?O^48
MG[;_ /V;]XV_])HJ_P IZOZ9\#\!@<7D6<3Q6"PF)G'-HQC/$8:C6E&/U/#R
MY8RJ0DU'F;=DTKZVN?,9[4G"O14)SBG1NU&3C=\[UT:[(^W/^'E__!1;_H_'
M]L3_ ,23^,/_ ,V%'_#R_P#X*+?]'X_MB?\ B2?QA_\ FPKXCHK]M_L7)_\
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M=?\ SQ/BO[7S#_H(?_@JC_\ *_+\^[/[,_\ B+NU'_HP"R_\2BG_ /H>Z/\
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MM1_Z, LO_$HI_P#Z'NOXS**/^(3>'_\ T3Z_\.F=?_/$/[7S#_H(?_@JC_\
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MFG_\\/7^EJ?ZP2_Z!8_^#G_\K]?Z6O\ L8_\+N^#'_17?AA_X7WA3_Y;4?\
M"[O@Q_T5WX8?^%]X4_\ EM7^.=11_P 0"PW_ $4]?_PTT_\ YX>O]+4_U@E_
MT"Q_\'/_ .5^O]+7_8Q_X7=\&/\ HKOPP_\ "^\*?_+:C_A=WP8_Z*[\,/\
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M%AO^BGK_ /AII_\ SP]?Z6I_K!+_ *!8_P#@Y_\ ROU_I:_[&/\ PN[X,?\
M17?AA_X7WA3_ .6U'_"[O@Q_T5WX8?\ A?>%/_EM7^.=11_Q +#?]%/7_P##
M33_^>'K_ $M3_6"7_0+'_P '/_Y7Z_TM?]C'_A=WP8_Z*[\,/_"^\*?_ "VH
M_P"%W?!C_HKOPP_\+[PI_P#+:O\ '.HH_P"(!8;_ **>O_X::?\ \\/7^EJ?
MZP2_Z!8_^#G_ /*_7^EK_L8_\+N^#'_17?AA_P"%]X4_^6U=+X<\=^!_&,EU
M%X1\9>%/%,MBD4E[%X<\0Z1KDEG'.SK#)=)IEY=-;I,T<BQ-,$61HW"$E6 _
MQJ:_K_\ ^#1__DJO[:W_ &3[X-?^I'X\KYWBSP?H<-</9CGD<^JXR6 A0DL-
M++H4(U?;8O#X9IU5C:KARJLY_P .5^51TO<Z<)G,L3B*5!X=0]HY+F55RM:+
MEM[-7VMNM_+7^X&BBBOPX]T0D $D@  DDG  ')))X  ZFO,?^%W?!C_HKOPP
M_P#"^\*?_+:O0M2_Y!U__P!>5U_Z(DK_ !C*_2O#W@"GQRLW=3-)Y;_9;P"7
M)A(XKVWUWZY>_-B*'L_9_5%:W/S>T^SR^]YF8Y@\![&U)5?:^TWGR<OL_9_W
M97OSOM:W4_V,?^%W?!C_ **[\,/_  OO"G_RVH_X7=\&/^BN_##_ ,+[PI_\
MMJ_QSJ*_2?\ B 6&_P"BGK_^&FG_ //#U_I:^9_K!+_H%C_X.?\ \K]?Z6O^
MQC_PN[X,?]%=^&'_ (7WA3_Y;4?\+N^#'_17?AA_X7WA3_Y;5_CG44?\0"PW
M_13U_P#PTT__ )X>O]+4_P!8)?\ 0+'_ ,'/_P"5^O\ 2U_V,?\ A=WP8_Z*
M[\,/_"^\*?\ RVH_X7=\&/\ HKOPP_\ "^\*?_+:O\<ZBC_B 6&_Z*>O_P"&
MFG_\\/7^EJ?ZP2_Z!8_^#G_\K]?Z6O\ L8_\+N^#'_17?AA_X7WA3_Y;4?\
M"[O@Q_T5WX8?^%]X4_\ EM7^.=11_P 0"PW_ $4]?_PTT_\ YX>O]+4_U@E_
MT"Q_\'/_ .5^O]+7_8Q_X7=\&/\ HKOPP_\ "^\*?_+:C_A=WP8_Z*[\,/\
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M%AO^BGK_ /AII_\ SP]?Z6I_K!+_ *!8_P#@Y_\ ROU_I:_[&/\ PN[X,?\
M17?AA_X7WA3_ .6U'_"[O@Q_T5WX8?\ A?>%/_EM7^.=11_Q +#?]%/7_P##
M33_^>'K_ $M3_6"7_0+'_P '/_Y7Z_TM?]C'_A=WP8_Z*[\,/_"^\*?_ "VH
M_P"%W?!C_HKOPP_\+[PI_P#+:O\ '.HH_P"(!8;_ **>O_X::?\ \\/7^EJ?
MZP2_Z!8_^#G_ /*_7^EK_L8_\+N^#'_17?AA_P"%]X4_^6U'_"[O@Q_T5WX8
M?^%]X4_^6U?XYU%'_$ L-_T4]?\ \--/_P">'K_2U/\ 6"7_ $"Q_P#!S_\
ME?K_ $M?]C'_ (7=\&/^BN_##_POO"G_ ,MJ/^%W?!C_ **[\,/_  OO"G_R
MVK_'.HH_X@%AO^BGK_\ AII__/#U_I:G^L$O^@6/_@Y__*_7^EK_ +&/_"[O
M@Q_T5WX8?^%]X4_^6U'_  N[X,?]%=^&'_A?>%/_ );5_CG44?\ $ L-_P!%
M/7_\--/_ .>'K_2U/]8)?] L?_!S_P#E?K_2U_V,?^%W?!C_ **[\,/_  OO
M"G_RVH_X7=\&/^BN_##_ ,+[PI_\MJ_QSJ*/^(!8;_HIZ_\ X::?_P \/7^E
MJ?ZP2_Z!8_\ @Y__ "OU_I:_[&/_  N[X,?]%=^&'_A?>%/_ );4?\+N^#'_
M $5WX8?^%]X4_P#EM7^.=11_Q +#?]%/7_\ #33_ /GAZ_TM3_6"7_0+'_P<
M_P#Y7Z_TM?\ 8Q_X7=\&/^BN_##_ ,+[PI_\MJ/^%W?!C_HKOPP_\+[PI_\
M+:O\<ZBC_B 6&_Z*>O\ ^&FG_P#/#U_I:G^L$O\ H%C_ .#G_P#*_7^EK_L8
M_P#"[O@Q_P!%=^&'_A?>%/\ Y;5J:-\4OAEXCU*VT;P]\1O FO:Q>>=]CTG1
MO%_A_5-2NOL]O+=W'V:QL=0GNI_(M8)[F;RHG\JWAEF?;'&[#_&ZK]H/^#>K
M_E,!^R)_W7W_ -9@^-5>9G/@C0RG)\VS2/$=:O++<MQV8*B\KA359X/"U<2J
M3J+'3<%4=+D<U"3BI<W+*UGK0SR5:M1I?5E'VM6G3YO:M\O/.,;V]FKVNW:Z
MOIKW_P!."BBBOY_/H3SF\^,7PCTZ[NM/U#XI_#FQO[&YGL[VRO/&_AFVN[.[
MMI6@N;6ZMI]32:WN;>9'AG@F1)8I4:.15=2!6_X7=\&/^BN_##_POO"G_P M
MJ_RA/V_?^3[OVUO^SMOVC_\ U<?C*ODFOZ+PG@3A\3A<-B7Q+6@\1AZ-=P65
M0DHNK3A4<5+Z^K\O,TG97T=NA\Y//I0G*/U5/EE*-_;-7Y7:_P##TO9_?Y:_
M[&/_  N[X,?]%=^&'_A?>%/_ );4?\+N^#'_ $5WX8?^%]X4_P#EM7^.=171
M_P 0"PW_ $4]?_PTT_\ YX>O]+6/]8)?] L?_!S_ /E?K_2U_P!C'_A=WP8_
MZ*[\,/\ POO"G_RVH_X7=\&/^BN_##_POO"G_P MJ_QSJ*/^(!8;_HIZ_P#X
M::?_ ,\/7^EJ?ZP2_P"@6/\ X.?_ ,K]?Z6O^QC_ ,+N^#'_ $5WX8?^%]X4
M_P#EM1_PN[X,?]%=^&'_ (7WA3_Y;5_CG44?\0"PW_13U_\ PTT__GAZ_P!+
M4_U@E_T"Q_\ !S_^5^O]+7_8Q_X7=\&/^BN_##_POO"G_P MJ/\ A=WP8_Z*
M[\,/_"^\*?\ RVK_ !SJ*/\ B 6&_P"BGK_^&FG_ //#U_I:G^L$O^@6/_@Y
M_P#ROU_I:_[&/_"[O@Q_T5WX8?\ A?>%/_EM1_PN[X,?]%=^&'_A?>%/_EM7
M^.=11_Q +#?]%/7_ /#33_\ GAZ_TM3_ %@E_P! L?\ P<__ )7Z_P!+7_8Q
M_P"%W?!C_HKOPP_\+[PI_P#+:C_A=WP8_P"BN_##_P +[PI_\MJ_QSJ*/^(!
M8;_HIZ__ (::?_SP]?Z6I_K!+_H%C_X.?_ROU_I:_P"QC_PN[X,?]%=^&'_A
M?>%/_EM1_P +N^#'_17?AA_X7WA3_P"6U?XYU%'_ ! +#?\ 13U__#33_P#G
MAZ_TM3_6"7_0+'_P<_\ Y7Z_TM?]C'_A=WP8_P"BN_##_P +[PI_\MJ/^%W?
M!C_HKOPP_P#"^\*?_+:O\<ZBC_B 6&_Z*>O_ .&FG_\ /#U_I:G^L$O^@6/_
M (.?_P K]?Z6O^QC_P +N^#'_17?AA_X7WA3_P"6U'_"[O@Q_P!%=^&'_A?>
M%/\ Y;5_CG44?\0"PW_13U__  TT_P#YX>O]+4_U@E_T"Q_\'/\ ^5^O]+7_
M &,?^%W?!C_HKOPP_P#"^\*?_+:C_A=WP8_Z*[\,/_"^\*?_ "VK_'.HH_X@
M%AO^BGK_ /AII_\ SP]?Z6I_K!+_ *!8_P#@Y_\ ROU_I:_[&/\ PN[X,?\
M17?AA_X7WA3_ .6U'_"[O@Q_T5WX8?\ A?>%/_EM7^.=11_Q +#?]%/7_P##
M33_^>'K_ $M3_6"7_0+'_P '/_Y7Z_TM?]C'_A=WP8_Z*[\,/_"^\*?_ "VH
M_P"%W?!C_HKOPP_\+[PI_P#+:O\ '.HH_P"(!8;_ **>O_X::?\ \\/7^EJ?
MZP2_Z!8_^#G_ /*_7^EK_L8_\+N^#'_17?AA_P"%]X4_^6U'_"[O@Q_T5WX8
M?^%]X4_^6U?XYU%'_$ L-_T4]?\ \--/_P">'K_2U/\ 6"7_ $"Q_P#!S_\
ME?K_ $M?]C'_ (7=\&/^BN_##_POO"G_ ,MJ/^%W?!C_ **[\,/_  OO"G_R
MVK_'.HH_X@%AO^BGK_\ AII__/#U_I:G^L$O^@6/_@Y__*_7^EK_ +&/_"[O
M@Q_T5WX8?^%]X4_^6U'_  N[X,?]%=^&'_A?>%/_ );5_CG44?\ $ L-_P!%
M/7_\--/_ .>'K_2U/]8)?] L?_!S_P#E?K_2U_V,?^%W?!C_ **[\,/_  OO
M"G_RVH_X7=\&/^BN_##_ ,+[PI_\MJ_QSJ*/^(!8;_HIZ_\ X::?_P \/7^E
MJ?ZP2_Z!8_\ @Y__ "OU_I:_[&/_  N[X,?]%=^&'_A?>%/_ );4?\+N^#'_
M $5WX8?^%]X4_P#EM7^.=11_Q +#?]%/7_\ #33_ /GAZ_TM3_6"7_0+'_P<
M_P#Y7Z_TM?\ 8Q_X7=\&/^BN_##_ ,+[PI_\MJ/^%W?!C_HKOPP_\+[PI_\
M+:O\<ZBC_B 6&_Z*>O\ ^&FG_P#/#U_I:G^L$O\ H%C_ .#G_P#*_7^EK_L8
M_P#"[O@Q_P!%=^&'_A?>%/\ Y;4?\+N^#'_17?AA_P"%]X4_^6U?XYU%'_$
ML-_T4]?_ ,--/_YX>O\ 2U/]8)?] L?_  <__E?K_2U_V,?^%W?!C_HKOPP_
M\+[PI_\ +:C_ (7=\&/^BN_##_POO"G_ ,MJ_P <ZBC_ (@%AO\ HIZ__AII
M_P#SP]?Z6I_K!+_H%C_X.?\ \K]?Z6O^QC_PN[X,?]%=^&'_ (7WA3_Y;4?\
M+N^#'_17?AA_X7WA3_Y;5_CG44?\0"PW_13U_P#PTT__ )X>O]+4_P!8)?\
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M $5WX8?^%]X4_P#EM1_PN[X,?]%=^&'_ (7WA3_Y;5_CG44?\0"PW_13U_\
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M[X,?]%=^&'_A?>%/_EM1_P +N^#'_17?AA_X7WA3_P"6U?XYU%'_ ! +#?\
M13U__#33_P#GAZ_TM3_6"7_0+'_P<_\ Y7Z_TM?]C'_A=WP8_P"BN_##_P +
M[PI_\MJ/^%W?!C_HKOPP_P#"^\*?_+:O\<ZBC_B 6&_Z*>O_ .&FG_\ /#U_
MI:G^L$O^@6/_ (.?_P K]?Z6O^QC_P +N^#'_17?AA_X7WA3_P"6U'_"[O@Q
M_P!%=^&'_A?>%/\ Y;5_CG44?\0"PW_13U__  TT_P#YX>O]+4_U@E_T"Q_\
M'/\ ^5^O]+7_ &,?^%W?!C_HKOPP_P#"^\*?_+:C_A=WP8_Z*[\,/_"^\*?_
M "VK_'.HH_X@%AO^BGK_ /AII_\ SP]?Z6I_K!+_ *!8_P#@Y_\ ROU_I:_[
M&/\ PN[X,?\ 17?AA_X7WA3_ .6U'_"[O@Q_T5WX8?\ A?>%/_EM7^.=11_Q
M +#?]%/7_P##33_^>'K_ $M3_6"7_0+'_P '/_Y7Z_TM?]C'_A=WP8_Z*[\,
M/_"^\*?_ "VH_P"%W?!C_HKOPP_\+[PI_P#+:O\ '.HH_P"(!8;_ **>O_X:
M:?\ \\/7^EJ?ZP2_Z!8_^#G_ /*_7^EK_L8_\+N^#'_17?AA_P"%]X4_^6U'
M_"[O@Q_T5WX8?^%]X4_^6U?XYU%'_$ L-_T4]?\ \--/_P">'K_2U/\ 6"7_
M $"Q_P#!S_\ E?K_ $M?]C'_ (7=\&/^BN_##_POO"G_ ,MJ/^%W?!C_ **[
M\,/_  OO"G_RVK_'.HH_X@%AO^BGK_\ AII__/#U_I:G^L$O^@6/_@Y__*_7
M^EK_ +&/_"[O@Q_T5WX8?^%]X4_^6U'_  N[X,?]%=^&'_A?>%/_ );5_CG4
M4?\ $ L-_P!%/7_\--/_ .>'K_2U/]8)?] L?_!S_P#E?K_2U_V,?^%W?!C_
M **[\,/_  OO"G_RVH_X7=\&/^BN_##_ ,+[PI_\MJ_QSJ*/^(!8;_HIZ_\
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M*4XQ>TI).V]FTCN>B;[)GY/_ /#_ (_X)&?]'A:-_P"&E^/_ /\ .IH_X?\
M'_!(S_H\+1O_  TOQ_\ _G4U_F#45_5?_$">%/\ H9\0_P#A3EO_ ,ZCY/\
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M_A3EO_SJ#^WL7_SZPW_@-7_Y;Z_TM?\ 3Y_X?\?\$C/^CPM&_P##2_'_ /\
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M $M?]/G_ (?\?\$C/^CPM&_\-+\?_P#YU-'_  _X_P""1G_1X6C?^&E^/_\
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MK_,&HH_X@3PI_P!#/B'_ ,*<M_\ G4']O8O_ )]8;_P&K_\ +?7^EK_I\_\
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M?7^EK_I\_P##_C_@D9_T>%HW_AI?C_\ _.IH_P"'_'_!(S_H\+1O_#2_'_\
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MA_\ "G+?_G4']O8O_GUAO_ :O_RWU_I:_P"GS_P_X_X)&?\ 1X6C?^&E^/\
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MA^(/_AE/B5_\H:_S8**_=/\ B!W!W_03GW_A;@__ )W?U=^5O!_MW&_RX?\
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M1_P2B_Z+#\0?_#*?$K_Y0T?\1)'_  2B_P"BP_$'_P ,I\2O_E#7^;!11_Q
M[@[_ *"<^_\ "W!__.[^KORL?V[C?Y</_P" 3_\ EG]7?E;_ $G_ /B)(_X)
M1?\ 18?B#_X93XE?_*&C_B)(_P""47_18?B#_P"&4^)7_P H:_S8**/^('<'
M?]!.??\ A;@__G=_5WY6/[=QO\N'_P# )_\ RS^KORM_I/\ _$21_P $HO\
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M_AE/B5_\H:_S8**/^('<'?\ 03GW_A;@_P#YW?U=^5C^W<;_ "X?_P  G_\
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M\,I\2O\ Y0T?\1)'_!*+_HL/Q!_\,I\2O_E#7^;!11_Q [@[_H)S[_PMP?\
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MT6'X@_\ AE/B5_\ *&O\V"BC_B!W!W_03GW_ (6X/_YW?U=^5C^W<;_+A_\
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MB"_&C_PUOCC_ .45'_#-_P"T1_T07XT?^&M\<?\ RBH^NX/_ *"\-_X/I?\
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M )9?^ O_ "/%Z*]H_P"&;_VB/^B"_&C_ ,-;XX_^45'_  S?^T1_T07XT?\
MAK?''_RBH^NX/_H+PW_@^E_\F')/^67_ ("_\CQ>BO:/^&;_ -HC_H@OQH_\
M-;XX_P#E%1_PS?\ M$?]$%^-'_AK?''_ ,HJ/KN#_P"@O#?^#Z7_ ,F')/\
MEE_X"_\ (\7HKVC_ (9O_:(_Z(+\:/\ PUOCC_Y14?\ #-_[1'_1!?C1_P"&
MM\<?_**CZ[@_^@O#?^#Z7_R8<D_Y9?\ @+_R/%Z*]H_X9O\ VB/^B"_&C_PU
MOCC_ .45'_#-_P"T1_T07XT?^&M\<?\ RBH^NX/_ *"\-_X/I?\ R8<D_P"6
M7_@+_P CQ>O]"G_@U:_Y1Q?$/_L[?XE_^JO^"5?P??\ #-_[1'_1!?C1_P"&
MM\<?_**O[YO^#83P7XQ\"?\ !/3Q_HWC?PGXE\&ZO-^U9\1M0BTKQ5H6J>'M
M2EL)_AI\&((;V.QU>UL[I[2:>VN88KE8C#)+;SQHY>*0+^4^,N)P]7@JK&G7
MHU)?VE@'RPJPG*RE4N[1DW9=78];)8R6.3<6E[*IJTUV/Z,J***_D8^P/S@_
MX*_?\HQ/VW_^S?O&W_I-%7^4]7^MQ_P4)^"_CK]HO]B3]IOX&_#*TT^^\?\
MQ1^$OB;PAX2L]5U&#2-.N-:U.!$M(KS4[G_1[*!F4A[B;Y$ZM7\(/_$-'_P5
M0_Z$'X2_^'D\*U_1?@SQ%D639+FU#-<WR_+JU7-%5I4\9BJ5"=2G]4H0YX1J
M2BY1YDX\RTNFNC/F\ZPV(K5Z,J-&I42I6;A!R2?/)V;2WMJ?@+17[]?\0T?_
M  50_P"A!^$O_AY/"M'_ !#1_P#!5#_H0?A+_P"'D\*U^Q_Z\\&_]%/D?_AQ
MPW_RSS_/LSQOJ&-_Z!:__@N7^1^ M%?OU_Q#1_\ !5#_ *$'X2_^'D\*T?\
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M#1_\%4/^A!^$O_AY/"M'^O/!O_13Y'_X<<-_\L\_S[,/J&-_Z!:__@N7^1^
MM%?OU_Q#1_\ !5#_ *$'X2_^'D\*T?\ $-'_ ,%4/^A!^$O_ (>3PK1_KSP;
M_P!%/D?_ (<<-_\ +//\^S#ZAC?^@6O_ ."Y?Y'X"T5^_7_$-'_P50_Z$'X2
M_P#AY/"M'_$-'_P50_Z$'X2_^'D\*T?Z\\&_]%/D?_AQPW_RSS_/LP^H8W_H
M%K_^"Y?Y'X"T5^_7_$-'_P %4/\ H0?A+_X>3PK1_P 0T?\ P50_Z$'X2_\
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M*T?Z\\&_]%/D?_AQPW_RSS_/LP^H8W_H%K_^"Y?Y'X"T5^_7_$-'_P %4/\
MH0?A+_X>3PK1_P 0T?\ P50_Z$'X2_\ AY/"M'^O/!O_ $4^1_\ AQPW_P L
M\_S[,/J&-_Z!:_\ X+E_D?@+17[]?\0T?_!5#_H0?A+_ .'D\*T?\0T?_!5#
M_H0?A+_X>3PK1_KSP;_T4^1_^''#?_+//\^S#ZAC?^@6O_X+E_D?@+7]N?\
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M?XQE?T;X ;<6>N1?EG!\WQ#_ ,P?_<Q_[@"BBBOZ+/FPHHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /MS_ ()H?\I%OV#O^SQ/V;/_ %</@^O]:2O\EO\ X)H?
M\I%OV#O^SQ/V;/\ U</@^O\ 6DK^8?'K_D<9!_V+<3_ZE'U.0?P,1_U]C_Z0
M@HHHK\%/?/\ ',^-?_)9?BW_ -E-\>_^I5JM>95Z;\:_^2R_%O\ [*;X]_\
M4JU6O,J_T1PO^[8?_KQ1_P#3<3\XEN_5_F%%%%;B"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]1/^"*W_*4_P#8J_[*XG_J
M,>(J_P!3RO\ +#_X(K?\I3_V*O\ LKB?^HQXBK_4\K^6/'C_ )*/*/\ L21_
M]3\8?5Y!_NU;_K^__3< KF/&W_(F>+O^Q8U__P!-5W73US'C;_D3/%W_ &+&
MO_\ IJNZ_$:?\2G_ (X_^E(]R6S]'^1_C34445_HJ?G 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5^W/_!NM_P I<_V9O^P-\=O_ %0'Q-K\1J_;
MG_@W6_Y2Y_LS?]@;X[?^J ^)M?-<9_\ )(<4_P#9/9S_ .J_$'3@O]\PG_83
M0_\ 3L#_ $QZ***_@P^_"O\ -2_X./?^4LOQU_[$SX(?^JB\(U_I6U_FI?\
M!Q[_ ,I9?CK_ -B9\$/_ %47A&OV7P-_Y+#&?]B#&_\ J=EAXN>_[G#_ +"(
M?^FZI^%E%%%?UF?(A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^Q
M_P#"7_DE7PR_[)]X,_\ 4<TVO\<"O]C_ .$O_)*OAE_V3[P9_P"HYIM?SQX_
M?P.%O^ON<?\ I&6GT7#_ ,>*_P -+\ZAZ#1117\W'TP4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#;X1_P#SJJ/^(3S]B+_HX3]JG_P;?"/_ .=57]2]%'_$2>.?^BDQ_P!V'_\
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M $<)^U3_ .#;X1__ #JJ/^(3S]B+_HX3]JG_ ,&WPC_^=57]2]%'_$2>.?\
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M8_[L/_\ */+\^[#^S,!_T#4_OE_\EY?GW9_+1_Q">?L1?]'"?M4_^#;X1_\
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MFQ'_ ('#_P"5_P!7?E;_ #7_ /B&X_X*O?\ 1'/A_P#^'K^&?_R_H_XAN/\
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M'#_Y7_5WY6_S7_\ B&X_X*O?]$<^'_\ X>OX9_\ R_H_XAN/^"KW_1'/A_\
M^'K^&?\ \OZ_TH**/^(X\8_] V0_^$6,_P#GC_5WY6/["P7\V(_\#A_\K_J[
M\K?YK_\ Q#<?\%7O^B.?#_\ \/7\,_\ Y?T?\0W'_!5[_HCGP_\ _#U_#/\
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M_P 1QXQ_Z!LA_P#"+&?_ #Q_J[\K']A8+^;$?^!P_P#E?]7?E;_-?_XAN/\
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M^>/]7?E8_L+!?S8C_P #A_\ *_ZN_*W^:_\ \0W'_!5[_HCGP_\ _#U_#/\
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M_P">/]7?E8_L+!?S8C_P.'_RO^KORM_FO_\ $-Q_P5>_Z(Y\/_\ P]?PS_\
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M>628.4I2<J]Y2<G:<+7;N[?N]O\ /T/\U_\ XAN/^"KW_1'/A_\ ^'K^&?\
M\OZ/^(;C_@J]_P!$<^'_ /X>OX9__+^O]*"BMO\ B./&/_0-D/\ X18S_P">
M/]7?E:?["P7\V(_\#A_\K_J[\K?YK_\ Q#<?\%7O^B.?#_\ \/7\,_\ Y?T?
M\0W'_!5[_HCGP_\ _#U_#/\ ^7]?Z4%%'_$<>,?^@;(?_"+&?_/'^KORL?V%
M@OYL1_X'#_Y7_5WY6_S7_P#B&X_X*O?]$<^'_P#X>OX9_P#R_H_XAN/^"KW_
M $1SX?\ _AZ_AG_\OZ_TH**/^(X\8_\ 0-D/_A%C/_GC_5WY6/["P7\V(_\
M X?_ "O^KORM_FO_ /$-Q_P5>_Z(Y\/_ /P]?PS_ /E_1_Q#<?\ !5[_ *(Y
M\/\ _P /7\,__E_7^E!11_Q''C'_ *!LA_\ "+&?_/'^KORL?V%@OYL1_P"!
MP_\ E?\ 5WY6_P U_P#XAN/^"KW_ $1SX?\ _AZ_AG_\OZ/^(;C_ (*O?]$<
M^'__ (>OX9__ "_K_2@HH_XCCQC_ - V0_\ A%C/_GC_ %=^5C^PL%_-B/\
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M-D/_ (18S_YX_P!7?E8_L+!?S8C_ ,#A_P#*_P"KORM_FO\ _$-Q_P %7O\
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M_FQ'_@</_E?]7?E;_-?_ .(;C_@J]_T1SX?_ /AZ_AG_ /+^C_B&X_X*O?\
M1'/A_P#^'K^&?_R_K_2@HH_XCCQC_P! V0_^$6,_^>/]7?E8_L+!?S8C_P #
MA_\ *_ZN_*W^:_\ \0W'_!5[_HCGP_\ _#U_#/\ ^7]'_$-Q_P %7O\ HCGP
M_P#_  ]?PS_^7]?Z4%%'_$<>,?\ H&R'_P (L9_\\?ZN_*Q_86"_FQ'_ ('#
M_P"5_P!7?E;_ #7_ /B&X_X*O?\ 1'/A_P#^'K^&?_R_H_XAN/\ @J]_T1SX
M?_\ AZ_AG_\ +^O]*"BC_B./&/\ T#9#_P"$6,_^>/\ 5WY6/["P7\V(_P#
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M_P#^'K^&?_R_K_2@HH_XCCQC_P! V0_^$6,_^>/]7?E8_L+!?S8C_P #A_\
M*_ZN_*W^:_\ \0W'_!5[_HCGP_\ _#U_#/\ ^7]'_$-Q_P %7O\ HCGP_P#_
M  ]?PS_^7]?Z4%%'_$<>,?\ H&R'_P (L9_\\?ZN_*Q_86"_FQ'_ ('#_P"5
M_P!7?E;_ #7_ /B&X_X*O?\ 1'/A_P#^'K^&?_R_H_XAN/\ @J]_T1SX?_\
MAZ_AG_\ +^O]*"BC_B./&/\ T#9#_P"$6,_^>/\ 5WY6/["P7\V(_P# X?\
MRO\ J[\K?YK_ /Q#<?\ !5[_ *(Y\/\ _P /7\,__E_1_P 0W'_!5[_HCGP_
M_P##U_#/_P"7]?Z4%%'_ !''C'_H&R'_ ,(L9_\ /'^KORL?V%@OYL1_X'#_
M .5_U=^5O\U__B&X_P""KW_1'/A__P"'K^&?_P OZ/\ B&X_X*O?]$<^'_\
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M?PS_ /E_1_Q#<?\ !5[_ *(Y\/\ _P /7\,__E_7^E!11_Q''C'_ *!LA_\
M"+&?_/'^KORL?V%@OYL1_P"!P_\ E?\ 5WY6_P U_P#XAN/^"KW_ $1SX?\
M_AZ_AG_\OZ/^(;C_ (*O?]$<^'__ (>OX9__ "_K_2@HH_XCCQC_ - V0_\
MA%C/_GC_ %=^5C^PL%_-B/\ P.'_ ,K_ *N_*W^:_P#\0W'_  5>_P"B.?#_
M /\ #U_#/_Y?T?\ $-Q_P5>_Z(Y\/_\ P]?PS_\ E_7^E!11_P 1QXQ_Z!LA
M_P#"+&?_ #Q_J[\K']A8+^;$?^!P_P#E?]7?E;_-?_XAN/\ @J]_T1SX?_\
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MRLO_ .@:/_@=7_Y/R_/NS^0S_B$B^#7_ $>9\3?_  U/A7_YJZ/^(2+X-?\
M1YGQ-_\ #4^%?_FKK^O.BC_B*7'O_10U_P#PCRW_ .8O+\^[#^RLO_Z!H_\
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MGQ-_\-3X5_\ FKH_XA(O@U_T>9\3?_#4^%?_ )JZ_KSHH_XBEQ[_ -%#7_\
M"/+?_F+R_/NP_LK+_P#H&C_X'5_^3\OS[L_D,_XA(O@U_P!'F?$W_P -3X5_
M^:NC_B$B^#7_ $>9\3?_  U/A7_YJZ_KSHH_XBEQ[_T4-?\ \(\M_P#F+R_/
MNP_LK+_^@:/_ ('5_P#D_+\^[/Y#/^(2+X-?]'F?$W_PU/A7_P":NC_B$B^#
M7_1YGQ-_\-3X5_\ FKK^O.BC_B*7'O\ T4-?_P (\M_^8O+\^[#^RLO_ .@:
M/_@=7_Y/R_/NS^0S_B$B^#7_ $>9\3?_  U/A7_YJZ/^(2+X-?\ 1YGQ-_\
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M(I<>_P#10U__  CRW_YB\OS[L/[*R_\ Z!H_^!U?_D_+\^[/Y#/^(2+X-?\
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M -%)C_NP_P#\H\OS[L/[,P'_ $#4_OE_\EY?GW9_+1_Q">?L1?\ 1PG[5/\
MX-OA'_\ .JH_XA//V(O^CA/VJ?\ P;?"/_YU5?U+T4?\1)XY_P"BDQ_W8?\
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M?WR_^2\OS[L_EH_XA//V(O\ HX3]JG_P;?"/_P"=51_Q">?L1?\ 1PG[5/\
MX-OA'_\ .JK^I>BC_B)/'/\ T4F/^[#_ /RCR_/NP_LS ?\ 0-3^^7_R7E^?
M=G\M'_$)Y^Q%_P!'"?M4_P#@V^$?_P ZJC_B$\_8B_Z.$_:I_P#!M\(__G55
M_4O11_Q$GCG_ **3'_=A_P#Y1Y?GW8?V9@/^@:G]\O\ Y+R_/NS^6C_B$\_8
MB_Z.$_:I_P#!M\(__G54?\0GG[$7_1PG[5/_ (-OA'_\ZJOZEZ*/^(D\<_\
M128_[L/_ /*/+\^[#^S,!_T#4_OE_P#)>7Y]V?RT?\0GG[$7_1PG[5/_ (-O
MA'_\ZJC_ (A//V(O^CA/VJ?_  ;?"/\ ^=57]2]%'_$2>.?^BDQ_W8?_ .4>
M7Y]V']F8#_H&I_?+_P"2\OS[L_EH_P"(3S]B+_HX3]JG_P &WPC_ /G54?\
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MJ?WR_P#DO+\^[/Y:/^(3S]B+_HX3]JG_ ,&WPC_^=51_Q">?L1?]'"?M4_\
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MM_\ (>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1-_:6_P#G5T?\-4^
M?^A#_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_ %_PZ^\^E:*^:O\
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ME?\ Q$W]I;_YU='_  U3X!_Z$/\ :5_\1-_:6_\ G5T?V/FO_0MQW_A-6_\
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M'^TK_P"(F_M+?_.KH_X:I\ _]"'^TK_XB;^TM_\ .KH_L?-?^A;CO_":M_\
M(>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1-_:6_P#G5T?\-4^ ?^A#
M_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_ %_PZ^\^E:*^:O\ AJGP
M#_T(?[2O_B)O[2W_ ,ZNC_AJGP#_ -"'^TK_ .(F_M+?_.KH_L?-?^A;CO\
MPFK?_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\ G5T?\-4^
M ?\ H0_VE?\ Q$W]I;_YU=']CYK_ -"W'?\ A-6_^0\U]X6?9_U_PZ^\^E:*
M^:O^&J? /_0A_M*_^(F_M+?_ #JZ/^&J? /_ $(?[2O_ (B;^TM_\ZNC^Q\U
M_P"A;CO_  FK?_(>:^\+/L_Z_P"'7WGTK17S5_PU3X!_Z$/]I7_Q$W]I;_YU
M='_#5/@'_H0_VE?_ !$W]I;_ .=71_8^:_\ 0MQW_A-6_P#D/-?>%GV?]?\
M#K[SZ5HKYJ_X:I\ _P#0A_M*_P#B)O[2W_SJZ/\ AJGP#_T(?[2O_B)O[2W_
M ,ZNC^Q\U_Z%N._\)JW_ ,AYK[PL^S_K_AU]Y]*T5\U?\-4^ ?\ H0_VE?\
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M_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\ G5T?\-4^ ?\
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M$/\ :5_\1-_:6_\ G5T?\-4^ ?\ H0_VE?\ Q$W]I;_YU=']CYK_ -"W'?\
MA-6_^0\U]X6?9_U_PZ^\^E:*^:O^&J? /_0A_M*_^(F_M+?_ #JZ/^&J? /_
M $(?[2O_ (B;^TM_\ZNC^Q\U_P"A;CO_  FK?_(>:^\+/L_Z_P"'7WGTK17S
M5_PU3X!_Z$/]I7_Q$W]I;_YU='_#5/@'_H0_VE?_ !$W]I;_ .=71_8^:_\
M0MQW_A-6_P#D/-?>%GV?]?\ #K[SZ5HKYJ_X:I\ _P#0A_M*_P#B)O[2W_SJ
MZ/\ AJGP#_T(?[2O_B)O[2W_ ,ZNC^Q\U_Z%N._\)JW_ ,AYK[PL^S_K_AU]
MY]*T5\U?\-4^ ?\ H0_VE?\ Q$W]I;_YU='_  U3X!_Z$/\ :5_\1-_:6_\
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ME?\ Q$W]I;_YU=']CYK_ -"W'?\ A-6_^0\U]X6?9_U_PZ^\^E:*^:O^&J?
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M.OO/I6BOFK_AJGP#_P!"'^TK_P"(F_M+?_.KH_X:I\ _]"'^TK_XB;^TM_\
M.KH_L?-?^A;CO_":M_\ (>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1
M-_:6_P#G5T?\-4^ ?^A#_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_
M %_PZ^\^E:*^:O\ AJGP#_T(?[2O_B)O[2W_ ,ZNC_AJGP#_ -"'^TK_ .(F
M_M+?_.KH_L?-?^A;CO\ PFK?_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\
M:5_\1-_:6_\ G5T?\-4^ ?\ H0_VE?\ Q$W]I;_YU=']CYK_ -"W'?\ A-6_
M^0\U]X6?9_U_PZ^\^E:*^:O^&J? /_0A_M*_^(F_M+?_ #JZ/^&J? /_ $(?
M[2O_ (B;^TM_\ZNC^Q\U_P"A;CO_  FK?_(>:^\+/L_Z_P"'7WGTK17S5_PU
M3X!_Z$/]I7_Q$W]I;_YU='_#5/@'_H0_VE?_ !$W]I;_ .=71_8^:_\ 0MQW
M_A-6_P#D/-?>%GV?]?\ #K[SZ5HKYJ_X:I\ _P#0A_M*_P#B)O[2W_SJZ/\
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ML_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\ G5T?\-4^ ?\ H0_VE?\
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M !$W]I;_ .=71_8^:_\ 0MQW_A-6_P#D/-?>%GV?]?\ #K[SZ5HKYJ_X:I\
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M?^A;CO\ PFK?_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\
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M_B)O[2W_ ,ZNC^Q\U_Z%N._\)JW_ ,AYK[PL^S_K_AU]Y]*T5\U?\-4^ ?\
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MK[PL^S_K_AU]Y]*T5\U?\-4^ ?\ H0_VE?\ Q$W]I;_YU='_  U3X!_Z$/\
M:5_\1-_:6_\ G5T?V/FO_0MQW_A-6_\ D/-?>%GV?]?\.OO/I6BOFK_AJGP#
M_P!"'^TK_P"(F_M+?_.KH_X:I\ _]"'^TK_XB;^TM_\ .KH_L?-?^A;CO_":
MM_\ (>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1-_:6_P#G5T?\-4^
M?^A#_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_ %_PZ^\^E:*^:O\
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ME?\ Q$W]I;_YU='_  U3X!_Z$/\ :5_\1-_:6_\ G5T?V/FO_0MQW_A-6_\
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M'^TK_P"(F_M+?_.KH_X:I\ _]"'^TK_XB;^TM_\ .KH_L?-?^A;CO_":M_\
M(>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1-_:6_P#G5T?\-4^ ?^A#
M_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_ %_PZ^\^E:*^:O\ AJGP
M#_T(?[2O_B)O[2W_ ,ZNC_AJGP#_ -"'^TK_ .(F_M+?_.KH_L?-?^A;CO\
MPFK?_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\ G5T?\-4^
M ?\ H0_VE?\ Q$W]I;_YU=']CYK_ -"W'?\ A-6_^0\U]X6?9_U_PZ^\^E:*
M^:O^&J? /_0A_M*_^(F_M+?_ #JZ/^&J? /_ $(?[2O_ (B;^TM_\ZNC^Q\U
M_P"A;CO_  FK?_(>:^\+/L_Z_P"'7WGTK17S5_PU3X!_Z$/]I7_Q$W]I;_YU
M='_#5/@'_H0_VE?_ !$W]I;_ .=71_8^:_\ 0MQW_A-6_P#D/-?>%GV?]?\
M#K[SZ5HKYJ_X:I\ _P#0A_M*_P#B)O[2W_SJZ/\ AJGP#_T(?[2O_B)O[2W_
M ,ZNC^Q\U_Z%N._\)JW_ ,AYK[PL^S_K_AU]Y]*T5\U?\-4^ ?\ H0_VE?\
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M_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\ G5T?\-4^ ?\
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M$/\ :5_\1-_:6_\ G5T?\-4^ ?\ H0_VE?\ Q$W]I;_YU=']CYK_ -"W'?\
MA-6_^0\U]X6?9_U_PZ^\^E:*^:O^&J? /_0A_M*_^(F_M+?_ #JZ/^&J? /_
M $(?[2O_ (B;^TM_\ZNC^Q\U_P"A;CO_  FK?_(>:^\+/L_Z_P"'7WGTK17S
M5_PU3X!_Z$/]I7_Q$W]I;_YU='_#5/@'_H0_VE?_ !$W]I;_ .=71_8^:_\
M0MQW_A-6_P#D/-?>%GV?]?\ #K[SZ5HKYJ_X:I\ _P#0A_M*_P#B)O[2W_SJ
MZ/\ AJGP#_T(?[2O_B)O[2W_ ,ZNC^Q\U_Z%N._\)JW_ ,AYK[PL^S_K_AU]
MY]*T5\U?\-4^ ?\ H0_VE?\ Q$W]I;_YU='_  U3X!_Z$/\ :5_\1-_:6_\
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ME?\ Q$W]I;_YU=']CYK_ -"W'?\ A-6_^0\U]X6?9_U_PZ^\^E:*^:O^&J?
M/_0A_M*_^(F_M+?_ #JZ/^&J? /_ $(?[2O_ (B;^TM_\ZNC^Q\U_P"A;CO_
M  FK?_(>:^\+/L_Z_P"'7WGTK17S5_PU3X!_Z$/]I7_Q$W]I;_YU='_#5/@'
M_H0_VE?_ !$W]I;_ .=71_8^:_\ 0MQW_A-6_P#D/-?>%GV?]?\ #K[SZ5HK
MYJ_X:I\ _P#0A_M*_P#B)O[2W_SJZ/\ AJGP#_T(?[2O_B)O[2W_ ,ZNC^Q\
MU_Z%N._\)JW_ ,AYK[PL^S_K_AU]Y]*T5\U?\-4^ ?\ H0_VE?\ Q$W]I;_Y
MU='_  U3X!_Z$/\ :5_\1-_:6_\ G5T?V/FO_0MQW_A-6_\ D/-?>%GV?]?\
M.OO/I6BOFK_AJGP#_P!"'^TK_P"(F_M+?_.KH_X:I\ _]"'^TK_XB;^TM_\
M.KH_L?-?^A;CO_":M_\ (>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1
M-_:6_P#G5T?\-4^ ?^A#_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_
M %_PZ^\^E:*^:O\ AJGP#_T(?[2O_B)O[2W_ ,ZNC_AJGP#_ -"'^TK_ .(F
M_M+?_.KH_L?-?^A;CO\ PFK?_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\
M:5_\1-_:6_\ G5T?\-4^ ?\ H0_VE?\ Q$W]I;_YU=']CYK_ -"W'?\ A-6_
M^0\U]X6?9_U_PZ^\^E:*^:O^&J? /_0A_M*_^(F_M+?_ #JZ/^&J? /_ $(?
M[2O_ (B;^TM_\ZNC^Q\U_P"A;CO_  FK?_(>:^\+/L_Z_P"'7WGTK17S5_PU
M3X!_Z$/]I7_Q$W]I;_YU='_#5/@'_H0_VE?_ !$W]I;_ .=71_8^:_\ 0MQW
M_A-6_P#D/-?>%GV?]?\ #K[SZ5HKYJ_X:I\ _P#0A_M*_P#B)O[2W_SJZ/\
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ML_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\ G5T?\-4^ ?\ H0_VE?\
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M !$W]I;_ .=71_8^:_\ 0MQW_A-6_P#D/-?>%GV?]?\ #K[SZ5HKYJ_X:I\
M_P#0A_M*_P#B)O[2W_SJZ/\ AJGP#_T(?[2O_B)O[2W_ ,ZNC^Q\U_Z%N._\
M)JW_ ,AYK[PL^S_K_AU]Y]*T5\U?\-4^ ?\ H0_VE?\ Q$W]I;_YU='_  U3
MX!_Z$/\ :5_\1-_:6_\ G5T?V/FO_0MQW_A-6_\ D/-?>%GV?]?\.OO/I6BO
MFK_AJGP#_P!"'^TK_P"(F_M+?_.KH_X:I\ _]"'^TK_XB;^TM_\ .KH_L?-?
M^A;CO_":M_\ (>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1-_:6_P#G
M5T?\-4^ ?^A#_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_ %_PZ^\^
ME:*^:O\ AJGP#_T(?[2O_B)O[2W_ ,ZNC_AJGP#_ -"'^TK_ .(F_M+?_.KH
M_L?-?^A;CO\ PFK?_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:
M6_\ G5T?\-4^ ?\ H0_VE?\ Q$W]I;_YU=']CYK_ -"W'?\ A-6_^0\U]X6?
M9_U_PZ^\^E:*^:O^&J? /_0A_M*_^(F_M+?_ #JZ/^&J? /_ $(?[2O_ (B;
M^TM_\ZNC^Q\U_P"A;CO_  FK?_(>:^\+/L_Z_P"'7WGTK17S5_PU3X!_Z$/]
MI7_Q$W]I;_YU='_#5/@'_H0_VE?_ !$W]I;_ .=71_8^:_\ 0MQW_A-6_P#D
M/-?>%GV?]?\ #K[SZ5HKYJ_X:I\ _P#0A_M*_P#B)O[2W_SJZ/\ AJGP#_T(
M?[2O_B)O[2W_ ,ZNC^Q\U_Z%N._\)JW_ ,AYK[PL^S_K_AU]Y]*T5\U?\-4^
M ?\ H0_VE?\ Q$W]I;_YU='_  U3X!_Z$/\ :5_\1-_:6_\ G5T?V/FO_0MQ
MW_A-6_\ D/-?>%GV?]?\.OO/I6BOFK_AJGP#_P!"'^TK_P"(F_M+?_.KH_X:
MI\ _]"'^TK_XB;^TM_\ .KH_L?-?^A;CO_":M_\ (>:^\+/L_P"O^'7WGTK1
M7S5_PU3X!_Z$/]I7_P 1-_:6_P#G5T?\-4^ ?^A#_:5_\1-_:6_^=71_8^:_
M]"W'?^$U;_Y#S7WA9]G_ %_PZ^\^E:*^:O\ AJGP#_T(?[2O_B)O[2W_ ,ZN
MC_AJGP#_ -"'^TK_ .(F_M+?_.KH_L?-?^A;CO\ PFK?_(>:^\+/L_Z_X=?>
M?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\ G5T?\-4^ ?\ H0_VE?\ Q$W]I;_Y
MU=']CYK_ -"W'?\ A-6_^0\U]X6?9_U_PZ^\^E:*^:O^&J? /_0A_M*_^(F_
MM+?_ #JZ/^&J? /_ $(?[2O_ (B;^TM_\ZNC^Q\U_P"A;CO_  FK?_(>:^\+
M/L_Z_P"'7WGTK17S5_PU3X!_Z$/]I7_Q$W]I;_YU='_#5/@'_H0_VE?_ !$W
M]I;_ .=71_8^:_\ 0MQW_A-6_P#D/-?>%GV?]?\ #K[SZ5HKYJ_X:I\ _P#0
MA_M*_P#B)O[2W_SJZ/\ AJGP#_T(?[2O_B)O[2W_ ,ZNC^Q\U_Z%N._\)JW_
M ,AYK[PL^S_K_AU]Y]*T5\U?\-4^ ?\ H0_VE?\ Q$W]I;_YU='_  U3X!_Z
M$/\ :5_\1-_:6_\ G5T?V/FO_0MQW_A-6_\ D/-?>%GV?]?\.OO/I6BOFK_A
MJGP#_P!"'^TK_P"(F_M+?_.KH_X:I\ _]"'^TK_XB;^TM_\ .KH_L?-?^A;C
MO_":M_\ (>:^\+/L_P"O^'7WGTK17S5_PU3X!_Z$/]I7_P 1-_:6_P#G5T?\
M-4^ ?^A#_:5_\1-_:6_^=71_8^:_]"W'?^$U;_Y#S7WA9]G_ %_PZ^\^E:*^
M:O\ AJGP#_T(?[2O_B)O[2W_ ,ZNC_AJGP#_ -"'^TK_ .(F_M+?_.KH_L?-
M?^A;CO\ PFK?_(>:^\+/L_Z_X=?>?2M%?-7_  U3X!_Z$/\ :5_\1-_:6_\
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M_B)O[2W_ ,ZNC^Q\U_Z%N._\)JW_ ,AYK[PL^S_K_AU]Y]*T5\U?\-4^ ?\
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M\)Z_JVK^#[]=7T;5]+-GXAL].N!J.E:E8F/[38W440![C1110 4444 %%%%
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MRI_X'+_/R7W'Z<_\/D_^"E/_ $<YJO\ X;CX-_\ SNJ/^'R?_!2G_HYS5?\
MPW'P;_\ G=5^8U%'_$&O"#_HU/AM_P"(-PO_ /.L/:U?^?E3_P #E_GY+[C]
M.?\ A\G_ ,%*?^CG-5_\-Q\&_P#YW5'_  ^3_P""E/\ T<YJO_AN/@W_ /.Z
MK\QJ*/\ B#7A!_T:GPV_\0;A?_YUA[6K_P _*G_@<O\ /R7W'Z<_\/D_^"E/
M_1SFJ_\ AN/@W_\ .ZH_X?)_\%*?^CG-5_\ #<?!O_YW5?F-11_Q!KP@_P"C
M4^&W_B#<+_\ SK#VM7_GY4_\#E_GY+[C].?^'R?_  4I_P"CG-5_\-Q\&_\
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M (*4_P#1SFJ_^&X^#?\ \[JC_A\G_P %*?\ HYS5?_#<?!O_ .=U7YC44?\
M$&O"#_HU/AM_X@W"_P#\ZP]K5_Y^5/\ P.7^?DON/TY_X?)_\%*?^CG-5_\
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M*G_@<O\ /R7W'Z<_\/D_^"E/_1SFJ_\ AN/@W_\ .ZH_X?)_\%*?^CG-5_\
M#<?!O_YW5?F-11_Q!KP@_P"C4^&W_B#<+_\ SK#VM7_GY4_\#E_GY+[C].?^
M'R?_  4I_P"CG-5_\-Q\&_\ YW5'_#Y/_@I3_P!'.:K_ .&X^#?_ ,[JOS&H
MH_X@UX0?]&I\-O\ Q!N%_P#YUA[6K_S\J?\ @<O\_)?<?IS_ ,/D_P#@I3_T
M<YJO_AN/@W_\[JC_ (?)_P#!2G_HYS5?_#<?!O\ ^=U7YC44?\0:\(/^C4^&
MW_B#<+__ #K#VM7_ )^5/_ Y?Y^2^X_3G_A\G_P4I_Z.<U7_ ,-Q\&__ )W5
M'_#Y/_@I3_T<YJO_ (;CX-__ #NJ_,:BC_B#7A!_T:GPV_\ $&X7_P#G6'M:
MO_/RI_X'+_/R7W'Z<_\ #Y/_ (*4_P#1SFJ_^&X^#?\ \[JC_A\G_P %*?\
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M ,-Q\&__ )W5'_#Y/_@I3_T<YJO_ (;CX-__ #NJ_,:BC_B#7A!_T:GPV_\
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MW_\ .ZH_X?)_\%*?^CG-5_\ #<?!O_YW5?F-11_Q!KP@_P"C4^&W_B#<+_\
MSK#VM7_GY4_\#E_GY+[C].?^'R?_  4I_P"CG-5_\-Q\&_\ YW5'_#Y/_@I3
M_P!'.:K_ .&X^#?_ ,[JOS&HH_X@UX0?]&I\-O\ Q!N%_P#YUA[6K_S\J?\
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MRI_X'+_/R7W'Z<_\/D_^"E/_ $<YJO\ X;CX-_\ SNJ/^'R?_!2G_HYS5?\
MPW'P;_\ G=5^8U%'_$&O"#_HU/AM_P"(-PO_ /.L/:U?^?E3_P #E_GY+[C]
M.?\ A\G_ ,%*?^CG-5_\-Q\&_P#YW5'_  ^3_P""E/\ T<YJO_AN/@W_ /.Z
MK\QJ*/\ B#7A!_T:GPV_\0;A?_YUA[6K_P _*G_@<O\ /R7W'Z<_\/D_^"E/
M_1SFJ_\ AN/@W_\ .ZH_X?)_\%*?^CG-5_\ #<?!O_YW5?F-11_Q!KP@_P"C
M4^&W_B#<+_\ SK#VM7_GY4_\#E_GY+[C].?^'R?_  4I_P"CG-5_\-Q\&_\
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M (*4_P#1SFJ_^&X^#?\ \[JC_A\G_P %*?\ HYS5?_#<?!O_ .=U7YC44?\
M$&O"#_HU/AM_X@W"_P#\ZP]K5_Y^5/\ P.7^?DON/TY_X?)_\%*?^CG-5_\
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M +3WQ9_8YTCP_P#M\>$?#GC[6-"_9/\ !.D>*OB)9>(;W0_&$VF>#=,T_0_
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MZ;M4I7ES)U7[6,4FXRAS727644I7O\*3=^MWL]#^S*OP'_X+\_\ !6OXT?\
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METVP CE>;5-7>TCTO2;2&&>XO-3O+2TMX)YYHXG]FK^3;_@Z[_:0\7']G?\
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M))4)1G3O+0?M(R=)QD[34FDDK.T;^\WJN7ROKHS^B>BOXX/@+^W[_P %R/\
M@M7XE^,OQ6_X)G>-_P!E[]BK]C#X6_%35OA1X5\;?&#PQ%XZ^*/CG5=#TG1/
M$[MJ6G:QX"^*EB^MWV@^)O"VK:O8VOAKP3H7AO2/$T&D:?KOBOQ!H]YJ5U]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\0QI6M79\%R)+X>U^)D\2#36630]80@-IEZ(/YDO^#.W]HWXI_&W_@F;X]\
M_$SQ-JOBZS_9V_:(U[X:?#/4M;U*\U/4='^&^I^ ? 7C'3/!BW%])/.=*\,Z
M[KGB(:#%]H,&FZ-J%EH-C;6FFZ-91'^;G_@FQ^P+XP_X*<?\%9?^"HW[)/BO
MXP?$#X:?L8#]IWXG?'C]J[PI\.]5AT/6/C+?_"C]H#XK>'?@I\/9]3>ROA!9
M?VS\4/&6OW(O;:\TN&UTFYU*&R7Q=IO@_5]& /\ 1"^'_P#P4<_X)]?%?Q\O
MPK^&/[<?[(WQ"^)4M^FEV?@/P9^T7\(_$OBS5-2?:#8Z+H6D>+KO4=<NX9'6
MWNH-'M[V2SO,V5VL-VK0C[.K^'S_ (+7_P#!L[_P3L^!'_!/;XT?M,_L9>!?
M&OP&^,/[,G@I/B=));_$_P")?Q%T+XE:!X8N[)_%UKXHT_XC>)_%MSHFKKH+
M:AKFD:QX)N?#-E8ZQIT$=WIDNESS);?I[_P22_X*4>+;?_@WA\,?MW_M*:IJ
M/CWQ3^SC\%?CTOB/6]8UBYO/$'Q/'P!\2>-?#O@&UU35[J&>\D\5^+M-T/PI
MX2O=8U&;4;K5/$,TOB#4[UI=1N5@ /W@^,_[1W[/7[.&B6?B7]H?X\?!GX#>
M'-1N?L>G^(/C/\4/!'PNT2^N]T:?9;/5?'&N:'875SOEB7R()WEW21KMRZ@\
ME\!?VR?V2/VIDNC^S7^T[\ OCU-I]HE[JEA\(OBYX#^(.K:-;.+<A]=T?POK
MNI:KH;+]JMA+#J]G930O<0I+&CRHI_AV_P"",7_!*N'_ (+T:U\8O^"KG_!7
M#QEX^^.6B^+_ (E>(/A]\(_@Y8^-/$O@GPO=Z?X9,-WK<@U#PCJNE^)/"_PP
M\)7^M?\ "(> / _@;6_"GE:GHWB75M<N]0-Q$=0]Q_X+3?\ !OC\$/V!?V?-
M2_X*2_\ !)?4_BC^RC\9/V19-+\?^(O"?A3XJ_$'Q19ZOX)BU&TTOQ)XM\+>
M)_B!XJ\1>-_#OB;PK9:E)KFN6,GBK4O"OB;P;9^(-"E\-"ZN(?M0!_<;XH\4
M^&/!'AW6O%_C3Q'H/A#PGX;TZZUCQ%XH\4:OI^@>'=!TFRC::]U36M;U:XM-
M-TO3K2%6ENKV^N8+:WC5GEE1037D6N_M5_LO>%_A-8_'OQ-^TC\!/#OP+U.Y
MGL]-^-.N_&'X>:1\)M0N[74[[1;JUL?B-J'B*W\'W=S;:QIFI:3/!!K,DL.I
MZ??6$BK=6D\4?\^VO?MXW_\ P4B_X->/VD_VI?$MI::?\2/$/[%'Q_\ !GQ?
ML;"UCL=.3XJ_#G1]>\'^,-5TRQA>6#3](\6W6EP^-M%TR&:<:3I'B6QTN:5K
MFRG"_A9_P;H_\$7?AK_P5#_91\-?'W_@H9XF^)7Q7_9V^ ?BCQ]\!OV2OV9=
M/\>>)O ?@#2-)G\57?Q:^+7CO5;WP3>Z'XGE;Q+\2?B3K&F6;:!XC\/ZI/=:
M)K$?B.\U?2]/\&VFB@']ZOP$_:R_9>_:GTF]US]FG]HGX)_'S3-+6W;6+CX0
M_$_P9\0GT)KI%>"#Q!:^%]9U.[T"[D5E_P!#UF"QNU)VO"K<5PWQ;_X*!?L(
M_ +QM'\-?CE^VA^RK\'OB&\D$<G@;XG?M _"GP-XMLA=65SJ%K/JGA[Q+XKT
MW5=(LKNVM9!:7^J6MG975S+:6-O<27M_8V]Q_GB_\%>?V&]:_P""'_\ P52_
M99O_ /@DEX_\<_!C7_VK_A[JWA'X?>%KKQ/K'BF7P-XO\?>(;KX-ZOX>LM=\
M1'7-5\2>#M4_X27POXA\/V/C4^,-4T'QGIAUS[5J$FF^'H--_IDT#_@TB_X)
M>WOP,OO"/Q?3XV?%G]I;Q1I%U>^-/VN]9^,/CZV^(-]\2-8BFN]<\8:9X,CU
MY_AG+82:_=37EEI?B_PIXNU>2PCM[?7?$VMZH][K=X ?T]>'_$&@>+-$TKQ-
MX6US2/$OAO7K"VU70_$'A_4K+6=$UG3+V)9[/4M*U73I[FPU&PNX72:VO+.X
MFMYXF62*1T8$XOCSXB?#_P"%?AC4?&WQ/\=>#OAQX,TA5?5O%WCSQ-HG@_PQ
MIB/G:^HZ_P"(;[3M*LE;:VUKF[B!P<$X-?QM?\&;/Q2^+]AX%_X*+_L5_$+Q
M+>^(/"'[('QJ^&__  @=K>W\]]#X:U3XEW_QO\._$/1- 2:XNXM*\,W.N_!B
MR\2VND:?<G34U[Q#XEU:.,WNL7]W>>G?M;?\$;_VX_\ @K+_ ,%@M=\3?\%"
M5USPO_P2C^#&D:X_[/\ X.^'_P 7O"*+XO?2(?#>CZ=I<_AK0M:NO%_A3Q1\
M4]6U#Q!XX\9^-]2\-Q:Q9^%/#T?P]L?$6C2)X5DM@#^A3PK_ ,%4/^"9?CGQ
M0/!?@_\ X*%?L4>)?%4MW:6-CH>C?M0?!:_OM9O+ZU-Y!;>'$@\:.OB680!O
MM$?A]]2:SF1[:\$%RCPK]Y(Z2(DD;K)'(JNCHP9'1@&5T925964@JP)!!!!(
M-?R5?\%"_P#@V)_X(Q^$_P!CWXX^,/AI\.KG]D[XA^"_AOXO\3>"/B[-^T!\
M7?$&DQ>,= \.:CJ_AS1_$VA_&GXG>+O">K:+KNJ6$.GZEIFF6VB:]=VUU/'H
M>KZ=>_9YHKO_  9V_M&_%/XV_P#!,WQ[X!^)GB;5?%UG^SM^T1KWPT^&>I:W
MJ5YJ>HZ/\-]3\ ^ O&.F>#%N+Z2><Z5X9UW7/$0T&+[08--T;4++0;&VM--T
M:RB(!Y__ ,%V_P#@D7^S1\./V*O^"IG_  42\?ZK\1/VA?VKO'>E:?J_@#QO
M\9/%%YXCT/\ 9T\%:_\ &OP)I^F_#;X$^$G<Z7X4T70_"VH-X;@U:_;6=;@L
MY-4@\.W7A?1M:U#0I/Z"_P#@D[_RBR_X)I_]F ?L;_\ K.OPYKY$_P"#C[_E
M";^WQ_V3OP)_ZNKX95]=_P#!)W_E%E_P33_[, _8W_\ 6=?AS0!]_P!%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5_/-_P7T_;5U#X1_"CP_P#L
MJ_#[6&L/&GQPTRZU?XCW=E<-%J&D?"*VNI=.71PT926 ?$36K>^TNXE21EF\
M/>'O$FDW<#0:TCC^AFO\\#_@J!\:+SXZ_MV_M&>+);N2ZTK0/'VI_#3PPA8F
MWM_#OPR<^"K-K%,GR[;5+K1[W7RO!DNM7N9W5'F91_7OT*_#;!<>^+U+-,WP
M\,5D_ F7OB6>'JP4Z&)SA8FEA<BHUHM--4<54JYK!/W9U,KA3FITYSA+EQ=3
MDI66CF^73HMY?>M/F? U%%%?[9GDA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3G6=1UC2=?L_#?A31?#]OJEQXD\2-H>K2V\%U:Z-9Z=>ZAKUE:3\CX$^,_\
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MQ.)S++HSC>%>.;4:E/!X6^MG1SVGAL4K[*K/E3O(JM%^T48[8A*,O+D:;?\
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M+2]LKN&.YM+NTN=?^/L-Q:W5O,KPW%O<0N\4T,J/'+&[1R*RL0?T1_X(2?\
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M6CXD\/7]W:V.DS>,]"M? OBGP9<:U9WFO>%_$.EOJNN&;TCPG^PC_P %4O\
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M/:]JGP^\(?"DVFB?%&[76=6NM:\:^([W18+/P!I.M:J]U>6O]IVT-M]FE/\
M0[7Y1B,LJX?+<NS.5;"U*&95<?1ITJ-9U,1AZN7RP\:T,93Y$J$YQQ5"M1CS
MSE.C4C4:C&4.;K4TY2A9IP46VU9-2O9Q?5:-/S304445YQ04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*WBE(6WNKI,N #^=#_@YX_Y3(?\ !#S_ +*)\.?_ %J;X<U_=Q7\UG_!8O\
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MM83:E^=G[07_  0>_P""E7[&O_!0CXJ_\%"/^")GQ]^$GA=/CSJ_B75OB7\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+H7PN^%/@FWAFUSQ/KC7$@>YO)EMM-T;1M+T^"\UCQ!XAUB[=+/1] T.PO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%?M9_P2-_X)BZ[^UQ\0-*^,_Q:T&ZL/V9O >LQW4ZZC;R6Z_&'Q'I
M5P'3P;HHD53<^%;2[B"^.-9AS T*2^%].E_M6[O[S0?C>/\ CSAOPUX5S7C#
MBK'0P65971E/EO!XK'XN49?5<LRZC*47B<?C:B5+#T8M)/FK5ITL/2K5J=PA
M*I)1BKM_<EU;[)?\#<_>7_@AG^RE>_L^?LCI\1_%>FOIWC[]H_4;#Q_=V]S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]F^>)/\ UC/]IJO<O^(1/]FG_H_?]O7_ ,+;P#_\Q%?E)^RI^PCX/_X)T?\
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MMJ=-M;K[69?YP_V^_!_PT^ __!T[_P $UM4_9*L+/P?\7_C!9^%]1_:D\+^
M+6VTO2-6TGQ7K'CWP]XF\2>)=-TA[6W;Q#XG^$MEK>K^,(KN(?:K+P_X<\87
M=M<ZIJ$M_>_LW_P6"_X+@?"[_@G%::7\"?A#X>7]HS]OGXHKI6E?"7]G?PS%
M>ZZVB:EXHN[*P\-ZY\3[7P[))KEG#J\E]')X/\#:4@\8?$"[-K:Z:FDZ-=R^
M)K+Y^_X(E?\ !(7XN?!CXD>.?^"H/_!1GQ#>?$3_ (*,_M)QZMKEWI6K2V=W
M;? /P[XQMX([S0HS:JUA#X]O- CL_"MY8Z"T'ACX<>";6#X9>$8!I<&IW%Y^
M@Y77QF7T<YXNSZM.']O8#,\'@<%4;]MGF)S&$J<JOL)-R65X+G565>:5/FA1
MHX=SE9'--1DX4::3=.4)-]*:BT]^LWM9:[MGP_\ \%SHI?V\_P#@N!_P2L_X
M)4^)[K5+[X!P6=G^T#\6O"NE1W<2^*+N]OOB3K/B;3=1:*.*9OL'PC^#&J:?
M9ZW:RRQ^'M.^(7B2YBE2YCO8XOZIOC_^Q[^SK^TG^S9XG_9.^)GPJ\%7_P $
M=?\ !TW@W3/!EEX:TC3](\#6\6D7.D>'M7\ 6-C:VMOX,UWP;'.MUX0U3PXN
MF7GAZZMX)-+GM=F*_E5_:%LV\-?\'F/[$^K:Q/;V=CXH_9PUR\TF:5I(EE6\
M_9>_:L\%V4!>:**-[B\\0Z7-8VRV[SQR2RP0B47)EMX?[1:X.)Z]; X+@C#X
M.K4H4J'#F&S6DZ4G#DS'&YAC:F)Q$7&W[[FH4ESWYDH12:22+I)2E7<E=NJX
M.ZO>,8QLM>FK=O,_DD_X-*OCI\1+[]EC]K;]BKQWK,?B7Q'^PW^T'?\ ASPI
M#>:F_P!FT?PG\1W\5-!X6M[B*/4)K3P]'\2_A[\2]:LKI+6\\L>(KV*VBN(;
M*&V3ZK_X(I?\$:_BG^PS\4?VK?VIOVX]9^#/QU_;-^/_ ,3M0U_2/C5X$U7Q
M3XQ71/!?B!I_$/BJ+3;OQ_X$\%:UX5\2^+_&6J7\_BB/3+2^MKC1=(\,:=;:
MN]M:W5N_P'_P:Q,FJ?M=_P#!>7Q9IEC):^&?$/[5'PW;0I#';Q0[(OB=^V7J
M36*1VLDMO')8Z?K>DM+' \EO&MU"L,DB8-?TA_\ !03_ (**?LR?\$T_@5J'
MQU_:5\7_ -EV4TEQIG@/P#H?V2_^(OQ4\4Q11R+X9\!^'9[NT;4;B%9X)]:U
M:ZGM-!\-V$J:AKVIV,$D'G^AQ3B,QI\3\0Y+D]!N7$;R:>*H8:ES8FM6JX'"
M9A5HTI4_>A3JXO$5IXB"]VHDO:W4+J**BZ5*I-_PE-)MZ)*3BF_-**2[=#^>
M+_@\/^&O[/MG^Q5\&/CSJ]CI/AO]JCP[^T#X2\*_!OQSH<%KIWQ U?P[<:%X
MHUKQCX=O=8M!#K%SX4T*/2]-\3VERTL@\-^*K71%TZ:P?Q%?)J'F/_!?'XQ?
M'WX_?LZ?\$8?^"9\?B+5O#?Q2_X*,ZU\")_VB[L6UPUZEW9VGP>T%+/Q3:1R
MR/-H,7Q1^(>I>/M;M266WO\ X76=W=7D-O:2?:(_V*/V,OVI_P#@O5^UGX$_
MX*J_\%-?"%U\+/V0?A:VG7G[%W[(<@O3I/C+1X[RS\1:;XGU6TU>VMYM0^'^
MLWT.F:YXJ\87^FV>J_&[4+'2-,L;?2_A9X<T+2Y?#?\ @ZVM/BG=?\%(?^"5
M&G_!CQ7J7P]^*?BG2=4\%_#7Q_IDKV-[X5\:^*_B_P"%_#.DZ[I>IJ8GL-2T
M2\U^ROX;^SN+?4-*F-M?V=U9W:6MU']'D5.A0S7A7ABIBJ&,S+(8\09GB<1*
M2Q&#RS'U<!.MA<!2J)356.7UL/#%8ITN:G'%IQIN<H2MG4;<:M6S4*CI04=I
M3BFDY-7TYD^6.SY=[:'])WAW]I/_ ((Q?\$]? ^@?\$^I?VB?V._@YX>\'Z$
M? 6N_!GQ;\0/AWOWSZ=_9^OM\;(;J9].A\4^*XHI+SQE>_$HV&H^(;B]:[U5
M98[^ 2>??\$GO^"2GP^_X)S_ !4_:J^,O[/G[2W_  LC]F[]L+Q#!\0/A[\$
M_#_A73K;X<?##0QX@US7_ ?_  A7CBP\>^+(/&5GHGACQ1?^$K7Q!:Z9HJ^(
M_#T'A^>]66;1[:27A/A__P &S_\ P21\+_ *W^#/C/\ 9X7XJ>+;W03:^,?V
M@?%7B[QI;?&CQ-XPN;=3J/CNT\0:9XCAM?"M]+J8.HV/A_0K*'PO;A$M-1TK
M68Y]4?4_RR_X-X_$GQ3_ &'/^"G'_!0[_@BKXG^(FJ_$CX,_!K3_ !'\9O@E
MJ?B&XC:\T-=*\3_#>Q%OIMK'*UOI=QX_\!?%;PKXD\5:!IJKHMAXG\)ZOJ&F
MV]I<:KJLNH?+>RPF+R;B5Y!GF:XBK"C0QF>X;-L)A8T\XPM+&4[X_"S57$U<
M/5P^*J0K.-::Q+IU+>V;<Z9K=QJ4?:4X*]XTW"4KP?+\+T2::NM---NI_:+1
M117YV=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*_TNO^&4/V6O^C:_@#_X9SX=_P#S.4?\,H?LM?\ 1M?P!_\ #.?#O_YG*/\
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M  SGP[_^9RC_ (90_9:_Z-K^ /\ X9SX=_\ S.4?\5$^&/\ HV>??^)!E_\
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M^C9Y]_XD&7__ #!Z_P!/0^HR_P"?D?\ P%_Y^O\ 3T_S1:*_TNO^&4/V6O\
MHVOX _\ AG/AW_\ ,Y1_PRA^RU_T;7\ ?_#.?#O_ .9RC_BHGPQ_T;//O_$@
MR_\ ^8/7^GH?49?\_(_^ O\ S]?Z>G^:+17^EU_PRA^RU_T;7\ ?_#.?#O\
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M?YHM%?Z77_#*'[+7_1M?P!_\,Y\._P#YG*/^&4/V6O\ HVOX _\ AG/AW_\
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MLM?]&U_ '_PSGP[_ /F<H_XJ)\,?]&SS[_Q(,O\ _F#U_IZ'U&7_ #\C_P"
MO_/U_IZ?YHM%?Z77_#*'[+7_ $;7\ ?_  SGP[_^9RC_ (90_9:_Z-K^ /\
MX9SX=_\ S.4?\5$^&/\ HV>??^)!E_\ \P>O]/0^HR_Y^1_\!?\ GZ_T]/\
M-%HK_2Z_X90_9:_Z-K^ /_AG/AW_ /,Y1_PRA^RU_P!&U_ '_P ,Y\.__F<H
M_P"*B?#'_1L\^_\ $@R__P"8/7^GH?49?\_(_P#@+_S]?Z>G^:+17^EU_P ,
MH?LM?]&U_ '_ ,,Y\.__ )G*/^&4/V6O^C:_@#_X9SX=_P#S.4?\5$^&/^C9
MY]_XD&7_ /S!Z_T]#ZC+_GY'_P !?^?K_3T_S1:*_P!+K_AE#]EK_HVOX _^
M&<^'?_S.4?\ #*'[+7_1M?P!_P##.?#O_P"9RC_BHGPQ_P!&SS[_ ,2#+_\
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M #.4?\5$^&/^C9Y]_P")!E__ ,P>O]/0^HR_Y^1_\!?^?K_3T_S1:*_TNO\
MAE#]EK_HVOX _P#AG/AW_P#,Y1_PRA^RU_T;7\ ?_#.?#O\ ^9RC_BHGPQ_T
M;//O_$@R_P#^8/7^GH?49?\ /R/_ ("_\_7^GI_FBT5_I=?\,H?LM?\ 1M?P
M!_\ #.?#O_YG*/\ AE#]EK_HVOX _P#AG/AW_P#,Y1_Q43X8_P"C9Y]_XD&7
M_P#S!Z_T]#ZC+_GY'_P%_P"?K_3T_P T6BO]+K_AE#]EK_HVOX _^&<^'?\
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M'[+7_1M?P!_\,Y\._P#YG*/^*B?#'_1L\^_\2#+_ /Y@]?Z>A]1E_P _(_\
M@+_S]?Z>G^:+17^EU_PRA^RU_P!&U_ '_P ,Y\.__F<H_P"&4/V6O^C:_@#_
M .&<^'?_ ,SE'_%1/AC_ *-GGW_B09?_ /,'K_3T/J,O^?D?_ 7_ )^O]/3_
M #1:*_TNO^&4/V6O^C:_@#_X9SX=_P#S.4?\,H?LM?\ 1M?P!_\ #.?#O_YG
M*/\ BHGPQ_T;//O_ !(,O_\ F#U_IZ'U&7_/R/\ X"_\_7^GI_FBT5_I=?\
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MPQ&+JQITU'LITH4E:"M?=O63]7^FRZ(****_+S0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK4A34>=+VCYESRI3=1U%52=DHITU+E76S<E:^MVDKWL?@7_P2P_X.#/V;/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *K7E[9Z=:SWVH7=M8V5K&TUS>7D\5
MM:V\2_>EGN)W2*&-?XGD=5'<BK-9VK:1I.OZ;>Z-KNEZ=K6CZE;O::CI.K65
MMJ.FW]K*,26U[8WD4UK=6\@X>&>*2-QPRFJCR\T>?FY.9<_*DY<MUS<J;2<K
M7LFTKVN[ <Y_PLCX=_\ 0^^"_P#PJ=#_ /DZC_A9'P[_ .A]\%_^%3H?_P G
M5R7_  SQ\ /^B&_![_PV?@K_ .4E'_#/'P _Z(;\'O\ PV?@K_Y25Z%LG_Y^
M9E_X)POE_P!/_7\/,>GG]W_!]?Z>G6_\+(^'?_0^^"__  J=#_\ DZC_ (61
M\._^A]\%_P#A4Z'_ /)U<E_PSQ\ /^B&_![_ ,-GX*_^4E'_  SQ\ /^B&_!
M[_PV?@K_ .4E%LG_ .?F9?\ @G"^7_3_ -?P\PT\_N_X/K_3TZW_ (61\._^
MA]\%_P#A4Z'_ /)U'_"R/AW_ -#[X+_\*G0__DZN2_X9X^ '_1#?@]_X;/P5
M_P#*2C_AGCX ?]$-^#W_ (;/P5_\I*+9/_S\S+_P3A?+_I_Z_AYAIY_=_P '
MU_IZ=;_PLCX=_P#0^^"__"IT/_Y.H_X61\._^A]\%_\ A4Z'_P#)U<E_PSQ\
M /\ HAOP>_\ #9^"O_E)1_PSQ\ /^B&_![_PV?@K_P"4E%LG_P"?F9?^"<+Y
M?]/_ %_#S#3S^[_@^O\ 3TZW_A9'P[_Z'WP7_P"%3H?_ ,G4?\+(^'?_ $/O
M@O\ \*G0_P#Y.KDO^&>/@!_T0WX/?^&S\%?_ "DH_P"&>/@!_P!$-^#W_AL_
M!7_RDHMD_P#S\S+_ ,$X7R_Z?^OX>8:>?W?\'U_IZ=;_ ,+(^'?_ $/O@O\
M\*G0_P#Y.H_X61\._P#H??!?_A4Z'_\ )U<E_P ,\? #_HAOP>_\-GX*_P#E
M)1_PSQ\ /^B&_![_ ,-GX*_^4E%LG_Y^9E_X)POE_P!/_7\/,-//[O\ @^O]
M/3K?^%D?#O\ Z'WP7_X5.A__ "=1_P +(^'?_0^^"_\ PJ=#_P#DZN2_X9X^
M '_1#?@]_P"&S\%?_*2C_AGCX ?]$-^#W_AL_!7_ ,I*+9/_ ,_,R_\ !.%\
MO^G_ *_AYAIY_=_P?7^GIUO_  LCX=_]#[X+_P#"IT/_ .3J/^%D?#O_ *'W
MP7_X5.A__)U<E_PSQ\ /^B&_![_PV?@K_P"4E'_#/'P _P"B&_![_P -GX*_
M^4E%LG_Y^9E_X)POE_T_]?P\PT\_N_X/K_3TZW_A9'P[_P"A]\%_^%3H?_R=
M1_PLCX=_]#[X+_\ "IT/_P"3JY+_ (9X^ '_ $0WX/?^&S\%?_*2C_AGCX ?
M]$-^#W_AL_!7_P I*+9/_P _,R_\$X7R_P"G_K^'F&GG]W_!]?Z>G6_\+(^'
M?_0^^"__  J=#_\ DZC_ (61\._^A]\%_P#A4Z'_ /)U<E_PSQ\ /^B&_![_
M ,-GX*_^4E'_  SQ\ /^B&_![_PV?@K_ .4E%LG_ .?F9?\ @G"^7_3_ -?P
M\PT\_N_X/K_3TZW_ (61\._^A]\%_P#A4Z'_ /)U'_"R/AW_ -#[X+_\*G0_
M_DZN2_X9X^ '_1#?@]_X;/P5_P#*2C_AGCX ?]$-^#W_ (;/P5_\I*+9/_S\
MS+_P3A?+_I_Z_AYAIY_=_P 'U_IZ=;_PLCX=_P#0^^"__"IT/_Y.H_X61\._
M^A]\%_\ A4Z'_P#)U<E_PSQ\ /\ HAOP>_\ #9^"O_E)1_PSQ\ /^B&_![_P
MV?@K_P"4E%LG_P"?F9?^"<+Y?]/_ %_#S#3S^[_@^O\ 3TZW_A9'P[_Z'WP7
M_P"%3H?_ ,G4?\+(^'?_ $/O@O\ \*G0_P#Y.KDO^&>/@!_T0WX/?^&S\%?_
M "DH_P"&>/@!_P!$-^#W_AL_!7_RDHMD_P#S\S+_ ,$X7R_Z?^OX>8:>?W?\
M'U_IZ=;_ ,+(^'?_ $/O@O\ \*G0_P#Y.H_X61\._P#H??!?_A4Z'_\ )U<E
M_P ,\? #_HAOP>_\-GX*_P#E)1_PSQ\ /^B&_![_ ,-GX*_^4E%LG_Y^9E_X
M)POE_P!/_7\/,-//[O\ @^O]/3K?^%D?#O\ Z'WP7_X5.A__ "=1_P +(^'?
M_0^^"_\ PJ=#_P#DZN2_X9X^ '_1#?@]_P"&S\%?_*2C_AGCX ?]$-^#W_AL
M_!7_ ,I*+9/_ ,_,R_\ !.%\O^G_ *_AYAIY_=_P?7^GIUO_  LCX=_]#[X+
M_P#"IT/_ .3J/^%D?#O_ *'WP7_X5.A__)U<E_PSQ\ /^B&_![_PV?@K_P"4
ME'_#/'P _P"B&_![_P -GX*_^4E%LG_Y^9E_X)POE_T_]?P\PT\_N_X/K_3T
MZW_A9'P[_P"A]\%_^%3H?_R=1_PLCX=_]#[X+_\ "IT/_P"3JY+_ (9X^ '_
M $0WX/?^&S\%?_*2C_AGCX ?]$-^#W_AL_!7_P I*+9/_P _,R_\$X7R_P"G
M_K^'F&GG]W_!]?Z>G6_\+(^'?_0^^"__  J=#_\ DZC_ (61\._^A]\%_P#A
M4Z'_ /)U<E_PSQ\ /^B&_![_ ,-GX*_^4E'_  SQ\ /^B&_![_PV?@K_ .4E
M%LG_ .?F9?\ @G"^7_3_ -?P\PT\_N_X/K_3TZW_ (61\._^A]\%_P#A4Z'_
M /)U'_"R/AW_ -#[X+_\*G0__DZN2_X9X^ '_1#?@]_X;/P5_P#*2C_AGCX
M?]$-^#W_ (;/P5_\I*+9/_S\S+_P3A?+_I_Z_AYAIY_=_P 'U_IZ=;_PLCX=
M_P#0^^"__"IT/_Y.H_X61\._^A]\%_\ A4Z'_P#)U<E_PSQ\ /\ HAOP>_\
M#9^"O_E)1_PSQ\ /^B&_![_PV?@K_P"4E%LG_P"?F9?^"<+Y?]/_ %_#S#3S
M^[_@^O\ 3TZW_A9'P[_Z'WP7_P"%3H?_ ,G4?\+(^'?_ $/O@O\ \*G0_P#Y
M.KDO^&>/@!_T0WX/?^&S\%?_ "DH_P"&>/@!_P!$-^#W_AL_!7_RDHMD_P#S
M\S+_ ,$X7R_Z?^OX>8:>?W?\'U_IZ=;_ ,+(^'?_ $/O@O\ \*G0_P#Y.H_X
M61\._P#H??!?_A4Z'_\ )U<E_P ,\? #_HAOP>_\-GX*_P#E)1_PSQ\ /^B&
M_![_ ,-GX*_^4E%LG_Y^9E_X)POE_P!/_7\/,-//[O\ @^O]/3K?^%D?#O\
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MSQ\ /^B&_![_ ,-GX*_^4E'_  SQ\ /^B&_![_PV?@K_ .4E%LG_ .?F9?\
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M!7_RDHMD_P#S\S+_ ,$X7R_Z?^OX>8:>?W?\'U_IZ=;_ ,+(^'?_ $/O@O\
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M /)U'_"R/AW_ -#[X+_\*G0__DZN2_X9X^ '_1#?@]_X;/P5_P#*2C_AGCX
M?]$-^#W_ (;/P5_\I*+9/_S\S+_P3A?+_I_Z_AYAIY_=_P 'U_IZ=;_PLCX=
M_P#0^^"__"IT/_Y.H_X61\._^A]\%_\ A4Z'_P#)U<E_PSQ\ /\ HAOP>_\
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M_![_ ,-GX*_^4E%LG_Y^9E_X)POE_P!/_7\/,-//[O\ @^O]/3K?^%D?#O\
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MSQ\ /^B&_![_ ,-GX*_^4E'_  SQ\ /^B&_![_PV?@K_ .4E%LG_ .?F9?\
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M!7_RDHMD_P#S\S+_ ,$X7R_Z?^OX>8:>?W?\'U_IZ=;_ ,+(^'?_ $/O@O\
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M /)U'_"R/AW_ -#[X+_\*G0__DZN2_X9X^ '_1#?@]_X;/P5_P#*2C_AGCX
M?]$-^#W_ (;/P5_\I*+9/_S\S+_P3A?+_I_Z_AYAIY_=_P 'U_IZ=;_PLCX=
M_P#0^^"__"IT/_Y.H_X61\._^A]\%_\ A4Z'_P#)U<E_PSQ\ /\ HAOP>_\
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M_![_ ,-GX*_^4E%LG_Y^9E_X)POE_P!/_7\/,-//[O\ @^O]/3K?^%D?#O\
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MSQ\ /^B&_![_ ,-GX*_^4E'_  SQ\ /^B&_![_PV?@K_ .4E%LG_ .?F9?\
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M!7_RDHMD_P#S\S+_ ,$X7R_Z?^OX>8:>?W?\'U_IZ=;_ ,+(^'?_ $/O@O\
M\*G0_P#Y.H_X61\._P#H??!?_A4Z'_\ )U<E_P ,\? #_HAOP>_\-GX*_P#E
M)1_PSQ\ /^B&_![_ ,-GX*_^4E%LG_Y^9E_X)POE_P!/_7\/,-//[O\ @^O]
M/3K?^%D?#O\ Z'WP7_X5.A__ "=1_P +(^'?_0^^"_\ PJ=#_P#DZN2_X9X^
M '_1#?@]_P"&S\%?_*2C_AGCX ?]$-^#W_AL_!7_ ,I*+9/_ ,_,R_\ !.%\
MO^G_ *_AYAIY_=_P?7^GIUO_  LCX=_]#[X+_P#"IT/_ .3J/^%D?#O_ *'W
MP7_X5.A__)U<E_PSQ\ /^B&_![_PV?@K_P"4E'_#/'P _P"B&_![_P -GX*_
M^4E%LG_Y^9E_X)POE_T_]?P\PT\_N_X/K_3TZW_A9'P[_P"A]\%_^%3H?_R=
M1_PLCX=_]#[X+_\ "IT/_P"3JY+_ (9X^ '_ $0WX/?^&S\%?_*2C_AGCX ?
M]$-^#W_AL_!7_P I*+9/_P _,R_\$X7R_P"G_K^'F&GG]W_!]?Z>G6_\+(^'
M?_0^^"__  J=#_\ DZG)\1?A]*Z1Q^.O!LDDC*D<:>)]$=W=R%1$5;XLS,Q"
MJJ@EB0 "37(?\,\? #_HAOP>_P##9^"O_E)4L/[/_P !K::*XM_@E\([>XMY
M8YH)X?AMX-BFAFB<21312QZ*KQRQNJO'(C*Z.H92" :3646=JF8WMI>CAK7T
MW_?WMO\ @+3^E_P?7^GIZY1117G %%%% !1110 4444 %%%% !1110 4444
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MPOE_T_\ 7\/,>GG]W_!]?Z>G6_\ "R/AW_T/O@O_ ,*G0_\ Y.H_X61\._\
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M'O\ PV?@K_Y24?\ #/'P _Z(;\'O_#9^"O\ Y246R?\ Y^9E_P""<+Y?]/\
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M .%3H?\ \G5R7_#/'P _Z(;\'O\ PV?@K_Y24?\ #/'P _Z(;\'O_#9^"O\
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M\%?_ "DHMD__ #\S+_P3A?+_ *?^OX>8:>?W?\'U_IZ=;_PLCX=_]#[X+_\
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M6R?_ )^9E_X)POE_T_\ 7\/,-//[O^#Z_P!/3K?^%D?#O_H??!?_ (5.A_\
MR=1_PLCX=_\ 0^^"_P#PJ=#_ /DZN2_X9X^ '_1#?@]_X;/P5_\ *2C_ (9X
M^ '_ $0WX/?^&S\%?_*2BV3_ //S,O\ P3A?+_I_Z_AYAIY_=_P?7^GIUO\
MPLCX=_\ 0^^"_P#PJ=#_ /DZC_A9'P[_ .A]\%_^%3H?_P G5R7_  SQ\ /^
MB&_![_PV?@K_ .4E'_#/'P _Z(;\'O\ PV?@K_Y246R?_GYF7_@G"^7_ $_]
M?P\PT\_N_P"#Z_T].M_X61\._P#H??!?_A4Z'_\ )U'_  LCX=_]#[X+_P#"
MIT/_ .3JY+_AGCX ?]$-^#W_ (;/P5_\I*/^&>/@!_T0WX/?^&S\%?\ RDHM
MD_\ S\S+_P $X7R_Z?\ K^'F&GG]W_!]?Z>G6_\ "R/AW_T/O@O_ ,*G0_\
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M'?\ T/O@O_PJ=#_^3JY+_AGCX ?]$-^#W_AL_!7_ ,I*/^&>/@!_T0WX/?\
MAL_!7_RDHMD__/S,O_!.%\O^G_K^'F&GG]W_  ?7^GIUO_"R/AW_ -#[X+_\
M*G0__DZC_A9'P[_Z'WP7_P"%3H?_ ,G5R7_#/'P _P"B&_![_P -GX*_^4E'
M_#/'P _Z(;\'O_#9^"O_ )246R?_ )^9E_X)POE_T_\ 7\/,-//[O^#Z_P!/
M3K?^%D?#O_H??!?_ (5.A_\ R=1_PLCX=_\ 0^^"_P#PJ=#_ /DZN2_X9X^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]YXV\9:%XLU?PMK'BG3O%/@WPEX \,Z?)I/ARX\1>(KG5=4PO^"@_P#P0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"\7^'[Y-2T/^"OW[3G[0OP>_X*Y_\$0/A%\+?C+\1/ 'PO\ CC\8=9T;XP>
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M -VV?^M>? *OWJK\%?\ @YT_Y0=?MN_]VV?^M>? *O?X4_Y*GAK_ +'^3_\
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M?4=<;PGHNI"VMWU72M"L]4GACN;R85^??_!";_@A%^S-^V]^P5\$?VJ_^"B
M^(O[1O\ PE&C^+_"7[/7P>U/XI?$3P'\//@A\&_!_P 1O&6B6]IHEG\-?$?@
M[7FUCQCXSM?%GC:_;_A(CH4UGK6E7+:-_;EQK>HWW]&'_!=K_E$#_P % ?\
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M+U9;K5H_ WBO4/$6K>%=$:YO?M-I=:7X-TG3H;'3=-L9OLSQ[_P0!_X(6?\
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M7O\ P1>^*EI965I#)<W=W=W/[)_C&&WM;6WA5YKBXN)G2*&&)'DED=8XU9F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OR\_X+9?\
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M%GCC4]/OM(GO+6_T_P '6/Q'U+Q-K\^GSRG3=/\ "NKSW12'3[P)^L?["_\
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MA^)^L:%?:;=/8ZGX1\(:1XD298/$&F)><-_P5@_:8^$W['__  =-_P#!,_\
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M8-4UA:F*H0FJ<6N;EC.S>DN2%3W$DO8U)34++W5RN#LOM;\KWL^Q]N?L:_\
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MBBUS5E?7VTG;K;EAJ?RW_P#!T[^V1XV^"7[/G[+O[)'@7XKR? @_MW?&:_\
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M;O!KEDD^6RY9?FNKL>)?\%*_V1M1_:-_X-A_V#OBWX(@NHOBY^Q9^QK^Q/\
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M]HDXM<^T$U&+<4VHW^3:3LG=604445\2;A1110 4444 %%%% !1110 4444
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M6'R0]U<JM!WBEHHO;1(^1_V[/V,OA?\ \%!_V5?BG^R#\9]>\>^&?AK\7/\
MA"/^$DUSX8:IX>T7QS9?\(#\1O"'Q/T?^P]2\5^%O&F@6WVG7_!>EVFI?;_#
M.I>=I%QJ%O:_8[V6VU"UZ/X(?LI?"GX&_LG^ /V,M+BUOQU\%_ /P;LO@0EM
M\1;G2]6USQ9\/[;PV_A2[LO&%UH.C^&M)O[K6=$EGM=6DTO1-&M)Q<3?9[*U
M1@B_2M%9+'8M82& 6(J+"4\7+'0H)VA#%RI0HRQ$6DI*HZ5*G"ZEHH*ROJ/E
MCS<UES-<M^O+>]O2[/YY/V(?^#;S]D3]@#]L7PQ^UQ\!?C?^T_%_PA=[XUO_
M  W\&?%'B[P/K'PY5_''@3Q'\/[VRUZ6'P!8^(]?T[1=(\5ZO/X=>YU6#7K2
M[M]&DU'7M5^Q7YU?^ANBBMLSS;,LYKPQ6:8NKC<13HPP\*U;E=14:<IRA!RC
M&+E:52<N:?--N3<I,4(1@K0BHIN]EWT5_P $%%%%><4%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^7G_!;+_E$;_P49_[
M-$^-7_J':C7ZAU^7G_!;+_E$;_P49_[-$^-7_J':C0!_ET?\$!/V-_@)^WK_
M ,%-_@]^S1^TOX8U/Q?\(_%_@[XP:QKNA:/XFU[PA?W-_P"$/AGXD\2Z%+%K
MOAJ^TW5[9;;5]-M)Y8H+M([F-&@G5XG93_H,?\0GG_!$W_HWCXB?^)#_ !J_
M^;*O\VK_ ()._P#!0;_AU_\ ML_#O]L7_A4?_"\?^$"\._$/0/\ A77_  GW
M_"M/[6_X3WP5K/@_[7_PEW_"%_$#[#_97]K_ -H^1_PC%Y]N^S_9/.L_-^U1
M?UM_\1SG_6+K_P W9_\ R1Z /W-T3_@U3_X(M^'M9TC7]+_9\^(4&IZ'J=AK
M&G3/^T%\9YDAO],NHKVSE>&7Q@\4JQW$$;M%(K1R %'5E)!_;C]J7_DV/]HS
M_LA'Q>_]5]XAK^'K_B.<_P"L77_F[/\ ^2/7]5'P%_;(_P"'@G_!(K4/VQ?^
M%<_\*D_X7C^S-\>]?_X5U_PE_P#PGO\ PB_]B6GQ'\'_ &3_ (2[_A%_!?\
M;7VG_A'/[1\__A&-)\G[9]D\F7[/]JG /\I[_@B;_P I<O\ @G-_V=W\%?\
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MQI$>N>(]+MY+;1[31-.L_P!3O^"G?_!R+_P3Q_9"_9[^(=Q\ ?VE/A5^T_\
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M7_#FBWGPKU/P=KGANSUR*_U!-8D\/:KI=WJ:ZEJ8OKB?^TK[[0[]F/\ 9=^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU^*7ADV\?BKP==:BMO:"_MUBO-+\1>'M1:UM)M4\)>(?#VJ75EI]U>SV%M^
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M_!"C_HQG_P V9_;#_P#H@J/^(7'_ ((4?]&,_P#FS/[8?_T05?O]10!^ /\
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MJU:[_>ZKKEZ"R'J?V(?^""G_  2]_P""?OCN#XL? 7]G:VOOBY82&30OB?\
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M_2%% 'X _P#$+C_P0H_Z,9_\V9_;#_\ H@J/^(7'_@A1_P!&,_\ FS/[8?\
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M)%CC544 6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%'_$#?!?_HTGAK_XA'#?_P [?+\^[#VU;_G[4_\  Y?Y^7Y]V?K%_P /O/\
M@I5_T7O2_P#PT'P9_P#F!H_X?>?\%*O^B]Z7_P"&@^#/_P P-?D[11_Q WP7
M_P"C2>&O_B$<-_\ SM\OS[L/;5O^?M3_ ,#E_GY?GW9^L7_#[S_@I5_T7O2_
M_#0?!G_Y@:/^'WG_  4J_P"B]Z7_ .&@^#/_ ,P-?D[11_Q WP7_ .C2>&O_
M (A'#?\ \[?+\^[#VU;_ )^U/_ Y?Y^7Y]V?K%_P^\_X*5?]%[TO_P -!\&?
M_F!H_P"'WG_!2K_HO>E_^&@^#/\ \P-?D[11_P 0-\%_^C2>&O\ XA'#?_SM
M\OS[L/;5O^?M3_P.7^?E^?=GZQ?\/O/^"E7_ $7O2_\ PT'P9_\ F!H_X?>?
M\%*O^B]Z7_X:#X,__,#7Y.T4?\0-\%_^C2>&O_B$<-__ #M\OS[L/;5O^?M3
M_P #E_GY?GW9^L7_  ^\_P""E7_1>]+_ /#0?!G_ .8&C_A]Y_P4J_Z+WI?_
M (:#X,__ # U^3M%'_$#?!?_ *-)X:_^(1PW_P#.WR_/NP]M6_Y^U/\ P.7^
M?E^?=GZQ?\/O/^"E7_1>]+_\-!\&?_F!H_X?>?\ !2K_ *+WI?\ X:#X,_\
MS U^3M%'_$#?!?\ Z-)X:_\ B$<-_P#SM\OS[L/;5O\ G[4_\#E_GY?GW9^L
M7_#[S_@I5_T7O2__  T'P9_^8&C_ (?>?\%*O^B]Z7_X:#X,_P#S U^3M%'_
M ! WP7_Z-)X:_P#B$<-__.WR_/NP]M6_Y^U/_ Y?Y^7Y]V?K%_P^\_X*5?\
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M_P -!\&?_F!H_P"'WG_!2K_HO>E_^&@^#/\ \P-?D[11_P 0-\%_^C2>&O\
MXA'#?_SM\OS[L/;5O^?M3_P.7^?E^?=GZQ?\/O/^"E7_ $7O2_\ PT'P9_\
MF!H_X?>?\%*O^B]Z7_X:#X,__,#7Y.T4?\0-\%_^C2>&O_B$<-__ #M\OS[L
M/;5O^?M3_P #E_GY?GW9^L7_  ^\_P""E7_1>]+_ /#0?!G_ .8&C_A]Y_P4
MJ_Z+WI?_ (:#X,__ # U^3M%'_$#?!?_ *-)X:_^(1PW_P#.WR_/NP]M6_Y^
MU/\ P.7^?E^?=GZQ?\/O/^"E7_1>]+_\-!\&?_F!H_X?>?\ !2K_ *+WI?\
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M /.WR_/NP]M6_P"?M3_P.7^?E^?=GZQ?\/O/^"E7_1>]+_\ #0?!G_Y@:/\
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M^C2>&O\ XA'#?_SM\OS[L/;5O^?M3_P.7^?E^?=GZQ?\/O/^"E7_ $7O2_\
MPT'P9_\ F!H_X?>?\%*O^B]Z7_X:#X,__,#7Y.T4?\0-\%_^C2>&O_B$<-__
M #M\OS[L/;5O^?M3_P #E_GY?GW9^L7_  ^\_P""E7_1>]+_ /#0?!G_ .8&
MC_A]Y_P4J_Z+WI?_ (:#X,__ # U^3M%'_$#?!?_ *-)X:_^(1PW_P#.WR_/
MNP]M6_Y^U/\ P.7^?E^?=GZQ?\/O/^"E7_1>]+_\-!\&?_F!H_X?>?\ !2K_
M *+WI?\ X:#X,_\ S U^3M%'_$#?!?\ Z-)X:_\ B$<-_P#SM\OS[L/;5O\
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M?Y^7Y]V?K%_P^\_X*5?]%[TO_P -!\&?_F!H_P"'WG_!2K_HO>E_^&@^#/\
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MTHS>S7PR\O)^6S[]#]Y:***_A4[ HHHH **** "BBB@ HHHH **** "BBB@
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MDJDDW+2FI-.W(ES-7VO?1W=[6L?JS17\:_[$O[+G_!6/_@M%\);']O7]IO\
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M-FN(7L]4.BKH^HW;V3Z9J_B'6?'?P^T'3_&/@G2!XLU:;YR_;!_83_X*@_\
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MS=/VE&"J181J-R490E!R3<;N+3MJU[K=I):V?2^I^Z%%%%?.&H4444 %%%%
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M634Z=.2E95(^_-JG54W\,Z3LI+E5N9MI*ST=ULM+GDW_  5S_;9G_P""F/\
MP;$Z5^V'I'@2\\$7OB?XI?">/XG^$K6>;4-,\)>)/!7QFN_AEXEFLM0?]Y<^
M$M4\80Z;>>&9[MGO(K'7]$L=4(UB&[5.]_8%_P""7O\ P4O^+_[$/[)7Q*^!
M?_!P-\7OAY\(?%W[/'PDU/X?_#?1?V2_#.L:=\,_#R^"=&M+7X9PZJW[0ED^
MH2?#I[:7P5=WDEG:RW%YH5Q)+;PR,T:_T"?!W_@F-^S#\)?^"=>G_P#!,IM
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M)<^'+2.*]2:.VENX%2YD\+&T\NRS@[$95'.<OS#,Z_$."QTZ&7U:M>C2PM+
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M4PD8KV]6I&C4G"E&HY2U5ITZ=.,9.]W4E"SE&[YFHW:5VVU=O1:J[L?T(_\
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M'[6QMO#_ ()\2:E>WVJ>)+")$L4M;875_=VEI-^$7_$9K_P2_P#^B$?MZ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDN)+S2_A=8Q76HZ%%J82(:=X5USQAIJZK)\1O$-WI/PG_L;H **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M445^>G2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4Y1Q.09;F%2WU;'5JN,AAX5:%;-H990^LU<+],?\%?!K'_"C_AN]M)(NA_\
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M_3ED_M;6-:\:_"V3PO\ M$>&;2VLD,][XD^($MOHNG>7'J5Y%/"M\L_]"/\
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M9/\ L^_LOVD.I06&MZK8W<UA-=V-[:Q7D<36\EQ9W4*2&2WE5 #^T>OY,_\
M@\PA\1R_\$E_ [Z&ZIIEM^V=\'YO&*LC,9?#C?#7XX6]JB,(9!&P\73^%I2[
M/;J4C>/SF9U@G_I5_P"&I?V8_P#HXSX$?^'>^'__ ,T-?%O_  5=_9$\._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M58VCE^.A5E&%:ABJ[KJ%-TF^:6N'JJ3C=1<5=VDKZ*<6XI._/%SCV<5;6_\
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MN+*'P5'>:1*ZE64_V[X*L=0U'4EDE=FEU#7-,L9WG$UQ>%0WVB3[J\'?M/\
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MX-\8VEM/'X<^('A4SM'8^)/#]Q)O4K(FR+5=+::2]T+4Q/IE]F2))9OEJO\
M?7)<ZRKB+*<OSW(\?ALTRC-<+2QN79A@ZBJX;%86O%2IU:<UW3Y9PDHU*<U*
MG4A"I"45XK3BW&2::=FGNF%%%%>F(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )6Q_P#@D9_V;Y\)/_5O?MCU_:C7TG%O_(NX*_[)>C_ZL,<94?CK_P#7U_\
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MU\&^)=)N$NM+\0>%_%&E6NM:#K.GW,1:.>SU+2[VUO+>120\4RFN*\ _M#_
M7XJ>(/B+X2^&OQH^%OCSQ9\(/$.L^$_BOX6\)^._#.N^)/AIXE\/7LVG:WHG
MCS0=.U*XU7PGJ&FWL$UO<V^NVEBZ.A(W(0Q_(Y_7*E:OB9_6)UZ=5UL36:J.
MK3K2JZU*U2W-"HZS^*;4O:.U^8[%:R2M:UDNEK=.ZL?QO_\ !NMJ&H?L/_\
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MA?\ ^L]?M1U_5C\/_P#D0_!/_8H^&_\ TS65?RG?\'FO_*+_ .!'_9^OPO\
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MYO3K1Q&9Y50E#%4\;*6/P-#%4L;B*. \8_X)A?M-?$.T^+>A_ #Q#KFI^(_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_$?/A+_\R-'_  PO^Q+_ -&=_LL?^(^?"7_YD:/^*B'!G_1NN)__  ZY5_\
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M!G_1NN)__#KE7_R(?49_\_(_<S_-NHK_ $D?^&%_V)?^C._V6/\ Q'SX2_\
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MG_1NN)__  ZY5_\ (A]1G_S\C]S/\VZBO])'_AA?]B7_ *,[_98_\1\^$O\
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M\VZBO])'_AA?]B7_ *,[_98_\1\^$O\ \R-'_#"_[$O_ $9W^RQ_XCY\)?\
MYD:/^*B'!G_1NN)__#KE7_R(?49_\_(_<S_-NHK_ $D?^&%_V)?^C._V6/\
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M6/\ Q'SX2_\ S(T?\,+_ +$O_1G?[+'_ (CY\)?_ )D:/^*B'!G_ $;KB?\
M\.N5?_(A]1G_ ,_(_<S_ #;J*_TD?^&%_P!B7_HSO]EC_P 1\^$O_P R-'_#
M"_[$O_1G?[+'_B/GPE_^9&C_ (J(<&?]&ZXG_P##KE7_ ,B'U&?_ #\C]S/\
MVZBO])'_ (87_8E_Z,[_ &6/_$?/A+_\R-'_  PO^Q+_ -&=_LL?^(^?"7_Y
MD:/^*B'!G_1NN)__  ZY5_\ (A]1G_S\C]S/\VZBO])'_AA?]B7_ *,[_98_
M\1\^$O\ \R-'_#"_[$O_ $9W^RQ_XCY\)?\ YD:/^*B'!G_1NN)__#KE7_R(
M?49_\_(_<S_-NHK_ $D?^&%_V)?^C._V6/\ Q'SX2_\ S(T?\,+_ +$O_1G?
M[+'_ (CY\)?_ )D:/^*B'!G_ $;KB?\ \.N5?_(A]1G_ ,_(_<S_ #;J*_TD
M?^&%_P!B7_HSO]EC_P 1\^$O_P R-'_#"_[$O_1G?[+'_B/GPE_^9&C_ (J(
M<&?]&ZXG_P##KE7_ ,B'U&?_ #\C]S/\VZBO])'_ (87_8E_Z,[_ &6/_$?/
MA+_\R-'_  PO^Q+_ -&=_LL?^(^?"7_YD:/^*B'!G_1NN)__  ZY5_\ (A]1
MG_S\C]S/\VZBO])'_AA?]B7_ *,[_98_\1\^$O\ \R-'_#"_[$O_ $9W^RQ_
MXCY\)?\ YD:/^*B'!G_1NN)__#KE7_R(?49_\_(_<S_-NHK_ $D?^&%_V)?^
MC._V6/\ Q'SX2_\ S(T?\,+_ +$O_1G?[+'_ (CY\)?_ )D:/^*B'!G_ $;K
MB?\ \.N5?_(A]1G_ ,_(_<S_ #;J*_TD?^&%_P!B7_HSO]EC_P 1\^$O_P R
M-'_#"_[$O_1G?[+'_B/GPE_^9&C_ (J(<&?]&ZXG_P##KE7_ ,B'U&?_ #\C
M]S/\VZBO])'_ (87_8E_Z,[_ &6/_$?/A+_\R-'_  PO^Q+_ -&=_LL?^(^?
M"7_YD:/^*B'!G_1NN)__  ZY5_\ (A]1G_S\C]S/\VZO6?A/\!OC3\=M:C\/
M?!OX6>//B5JKRK#)#X/\,ZKK4%D6V_O=5U"TMGT[1[5 RM->ZK=V=I C!YIX
MT.:_T3=*_8U_9!T&X2[T/]E3]FW1KJ*198KG2O@9\,-.N(Y5^[(DUGX7AD21
M<#:ZL&&."*^@]+TG2]#L;?2]%TW3](TRT0QVNG:79V^GV-LA)8I;VEI'#;PH
M6)8K'&HR2<9)KP,^_:)X186I#ACPSQ$L;*+5+$9]Q!2AA:$[>[.I@\OR^=7%
M13WIQQV#;6JJIZ#C@7?WJBMVC'7[V]/N9_*I^Q+_ ,&_/B"[U#1_'_[;.M6N
MDZ- UO?1? WP3K"WNLZDRE9/L7CSQQI<AT_2;,,IBN]*\%7FJWE[!*##XLT6
M>)HI/ZF/"/A#PMX!\,:'X+\$^'M'\*>$O#.FVVD>'_#F@6%MI>CZ/IEH@CM[
M+3["TCBM[:"-1G;&@W.6D<M([,>BHK^%?%/QH\0?&+-*>8\:9P\1A\+*<LLR
M/ TW@\BRE5-)_4< IU+UIKW:F-QE7%YA5@HTJN+G2ITX0[*=&%)6@M>LGK)^
MK_167D%%%%?E)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\C_M__  P\
M<_&W]@_]MCX,?##0_P#A)OB5\7/V1_VD/AA\//#?]I:/HO\ PD'CGQ]\'/&?
MA3PEH?\ ;'B'4-)T#2?[6U_5M/L/[2US5--T>P^T?:M2U"SLHI[F/ZXHK;#U
MYX;$4,3347/#UJ5>"FFX.=*<:D5)1<6XMQ2DE*+:O9IZB:NFGU37WGX=?\&\
MO['O[1G[#/\ P3:\(? +]J;X=_\ "KOBUI?Q6^*_B6^\)_\ "6^!?&WD:+XE
MUV"\T2]_MWX=>)_%WAJ7[;;(TGV:'69+NVQLNX()"$/[BT45T9GF%;-LQQN9
MXB-*%?'XFMBJT*,9QHQJ5IN<HTXU)U)J";:BI5)R2WDWJ*$5",8J]HI)7WLN
M]K?D>5?'?PUK7C/X'_&7P?X:LO[2\1>*_A3\0_#6@:=]IM+/[?K6N^$=8TO2
MK+[7?SVMC:_:KZZ@@^TWMU;6D'F>;<SPPJ\B_B]_P;??L4?M-_L$?\$]=6^!
MO[67PT_X51\4KG]H?XD^.H/"_P#PF7P_\=;_  KK_AOX?6&D:I_;?PU\5^,?
M#J_:[O0]4B^POJZZC!]E\RYLX8I[=YOWVHK6CFN(H95C<GA"B\-C\5@\76G*
M,W7C4P4:\:4:<E45.,)+$3]HI4IR;4>64+/F'!.:GK>,7%=K2:;OI>^BMJ?S
M3_\ !=__ ()__M<_MF_M8_\ !';XE_LV?"7_ (61X)_97_:'\9>.OCSK?_">
M?#+P?_P@GA75OB3^RKK^GZI_9OCWQGX6U?Q/]HTCX;>-+O[#X-L/$.HQ?V+Y
M$UG'<ZCI,-]X9_P5C_X)P_\ !0GP#_P5$^!__!93_@FMX-\)?'SX@> ?"6G^
M$OB=^S_XKU_2M"U748++PMXF^'&K7>A+KFK>&=*USPUXJ^&/BFZT2]L;/Q!!
MXO\ "_BC3[3Q-H&G^(#>+!H/]9=%>O@.+LQP%++,/##X&MALMP.:98Z%>C5G
M3QV!SC$SQ6-P^-M7BY*52=J<L.\/*$8Q4G-\SE$J,9<S;DG*4)W35XR@DHN.
MG9=;]3^5OQ5\5/\ @X-_X*:> ->_9NB_8I^''_!+;X5?$RPO_"7Q?_:2^(_Q
M7M_B3\1=.^'^JP26/BC0OA5X"T.71_$EMXKU[29KK3K76-0T"/2_LUQ<16OB
M[PCJ$MIK]EM_\&\G_!,[]I_]B;]G3]N_]D/]M7X*?\(Q\//BG\5M2N?!'BJW
M\??#3Q-I_P 8/AYXN\"WOPQ\526UM\//B!XH\1>$]^A^&]&U)+/Q7I'AG4XX
M/%D4=N;F^L=2MM*_J)HHK\5XB66XS*,%EF599E^,JX7$2IX.GBW7I8C"5E6I
MXB.+Q&,KXBI4ERJFU7G5I4Z=_J]*C4E*I)*BE.,W.<I135Y-6::LU912MUTL
M[[MK0_BG_9C^ O\ P7+_ ."#.K?%C]GO]F?]E;PQ_P %*?V%_$'C_5_'_P +
M-5L?B!H7@SXC>%;S7X+'3V@GTJ36CXD\/7]W:V.DS>,]"M? OBGP9<:U9WFO
M>%_$.EOJNN&;TCPG^PC_ ,%4O^"OG[?O[*'[97_!3'X+> OV)_V9OV+O$MIX
MW^$W[/NA^,(/%GQ,\;>(K/Q!X:\<)_:9TW5_$']G6_B7Q3X2\*6GCK6O$+^!
MM1C\+^%;'0?#?@<W^H77BV#^Q"BNJIQMC)U*^-CE63T<ZQ6'J8:OGE&AB8XZ
M<:U%X>O6C2>+E@*6+KTI3A5Q-+"0G+GFXJ,I-B5!:1YYN$6FH-KET::3?+S.
M*LK)O='\['_!;W_@D)\:?VT/&O[/W[;_ .PI\1-&^$G[?O[)=Q9MX$U76KN/
M1M(^)'A/1]?E\6Z%X9O?$#Z=JMMINN^$_$%WK]UX8M]>L+KP5XCLO&'BGPMX
MV6#1]5BU+2_D77?V^_\ @Y[\=>!-0^!/AW_@DAX ^&GQ\O\ 26\,ZA^T6_Q2
M\%3?#;P_?RVUO8ZEXV\-Z/K'Q$O? \E]9F:XU;2$_P"%B>-M)CNEC$>A>(X;
M273;O^N&BN3"<4U:."P>!Q^4Y3G5++7/^SIYE2Q4JV$A4J>UE0Y\+B\+]8PO
MM'*:PV*5:$7)J/+#W!RHIRE*,YP<[<W*U9V5KV:=G;JK=]S\.O\ @AA_P24U
M/_@EO\!OB'=?%OQO9_$_]J_]I?Q3IGQ _:&\<:9<WVI:/!?:0FL/X<\%:+K6
MK06NL>)+?0;OQ/XJUK5_%6J6EE>>(/$OBG6)Q:1Z?;:=G]Q:**\3,\RQ>;X_
M$YECJBJXK%5%.K-14(KEC&G3IPA%*,*=*E"%*E!:1IPC'6QI"$814(JT8JR7
MXOYMZOS/X'O^"HO_  3W_P""[/[3'_!6W7?VR_ G[$'P^^/GP=^!/BVQT#]E
M'P;\6OC%^SIJ7PAG\!>"HB/#WB35?AGX@_:%\%^()KCQ+XL>\^)FJZ3XFMM/
M>YUZ[L],U[2KG0M+MM#C^P?^&CO^#RC_ *,%_9+_ /"R_9S_ /HU*_L@HKZN
M7'-:KA<!A,3PWPMC*6682G@\(\5@<?4E3HTTKO3-(P]I5DO:5IQA%U:C<I=E
ME]72<I*K5BY/F=I1M?YQ>VR\M#\T_P#@EAXU_P""E_CO]GSQCJ__  52^$/P
M[^"W[0EM\9/$.F^#O"WPTU/P5JNA7_P:A\$_#RZ\/:_=W'@3XG_%G2$U>Z\;
MWGQ#TZ>&Y\1V6I+9Z58/-HEM:R6=]J7Z6445\AC<2L9BJ^)CAL+@U6GSK"X*
M$Z6%HZ)<E&G4J59QAI>TJDW=O4VBN5)7<K*UY.[?JTEK\C^.G_@M]^P5_P %
M7_B+_P %=OV3_P#@H!_P3H_9O\.?&1/V=OV;O 'AW3=>\7?$GX)^&O#=K\3=
M!^*W[0^MZAH6K^$_B%\7_AIXHU:UMO#7Q"T#4#>Z:D>E3R:DEO;ZI+=V.HVE
MM73]H+_@\GU!UL&_89_9)T07K+:'6G\7?L[3)I N2(3JC11_MAZN\JZ>'^UM
M&FDZH[B$JNG7I(MI?['J*^HI<9U5@LOP6*X?X:S&.6X6.#PV(S# XROB50C4
MG4493AF-*F_?J2E[M*,;M^[J[XN@N:4E4JQYW=J,HI7T_NM].Y_([^Q;_P $
M*_VS_CK^VGX1_P""CO\ P6T^.GA3XV_%;X;W^E:O\(_V??!LUMJW@GPMJ/AN
M\N-1\')XA?2-&\-^"=%\.>"M<=/$VD^ _ VFZMIOB3Q$L.O>-?$NKW%QX@TS
M6_M__@X?_P""4_Q8_P""HW[*OP^TK]GK7=&T_P"/?[/WQ!O?B'X$\.^)M8'A
M[0?'FEZUHC:/XH\*1^(&B>#P_P"*9#:Z)JOA36-3EMM$%[I=QI&KW>EVVL?V
M]HW] =%<L^+\YEF^7YS&>&I5LJ4:>782AAH4<OPF'2E&6%HX2GRQC1J0G.%7
MWO:SC+^*G&#C7L:?)*G9M3UDVVY2>CNY.^MU?MY'\K/P\_X* _\ !REXO\,Z
M;\'IO^"/WPR\.?&NUT.T\.ZY^T1\1OC;X9T'X.6WB%8197/Q"O/!>E^)1'JN
MGI)C5KSPWX%\=:[)-,)H]&M9;:2WTU/G[_@FC_P2,_X*6_L3?\%LM4_:N_:"
M%C^TW\._CI\%_'R?'+]JSP_XK^'6AZ1I'Q<^)5CIGC/7-(L?AQKWCG1?BI=Z
M!HOC3PAI_@O0M3T?X<?V;)H>K:1>0:#X=TVVOK3P[_9/16_^MU2C0S+"Y?DF
M1Y;A\VP=;!XZ&&HXV<ZD:UFJE.MB<=6JT'1DG.A1HRAA4W>K0K<L.5>Q3<7.
MI.;A)2BVXI*W2RBD[]6]>S6I_''_ ,%"?V+/^"L?[+?_  6I\1?\%7?^"</[
M.W@;]J#1?C)\*?#7@/QMX.UKQ7IFFC3;_3?AKX8^&6L:/XK\/:I\2?A]KDUO
M/IWPW\)>*/#GB+PK>W6AVVI6MO9:_IR7R?\ $\]5_P""O_\ P37_ ."B7[9&
ME?\ !-7_ (*0_L[>$?!7AS_@H5^R/X2^&'C?XG_LTZQXD\.P>'D^(VEWOA'X
MLW6A>!-=O_$^H>"]9_X0+XKV7B/0=1T37/B$VC^-?!]["+'Q=/>::EOXC_K'
MHITN-,QHU,FKPP>6/%9-@UEL,3*A6E4QV71P\\+' X^+Q/LJM&-"I.%Z5.C5
MUC+VBE%,'0BU-<T[5)<S5U:,KI\T?=T=TM[KR/Y<+#]M+_@X_P#VIO#][\'?
MA_\ \$POA/\ L3>+/$%HGAK7OVIOC-\:+#7?"/PV^UP"TUCQCX4^'5N\WB76
M]3MBUQ=>&(].L/B38:?>FR;5;#6[2&:67S__ (($?\$JOVVO^"8?[</[>6G_
M !U\)W'CGX$_%[PMX7?P!^U4?&/PVN#\4?%/A'Q7>ZL]SJ7@"R^)?B'XI^&=
M0\3V_CWQ'J-T_B;PN;=+WPY=)<ZXKWFF/K/]9]%95.*ZJP&995@<GR?+<!FM
M*E3Q=+#4L9.K.=&O3Q%&NL5B<;7Q'/2G3<:=)S>%C"I4_P!G=27M$>Q7-"<I
MSE*#O%MQ2LU9JRBE9]7;F;2UZ!7\C?\ P=5_"?Q9\/\ 0/\ @G__ ,%._A[H
M4FK:S^P3^TWX5U;QH+.00W">&?$7C7P%XN\%:I?SO')'#I^E?$GX=Z1X9MIP
M"\&I_$:#=!<1R,UM_7)7C?[0WP&^&_[4/P-^*O[//Q?T1?$/PU^,7@C7O ?B
M_3-YAN&TO7;*2V^W:;=I^]T[6M'N3;ZQH6JVY2[TG6;&PU*TDCN;6)U\_AW-
M5DF=8#,IP=6C1JRABJ2WJX/$TYX;&4EJES3PU:JH7=E/E?0JK#VD)13LW9Q?
M:2::?WI7\CM_ /CGPO\ $_P)X*^)7@?5K?7O!7Q#\)>'/'/A#7+1@]IK7A?Q
M;H]GK_A_5K5U)5[?4=)U"TO(&!(:*92"0<U_-'_P0N_X)U?MD?L<?MX?\%8O
MC/\ M'_![_A7/PU_:7^*T_B7X)>)/^%@_"SQ?_PFNB/\8_C-XK6]_L?P)XW\
M4:_X;SH'BSP_?_9O%NEZ#=C[?]E, O;6]MK;[_\ ^"+'P*_;)_9#_9L\6_L6
M_M9^&5U#0/V8?B1KW@K]E[X]V/BCP1J^D?'7]G/5+_4-7\%W1\-Z'XGU?QIX
M)U_P*[76AZCH/CK0M!6ST.]\*Z7X=O/$<6D:K?0?L56];&SR3_6')<#6P>.P
M&:>PP\L;%RJNIA<-BH8W"5L/.E5C3IU:B5-8BG5A4E2;J490IU82Y4HJI[*I
M)2C*%WR[6;5FFFF[+I9Z[W:. ^*WPL\ ?&_X:>//@]\5?"^F^-/AM\3/"FN>
M"?&_A75XVDT_7?#7B*PGTW5;"<QM'/ TMK<.;>\M98+VQN5AO;&XM[N"&>/^
M&S_@F7_P;Z?MQ?\ !/3_ (+J_"[XQP?#Q?&W[#/PD\5_'MO#'[13?$;X21W]
M]X(\??LX?%GPIX"37OAQ_P )I9_$\>)[3Q%XST#P3XG_ +/^'_\ 9AU^#4=<
MTYF\'^3K _O2HI9/Q/F>28+.,OPCHU,'G>"K8+%T,1&I.$%7I3H/$X?V=6E[
M/%0I5)PC.7M*<DU[6E4Y*?*YTH5)0E*ZE3DI1:LMFG9Z.ZNEY]FKL_ W_@N-
M_P $8KO_ (*?>%OA5\5_@7\2;/X'_MH_LV7DVI_!KXCW\VM:;HVO:>-1MO$%
MKX/\1>(?#7G>(O"-QHOBJQL_%7@KQUHNF:[?^%-8_M6*/1;B+7Y[[3/RT\(?
MMJ_\'9O[-6A1?#'XJ?\ !.OX2_M3ZIH\:V6C_%^%?#^K:QXAM;"%;7^T=?O/
M@Q\;=#\,7GVY1:WEL;OP7X-U]Y'OVU2&>YD,>F_V>T5TX#BJOALOH97C\LRK
M.\#A)5)8*GF="M*M@O:R]I5IX7%8:OAZT*-2I[\Z4Y5(.6RBDDIE13DY1G.G
M*7Q<CTE:UFTTU=)635GON?QI?"7_ ()5_P#!5_\ X*M?M;_ G]KK_@MEJ'PY
M^#/P2_9SUT>+/AC^QS\,[G3KLZIJ2ZUIVNG2+BP\.>*O&^G^$_#7B;4=$\/S
M>-O$/BCXC^,_B9K>@:%8>"18:!#+;ZYX>_J2_;%_9%^"?[=/[.OQ'_9A_:!\
M/2>(/AO\2=+CM+N2QFCLO$/AK6]/N8M1\.>,?"6JR07(TGQ3X7UBWM=5TB\:
MWN;262&33]6L=2T6^U+3+SZ;HKDS+B/,<QQ.!Q$?89=#*DEE>%RRD\)ALNM5
M5=SPT5.=159UDJM2O4JU*U2:3E-J,4JC2A%26LN?XW-\SEI;5]K:)6L?Q1_"
M;]G+_@XP_P""),=_\%?V3?#7PP_X*9?L1:9J^H7/PW\.^)KRVTOQO\/M)U&2
M[U&XL])\-7OC[P?XW\$75_J4LUW?>&_#FM?%SX=0W37&IZ5::-K/B+4V?\Q?
MB!_P1Y_X+)_\% OVE?'/[0'PO_84^%__  2FO?B'X<^(MK\3O%.F_M!>/?!<
M?Q<OO'CW\WC/3_'.EZ=\1_B7XONIO'[27.FZW:^&?A9X-\#>(HM1N[[QFNJ2
M7HOJ_P!):BOH<-XB9EA:M;&4LIR..:8FFZ6+S*.&Q5*IC$]95<7@Z&,I9?B*
M\I_O'4GA+>T;GR<S;>3PT&E%SJ<B::C=/EMVDXN27DG\S^2'_@W*^).J_L=W
M>H?\$A_C9_P3_P#C1^S+^U%X?L?'/QO\<?&.XM]+\5_#+XY:;IMWHFF7?Q$U
M#Q[%-80BUM$UCPKX#\)P>"I?'W@]!!:V1U[3-:FU:V;^MZBBOEL\S2.=9C6S
M/ZJL)6Q=JN+A'$5L13J8N3;K5J3Q#E5HTJC:Y,.ZE2-&*4(3<%&,=J<'3BH<
MW,EI'1)J/1.V[[O2Y_)!_P 'FO\ RB_^!'_9^OPO_P#6>OVHZ_JQ^'__ "(?
M@G_L4?#?_IFLJ_E7_P"#RVRO+K_@EU\%9[6TN;F#3?V[/A;>ZC-!!+-%86<G
MP'_:8TY+N]DC1DM;9]0O[&Q2><QQ->7MI:AS/<PH_,^%_P#@\A_X)C:)X9\.
MZ-=? K]N^2ZTC0M(TRYDM_AC^SZ]N]Q8:?;VDSP/)^T_%(T+21,T3211.R%2
M\:,2H^QCD.<9YP7PVLIP%?'O"YGQ#]85!1?LO;/+?9<_-*-N?V<[;_"VS'VD
M*=:KSR4;QI6OULIW^ZZ/Z_**_D@_XC-?^"7_ /T0C]O7_P -?^SU_P#11T?\
M1FO_  2__P"B$?MZ_P#AK_V>O_HHZ\;_ %"XQ_Z)_,/_  "G_P#+//\ /LR_
MK%'_ )^1_'_(_9W_ (*N?#WQ-XP^ 7A[Q'X>M+S4;;X?^-8=:\1V-G'-.T.A
MZCI-_I<FM200H[/'I5[+9QSRE0MI9W]W=2.EO#.X_G*LK*\U*\M=/TZTN;^_
MO9XK6RL;*"6ZO+NZG=8H+:UMH$DFN)YI&6.*&)'DD=E1%+$"OI9_^#S+_@EY
M(K(_P%_;S='5D='^%W[/+*Z,"&5E/[49#*P)#*0002",5YWH7_!VG_P1C\+:
MW)XF\,_L:_M7^'?$DID,OB#0OV>/V5-(UN0RY\TR:KI_[2%O?N9,GS"UP2^3
MNSFOP;Q"^BUQEQKQ)#/L-2QN7+$4,-A\PH5L"L3*V&BJ4:^%E'%4DY2H\D'1
MJ*$5.FZGM7SRA#_-OZ4/T"H?2!\5\/XDY3XC8;A6&99=E.6<3Y?CLDKYM42R
MBG]4I9AD]2CF&#INK6R^-"A/ 8J-&E"OAWB5C)K$RH4OZPOV>?!VL?#[X%?"
M+P3XAC6#7O#/P\\*:3K5LC*ZVFJVNCVJZA9B1&9)?L=T9;4S(VR8Q&5 %<*/
M8Z_D@_XC-?\ @E__ -$(_;U_\-?^SU_]%'1_Q&:_\$O_ /HA'[>O_AK_ -GK
M_P"BCK]OP7AOQ9@,'A,#0X?S)T<'AL/A*+G&FYNEAZ4*--S?.DY<D8\SLKN[
MLM;?Z&Y!EN7<.9#DG#V JSE@,ARC+<EP4J\U4KO"97@Z.!PSK348J=5T:$'4
MFHQ4IW:BD[+^M^OY(/\ @\U_Y1?_  (_[/U^%_\ ZSU^U'1_Q&:_\$O_ /HA
M'[>O_AK_ -GK_P"BCK\.?^"_/_!?G]C[_@K%^Q]\+OV;_P!F_P"%W[3_ (6\
M?>%OVG_!/Q?N[OXO^"?A?H?AZ_\ #VA_"_XR^ [C2M*N/ ?QE^(VM77B2ZUG
MXC:%+8V,NA6]C/8V^IN^IPW<-G9WWU_!W!O%& XGR7&8S)<;A\+A\;"I7KU(
MP4*<%&2<I-3;25UT_)GI5ZU*5*I&,XMN-DEU/]'?X?\ _(A^"?\ L4?#?_IF
MLJZZN7\#V\]IX+\(6EU#+;W-MX7\/V]Q;S(T4T$\.DVD<T,T;@/'+%(K)(C
M,CJ58 @BNHK\NJ:U)M;<\OS9UA1114 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]0TF[\,:Y-X@C$WCR'4O(MK[2V,>FRVWFAKE)H?V4K_-3_X*9?M[_&/]L?\
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MXET64RR0P?U'Z'H/PD\3^']'\6>'-#^'FN^%_$.C:?XBT'Q%I&E>'=0T36=
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MZXT./['/XW\)>(?AUXUT;6O$VA>6=:TNW\/ZG/;3:\=3UG6ODWQ3_P '&?\
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MB[P;K)^)<FGPZD/!=U?_  XU:PA\33Z# ]M9WZ6UU<>;_&_P;^V#_P $:/\
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MMTBKVU9SW_!Q=91^#O\ @L+_ ,$ /BUKTTEGX2B_:3\!V5_J#VS?9+./X?\
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M?=^,T_X.#_\ @LE&B1Q_\&['[64<<:JB(G@']J=41% 5415_9D"JJJ %4
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M2YU'01JFO>'O'7A+0KZV\)^(/ \;:-:F+TO]D_\ 9V_;<_X+&?\ !5KX3_\
M!4G]L_\ 9M\7_L@?LD?L@V-HO[*OP+^*=M>V'Q&\9>+] U+4=;\+>([[0-=T
MC0==A6U\97T'Q*U_QO?>&]#TJ[DT'P'X*\%MXKLM,UGQ3IWI0CF.!SGB//,V
MS/#XGAS&X'.(PJK,L/B,/G%'&4*L,KP6#PD:\ZCJPG.@XTO8Q6"A0G&<J<(I
MRGW90I4X0:JQ=/3D:<'%KGE*35K-)];RNM&?V/T445^-':%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 9.O:!H7BK1=5\-^*-$TCQ)X=URQN=+UO0->TVSUC1=8TR\
MB:&[T[5=*U"&XL=0L;J%VBN;2[@FMYXF:.6-D8@_$W[<OQ4\:?L9_L,?$_Q'
M^R;^S]XK^(_Q*\"_#NT^'_[-WP*^ WPEUGQ>EAXNU&WMO!_P[ALOA_X \.ZA
M:Z-\-_AVT]IXBU^$Z?I7AW3_  EX<NM(AN;.XNM-MY?N^BNC#5XT:U"=6DL3
MAZ6(I5ZF$G.4:5=4Y)RISY;M*I%.G*45SJ$FHM.S$U=.SLVK)VNU_P ,?D/_
M ,$4/^"=NH_\$Y_V+="\$?$>YCUW]I?XS^(=0^.G[47BU[Q=6O=3^+?C:&WG
MN_#S:WYD[:I9^!],CL_#IO(;F73]6UZ'Q'XHL@A\1S[_ ->***TS#'8G,\;B
MLPQ<U/$XNM.O5DERQ4INZA".JA3IQM"E!:0IQC!:10HQ4(J,=%%)+T7Z]^["
MBBBN,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/SX/?
ML+2>!_V\?VD/V_/B5\6M2^*_Q-^+/P\\*_ +X/Z%+X6T[POH7P _9N\-:M!X
MUN?AAHKVU_J=]XFOO$OQ,>[\8^(_$E[/81WMU%8_9]%LI3=O-^@=%%=&)Q5?
M%SA/$3YY4J%##4[1A",*&&I1HT:<84XQA%1A%7:BG.;E4FY5)SE))):);MM]
M;MN[;;U_JVP4445SC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-_X:SX!?_.VH_P"%,_'?_H\'XC?^&L^ 7_SMJ^GJ*/[6Q7_/K+/_  RY-_\
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MY?UT_/NSYA_X4S\=_P#H\'XC?^&L^ 7_ ,[:C_A3/QW_ .CP?B-_X:SX!?\
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MXC?^&L^ 7_SMJ^GJ*/[6Q7_/K+/_  RY-_\ , 7]/N7]=/S[L^8?^%,_'?\
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M %_3[E_73\^[/F'_ (4S\=_^CP?B-_X:SX!?_.VH_P"%,_'?_H\'XC?^&L^
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M_P ,N3?_ # %_3[E_73\^[/F'_A3/QW_ .CP?B-_X:SX!?\ SMJ/^%,_'?\
MZ/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3?_, 7]/N7]=/S[L^8?\ A3/Q
MW_Z/!^(W_AK/@%_\[:C_ (4S\=_^CP?B-_X:SX!?_.VKZ>HH_M;%?\^LL_\
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M ,[:OIZBC^UL5_SZRS_PRY-_\P!?T^Y?UT_/NSYA_P"%,_'?_H\'XC?^&L^
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MC^UL5_SZRS_PRY-_\P!?T^Y?UT_/NSYA_P"%,_'?_H\'XC?^&L^ 7_SMJ/\
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MX:SX!?\ SMJ/^%,_'?\ Z/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3?_,
M7]/N7]=/S[L^8?\ A3/QW_Z/!^(W_AK/@%_\[:C_ (4S\=_^CP?B-_X:SX!?
M_.VKZ>HH_M;%?\^LL_\ #+DW_P P!?T^Y?UT_/NSYA_X4S\=_P#H\'XC?^&L
M^ 7_ ,[:C_A3/QW_ .CP?B-_X:SX!?\ SMJ^GJ*/[6Q7_/K+/_#+DW_S %_3
M[E_73\^[/F'_ (4S\=_^CP?B-_X:SX!?_.VH_P"%,_'?_H\'XC?^&L^ 7_SM
MJ^GJ*/[6Q7_/K+/_  RY-_\ , 7]/N7]=/S[L^8?^%,_'?\ Z/!^(W_AK/@%
M_P#.VH_X4S\=_P#H\'XC?^&L^ 7_ ,[:OIZBC^UL5_SZRS_PRY-_\P!?T^Y?
MUT_/NSYA_P"%,_'?_H\'XC?^&L^ 7_SMJ/\ A3/QW_Z/!^(W_AK/@%_\[:OI
MZBC^UL5_SZRS_P ,N3?_ # %_3[E_73\^[/F'_A3/QW_ .CP?B-_X:SX!?\
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M'?\ Z/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3?_, 7]/N7]=/S[L^8?\
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M-_X:SX!?_.VH_P"%,_'?_H\'XC?^&L^ 7_SMJ^GJ*/[6Q7_/K+/_  RY-_\
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MY?UT_/NSYA_X4S\=_P#H\'XC?^&L^ 7_ ,[:C_A3/QW_ .CP?B-_X:SX!?\
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MXC?^&L^ 7_SMJ^GJ*/[6Q7_/K+/_  RY-_\ , 7]/N7]=/S[L^8?^%,_'?\
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M %_3[E_73\^[/F'_ (4S\=_^CP?B-_X:SX!?_.VH_P"%,_'?_H\'XC?^&L^
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M_P ,N3?_ # %_3[E_73\^[/F'_A3/QW_ .CP?B-_X:SX!?\ SMJ/^%,_'?\
MZ/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3?_, 7]/N7]=/S[L^8?\ A3/Q
MW_Z/!^(W_AK/@%_\[:C_ (4S\=_^CP?B-_X:SX!?_.VKZ>HH_M;%?\^LL_\
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M ,[:OIZBC^UL5_SZRS_PRY-_\P!?T^Y?UT_/NSYA_P"%,_'?_H\'XC?^&L^
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MC^UL5_SZRS_PRY-_\P!?T^Y?UT_/NSYA_P"%,_'?_H\'XC?^&L^ 7_SMJ/\
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MX:SX!?\ SMJ/^%,_'?\ Z/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3?_,
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MZBC^UL5_SZRS_P ,N3?_ # %_3[E_73\^[/F'_A3/QW_ .CP?B-_X:SX!?\
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M'?\ Z/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3?_, 7]/N7]=/S[L^8?\
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M-_X:SX!?_.VH_P"%,_'?_H\'XC?^&L^ 7_SMJ^GJ*/[6Q7_/K+/_  RY-_\
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MY?UT_/NSYA_X4S\=_P#H\'XC?^&L^ 7_ ,[:C_A3/QW_ .CP?B-_X:SX!?\
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MXC?^&L^ 7_SMJ^GJ*/[6Q7_/K+/_  RY-_\ , 7]/N7]=/S[L^8?^%,_'?\
MZ/!^(W_AK/@%_P#.VH_X4S\=_P#H\'XC?^&L^ 7_ ,[:OIZBC^UL5_SZRS_P
MRY-_\P!?T^Y?UT_/NSYA_P"%,_'?_H\'XC?^&L^ 7_SMJ/\ A3/QW_Z/!^(W
M_AK/@%_\[:OIZBC^UL5_SZRS_P ,N3?_ # %_3[E_73\^[/F'_A3/QW_ .CP
M?B-_X:SX!?\ SMJ/^%,_'?\ Z/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3
M?_, 7]/N7]=/S[L^8?\ A3/QW_Z/!^(W_AK/@%_\[:C_ (4S\=_^CP?B-_X:
MSX!?_.VKZ>HH_M;%?\^LL_\ #+DW_P P!?T^Y?UT_/NSYA_X4S\=_P#H\'XC
M?^&L^ 7_ ,[:C_A3/QW_ .CP?B-_X:SX!?\ SMJ^GJ*/[6Q7_/K+/_#+DW_S
M %_3[E_73\^[/F'_ (4S\=_^CP?B-_X:SX!?_.VH_P"%,_'?_H\'XC?^&L^
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M_P ,N3?_ # %_3[E_73\^[/F'_A3/QW_ .CP?B-_X:SX!?\ SMJ/^%,_'?\
MZ/!^(W_AK/@%_P#.VKZ>HH_M;%?\^LL_\,N3?_, 7]/N7]=/S[L^8?\ A3/Q
MW_Z/!^(W_AK/@%_\[:C_ (4S\=_^CP?B-_X:SX!?_.VKZ>HH_M;%?\^LL_\
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M ,[:OIZBC^UL5_SZRS_PRY-_\P!?T^Y?UT_/NSYA_P"%,_'?_H\'XC?^&L^
M7_SMJ]5^'/A#QOX2M]4B\:_%GQ!\59KV:UDL+K7_  SX%\-2:-%"DRSV]M'X
M(\.^'X+M+QY(Y)'U".YEB:!%MWC1Y5?TFBLJV88C$4Y4JE/ QC*S;HY9EN&J
M+E:DN6MA\)2K1U6JC-*2O&5XMIH****X0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^B!_M__ /AK/V=?_HJJ /Z_:*_F[_9C_P"#K#_@D1^TMXZ\+_#J?XB_%/\
M9\\1>,+NTTS1+C]HKX>6?A'PL-8OC$EKI6L^./!WBKX@^#?#+22RM =6\2:[
MI/AR.:)DEUM#+:FX_I"1TD1)(W62.15='1@R.C ,KHRDJRLI!5@2""""0: '
M4444 %%%% !1110 4444 %%%% !17@7C']J;]G?P!\<_A'^S+XM^+_@K2?V@
MOCLWB8_"KX/'5!?>/_%=GX.\&^)_'_B365\.Z;'>7VB^&],\+>#O$5Z_BCQ%
M'I'AVYO;!-"L]4N-?O\ 3M+N_?: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ5UJ9NI/$7B3X!ZCKWA[XH_#SQ!/(FM2:+KFE^$=3UU8M;\7W>J?V6?M,?\
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M>'M,\C4;FRUSQ]X+\"ZGJ/A7PHVHQ7.M^&M C^W6O]W_ /P2)_;I_9@_;_\
MV(/A;\6/V4O"-M\*_ /@JRM/@]K'P*BBTZ"7X$>)_ FB:-"_PQ6/28;;3;G1
M=+T&^T'4?">KV-I90:UX4U31M1ET[2-0FOM&TX ^+_$W_!R__P $R/!GA?\
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M2=0O;PZWXW\7?"3P%H]SX@^'GBVV\,^+_ NNZEXD;7/#ZQ^)-.T")W\02M;
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MNC_A['_P3L_Z.G\ _P#@#XO_ /F;K_/7HH_XI[>%G_18^('_ (4<._\ T/\
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M _\ "CAW_P"A_P!?Z6I]>J?R0_\ )O\ ,_T*/^'L?_!.S_HZ?P#_ . /B_\
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M -#_ *_TM3Z]4_DA_P"3?YG^A1_P]C_X)V?]'3^ ?_ 'Q?\ _,W1_P /8_\
M@G9_T=/X!_\  'Q?_P#,W7^>O11_Q3V\+/\ HL?$#_PHX=_^A_U_I:GUZI_)
M#_R;_,_T*/\ A['_ ,$[/^CI_ /_ ( ^+_\ YFZ/^'L?_!.S_HZ?P#_X ^+_
M /YFZ_SUZ*/^*>WA9_T6/B!_X4<._P#T/^O]+4^O5/Y(?^3?YG^A1_P]C_X)
MV?\ 1T_@'_P!\7__ #-T?\/8_P#@G9_T=/X!_P# 'Q?_ /,W7^>O11_Q3V\+
M/^BQ\0/_  HX=_\ H?\ 7^EJ?7JG\D/_ ";_ #/]"C_A['_P3L_Z.G\ _P#@
M#XO_ /F;H_X>Q_\ !.S_ *.G\ _^ /B__P"9NO\ /7HH_P"*>WA9_P!%CX@?
M^%'#O_T/^O\ 2U/KU3^2'_DW^9_H4?\ #V/_ ()V?]'3^ ?_  !\7_\ S-T?
M\/8_^"=G_1T_@'_P!\7_ /S-U_GKT4?\4]O"S_HL?$#_ ,*.'?\ Z'_7^EJ?
M7JG\D/\ R;_,_P!"C_A['_P3L_Z.G\ _^ /B_P#^9NC_ (>Q_P#!.S_HZ?P#
M_P" /B__ .9NO\]>BC_BGMX6?]%CX@?^%'#O_P!#_K_2U/KU3^2'_DW^9_H4
M?\/8_P#@G9_T=/X!_P# 'Q?_ /,W1_P]C_X)V?\ 1T_@'_P!\7__ #-U_GKT
M4?\ %/;PL_Z+'Q _\*.'?_H?]?Z6I]>J?R0_\F_S/]"C_A['_P $[/\ HZ?P
M#_X ^+__ )FZ/^'L?_!.S_HZ?P#_ . /B_\ ^9NO\]>BC_BGMX6?]%CX@?\
MA1P[_P#0_P"O]+4^O5/Y(?\ DW^9_H4?\/8_^"=G_1T_@'_P!\7_ /S-T?\
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M /\ X ^+_P#YFZ/^'L?_  3L_P"CI_ /_@#XO_\ F;K_ #UZ*/\ BGMX6?\
M18^('_A1P[_]#_K_ $M3Z]4_DA_Y-_F?Z%'_  ]C_P""=G_1T_@'_P  ?%__
M ,S='_#V/_@G9_T=/X!_\ ?%_P#\S=?YZ]%'_%/;PL_Z+'Q _P#"CAW_ .A_
MU_I:GUZI_)#_ ,F_S/\ 0H_X>Q_\$[/^CI_ /_@#XO\ _F;H_P"'L?\ P3L_
MZ.G\ _\ @#XO_P#F;K_/7HH_XI[>%G_18^('_A1P[_\ 0_Z_TM3Z]4_DA_Y-
M_F?Z%'_#V/\ X)V?]'3^ ?\ P!\7_P#S-T?\/8_^"=G_ $=/X!_\ ?%__P S
M=?YZ]%'_ !3V\+/^BQ\0/_"CAW_Z'_7^EJ?7JG\D/_)O\S_0H_X>Q_\ !.S_
M *.G\ _^ /B__P"9NC_A['_P3L_Z.G\ _P#@#XO_ /F;K_/7HH_XI[>%G_18
M^('_ (4<._\ T/\ K_2U/KU3^2'_ )-_F?Z%'_#V/_@G9_T=/X!_\ ?%_P#\
MS='_  ]C_P""=G_1T_@'_P  ?%__ ,S=?YZ]%'_%/;PL_P"BQ\0/_"CAW_Z'
M_7^EJ?7JG\D/_)O\S_0H_P"'L?\ P3L_Z.G\ _\ @#XO_P#F;H_X>Q_\$[/^
MCI_ /_@#XO\ _F;K_/7HH_XI[>%G_18^('_A1P[_ /0_Z_TM3Z]4_DA_Y-_F
M?Z%'_#V/_@G9_P!'3^ ?_ 'Q?_\ ,W1_P]C_ ."=G_1T_@'_ , ?%_\ \S=?
MYZ]%'_%/;PL_Z+'Q _\ "CAW_P"A_P!?Z6I]>J?R0_\ )O\ ,_T*/^'L?_!.
MS_HZ?P#_ . /B_\ ^9NC_A['_P $[/\ HZ?P#_X ^+__ )FZ_P ]>BC_ (I[
M>%G_ $6/B!_X4<.__0_Z_P!+4^O5/Y(?^3?YG^A1_P /8_\ @G9_T=/X!_\
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MKU3^2'_DW^9_H4?\/8_^"=G_ $=/X!_\ ?%__P S='_#V/\ X)V?]'3^ ?\
MP!\7_P#S-U_GKT4?\4]O"S_HL?$#_P *.'?_ *'_ %_I:GUZI_)#_P F_P S
M_0H_X>Q_\$[/^CI_ /\ X ^+_P#YFZ/^'L?_  3L_P"CI_ /_@#XO_\ F;K_
M #UZ*/\ BGMX6?\ 18^('_A1P[_]#_K_ $M3Z]4_DA_Y-_F?Z%'_  ]C_P""
M=G_1T_@'_P  ?%__ ,S='_#V/_@G9_T=/X!_\ ?%_P#\S=?YZ]%'_%/;PL_Z
M+'Q _P#"CAW_ .A_U_I:GUZI_)#_ ,F_S/\ 0H_X>Q_\$[/^CI_ /_@#XO\
M_F;H_P"'L?\ P3L_Z.G\ _\ @#XO_P#F;K_/7HH_XI[>%G_18^('_A1P[_\
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MISB^DHJZ:DKQ:;[4TTFFFFKIK9H****\\84444 %%%% !1110 4444 %%%%
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MK_\ *%W]A#_LGWCG_P!7/\2J]F_:,_X+3_\ !+3]E#Q[>_"WXZ_MH?"GPO\
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M,]\Z6D0>X81F*=*I6FJ=&G.K4E\,*<)3F_2,4Y/Y(&TE=M)=WHCVBBOXH/\
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M2#:;5XSC*+LVKK1M&R:DE).Z:33[IJZ?W!17^?#^U=^QS:?\%'/^#IC]K_\
M9'\>_&_XU?"?X?3_  Q^&7CB+4/A/XHBTW5+/4/"W[('[.NH06EI::S:ZMHD
M-G?W6I7,U^%TT3R2N94E21Y&?])M:_X-%?@]%;)=?#__ (*-?MN>%/%%G(+K
M2=<UK5O"_B2VT[4(!YNGWJ6&B0>!]1\RSO$AN0UMKUG.PBVP7%K*4N(_LZ_"
M^0X&EECS/BF>"Q&995E^:JA'(L3BH4:68456A"5>CC/?<&Y1<HTTWR\W(KJ)
MBJM23GR4N91G*%_:)7<6DW9Q\V]^A_7Q17\2O["?[;?[?O\ P1^_X*5>"/\
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M%%% !1110 4444 %%%% !1110 4444 %%%?"_P#P4W^.'Q%_9I_X)[?MD_M
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MQ5<6-];Z#HUFZVUCJVOZCH.@:Q_G@_&#_@['_P""T7QO\9ZUJ'P-\6_#_P"
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M?&'PE\1IX_M8=6LI[S1['P)J,+/IUQ=75I. ?VST45^27_!=3]K'XV_L.?\
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MH;6]^#WP_AM)W3JL=Q+I]['$QX9K68#[AKQ#_@V'_P"4R'_!</\ [*)\1O\
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MT_PI\,/!6MZ;;1ZWKMY:VR:_XA\32II4=M!+--=I+?3?K+0!_'-_P;:^#?\
M@D+^WM_P3W^&'@SQ?^QE^P?X]_:Z_9[T.Y\$?M!:3XZ_9C^!7B?XI:M;V7B+
M5K?P-\4]6U;Q-X F\1>+],\9^%&T,ZEXLDGU*.#Q?%K6@ZAJ$E]9I)=>Q?\
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M7P?I&D6<GB7Q7I=Q;>?8W_C[Q!XPTVRN%LM1T[1K'6=+L=4B /SZ_P"#F/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB_L(?$_Q=UWX865I=F-8M1T_1_%5C%%?);W\4/F?_!PK\4-;_P""4W_!%?\
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MW[.^F^)?'6B:;>V<3WD5QXMO++PMX1O[2TE@GU7PUKWB'3B\EM<7-M/]J_\
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M<6\5Q-)X.\/7>N^(_B#XPLVMY([B3PCX8;R;N**ZMG_*S_@O#^Q+_P $_?\
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MX5A^(G_"8W#75[=0^(-'\0:1=:)->SP^&%T*P6VLK?XN_P"#;7]HCP1\%_\
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M=TY;5*+YJ47=\JIQE>4;:IV;7+:SN]%IJ?TZT445^5G6%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1\3?AQX*^,?
MPW^(/PB^)6A0^*?AS\5/!'BOX<>/_#-S=:A8V_B+P5XXT&_\,>*M"GO=*N[#
M5+.'5]"U2_T^6ZTV^LM0MTN&EL[NVN$CF3^;W_@Y&^"WPC_9\_X(-_&/X3_
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MWPG\8ZKK=_H%C=07!6\N+KP-X]TWX@^"M0@C6>'P[HUIX+TR:2W2[L(#K?\
M$']_P2<_Z#O[6G_AXO!__P ZBOQYT?X+^%?^#</_ (.!OV<?#_@#Q#XS7]B;
M]L+X>>'OAS=ZIX[UJTUG4K+2/'VI6G@O78O$VKZ=I^CV=Y-\._C7H'@_XC7&
MHC0;5].\"Z^FE0-/*]]<R^[AUE7$&5\393A<YQ>;9KCJU7BC T\3E']G*.8X
M15)XZ%"2S''.K5QN#J3I1I<M-15&,E)J*B\WSTYTING&$8I4I-3YGR2Y>6_N
MQLHM>>[TV/\ 0DK\P?\ @K_\)OV[?CS^Q%X\^#'_  3S\4>%O WQO^)6LZ/X
M:\0^,_$7C;4?A]J?A_X3O:ZMJ'C9? _B;3='UF:Q\8^)9K#1?!5O,PTLV>@^
M)O$&IV>N:3J=A87:?I]7\NW_  =4_MZ_M#_L8?L8_";P=^SCXSUGX4^)/VEO
MBEJW@+Q=\6_#=U?Z9XI\)>!/#GAB36=7TKPKK^E :KX7UWQ/>WNF(WB/1777
M;+0=*UZTT<PWNH1WUE\%PO@\5CN(<IPN"CA)XJ>,ISHK'0=7")T5*O*>(I*S
MJTZ<*<INDM:CBH6?-8Z*KC&G-RYK<NO+I+731]'J0?"O_@W$_P""*O[-_P"S
MSX4\.?MF^&/"'C+XN7_@S1;_ .+7QH^+?[2/Q ^&5QJGC&/35U+Q3J?A*#1_
MB?X&\/\ A?PQ::[9ZW/I0M+&749M#MFM?%6M^(T@NY7_ #8_X-_]8\$_LH?\
M%R?V[/V OV3_ -H&/X_?L*:Q\)=9^(_PYU70OB)I/Q#\%R^)]$E^#.O:1K^E
M>(_#L3^&-<\0^$=,\>>,?A)XLUCP]'8)XAO='MI]3N[YO#6FPC]'_@'_ ,&J
M?_!+C1/"?AWX@_M"^)OC!^V!XTUC2=-\7^-/B7XT^-FMZ!X)\8W-U86VHW>M
MZ0WPXNO#&K#PA>P#[7876J>-O$&HS:9*MQ<>(;E'1H_R<_X(OW7[+T__  <Y
M?M>6?[%VA^#/#W[,?AS]G[XC^"/A5I_P]%XW@R?3O -M^S]X)U[6] O+[4=6
MN=9M?$OB[P_X@\1R>(VU&ZC\376JW'B&WD%OJ<2+^DT,=3S/*N-:<L_SWB.$
M,DKXJK+,<#]6RG#XJGB\-+#U,'3JX[%5J-=-5/84XT<+%4:<[P;IPC#E<7"5
M!^SITFZD8KEE>;C9I\S48IK:[NW=KYZ__!3CX _$W]K'_@Z!\(?LM_#GXL^,
M?@II7Q\_9@\'>!OC+X]\ W4.G^*X/@+8> ?&'CGXK>&]'U62WN9-+O/&WA[P
M>W@ZVNHXV@EN=<AL-8@OO#]YJ^FWOVI_P5"_X-G_ /@F?\)?^">?[1GQA_9E
M^''C7X/_ !Q_9K^"/CWXXZ)\0A\8/B;XN?QB/A#X8O?'6O:1XQ\/^-?$GB+P
MPG]NZ!X?U>VL;CP9HO@VYT_7KK3[V*<V-M+IMP>-/^5Q_P"$?_9G>I?^J(^)
MU?T-_P#!53_E%_\ \%(/^S"OVP?_ %GKXB5PXW/LWRW%< X3+\=B,'AY9%P_
M6KT</-TH8N=;%5J,_KD8-+%0]C3C3C3K^TIPCS<D8N<VZC3A-8ARBI-5*B3>
MK244].VK;NK,_)C_ ()K?\%+_B/H'_!N78_MX?&Z]N/B-\3?V?/@I\<M+75M
M?U&[O+[XE:]\(?&'BWP+\(T\5:G<O)J,FHZ\;/P1X=\5ZY<76HZGJ=XNI^)I
MI)KW4&LH_P Y?^"*O_!&#X(_\%+O@/J7_!4+_@JDGC7]J_XT?M9>,?'NN>$]
M"\6^/O&_A3PWX6\%>'/%.N>!HM4>R\!Z]X6U6?4-5UG1/$!\-Z.VJ)X*\*^!
M[?PA:^%?#.G30?;6W?\ @G/\ O&'[3W_  :.?%;X*?#[3;S6_'/BCPE^T]J_
MA#0--91J7B/Q'X ^.NO?$71_#6G*\%PDVH>([[PG#H=C;,L0N[J_BMC>6'F_
M;K?]*?\ @UP_:8^&/QM_X)+_  1^%WA;Q!I<OQ)_9HO/'/PU^*W@U-0@DUSP
M_/J_Q&\9^,_!>O7&G%DODT+Q;X4UZRN-,U1K8:?<ZQIWB71K.ZN;GP_J'E5F
MLZN2Y?QKB\BE/ XU<<5,NQ=?!-T<1@\G:Q=7#TJ56DXU,+AZ^.C[.3I.G&HZ
M5.BVXJ,0BE.5"-2TH_5U)*6JE/W+MI_$U'76_5]S^9'_ (*I?\$QM'_X)F?\
M%4_^"5_A'X*>+_'=[^Q_\6_VFO 7C3X'_"WQKXJU7Q5;?!3Q]8?'?X-VWQK\
M(>$[W6+N\OKCPYJD.H_#+Q';ZEJ,K:U=S:C+8:S=:O>Z0VNZI_I/5_$'_P '
M)O[2?P[\:?\ !4O_ ((R?LP^%=?T36_'?P4_:1\&_$3XJ6&GSVU_?>$I/BS\
M9/@)8^ M!U2> .VC:O>:3X%UWQ#?:#<3)?2Z-JWA/6;FSAL;[1[F]_M\KQ>,
M<7CL=D' ^*S)SEBZV79K*=2HK5*\%F3C0Q%2Z3G.O05.M*K*\J[FZ\I2E4;>
ME%1C.NH:14XV2V3Y%=+T=U;IMT"OQ$_X*%?LG_LW?L<_\$5?^"@OPF_9@^#'
M@3X*^ ;?]E'XS7<^B>"M&CLI]:U(>"[^$ZSXIUVX:Z\0^,-?:W2.VD\0>*M6
MUC6I+6&"VDOV@MX8X_V[K\R?^"T'_*)S_@H=_P!FE_&;_P!0_4:^5R&M6CFV
M5T(U:D:-;-LKG5HQG)4JLZ.+A[*52FFH3E2]I4]G*2;A[2?*US2OK-+ED[*Z
MC))VU2:U2?2]E?O9'R7_ ,&Q?_*#K]B+_NY/_P!:\^/M?C7_ ,%D+&U^*?\
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M.G:(SZK\;_BK^UMXJ^'WQ)M]1^P)9#QE=7FM?$G0/A[830_VE:7D>CMX&C\
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M7\1]3TE[JVFET[4_$5NG@K2(M4T^:UO(M*LM>TQWDL]9NHF^;_\ @]1_99\
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MX&UKP5^V=^W;_P %-O"_QG^#6@7=GINM^$O!/CW6?B'\<_"$=V8=9USX6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(BHUE5HTJ<*52=2,4I59P=732:NR(T:4;6@DTTT]6U;:S;;27:]O(_-G4_\
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M:]\3M/\ @KXK\%Z?X=\3Z_<1V46K>(M.M_%/@7Q+J'A[6_$8MI[KQ(8=0O\
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MWHNH4445XAH%?CA_P<$_\H:_V]O^R2:5_P"K%\$U^Q]?CA_P<$_\H:_V]O\
MLDFE?^K%\$U[7#?_ "460?\ 8ZRK_P!3J!%3^'4_P2_])9?_ ."!'_*'3]@7
M_LBO_NX^*J^>/VU?^"@OQEMOB_XO^&/P@\22> ?"GP^UR_\ "VH:EIEG82^(
M/$7B'1;DV>MSW.I7UO>2:?IUCJEM<V%A9:7]D>XBAEN=2GNA=0VEC]#_ /!
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M-*_]6+X)J_\ \$"/^4.G[ O_ &17_P!W'Q57^B;_ .3?1_[+*7_JD@?]#O\
MS$?]P?\ V\_8"BBBOC38**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K\O/^"V7_ "B-_P""C/\ V:)\:O\ U#M1K]0Z^#?^"HOP7^)?[1?_  3I
M_;3^!'P;\-_\)C\5OBU^SG\4/ ?P^\*_VQH'A[_A(/%?B+PU>Z?HVE?VYXJU
M70_#FE?;+N:.'[=K>L:;IMON\RZO((@S@ _S._\ @T\_Y39?L\?]D[_:'_\
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M&E?V'\3?BMX,\1M]CM-=TJ;[<FCMIMQ]J\NUO)Y8+E(0#^C7_@W!_P"4)O[
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M4_Q.C^)4_P *VN_&/PT^']Q\3-2%[XYM+E=5O[[05MCK7V73[@ \H_X,WO\
ME$;KW_9W?QF_]0[X2U_3;\9O@W\,?VA?A5X^^"/QG\&:+\0?A9\3_#.I^$/'
M'@[7[?[1IFMZ'JL)BGA8HT=Q9WMM((K[2=6L)K75=%U:ULM7TB\LM3L;2[A_
M$#_@VG_8@_:A_P""?W_!.G5O@1^US\,?^%2_%:Z_:,^)GCR#PK_PFGP\\>;_
M  IXA\-?#O3]'U7^W/AEXL\9^'%^V7>A:K#]A?6%U*W^R^9=6<$4]L\W]!=
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M&>"+]2Z "BBB@ HHHH **** "BBB@ HHHH **** "O\ *^_X($_\$B?V4O\
M@K'^TG_P4#\.?M27WQ7LM/\ @KJ_AK6_!S?"SQAI'A*XDO/&WCWXG6&LC69-
M6\*^*%OH5@\.:>;-(8[-H)#<,[S"55C_ -4&O\K[_@@3_P %=OV4O^"3G[2?
M_!0/Q'^U)8_%>]T_XU:OX:T3P<OPL\'Z1XMN([SP3X]^)U_K)UF/5O%7A=;&
M%H/$>GBS>&2\:>07"ND(B5I #^H2;_@S;_X)'RPRQIXD_:_MWDC=$N(?C+X(
M::!G4JLT2W'P@G@,D1(=!/!-"64"2*1-R'\3_P!D/3OC]_P;J?\ !?7X/_\
M!.^W^-7BWXJ?L<_MD^(/AMHVB>&M::ZMK'6]"_:"\3ZM\,OA1X\O/#$(N=!T
M'XG^!/B[H?\ PBWB7Q5X:M;2V\4^&=(UA;A-(L-7BT[P_P#M'J__  >6?\$F
M;#3+Z\T[P9^V)KE_;VTDMII%I\(OA_9W&H7"C]U;1W6I_&.SL+?S'(#S7-PB
M1H&<"1PL;_CI^Q!IW[3/_!P[_P %VOA?_P %.?$'P8\1?"']B_\ 9(U[P3K'
M@?7M?M[^_P!(M],^ /B+4?&?PG^%^C^)I(+31_%OQ-\1_%O7I_B!XYL_#[?V
M/X)TB^U])KFXN+7P\GB@ _T"?&?QJ^#?PY\3^"_!/Q"^+7PR\">,_B1J,.C_
M  [\(^,_'GA;POXG\>ZM<:A8:3;Z7X+T#6]5L=5\4ZC/JNJ:9ID-EH=I?7,N
MH:C8621-<W=O%)Y5_P -O?L9?\+KN?V;3^UE^S<O[0=G>QZ7<_!)_C9\-T^*
MD.KR-(HT1O ;>)!XE_MY!&99M"&FG5[>"2WN9[*.WNK:27^+?_@\1\1_$[P?
M^V7_ ,$B?%WP3O+O3_C-X6U/XB^(_A)?V"0/?6/Q.T3XJ? W4_ 5Y9)=*UL]
MW;>*K72IK=+A6@:9$$JF,L#^G?[)_P#P:7?L,? 3QG^S?\>_B+\5/C[\8OVD
M_@]\0O OQH\>ZYK_ (J\+W7PL^)GQ/\ #&I)XIOX+[P=>^!6\0/X.G\8I;ZI
M;P:CXLN]=U&+3;:/Q)J>JP7^L65X ?U$>,?&O@WX=^&]5\9?$#Q;X9\"^$-"
MMC>:YXK\8Z]I7ACPWHUHI"M=:KKNMW=CI>G6RLP!GN[J&($@%LD5\I_#3_@I
M%_P3T^,_C.+X=?"+]NC]D+XG>/;J[@LM.\'> OVCOA#XK\2:U<W,5G+"GA_1
M]$\7WM]XA4F_M;9YM#AU"&*_D;399$U"&>VC_BO\9^'_ (D_\'-'_!;GX\?L
MV^/?BUXW\&_\$V?V!]:\5V[>#? VK)80>+#X$\5O\-(];TQ+BWFTYO'GQG\7
MQ^(=8L/&>N:+J5[X2^%>FWF@Z3'::D(WOOV'_:K_ .#2'_@E=\3/@9XF\,?L
MP?#CQ7^S'\>+31;BZ^'WQ8T[XO?&+XB6$WBRRLRVDVWCSPG\3O'?C+1+WPSJ
M=_'&-;_X12T\*ZY:I/)<Z1J=L(([*0 _J;KP#XZ_M8?LN_LOV%EJ?[27[1OP
M,^ 5EJD<\ND3?&/XK>!OALVMBW29Y8]#A\7ZYI$^MW.+>98[32HKRZFDC:*&
M&24;*_FG_P"#5;_@HS\?OVB_A9^T=^PI^UUK_B+Q7\?_ -ACQ7IVAZ9XM\7Z
MD^N>+=6^'&IZKXA\*W?@_P 4>()KN_O/$6O?"GQMX1U313X@U"[DFO?#7B/P
MII<4UZ= N;R7\ ?^".GPY_X)S?\ !6']K7]M3XO_ /!</XN6VN_M;^)OB1:P
M> /@=\9/CCXK^ 'AR73;I_$#:[I7A.^TCQ5\/O$&I:C\.+K3;3P9X=^%^B^+
M[&T\$^%M*42>$M0MIX;G2 #_ $4?@=^UM^RM^TY'?2?LW_M*_ 3X^C2K9;O5
MX_@S\7OA_P#$R?1[=VMT$FL6W@WQ!K-QI.V2[M8I$U&*V>*:XAAE5)9%0_!_
M_!;O]K6Q_95_X)Q_M7Z]X1^/_A?X(_M#7?P.\77_ ,#C)X[\,^%OB7JNOVES
MI6GW-[\-M(U>^AUG6M7TZ/4PBW'A^QO+W3+BYMKB%[:[%M*OX7?MI_\ !L#J
MOPF^-_[,?[47_!![Q)HO[*?Q6\!>,TO_ !;IOQ'^-WQ3U/X;V6D16UE<:-XL
MT;Q+K$7Q6^(U_9:HR:GHGQ \%7%SXE\/^,?#&MM:VVFV-K;WFFZY]Z?\')?[
M!7[/O[27_!.7XO\ [5GQW\$3:G^T+^R/^SSXSUKX3ZQX:\<^+[+PSX3\2^)K
MWPA<>)U73+:;1++Q?IAU#2;==.F\3Z()C;0I(]C://- H!L?\&R7[3_PQ\=_
M\$F_V/?ASXJ_:'\!^,OVE]8O?VI/$?B[P)X@^+7A_P 0_'35=1U3]J_X_>,+
M[7O$?AC4O$%YX_OKW4=$OX?%-WJFIV,L]WI=['K<T\EI<+=/^]'Q9^.'P5^
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M'P/XXT+X7:/#%>":XT?2)_!6L165L\5IJMWK\L3WD_Y;?\$A?'OQM_X(W_\
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M_$VIV\X!^AWQ(_X*9?\ !.?X/>)Y/!/Q3_;Q_8^^'_C*WU.+2+_PGXL_:/\
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M:6'H9E7Q-62A1<ES8JFZE)M:N#YEW:LTU]SO\C^(ZBBBO]P3R HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OVI_P""#?P-N_BE^W-H_P 09[,S>&O@)X/\1^.M
M1N)$)M&\0Z]I]SX)\):<S '%ZUQKVI>(;%244CPO<R%R8A%)^+MK:W5]=6UE
M96T]Y>7D\-K:6EK#)<75U=7$BPP6UM;PJ\L\\\KI%##$C22R,J(K,P!_OJ_X
M)*?L37/[&'[,&GV/C'3X[3XS?%JZL_'OQ21E0W6A2O9^3X7\!RS)D2#P?I4\
MQOT#2Q1>*-9\3?9;B>R>VD/\K_3 \3\%X?>#^>97#$PCQ%QYA<5PMDV$C-*N
M\'C:2HY_C^5>_'#X/*JU:C[>.D,=C<!"Z=6ZZ,+3]I53^S#WGZKX5\W^"9^H
M]%%%?X;GL!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45GZOJVFZ#I6IZ[K-
M[;Z;H^BZ?>ZMJVHW<@BM-/TW3K:6\OKVZE;Y8K>UM899YI&X2.-F/ K^&K]F
MKP1^TI_P="?M"?M$?'3XP_M-?'#]G/\ X)C_  (^)%[\,?@M\$O@7KZ^"_$?
MCC68[>RUW2[G7;R[T;4_#%WXGL/#%UX=\7^-?$?C'1?&.KZ+?^+]-\)>";#1
MM%>?4;/WLFR19G2Q^-Q6-IY;E>5TZ,L;CJE&IB)*IB9NGA<-A\-3<9XC$5YQ
MGRPYZ<(0ISG4J122EG.IR.,5%SE-M1BFEHK<S;>R2?9ZM*VI_=+17\,G[=7[
M%/[0W_!M]IGPX_;U_P""=O[4GQ[^(G[+F@_$7PCX&_:&_9,^/OBV#QCX.N/#
M7B*X^PZ1<6CZ1I7A[P]'H5[);0^"=.U6/PI9>// NJZKH-]H_BO5[*^U.QM?
MW-_X*@?LIZM_P5X_X)N>!/BE^R+\2O&/PX^-&H_#GPG^T?\ LP>+/#/C77_
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M^!O',NNW O87G73]<MM+T]%=F34 TLL9_7"OY(/^#LKXB?$#X>?"[_@GM<>
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M*>,IM(L_B9X+\8W7BBUB\-:B?$7AF\DO[ZVNM0^G+G_@\V_X)CK;SM:? /\
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M7^,+X,^-?%G_  7J_P""_/PU_:T^$&@Z_IO[ '_!,R:UT[PM\5-2TZ_L-/\
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M3[CPUK$UY;:)<-J_P@\'67V[7)'^RV(;7(G,JGRX+AODK^V3_@E7_P HO_\
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M"M_VX_@I_P %4/C%^WQ\'/A?KOAR]^/7P6_:DL?%/BV5/"6L:MI?A^75+/\
MX33XB?%._NO"TNIWEA:Z]-X.UWX?^*?"%I>_V]87NI6<.N7EG^X_QF_X++?"
M3X9?\$?-&_X*M6/AAKFQ\>?"OPQK/PX^%&K:KLN=5^,WC"\;PM9?#"]UK3[:
M4RVOAWQM;:U!XDUJSM$E'AKPQK>L6UI'-'':#\T?^#E+_@H?;ZU\-;3_ ()
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MSA2RG#Q]M.OF4\/1IVIQJXFE^<;:1\=3X[6RGTOXX'2H_A:+@Z2NH^3\3_\
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MY5P=X_+PB\4.,.#.*>'/$WAJEG>>83AWAQ8*M#CCP]QV&Q,:F3TL7"6)KX[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@[2^$W[;?\ PK?]FS]IC]F']I?Q!\%? GPZ\02_!GQGX#\#_&7XM_#7Q_\
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M\/\ PEH'@W1%>*)8(W72O#NGZ;8!HX42%&%N"D2+&I"* .YHH _E1_X.9/\
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MX@_1G_@O/_P1(B_X*Z_#3X5Z_P##'XE:1\&/VIOV>;_7KOX4>-_$D&MMX/\
M$6B>)CI=SJ_@CQA?>&OM&O\ AV%-:T+0_$/A[QII&B^)]2\,WMGJ=K:^'KV+
MQ%=SV@!^:?A'_@U,^+7QPT/3]3_X*-_\%=/VS/CUXI\0VVG7'C_PGX+\7ZW<
M^';>;;=?VCH&E>+OC1KOQ-D\065M'=R6>E:Q??#W0((HVN"/"\<%P+6+\@?A
M)^Q[^RW^P3_P=@?L=?LJ?LEZAKVI> ?A;'H]MXKF\4^*I/&'B9/B5KW[-_Q)
M\3>(TU_6%LM-TU=5ETW5] N[O3M$T[3M*TQ[D6<=A9W<5Y;1?M?\/_@;_P '
M?WB#P_I?P6\8?M4?L2?#30+:P@\-ZK^T?>:3X=\9?$]M%M9A:W&NZ;9Z5\+=
M0L];\6W.E*RV-UJWA+PW<WT_E76IZWHVMRSZW%Y1X"_X-B?VG/V7O^"CW[$_
M[<OP$_:?\!_M WWPQ\3:9\0OVQ/&'[4GC/XG>%?BK\9OB9K?CGQG)\4/&/@.
MU\)> ?BK901ZY\,O%EGH^B:/XO\ '#2CQ-X>^V>(=:U:UU_4)K< YW_@]W_Y
M--_8E_[.(\<_^JUEK^C'_@ME_P HC?\ @HS_ -FB?&K_ -0[4:^:O^"_7_!(
MKQ5_P5X_90\%_#+X7?$7PS\-_C1\'/B1_P +)^'=[X]76!\/_$RWWA[5/#7B
M'PAXJOO#^G:UK7A^/4+>^L-5T[Q+IV@>(IK"]T1=.ET6:UUFXOM.^./V7O\
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M'I6K:,+VUU"YM9[W3+U8)9(XED?^5OXK_P#!([_@X._X*QWGA'X3_P#!4O\
M:^^ WP0_9&\-^(-.\0^*OAY^SQ;65_XC\<ZEI;6\MK=_\(_X?\+:7HNNW:@3
MG3+SX@^/;[0_!^LK#K^C^ -4NTPW]?\ ^SY\!OAC^R]\$?A=^SS\&/#T?A;X
M7?!_P9HO@7P7HB2>?-;Z/HMJL"W6HWA5)-2UK5;CS]6UW5IU^U:OK-]?ZG=L
MUS=RL0#V*BBB@ HHHH **** "BBB@#^5'_@JO_P1@UMM:\3?M)?L<^%VU:QU
M6:[UWXD? G0;8'4]/U&9GN=2\3_"W3(%']H:??.9+K4_ =FG]H6%XTDGA*WO
MK"[BT+1?Y>[FVN+.XN+.\MYK6[M9I;:ZM;F*2"XMKB"1HI[>X@E5)89H95:.
M6*15DCD5D=0P('^IE7Y[?M8_\$O_ -D']L*:]U[XB?#]O"WQ%O%._P"*GPUG
MM?"?C:YEV;%EUN06-]H'BN156*-9_%>A:S>001);V=W:1Y%?Z%> OTWL9PEE
MN!X1\5L)F.?Y1@:=/"Y;Q7E[AB,]P6%II4Z.&S?"XBK26;T*$%&,,=3Q%/,J
M=&GRU:.9591E#AKX13;G3:C)ZN+TBWW3Z/RV?EU_ST**_IA^*?\ P;=?$VRN
M[B;X)_M'>!?$=A(TCVNG?%'PSK_@R\M$S^ZMI]8\*+XZ@U%POW[U-$TI68X%
MB@&:^;IO^#>W]NZ*1D37OV?;A1TFA^(/BI8W]U%Q\.X)1_P*)3[5_=.5_2C\
M <VPT,5A_$W(,/&<4W2S18_*,3!O>,\/F>#PE92B[IM0E!VO"4HM2?&\-73M
M[.3]+-?>FT?A?17[E_\ $/C^WC_T%_@%_P"'"\2?_,#1_P 0^/[>/_07^ 7_
M (<+Q)_\P->E_P 3'>!/_1U.#O\ PZT_\A>PK?\ /N?W?UW_ #[,_#2BOW+_
M .(?']O'_H+_  "_\.%XD_\ F!H_XA\?V\?^@O\  +_PX7B3_P"8&C_B8[P)
M_P"CJ<'?^'6G_D'L*W_/N?W?UW_/LS\-**_<O_B'Q_;Q_P"@O\ O_#A>)/\
MY@:/^(?']O'_ *"_P"_\.%XD_P#F!H_XF.\"?^CJ<'?^'6G_ )!["M_S[G]W
M]=_S[,_#2BOW+_XA\?V\?^@O\ O_  X7B3_Y@:/^(?']O'_H+_ +_P .%XD_
M^8&C_B8[P)_Z.IP=_P"'6G_D'L*W_/N?W?UW_/LS\-**_<O_ (A\?V\?^@O\
M O\ PX7B3_Y@:/\ B'Q_;Q_Z"_P"_P##A>)/_F!H_P")CO G_HZG!W_AUI_Y
M!["M_P ^Y_=_7?\ /LS\-**_<O\ XA\?V\?^@O\  +_PX7B3_P"8&C_B'Q_;
MQ_Z"_P  O_#A>)/_ )@:/^)CO G_ *.IP=_X=:?^0>PK?\^Y_=_7?\^S/PTH
MK]R_^(?']O'_ *"_P"_\.%XD_P#F!H_XA\?V\?\ H+_ +_PX7B3_ .8&C_B8
M[P)_Z.IP=_X=:?\ D'L*W_/N?W?UW_/LS\-**_<O_B'Q_;Q_Z"_P"_\ #A>)
M/_F!H_XA\?V\?^@O\ O_  X7B3_Y@:/^)CO G_HZG!W_ (=:?^0>PK?\^Y_=
M_7?\^S/PTHK]R_\ B'Q_;Q_Z"_P"_P##A>)/_F!H_P"(?']O'_H+_ +_ ,.%
MXD_^8&C_ (F.\"?^CJ<'?^'6G_D'L*W_ #[G]W]=_P ^S/PTHK]R_P#B'Q_;
MQ_Z"_P  O_#A>)/_ )@:/^(?']O'_H+_  "_\.%XD_\ F!H_XF.\"?\ HZG!
MW_AUI_Y!["M_S[G]W]=_S[,_#2BOW+_XA\?V\?\ H+_ +_PX7B3_ .8&C_B'
MQ_;Q_P"@O\ O_#A>)/\ Y@:/^)CO G_HZG!W_AUI_P"0>PK?\^Y_=_7?\^S/
MPTHK]R_^(?']O'_H+_ +_P .%XD_^8&C_B'Q_;Q_Z"_P"_\ #A>)/_F!H_XF
M.\"?^CJ<'?\ AUI_Y!["M_S[G]W]=_S[,_#2BOW+_P"(?']O'_H+_ +_ ,.%
MXD_^8&C_ (A\?V\?^@O\ O\ PX7B3_Y@:/\ B8[P)_Z.IP=_X=:?^0>PK?\
M/N?W?UW_ #[,_#2BOW+_ .(?']O'_H+_  "_\.%XD_\ F!H_XA\?V\?^@O\
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M_P")CO G_HZG!W_AUI_Y!["M_P ^Y_=_7?\ /LS\-**_<O\ XA\?V\?^@O\
M +_PX7B3_P"8&C_B'Q_;Q_Z"_P  O_#A>)/_ )@:/^)CO G_ *.IP=_X=:?^
M0>PK?\^Y_=_7?\^S/PTHK]R_^(?']O'_ *"_P"_\.%XD_P#F!H_XA\?V\?\
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MD_\ F!H_XF.\"?\ HZG!W_AUI_Y!["M_S[G]W]=_S[,_#2BOW+_XA\?V\?\
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MS[,_#2BOW+_XA\?V\?\ H+_ +_PX7B3_ .8&C_B'Q_;Q_P"@O\ O_#A>)/\
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M_P"CJ<'?^'6G_D'L*W_/N?W?UW_/LS\-**_<O_B'Q_;Q_P"@O\ O_#A>)/\
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MXD_^8&C_ (A\?V\?^@O\ O\ PX7B3_Y@:/\ B8[P)_Z.IP=_X=:?^0>PK?\
M/N?W?UW_ #[,_#2BOW+_ .(?']O'_H+_  "_\.%XD_\ F!H_XA\?V\?^@O\
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M_P")CO G_HZG!W_AUI_Y!["M_P ^Y_=_7?\ /LS\-**_<O\ XA\?V\?^@O\
M +_PX7B3_P"8&C_B'Q_;Q_Z"_P  O_#A>)/_ )@:/^)CO G_ *.IP=_X=:?^
M0>PK?\^Y_=_7?\^S/PTHK]R_^(?']O'_ *"_P"_\.%XD_P#F!H_XA\?V\?\
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MD_\ F!H_XF.\"?\ HZG!W_AUI_Y!["M_S[G]W]=_S[,_#2BOW+_XA\?V\?\
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M_P"24_\ !.+_ +/$?_U&[*C_ (.^O^24_P#!.+_L\1__ %&[*OV(_P""OO\
MP2<_X>L^%/V</#'_  OW_A0W_#/WQB;XL_;O^%6?\+1_X2W=IL.G_P!@?9O^
M%C_#K^P<>3YW]J_:-:^]Y?\ 9O&\G_!7W_@DY_P]9\*?LX>&/^%^_P#"AO\
MAG[XQ-\6?MW_  JS_A:/_"6[M-AT_P#L#[-_PL?X=?V#CR?._M7[1K7WO+_L
MWC>>+(L_RC!_ZB_6<7[/^QL1Q'/,OW&)G]6CC[?5'^[HS]M[6VU#VKI_\O5
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MAY?MJ%EX=\5:'X&TA;?5/#.NZ-I>E7O@KQ;XA;24BOO$7BF?5K[4[67\W_\
M@J)_P3L_92_X)N_\%,_^"1?PL^!WQ(^+WQ8^,_CW]H/X>_$?]H+QQ\<?B=9_
M$#X@ZS:7OQY^#FC?#.XO]/TOPYX<T[P[9RWFD_$J:QF^SW.I:S%*R:C<W TB
MUN[O]P?A!_P0!_X*:?L7_P!L_"?]@7_@L[XM^#O[+NM>*=0\26/@;QQ\$]%\
M;>)?![ZIM6[.FPWFJ7?AF]U6Y51-JVH>&(?AE8Z[J"C4;G1+6[/F+M?%'_@U
ME\+^/=1^#WQKM?V]/C)J_P"V]X+^-&D_&KXJ?M:?&WP5?_&74OBSJGAV31[W
MPOX6TSX?V_Q<^'T'PZ\*>%=6T&PNO#UO:^+O$^JV%A)=:(VJSZ;!H46A?48;
MBC*L'G-;$/BG!PR"M#'TLOR?*LEQ6$AAJ.(PU:EA:>:0I9=0<H853C=TZF/J
MU,3"G55.$$YT\G2FX)>Q;J+E<ISJ*3;BTWR7D[.7FHI*ZO?0Q?\ @\U_Y1?_
M  (_[/U^%_\ ZSU^U'7L_P#P<B^$=?\ 'O\ P01UC5O!]A)XAL?"/_#+GC_6
MYM)_T_R?"$&L>&M)NM>A%J)C<Z=9R^(=.O;VZAW06FD_:M5GDCL;.XG3]7/^
M"IG_  3D\#?\%2?V0_$/[+'CWQWK?PSN+GQ/X8\>^#?B)X>TF+77\*>.O"GV
MZ#3]3OO"=WJNDP>)M$NM,UC6]*U'09M=TN62WU+[39ZQ8ZC9VEY'\Q?\$R?^
M"67[0/[)OP5^/W[/W[;O[:>N_P#!0?X._%[P-X(^%7A/X8_$CP]XL'A3X:_#
M/P[H'CCPUXI\(::GB[XB^-?M&A>.="\6Z3HE[I%C8Z/'IFF^#='BCO;Z)K2V
MT?Y'*\[RW"9+P[B)8N,<RX8S^OF#RN=#$.>98;%XC+92>&Q,*<L-2E2AAZSD
MJ]2#]RZ3;A&>LJ<I5*JM[M6FH\Z:]UI/=-IN[:V_S:_('_@F_P#\$'?V.OVQ
MOV%?V6_VBO!?_!0G_@J+I5E\0O@WX*GU[PK\/?VK_A[8^#O /CO1=&M?#_Q!
M^'7A[2D^!E^^BZ1X"\::7KGA73-'N+J:YL-.TNTAE=B [9OQ2_X)*?\ !%_]
ME3]O?]B_X4?M"_\ !1'_ (*/>,/VLM9^(/PW^('[-OPV^(GQ!TGXX6VJ^(X/
MBIX>M?!NCZ\WA']E/Q#<^"?#WC/QCHJ6]W?:UK7@K2+K2- UW4+KQ-I,&D-J
M$'O&G?\ !NY^V1^QQXL\;/\ \$EO^"K?Q,_9=^#7Q$U^Y\0:M\!_B=X0'Q"T
M'PYJ4\#V_P!OT?7/M]YHVLW4=D;/1+34=0^'>F^,(]&TC24UWQMXIN[.WN+?
M[&_X)U?\$%?"O[*7[2FM?MU_M:?M*>/?V]/VW-6CO!H_Q:^(^D2Z'X?^'TNI
M:=+H]Y?^%/#M_P"(_&&IW7B&'09Y_#&E:WJ.O1:7H/AR5]/\+>$_#9?S%]K%
M<18>%3,L='C;&XG"5Z.+EEV5X+!5<-FOML1%JEAL;7Q.7RP5"A0Y^3$UJ=>O
M+$4X2]A'FGI$:;M"/U>*DG'FG*2<++=Q2ES-NUTM+/=Z'Y]?\%N/^4_'_!!/
M_LH6A_\ J[?#E?V(5^._[;G_  2<_P"&R/V_/V"?VY?^%^_\*Y_X8@\0V.O?
M\*O_ .%6?\)?_P +.^Q>-]-\9?9/^$V_X6/X7_X0OS?[/_L[S_\ A$?%FSSO
MMGDOY?V5_P!B*^)SO,,'C,IX6PV'K>TKY=E>*P^-A[.K#V-:IF>+Q$(<U2$8
M5.:C5A/FI2J07-RN2DG%;PBXRJMJRE-..JU7)%7\M4]PK^&K_@J?J<G_  2S
M_P"#D?\ 9$_X*9>.+.ZM?V;/VFO#FD>"?BCXQBL);C3]$U*P^&\W[.7CX:FT
M223!O G@B[^%OQ2C2S9-1U:RTV^L-/LM1_L^_M;K^Y6ODG]MC]A_]G'_ (*#
M_ ;Q!^SI^T]X'7QEX!UBZ@UK2KRRO)-(\6>!?&&GVU[:Z+XZ\">(H$DN- \5
MZ+%J-]#;71AN]-U'3[W4=!\0Z7K7AO5]7T:_CA?.,/DV8U9XVE4K9;F.!Q>4
MYI2H\JKO XZ"A5G0YFH^VHSC2K04FE)T^7F@VIQ*L'.*Y6E.,E.#>W-':_DU
M=/UZ['U%H>N:)XGT;2O$?AK6-*\0^'M=T^SU?0]>T/4+35M&UG2M0@2ZL-3T
MK5+":XL=1T^^MI8KBSO;2>:VN8)$FAE>-U8_A'_P7S_X+ S_ /!*_P#9Y\'?
M\*9O/AYXF_:[^+7C?PS9_#'X9^,[2\\2VT?@/2]6^W>._&WB;PIH6O\ AW7W
M\,75KIK> M+N[;5M,N;OQ+XEBDT::>70M5:P_-WPQ_P;E_\ !2+]E(:QX-_8
M _X+6_&#X6_!+46NETCX9>-M!\6P6WA6UO7NFN%L8?#OCC5?!DFMNTJ3S^*?
M#/@?P#?W<TQ)LX'L+>>X^I?V&O\ @VJ^%7P3_:#TO]L?]NC]I7XG?\%#OVHM
M!UVQ\4>&?$/Q3BU*T\#:!XETJX-UHGB/4])\2^*/'WBOQ[XA\-7*077AFY\1
M^++?PSHUW&E[!X,;4K+2;_3O:P>7\'99BXYCB^(:6>8+#MUL/E&'RW'T,7CZ
MD5>EA\8\32AA<+1Y^7ZQ)5ZRG",H4U+F1$I5Y1Y8T_9R>CFY1<8]W&S;D^VB
MMU/%_P#@XK\6?&CQ[_P;U>#?'/[17A'PY\/_ (Y^-/$7[+/BSXI^ _"::K'H
M/@GQEXCNUUC5_"-I'K=_JFIQS>&Y[S^QM12YU/40NIV5XMO?W=L(;B3^B']@
M7_DQ3]BO_LTO]G'_ -4[X-KP7_@K/_P3M_X>B_L=Z_\ LG?\+@_X4;_;GCGP
M+XT_X3[_ (5__P +,^R_\(5J<NI?V;_PBO\ PFWP^\_^TO,\G[9_PD</V/;Y
MGV6ZSY8^U/@%\+?^%'? GX*_!3^W?^$H_P"%/_"7X<?"W_A)?[,_L3_A(O\
MA7_@[1O"?]N_V-_:&K_V1_:_]D?VA_9G]JZG]@^T?9?[0O?*^TR^7CLSP6(X
M8P& IRA3QE+/LVQU7"4Z=94Z&&Q>'P,*')4G%TY0YZ52G&"JSJ1C!.:2<7*H
MPDJKD[N/LH1YFU=M-WNM[];VL?R<_LX_\KE'[?7_ &:7X-_]9S_8KK0\:?\
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MX&TA;?5/#.NZ-I>E7O@KQ;XA;24BOO$7BF?5K[4[67^A7]A__@DS\.?V6O\
M@F7>?\$R/B[XZC_:2^&?B+2OC#X>\:^*'\$/\+Y/$.@_%[Q'K^O7EO9>'XO&
M7CV?0-4\/C7%32-<M?$]S>6^J:=9Z[9+I]W%#%!^1?P@_P"" /\ P4T_8O\
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M\Q%Y_P &U_[2W[+_ ,;OB+\0_P#@E#_P4[^(?[&OPS^+^K1WOB[X/:QX5O\
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M_P#*+_\ X)O_ /9A7['W_K/7P[KAO^"L_P#P3M_X>B_L=Z_^R=_PN#_A1O\
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MRCSUIRA)QE+55U'*=%S47^[2J0459_%9N[D][O;:RW7]"_\ P5D^#GBCX_\
M_!-+]N+X1^"+*XU3QGXM_9L^* \*:/9H9+S7O$>A>';OQ+HOAZRC"2;[SQ!J
M.C6^BVB$*&N+Z(-)"I,J?D3_ ,&COC3X9Z__ ,$EM(\*>#;S33XW\!_'GXNV
M7Q>TR!X8]5A\3>(-3L?$'AG5M1M1,]R]KJ7P^N_"VGZ;JDD,-M=OH-_IULTL
MVBWA3]4_^"6'["'Q8_X)Z?L^>,?@O\8_VQ/B)^VWXF\3_&3Q#\4+'XK?$O1O
M$NAZ[X?T+6O!/P\\*6OP^M+3Q3\5?B_J$FD:5J'@K5/$<%Q#XEL;-[SQ9?Q1
MZ';3PW%_J?Y:?'C_ (-Z_'_@#]I3Q_\ M:?\$E?VXO&?_!/#Q]\6IGO/BC\*
M-.\*KXM^"GB?4;F\N-0O;G2]%@U2QM=$TA]2N+G6K;PEKWACQUHFCZQJ.I2>
M$?\ A$M*DMM'M?%P6*RAY7G'"E;.84L+4S+"YIE>=/!XV.#KUZ%&>&JT<7AX
MTIXZA1K4JD94I_5Y^SJT7*I%1<67)3YX5E"[4'"<.:/,DVFG%_"VFM=5=/3L
M?&?_  >-G0?&?PQ_X)Z_!GPA%#J_[3'C;]I'7C\*-#TN1!XN?0=1\/Z;X5U6
M+3I(IDNM.AUWQ_K7PSM+21A$FH:GID;6TWF:1<"/]K/^"_R7,7_!&']NR.]N
M([N\C^#FAI=W4-N;2*YN4^('@=9[B*U,UP;:.:4/(EN;B<PJPC\Z7;O;Y@_8
M@_X()ZU\-_VL=(_;^_X**?M?>-_^"@?[6WA"&T7X67OB?1)?#GPR^$MU913"
MPU'0_#]]K.N2ZOJ7ARYN]1O_  7'8VW@OPCX6U75;_Q%;>";CQ>NF^)--^I_
M^#@G_E#7^WM_V232O_5B^":[(8[ ?VAP%D.7XO\ M&GDN;TZM?,(TJU&C7Q6
M:9K@ZU6EA:>(A3KK#X:-"$54J4Z3K5959^S4>47++EQ%24>5U(:1NFTH0:3D
MUI=WV3=E9;E__@@1_P H=/V!?^R*_P#NX^*J\1_;1_X)V?%W6OBSXL^*/P5T
M6W\:Z!X]U>]\3:QH$.K:3I>O:#XAU:<W6N.L.LW>FVVIZ;J6I3SZA;26%S/?
M0/<W%O<V20VT=W<>W?\ ! C_ )0Z?L"_]D5_]W'Q57[ 5^1^*G!62\<XS.<L
MSE8F$*&?YCBL+BL'4A2Q6&KK%8FFY4Y5:5:E*%2G.4*M.K2J0DK22C4A3G#\
M4\=_H^\ _2+X,P?"''BS;#T<NQ]+-\GSC(<7A\%G&4YA'#U,-.IAJN+P>88.
MK0Q.'K5*&+PN+P6(HU8<E2,:6)H8?$4?PU_92_X)<:]9>(=,\=?M)QZ;:V.C
MW4%]IWPOT^_LM:?5+VVD2:$^,-4T^2[T<Z1%(H,FC:5>:A_:V/*OKVVLUFL[
M_P#6CX]?$RU^"7P5^(?Q)\F'_BCO"]U<:3:,J);2ZS<&+2O#=BZ#:J6]QK=[
MIMHZH,K%(1&C,%0^Q5\)_P#!2/0-=\0?LC?$1-"BEN#I%YX6U_5[:&,22RZ%
MI/B&PN-2E (RL6G+Y>K74BX,=II\[D[%8'XN'#.5^&W!/$;X5PE58S#Y1F..
M^M5I+$8_&8S"X*O+#U<144(*:H27-"A1I4J,%[3V5&,ZLW/\_P /X1\'?1.^
MCWXK3\&<DQBSS+.!N*N(WG..J0S/B7/<]RCA_,:V58W-,73P^'IUX9=4BJM#
M+L#A,)@*$/K+PF!IXC%XB=;^8(:_K*Z\/% U*Z_X2$:N-?&KF0M>_P!LB]_M
M'^TC*P):Z^W?Z49&!)F^8@U_89\"_B79?&SX,_#[XDQQ0;/&?A:SO-5LT"2V
MMOK,:OIOB735!+K)!9:Y::G8*)/F>. >;&CEHU_C<K^IW_@G'H6LZ!^R%\+X
M=:M9[.74G\5:[I]O<!UE_L;6?%>L7VE70C<#9!J5G+'J=H4RDUI>P7(.9B!^
M"_1RS'&KB7/LMO.I@L9DWU[$N7-**Q>$QN'HT*DI.Z4JE/'8J,KM2J:-\WL]
M/\U_V5'%&?4_%KQ(X43Q&)R#/N _]8LVE4]I5IT\ZR+B#*\%EF(JU)J455Q.
M%XCSBE44I1J8E\DY.:PWN_!_[5?_  2W\02:]J7C?]FJ#3KW2]5NGN[SX77E
M_::/<:-<3;I)_P#A%-4U2XMM*FTEI=SQZ3J5[82Z:)!;V-Q=VHBM[7,_8I_X
M)V?%C0_BMX6^*GQNT>V\&:'X#U6W\1Z'X:EU+2M6U[7O$6ER+<:%/,FD7FH6
M>D:9IFI)#JDDEW<C4;B>P@M8;!(+HZA!^\U%?M?_ !!;@>/$='B.EA<70J4<
M5''1RJCB*<,G>+IU%6IU?JWL'7A3C57M/JM/$PPC:C35!45*E/\ T#?T /H\
M4_%; ^*V"RC/,MQ& SBCQ#3X+P&986CP-/.\-BH8[#XS^RGEL\PH8:GC8+$O
M)\)F^'R9RA3PT<!#+U4P57\</^#@G_E#7^WM_P!DDTK_ -6+X)J__P $"/\
ME#I^P+_V17_W<?%54/\ @X)_Y0U_M[?]DDTK_P!6+X)J_P#\$"/^4.G[ O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)_:O=\R1Z-1117QIL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $2S]F#_ ,/Y\5O_ *&VC^W?VT/^B6?LP?\ A_/BM_\ 0VT?V57_ .@C+/\
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M_P##^?%;_P"AMH_MW]M#_HEG[,'_ (?SXK?_ $-M']E5_P#H(RS_ ,.N7_\
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M^W?VT/\ HEG[,'_A_/BM_P#0VT?V[^VA_P!$L_9@_P##^?%;_P"AMH_LJO\
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M]N_MH?\ 1+/V8/\ P_GQ6_\ H;:/[=_;0_Z)9^S!_P"'\^*W_P!#;1_95?\
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M $2S]F#_ ,/Y\5O_ *&VC^W?VT/^B6?LP?\ A_/BM_\ 0VT?V57_ .@C+/\
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M_P##^?%;_P"AMH_MW]M#_HEG[,'_ (?SXK?_ $-M']E5_P#H(RS_ ,.N7_\
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M^W?VT/\ HEG[,'_A_/BM_P#0VT?V[^VA_P!$L_9@_P##^?%;_P"AMH_LJO\
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M]N_MH?\ 1+/V8/\ P_GQ6_\ H;:/[=_;0_Z)9^S!_P"'\^*W_P!#;1_95?\
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M $2S]F#_ ,/Y\5O_ *&VC^W?VT/^B6?LP?\ A_/BM_\ 0VT?V57_ .@C+/\
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M_P##^?%;_P"AMH_MW]M#_HEG[,'_ (?SXK?_ $-M']E5_P#H(RS_ ,.N7_\
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M^W?VT/\ HEG[,'_A_/BM_P#0VT?V[^VA_P!$L_9@_P##^?%;_P"AMH_LJO\
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M]N_MH?\ 1+/V8/\ P_GQ6_\ H;:/[=_;0_Z)9^S!_P"'\^*W_P!#;1_95?\
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M $2S]F#_ ,/Y\5O_ *&VC^W?VT/^B6?LP?\ A_/BM_\ 0VT?V57_ .@C+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM0U[PEXB\/WKZ=KVAW/B'P[Y5GJMIIMS=Z=>6VZVG[W_ ()_?L!_ C_@FO\
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M;.'3_%VE:M96<W]K:+I\_P!LMH8KKRXG@\SRI9%8 _I5HK^,*W_:$_X.9?\
M@K3X5U+]J+_@GYJW[/\ _P $^_V/-7O=5U/]GCP_\6H/"M]\:/COX)T75O\
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M)GBRSFO=&L+VTT?3)H8K-]8\0:5H]E?30SW-KXGNS8>$-? /]32BOX-OVO\
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M;NKVUM<2:P_A+2].\6?L:>#OAY)K3$OI)U5OB/8ZM=6YCLX/%\RK!.OZ&?\
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M\9O%OCEM(M9C;:M?06GEQ@']R5%?D#_P1%_X*CVO_!6?]B/1_P!H75O"^B^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]%UKQ#X7^$?PFUGXHKK.N:6NI-_8VKZWXQL?#NA70M-=U[3]2LX9M&E_;/\
MX-WO^"3OBG_@F=^P1J_@']H&STZY^/'[27B:Z^)7QP\'1WMGK^@^"]/N] MO
M"_A?X4O>6;S:/K=SHGAJ&YN_%U[9->:?+XH\2Z_HVG:IK>@:3I&JW@!^4?\
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MG2:'J%N9].N[+1WTK2+K6=*T"R\5>)/W1_X/:?\ DPO]DW_L[M/_ %37Q,H
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MU]87,]K.JNK&*5@K*<$?Y0G[$_[)WQAU+_@LI^SS_P $9?'$NM:I\%/V1_\
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MS:7EI<_!7X;0W-K=6TRO#<6UQ"[Q3P2H\4L3M'(K(Q!^#/@O\2?C;_P:=_\
M!0']HCP#\9?@I\3?BC_P2R_:M\7VVM_#GXI^!M-CU>]\.6^CW.O77@&?1M0U
M+4=/\,7'Q$\(:)X@O/ ?Q2\!>(-9\*ZUXML=*T7Q[H,ITNPT.PUL _K5_P""
M[GA+0/&O_!'G_@H?HWB73X=3TZS_ &:/''BVVMKA$DCBU_P MIX[\*:@JR(Z
MB;2/%/AO1M5MG #QW%E%)&\<B(Z_$G_!IY_RA-_9X_[*)^T/_P"KJ\95^+G_
M  6%_P""_>F?\%-OV.OC_P#LF_\ !+SX*_&SX@>"6^&&K?$7]K[]H_QGX$E\
M(^"_A3\"O ,?_"<:[H>GB2]U&6RU?QK+X:3PS<ZMXN30;:YMKUO"W@ZR\1^(
M?$L&H^&?VC_X-//^4)O[/'_91/VA_P#U=7C*@#^D*BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 5_)9_P %*?\ @K9^VO\
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M]I*2O7M%!U924DXJG=<W->4EI&*LK:NS>SW=DC^E*BOY(-,_X-/?AOK?P_\
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M?0?#6M>$-?\ &WC/Q1X9\;7=]K7BV7PYX(@\,:#8!+";]NK]A[]IG_@V_LO
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M>6Y\8:F+.'4-625+DW:-!Z6$6'R?@3'5Z.-AA<SQ6<XC+<;[7**6(KMTLO\
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MSMXW\9^+_"?[.7[+?P!\70^"O!UCX5\*ZUJ7AW7[B>'6O#FN^%U\,6MZFJ>
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MUW8^'+YX[V?0-.\2:QX\\3^*="_LGQ)K/B>VGN;$5Z=^R'^VQ_P4;_X)F?\
M!5#X9_\ !*G_ (*3_&M?VOOA!^T[IMI<?LR?M-W^E1Z;XRMM3U:76K#PPNK7
M\^_5]1AUKQ/H5YX)\7>#_%6L^+==\,:]J/AO7/#_ (MO/"]R(M<_JZLK'X0_
MLZ?"F&QT^V\ ?!3X)_"7PH4M[6W30O /PV^'/@CP]:,PB@A0:9X=\*^&-#L8
MBL4,:V6F:;9Q+'$D,$:JO\87P9\:^+/^"]7_  7Y^&O[6GP@T'7]-_8 _P""
M9DUKIWA;XJ:EIU_8:?\ $KQCX7U/6?$NAW6CK<Q6S0:W\1O'>I:3KL&@3O\
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MU_G&?\$3?^4N7_!.;_L[OX*_^ICIU?Z.?_!V'_RA-_:'_P"RB?L\?^KJ\&T
M?RC?\&5/_*4WX^?]F ?%/_UHK]E6O[EO^"OO_!6KX&_\$E_V:]2^*GCRXTKQ
M=\9_%UMJ.D?L_? L:J;+7?B=XOMTA6:\O/LL-W>:+\/_  I]KMM2\:^*I;9;
M6T@:ST.PFF\2Z]H.GWO^;K_P;G?\%#_@9_P3!_:D_:L_:E^.\M_?:5IG[!_Q
M'\(^ / VB/%'XD^*?Q2UWX]_LUW_ (6^'OAZ:Y5K2SN]2M-$UG6-5U:[62VT
M'POH7B#7Y+:^_LP6%U^9O[??[>O[07_!2/\ :7\8?M+?M&>*6U/Q)XBF.E>%
M/#5M)<+X/^%?@"UOKNX\._#SP1I@$AT_PWX?CO;B2218I-3U[5KK5/$NN3ZC
MXAUC4KZZ /8_#/AK]N__ (+M?\%";FVM[B]^+_[2W[0'B*[UG6M6U*YN].\!
M_##P+ITR?:KZZFE;4H_ ?P=^&&BSV]AIFFVJWDUM9QZ;H.BVFN^*M7L++5O]
M6C_@DK_P25_9Y_X)+_L\VOPJ^%5K#XM^*GBV'3-4^.WQVU33(+3Q9\5/%EI!
M($CC0/<R^'? /AV6YO+;P1X(MKR>TT6TGN=0U"YU?Q/J^OZ_JOBO_!!__@F=
M^R!^P%^QG\/?%O[-_B7P_P#''Q=^T5X&\(?$7XA?M46EB(KSXLVNM:9#K&BZ
M=X7BN5.H>$_AKX?%[)#X>\%3-%J%K=_:]0\5I/XKGU&2+]P* /SU_P""@?\
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M\?:A:K>!+>;5/AM\/=/\.Z//+8>0S7,UM:?%;7([>\%Q$+%+JYA:"X.H+);
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MA\?=*\;1Q7K2+"E_\-= \0?$;2[E#''*WVNRU/PK9WE@I41M?06ZRR0Q%Y4
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M=+MI9K<:EX@U[4)+/0?#6C13)<ZWX@U+3-(L]UU>PHW^61\-O"O[27_!T?\
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M$"M-#<PS,+>**W B,0+,2YX_?;_B"(_9-_Z/:_:(_P#"&^&O_P :H_X,B/\
MDTW]MK_LXCP-_P"JUBK^W2@#_*U_X*'_ /!,_P#;C_X-E/C7\&/VN?V3?VI?
M$'BKX3>-?&,7AG0_B+IFCW7@N=/&6EV.H^(X_A!\=/APFN:]X2\<>&_$_ANR
MU^\T>2:\O=-\06NC^)Y)=!\+:CIEA-=_Z.W_  3G_;#T3]OW]B']F[]K[0],
MMM#7XU_#NUUOQ!H%E,US8^'?'FA:GJ7@WXD^&]/N9)IYKG3O#OQ"\.>)]%T^
MXNI!>3V=C!+>1P73S0Q_R:_\'CO_  4'_9NU[]F#X8?L(_#SXC^$/B-\=-1^
M._A_XK?$30_!OB#3?$:_"CPCX \+^-M%AL?&\^D7-U!H7B_Q/K_BS3_['\,7
M\L>L1Z)I.L:MJ-C96MUH4^I?O5_P;I_L_>,OV;/^"-_[%O@+X@V6IZ5XO\0^
M#O%WQ=U+1M566"YT;3OC3\2/&'Q1\):<=/G GTF:/P7XI\.3:GIMP$N;?6I]
M3-U#;7$DMK  ?DA_P>4_MN3?"#]BSX3_ +%/A#4Y(?&7[7/CP>(?'%M93L;E
M/@Q\&K[2-<FTRZMX8_.B_P"$M^)VH>!&TZ8SI'?67@_Q/IWV:[CEN&MOQ+_X
M([7GQ*_X(5?\%XO"?[%GQVN[_3?!/[5GPP^#7PH\976IQQ66GW'C7XQ_#_PA
MX\^%OB2PBF%K&6\.?'.^U;X-2E[IQH]KK7B^":;5[_34DN?0->NV_P""ZG_!
MU/IFD0.WBG]F;]DSQJEL#;7%WJ&AR_!+]D#66O\ 6+IY5,D+^&_C)^T%J#Z=
M'=6,>G(^A_$O3(X[AKV%=2N?NK_@]%_8ZU!O!_[*7_!1SX>07>G>*_A5XD7]
MG[XE:]I(\G5+/0=9O=2^(/P6\1B^MS#=:?#X0\:VGCO3%O-\Q_M;Q[H,=NUG
M)$3= ']UM?@#_P '1W_*"C]N;_NV;_UL/]GVONS_ ()0?MM:3_P4+_X)^_LU
M?M36UY:3^*/&W@&RT7XK6-J$A_L;XR>"))/"'Q1T]K(!)+&TG\7Z/J6LZ##-
M'&USX8U;0]2A$EI?6TTOPG_P='?\H*/VYO\ NV;_ -;#_9]H _D@_P""$O\
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M7[1'P]\%ZOXL\.V=C?ZWH=I+^S_X'U)KS3;/4O\ 0)[D/IZ1*ET#$%D9B"5
M/[V_\01'[)O_ $>U^T1_X0WPU_\ C5?EYX\_Y72;'_L[OX<?^LV^%Z_TMZ /
M\]3]LS_@S)USX0?!CQ1\7OV(/VK_ !O\2_B_\,]*N_&>E?"KXA>"M*\/ZKXX
ME\.QMJYL/ 7COP=K$$F@>-UCLR?"MC?^'KRTUG7/L=E+K_AP2#4(_NS_ (-*
MO^"OOQI_;%\+?%;]AO\ :>\:ZG\3/B5\ / VD_$KX/?$CQ-?2ZKXZ\2?!U-=
MT_P=XH\.>-M;O+A]1\27?P_\1:_X*CT+Q)J/V[6;W2?%C:7K.H2+H>EO<_U
M?MK?MT_LT?L _!'QC\<OVDOB?X4\$:+X:\.ZOJ^@>%M0U[2[7QO\2M9L+623
M3_!GPY\,7%RFK>*O$VN7WD:=:6NEVEQ#8^>^IZQ-I^BV.H:C:?P5_P#!F?\
M!SQQ\3O^"@G[77[7\VE7^F^ /!GP.\0>!M0O+4SQ:3<?$7XY?$_PEXOTGP]'
M=3*$U6'2_#7P[\57U]91[YK&>;PU?WKVWVFQ2] /]"_X\_M#? W]E[X;:[\8
M/VA_BOX&^#?PT\.0O+JOC#Q_X@L/#^E+*(Y)(=.L#>2K<ZSKE_Y;0Z3X?T:W
MO]<UB[,=EI6GWEY+% _^9K_P<!_\'!WB[_@IYH^O_LX?LD^&O&_A+]A/X?>*
M]&OO'?CW4--U;3-?^.VO0W3?\(=>^-["#=:^"?AO%KFG7FK^ O!GB"8:[XDU
M/3]-\4>);32M<TFR\,>&_P"ZO_@KC_P2"^'7_!7K0_V;_A_\7?BQXO\ AE\-
M/@E\3=?^(OBFQ\ :1I-SXR\>6^K>'4\/1>&=&\1Z\UYI'@O >>\N=?NO#'BY
M]L4=E!HR/<G4+/\ !#_@Y3_83_94_P""?O\ P0S\+_!?]D[X0>&_A5X/_P"&
MO?@==^(+O3XI+[Q;X[URT\!_%BS'B;X@>,=1>Y\0^,/$$D(9$O=8OIXM/@D.
MGZ/;:;I4=O80@'[<?\&X/_*$W]@?_LG?CO\ ]75\3:_;JOQ%_P"#<'_E";^P
M/_V3OQW_ .KJ^)M?MU0 4444 %%%% !1110 4444 %%%% !7*^+O G@?X@:<
MNC^//!OA3QMI"R+,NE^+O#VD>)-.697CD65;'6;.]MA(KQ1.KB(,'CC8$%%(
MZJB@#BO!?PU^'7PWM[ZS^'?@#P5X"M-3FBN=2M?!?A70O"UOJ%Q C107%]!H
M=A8Q7<T,3O'%+<+))&C,B,%8@]K110!0U32M,UO3[O2-:TVPU?2M0A>VO],U
M2SM]0T^]MW^_;W=E=QS6US"^!OBFB>-L<J:Y/P7\+/AC\-_MG_"O/ASX#\!?
MVCL_M#_A"_"'A_PM]N\O'E_;/[#T^Q^U;-HV>?OVX&,8%=W10 4444 %%%%
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M?B5\=M&G5[U-1A=[74_"OPNOHRT=H;%UEM-5\>6Y>Z-X)8?"4EI]DB\0W?\
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M<Z^8X_$S4I/5Q@X4XMVA"$;17&\37?\ R\:]$E^21^\'_$0_^W-_T)?[-O\
MX0?C_P#^>O1_Q$/_ +<W_0E_LV_^$'X__P#GKU^#]%>E_P 2U^ __1K>$_\
MPAE_\M)]O6_Y^3^_^NWY]V?O!_Q$/_MS?]"7^S;_ .$'X_\ _GKT?\1#_P"W
M-_T)?[-O_A!^/_\ YZ]?@_11_P 2U^ __1K>$_\ PAE_\M#V];_GY/[_ .NW
MY]V?O!_Q$/\ [<W_ $)?[-O_ (0?C_\ ^>O1_P 1#_[<W_0E_LV_^$'X_P#_
M )Z]?@_11_Q+7X#_ /1K>$__  AE_P#+0]O6_P"?D_O_ *[?GW9^\'_$0_\
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M(9?_ "T/;UO^?D_O_KM^?=G[P?\ $0_^W-_T)?[-O_A!^/\ _P">O1_Q$/\
M[<W_ $)?[-O_ (0?C_\ ^>O7X/T4?\2U^ __ $:WA/\ \(9?_+0]O6_Y^3^_
M^NWY]V?O!_Q$/_MS?]"7^S;_ .$'X_\ _GKT?\1#_P"W-_T)?[-O_A!^/_\
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M_1K>$_\ PAE_\M#V];_GY/[_ .NWY]V?O!_Q$/\ [<W_ $)?[-O_ (0?C_\
M^>O1_P 1#_[<W_0E_LV_^$'X_P#_ )Z]?@_11_Q+7X#_ /1K>$__  AE_P#+
M0]O6_P"?D_O_ *[?GW9^\'_$0_\ MS?]"7^S;_X0?C__ .>O1_Q$/_MS?]"7
M^S;_ .$'X_\ _GKU^#]%'_$M?@/_ -&MX3_\(9?_ "T/;UO^?D_O_KM^?=G[
MP?\ $0_^W-_T)?[-O_A!^/\ _P">O1_Q$/\ [<W_ $)?[-O_ (0?C_\ ^>O7
MX/T4?\2U^ __ $:WA/\ \(9?_+0]O6_Y^3^_^NWY]V?O!_Q$/_MS?]"7^S;_
M .$'X_\ _GKT?\1#_P"W-_T)?[-O_A!^/_\ YZ]?@_11_P 2U^ __1K>$_\
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M^ __ $:WA/\ \(9?_+0]O6_Y^3^_^NWY]V?O!_Q$/_MS?]"7^S;_ .$'X_\
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M?@/_ -&MX3_\(9?_ "T/;UO^?D_O_KM^?=G[P?\ $0_^W-_T)?[-O_A!^/\
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MU'5_$'@+2_@W8^,?A[<ZEJ-PI>YN-"T7Q;+X&@\V:XO#IGA#3[J\E>6[#O\
MG3_P:I_\$M?V7?VFOV8O'_[7'[6?PP\+?M&ZCH?Q>\2_!+X*_#KXQZ=;_$/X
M7_#CPEX<T/PMXT\5:SIGP\\2?VCX0GUGQEXO\>7XNQJNB7J:>NA#4=-6WN_$
M.K37'*N$\ORZEQ'5S[%XV+X>S7!8!T\NA1<\?'%QQ+@Z3Q'NT)3C2I5U4J.<
M:='VD72J5.1%>UE)TE34?WD'*\K^[:U[VWM=KS=M4M3^MW]D3_@I_P#L"?MX
M:AJ&B?LG?M/?#SXN>)M*TB/7]0\&6G]O^$_'EMH;_9E?6'\!>/=%\*^,FTRT
MEO+2VU&]CT-[;2[VY@L=1DM;R5(&^J?B[\9/A/\  'X?>(/BO\;OB1X*^$WP
MU\*VZ7/B'QQ\0/$FE>%?#.EI-*EO:Q7&K:Q<VEJ;R_NI(K'3-/BDDO\ 5-0G
MM]/TZVN;VX@@D_B0_P""R/[)7P1_X)H_\%?/^",'[2'[$/@#PI^SIK'Q[_:!
M?PAX^\$_"_1XO"?P^U"+PA\3_@?X7U^2U\'Z,]GH6@V/C_P%\<M<\$>*M'\+
MV>A:;=Z/9I/#;V^JW5UJ,WT-_P ';EGXYTC4?^":/Q2^(O@+QG\4OV _AC\?
M=3US]JGP+X/GOK.UUNY_X2/X8/IFA^)M1@>SM=%O_&GP[M_B;X-^'NO7>I6D
M.GZQJVOVIN["[U33S>:4^$<LQ^9\,QR['8REE7$F'QM>DL;'#RS"A5RV>)I8
MG!Q=-T<+6K5ZN']C@ZG[J,IU8\\-+3/;3C"JY1BYTG%/E;Y6I<K4NK22E>2U
MLD]3]J?"'_!P'_P1P\;^+QX(T3]O3X1VVMM?6^G+<^*=,^(7@3PL]S=%!$8_
M'?CCP7X=\#R6N9%$M^GB)K"!MRSW,11PO[ 6-]9:I96>IZ9>6NHZ;J-K;WVG
MZA8W$-W97UE=PI<6EY9W=N\D%U:W4$D<]O<02/#-"Z21NR,K'^0L^/\ _@UV
M_P""H?[-GB']FCX:W/['/[+/C?7?"FJ^'?AGK/BCX)^$/V8OBY\)/'.IV\J^
M&O$7A3Q1K&F?#[3O'&I0^($TW6]9\*:!\2M=T[X@R0_V-XJ>[FOYE3WW]LB7
MXH?\$)O^#?/QC\.?A=^T'XE^.7CWP?9V?P=^"/QMU+0[3PQJOA'1_C=XZ:.T
MO-)MK;Q#XK2&/X<>$];\2-\.[N+5KV/3[FT\*VD$,.EZ=%''S8[AK 3KX#+\
MOI9[E><8S,Z&7K+.(<,HNK2Q'+&./HXRAAL/1C2I5'&-6C.$IN-2,Z52I&+<
MB-624I2=.<(P<N>D]FOLN+E)W>MG?IJD?J/^TE_P6<_X)>_LC_$'4OA1\?OV
MR?A;X-^).B7EMIWB+P5I,/BWXB>(/"VI75Q9VT>G>+M/^&?AKQC+X3U",W]K
M<W=CXC&EW5AIKOJU]#;Z7!<7D7UC^S5^UO\ LS_MB^!I/B3^R]\;_AY\;_!M
MM=1Z?J>J^ _$%KJD^@:E+%]HBTKQ1HS&'7?"NKRVV+F/2O$>FZ7J,EJR7*6Q
M@=)&_CK_ .".<O\ P;G?LW_L<?##Q#^U+\7?V,/C!^UM\8_"%C\0OCWKG[1>
MAZ)\6/$?A#Q'XYTXZC>?##2K'QQX1UJQ\*0^%=-U/_A'O%T.EQ-?^(O$B:_=
M:WJ^K6DNGV]C\Q:Q^T1^P3^P=_P78_8J^,G_  22^,_@'6OV<?VP/$/AKX)_
MM5? WX.:SJ\_P[\+W7CKQ[I'@:XOX?#\UJMMI>C!_%7A_P"(_A'PQI<36^B^
M)?!.N6N@1Z1HNKQZ5'ZM3@G UZF89=@*/$T,PP&'Q=6CF&89?&CD^95<#3E4
MKTJ48THU<%'$1IS>"JUL3B(U/<C44)3BG*KRM"4G2<9.*<8RO.'-HF]6I6;U
M22:\['^AU1117YB=04444 %%%% !1110 4444 %%%% !1110 4444 %?PJ_\
M$$?&&D?\$J?^"N?_  4+_P""4_QVO+7P)9_&/QGI6O\ [-VM>(3#I&B>*G\$
M:AXNU?X=Z;I&H73Q1M??%CX._$'3-9T>UFGN;<ZWX(E\)65POB6[CL-4_NJK
M\>?^"J?_  10_9+_ ."K>C^'=:^*1\1_"[X]^ =,_L?X>?M"?#<V<?C'2=$2
M\NM3@\)^*M*U!&TKQOX,M]8O;G6++2KYM/UO0M1N=0G\*>)O#HUOQ"FK_5<-
M9K@,+2S?)\WE6IY5GV%H4*^)P]/VU7!8O!UUB<!C51O%UZ="JYJM1A*-2=*I
M+D;:Y99582;A.%G.FVTF[*2DK2BWTNMGT:/V&K^9;]MG_@M;\;_"O_!7O]D[
M_@F5^P1X=^#/QMU7Q/K-KX?_ &K;CQ58^(?$<'P^NM<UVSO=:M]/UWP=XMT-
MO#OB'X+_  S\/>*/'7CFWO++Q%;QPZW::'=:4WB#3)K"U^7H?^"!W_!9_2?#
M!^"VB_\ !?7XP#X(E9]-6YN-*^+<'CB#03'=6L6G6C?\+?U#7+73&LI(K=O#
M=M\4(-&MK>1[.'S+:SMQ+^LO_!*C_@AO^RE_P2M/B'QYX,U/Q3\;?VE/'6ES
M:1XZ_:&^)B6:^()M,O;V+4M4T'P-X>LVN;/P/X>UG4;:UU+6XWU/Q%XGUV]M
MX?[=\6:G8V>F6.G^A0PO">24\9C*^;8;B;$RPV(HY9EN&P./H8=5Z]-TZ>,S
M"KC*6'5..&4G4CAZ+J5955!J<5'F(;K3<8J#I*Z<Y.46[)IN,>5N]]KM6M?0
M_$CX[:I9_LZ_\'B'P!^('Q8NF\,^"OVB/@GHOAKX<>)-4*VFB7>N>)_@/XQ^
M#7AW1XKZXE6"6ZUGXG^&%\*6UK;DW']M>(]'BDMUCO4N)/[5+N[M-/M+J_O[
MJWLK&RMYKN]O;N:.VM+2TMHVFN+JZN)F2&WM[>%'EFFE=(XHT:21E521^6W_
M  5/_P""2'[.'_!5KX7^&?"GQ;N]?^'OQ2^&=]=ZM\&_COX$6V_X3?X>7VHR
M6,NK:>UK=M'9>(_"FN2:9ITNK>'[V:UF6ZL+/4M$U;0]5@6_/X\ZY_P0>_X*
MV_%WPB?V<_V@_P#@NI\3O&'[*,UG;^'_ !!HF@_"[4;/XD^/?!<,=O!=^%_%
M&MW7CM-3N[;6+&)]/O?^$K\<?$+3'C<RZKHVOPR7%A->)JY'Q'@LBJXO.Z.2
MXS*,KP^38ZABL'CL0JV&P52H\/B\!+!T*\*M6I2K.%3#UY89JK"ZFZ;YP2J4
MI5$J;G&<W.+4HJSDDFI)M62:W5].G0\!_P"#9::/XX_\%*O^"X/[8G@A+B[^
M#'Q.^/\ XGF\#^)#;L-/U^/XI?'SXQ_%'2DL;N1H6FN-/\*+HU_?V\=J[00>
M(=*ENFM#<VL=UZ+_ ,&IW_)5O^"S_P#V>)H7_J2?'NOZ2/V$/V$/V>/^"<_[
M/'AO]FO]FOPW>:-X+T:\N]>U[7M>NX=5\:_$+QKJL-I!K?COQWKD%I80ZMXE
MU:&PL+0FTL-.TG2M)T[2] T#2]*T+2M-TVU^/_\ @E/_ ,$G/^'8_BO]L_Q/
M_P +]_X7=_PUY\8K#XL_8?\ A5G_  K;_A7OV+4O'NH?V!]I_P"%C^/O^$L\
MW_A./)_M7[/X:V?V7YG]FO\ ;=EITYKQ+EF8T>,U2G4H1S&APY@\GHUJ<Y5J
M^'R>O0ISG5G3A.E2J.A0^L256I!7G[.#G*-FH4I0=&^O+[1S::LG-7TV;5W;
M;S9^,_\ P<_?\GU_\&^?_9VGQ#_]7%^P[7]5W[3W_)M7[0W_ &0WXM?^H#X@
MK\X?^"G_ /P24_X>0_';_@GS\:_^%_\ _"F?^&$OBUXB^*7_  C7_"JO^%B?
M\+3_ +>\8_ [Q9_87]L_\+(\"_\ "#_9/^%,?V?_ &G_ &5XO\__ (23[5_9
M\/\ 8_V;5/U7^)_@O_A9'PT^(?P[_M+^QO\ A/? WBWP7_;'V/\ M'^RO^$I
MT#4-#_M+^S_M5C]N^P_;OM7V/[;9_:O*\C[5;[_.3Q<?F>"KY-P;A*5?FQ&4
MPS19A3]G6C]7>)SFKBZ*YY4U"KSX>4:G[F53EOR3Y9IQ-(QDIUFUI-QY=5K:
MFHOKIJK:V^X_F:_X,_O^43FN_P#9VGQB_P#4/^%%>#_\&K7Q1\$R?%[_ (*^
M_!4ZG:P?$:T_:^U;XHIHTTD$5]JO@G4?$_C_ ,)RZGIL)<7-[:Z!KNEPVFM2
M1HT&ES>)= 69TDU> /\ N/\ \$?O^"9__#J+]DV__9>_X77_ ,+Z^V_%KQC\
M4O\ A.?^%<?\*M\K_A+-'\*:3_87_",_\)Y\1=_]G_\ ",?:/[3_ .$@3[5]
MN\K^S[;[-YEQ_&K_ ,$@O^"9'B?]N#XX_P#!3/XV_ 3]JKXH?L8_M;?LW_M?
M:UIWPG^-'P_CDUO1KGPQ\1O$'QAC\9^#?''@\:KH4FLZ3JP\/Z>+>XM-:M8[
M82WR:QI/B6TDMK*T^Q=;*<\GXEXIYA]7RW&XC**V&S%X;$3IP<\SE]7J5L/[
M..*5&=3EIU>6C*M2A-U(TJC@H2PM.'U5<MY1C).-TMH)-)WM==+NSVNMS^CG
M_@ZR^+G@SX??\$<?C9X"\0ZAI\/B;X[_ !!^!OP_\ :;<7D,.HW^L>&?B]X-
M^+VM7&G631RSWD=AX5^&^M"^DC\B&T2\@,]TKS6]K>?AM_P6I^&WBKX0?\$@
M?^#?7X;>.+"32/&/A+6/@GIWB;1YXY8;K1=:?X.>%KS4-%OHIDCDBU'1[BY?
M3-1B*[8[ZUN$1GC"NW[$?!O_ (-[/BG\6?VA_AU^T_\ \%=OV[_&O_!0/Q3\
M&]1MM0^%GP<7PNG@KX*:)>:??PZG;W7B#26OI;37-.OM1M=.U'6/#&@^$_!5
MCKMSH^GVGC'4?&6A>9HP^^?^"OO_  2<_P"'K/A3]G#PQ_POW_A0W_#/WQB;
MXL_;O^%6?\+1_P"$MW:;#I_]@?9O^%C_  Z_L''D^=_:OVC6OO>7_9O&\\N4
M9WD605^',LAF4<9AL#FN99QFV:4L-C%A8XG%Y8LOH8?"4JE".,K4Z<*<55JO
M#04JDTX1Y%*2<Z=2I[2;ARN480A!N-[*:DVVGRJ_17OH?C7_ ,'FG@K6M5_8
MS_9+\>#1-5U3P/X(_:?GTSQQ>:0RQW.E0^+_ (>Z\-*:2Y>TOH--CU$^']1T
MZVU6]M)K"WU>?2[2:.>?4+6UN/H7X7?\&Y?[&GQF^&W@+XN?#;_@IA_P5J\4
M?#_XF>$/#WCKP9XBTS]K_P"'=U8ZSX9\4Z5:ZSHVH6\]O\!)H66XL;R%V5)7
M\N0O$QWHP']#_P"TY^S1\&?VPO@5\1?V</V@/!]KXY^$_P 4-$&B^)M"N)9;
M6X1K>[MM3T?6]&U*W*W>C^(_#>MV.G:_X=UFS=+K2M9TZRO826AVM_,UX+_X
M(!?\%-?V1["^^$7_  3[_P""TWQ(^%/[,%_J6IWNC_#;XE?#6#Q)KWP\M=9O
M5N-2MO#>HVFK7N@2WUW,UUK%YJG@_0_A+!>ZS=W5PVD6]Y>7NJW/+DW$$9\.
MX+)Z6?QX<QV68O&U(U<1AJ^(P6883&RI5FI5,-A<95H8G"U:<^2,J,:=6G42
M]HYVC%SIVJ2FZ?M8S44TFE*+CIHFTFFGWNFNQSW[,W_!.3_@CE^R]_P61^#_
M ,.M&_;O_;O^-'_!1[X/V-WXH\(?#+XQ^*K#XN^&9]-U#X5^.-;O='\9^._"
M_P"S'9Z5X<AT'P#J.J>*!HNO_$_P5+#<ZQX=2R%_>:W%I=YR_P#P44N;>U_X
M.WO^"3$MS/#;1M^RCH%LLD\J0HUQ>>)OVZ+2T@5Y&53-=7<\-M;1 EY[B:*&
M)6DD13^N/_!*K_@B-\&O^":GB7XB?'/Q)\4_&O[5O[8OQACO;?XC_M+_ !0M
M&L]:ET_5M0@UC7M+\)Z)=:WXJU#1H_$VL6MIJGBK6=<\6>*O$OB"[LK-9M9M
MM.A&FUP7_!8#_@B1J/\ P4G^*WP _:9^#'[57C']D?\ :>_9TT\Z%X/^(6@:
M+JFOVEUHL7B-_$^C36,VA>,/!/B'P9XI\+ZSJ&N:AI?B;1-4O&OH]1?2M1TT
MI'9:CIV]+B#*I\12^M9WC\7@:G#6.R&6<X[#R<(XG&82O"5?#8+#X>&)H9<J
M]7]U1J0JXB+E.I4DHRY8'LYJFK4XQDJL:BIQ?12CHY-V<K*[::71:GYP_P#!
MWU_R2G_@G%_V>(__ *C=E7FO_!P;J-M\!?\ @MQ_P1._:O\ B7/)H/P,TCQ;
MX(\,>(/&EX!!H'AJ?P-\>[#7O%^I:MJ,TB6EG;Z/X<^(FD:]?B4Q3-I.FW\]
MN+HVLD</Z0?M,_\ !"KXT?MC_L8?L/?LW_M"_P#!077_ !K\7_V2_BYXM^+7
MC#]HGQ1\&]5\?:]\9IO$GB?Q!K>E^'+_ $W6_C=I6I:&OA31-7TWPC8:]<>)
M->%WIF@64D6@:3"Z:=:_JG_P4+_X)Y_LZ_\ !2_]G?6?V=OVC-#OI]&DOH_$
M?@CQKX<G@L/&_P ,?'5G97ECIGC/P=J-S;W=JE];VM_>V.H:9J=G?Z+KFE7E
MWIVJ6$\<D4D$9?Q%D^4T^&<++%2QU# 2XLR_,YX6A7ISC@LXJ0H8?&8=8JE1
MYW.E_M4:7\6,8NE6C3J240E3G+VKMRN7L913:?O02;B[-[/2^W571]RHZ2(D
MD;K)'(JNCHP9'1@&5T925964@JP)!!!!(-?Q2?L+:C8_M+?\'<7_  4*^.OP
MNG_M[X:?"/X0W_@WQ+XIT\)>:(OBCP1\-/@%^SGJ.CKJ:R16_P!HN_&WA/Q<
M^FBW^UF]M/#>IS6R36EO/?0_0FD_\$(O^"O7@KP7#^S5\._^"[WQ,T#]E*VT
MU_#.DV<OPJU<_%+PUX)9)[2W\*Z-K-O\15U^WL=,TF2+2K*'1_B?X<TN.U18
M;#2-(L(+;3XOVI_X)A?\$J?V9?\ @E1\'=:^&?P$M]>\1^*?'FI6.O\ Q<^,
M7CJ:QO/B!\2];TR&ZATE-2FTZTLM/TCPQX<CU#4H?"OA72K:.QTE=2U._NY]
M6\0ZSKFNZIYM"KDO#F7YZ\)G='.L=G.6SRC"4L)@\=AZ=#"8G$8>MB,5C98V
MA05.M[/#QA2P]!XAQJ2?//D]Y4U4JRIW@Z<824VY2BVY)-*,>5O35W;LK>9^
M#_\ P2F_Y6<O^"TW_9/;[_U._@G7Z3?\'.G_ "@Z_;=_[ML_]:\^ 5>Q?LI_
M\$G/^&8_^"G/[:?_  4<_P"%^_\ ";_\-?\ AZ?0?^%-_P#"K/\ A&O^%>>=
MKO@G6_M?_"P_^%CZ_P#\);M_X0[[-Y'_  @_AG=_:/G></L?E77TG_P4Z_8A
M_P"'CO[#OQN_8R_X6=_PIO\ X7)_PK7_ (N1_P (7_PL/_A'/^%>?%[P!\5?
M^1/_ .$L\#?VQ_:__"#?V#_R-.E_V?\ VI_:G^F_8O[.NWB<ZRRIQ;PQF<,3
M? Y=#A-8RO['$+V+RRG@8XY>R=)5JGL'1J+]U3G[3E_<^T3C<C3FJ-:+7O2=
M;E5UKS7Y=;V5[]6K=;'GW_!%_P#Y1.?\$\?^S2_@S_ZA^G5];_M8>"-?^)O[
M+/[2OPW\*123^*?B#\ /C)X(\-0PC,LVO^+/AUXCT'1XH@'B)DDU&_MD0"2/
MYB/G3[PP_P!B_P#9R_X9"_9-_9X_9>_X3'_A87_"A/A+X,^%O_"<_P#"/?\
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M_P >?LW?\+U_X:#_ .$V^/?BCXW_ /"9_P#"L?\ A5']F?\ "2?#WX6^ _\
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M%% !1110 4444 %?EY_P6R_Y1&_\%&?^S1/C5_ZAVHU^H=?EY_P6R_Y1&_\
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MUN9-1\/WL\":=XDU6)K*6UDDFBG>6VA /\F?_@B;_P I<O\ @G-_V=W\%?\
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MX9\-6M_XFN/#_B[PYXLO;;5K_0-*U[4[/4O#/AJ&/1WL[O4+VS\3_P"#D_\
MX*S?!_\ X*H_M;_#/4_V;SXBO?V?_P!GWX97?@GPEXH\4:)>>&]1\<^,/%FO
M2^(/''BW3_#^IB'5]&\.R6EIX1\/:59Z[8V&M33^'-1U2[M;>WU*RM+8 _<W
M_@VS^'VH^-?^#>W_ (+):(]E?RZ9\1&_:V^'UB^E26SZG>:C<?L1^$[34K+3
M;=ENI4OXK?Q5I)LY+BQDMI[B\C2%;IH+J&/^:S_@W3U*TTK_ (+5?L!W5Z[)
M#+\4_$VFHR(TA-WK/PH^(.CV"%4!(62^OK>-W/RQ(S2.0B,1_I"?\$ _V$M4
M_8^_X)%? WX%_&+PY-9>./B_H?C'XM_&;PCJD L;FPO?C;++=V_A'5K>UD6[
MM-3T;X:GPEX9\0P3W1O[;6K#4X2UD(X;*S_S#_&O@SXP_P#!%[_@JW967B#P
M_JK>-?V*OVHO#7C;P]:ZOG3D^)OP^\(>,;+Q/X2U:&]6TBCD\._%OX=K93+?
MVMK&%T[Q%/'Y%K=P2VT !_KN?\%,]?\ ^$4_X)O?\%!/%'V3[?\ \(W^Q%^U
M=K_V'S_LOVW^Q_@/X]U'[)]J\FY^S?:?LWD^?]GG\G?YGDR[=C?Y5_\ P;6Z
M3J&M?\%O/V"[/3+?[3<P^,_BGJTD?FP0[=/T']G[XM:[JUQON)(HS]DTK3KR
MZ\I6,\_D^1;1S7,D4+_T]_\ !9K_ (.>OV!OVD_^"9GQ8^ 7[(GB#XC>+_CE
M^T]X.TWX>ZWX=\3?#CQ+X,M_@[X1UW4[&X^(9\::SK5O;^'M?U>Z\*V>J^%=
M)L_A]KGBS3SJ>OVNJW.I_P!GZ;<V]S\ ?\&8?[%OBGX@_MA?&#]N+6=)N[?X
M9?L^?#G6OA7X2UJ2WA6TUCXS?%./3$OK#3[J8L\S>%?AC'KLVOP6<2S6C>-_
M"CW%W#;WWV6_ -C_ (/"_P#@I]XY^)'[2,/_  3!\$'5?#'PJ_9W_P"$&^('
MQKE2ZDMO^%J?%;QYX#T'Q_X(T^YA@D*7?@SX=^!?&.CW^G6]PX34/&_B'5[N
M_P!/:7PCX8U!?K3_ ((8_P#!6#_@A!_P2>_8WT+X=:E\?O%NJ_M)_%5=*\=_
MM.>.]-_9]^-%]#J7C?[)*FE^ _#VIMX'AFF\#?#&PO;C0=!X2#5M7N/$WC%;
M:QF\536-K^C?_!3'_@U8^'G_  4B_;<^-?[:.N_ME^,_A1JOQF_X5O\ :O &
MD_!C0_%FGZ!_PKOX2> OA1!]G\07GQ#T*YO_ .U+;P+#K4OF:5:_99]1DLD\
M^.V6YF^$?^('7X3?])#_ (B?^([>&O\ Y[5 '\4_@WXX?#K1O^"E_A3]I*_U
M:[C^$NE?MT:'\<+W7$TK49;Y/AU8_'VU\>W&K)H:6YU:2[7PU$]XNE):'47F
M LUMS<D1U_L!?\$_O^"I7[&G_!3K1OB;K_['WC_Q!X\TSX0ZGX8T?QU-KW@#
MQEX#?3;_ ,86NM7NA16T/B_2-)EU);FWT#4WEEL5GCMC"B3LC31AO\<'PS^S
MA8Z_^W#X>_9$D\5W=MINM_M6:3^S@_CA-)ADOK>QU+XNV_PQ;Q6FA-?+;R7<
M5O,=7723J:PM,HLS?!#]H'^LA_P18_X(L>%?^"-OA7X_>%_"_P ?O$'QXC^/
M'B#X?Z]>7FO?#_3O 3^&W\!:=XJT^&VMH=/\5>*%U)=27Q1)++++)9FV-FB(
MDPF9HP#]O**** "BBB@ HHHH **** "BBB@ HHHH **** "OR\_X+9?\HC?^
M"C/_ &:)\:O_ %#M1K]0Z_+S_@ME_P HC?\ @HS_ -FB?&K_ -0[4: /\V[_
M ((M?\$._P!HO_@JW\+/C1\1O@K^U?H/[/&D_"KX@:'X*UK1=6LO'5U-XBU'
M5O#@UV'5(F\)ZIIULD=K;,+0B[66<MDHRQ@ _M&__!FI^W#J:/INM_\ !3+P
M5/HVH*UCJ\#^&?B[JB3:9=@P7\3Z9=^++:TU%9+225&L;JYM[>[!-O-/%'(T
MB_7O_!D1_P FF_MM?]G$>!O_ %6L5?VZ4 ?QV_L!_P#!G7^R'^S9\0O"_P 6
M?VL?C/XB_;%U_P ):C9Z]HOPU'@BU^%7P4.M6,L%W8-XPT!/$_C7Q1\0;+2[
MZ!+B/3+SQ+X>\,ZXJ_8_%'A76-(FNM*N/W _X+3?ML1?\$^?^":/[3G[0.D:
MHVB_$&'P-/\ #3X*/9F2*\B^+WQ-#>#? VH:<+=HMK>#[G49_'=RHGML:5X3
MOQ#*+CR(Y/U2K_/'_P"#QK]J?Q1\=_VG?V0?^"7WP?2]\2ZQX=N=$^)WBWPM
MI+3R2^(?C;\9[V3X??!?PB;1_+B?7M$\*7&L:A921+-'+:?%VUA6X2:.Z@0
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M*\,?%GP_:$S21-=^(/!=OX1\36EO';VZ16GP_P#$=S-<32W$$0_I$_X.CO\
ME!1^W-_W;-_ZV'^S[7\?/_!<#X?^*_\ @C!_P< ?##]NKX+Z%_9/@+XE>+_"
M'[6'A/2=(M[?3M(U*]>^;PA^TQ\+!]D>S6./QFP\2W.LPPBQ%MX?^+EE;070
ME1KE/ZS_ /@Y!^(W@WXP_P#!O#^U1\6?AWK5MXD\ ?$[P9^Q_P#$#P3XAM-P
MM=;\)^,?VJ?V</$/A[58%<+(D=_I.H6ETL<BK+&)=DBJZLH /Y@_^"!?_!N;
M^Q)_P5/_ &&-3_:;_:#^*7[5'@[QY9?'7X@?#&+2/@WXW^$GA[PBV@>%- \#
MZKIUW)8>-O@?\0]9.KS7'B:_2]N%U]+*2&&T6#3[9XYI+CW?_@I1_P &;D'P
M@^!WC'XQ?\$\_C3\5_C'XM^'VF:KXDU+X ?&+3_"6L>-/'OAW3Q]KNK7X<^,
M? F@^"K&[\:Z9ID-S-9>$K_P:[>-KE18:+J6F:P=/T?5_P!@?^#-[_E$;KW_
M &=W\9O_ %#OA+7]7- '^=W_ ,&H7C3_ ()#_$SXIZ5\*?'/[)/@SP+_ ,%(
MO!6E-XF^&_Q2^(GBSQ)\1]"^*Z^$[1[C6]7^$OAGQ]JVH>'_ (8?%[PO:Q77
MB?4M&\.Z,^NW.C0ZSXF\,:[!I/A[4]'\.?Z(E?YI7_!SM_P36\<?\$Y/VS/A
MW_P54_8Y_M/X>> OBU\4].\7:WJG@J)--'P._:QT>Z;Q9#K=B+18X[+0_BX=
M,O\ QA8QM%<6B^,=+\=V&H-;Z?K/AW3)_P"WO_@D3_P4F\!?\%3/V*/AQ^TK
MX;72M$^("1MX)^/'P[T^\6=_AW\8/#UO;IXDTM(&N+F\@\.^(89K/QEX(EO9
M9;NX\(>(-'6^D_M:WU*"W /\[3_@J7^S-XO_ &R?^#G/X^?LP> ?'=I\,O&/
MQF^/OP]\(Z!X^OH]4EM/"]])\ _ >H#4YHM%FM]4=4BL98@ME/%,6E7YPNZO
MU6_X@XOV]/\ I)OX,_\ !/\ &7_YIJ^=_'G_ "NDV/\ V=W\./\ UFWPO7^E
MO0!_ A\+O^#)37-<\76WB/\ :C_X*'WOB'3))(&\0:9\+OA#>3>+M;A@#6D4
M%M\1?B'X[U.WTF2'3[>Q2"ZO? /B-8QNLULU@M(9[C^S;]B/]AO]FW_@GG\
M_#O[-_[+?@1?!'P[T.[NM9U&>\OKC6O%7C7Q=J<-K#K?C?QQXCO/]+U_Q1K2
MV5I'<7)2UT[3K"ST_0O#^F:-X<TK2='L?KFB@ K^4;_@\A_Y1&Z#_P!G=_!G
M_P!0[XM5_5S7\HW_  >0_P#*(W0?^SN_@S_ZAWQ:H ^__P#@W!_Y0F_L#_\
M9._'?_JZOB;7[=5^(O\ P;@_\H3?V!_^R=^._P#U=7Q-K]NJ "BBB@ HHHH
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M>!/A5K'A2P_8NO8?$H^-OBZTO/V>OC)\.W\0Z/')\+[?6SIUM8>,KWQG*8?
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M.6VNS:/!J+Z6VMZU%H\NI0Z:VLZBZ)=W']L=?P!_\$"_^5IK_@M1_P!Y&_\
MUXI\&Z /5=-_X/1?$]I-->>/?^"1OQ5\*>&+.VDN=1US3?VB]0UN:QAB:,RS
M36FL_LO>#M/2VCM_/EDN)]<MU1HXT8!)7FA_HK_X)3?\%K?V._\ @K?X7\3-
M\"KWQ)X$^+W@"PMM4^(?P&^)D6D6'C_0]%N;J+3X_%VA2:/J>J:1XR\#/JD\
M&FOXBT:Z%SI-[>Z5:>*M'\-WNMZ-:W_Z].B2(\<B+)'(K(Z.H9'1@59'5@59
M64D,I!!!(((-?Y\O[,7@[P-:?\'D_CQ?V"H_#Z_!+P[:?$76OV@(_AQ%:2_"
M[16U']F+^S?C#IZQ^&3::=!:-^T9J^@6UQ;"6:STSXR7.R2)[73_ .SHP#_0
M<HK\>O\ @LO_ ,%<O#?_  1\^!OPL^-GB;X(:Y\=+3XG_%<?"RW\/Z%XXL/
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M(N9=.UFTCNK>6/3==TK7-$TK])Z "BBB@ HHHH **** "BBB@ HHHH ****
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M_->BBBO]PSR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX4_MOQ%X;_MW0;N2&6XL/[=\):OH/B73/,D@B;[5HVL:?>ILPEPJLP/-'/\
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MDFD^'?$OBF[\2:MJ7Q ATU)9+33=3^(#^*->TO3V&GZ9JUG9QQP)]O?L5_\
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MX)T^XBG>:*.X\+-KMCIOB:P576"32_&J>)M,NH(D%Y:7$ADED_7O]H3]DO\
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MX$4L<AAF?8Z-AA\O?M?_ + G[)7[>FD_#C0_VL/A/_PM;2_A)XQ/C_X>VO\
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MX1/B#Q7J_@[^UV^&7BG2;BZN/$_A:Y\)Z8->TZRL]8T2YO\ Z"_X*&_M.?\
M!'O]E;]I#]G7]D']DO\ X)'_ /!.?]OC]ICXU>,XO#'B'X6_#SX._LX^&K7X
M?1:S]GTWPI!KWC?0/@/\4;'3O$>K:O?#5KW1+G0YI-!\&:+JVO\ B)]$LKW1
M;R[_ &(_;2_X(4?\$Q/V\_&U]\4_CI^SG8V7Q;U::.?7?BE\+?$OB3X7^+O$
M\B)%$\_C!/"FHV7AOQGJ4T%O:VK>(/%?A[6?$EO9VL%G9:Q:VJM$W??L.?\
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M*/!'[3&K?%?PE+\&/%NN^*O _C3X+Z]X,\.>-;./Q3H\&D>*/"]S?^.OA_\
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M/!WP*^'^OVWBWPO'J&OZ=HVHVWB2*S&F>)]=M-1T[4/.LY++]KZ* /PZU?\
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MSY8!)INCH]E922&:>VMIYX(YRDTN_P#NKK^'K_@UY_Y2F_\ !>O_ ++O=?\
MK17[1M?W"T %%%% !1110 4444 %%%% !1110 4444 %%%% !7^7[\2]9NO$
M7Q'^('B"^DDEOM=\;>*]9O)9?];)=:IKM_?7$DG_ $T>:=V?_:)K_4"K_,\_
M:A\ W?PM_:2^/?PYO8)+>;P7\8?B-X>C212OF6>F^+-5@TZZCZ;K>]T];6\M
MI!\LMO/%(ORN*_TD_9U8C"QSOQ3PDW'Z[7ROA3$8>+MSO"X7%YY2QCBM^55<
M9@5.VEY0OJXG!CD[4WTO-/U?+;\F>%4445_J8><%%%% !1110 4444 %%%%
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MC>6UUBI910Q45.WVEA,3A=]>7E6UCUL)?V$?\4K>E_\ .X4445_)!U!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW\1_V?/C?#XJUZZU+PEH-H]UXKOO#?@?QQX\^+/@WQQ-#I,-UJ&KV&D+\/\
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MCLC>SVD,%]H'C?1-#U*&4WU@'2"6VEOK:WN)Y!](_LP_\FU?L\_]D-^$O_J
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M7OAG\&+WQ9&4"VUSX:UNVN+@QI<7#K_0!_P;8>(?#'B#_@BQ^Q6GAB[L;A-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M48U(TJ4:LU4JQIPC5J*/*IU%%*<U&[Y5*2<E&[LG:Y_&]_P=O_$;6O$'AO\
M85_9.\)^;J>M_$SXG^-?B--X>MY0KW&M:#8:!\-OAYOB9E1I=4N_B7XSL;&5
MAB(V]XI9!*=WI5E_P:'?L;BSM!J/[37[3+:@+: 7S61^%B6;7GE)]I:T2?X?
MR3I;&?>8%F=Y5BV"1V<$GX2_X*K_ !R^#_CO_@Y(_9BTKXT?$+P]X&^#/[(L
MG[/\'COQ-XJNA9^$=)NO!W]K?M/7=O?7 $\5S)K=UXH\.^$[I4C:2XOS!H4L
M1GM60?T^7'_!;#_@E+;03W,G[<OP/:.WADGD6WUC5KN=DB1I&6"UM='FNKF8
MJI$=O;0RSS/MCACDD95/V56KF^797DN'RR.+BZF%JXS$3P]"513>*K<]&,VJ
M<TG"FDDM':2O=-'R=.EE>.S/.*^8RPTE3Q%+"T(5ZT:?(L-24*KBG.#:E/=Z
MJZ:75'\Q?_!0#_@B#\5?^"2_[/6M?MM_L.?MO?'FVF^!_B3PWK'B?PE>W4?A
M35+;PUXB\6:7X>@US2]8\(:KI>CZW_9>L:MHL7B?POK7A*XTKQ)H=UJMW=-%
M;6,FBZE_5Y_P2T_:XUG]N?\ 8'_9R_::\4VMA8^-O'GA/5-+\?VVFI#!9-X]
M^'_BO7_AUXNU.TT^!Y%TFP\1:YX5O/$VE:0SL^G:3K-A;>9,B)-)_+[_ ,%G
MO^"RG@O_ (*+^"=%_P"":_\ P36\/^,_V@M3^.?B_P +6?CGQMHWA3Q-H4?B
M*/PUXBT[Q-H?@/P'H/B+3M$\07D$WB/1=/USQCXSUVPT3PSH^@Z$WDSZII&I
M:EK.B_IW^T-^T#8_\&]O_!&_X _"+09-%\8?M$P^&IOAM\-=.NA+>>'+KXR>
M,;O7?B7\6?'UY;231W=[X$\$>)?$VOZG:VH:-M5N[[PCH%Q_9UOK,]U83CZ&
M/QV79;0Q]-2SK%YA-855*<*6)^H>RM-XE1C&48JO:2=6*DH1<MDRL%6P6#Q^
M85L%-QRC#8&+Q,H3G5P_UU5$XK#N4I*4W1]UJG)IR<8VNT?T?7=[9V$/VF^N
M[:RM_.MK?S[N>*VA\^\N8K.T@\V9T3SKJ[G@M;:/=OGN9HH(E:61%:S7\A7[
M,G_! 'QK^W;X \/?M4?\%=_VF?VCOB%\:_BMI=MXTT/X6>&O&>EZ+IGPL\-^
M)K.VU'2M$U?_ (2#PQXCM]*US[!):37G@[P1I7@_PYX/F_XD31:Q/:2S1\#\
M*;;XX_\ !!C_ (*H?LR?L;6WQV^('QI_X)]?MK7NC^$?A[X:^)^J#4=2^''B
MWQ)KUEX!T^6S:TL+?1=$U_POXWU#PB^O:CX5TCP[X7\3>!O%,7]LZ/9:MI%K
MJ.D>5_8^%J.O0PF9PQ6.P]*K5E06&G3H5O81<JT,-B95'[64(QDX\U&G&HHM
MQ=M7Z:S7$TU1KXK+I8;!UZE*G&L\1"=:E[:2C2GB,.H+V<92E%2Y:M25-NTH
MWT/[,Z*_F;_X.I/C]JGPE_X)Y^#OAWX:U6^TKQ%\<_C[X/T">YTV_N],O(/"
M/@;1]?\ 'NLW5O=64L4QD7Q)I'@FQ>W9A%);:C<RLX>"-)/$_P!F[_@DS^T)
M_P %,?V4_P!G_P 0?M^_M(_'#X%_L]:=\&OAWX>^ 7[&O[/^N:5X;DT;X<Z%
MX1T;3/"WQ!^.WBCQGX7\3V?CSXK>/+.RB\7ZZVO>#+S4],DUF86^H^'9-2OO
M"FB94<IIRP%',<5C882A6KU:*BZ,JM62I*/O4H0FG4DY.2<7[.$(P<I5>:4(
M2TJYG46.K8##8.>)K4J-*JY*K&E3BZCEI5G*+5.,8J+37/.;FE&E:,I+^LFU
MNK6^M;:]LKF"\L[R"&ZM+NUFCN+6ZM;B-9H+FVN(6>*>">)TEAFB=HY8V5T9
ME8$SU_#_ /\ !.CP'XS_ ."8O_!P?KG_  39^!GQ?^(GQ _9>\=>$=9O_%GA
MKQOJ-AJ$NFI)^SE>_'+POK>OV&BV.G>&X/&NA>(K73/#B>*M'T'PS/JWA_Q$
MT,UC#;ZD+1OT/_X+7_\ !2;]I/1_C]\%?^"5_P#P3PU-M)_:O^/\NB'QS\1;
M&:.WU'X;>'/%AO(]"T31=6,-VWA;6+G1K+4O'?C+QBEH^H>"? 5C8:GH@;4-
M9^W:-I4R*K]>P^%PV(IUJ6*P5/,88JI%X>%/!S4Y2K8B#<W2]FH2YDI2O>-M
M9644\ZI_4Z^)Q%"=*KAL7/ SPU.4:\ZF*BXQ5*A)*"J\[FK.T;6E?2+9_30]
M[9Q75O8R7=M'?7<-S<6EF\\275U!9-;K>3V]NSB::&T:[M%N9(T9(&N;<2LA
MFC#6:_E=T'_@U6_9J\0^"SKWQW_:I_:I^(?[4.LVEIJOB'XW:=XP\.PZ?:^.
M(%AN%U+1]$\3^%/$GB?4=,M;V)8S)XA\;7>NWULAGM=3T"[DA^PW_P#@B#^U
M#^U)X/\ VE?VR?\ @D'^UM\5=6^*'Q%_9@TG5M>^#7Q@U>ZO-5\22^ M&U;0
M/"US;G4->2\O]9TE[#QQ\//&W@6R\1ZA>:SHFF:EK&ASRW^C:=96^BYU,KPL
M\/B:^ S%8R6#C&IB*4\+4PS]C*<:;K4&ZE7VM.$Y+GYHTIJ/O<NJ1=/,<3"O
MAZ..P/U18N4H4*D,3#$+VJ@ZBHUDJ=/V<Y1C+EY74BY)QYM.8Z;_ (+\_MV?
MM*_"OXK_ +%7[!'[)_Q%O?A9XX_;*\5IX;^(7C?PI;VW_"S-'\-^,/'O@SX9
M>!;#P'K;S/=>$[G7=9UCQC)?:[IEK9>(5FT+2HO#VOZ9C5EF_IBL+&VTRQLM
M-LUD2TT^TMK&U26>XNI4MK2%((%DN;J6>ZN9%BC4//<S37$S R32R2,SG_.
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M1K4HR4XPEAW2KQCSJ,5/V;G4@I))--V5F?UQ4445\\>Z%%%% !1110 4444
M%%%% !1110 4444 %>._M ? 'X0_M3?!GXA?L^?'OP;;?$'X/_%307\->//!
MUUJFO:'%KFCO=6U\L"ZUX7U30_$>DW,%]9VE[9ZEHFL:;J=C=VT%S9WD$\2.
M/8J* /DK]C+]A;]E3_@GO\)M0^!O['WPFM/@[\+]7\:ZQ\1=5\-V_BOQWXUF
MU+QKKVE:#H>J^(+_ ,0_$?Q1XP\3W=W<Z/X7\/:8D<^M26EK8Z196UG;V\46
MT^/?M-_\$F/^">W[9'[0OPS_ &JOVD_V=-,^)OQX^$%AX.TOP#XWNO'_ ,6?
M#<.FZ;X!\8ZKX]\)V.K>$/!OCWP[X'\76FE^*=;U2_:#QCX:U^/4;:\DT?55
MOM$6/3D_1:B@ KX1_9A_X)G?L1_L:?&3XX_M ?LV_!3_ (5Q\7/VD=1U+5OC
M1XM_X61\6_&'_"9ZAJWBG4O&NH7']@^/?'OBCPSX=^T>)M7U#4_*\*:+H4$7
MVC['!'%I\4%I%]W44 ?FY^WI_P $D/V ?^"EMQX1U;]K[X#6'Q \6^ K"71_
M"/C[1/%'C#X?^.])T&>]EU&7PY+XF\#:[H%]KGAL7UU?7EIH'B,ZQI.EW^IZ
MIJ6D6FGZEJ-W>2MM?^"1W[ T?["FE?\ !-C4O@SJNO\ ['&D:JVNVGPJUCXM
M?&,W*ZN_Q!N_BI)=IXZTWQ[IOC^SCD\?W][XD?3=-\36.D-=75S!_9_V*XGM
MI/TEHH \B^ GP'^%/[,/P<^'GP ^!OA7_A!_A'\*?#MMX3\ ^$O[<\2>)?[!
MT"TDFFM[#^WO%^L>(/$VJ>7)<2M]JUK6=1O7WX>Y954+\W?M9_\ !,[]B/\
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M$?B/Q8U[_8WC[QSXI\/^&L^(/%OB'4/LWA#2M M!_:'V46XLK2QMK;[AHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OXN_\ @X _9?O?AC^TWHO[
M1.B:<5\%?M Z+:Q:Q=P1L+?3_B=X*TZST;5K6X"*8+7^W?"\'AW6;)G9)=4U
M"#Q1.L;M97,S_P!HE?,'[8?[+'@3]LCX!^,_@;X[ LXM<@34O"GB:.V2ZO\
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MI2JTY1G"<6TXM,\9IIM---.S3W3"BBBNT04444 %%%% !1110 4444 %%%%
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MI,%K<3^:EQN;QW]C#_@A1^TK^WWX)_9>_P""F7[6G_!0[XZ>#?C5\2[7X/\
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M*/LW.M.G3BYQITXJI.[5&/-&3<Y2B]'*3>ZM:VUN]DF^K=D?@K^Q1_P2W_:
M_9O_ ."P_P#P4(_X*#>./&'P=U7X,_M8^%KG0_AUX9\*>(/&M]\3M%NYO$OP
M[UE9/&NBZO\ #[0O"NG6XM?"6I1L^A>-/$<HGGL5$)CDGEMOSAN/^".?_!5[
M_@FQ^V-^T?\ M(?\$<OC!^SQXF^#O[5&NW7B'QW^S[^T2NKZ>WA^^EUW7?$6
MB::'CM'LO$NG^ M3\6>*U\$>*+;QIX5\16>B:]=Z!KFB^(,W>KZI_81111XN
MS:E6K59QP6*I8G+\#EF*P6+PD*^"Q6%RV%.&#5:A)INK0]E&<*U.<*D:EY*2
MYFFG0@TDN9-2E-24K24I/WK/:SZIJUC^/_\ :N_X(H?\%<?^"J'P:\57G_!1
M']M#X$Z#\0/!WA^?4/V8/V9O@#I/B7P_^SAH7Q2N6@A;QS\;_&=WX2U/QEJ]
MX-$?5O#\-KH_A_QO-HB:F;_P_P"(;6TEUS0->_<']D7]B+XC>"_^"3W@C_@G
MI^T]K?@*[\6V_P"S!XV_9<\>>(_A/?:IXO\ !EQX3U[0/%'P^TG5M"D\;^"O
M M]J5PO@/5-*EU+3M;\)VUL-:COK&2;5[)1J=[^G]%98[BC-,=A,/@)K!X?"
M8/&QQV"H8+!T<+#!UHP<+4%2BO<DY.K4]K[2I4J_O)U&QQI0BW+WG)QY9.4G
M)R6F[?I96LDM$C^4?_@C3_P3'_X+0?\ !,OXS>$?@/XT_:'_ &9O''_!-;0/
M%_Q0\7^)O"WAP3R?$/Q!>>*_ NLVGAN\\,G6_@[#XKT"Z;X@-X/\0>)/#<_Q
M!@T&S32?$*:7K.J17GE>(OL[]BC_ ();_M ?LW_\%A_^"A'_  4&\<>,/@[J
MOP9_:Q\+7.A_#KPSX4\0>-;[XG:+=S>)?AWK*R>-=%U?X?:%X5TZW%KX2U*-
MGT+QIXCE$\]BHA,<D\MM^]5%7C>*\SQU?,<14I8"C5S; 1R_,)87!T\/]:@L
M5#%RQ%10:3QE2M3A[3$6YIPBH-62L1HPBHJ\FH2YHWDW9VM;7HELMM6?S#?M
MQ?\ !$S]J7PY^W'J_P#P4Z_X)!_M$>#OV=?VF_'5O>)\<?A7\4X;\_"+XNRZ
M@^D-X@N6GTWP[XK@BC\9'1[/5/%?A7Q#X9OM+U/QI9V7C?2?$GA'Q%%_:"?.
M'Q9_X)<_\%X_^"KL?ACX2?\ !3K]J/\ 9T_9T_9'T;Q#H_B#QM\+_P!EK3[S
M5O&/Q,O=$N[6[LC>07.FS:/-Y/DSSZ5>>*/'FJ^'_#/B$Z=XDC^&'B&\TVS^
MR?V$45OA^,\WP]/"_N\LKXS 488? 9IBLNPV(S/!T:::HPHXJI%\WL$VJ$ZT
M*M2BG[DXZ63H0;>LE&3O*"DU"3=KW7G;6UKGYE_M<?L 6?CK_@E?\5O^"<_[
M*=IX,^'%AJ/[/5M\#/@];^-M4UZU\(Z!:Z7%I=MIL_BO7='T/Q7XEN&GBL);
MO6M;CT36]8U75;FYU&]CNKN[N)SU7_!*;]DWXB_L,?\ !/K]FK]E#XM:UX*\
M1?$3X-^%O$FB>)]9^'6HZ[JW@N_N]8^('B[Q7;2:#J/B7PYX1URZMX].U^SA
MG?4/#FER+>Q7,<<4L"17,WZ%45XD\VQM7+JF65*BJ8:KF3S:I*:YJ\\:Z$\/
M*I*LVY24J<Y.2=^:;YF[E\D5)32LU#D5ME&Z=K;:-:'X%_M4?\$L/V@_CC_P
M7-_8?_X*:^$_&/P;T_X#?LT_ ZQ^&GCKPEXB\0^-K3XN:MKMMJ?[2E[)=^$M
M!TWX>:MX-O\ 2#%\8_#"I/K'CW0;PR6.O!K!5M=/?5/%O^#G2]_;D^'/[(WP
M]_:-_8Y_:FU7]G#2O@GXMO;3XKZ'X2^('CSP=\1OC-=_%;Q#\.O 'PM\&?#O
M1/!?AK68?&_B&Q\1WVJZA/I.M:KX>BTW1Y=2U:UN+J.WOD@_I=KYX^.G[*7P
M!_:7UWX+>(?CG\.]/^(MY^SY\2K7XO?"JSUS4-:.@:#\1-/T^ZT[2O$U_P"&
M;74K?P[XFO-%%U]NT1?$^F:Q#HVK06VJ:9':WD9E?U<NXCJ4LTR'&9C3I8G"
MY%AU@Z6'6%HU56P<'B:GL*E.M)4I3JSQ-2'UB?,Z'-&M&G4E2C3E,J=X5(Q;
M3G+F;YFK2]W5-:K2*TZ[/1GT/7R/^WI\,/VA/C7^QS^T1\'_ -E;QKX2^''Q
M\^)_PUUGP%\/_'7CC4]>T3PYX7F\5/;Z+XAU:XUKPOX<\6^(='U&W\)7FO?V
M!JVC^'M0O]-\0MI=Y;BU> 7MM]<45\]AZ\L-B*&(A&G.>'K4J\(58*I2E*E.
M-2,:E-Z3IR<4IP>DHMQ>C-&KIK75-::/7L^Y_!7^R1_P0'_X.*OV$?"WBGP9
M^R3^WI^P]\%/#_C?7;;Q)XNM_#NN>.M2O_$6KV5BNFZ?/JNN>)_V*-=UV[M]
M-L_-CTO39-2.F:8]YJ4]A9V]QJFHRW7UI_P[R_X.XO\ I+-^R7_X-]>_^@2K
M^R"BOLJ_'V:XJM/$8K+.&L37JM.I7Q&08"M6J-)13G5J4Y3FU&*BG*3:226B
M5L5AX15E*JDMDJDDE\DS\-/^#@'_ ()E_'C_ (*L?L;_  T_9Y_9Y\6_"/P;
MXT\&_M,^#?C/JFJ?&?7O&7A[PO/X7\/?"SXS>![VPL+WP/X"^(FK2Z_+JWQ$
MT2XM;6XT2UTY].M=4EEU2"Y@M+2^_83X.>#]3^'OPB^%?@'6I[&ZUCP/\./
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MA*,%T2<(I+HD[H\#*</'$\.4L,GR_6,)B:;EJ[3K3K1E)]6U.3;[M:GXG?\
M!N'\7/"WQ/\ ^"2_[/.C:%>02:Y\(-3^)OPN\<Z;%,DLND>(++XC>)O%>F),
M 1(O]J>#/%GA;7%$D<81M3DMXS,EOY\G[I5_%3JW_!*C_@K5_P $@?V@O'_Q
M<_X)%ZYIGQZ_9V^(,\-WK?P3\8ZOX<N=:72K":[N-)\/_$+P9XKUKP?;^,KC
MPN^H3V?A;Q_\,O$^G_$"ZL+G4K:\T[1;*]U6'5O7O%G[07_!T%^V1ITGP9\&
M_LG?##]B?3_$&G_V;XK^-<5RW@S5M"L]1)L[V_TCQ/XN^)GC[7-'5(G)BD^'
M/@C7/'VCEFU'2M1@N(K>YMZQV54<=BZV.P>9Y:L'BZL\2Y8C%0H5L,ZTG4J4
MZU"?[WFA*4E%04W-<MM63@\RJX/"T<'BLOS!XK#4H8=*AAI5J6(5**IPJ4JT
M?W?+**BY.;@H-N^B/T-\0?\ !9[7-=_X*Z>&_P#@F?\ L\? WP]\</#MA)IF
MD?&;XM6_CW5- ?X8ZSIMIJNO?%.\BBL?"7BC1M:L/AQX?;0[";3[FYT=M3^(
M2ZCX#N=;T6\N(;^P_,/_ (.QO&^N?$#5/^"?W[&'@K_3O$GQ2^)/BGQO-I/F
M[=^N7-QX8^%/PO\ W(!\S^T;_P 9^/;;S7,?D?9=L8F^T2^1^S'_  23_P""
M0'PT_P""9G@WQ)XEUCQ-_P +F_:G^*T;2?%SXWW]K=P;[6XO5U9_!?@JVU*Z
MO=0LO#46J :CK.LZC.?$'CG7(H]<UQ;&VMM#\.^'_@W]L#_@G;^V1^U1_P %
M[_V4_P!IW5_A'C]B[]G"T^$[V?Q3O/'OPL2R^V_"]/%WQHA:'X?1^-I?B9<S
MW_Q?UFQ\'&[E\#J\DL%M>SR+X4L(=8CUP%;*<-G%.MA94X8?+,!7G[>O.5-Y
MABZ="<.>%.K/W95*E1>QHTTIRC"_*VVEEC*69XC*ITL3&<J^8XVC#V%&"J+
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MX)_$^JZ?%-$DUOI^H:M<65O,#+!!'([LW\D?_!RUX3\0_'W_ (*>_P#!,/\
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M_P"#/"5F?#&LZCXD\ ^*/%VD27%[XK\8?$3-C<ZNVI0&-[VYMXUU*)Y?"_\
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M^_*RM#+H_P :?BOXE^(ATW2GF0RK:>'/#?PS\#V.+ETN5LK_ $Q"9V:Z:/\
MH%_8H_9)\9? #_@EQ\'?V1F-I\/_ (J:7^S#>^$O$4D=U9:E9^#?C)\1?#FL
M:YXTG.H:!<W]AJL>@_$GQ;K4TNIZ-=WMKJAM7OK&YN8[B*5_YY_^",/[-?\
MP6@_X)K_ !;NOV7-5_8Z^%UQ^SQ\5/CSX:\2?%WX^ZSXK\/:^?#W@[2=-MM.
M\2ZUX)U+PQ\4=*O=3@U7PIIB?\(?INN^$)]0T?Q1J'_$WT3SKC4M%AZWB:6,
MCQ56CB<-"OBJE*&'5:O3I.>#IXB4ZCIN;2J-T:5**C"\GHHIMQ3Y5AZF$EPU
M2GA\1.CAJ=65?V-&=50Q=2A"$/:**?LU&K5JRYYV2U;LHRM_4%^WQ\8+#X!?
ML2_M8?&*_N8[7_A ?V?_ (J:UI9DD:$77B0^#]6LO">EQRHR/'<:QXGN](TF
MV=70K<7L1WI]X?AY_P &H/PBOO W_!.;QO\ $O4[22"7XV_M&>-M=T*X:*%$
MO?"'@GPYX1\ VDL<@A%Q+Y/C'1/'=LYDN)+=&BV6\$$HNY;K&_X.1/CKXO\
MBMI/[.'_  29_9Z?^W_CU^V1\1O"&M^,?#]I)<8TGX6^'O$+R>%F\2-;J?L.
MBZWX^T<^++O49$N8=*T#X3^([_4+>&W>UN6_H1_92_9T\%_LD?LX?!G]FSX?
M!G\*_!WP'HG@ZSOI88[>ZUW4+2$W'B'Q1J$,.(4U3Q9XBN=6\2ZL(0(CJ6JW
M1C 0@#S9-8/A^-*6E?-L7&NH=5@L&I0A.2W7M,1*7L[Z3C!RBVDST8WQ>>.I
M'6CEF%E1<NCQ>+<9R@GL^2A&//;6,I).W7Z"HHHKP#VPHHHH **** "BBB@
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M24^+/@9[CP%\55:(?/;QR^/_  SXAO+&*8+(VF75C/\ /'-'+)\J_P#!P_\
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MT]/\^RBO]!/_ (=!_P#!.'_HUWPM_P"%9\2O_FUH_P"'0?\ P3A_Z-=\+?\
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M/J-7^:G]\O\ Y'U_IZ?Y]E%?Z"?_  Z#_P""</\ T:[X6_\ "L^)7_S:T?\
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M]$_K_3T/J-7^:G]\O_D?7^GI_GV45_H)_P##H/\ X)P_]&N^%O\ PK/B5_\
M-K1_PZ#_ ."</_1KOA;_ ,*SXE?_ #:T?\5"/"7_ *)+Q%_\(>&O_HG]?Z>A
M]1J_S4_OE_\ (^O]/3_/LHK_ $$_^'0?_!.'_HUWPM_X5GQ*_P#FUH_X=!_\
M$X?^C7?"W_A6?$K_ .;6C_BH1X2_]$EXB_\ A#PU_P#1/Z_T]#ZC5_FI_?+_
M .1]?Z>G^?917^@G_P .@_\ @G#_ -&N^%O_  K/B5_\VM'_  Z#_P""</\
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M_P!&N^%O_"L^)7_S:T?\.@_^"</_ $:[X6_\*SXE?_-K1_Q4(\)?^B2\1?\
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MZ>G^?917^@G_ ,.@_P#@G#_T:[X6_P#"L^)7_P VM'_#H/\ X)P_]&N^%O\
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M^GH?4:O\U/[Y?_(^O]/3_/LHK_03_P"'0?\ P3A_Z-=\+?\ A6?$K_YM:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1O\ '_\ P25_X:1_X2'_ (3GP]\4M!_X7_\ \*>_LG^R_P#A97CR]\;?:_\
MA57_  M+4_MO]B_;/[,\C_A9%I_:/E_;?.L-_P!D7Z\_8Z_8+_X9-_X)R>"_
M^"?W_"UO^$__ .$0^$OQ)^%W_"VO^$&_X17^T?\ A8>J^-=3_MW_ (0/_A,?
M$GV3^R/^$P\C^S/^$SN?[0_L[S/[0LOM?EVOZ&T5Q8G/LUQD,13Q.*]I#%9K
M+.Z\?88:'/F<X2IRQ5Z=&+C>$Y+V,''#J]U232:I4X)II6:A[-:O2&FF_DM=
M_,_+#_@C]_P3/_X=1?LFW_[+W_"Z_P#A?7VWXM>,?BE_PG/_  KC_A5OE?\
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MH;FP2XM=$M+B*5+(WUK)>F K-?1S3/<CX<_X(_?\$S_^'47[)M_^R]_PNO\
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M+KI:RVMYGYH_\%9_^"=O_#T7]CO7_P!D[_A<'_"C?[<\<^!?&G_"??\ "O\
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MC"U<//#UU145R5:M.=>]VZK<I-PZ--]&GS.=U*2:E+=IIW5^RT\C^5_XC_\
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M#YHJTK<KDVVVKWUNW=W6[UZ)VT"BBBO$- HHHH **** "BBB@ HHHH ****
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M[3-7\1S0VFKW>AVNOW]O>:=X6T_3M \1>)/$M]97@TO0);"ROM1M/AKX/?\
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M\*^*_A-\,M TZ;4(9H[W1M-/Q(GN_$.GK/=:"-1$.Q_Z>_@O\9?AE^T-\*?
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M>JNM%=[O[:HHHKXPW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /YPO^":O[*?QN_8@_X*[?\ !2WP6OPH
M\<P_LF?M16VD_'GX7_%ZWT&\?X:6_BV+Q-=^*?\ A6T.K6\,UCI>JZ,?B_\
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MLLLS6_AFQ\4>%? /B?3#;S75E>M\3I=2M;J:.\6XN>F_X+1+'_P4C_X+@?\
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MA:":WM/&/Q$T?PM\<-<\7Z>UM)]M\8>%O&GB'5;@H-33Q/?V5Y#?77W_ /\
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M $=K+PKXHTW0W\,?#[XVRWNBZQ?Z?=7-CJ^DZAH^N:G;_P!E>(['5B]Q9/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^)K[0]%TFTU%-,FU+2]$\6?$34/ACI'AO49X?$%S'=W6G0Z)=_O%_P $;O\
M@G;;_P#!,/\ 8/\ AG^S3J.J:5X@^)5QJ&M?$WXV^)-#5_[%UGXL^-5L!K<>
MC336]I=7NC^&-$TGPYX&T?5+RVM;S6-+\+6>JW%EI\EZ=/M?%S"GC<JX/Q>5
MY]7C+'8O.<'BLJP,\90QF)PE*A1Q"QV.?L:U=8>ABO:4J$%*<77G&=2$)14I
MFD7&=92IKW5"2G+E<4[M<L5=*[5F^R6E^A^I=%%%?G9TA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7X _L"_\$,?^&'/^"IO[:G_  4N_P"&HO\ A:'_
M  V!_P -'?\ %E?^%)?\(5_PKO\ X: _:*\&_'W_ )*/_P +<\6_\);_ ,(E
M_P (E_PB?_(A^&?[>_M#^W?^)+]D_L:Y_?ZB@#\<O^"U'_!(+P=_P6*_9W^'
MWP8U?XLM\!_&7PO^*=I\1_!WQ6A^'H^)\MC93^'=:\.>*?"%QX3;QS\/5N-,
M\40:CI.H3W:>(H+BRU/PQH\R17$ NK:?ZE_X)L_L,^#?^";_ .Q=\%/V/?!6
MOP^,[;X5:1JX\0?$!/#$7A"Z^(?C+Q/XBU;Q3XJ\9:AH":UXEETV;5-6UB>*
MST^Y\2:]+I.C6FEZ+%JEQ9Z;:A/NBB@#\(_A%_P10_X55_P6@^-'_!7G_AI?
M^WO^%O>'=<T#_AGO_A37]E_\(]_;7@'P5X'^U_\ "V?^%K:C_:WV;_A#_P"U
M/(_X5IIGG?VC]B\Z+[)]KNO9/^"M'_!&']E7_@KM\.?#>A?&8ZY\/?BY\.5O
MU^%7QZ\!PV#^,O"=IJLD4^J>&-;TS44.F>-? VIW5O;WMSX<U1[6\T^^CEO?
M#&N^'+K4=8FU']>** /XQ+W_ (-X/^"RNN^ G_9M\1?\%\?BGJ/[,<\,/AR\
MT^7P[\4[GQ=?>!EMH].E\.75E<?%H:E<>'SI7F:8/ UW\4KGPI+IR0Z=-$;$
M^1'^^7_!*O\ X)(?LO\ _!)/X,:O\,O@)#KGBGQGX\N]*UCXP?&CQL;&3QQ\
M2=:TBUFM]-@DCTZWM]/\.>#M -[J?_"*>#M,62VTA-2O[K4-0UW7M1U77=1_
M4FB@#^:;_@L;_P &\%C_ ,%+/VB_AS^V/\#OVJO%'[(O[2_@7POH7@[4?$VE
M^&-1\2Z7XBT_PKJ>JW_A3Q%I.H>'?&?@3Q7X%\<Z#'KE]8-K^F:KJUKJFDV6
MB6":5I-U97&KWGO>H_\ !$70OC]_P2:\!?\ !-+]N_\ :%\8_M)^,_A]J_B'
MQ?X:_:NM].OM.^*6@>.+KQMXV\4>$?$5M-X^\2_$J[UB;POX?\:WWPTU :KJ
MB)XD^'XETA(M!O)+?4[/]WJ* /XWOA!_P;[?\%E?@3X6T[]GWX3?\%Z_B%\/
M_P!F7P^MSH7A6Q\/_#OQFWB[PMX0FC6&+3_">C7GQ,=_!JVD.Y=,T;PS\3;#
M2]"F+76CSVLLLF>F^,7_  :*? CQ!I7P!\3? K]KWXG_  Z_:4^%GQ7\2?&;
MXJ?M-?&SP#'^TGXX_:!\::W=^!]:TF7Q9I4WQ(^%-AH]AX/\2>#;G5M @CN]
M:N;I/%OB:/Q+>:_J5]_;(_K[HH _,7_@J#_P2I_9Z_X*P_LYZ=\#_P!HF74=
M$\5^$;UO$WPO^,W@.SMK#Q7\-O'$^GQV.J:CHFGZO+J]O?\ A#Q-'##:>*_
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ML&U_3-5U:UU32;+1+!-*TFZLKC5[S^EFB@#^:3XT?\&Z>@?M<_\ !-+]G?\
M8Q_;!_:L\9_%3]IC]F34?B9JOPQ_;<@\*WNH^-HQ\2O&>M^)[[PMXX\/>.O'
M/BG6/'W@R#3;[P]H%WIY\>>%=3OH_ G@^]L-4T,Z?>6VH_+_ ,/_ /@@U_P6
M@_X1_2_@K\3/^"_?QHT_]GG3+"#PY/9?#;P_XW;XH:AX+LIA''X=LO&6L^/M
M,U[0&O-*7^RUO;CQ7XGMM)LW33FTO7-(MQITW]?=% '\J?A;_@U@^!?P!_:^
M_8E_:N_8U_:-U[X)W/[)DGAF_P#&WACXE?"Q/CKKG[1OB+2_'?BCQ-XF\7^,
M_'$7Q.^%T'A?Q-XS\+>++WP!=W.A>#KO3-$TK2O#E_H>DVESI+P7GZ!_\%@O
M^"(7[.O_  5W\+>!]1\8^+/$7P._:&^$L=Q:_"O]H/P1I5GK>KZ3HUY>#4;G
MPEXR\,75_HB^-?"$6J%]=T>Q@\1^&==\.>('N+_P_P")-.M-7\3:;K_[4T4
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M%XI\3ZEK_A?0=;<>(M'\">'-)^''A)=>B$^NZ9XCTV\U+2KW^JZBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D_&OBL^"] GUY
M?#/BSQ<8)[:#^Q/!6D)K>OS?:91%YT%A)=V2/!;Y\VYD-POE1 L%8C:?%O\
MAI"7_HW[]I7_ ,-I9_\ S35]*T5UT*V%IP<:V"6(GS-J;Q%6E[K2M'EA[NC3
M=]WS6Z(/E^?^?]7]#YJ_X:0E_P"C?OVE?_#:6?\ \TU'_#2$O_1OW[2O_AM+
M/_YIJ^E:*W^M9?\ ]"N/_A9B/Z_X=^5G\E^/^?\ 5WY6^:O^&D)?^C?OVE?_
M  VEG_\ --1_PTA+_P!&_?M*_P#AM+/_ .::OI6BCZUE_P#T*X_^%F(_K_AW
MY6/DOQ_S_J[\K?-7_#2$O_1OW[2O_AM+/_YIJ/\ AI"7_HW[]I7_ ,-I9_\
MS35]*T4?6LO_ .A7'_PLQ']?\._*Q\E^/^?]7?E;YJ_X:0E_Z-^_:5_\-I9_
M_--1_P -(2_]&_?M*_\ AM+/_P"::OI6BCZUE_\ T*X_^%F(_K_AWY6/DOQ_
MS_J[\K?-7_#2$O\ T;]^TK_X;2S_ /FFH_X:0E_Z-^_:5_\ #:6?_P TU?2M
M%'UK+_\ H5Q_\+,1_7_#ORL?)?C_ )_U=^5OFK_AI"7_ *-^_:5_\-I9_P#S
M34?\-(2_]&_?M*_^&TL__FFKZ5HH^M9?_P!"N/\ X68C^O\ AWY6/DOQ_P _
MZN_*WS5_PTA+_P!&_?M*_P#AM+/_ .::C_AI"7_HW[]I7_PVEG_\TU?2M%'U
MK+_^A7'_ ,+,1_7_  [\K'R7X_Y_U=^5OFK_ (:0E_Z-^_:5_P##:6?_ ,TU
M'_#2$O\ T;]^TK_X;2S_ /FFKZ5HH^M9?_T*X_\ A9B/Z_X=^5CY+\?\_P"K
MORM\U?\ #2$O_1OW[2O_ (;2S_\ FFH_X:0E_P"C?OVE?_#:6?\ \TU?2M%'
MUK+_ /H5Q_\ "S$?U_P[\K'R7X_Y_P!7?E;YJ_X:0E_Z-^_:5_\ #:6?_P T
MU'_#2$O_ $;]^TK_ .&TL_\ YIJ^E:*/K67_ /0KC_X68C^O^'?E8^2_'_/^
MKORM\U?\-(2_]&_?M*_^&TL__FFH_P"&D)?^C?OVE?\ PVEG_P#--7TK11]:
MR_\ Z%<?_"S$?U_P[\K'R7X_Y_U=^5OFK_AI"7_HW[]I7_PVEG_\TU'_  TA
M+_T;]^TK_P"&TL__ )IJ^E:*/K67_P#0KC_X68C^O^'?E8^2_'_/^KORM\U?
M\-(2_P#1OW[2O_AM+/\ ^::C_AI"7_HW[]I7_P -I9__ #35]*T4?6LO_P"A
M7'_PLQ']?\._*Q\E^/\ G_5WY6^:O^&D)?\ HW[]I7_PVEG_ /--1_PTA+_T
M;]^TK_X;2S_^::OI6BCZUE__ $*X_P#A9B/Z_P"'?E8^2_'_ #_J[\K?-7_#
M2$O_ $;]^TK_ .&TL_\ YIJ/^&D)?^C?OVE?_#:6?_S35]*T4?6LO_Z%<?\
MPLQ']?\ #ORL?)?C_G_5WY6^:O\ AI"7_HW[]I7_ ,-I9_\ S34?\-(2_P#1
MOW[2O_AM+/\ ^::OI6BCZUE__0KC_P"%F(_K_AWY6/DOQ_S_ *N_*WS5_P -
M(2_]&_?M*_\ AM+/_P"::C_AI"7_ *-^_:5_\-I9_P#S35]*T4?6LO\ ^A7'
M_P +,1_7_#ORL?)?C_G_ %=^5OFK_AI"7_HW[]I7_P -I9__ #34?\-(2_\
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MH^M9?_T*X_\ A9B/Z_X=^5CY+\?\_P"KORM\U?\ #2$O_1OW[2O_ (;2S_\
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M?^C?OVE?_#:6?_S35]*T4?6LO_Z%<?\ PLQ']?\ #ORL?)?C_G_5WY6^:O\
MAI"7_HW[]I7_ ,-I9_\ S34?\-(2_P#1OW[2O_AM+/\ ^::OI6BCZUE__0KC
M_P"%F(_K_AWY6/DOQ_S_ *N_*WS5_P -(2_]&_?M*_\ AM+/_P"::C_AI"7_
M *-^_:5_\-I9_P#S35]*T4?6LO\ ^A7'_P +,1_7_#ORL?)?C_G_ %=^5OFK
M_AI"7_HW[]I7_P -I9__ #34?\-(2_\ 1OW[2O\ X;2S_P#FFKZ5HH^M9?\
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M_P -(2_]&_?M*_\ AM+/_P"::C_AI"7_ *-^_:5_\-I9_P#S35]*T4?6LO\
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M_AM+/_YIJ^E:*/K67_\ 0KC_ .%F(_K_ (=^5CY+\?\ /^KORM\U?\-(2_\
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M7X_Y_P!7?E;YJ_X:0E_Z-^_:5_\ #:6?_P TU'_#2$O_ $;]^TK_ .&TL_\
MYIJ^E:*/K67_ /0KC_X68C^O^'?E8^2_'_/^KORM\U?\-(2_]&_?M*_^&TL_
M_FFH_P"&D)?^C?OVE?\ PVEG_P#--7TK11]:R_\ Z%<?_"S$?U_P[\K'R7X_
MY_U=^5OFK_AI"7_HW[]I7_PVEG_\TU'_  TA+_T;]^TK_P"&TL__ )IJ^E:*
M/K67_P#0KC_X68C^O^'?E8^2_'_/^KORM\U?\-(2_P#1OW[2O_AM+/\ ^::C
M_AI"7_HW[]I7_P -I9__ #35]*T4?6LO_P"A7'_PLQ']?\._*Q\E^/\ G_5W
MY6^:O^&D)?\ HW[]I7_PVEG_ /--1_PTA+_T;]^TK_X;2S_^::OI6BCZUE__
M $*X_P#A9B/Z_P"'?E8^2_'_ #_J[\K?-7_#2$O_ $;]^TK_ .&TL_\ YIJ/
M^&D)?^C?OVE?_#:6?_S35]*T4?6LO_Z%<?\ PLQ']?\ #ORL?)?C_G_5WY6^
M:O\ AI"7_HW[]I7_ ,-I9_\ S34?\-(2_P#1OW[2O_AM+/\ ^::OI6BCZUE_
M_0KC_P"%F(_K_AWY6/DOQ_S_ *N_*WS5_P -(2_]&_?M*_\ AM+/_P"::C_A
MI"7_ *-^_:5_\-I9_P#S35]*T4?6LO\ ^A7'_P +,1_7_#ORL?)?C_G_ %=^
M5OFK_AI"7_HW[]I7_P -I9__ #34?\-(2_\ 1OW[2O\ X;2S_P#FFKZ5HH^M
M9?\ ]"N/_A9B/Z_X=^5CY+\?\_ZN_*WS5_PTA+_T;]^TK_X;2S_^::C_ (:0
ME_Z-^_:5_P##:6?_ ,TU?2M%'UK+_P#H5Q_\+,1_7_#ORL?)?C_G_5WY6^:O
M^&D)?^C?OVE?_#:6?_S34?\ #2$O_1OW[2O_ (;2S_\ FFKZ5HH^M9?_ -"N
M/_A9B/Z_X=^5CY+\?\_ZN_*WS5_PTA+_ -&_?M*_^&TL_P#YIJ/^&D)?^C?O
MVE?_  VEG_\ --7TK11]:R__ *%<?_"S$?U_P[\K'R7X_P"?]7?E;YJ_X:0E
M_P"C?OVE?_#:6?\ \TU'_#2$O_1OW[2O_AM+/_YIJ^E:*/K67_\ 0KC_ .%F
M(_K_ (=^5CY+\?\ /^KORM\U?\-(2_\ 1OW[2O\ X;2S_P#FFH_X:0E_Z-^_
M:5_\-I9__--7TK11]:R__H5Q_P#"S$?U_P ._*Q\E^/^?]7?E;YJ_P"&D)?^
MC?OVE?\ PVEG_P#--1_PTA+_ -&_?M*_^&TL_P#YIJ^E:*/K67_]"N/_ (68
MC^O^'?E8^2_'_/\ J[\K?-7_  TA+_T;]^TK_P"&TL__ )IJ/^&D)?\ HW[]
MI7_PVEG_ /--7TK11]:R_P#Z%<?_  LQ']?\._*Q\E^/^?\ 5WY6^:O^&D)?
M^C?OVE?_  VEG_\ --1_PTA+_P!&_?M*_P#AM+/_ .::OI6BCZUE_P#T*X_^
M%F(_K_AWY6/DOQ_S_J[\K?-7_#2$O_1OW[2O_AM+/_YIJ/\ AI"7_HW[]I7_
M ,-I9_\ S35]*T4?6LO_ .A7'_PLQ']?\._*Q\E^/^?]7?E;YJ_X:0E_Z-^_
M:5_\-I9__--1_P -(2_]&_?M*_\ AM+/_P"::OI6BCZUE_\ T*X_^%F(_K_A
MWY6/DOQ_S_J[\K?-7_#2$O\ T;]^TK_X;2S_ /FFH_X:0E_Z-^_:5_\ #:6?
M_P TU?2M%'UK+_\ H5Q_\+,1_7_#ORL?)?C_ )_U=^5OFK_AI"7_ *-^_:5_
M\-I9_P#S34?\-(2_]&_?M*_^&TL__FFKZ5HH^M9?_P!"N/\ X68C^O\ AWY6
M/DOQ_P _ZN_*WS5_PTA+_P!&_?M*_P#AM+/_ .::C_AI"7_HW[]I7_PVEG_\
MTU?2M%'UK+_^A7'_ ,+,1_7_  [\K'R7X_Y_U=^5OFK_ (:0E_Z-^_:5_P##
M:6?_ ,TU'_#2$O\ T;]^TK_X;2S_ /FFKZ5HH^M9?_T*X_\ A9B/Z_X=^5CY
M+\?\_P"KORM\U?\ #2$O_1OW[2O_ (;2S_\ FFH_X:0E_P"C?OVE?_#:6?\
M\TU?2M%'UK+_ /H5Q_\ "S$?U_P[\K'R7X_Y_P!7?E;YJ_X:0E_Z-^_:5_\
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MQ']?\._*Q\E^/^?]7?E;YJ_X:0E_Z-^_:5_\-I9__--1_P -(2_]&_?M*_\
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M^E:*/K67_P#0KC_X68C^O^'?E8^2_'_/^KORM\U?\-(2_P#1OW[2O_AM+/\
M^::C_AI"7_HW[]I7_P -I9__ #35]*T4?6LO_P"A7'_PLQ']?\._*Q\E^/\
MG_5WY6^:O^&D)?\ HW[]I7_PVEG_ /--1_PTA+_T;]^TK_X;2S_^::OI6BCZ
MUE__ $*X_P#A9B/Z_P"'?E8^2_'_ #_J[\K?-7_#2$O_ $;]^TK_ .&TL_\
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M (68C^O^'?E8^2_'_/\ J[\K?-7_  TA+_T;]^TK_P"&TL__ )IJ/^&D)?\
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M_K_AWY6/DOQ_S_J[\K?-7_#2$O\ T;]^TK_X;2S_ /FFH_X:0E_Z-^_:5_\
M#:6?_P TU?2M%'UK+_\ H5Q_\+,1_7_#ORL?)?C_ )_U=^5OFK_AI"7_ *-^
M_:5_\-I9_P#S34?\-(2_]&_?M*_^&TL__FFKZ5HH^M9?_P!"N/\ X68C^O\
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M4?6LO_Z%<?\ PLQ']?\ #ORL?)?C_G_5WY6^:O\ AI"7_HW[]I7_ ,-I9_\
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M'UK+_P#H5Q_\+,1_7_#ORL?)?C_G_5WY6^:O^&D)?^C?OVE?_#:6?_S34?\
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M*_\ AM+/_P"::OI6BCZUE_\ T*X_^%F(_K_AWY6/DOQ_S_J[\K?-7_#2$O\
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M;YJ_X:0E_P"C?OVE?_#:6?\ \TU'_#2$O_1OW[2O_AM+/_YIJ^E:*/K67_\
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M8C^O^'?E8^2_'_/^KORM\U?\-(2_]&_?M*_^&TL__FFH_P"&D)?^C?OVE?\
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M_1OW[2O_ (;2S_\ FFH_X:0E_P"C?OVE?_#:6?\ \TU?2M%'UK+_ /H5Q_\
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M?)?C_G_5WY6^:O\ AI"7_HW[]I7_ ,-I9_\ S34?\-(2_P#1OW[2O_AM+/\
M^::OI6BCZUE__0KC_P"%F(_K_AWY6/DOQ_S_ *N_*WS5_P -(2_]&_?M*_\
MAM+/_P"::C_AI"7_ *-^_:5_\-I9_P#S35]*T4?6LO\ ^A7'_P +,1_7_#OR
ML?)?C_G_ %=^5OFK_AI"7_HW[]I7_P -I9__ #35ZA\/?B&WQ M]3N&\"?$7
MP-_9DUM"(/B%X<B\/7&H_:4E?S=,CBU'41=0V_E;+EV:(Q/+$H5M^1Z+165:
MOA)TY1I8%4*CM:HL36J<MFF_<G[KNDUKM>ZV0@HHHKB **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#-E7\1%%'_ !(?X%=^,_\ Q(:'_P ZP^N5O[G_ (#_ ,'^KORM_;O_ ,1
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M44?\2'^!7?C/_P 2&A_\ZP^N5O[G_@/_  ?ZN_*W]N__ !$#?L$_\^WQS_\
M#=:3_P#-E1_Q$#?L$_\ /M\<_P#PW6D__-E7\1%%'_$A_@5WXS_\2&A_\ZP^
MN5O[G_@/_!_J[\K?V[_\1 W[!/\ S[?'/_PW6D__ #94?\1 W[!/_/M\<_\
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M /$AH?\ SK#ZY6_N?^ _\'^KORM_;O\ \1 W[!/_ #[?'/\ \-UI/_S94?\
M$0-^P3_S[?'/_P -UI/_ ,V5?Q$44?\ $A_@5WXS_P#$AH?_ #K#ZY6_N?\
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MP^N5O[G_ (#_ ,'^KORM_;O_ ,1 W[!/_/M\<_\ PW6D_P#S94?\1 W[!/\
MS[?'/_PW6D__ #95_$111_Q(?X%=^,__ !(:'_SK#ZY6_N?^ _\ !_J[\K?V
M[_\ $0-^P3_S[?'/_P -UI/_ ,V5'_$0-^P3_P ^WQS_ /#=:3_\V5?Q$44?
M\2'^!7?C/_Q(:'_SK#ZY6_N?^ _\'^KORM_;O_Q$#?L$_P#/M\<__#=:3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !117XF?\%YO^"G7Q8_X)0?LA?#C]HGX.?#_ .'?Q'\3>,_VD?"'P6OM#^)8
M\2G0K70O$7PQ^,/CFZU6T'A;6] U#^UX-0^'.EV<'G7DMG]COK_S+9Y_L\L/
M=EN78G-L?A<NP<8SQ6,JJC0C.<:<93:;2E.7NQ5D]7H3*2A%REHHJ[ZZ'[9T
M5_(1X=_X*?\ _!SKXL\/Z%XJ\._\$=/@1J?A_P 2Z-IGB#0]2A\9F.+4-'UF
MR@U'3+Z*.X_:/AN(X[NRN8+A$GBBF59 LL:.&4<K'_P<C_MT?L:?%+P'X2_X
M*^_\$Q=<_9R^&7Q#UU]&L_C%\,;KQ++I^AQ6\QAU#4+#1M7N/&_AWXD?V.-M
M_K&C^&OB-I/B&#0BVK:5I.N2/8:=J7T:X&SNHYPPE7)LPQ$(SE]3P&>97BL9
M-4TY35/#4\3[2I**3;A!.;LU&,I63R^L4UJU.*_FE3FHZVM=VMK=:[?*Q_9#
M17X__P#!8C_@I'XN_P""??\ P3XF_;3_ &?]#^&OQ=N+SQ;\*+#PS%XMGUG4
M? _B+PE\3)R;7Q!I]]X3UO1KNYCN-.FL]2TB]MM0DL[FWF5S'-'*CI^BW[-?
MQ-U7XU_LZ? +XRZ]I^GZ3KGQ;^"OPK^)NLZ5I'VG^RM,U7Q[X%T+Q5J.GZ9]
MLGN;S^S[.\U6:VLOM5S<7/V:.+SYY9=\C?.U,LQ=++J&:5(1CA,1B\1@:<G-
M>T^L86G1J5H2I_'%1C7IVDU9MM+5,U4XN3@OB45+RL]$[GM5%%%<!04444 %
M%%% !1110 4444 %%<QXT\;>#OAOX2\1>/?B%XK\.>!O _A#2+W7_%7C#Q=K
M6G>'/#'AO0]-A:XU#6-=UW5[FTTS2M-LH$:6ZO;ZY@MX(U+22**_G:_X)N?\
M%Y)O^"EO_!5[]I#]D[X+^&/ TO[&OPF_9T\5_$GX;?%*YT+Q=I_Q=^(WC+P;
M\3/@OX!U#Q!/-?\ BE?#NF?#;6Q\1/$5SX<T*?P'9^+I+/3_  _K&JZSITUW
MJ'ANW]3 Y-F&8X7,<;A:$I83*\/]9QN(E[M*G%SC"--3>DZTW*\*4;S<(SG9
M1BV1*<8N,6]9NT5U?_ 7<_I,HHHKRRPHK^+;4_\ @OY_P5X^+?[>'[:'[&G[
M$G[!/[/G[0EY^RI\:OCGX)82:KXKT?Q+)\._A9\9-8^%>D>*_$$^M_%[PGH<
MVH:A+;:/_:46D)&G]H7\CVNGP6:XB]J_X>/_ /!T;_TAF^!G_A;1?_1)U]E/
M@;-Z*I_6,7D.%G5HT:\:6+SW+<-65*O3C4I2E1K5X5(J<)*2O%76U]+XJO![
M1J.S:NJ<FKII/5+HW_6E_P"M^BOR<_81_:2_X*6_%/\ 9?\ V@?B1^W/^Q_X
M2_9S^/?@6\\6-\'?A;X+N+SQ5:?$'1M(^'MGKVAWEQ::3X_\=ZE=WFJ^,WO_
M  ZNF:?JNGW]U%;Q16EHMQ-'<R=5_P $F/VJ_P!K[]L3]EF]^+7[;7[,6K?L
ME_&6#XJ>+O"-O\+-:^'GQ/\ AE>3^#-&TGPO>:'XJ'AOXM,WBIX=7O=6UBT3
M4D/]E73:6\5G^^MKJO"Q.3XK#4\=5E5P56GE^(P^&K3P^-PV(C.IB83G3EAG
M2J26)I)0DJE6BYPIRM&;3:1:FGRZ27,G)7BUHK;WV>NB['Z<T445Y184444
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MO!^NW5M'IWB"R@G?4?#>E2K>Q74<<,L"17,P!^BE%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^>OB'_@JS_P $^O"?[6EO^PKXE_:5\+Z)^UC=
M>+?#/@6V^#6I>&_B!;:Y-XL\9Z+I/B+PIHT>L2>$1X4:;Q!HNNZ-?Z5.-?\
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M4;!H/@]\&;&2-8VGN8?$7B#Q[\18XHVDCMH[WP];3/!=W"6TE@ ?UE?L=?\
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MNW@EU?6KO3]-MEDO;U2X!^NE%?PN? []N+_@Y*_X+@:E\0?CC_P3J\4_L_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS=?M9>%M'GU$@M<-IEAXN_:)O;6R5F)6.&.[U*\G<1*AF>1#.9!!;B+]9?\
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M)B:1K&O_ !$\,_"/_@H_\"/!%K?ZGK?B2UAT3Q[KVG^&=*ANM2U.\MW\+O\
M!K]HF]NCIEO>7G]JZ_X1\?V6D/ D-RDL'V6QN_Z+?^"1_P#P5 ^''_!6#]E.
MV_:&\%>$M0^''BKPWXMU#X:_%SX9ZEJ(UO\ X0WX@:3I6C:[+%HOB$6.E?\
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MAL1D,<15BL%23ER+.H1H<VML*I0C6]A\/MU[7X@LXPQ$HRFFJO*O>?7V>O\
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MI<\Y1='G7-)N2=VFE)ZV=MF_+8_/C_@U:\+_ /!3$_LP?L]>)Q\1_P!EU?\
M@FFNM_M!1-\.EL?&'_#3\GBX^)?&=I]H>^;P&W@\:(/B6PU,+'XZ2Z_X1I%C
M,!NB^GO_ &95_.I_P:L?\H7?V?/^R@_M _\ JY_&-?T5U\[QQB7B.*\\O1P]
M'V&9X[#+ZO1C1]JJ6+KVK5^7^+B*G-^]K2]Z=HWV1K05J5/5N\(/5WM>*T79
M+HN@4445\H:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7Y>?\%LO^41O_!1G_LT3XU?^H=J-?J'7Y>?\%LO^41O_
M  49_P"S1/C5_P"H=J- '^3]_P $AO\ @H#HW_!,7]NCX;_M@Z_\,M3^+VF>
M _#?Q(T&;P+H_B>U\'W^I/X\\#:WX0AN8M=O=%U^WMETV75EOI8GTR8W,<#0
M(\+.)%_L,_XCBOA-_P!(\/B)_P")$^&O_G2U_*[_ ,$!/V-_@)^WK_P4W^#W
M[-'[2_AC4_%_PC\7^#OC!K&NZ%H_B;7O"%_<W_A#X9^)/$NA2Q:[X:OM-U>V
M6VU?3;2>6*"[2.YC1H)U>)V4_P"@Q_Q">?\ !$W_ *-X^(G_ (D/\:O_ )LJ
M /RI\)_\'M?PI\5>*O#/A>/_ ()\_$*RD\2>(-&T%+Q_VA/#<Z6CZQJ-MIZW
M+PK\*8VF6!K@2M$)(S($*!T)W#^R']J7_DV/]HS_ +(1\7O_ %7WB&OQ'T3_
M (-4_P#@BWX>UG2-?TO]GSXA0:GH>IV&L:=,_P"T%\9YDAO],NHKVSE>&7Q@
M\4JQW$$;M%(K1R %'5E)!_;C]J7_ )-C_:,_[(1\7O\ U7WB&@#_ !P?^")O
M_*7+_@G-_P!G=_!7_P!3'3J_T<_^#L/_ )0F_M#_ /91/V>/_5U>#:_SC/\
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MOQ/\-O'/ANP^:5T0_P"GZM;?NP3++_JH4DF>-& /]5__ (*K>$QXZ_X)B_\
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M? 5[XR\7:7\&6^-'Q,TG1?A=#XV71[#PMH^JVOB;PKIFARW/C[5-1U^6_P#
MVJW-[>6.AE]0M[6P-K/_ *ZG[7O[ 7['?[>V@>%_#'[7OP(\)?'#1O!$VMW/
M@^W\377B'3[GPS=>(TTJ+7+O1-3\,ZUH>J:;=ZE%HFEPW%U:WL<_DV@A21(Y
M9UEM?L=_L(?LC?L _#:X^$O[('P.\*?!7P3?ZK<ZYK%OH]SK_B'Q%XCU>Z<E
MM0\5^._&NL>)?'?BRYMHBMGIC^)?$FJ_V1ID-OI6E"STVVM[2( _SN_V+O\
M@\%_X**?!+XE:5HO[<>C>$/VI?A8NM#3?'WV?X>^$O@_\<O#5K'=_9M1N?"=
MQX#T[P7\/KG5=''VB23PQXK\%0C6+BVCTI_$_A9I9M5A_P!)OX ?'KX4?M0_
M!?X;_M!? WQ?8>._A-\6?"]AXO\ !'BG3EFBBU'2;X.CPW5G=1PWVE:OI=]#
M=Z1KVB:E;VVJ:%K=AJ&CZI:VNHV-S;Q_P*?\'L7[+?PK\#_$;]C3]JGP9X7T
M/PU\1/C):?&#X<_%O4-(TZVTZ;QR?A['\/-9\!^(M:^QPPIJ7B#3+/Q5XGT2
M_P!;OS/JE[I$?AK3'N&LM"LXH?U2_P"#+_XH^)O&'_!,OXP_#S7+F2\TCX0_
MM9^--*\&-+.[C3?#_C+X>_#?QE>Z)! R[8;:'Q9J7B;70Z.?.NO$5WNB0Q^9
M, ?U\T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\HW_!X7^S)_
MPN7_ ()8V/QOTO3_ +1XB_9/^-_@;QW=7L47G747P^^(\LGPD\5V$2*#(+:;
MQ-XJ^'FMW\L8(@MO#;3S!;>*:6/^KFOEG]N']G6P_:X_8Z_:>_9EOX[9C\<?
M@9\2_AQI5Q=%!%I7B?Q'X4U.R\(:^K2_NDN?#GBEM'UZSDF5X([O38'GCDB5
MXV /S^_X-XOVAD_:3_X(Z?L1>+)[]KW7? 'PP?X"^)(IL&[L;[X"ZYJGPKT>
M*]==RRS7_@[PQX8UV.;S)9I[/5[66\9;Y[F*/^8Z6:#_ (*B_P#!XA;(?)\0
M?";]@C4VA7<3J,>F1_L@:/<7'R!8Y+6-8/VPO%9R)&BBMXKQV$DNH!(KCK_^
M#3W]N;3/V;O^">'_  50\(?%"9K*']B2_P!=_:QN/#6M++8WPTK5?A9KVG^*
M?#UL2LMYYT?B'X%6>GOI$%F]W#KOBB&.TM[N_P!7$ ] _P"#,7X(^(/')_X*
M ?\ !0_XC)-JOC+XM_$K3/@[I/B>:&& WVJM/-\9_C;.BJ/,==;UWQC\+[E_
M*6&TAGTJ:%3<RATL@#YU_P"#G'2-5_X)_?\ !:G_ ()Y_P#!3SP=8WMIIOBF
M/X?>(O%LMI'&X\1^+/V9?'>CV'CO29I(]LGE^)O@KXM\#>$I[68++-90WIL[
MMB72P_N-_:G_ &F?"O[/W[&?QX_:VM=5T[4O"_PO_9[\>?&OP_J*L)M/\0QZ
M)X%U#Q3X3@LPS1?:_P#A)KQ-*L=,@W1M>3ZE;0*5:8$?@5_P=Y_LM?\ "]?^
M"4M]\8])TV2[\5?LD_%[P-\5%GM(?/OF\">,;I_A/XXT]8PDDG]G1W'C+PMX
MMU:2((UM:^#?MLTB6=M=;OR'_:__ ."D,OB[_@S^_9ELY]?9_B1\9[_X;?L,
M:L'ECGUQ;+]GCQCK5QJ][=NA#RKKGPQ^!OAR/6-3N5N+B>+QY:IJ$S:KJ@NB
M >G?\&4?[.^IZGHW[='[='C)+W4]=\<^+_"GP#\+>);^(FYO+C3HY?BO\8YY
M+^4M)J$FMZKXG^%-Q<-&L*076D3F62[EN EA]D?\'JW_ "BR^ ?_ &?_ /"S
M_P!9U_:JK]6/^#>K]ES_ (9,_P""0_['/@B_T^2P\6_$3X?G]H'QQ]I3R;Z7
M7OCK>S_$73+?4+<2R+;7N@>"M9\)^%)K?$,T8\/H+R"*_-TH_*?_ (/5O^46
M7P#_ .S_ /X6?^LZ_M54 >9_\$4?^#@#_@D=^R/_ ,$N?V1?V=/VA?VM/^%?
M?&3X7^#/%FD^.?!W_"A_VF?%?]AZAJ?Q0\<^(K&W_P"$A\$?!GQ+X5U/S]&U
MG3;SS='US4((_M/V>:2.ZAG@B_3[4?\ @Z8_X(7V5E<W=M^VI>ZO/!&7BTS3
MOV:?VLXKV\8$#R;:35O@9I>FK(020;S4+6' .90< _F#_P $4?\ @W__ ."1
MW[7'_!+G]D7]HO\ :%_9+_X6#\9/BAX,\6:MXY\8_P#"^/VF?"G]N:AIGQ0\
M<^';&X_X1[P1\9O#7A73/(T;1M-L_*T?0]/@D^S?:)HY+J:>>7YJ_P""S/\
MP::?!7P!^SYXM_:1_P""8FE_$#2_'7PCT6Y\4^,?V:]?\2ZK\2M/^(G@O1(;
MB_U^^^&-_P"(UU/QDOQ$TBQ5]2C\(ZCK.OV'C;3["31O#EC8>*&L;'Q& ?FG
M_P %I_\ @J'XP_X.'_VC?V9OV(_^"=/P/^)_BCP'X*\4:[JWAJ/Q'I5EI7B[
MXG?$3Q):V.AW?C77-)M=2U72?A[\,/AWX<@U!X/$7B36[)K?3O$'B+7?%Z:#
M;6UE96O^BU^PE^S);?L8_L;?LS_LKV^L+XBF^!7P;\#_  ]U?Q#$TQMM>\2Z
M-HUN/%>MV"7$-O<0:9JWB675M0TNTGACFLM.N+6TD!> D_RS?\&I?_!4;]D[
MXZ^'?$?['EQ^SG^SG^RW^U[H.@MXBM->^"_PZ\-?#FP_:K\&:/&CZWK=TVG6
M<=_<_$WP8D<.H>)_"\^JWEI?^''_ .$H\&Z;9:'X>\3Z9X8_M)H _P U7_@@
MOX,\)_$?_@XV_P""DGP^\>>'M*\6^"/''AW_ (*)>$O%_A;7;.+4-%\1^&?$
M7[0V@Z3KFAZM8SJT-WIVJ:;=W-E>6\BE)K>:1&X->)>.M&^,_P#P:H_\%J--
M\5>&(?%'BS]BOXR->7FF:7#=74L/Q1_9A\1Z[$FN^#+RYOB;"_\ C!\ -8DM
M+C3;F>YBO;V^TSPYJM]<Z3X<^)5]92_2?_!O%_RLS?M]?]W\_P#K2WAFO['?
M^"SG_!+OP+_P5;_8P\7_  +U-[#0/C!X2:Z^(/[.GQ"NH@/^$1^*NEZ;<Q6.
MF:K<HCSCP5X[M7?PEXT@1+@6^GWUMXCM;*ZUOPWHOE@'Z6?"[XG> OC3\./
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MRV=G)<1(PCFDM;9Y%9H(BGVE_P &BG_*&CX??]EW^//_ *E%K7QG_P 'M/\
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MTUFV^)%]+#J44,/VM6TKX\? :\TT/*R,TL=C=7-S<6T,N^&*6YN&5 9Y=_\
M=I7\(_\ P=F_\I"_^"*'_91->_\ 5W_ "O[N* "O._B]_P DF^*'_9._&W_J
M-:G7HE>=_%[_ ))-\4/^R=^-O_4:U.@#^(O_ (,=?^23?\%#_P#LHG[.W_J-
M?%JO[N*_A'_X,=?^23?\%#_^RB?L[?\ J-?%JO[N* /X>OV'/^5R3_@HM_V0
MCQ7_ .H-^RQ7]AW[4O\ R;'^T9_V0CXO?^J^\0U_"]_P4O\ $/QJ_P""(_\
MP<0WW_!5_P 2?!'QK\6_V/\ ]HKP_966M>(O#EE$ZV*Z]\)?#/PR\>>";;Q,
MSP:!H'Q"\/\ B[PKIGCGPKI/BLZ5:>+/"E[!H%IJ$ERNL^(=(^XOV@_^#BBS
M_P""I?PW\6?L#?\ !(']F7]H[XD?M&_M-^$M8^%.M_$[XH^%/#O@7X9_L^^
M_']C<^&_%_Q&\4ZIX?\ $WQ N(6T;PY=ZP(=2U:#P_H>CW<UGJEAJGB76+6V
M\):H 5/^#);_ ),+_:R_[.[?_P!4U\,Z^<_^#8W0](N/^"UG_!;+Q+-I]M)K
MVD^+_B_H>FZJR9N[/2/$/[6/BF_UO3X),_+;:G>>&/#]S=)@[Y=)LVR/+P?H
MS_@R6_Y,+_:R_P"SNW_]4U\,Z\(_X-A_^4R'_!</_LHGQ&_]:F^(U 'ZA_\
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MZ\.Z3=Z[XAUCPK\-O%VH^// _C>P\):4\.J^-]*L9-;\5>#?BCH&E-<:_?\
M@C4M#:SM9-&T;6[G3P#^Q*OX*_\ @HSIUM\*_P#@\,_X)X^+?A9;PKXK^)_A
M?X :C\21I%I-I5U)<^*#\9O@IXLN-5N@D:ZO,/@OH>EO=W<320S:,D&C3N9+
M.XC7[=\"?\'EO_!.2Z^#*^)OBO\ "?\ :7\!_'?2=($/B;X(:-X*\/>);6?Q
MG;0F._TWPKX^NO%FAZ5-X?74E:%-3\76/A'6[> 2&X\-M<0K#/\ ,'_!'/\
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M5,=OK>M>#?"&E:+K6I6$+(DEMI5UJMK>2Z1:3>9<6FEM:6UQ/<SQ27$OU-0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%%?C9J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '\7WQJU+Q%^P_P#\':GP$\13ZWKMI\'/V^_A;8:?
M-I%QKNHCPM;^+?&/@;7_ (4KI^EZ=).NFQZK>_%WX6>!_$6H6CQ3R-<>-'NH
M&CEU"TB@_JZ_:W^/FB?LL?LN_M"?M'^(9+=-,^"/P=^(7Q+:&Y*[-2O_  GX
M8U+5M'T2)&E@$]YK^L6]AHFGVHGB>[OK^VM8Y$>96'\R?_!VC\/O$/P[^&_[
M 7_!1CX>6'G>/_V+OVL/#_\ I%LTEK-%IGBFXTCXA^&M3U*^@7S(M.T;X@_!
MKPYI%G*IDN+*_P#&S/9PD75VZ>I_\'0/[5)U+_@EC\)/A)\%+ZZUOQ#_ ,%&
M/BQ\%?!/@*QTV5+75/$GPZN!IWQ::XM"-\WDZOK5A\-/#-_:V\T7VJU\8/97
M4TNGSWEI=_IE3+X\2_\ $/*R22QE)Y!F,EHH1R/%*52K4EHN=Y5B(5G*33E&
MF[OW'(Y5+V7UA?ROVD?/GBDDM=N=-?IL?S@_\$3?&W[1O[&W_!1C_@F'^T;\
M>_'OBW6_AA_P57\+?&_P+"WB?6=55I=?\0?%?Q;\-M$M38W^H+IDUQJWQ3\.
M?!KQ;I]S';P_:M$\=P0Z9IY8Z;=7W^B;^V-\=K/]F#]D[]I/]HJ\N+6W'P4^
M!_Q.^)=E]L57@N]9\)>#]7UC0=,\IN+B;5];MM/TJUMNMU=7D-N.917\LO\
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MRG_"1>(M4U&QT+]KC18;#^VM6N[RTT;3XM?^._F16GVZXDAT^SCAMXMZ0^3
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M;P[IS,S,Q)9F))9B22223DU_G4?\',G_  1\^&'_  3C^&'PF^+7['FI>-_
MO[*'QA^,D/ASXB_LZ:KXW\3^+? G@_X\Z?X%\5ZEX \>>#G\5ZQK6MO-XE\"
M6/Q(TC4HM8O]0NM%.D0PZ=J;Z3J\&D:)_HJ_"7_DE7PR_P"R?>#/_4<TVNSB
M:AE]'A#A'^S<5/&86>,XAG"K7P\<-B8.53 .5#$T8U:\(U:,KQ;A6J4ZD>6K
M"7+-)32<G7K<RLU&GHFW'9ZQ;2T?HFMGJCT&BBBOSPZ0HHHH **** "BBB@
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MQCAX."C2C)2<W*<DTHPH)3=36[BHM:6LFVNE[Z]S^:?X*_\ !/\ _:Y\)?\
M!R]^UW_P4#\0_"7^S_V1/BA^SQX:\"^!?BW_ ,)Y\,KO^W/%6G_!;]F#PE>:
M7_P@5CXSN?B;IGD^(/AWXQT_[=K'@O3].D_L?[7%>/9:AI=S??'/[2?["'_!
M47_@G%_P5X^-?_!4O_@G;\#?#'[9WPH_:@T#6-*^+_P4O?%^D^&_'>A1^*YO
M"&N^,-&6#5;_ $>YDA?QUX%T3Q3X'\7>#[?Q7J.FV5Q?^%/$7A<6"2ZGKO\
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MIN4G!T^9W%02Y;SG*,&G&#:Y5R[7M%-VZ7>ENI_+M_P5;_X),?MF+^W'\/\
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M7_"87\OBSX7:FD'_  B'A[QEJWCSP_NL?#FLS^;XH\+Z)"/L?EF037%K'/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:;92_$.7PSK7CGXX:=.\6JV3?$3XKZE>^*?%/AB[5XA87MMX3L-4T_X?R^1
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M/0O[&^*7Q1\;>'[;[3X@\$^&-0_M.STJWUB'^S/LMOJ$5E>ZA;78!^G]%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0LM5N)%!AT)M1M?B!X U!W:1I6^+5E% UH\?G-@?\$MK^Q_X*F_\%\OVY/\
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M+VUF\VV*W&I7QAD6YG2&Y\I_X(SZ[X1_X*<_\%:?^"N/_!1VZM6\3_!@>"/
MW['/P8@UF "QU'X=>(=,L+?Q;'800RR"T:[T;X3Z'J5[=PSI<S0_$S4A:3K!
MJ-["/Z??VJ_V:OAQ^V+^SG\8OV8/BY_;:?#KXV>"-5\#>)KOPS=:=8^)M)MM
M16.6SU[PU>ZQI6NZ39^(_#VIV]CKF@W6IZ)K&GV^K:?9S7FEW]NDEK+\[_\
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M5+WQ%X2\5:IX;O;-M*L--2V^A_\ @HM_P3;_ &</^"AG[;'[)-Q\9/VQ-?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P -%J__ ,WU'_$-;XW_ .CM/"O_ (:+5_\ YOJ/^)O/HZ?]')PO_B/<7_\
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M\^CI_P!')PO_ (CW%_\ ]#X?5:__ #[?_@4?_DO/\^S/YC:*_IR_XAK?&_\
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MX?5:_P#S[?\ X%'_ .2\_P ^S/YC:*_IR_XAK?&__1VGA7_PT6K_ /S?4?\
M$-;XW_Z.T\*_^&BU?_YOJ/\ B;SZ.G_1R<+_ .(]Q?\ _0^'U6O_ ,^W_P"!
M1_\ DO/\^S/YC:*_IR_XAK?&_P#T=IX5_P##1:O_ /-]1_Q#6^-_^CM/"O\
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M?#GA[28FCL]/L8-S'+R-)<7=Y=3R37NHZC>37&H:GJ%Q=:CJ%S<WMU//)W
M P!@#@ = /2BO\R_&WQ^XU\<<WHXG/YT\LR#+JE2>1\+9?4J2R[+G-.#Q6(J
MS4:F99I.D_9U<?7A!1BZE/!X?!4*LZ,O0HT(45:.LGO)[OR\EY??<****_#3
M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUG1C!W?M(U)+K",-7S=G>R\W>Q_5?\5/BK\-_@?\.O&'Q;^+_C;PY\.?AIX
MT2Z\1>,O&WBS4[?2- \/Z/:;1)=WU[<LJ!I9I(;2RM8A+>:C?W%KIUA;W-]=
M6]O+_%#\9OC=^U+_ ,'27QU'[+W[+^F^,_V?/^"17PA\?Z?JOQO_ &@]9TFY
MTSQ%\;-8\-KIVHV.C+I]R387FMI-=IJWP_\ A=))>6?AXW&C?%7XJ1KJVG>#
M_#&D_GO_ ,'"'_!4[PS^TG_P4UB_8X^..H?%ZT_X)X?L@?$JUT#XK?#GX,-H
M>G_$#XS?$CP[9+/X[U2>?Q!K&DZ.GV37G?X=>$KO5+Z[M_"FB6FM>.-(TNXU
M[7I--'Z9_!3_ (.VO^"7G[.7PL\%_!/X&_L,?M)_#+X5?#S1XM!\'^"O#%C\
M'[32='T^-Y)Y#F7XFS7E_J%_>37&I:QK.J75[K.N:M=WNKZQ?WVIWMU=S>ME
M'".=9'EF#SC+\EKYMQ!F&'CB<#5:H_4<@H5HWHXEPK5(_6LUG"2J4H3BZ&"N
MIS4ZL$G$ZT*DW"510IQ=I+7FJ--7CMI#H];O7IJ?M7_P51_9]^&?[,/_  06
M_:V_9W^!_A9?#'PP^$?[)NL>%?"&@6N^ZGM]*TFZT^[OM2U*Y""74-7U.Y;4
M/$/B369U\_4M6O=3U>];S;B9Z_!O_@W+_P""/?[._P"VO^R!X-_;(_;STS4/
MVG([*Y\5_!7]F?X0>.-<UE?A9\&?A7\/O%&KP:O-I_A?1-6TVTU+6?$_C_4_
M&>H7%GK$,VD6CN_B%=.N_$NMW6M1_P!$O[%?[:W[//\ P7I_8,_:2O/#7PZ^
M)'P]^$?C?5OBU^R%XXT+XB)X7_X2B;^V_A)X/U+7-?T8^&M;U_38H8M%^+.G
MC1[F6\AU"VUK2I[@00K%:7$O\[7_  32_P""A_B'_@WDG^)'_!,3_@JQ\.?B
M5X1^&6@?$;Q3X]_9I_:9\#>#=:\9?#KQ=X8\4S6]QK%KI<5DJWNI^$M4U&VE
M\6Z7=>&K?7/$7ASQ+XA\4^$_'.B:/?Z=&+7DRJ6?T^'^),@P<L51XJI9U0S'
M%8>G52S7$82MAW2QWU2<)NO4KQK1HSQ:P\W5G0JRB^>$YQ=35/VE*I))TG3<
M8MKW4TTX\UU9)JZ5^J/.?^"S?[&_@+_@@3^U)^QQ_P %/_\ @G3#JOP>\)>(
M_BM=?#OXP_ /3O$.LZAX(UU4TQ_$FJ:-I4&N:KJ%^/"7Q,\&V'B_2/$/AB\O
M)M%\+ZWIGAS7_"":)>K:C3?ZC/V^_P#@FO<_MA?$G]GO]K[]F[]HG6_V4/VT
M/V<+75(/A)\>]#\*6'Q)\+^)OAYXJM+R?5OAG\2?AYJVK:-IWBGP9K;ZE=M;
MS_;TDTN#7->:33M;2_BM;?\ FD_:Z^/.I_\ !S]^V5^RQ^RS^Q]\-/B='_P3
MY_9J^(O_  LO]IS]HSQQX6OO"F@:S<W<>GV^I:;IJO<2/INJ?\(0NK^%_ASH
M-[<V/C;Q%K_C?6]<U#PWI/@_PK<>(%_O KCXDS'-,MPG"DL;7:XIPN"S2GF3
MQ,:6)Q2RS%5HPR[!9K3KQK0KRGAI8OGPV+C.2H5HJO!RGHZ482E6Y5^Y<H.%
MKQ7,E[TH-6:LU'5/=:;'XH? #_@EQ\=M;_:P^'G[;/\ P4B_:WL?VPOC#\!-
M(\1Z-^S)X \$_"32_@S\#?@?=>+K:UL_$WCNR\+6FLZY?>+/B'J]I;);1:YK
M,\*Z4D5E,$U*]T7PQ=^'OVOHHKX/'9CBLQJ4ZF*E3M1I*A0I4*%'"X?#T8RG
M-4J&&PU.E0I0=2I4JS4*<74JU*E6;E4G*3Z(Q44TKZN[;;DV[)7;;;>B2\DD
MEH@HHHKA*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK\U]X6?9_P!?\.OO/H2BOGO_ (:W_92_Z.;_ &>__#T?#C_YI*/^&M_V4O\
MHYO]GO\ \/1\./\ YI*/[)S3_H6YA_X1XC_Y7YK[PL^S_K_AU]Y]"45\]_\
M#6_[*7_1S?[/?_AZ/AQ_\TE'_#6_[*7_ $<W^SW_ .'H^''_ ,TE']DYI_T+
M<P_\(\1_\K\U]X6?9_U_PZ^\^A**^>_^&M_V4O\ HYO]GO\ \/1\./\ YI*/
M^&M_V4O^CF_V>_\ P]'PX_\ FDH_LG-/^A;F'_A'B/\ Y7YK[PL^S_K_ (=?
M>?0E%?/?_#6_[*7_ $<W^SW_ .'H^''_ ,TE'_#6_P"RE_T<W^SW_P"'H^''
M_P TE']DYI_T+<P_\(\1_P#*_-?>%GV?]?\ #K[SZ$HKY[_X:W_92_Z.;_9[
M_P##T?#C_P":2C_AK?\ 92_Z.;_9[_\ #T?#C_YI*/[)S3_H6YA_X1XC_P"5
M^:^\+/L_Z_X=?>?0E%?/?_#6_P"RE_T<W^SW_P"'H^''_P TE'_#6_[*7_1S
M?[/?_AZ/AQ_\TE']DYI_T+<P_P#"/$?_ "OS7WA9]G_7_#K[SZ$HKY[_ .&M
M_P!E+_HYO]GO_P /1\./_FDH_P"&M_V4O^CF_P!GO_P]'PX_^:2C^R<T_P"A
M;F'_ (1XC_Y7YK[PL^S_ *_X=?>?0E%?/?\ PUO^RE_T<W^SW_X>CX<?_-)1
M_P -;_LI?]'-_L]_^'H^''_S24?V3FG_ $+<P_\ "/$?_*_-?>%GV?\ 7_#K
M[SZ$HKY[_P"&M_V4O^CF_P!GO_P]'PX_^:2C_AK?]E+_ *.;_9[_ /#T?#C_
M .:2C^R<T_Z%N8?^$>(_^5^:^\+/L_Z_X=?>?0E%?/?_  UO^RE_T<W^SW_X
M>CX<?_-)1_PUO^RE_P!'-_L]_P#AZ/AQ_P#-)1_9.:?]"W,/_"/$?_*_-?>%
MGV?]?\.OO/H2BOGO_AK?]E+_ *.;_9[_ /#T?#C_ .:2C_AK?]E+_HYO]GO_
M ,/1\./_ )I*/[)S3_H6YA_X1XC_ .5^:^\+/L_Z_P"'7WGT)17SW_PUO^RE
M_P!'-_L]_P#AZ/AQ_P#-)1_PUO\ LI?]'-_L]_\ AZ/AQ_\ -)1_9.:?]"W,
M/_"/$?\ ROS7WA9]G_7_  Z^\^A**^>_^&M_V4O^CF_V>_\ P]'PX_\ FDH_
MX:W_ &4O^CF_V>__  ]'PX_^:2C^R<T_Z%N8?^$>(_\ E?FOO"S[/^O^'7WG
MT)17SW_PUO\ LI?]'-_L]_\ AZ/AQ_\ -)1_PUO^RE_T<W^SW_X>CX<?_-)1
M_9.:?]"W,/\ PCQ'_P K\U]X6?9_U_PZ^\^A**^>_P#AK?\ 92_Z.;_9[_\
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MGO\ \/1\./\ YI*/^&M_V4O^CF_V>_\ P]'PX_\ FDH_LG-/^A;F'_A'B/\
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M>_\ P]'PX_\ FDH_X:W_ &4O^CF_V>__  ]'PX_^:2C^R<T_Z%N8?^$>(_\
ME?FOO"S[/^O^'7WGT)17SW_PUO\ LI?]'-_L]_\ AZ/AQ_\ -)1_PUO^RE_T
M<W^SW_X>CX<?_-)1_9.:?]"W,/\ PCQ'_P K\U]X6?9_U_PZ^\^A**^>_P#A
MK?\ 92_Z.;_9[_\ #T?#C_YI*/\ AK?]E+_HYO\ 9[_\/1\./_FDH_LG-/\
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M .5^:^\+/L_Z_P"'7WGT)17SW_PUO^RE_P!'-_L]_P#AZ/AQ_P#-)1_PUO\
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MDH_X:W_92_Z.;_9[_P##T?#C_P":2C^R<T_Z%N8?^$>(_P#E?FOO"S[/^O\
MAU]Y]"45\]_\-;_LI?\ 1S?[/?\ X>CX<?\ S24?\-;_ +*7_1S?[/?_ (>C
MX<?_ #24?V3FG_0MS#_PCQ'_ ,K\U]X6?9_U_P .OO/H2BOGO_AK?]E+_HYO
M]GO_ ,/1\./_ )I*/^&M_P!E+_HYO]GO_P /1\./_FDH_LG-/^A;F'_A'B/_
M )7YK[PL^S_K_AU]Y]"45\]_\-;_ +*7_1S?[/?_ (>CX<?_ #24?\-;_LI?
M]'-_L]_^'H^''_S24?V3FG_0MS#_ ,(\1_\ *_-?>%GV?]?\.OO/H2BOGO\
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MV>__  ]'PX_^:2C^R<T_Z%N8?^$>(_\ E?FOO"S[/^O^'7WGT)17SW_PUO\
MLI?]'-_L]_\ AZ/AQ_\ -)1_PUO^RE_T<W^SW_X>CX<?_-)1_9.:?]"W,/\
MPCQ'_P K\U]X6?9_U_PZ^\^A**^>_P#AK?\ 92_Z.;_9[_\ #T?#C_YI*/\
MAK?]E+_HYO\ 9[_\/1\./_FDH_LG-/\ H6YA_P"$>(_^5^:^\+/L_P"O^'7W
MGT)17SW_ ,-;_LI?]'-_L]_^'H^''_S24?\ #6_[*7_1S?[/?_AZ/AQ_\TE'
M]DYI_P!"W,/_  CQ'_ROS7WA9]G_ %_PZ^\^A**^>_\ AK?]E+_HYO\ 9[_\
M/1\./_FDH_X:W_92_P"CF_V>_P#P]'PX_P#FDH_LG-/^A;F'_A'B/_E?FOO"
MS[/^O^'7WGT)17SW_P -;_LI?]'-_L]_^'H^''_S24?\-;_LI?\ 1S?[/?\
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MI_T+<P_\(\1_\K\U]X6?9_U_PZ^\^A**^>_^&M_V4O\ HYO]GO\ \/1\./\
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M_-)1_P -;_LI?]'-_L]_^'H^''_S24?V3FG_ $+<P_\ "/$?_*_-?>%GV?\
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M]"W,/_"/$?\ ROS7WA9]G_7_  Z^\^A**^>_^&M_V4O^CF_V>_\ P]'PX_\
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MS?[/?_AZ/AQ_\TE']DYI_P!"W,/_  CQ'_ROS7WA9]G_ %_PZ^\^A**^>_\
MAK?]E+_HYO\ 9[_\/1\./_FDH_X:W_92_P"CF_V>_P#P]'PX_P#FDH_LG-/^
MA;F'_A'B/_E?FOO"S[/^O^'7WGT)17SW_P -;_LI?]'-_L]_^'H^''_S24?\
M-;_LI?\ 1S?[/?\ X>CX<?\ S24?V3FG_0MS#_PCQ'_ROS7WA9]G_7_#K[SZ
M$HKY[_X:W_92_P"CF_V>_P#P]'PX_P#FDH_X:W_92_Z.;_9[_P##T?#C_P":
M2C^R<T_Z%N8?^$>(_P#E?FOO"S[/^O\ AU]Y]"45\]_\-;_LI?\ 1S?[/?\
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M .'H^''_ ,TE']DYI_T+<P_\(\1_\K\U]X6?9_U_PZ^\^A**^>_^&M_V4O\
MHYO]GO\ \/1\./\ YI*/^&M_V4O^CF_V>_\ P]'PX_\ FDH_LG-/^A;F'_A'
MB/\ Y7YK[PL^S_K_ (=?>?0E%?/?_#6_[*7_ $<W^SW_ .'H^''_ ,TE'_#6
M_P"RE_T<W^SW_P"'H^''_P TE']DYI_T+<P_\(\1_P#*_-?>%GV?]?\ #K[S
MZ$HKY[_X:W_92_Z.;_9[_P##T?#C_P":2C_AK?\ 92_Z.;_9[_\ #T?#C_YI
M*/[)S3_H6YA_X1XC_P"5^:^\+/L_Z_X=?>?0E%?/?_#6_P"RE_T<W^SW_P"'
MH^''_P TE'_#6_[*7_1S?[/?_AZ/AQ_\TE']DYI_T+<P_P#"/$?_ "OS7WA9
M]G_7_#K[SZ$HKY[_ .&M_P!E+_HYO]GO_P /1\./_FDH_P"&M_V4O^CF_P!G
MO_P]'PX_^:2C^R<T_P"A;F'_ (1XC_Y7YK[PL^S_ *_X=?>?0E%?/?\ PUO^
MRE_T<W^SW_X>CX<?_-)1_P -;_LI?]'-_L]_^'H^''_S24?V3FG_ $+<P_\
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M_P"'7WGT)17SW_PUO^RE_P!'-_L]_P#AZ/AQ_P#-)1_PUO\ LI?]'-_L]_\
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M^A**^>_^&M_V4O\ HYO]GO\ \/1\./\ YI*/^&M_V4O^CF_V>_\ P]'PX_\
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M:2C^R<T_Z%N8?^$>(_\ E?FOO"S[/^O^'7WGT)17SW_PUO\ LI?]'-_L]_\
MAZ/AQ_\ -)1_PUO^RE_T<W^SW_X>CX<?_-)1_9.:?]"W,/\ PCQ'_P K\U]X
M6?9_U_PZ^\^A**^>_P#AK?\ 92_Z.;_9[_\ #T?#C_YI*/\ AK?]E+_HYO\
M9[_\/1\./_FDH_LG-/\ H6YA_P"$>(_^5^:^\+/L_P"O^'7WGT)17SW_ ,-;
M_LI?]'-_L]_^'H^''_S24?\ #6_[*7_1S?[/?_AZ/AQ_\TE']DYI_P!"W,/_
M  CQ'_ROS7WA9]G_ %_PZ^\^A**^>_\ AK?]E+_HYO\ 9[_\/1\./_FDH_X:
MW_92_P"CF_V>_P#P]'PX_P#FDH_LG-/^A;F'_A'B/_E?FOO"S[/^O^'7WGT)
M17SW_P -;_LI?]'-_L]_^'H^''_S24?\-;_LI?\ 1S?[/?\ X>CX<?\ S24?
MV3FG_0MS#_PCQ'_ROS7WA9]G_7_#K[SZ$HKY[_X:W_92_P"CF_V>_P#P]'PX
M_P#FDH_X:W_92_Z.;_9[_P##T?#C_P":2C^R<T_Z%N8?^$>(_P#E?FOO"S[/
M^O\ AU]Y]"45\]_\-;_LI?\ 1S?[/?\ X>CX<?\ S24?\-;_ +*7_1S?[/?_
M (>CX<?_ #24?V3FG_0MS#_PCQ'_ ,K\U]X6?9_U_P .OO/H2BOGO_AK?]E+
M_HYO]GO_ ,/1\./_ )I*/^&M_P!E+_HYO]GO_P /1\./_FDH_LG-/^A;F'_A
M'B/_ )7YK[PL^S_K_AU]Y]"45\]_\-;_ +*7_1S?[/?_ (>CX<?_ #24?\-;
M_LI?]'-_L]_^'H^''_S24?V3FG_0MS#_ ,(\1_\ *_-?>%GV?]?\.OO/H2BO
MGO\ X:W_ &4O^CF_V>__  ]'PX_^:2C_ (:W_92_Z.;_ &>__#T?#C_YI*/[
M)S3_ *%N8?\ A'B/_E?FOO"S[/\ K_AU]Y]"45\]_P##6_[*7_1S?[/?_AZ/
MAQ_\TE'_  UO^RE_T<W^SW_X>CX<?_-)1_9.:?\ 0MS#_P (\1_\K\U]X6?9
M_P!?\.OO/H2BOGO_ (:W_92_Z.;_ &>__#T?#C_YI*/^&M_V4O\ HYO]GO\
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M_P#AZ/AQ_P#-)1_PUO\ LI?]'-_L]_\ AZ/AQ_\ -)1_9.:?]"W,/_"/$?\
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M\TE']DYI_P!"W,/_  CQ'_ROS7WA9]G_ %_PZ^\^A**^>_\ AK?]E+_HYO\
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M:2C_ (:W_92_Z.;_ &>__#T?#C_YI*/[)S3_ *%N8?\ A'B/_E?FOO"S[/\
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M?2?^@7IW_@%;?_&J/['TG_H%Z=_X!6W_ ,:K1HHYY_S2_P# G_F!G?V/I/\
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M!>G?^ 5M_P#&JT:*.>?\TO\ P)_Y@9W]CZ3_ - O3O\ P"MO_C5']CZ3_P!
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M?^8&=_8^D_\ 0+T[_P  K;_XU1_8^D_] O3O_ *V_P#C5:-%'//^:7_@3_S
MSO['TG_H%Z=_X!6W_P :H_L?2?\ H%Z=_P" 5M_\:K1HHYY_S2_\"?\ F!G?
MV/I/_0+T[_P"MO\ XU1_8^D_] O3O_ *V_\ C5:-%'//^:7_ ($_\P,[^Q])
M_P"@7IW_ (!6W_QJC^Q])_Z!>G?^ 5M_\:K1HHYY_P TO_ G_F!G?V/I/_0+
MT[_P"MO_ (U1_8^D_P#0+T[_ , K;_XU6C11SS_FE_X$_P#,#._L?2?^@7IW
M_@%;?_&J/['TG_H%Z=_X!6W_ ,:K1HHYY_S2_P# G_F!G?V/I/\ T"]._P#
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MO_C5:-%'//\ FE_X$_\ ,#._L?2?^@7IW_@%;?\ QJC^Q])_Z!>G?^ 5M_\
M&JT:*.>?\TO_  )_Y@9W]CZ3_P! O3O_  "MO_C5']CZ3_T"]._\ K;_ .-5
MHT4<\_YI?^!/_,#._L?2?^@7IW_@%;?_ !JC^Q])_P"@7IW_ (!6W_QJM&BC
MGG_-+_P)_P"8&=_8^D_] O3O_ *V_P#C5']CZ3_T"]._\ K;_P"-5HT4<\_Y
MI?\ @3_S SO['TG_ *!>G?\ @%;?_&J/['TG_H%Z=_X!6W_QJM&BCGG_ #2_
M\"?^8&=_8^D_] O3O_ *V_\ C5']CZ3_ - O3O\ P"MO_C5:-%'//^:7_@3_
M ,P,[^Q])_Z!>G?^ 5M_\:H_L?2?^@7IW_@%;?\ QJM&BCGG_-+_ ,"?^8&=
M_8^D_P#0+T[_ , K;_XU1_8^D_\ 0+T[_P  K;_XU6C11SS_ )I?^!/_ # S
MO['TG_H%Z=_X!6W_ ,:H_L?2?^@7IW_@%;?_ !JM&BCGG_-+_P "?^8&=_8^
MD_\ 0+T[_P  K;_XU1_8^D_] O3O_ *V_P#C5:-%'//^:7_@3_S SO['TG_H
M%Z=_X!6W_P :H_L?2?\ H%Z=_P" 5M_\:K1HHYY_S2_\"?\ F!G?V/I/_0+T
M[_P"MO\ XU1_8^D_] O3O_ *V_\ C5:-%'//^:7_ ($_\P,[^Q])_P"@7IW_
M (!6W_QJC^Q])_Z!>G?^ 5M_\:K1HHYY_P TO_ G_F!G?V/I/_0+T[_P"MO_
M (U1_8^D_P#0+T[_ , K;_XU6C11SS_FE_X$_P#,#._L?2?^@7IW_@%;?_&J
M/['TG_H%Z=_X!6W_ ,:K1HHYY_S2_P# G_F!G?V/I/\ T"]._P# *V_^-4?V
M/I/_ $"]._\  *V_^-5HT4<\_P":7_@3_P P,[^Q])_Z!>G?^ 5M_P#&J/['
MTG_H%Z=_X!6W_P :K1HHYY_S2_\  G_F!G?V/I/_ $"]._\  *V_^-4?V/I/
M_0+T[_P"MO\ XU6C11SS_FE_X$_\P,[^Q])_Z!>G?^ 5M_\ &J/['TG_ *!>
MG?\ @%;?_&JT:*.>?\TO_ G_ )@9W]CZ3_T"]._\ K;_ .-4?V/I/_0+T[_P
M"MO_ (U6C11SS_FE_P"!/_,#._L?2?\ H%Z=_P" 5M_\:H_L?2?^@7IW_@%;
M?_&JT:*.>?\ -+_P)_Y@9W]CZ3_T"]._\ K;_P"-4?V/I/\ T"]._P# *V_^
M-5HT4<\_YI?^!/\ S SO['TG_H%Z=_X!6W_QJC^Q])_Z!>G?^ 5M_P#&JT:*
M.>?\TO\ P)_Y@9W]CZ3_ - O3O\ P"MO_C5']CZ3_P! O3O_  "MO_C5:-%'
M//\ FE_X$_\ ,#._L?2?^@7IW_@%;?\ QJC^Q])_Z!>G?^ 5M_\ &JT:*.>?
M\TO_  )_Y@9W]CZ3_P! O3O_  "MO_C5']CZ3_T"]._\ K;_ .-5HT4<\_YI
M?^!/_,#._L?2?^@7IW_@%;?_ !JC^Q])_P"@7IW_ (!6W_QJM&BCGG_-+_P)
M_P"8&=_8^D_] O3O_ *V_P#C5']CZ3_T"]._\ K;_P"-5HT4<\_YI?\ @3_S
M SO['TG_ *!>G?\ @%;?_&J/['TG_H%Z=_X!6W_QJM&BCGG_ #2_\"?^8&=_
M8^D_] O3O_ *V_\ C5']CZ3_ - O3O\ P"MO_C5:-%'//^:7_@3_ ,P,[^Q]
M)_Z!>G?^ 5M_\:H_L?2?^@7IW_@%;?\ QJM&BCGG_-+_ ,"?^8&=_8^D_P#0
M+T[_ , K;_XU1_8^D_\ 0+T[_P  K;_XU6C11SS_ )I?^!/_ # SO['TG_H%
MZ=_X!6W_ ,:H_L?2?^@7IW_@%;?_ !JM&BCGG_-+_P "?^8&=_8^D_\ 0+T[
M_P  K;_XU1_8^D_] O3O_ *V_P#C5:-%'//^:7_@3_S SO['TG_H%Z=_X!6W
M_P :H_L?2?\ H%Z=_P" 5M_\:K1HHYY_S2_\"?\ F!G?V/I/_0+T[_P"MO\
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MYI?^!/\ S SO['TG_H%Z=_X!6W_QJC^Q])_Z!>G?^ 5M_P#&JT:*.>?\TO\
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M)_Y@9W]CZ3_T"]._\ K;_P"-4?V/I/\ T"]._P# *V_^-5HT4<\_YI?^!/\
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M_ *V_P#C5']CZ3_T"]._\ K;_P"-5HT4<\_YI?\ @3_S SO['TG_ *!>G?\
M@%;?_&J/['TG_H%Z=_X!6W_QJM&BCGG_ #2_\"?^8&=_8^D_] O3O_ *V_\
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ME_X$_P#,#._L?2?^@7IW_@%;?_&J/['TG_H%Z=_X!6W_ ,:K1HHYY_S2_P#
MG_F!G?V/I/\ T"]._P# *V_^-4?V/I/_ $"]._\  *V_^-5HT4<\_P":7_@3
M_P P,[^Q])_Z!>G?^ 5M_P#&J/['TG_H%Z=_X!6W_P :K1HHYY_S2_\  G_F
M!G?V/I/_ $"]._\  *V_^-4?V/I/_0+T[_P"MO\ XU6C11SS_FE_X$_\P,[^
MQ])_Z!>G?^ 5M_\ &J/['TG_ *!>G?\ @%;?_&JT:*.>?\TO_ G_ )@9W]CZ
M3_T"]._\ K;_ .-4?V/I/_0+T[_P"MO_ (U6C11SS_FE_P"!/_,#._L?2?\
MH%Z=_P" 5M_\:H_L?2?^@7IW_@%;?_&JT:*.>?\ -+_P)_Y@9W]CZ3_T"]._
M\ K;_P"-4?V/I/\ T"]._P# *V_^-5HT4<\_YI?^!/\ S SO['TG_H%Z=_X!
M6W_QJC^Q])_Z!>G?^ 5M_P#&JT:*.>?\TO\ P)_Y@9W]CZ3_ - O3O\ P"MO
M_C5']CZ3_P! O3O_  "MO_C5:-%'//\ FE_X$_\ ,#._L?2?^@7IW_@%;?\
MQJC^Q])_Z!>G?^ 5M_\ &JT:*.>?\TO_  )_Y@9W]CZ3_P! O3O_  "MO_C5
M']CZ3_T"]._\ K;_ .-5HT4<\_YI?^!/_,#._L?2?^@7IW_@%;?_ !JC^Q])
M_P"@7IW_ (!6W_QJM&BCGG_-+_P)_P"8&=_8^D_] O3O_ *V_P#C5']CZ3_T
M"]._\ K;_P"-5HT4<\_YI?\ @3_S SO['TG_ *!>G?\ @%;?_&J/['TG_H%Z
M=_X!6W_QJM&BCGG_ #2_\"?^8&=_8^D_] O3O_ *V_\ C5']CZ3_ - O3O\
MP"MO_C5:-%'//^:7_@3_ ,P,[^Q])_Z!>G?^ 5M_\:H_L?2?^@7IW_@%;?\
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M K;_ .-4?V/I/_0+T[_P"MO_ (U6C11SS_FE_P"!/_,#._L?2?\ H%Z=_P"
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M3_S SO['TG_H%Z=_X!6W_P :H_L?2?\ H%Z=_P" 5M_\:K1HHYY_S2_\"?\
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M^ 5M_P#&J/['TG_H%Z=_X!6W_P :K1HHYY_S2_\  G_F!G?V/I/_ $"]._\
M *V_^-4?V/I/_0+T[_P"MO\ XU6C11SS_FE_X$_\P,[^Q])_Z!>G?^ 5M_\
M&J/['TG_ *!>G?\ @%;?_&JT:*.>?\TO_ G_ )@9W]CZ3_T"]._\ K;_ .-4
M?V/I/_0+T[_P"MO_ (U6C11SS_FE_P"!/_,#._L?2?\ H%Z=_P" 5M_\:H_L
M?2?^@7IW_@%;?_&JT:*.>?\ -+_P)_Y@9W]CZ3_T"]._\ K;_P"-4?V/I/\
MT"]._P# *V_^-5HT4<\_YI?^!/\ S SO['TG_H%Z=_X!6W_QJC^Q])_Z!>G?
M^ 5M_P#&JT:*.>?\TO\ P)_Y@9W]CZ3_ - O3O\ P"MO_C5']CZ3_P! O3O_
M  "MO_C5:-%'//\ FE_X$_\ ,#._L?2?^@7IW_@%;?\ QJC^Q])_Z!>G?^ 5
MM_\ &JT:*.>?\TO_  )_Y@9W]CZ3_P! O3O_  "MO_C5']CZ3_T"]._\ K;_
M .-5HT4<\_YI?^!/_,#._L?2?^@7IW_@%;?_ !JC^Q])_P"@7IW_ (!6W_QJ
MM&BCGG_-+_P)_P"8&=_8^D_] O3O_ *V_P#C5']CZ3_T"]._\ K;_P"-5HT4
M<\_YI?\ @3_S SO['TG_ *!>G?\ @%;?_&J/['TG_H%Z=_X!6W_QJM&BCGG_
M #2_\"?^8&=_8^D_] O3O_ *V_\ C5']CZ3_ - O3O\ P"MO_C5:-%'//^:7
M_@3_ ,P,[^Q])_Z!>G?^ 5M_\:H_L?2?^@7IW_@%;?\ QJM&BCGG_-+_ ,"?
M^8&=_8^D_P#0+T[_ , K;_XU5FWM+6T#"UMK>V#D%Q;PQPARN0"PC50Q )P3
MG&3CK5BBARDU9RDUV;;0!1114@%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%(2 "20  223@ #DDD\  =30 M?FW^UK_P %
M6OV/_P!D&ZU#PSXO\;7'C_XFZ>9(;CX7_"Z&S\3>)--NT&/L_B>_DOK'PUX3
MEC=HC<6&N:U;:ZMO(+FTT6]0;3^*_P#P58_X+.:_K>M>)?V;_P!CWQ7-HGA;
M2Y;S0OB-\</#UVT6L>)[^%Y+74?#GPTU>V<2:5X;M)%DM[_QIITB:EX@N5>/
MPW=V6@0C4_$O\RTDDDTDDTTCRRRN\DLLCL\DDCL6>21V)9W=B6=V)9F)))))
MK_1'P&^@_B.*,MP/%OBSBLQR3+<=3IXO+>$<O<<+G6*PM1*I1Q&=XRM3JO*J
M5>#4EEU"B\Q=*HI5\3EU>+HOAK8OE;C22DUO-ZJ_DEOZ[7[G]('Q3_X./OCC
MJMW<1?!CX ?##P5IFZ2*WNOB+K'B?XA:N\88B.[$?A^\^'FG65PZ8<VLD6K0
MV[GRS<7:KO?YMG_X+]?M_P LC/'??!RU4](8/AL6C7_=-SK]Q,?^!2MT^M?B
M=17]TY7]&3P$RC#0PN&\+^&:].$5%5,TH8C.<3*W6>*S;$XW$3D]VW5]$EH<
M;Q%9ZNI+Y.WX*R/VK_X?Z_\ !0+_ *"OPB_\-I#_ /+BC_A_K_P4"_Z"OPB_
M\-I#_P#+BOQ4HKTO^)>? W_HU/ __A@P/_RL7MZW_/R?_@3/VK_X?Z_\% O^
M@K\(O_#:0_\ RXH_X?Z_\% O^@K\(O\ PVD/_P N*_%2BC_B7GP-_P"C4\#_
M /A@P/\ \K#V];_GY/\ \"9^U?\ P_U_X*!?]!7X1?\ AM(?_EQ1_P /]?\
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M_P#RXK\5**/^)>? W_HU/ __ (8,#_\ *P]O6_Y^3_\  F?M7_P_U_X*!?\
M05^$7_AM(?\ Y<4?\/\ 7_@H%_T%?A%_X;2'_P"7%?BI11_Q+SX&_P#1J>!_
M_#!@?_E8>WK?\_)_^!,_:O\ X?Z_\% O^@K\(O\ PVD/_P N*/\ A_K_ ,%
MO^@K\(O_  VD/_RXK\5**/\ B7GP-_Z-3P/_ .&# _\ RL/;UO\ GY/_ ,"9
M^U?_  _U_P""@7_05^$7_AM(?_EQ1_P_U_X*!?\ 05^$7_AM(?\ Y<5^*E%'
M_$O/@;_T:G@?_P ,&!_^5A[>M_S\G_X$S]Q]$_X."OV\M*NHY]0T[X$^)8%;
M+V>L?#W7+:&53U4R>'_&VB7*$#[K+.,'!8.,J?O?X%?\''GAG4+NRTK]I#X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME?$G6/%&D^!?AGI/P]U*[^,6O0^#=271]>\03>#)+RWMO#7A:/5/.T_3=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHM'B(559-.*]NE/VE.,^K6OJG9_BM/(****_+S0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^TA[-_:YH]R5.+Y;23YK\NN]M[>G4_0ZBBBO.*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HK\[?^"C_P#P4Z_9N_X);?"_P+\7/VF+/XE7OA3XA^/1
M\.- 3X9>%]+\5:JGB$^'M9\3!]0L]4\2>&H;;3_[-T*]'VF.ZN)/M)@B^S[9
M&D3[\T#6K/Q)H6B^(M/$RV&O:3INM6*W*+'<"SU2SAOK83QH\BQS"&=!*BR2
M*C[E#L &/34P>*I87#XVI0J0PF+G7IX;$2C:G6GAG!5XTY?:=)U(*:Z.2$I1
M;<4TY1M=7U5]KKS-:BBBN884444 %%%% !1110 4444 %%%% !1110 4444
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M&G3C4C>%.:IU8*4$US2GFYH0T@K8N";IWY).Z;DK]&W;=K31GAWP(^'O@_\
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MJU?1[F\TC48IK6>;3-3M+:_LY'C+074$<J$,H-?Z9W_#DW_@D;_TCF_9$_\
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MV\-Q=?&+XAQ75Q% 6,4<US%9V<=Q*BB2:.UMDD9E@B"?EA_P3-_8-_X*D?\
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MB1[B\NOC1%;P*\LD<:M+(H:1T0$LP!^,X_\ @ZP_X+D?M%^/K+]F3X3?!_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^+S]K[_ (.ZM?\
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M^)]:\<?#3X4_&_Q#\!+[QQJ/AZ\\.:/XN\6^%_!/P^\<ZKK'@JVU5H=;O_"
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M%YW1QCCUY55QV!4[:7E"_0X,<G:F^B<D_5I6_)G@-%%%?ZFGG!1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1WM[=Y1;I/.OB#X^-%"TY240K+(%1I3'((PQ?8^W:9O^#4[_ )*M_P %G_\
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M?_!9*^\>?LJ?M+_LR_ KPIX:U_\ :C_9B\(?M%?"/Q[\/FTS4]$\,_&2ZOM
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M[.52HX<\BDI*O64GS/EI^]9*ZL[-I:)][:'H-%%%?GIU!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >*_"?]FS]G3X":KXZU[X&? +X*_!?7/BCJ%EJ_P 3-9^$
M_P +/ WPZU7XBZKIMSK=YIVI^.M1\'Z%H]YXNU#3[SQ+XCNK*]\03:A<VMSK
M^MSP2QRZK?/.W1/V:?V<O#/QA\1?M#>&_@!\$_#_ ,?O%UC+I?BSXY:)\*O
MFE?&'Q/ID\&EVL^G>(OB98:#;^--:L9K;0]%MY;34M;N;>2#1]+B>,QZ?:+#
M[916[Q6)E*I.6(KN=:FJ5:;JU'*K22BE3J2<KU*:4()0DW%*$4E:*LK+165E
MJE9:/NNP5X)X[_95_9?^*7Q/\&_&WXF_LW_ 3XB_&?X=2>'YOA]\7/'?P?\
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ME_IVHV%W'-:WMC>VLTMM=VES%+;W-O+)#-&\;LI\Y^#_ ,"_@E^SUX3D\ _
M'X.?"OX'>!9=7O-?E\%_!_X>^$OAGX3DUW48;2WU#6Y/#G@O2-$T=]7OK>PL
M8+S4FLS>74-E:13S.EM"J>J45@JE14Y4E4FJ4Y1E.FIR5.<H7Y92@GRRE&[Y
M6TVKNS5V.RWMJMGVON>-_%#]G3]GSXWZ[\/O%/QH^!/P;^+WB;X2:O<:_P#"
MGQ'\4/AAX)\?Z[\,M=O+S0]1N];^'VK^*]#U;4/!FKW6H>&/#5]<:EX<N--O
M)[SP]H=U+,T^DV#V_P 8_P#!7CX'_$/]H[]A'XO?!;X0_LV?"W]IGXK_ !'M
M[;P1\.]%^+\7@"3PA\(O$GCBWOO!'_#12R?$*QU.RMM=^"FD^)-4\7:'<^']
M/O?%<=_!&-)M+F)KV"3],J*ZL)C\1@\3@L3&3JO 5H5\/1K3JNC%QJJJX<M.
MI3E&G4FKU(TYTW.[N[MLF45)26W,K-I*^UNJ:V[IG@_[+'P53]FS]F+]G']G
M6/66\1)\ O@-\(/@JGB!XA"^NI\+/A]X>\#+K+0JD0B;4QH0O6B$<8C,Y0(@
M&T>\445S5:LZ]6I6J/FJ5JDZM25DN:=23G-V225Y-NR22Z*PTDDDMDK+T044
M45F,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K\O/^"V7_ "B-_P""C/\ V:)\:O\ U#M1K]0Z_.3_
M (*^>!_&OQ+_ ."7?[>WP_\ AQX/\4?$#QYXQ_9;^+OA_P (^"?!/A_5O%?B
M[Q3K^I>%+^VT[0_#GAO0K2_UG7-7U"X=(++3=,LKJ]NIG6*""1V"D _S9/\
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M#G_!1O\ X)P?\%%?C?\ LP?'_P#9 _:J\+?L\?'+3O%/@7Q%\6;[]G_XO0_
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MX1\9^!=4U&;PIKGP\\8Z=8GQ?%H^AZMIT^FZ/-H>M']-O$W_  70_P"" /\
MP6L^$&B?LL?MSR_$#X":9JWB_P ,^*[70?CO97O@C0=-\=>'G>&QO=#^/7PP
MUCQ%HGA+3GM=6U;3KCQ%XKUCX<0WFA3ZM8:K]@@OUM+OW7]DO_@X2O-2_P""
MCO[7O_!.;_@J=X8^ 7[(MQ\/O$%UX(^!OB;4YO$7ACP;\09=-UOQ+!J5M\0O
M%WQ'\4:KX2CL/BQ\/=3^'_B_X4326WA;1-5L7US3Y=2U_4?%?A72K7XY_P"#
MDKX0?\$&M"_8B^*7Q"\/Z/\ LF>%/VT]>CT2\_9^E_9?U'P%HGQ0\9^,9O$%
MC'?:EXN\+?"FYBTWQ+X#.@-K8\6>*/B!H]SI]M#';P:1K4'C%O#,,H!_4SXD
M^%OPD^"7_!/3QI\)/@)90Z=\$OA[^R5XW\+_  FL+3Q;K_CRPLOA[IGPJUF'
MPG:Z7XP\4:[XGUWQ!I$&B_8X]'U&_P!?U9I-,6T6"\DM4@ _G9_X,J?^467Q
M\_[/_P#BG_ZSK^RK7V1_P1<\&?'?PU_P;I?#'PW\;[77G\97_P"S%^T3J'@;
M1=8%U=^);3X4^)KKXFZK\&]+G@DA^U>7/X%U'0;CPMIBM<O8>%+WP[I2"V:U
M&F67Y#_\&=?[<_[)'PE_8Z^)G[)_Q2^/?PY^'G[0?Q&_;CU;7_AO\,O&/B*Q
MT#Q'\0[3XE_"3X#^ _!]MX(M=0EA/B74]2\6>!->T9M,TSS[RWNSID<T2G5;
M(2@'Z<?M#^&O^"&__!(O_@H]\0?^"E/[4O[37B;1?VR_CEX=\4WUI\-?%NKW
M7QEU#0K7QJ='TE?&'@/X4_#[X::U\0_ L::!X0O?ASX0\4>(]<M?"$/AB^\4
M>'8;F>4";3?DC]KS_@ZM_P""<7Q^^"GQH_9L^!7[.?[5W[6?B'XO_"'XB>"9
M?#=E\'_#NG^"I])\2>#]2TK5KOQ#!K/BO4O&,NG:1!J#7E\++X=ZE;+#97,L
ME[9HMM<R_D+_ ,$Q]*_9(^,__!P;_P %#I/^"Q\7P_U7XPVWQ(^+H^"_A7]J
M*ZTJS^$]Y\0-%^+8T;3?#IT?QU.OA37;G1?AE#HUG\%O"^NRZCX;O/"-O)<^
M'[#5+VR\-75O_5!_P4V_X*5?\$Y_^"??[%GQJ\#?!;Q-^SGJGQL^+/PN\1_#
M'X%_LT_L[MX)U+Q3XZ\;>,O#^I^"?!1OO!?PF2:\TCP9HUYJC3W>LZG;Z792
MV=C=^'O#EW<^)+_3-+N@#\RO^#)BYN'_ & OVK;-KB9K2#]L&[N8+5I9#;PW
M%U\%OA7%=7$4!8Q1S7,5G9QW$J*))DM;9)&98(@G#?\ !*O_ )6Y/^"P?_9N
M_P 7_P#U<7[&-=)_P9):E:2_L/?M>Z.CL;ZQ_:LL-2N(RC!%M-5^$7@BULG6
M0C8[/-HU^KHI+1B-&< 2IGY3_9*_:P_9X_8M_P"#K[_@JAXV_:H^*OA3X%^"
M?'GPN^)_P[T#QC\1=0C\.>&#XKUCQ1^S!\1M&L-0UG4/)L]-CUGPKX'UZ\TF
M[O)([?49UL;2UDDGU&S64 \$_P"#I3]I_P"&U[_P6J_8Q^%7[5&G^//%_P"Q
MI^R[X#^%/Q ^)OPM\"VFEZOKWC&/Q[X_U;Q;\4[70M*U_P 2^#M%EO?'O@OP
MG\/_  )>R7GB32&M-.TNYNK?4$G*0G]:='_X//O^"3GA[2=+T#0/V;_V[M#T
M+0].LM'T71='^#_[-FF:3H^DZ9;166G:7I>FV7[4L%GI^G:?9P0VEE96D,-M
M:6T,4$$4<4:(/C'_ (.&8_$G[(/_  4Z_P""97_!>+X/:6WQ9_9HO-,^$&E^
M,O$W@=[?5](U6+0=4U[Q':?8]?AGMM*BA^.7P \=W^G?#75KB\ETR?4?".IW
M=W<&UDL;2Y_K5^#W_!5O_@G+\</@;8?M$>#/VR_V=[/X9S>';3Q'KMWXR^+7
M@7P3KW@&*YMQ/+H_Q'\,>)=>T[7/ WB*Q8M;W>B^(;.SNS,J/9K=VUQ:7%P
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M1+/0/#VG#2])T'PS'\7KSX16,-AI%CI]IIUJ;B:SLFB:U:UN;BW$T\7Y:?\
M!Y5>^*-#\8_\$P_AMXN/C'1/V(8M7\9S^-HO"2WK6;^(]#UCX?:+J,<\[?;+
M2Y\6^&_A/<ZHWP]BU6&6[5=6\7RZ>+U)-86#^EW]G?5O^"&G[*7P+\*_$O\
M9Z\3_P#!._X2?!_0O#.DZ]HOQ2T3Q/\ !+3M5NM.LD<Z=K&N?$#4[]_'&O\
MBM;J6:WDN?$FK7_C!]<DGTZX!U@R6H /XQ_@#^V3X6_;G_X.MOV/OVJOAY\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;[:O37]6VV%%%%?+FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3[3:PM#;W-M<-MCFB=OYB?\ @N%XU^+G_!1O_@J]^Q__ ,$,_AY\1_%/PO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?B#5"GE#6?&'BS6[O5O%_C;7$MPEG'K?B[7M;U:*PAM[".\6RMK>"+Z;HHH
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M^B(XX^_(?_GL'U&I_/#_ ,F_R/\ .XHK_1'_ .'8'_!/W_HT_P"$7_@BF_\
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M/I$'A_P7X7\.^$-!M?\ CVT3POHFF^'](M\A5/D:;I-M:6</RJJ_NX5X51T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@K_P
M<Z?\H.OVW?\ NVS_ -:\^ 5>G?\ !#7XD_#K2?\ @D=^P/INJ^/O!6F:C9_
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M]J/AKPYX1T.ZN(]1U^\A@?3_  YI<:V45M')%+.DMS-\Y?&7_@EA^SY\<?\
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MKGB60ZG>V]I)X@UNST^X?PYX.T2.>:!M2\2^,-;6R\/>'M(M7-WJ6JZA;6T
MW.67Y>_X*/?\$E?V-O\ @J/X0\/:%^TMX/UJT\8^"%O$^'WQE^&VJV?A3XL^
M"(;X.]UIVF>(+O2M;TS5M FNG&H-X:\5:'X@T"/4D74[73[;4<W9_*#PO_P:
ML_LO:UXI\-W_ .U1^V-^W'^V!\/?!%\+OPA\'OBM\76M/!-M BS01:?JMSIE
MK-XE2U6TF,+MX'UOP!=2.&_TA+.66Q?W,5C>&,_>5YCFN88[+L5@\!@<!F>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **Y#QQX%\-?$;P_/X7\6VNH7FBW-Q:W,T&F:_XA
M\,W;36<HGMV35O#&J:/JT2+(H+Q17R13KF.=)(R5/B/_  QW\ O^A?\ &O\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
M/$H_X8[^ 7_0O^-?_#T_&W_YXE'LLF_Z#\S_ /#3A?\ Y] ?3M%?,7_#'?P"
M_P"A?\:_^'I^-O\ \\2C_ACOX!?]"_XU_P##T_&W_P">)1[+)O\ H/S/_P -
M.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\ /$H_X8[^ 7_0O^-?_#T_&W_Y
MXE'LLF_Z#\S_ /#3A?\ Y] ?3M%?,7_#'?P"_P"A?\:_^'I^-O\ \\2C_ACO
MX!?]"_XU_P##T_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\
M:_\ AZ?C;_\ /$H_X8[^ 7_0O^-?_#T_&W_YXE'LLF_Z#\S_ /#3A?\ Y] ?
M3M%?,7_#'?P"_P"A?\:_^'I^-O\ \\2C_ACOX!?]"_XU_P##T_&W_P">)1[+
M)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\ /$H_X8[^ 7_0
MO^-?_#T_&W_YXE'LLF_Z#\S_ /#3A?\ Y] ?3M%?,7_#'?P"_P"A?\:_^'I^
M-O\ \\2C_ACOX!?]"_XU_P##T_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S
M%_PQW\ O^A?\:_\ AZ?C;_\ /$H_X8[^ 7_0O^-?_#T_&W_YXE'LLF_Z#\S_
M /#3A?\ Y] ?3M%?,7_#'?P"_P"A?\:_^'I^-O\ \\2C_ACOX!?]"_XU_P##
MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
M/$H_X8[^ 7_0O^-?_#T_&W_YXE'LLF_Z#\S_ /#3A?\ Y] ?3M%?,7_#'?P"
M_P"A?\:_^'I^-O\ \\2C_ACOX!?]"_XU_P##T_&W_P">)1[+)O\ H/S/_P -
M.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\ /$H_X8[^ 7_0O^-?_#T_&W_Y
MXE'LLF_Z#\S_ /#3A?\ Y] ?3M%?,7_#'?P"_P"A?\:_^'I^-O\ \\2C_ACO
MX!?]"_XU_P##T_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\
M:_\ AZ?C;_\ /$H_X8[^ 7_0O^-?_#T_&W_YXE'LLF_Z#\S_ /#3A?\ Y] ?
M3M%?,7_#'?P"_P"A?\:_^'I^-O\ \\2C_ACOX!?]"_XU_P##T_&W_P">)1[+
M)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\ /$H_X8[^ 7_0
MO^-?_#T_&W_YXE'LLF_Z#\S_ /#3A?\ Y] ?3M%?,7_#'?P"_P"A?\:_^'I^
M-O\ \\2C_ACOX!?]"_XU_P##T_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S
M%_PQW\ O^A?\:_\ AZ?C;_\ /$H_X8[^ 7_0O^-?_#T_&W_YXE'LLF_Z#\S_
M /#3A?\ Y] ?3M%?,7_#'?P"_P"A?\:_^'I^-O\ \\2C_ACOX!?]"_XU_P##
MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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MT_&W_P">)1[+)O\ H/S/_P -.%_^?0'T[17S%_PQW\ O^A?\:_\ AZ?C;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]F;_ ,,M>?\ S;U_H??\.O\ _@FC_P!([_V&/_$2?@%_\[^C_AU__P $T?\
MI'?^PQ_XB3\ O_G?T?Z[>'W_ $0-#[L'_P#(>O\ 3T/88G_H(?X_UT_/NS_/
M!_XB[/\ @KE_S\?LS?\ AEKS_P";>C_B+L_X*Y?\_'[,W_AEKS_YMZ_T/O\
MAU__ ,$T?^D=_P"PQ_XB3\ O_G?T?\.O_P#@FC_TCO\ V&/_ !$GX!?_ #OZ
M/]=O#[_H@:'W8/\ ^0]?Z>A[#$_]!#_'^NGY]V?YX/\ Q%V?\%<O^?C]F;_P
MRUY_\V]'_$79_P %<O\ GX_9F_\ #+7G_P V]?Z'W_#K_P#X)H_]([_V&/\
MQ$GX!?\ SOZ/^'7_ /P31_Z1W_L,?^(D_ +_ .=_1_KMX??]$#0^[!__ "'K
M_3T/88G_ *"'^/\ 73\^[/\ /!_XB[/^"N7_ #\?LS?^&6O/_FWH_P"(NS_@
MKE_S\?LS?^&6O/\ YMZ_T/O^'7__  31_P"D=_[#'_B)/P"_^=_1_P .O_\
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M79_P5R_Y^/V9O_#+7G_S;U_H??\ #K__ ()H_P#2._\ 88_\1)^ 7_SOZ/\
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M *1W_L,?^(D_ +_YW]'_  Z__P"":/\ TCO_ &&/_$2?@%_\[^C_ %V\/O\
MH@:'W8/_ .0]?Z>A[#$_]!#_ !_KI^?=G^>#_P 1=G_!7+_GX_9F_P##+7G_
M ,V]'_$79_P5R_Y^/V9O_#+7G_S;U_H??\.O_P#@FC_TCO\ V&/_ !$GX!?_
M #OZ/^'7_P#P31_Z1W_L,?\ B)/P"_\ G?T?Z[>'W_1 T/NP?_R'K_3T/88G
M_H(?X_UT_/NS_/!_XB[/^"N7_/Q^S-_X9:\_^;>C_B+L_P""N7_/Q^S-_P"&
M6O/_ )MZ_P!#[_AU_P#\$T?^D=_[#'_B)/P"_P#G?T?\.O\ _@FC_P!([_V&
M/_$2?@%_\[^C_7;P^_Z(&A]V#_\ D/7^GH>PQ/\ T$/\?ZZ?GW9_G@_\1=G_
M  5R_P"?C]F;_P ,M>?_ #;T?\1=G_!7+_GX_9F_\,M>?_-O7^A]_P .O_\
M@FC_ -([_P!AC_Q$GX!?_._H_P"'7_\ P31_Z1W_ +#'_B)/P"_^=_1_KMX?
M?]$#0^[!_P#R'K_3T/88G_H(?X_UT_/NS_/!_P"(NS_@KE_S\?LS?^&6O/\
MYMZ/^(NS_@KE_P _'[,W_AEKS_YMZ_T/O^'7_P#P31_Z1W_L,?\ B)/P"_\
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M?@%_\[^C_AU__P $T?\ I'?^PQ_XB3\ O_G?T?Z[>'W_ $0-#[L'_P#(>O\
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M?_._H_UV\/O^B!H?=@__ )#U_IZ'L,3_ -!#_'^NGY]V?YX/_$79_P %<O\
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M?T?\.O\ _@FC_P!([_V&/_$2?@%_\[^C_7;P^_Z(&A]V#_\ D/7^GH>PQ/\
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MG_!7+_GX_9F_\,M>?_-O1_Q%V?\ !7+_ )^/V9O_  RUY_\ -O7^A]_PZ_\
M^":/_2._]AC_ ,1)^ 7_ ,[^C_AU_P#\$T?^D=_[#'_B)/P"_P#G?T?Z[>'W
M_1 T/NP?_P AZ_T]#V&)_P"@A_C_ %T_/NS_ #P?^(NS_@KE_P _'[,W_AEK
MS_YMZ/\ B+L_X*Y?\_'[,W_AEKS_ .;>O]#[_AU__P $T?\ I'?^PQ_XB3\
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M>'W_ $0-#[L'_P#(>O\ 3T/88G_H(?X_UT_/NS_/!_XB[/\ @KE_S\?LS?\
MAEKS_P";>C_B+L_X*Y?\_'[,W_AEKS_YMZ_T/O\ AU__ ,$T?^D=_P"PQ_XB
M3\ O_G?T?\.O_P#@FC_TCO\ V&/_ !$GX!?_ #OZ/]=O#[_H@:'W8/\ ^0]?
MZ>A[#$_]!#_'^NGY]V?YX/\ Q%V?\%<O^?C]F;_PRUY_\V]'_$79_P %<O\
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ML'_\AZ_T]#V&)_Z"'^/]=/S[L_SP?^(NS_@KE_S\?LS?^&6O/_FWH_XB[/\
M@KE_S\?LS?\ AEKS_P";>O\ 0^_X=?\ _!-'_I'?^PQ_XB3\ O\ YW]'_#K_
M /X)H_\ 2._]AC_Q$GX!?_._H_UV\/O^B!H?=@__ )#U_IZ'L,3_ -!#_'^N
MGY]V?YY%M_P=Y?\ !6Z"9)95_9?O$4Y:WN?@QJR0R>SM9^/[6X _ZYSH?>ON
M#]G_ /X/3OVB-'U*RM?VH_V._@[\0-$>2""^UCX%^*O&7PJUVRM]P6?48]%\
M=WOQ;TO7+M(LR#31J_A>VN9LJNH6$3#9_:==_P#!+/\ X)DWUO):W7_!.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BE_P '%G_*%O\
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MCQ[_ .(^?&S_ .8JC_5#BK_HF\\_\->,_P#E/G^?9A[:C_S]I_\ @<?\_/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?X^?_! O_E-+^PS_P!EJU__ -0/QS7^
MP97^/G_P0+_Y32_L,_\ 9:M?_P#4#\<U_L&5^Q>-'_(_RK_L2T__ %-QAQX'
M^%+_ *^/_P!)@%%%%?CIV!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?X^?_! O_E-+^PS_ -EJU_\ ]0/Q
MS7^P97^/G_P0+_Y32_L,_P#9:M?_ /4#\<U_L&5^Q>-'_(_RK_L2T_\ U-QA
MQX'^%+_KX_\ TF 4445^.G8%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'XI?\'%G_*%O]NW_ +$+P!_ZNSX95_*;_P &5O\ R=M^V7_V
M;IX2_P#5EZ?7]67_  <6?\H6_P!NW_L0O '_ *NSX95_*;_P96_\G;?ME_\
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M4-1TG6-2^&_PK.M7-E:> -,^'6DK\1/$T5S!J4D^LSZY;^$_#OG/[1O[//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _%+_ (.+/^4+?[=O_8A> /\
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M0F1?]E!G?_J)EA_8$?X]3_KW3_\ 2IGTU1117QIL?Y]7_![-_P E5_X)]?\
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M7_A*_C'\6OMW_"+_ -@_#_[#]@_X1_[+_P )%>?:O[5^T6W]F_F!_P %._\
M@YGU?X/?M%W?[#?_  3%^!5G^UW^TW8>))_ FO>);G2O%GC7P38_$.TEN;?5
MOAYX!\ _#R\TWQ=\4O%.@2VUU!X@U&QU_1?#^A:E975E&/$GV/5!8?T._P#!
M1/XV>(?V</V"_P!L?X[^$))H/&'PI_9J^,OC3P;=0%0]EXPT?P'KD_A2_8LR
MXAL/$']G7MR5)D%O!*8DDEV(W\B7_!F'^S/X*UO1OVP/VU_%-E;^)/BK%XUT
M'X$^#O$&KQ_;M6\+:5-H47C_ .)%_8W]R\L_]H^.[OQ!X/MM3OV O1:^&I;:
M.Z,&KZI#-SY/A\FQ6#XAXTS/)\+]3RZ>!PF7Y!@YUZ. JX^O"E14JLI5*E;V
M$/<Q-6#JM595*UTU&%.1-S4J=",Y7ES2E4=G)13OITOTO;33S*_C'_@J+_P=
M;_LS^'+WX\_';]@WP+KGP<\,6_\ ;OC+3/\ A3MMK$&C^&,QWFHZCJ<'PE^+
M5_\ $#PO9Z1IHF>\U_6;:;3/#<*RZAXF@E@L[A1_0M_P1T_X+9? '_@KCX \
M0P^&=!O/A'^T5\,]+T[4OBO\#]:U2+6OLNE:A<?8+?QM\/\ Q*EKIW_"8>!K
MC4?*T^]N9=+TK6O"^K75EI>OZ9%!J?AW5_$'[3NB2(\<B+)'(K(Z.H9'1@59
M'5@5964D,I!!!(((-?YP/B+P9I/_  2R_P"#M#X:>&/@A81^"OA1\<?CG\*M
M$T[P;I*FQT"/PA^V;X>TGP;XH\+0Z5IL;VT/AK0/BKXLU74_"FC"U@T_1/\
MA'/#)A2TATFWNXMLO63<:X+.,''(LOR3.\MRS$9KEV(RA5:&&Q5/"<GML'BL
M-5JU8RG44X^SK*7,FW+W53E"LI<]"4'[252G*2A)3LVF]I)I)]'IMTW=U_I
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M,TS]E;X8_&O_ (*)?$OXU3> ?@-\&O@GX#^+UA\.[;P"GA#0M0A\9>--)O\
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M!XO\=> /@AX,U?5[)TUJY\%P/K.I>'["]0R^*=5L+;^V;K&UW_@X/_X+7?\
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M*\NM<N+=+'Q+<0SZ'+<7$%YIOXF?\'H7P_\ #.H?L"?LP_%.YTZV?QEX2_;
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M^"3_ ,+)'\0W&G_$_P#:;\8:5/-\(OV>=*U4V^JZIETMQXP^(.I6EO?'P/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQOCI<7\$=VZB!YK*"_L9[N)9"]M#>VDDRHEQ"S_Z(%?S'?\ !PA_P0C^(O\
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MB6;Z?X:T.UOM<U[4)+H06<$-I:,?MNJ:?#/[%\!?^"BW_!/K]EC_ ()'2_\
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M-H%E\2?A[XH\">-O@9\1;KPQ;7<]E:^++E+2]NA<ZF]EX4T&UU2ZT]]7Q_\
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MUFY7TV3?FNFR_7#_ ((??M)?\$I?VY)/VD-1_8#_ ."?FO\ [(VM^%? FB^
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M^C_ _P"&L?B#PW<6&I6FD^%?!&A>)Y+-[?5%O+FW^'NFVE\VH0WU_,?[I?\
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M,FGB"RTK1?#GBCPEI6DZ/-XH@TNRT[3M"^(\GB?76L-*L]5OK7]"/^".?_!
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M:S;Z=:^.Y;O4'\7?#;QEI<?@W49=3UE!K=OX?U)?"UM\H?%?_@C;_P ')_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH _%+_@XL_P"4+?[=O_8A> /_ %=GPRK^4W_@RM_Y.V_;+_[-
MT\)?^K+T^OZLO^#BS_E"W^W;_P!B%X _]79\,J_E-_X,K?\ D[;]LO\ [-T\
M)?\ JR]/K]BX;_Y-/QC_ -C)?^D9.<=7_>Z'^%_^WG^B_1117XZ=@4444 %?
MQX_\'77_ "/G_!'/_L\;5_\ T\_!:O[#J_CQ_P"#KK_D?/\ @CG_ -GC:O\
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M?^)X6MO$.D:+J.H:Q9.5,NG7_BGQ%K/BRXTN8I\GVC2WUPZ?<;"RB:VD"R2
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M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!?'_Z3 ****_'3L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ_8N&_\ DT_&/_8R7_I&3G'5_P![H?X7_P"WG^B_1117XZ=@4444 %?QV_\
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M6-?RU_\ $&K_ ,$M_P#HLG[<_P#X=3X&_P#T-E'_ !!J_P#!+?\ Z+)^W/\
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M** "BBB@ HHHH **** /\?/_ ((%_P#*:7]AG_LM6O\ _J!^.:_V#*_Q\_\
M@@7_ ,II?V&?^RU:_P#^H'XYK_8,K]B\:/\ D?Y5_P!B6G_ZFXPX\#_"E_U\
M?_I, HHHK\=.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,X3BW&491:3C*,DU)-)IIIJYV[[!1114@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR^6B7Y7^84445^8G4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>'C\0?AAJ^H%=N;G58D\2>--">ZD^?>=(T31;,93R[*/8WF>Y_\ $;'\9?\
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M-'_$+.-_^A32_P##CEO_ ,U_U9^5SZW0_F?_ (#+_(_T(:*_SWO^(V/XR_\
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M+_T8)\,O_#[>*O\ YW-'_$+.-_\ H4TO_#CEO_S7_5GY7/K=#^9_^ R_R/\
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M32_\..6__-?]6?E<^MT/YG_X#+_(_P!"&BO\][_B-C^,O_1@GPR_\/MXJ_\
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MSZW0_F?_ (#+_(_T(:*_SWO^(V/XR_\ 1@GPR_\ #[>*O_G<T?\ $;'\9?\
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MW_$;'\9?^C!/AE_X?;Q5_P#.YH_XC8_C+_T8)\,O_#[>*O\ YW-'_$+.-_\
MH4TO_#CEO_S7_5GY7/K=#^9_^ R_R/\ 0AHK_/>_XC8_C+_T8)\,O_#[>*O_
M )W-'_$;'\9?^C!/AE_X?;Q5_P#.YH_XA9QO_P!"FE_X<<M_^:_ZL_*Y];H?
MS/\ \!E_D?Z$-%?Y[W_$;'\9?^C!/AE_X?;Q5_\ .YH_XC8_C+_T8)\,O_#[
M>*O_ )W-'_$+.-_^A32_\..6_P#S7_5GY7/K=#^9_P#@,O\ (_T(:*_SWO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5QWCWX=?#[XJ>&;_ ,%?$_P+X.^(_@W50HU/PEX]\,:)XP\,ZD$S
ML%_H/B&QU'2KP)N;:+BTD"[CC&378T5492A*,X2E"<6I1E%N,HR6J<9)IIIZ
MIIW0'XY?$;_@WX_X(V?%+49]3\3?L$_"/3+FXDEDDC^'6I_$/X/Z>K2DLX@T
MCX2>-/!&E6T8)/EQ6UE%%",+"D:@ >1?\0Q?_!#K_HR+_P V3_:\_P#G^U^]
M5%>U3XGXEI14*7$.>4X15E"GFV/A%+LHQQ"27HC/V5+_ )]T_P#P"/\ D?@K
M_P 0Q?\ P0Z_Z,B_\V3_ &O/_G^T?\0Q?_!#K_HR+_S9/]KS_P"?[7[U45?^
MM?%/_12Y_P#^'C,?_FD/8TO^?5/_ , C_D?@K_Q#%_\ !#K_ *,B_P#-D_VO
M/_G^T?\ $,7_ ,$.O^C(O_-D_P!KS_Y_M?O511_K7Q3_ -%+G_\ X>,Q_P#F
MD/8TO^?5/_P"/^1^"O\ Q#%_\$.O^C(O_-D_VO/_ )_M'_$,7_P0Z_Z,B_\
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M_P#^'C,?_FD/8TO^?5/_ , C_D?@K_Q#%_\ !#K_ *,B_P#-D_VO/_G^T?\
M$,7_ ,$.O^C(O_-D_P!KS_Y_M?O511_K7Q3_ -%+G_\ X>,Q_P#FD/8TO^?5
M/_P"/^1^"O\ Q#%_\$.O^C(O_-D_VO/_ )_M'_$,7_P0Z_Z,B_\ -D_VO/\
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MKS_Y_M'_ !#%_P#!#K_HR+_S9/\ :\_^?[7[U44?ZU\4_P#12Y__ .'C,?\
MYI#V-+_GU3_\ C_D?@K_ ,0Q?_!#K_HR+_S9/]KS_P"?[1_Q#%_\$.O^C(O_
M #9/]KS_ .?[7[U44?ZU\4_]%+G_ /X>,Q_^:0]C2_Y]4_\ P"/^1^"O_$,7
M_P $.O\ HR+_ ,V3_:\_^?[1_P 0Q?\ P0Z_Z,B_\V3_ &O/_G^U^]5%'^M?
M%/\ T4N?_P#AXS'_ .:0]C2_Y]4__ (_Y'X*_P#$,7_P0Z_Z,B_\V3_:\_\
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M .?[7[U44?ZU\4_]%+G_ /X>,Q_^:0]C2_Y]4_\ P"/^1^"O_$,7_P $.O\
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M7_P0Z_Z,B_\ -D_VO/\ Y_M?O511_K7Q3_T4N?\ _AXS'_YI#V-+_GU3_P#
M(_Y'X*_\0Q?_  0Z_P"C(O\ S9/]KS_Y_M'_ !#%_P#!#K_HR+_S9/\ :\_^
M?[7[U44?ZU\4_P#12Y__ .'C,?\ YI#V-+_GU3_\ C_D?@K_ ,0Q?_!#K_HR
M+_S9/]KS_P"?[1_Q#%_\$.O^C(O_ #9/]KS_ .?[7[U44?ZU\4_]%+G_ /X>
M,Q_^:0]C2_Y]4_\ P"/^1^"O_$,7_P $.O\ HR+_ ,V3_:\_^?[1_P 0Q?\
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M#%_\$.O^C(O_ #9/]KS_ .?[7[U44?ZU\4_]%+G_ /X>,Q_^:0]C2_Y]4_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>eikn-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-05-11T16:11:46.7714+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.eikontx.com/20260331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eikn="http://www.eikontx.com/20260331" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>75010 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75030 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>75040 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>75050 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows" id="StatementCondensedStatementsOfCashFlows">
        <link:definition>75060 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows2" id="StatementCondensedStatementsOfCashFlows2">
        <link:definition>75070 - Statement - Condensed Statements of Cash Flows 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>995455 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>995475 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>995495 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>995505 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingencies1" id="DisclosureCommitmentsAndContingencies1">
        <link:definition>995515 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructure1" id="DisclosureCapitalStructure1">
        <link:definition>995525 - Disclosure - Capital Structure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpense" id="DisclosureEquityIncentivePlansAndStockbasedCompensationExpense">
        <link:definition>995535 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprd" id="DisclosureAcquisitionsOfIprd">
        <link:definition>995545 - Disclosure - Acquisitions of IPR&amp;D</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangements" id="DisclosureResearchAndDevelopmentArrangements">
        <link:definition>995555 - Disclosure - Research and Development Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlan" id="DisclosureEmployee401kPlan">
        <link:definition>995565 - Disclosure - Employee 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegment" id="DisclosureSegment">
        <link:definition>995575 - Disclosure - Segment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995585 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995595 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>995605 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995615 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>995625 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>995635 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureTables" id="DisclosureCapitalStructureTables">
        <link:definition>995645 - Disclosure - Capital Structure (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables" id="DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables">
        <link:definition>995655 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentTables" id="DisclosureSegmentTables">
        <link:definition>995665 - Disclosure - Segment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>995675 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995685 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh" id="DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh">
        <link:definition>995695 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe" id="DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe">
        <link:definition>995705 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured At Fair Value On Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995725 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>995735 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>995745 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995755 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>995765 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3" id="DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3">
        <link:definition>995775 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Non-cancellable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2" id="DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2">
        <link:definition>995785 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Non-cancellable Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995795 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails" id="DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails">
        <link:definition>995805 - Disclosure - Capital Structure - Summary of Issued and Outstanding Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails" id="DisclosureCapitalStructureAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Capital Structure - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>995825 - Disclosure - Capital Structure - Summary of Common Stock Reserved for Future issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails" id="DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" id="DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails">
        <link:definition>995845 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails" id="DisclosureAcquisitionsOfIprdAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Acquisitions of IPR&amp;D - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails" id="DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Research and Development Arrangements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlanAdditionalInformationDetails" id="DisclosureEmployee401kPlanAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Employee 401(k) Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails" id="DisclosureSegmentAdditionalInformationDetails">
        <link:definition>995885 - Disclosure - Segment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails" id="DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails">
        <link:definition>995895 - Disclosure - Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eikn-20260331.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets" xlink:href="eikn-20260331.xsd#StatementCondensedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:href="eikn-20260331.xsd#StatementCondensedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" xlink:href="eikn-20260331.xsd#StatementCondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="eikn-20260331.xsd#StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="eikn-20260331.xsd#StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows" xlink:href="eikn-20260331.xsd#StatementCondensedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="eikn-20260331.xsd#DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="eikn-20260331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="eikn-20260331.xsd#DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="eikn-20260331.xsd#DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="eikn-20260331.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeases" xlink:href="eikn-20260331.xsd#DisclosureOperatingLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:href="eikn-20260331.xsd#DisclosureCommitmentsAndContingencies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructure1" xlink:href="eikn-20260331.xsd#DisclosureCapitalStructure1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpense" xlink:href="eikn-20260331.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationExpense" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprd" xlink:href="eikn-20260331.xsd#DisclosureAcquisitionsOfIprd" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangements" xlink:href="eikn-20260331.xsd#DisclosureResearchAndDevelopmentArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlan" xlink:href="eikn-20260331.xsd#DisclosureEmployee401kPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegment" xlink:href="eikn-20260331.xsd#DisclosureSegment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEvents" xlink:href="eikn-20260331.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eikn-20260331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="eikn-20260331.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="eikn-20260331.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="eikn-20260331.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesTables" xlink:href="eikn-20260331.xsd#DisclosureOperatingLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureTables" xlink:href="eikn-20260331.xsd#DisclosureCapitalStructureTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables" xlink:href="eikn-20260331.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentTables" xlink:href="eikn-20260331.xsd#DisclosureSegmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh" xlink:href="eikn-20260331.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe" xlink:href="eikn-20260331.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="eikn-20260331.xsd#DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="eikn-20260331.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="eikn-20260331.xsd#DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3" xlink:href="eikn-20260331.xsd#DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails" xlink:href="eikn-20260331.xsd#DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureCapitalStructureAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:href="eikn-20260331.xsd#DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" xlink:href="eikn-20260331.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureAcquisitionsOfIprdAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlanAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureEmployee401kPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureSegmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails" xlink:href="eikn-20260331.xsd#DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="eikn-20260331.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2" xlink:href="eikn-20260331.xsd#DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows2" xlink:href="eikn-20260331.xsd#StatementCondensedStatementsOfCashFlows2" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock" xlink:label="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:label="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock" xlink:label="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInOtherAssets" xlink:label="eikn_IncreaseDecreaseInOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" xlink:label="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" xlink:label="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DividendsDeclared" xlink:label="eikn_DividendsDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseTerminationDate" xlink:label="eikn_OperatingLeaseTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TheColumnGroupAndCatalyst4AgreementMember" xlink:label="eikn_TheColumnGroupAndCatalyst4AgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactAgreementMember" xlink:label="eikn_ImpactAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_InProcessResearchAndDevelopmentExpenses" xlink:label="eikn_InProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" xlink:label="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPayments" xlink:label="eikn_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" xlink:label="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquitySharesRedeemedUponConversionShares" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CaliforniaNewYorkAndNewJerseyMember" xlink:label="eikn_CaliforniaNewYorkAndNewJerseyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PaymentForAchievementOfCertainRegulatoryMilestone" xlink:label="eikn_PaymentForAchievementOfCertainRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpairmentOnMarketableSecurities" xlink:label="eikn_ImpairmentOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SevenAndEightMember" xlink:label="eikn_SevenAndEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EngineeringEquipmentMember" xlink:label="eikn_EngineeringEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SuperbWisdomLimitedMember" xlink:label="eikn_SuperbWisdomLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" xlink:label="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SalesMilestones" xlink:label="eikn_SalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FutureMilestonesAccrued" xlink:label="eikn_FutureMilestonesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityFairValueExceededCarryingValue" xlink:label="eikn_TemporaryEquityFairValueExceededCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CommonStockWarrantsMember" xlink:label="eikn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CommonStockWarrantsPolicyPolicyTextBlock" xlink:label="eikn_CommonStockWarrantsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" xlink:label="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontsAndMilestonePayments" xlink:label="eikn_UpfrontsAndMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SimpleAgreementsForFutureEquityIssuedAmount" xlink:label="eikn_SimpleAgreementsForFutureEquityIssuedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CashPaidForOperatingLeaseLiabilities" xlink:label="eikn_CashPaidForOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="eikn_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FurnitureFittingsOfficeEquipmentMember" xlink:label="eikn_FurnitureFittingsOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" xlink:label="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" xlink:label="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:label="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityCarryingValueExceededFairValue" xlink:label="eikn_TemporaryEquityCarryingValueExceededFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" xlink:label="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestonesPaid" xlink:label="eikn_DevelopmentAndRegulatoryMilestonesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ResearchAndEngineeringExpenses" xlink:label="eikn_ResearchAndEngineeringExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UnderwritingDiscountsAndCommissions" xlink:label="eikn_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionOwnershipPercentageLessThanTenPercentMember" xlink:label="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionsIssuedAndOutstandingMember" xlink:label="eikn_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_LabEquipmentMember" xlink:label="eikn_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" xlink:label="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" xlink:label="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember" xlink:label="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember" xlink:label="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" xlink:label="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SalesRoyaltyPayable" xlink:label="eikn_SalesRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue" xlink:label="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SharesReservedForEmployeeStockPurchasePlanMember" xlink:label="eikn_SharesReservedForEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ConversionOfRedeemableConvertiblePreferredStockMember" xlink:label="eikn_ConversionOfRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_WeightedAverageCommonSharesOutstanding" xlink:label="eikn_WeightedAverageCommonSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" xlink:label="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" xlink:label="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedInProcessResearchAndDevelopment" xlink:label="eikn_AccruedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityOffsetFairValueExceededCarryingValue" xlink:label="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontFeePaidInCash" xlink:label="eikn_UpfrontFeePaidInCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="eikn_AccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_RedeemableConvertiblePreferredStockHoldersPercent" xlink:label="eikn_RedeemableConvertiblePreferredStockHoldersPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PercentageOfIncrementalBorrowingRate" xlink:label="eikn_PercentageOfIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayable" xlink:label="eikn_AdditionalMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" xlink:label="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseDepositLiability" xlink:label="us-gaap_LeaseDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AggregatePaymentToPerformResearchAndDevelopment" xlink:label="eikn_AggregatePaymentToPerformResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock" xlink:label="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestones" xlink:label="eikn_DevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MidDoubleDigitPercentagePaymentsReceived" xlink:label="eikn_MidDoubleDigitPercentagePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ClinicalExpenses" xlink:label="eikn_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedClinicalExpenses" xlink:label="eikn_AccruedClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedVendorExpenses" xlink:label="eikn_AccruedVendorExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense" xlink:label="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" xlink:label="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdjustmentNetOfIssuanceCosts" xlink:label="eikn_AdjustmentNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock" xlink:label="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityOffsetCarryingValueExceededFairValue" xlink:label="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionsAvailableForFutureIssuanceMember" xlink:label="eikn_StockOptionsAvailableForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" xlink:label="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixLong-TermIncentivePlanMember" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing and investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expenses and Accruals [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenses and accruals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Initial Public Offering Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Initial Public Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred initial public offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Value in Exchange for Extinguished Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period value in exchange for extinguished preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Original issue price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held-to-Maturity Non Current Accumulated Gross Unrealized Loss Before Tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities held-to-maturity non current accumulated gross unrealized loss before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable Securities, Unrealized Losses, Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent and Trademark Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent and Trademark Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent and trademark costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in other assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishments Reduction To Net Loss Available To Common Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extinguishments reduction to net loss available to common shareholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishments reduction to net loss available to common shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vehicles [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Motor Vehicles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of significant accounting policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease in the lease liability from the remeasurement of the lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease in the lease liability from the remeasurement of the lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Fair Value, Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DividendsDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Six Long-Term Incentive Plan and Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty six long-term incentive plan and Two thousand nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 LTIP and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee 401(k) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Termination date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Termination date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TheColumnGroupAndCatalyst4AgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The Column Group and Catalyst4 Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TheColumnGroupAndCatalyst4AgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The column group and catalyst4 agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TheColumnGroupAndCatalyst4AgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Column Group and Catalyst4 Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award, Exercise Price Of Options Granted At Fair Market Value Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, exercise price of options granted at fair market value ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of options granted at fair market value ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee 401(k) Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpactAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpactAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impact Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpactAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impact agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Redeemed Upon Conversion, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, shares redeemed upon conversion, amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments Due, after Year four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, Operating Lease, Liability, Payments Due, after Year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity (deficit):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payable for a Compound that is not a Conjugate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payable for a compound that is not a conjugate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payable upon the achievement of certain development and regulatory milestones for a compound that is not a conjugate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_InProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_InProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In process research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_InProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans and Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues In Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, new issues in initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercised Stock Options And Unvested Restricted Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercised stock options and unvested restricted common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercised Stock Options and Unvested Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B One and C One Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 and C-1 redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 and C-1 Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Redeemed Upon Conversion, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, shares redeemed upon conversion, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impact Of Preferred Stock Extinguishments And Modifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impact of preferred stock extinguishments and modifications.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of preferred stock extinguishments and modifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CaliforniaNewYorkAndNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California, New York and New Jersey [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CaliforniaNewYorkAndNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California, New York and New Jersey.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CaliforniaNewYorkAndNewJerseyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hayward, California, New York, New York and Jersey City, New Jersey</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted (in term)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share-Based Payment Award, Granted Term One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share-based payment award, granted term one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contributions to the plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income (Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Fair Value, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Fair Value, Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Amortized Cost, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PaymentForAchievementOfCertainRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for achievement of certain regulatory milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PaymentForAchievementOfCertainRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Achievement Of Certain Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PaymentForAchievementOfCertainRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for achievement of certain regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpairmentOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpairmentOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment on Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ImpairmentOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment on Marketable Securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SevenAndEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Seven and Eight [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SevenAndEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Seven and Eight.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SevenAndEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seven and Eight</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EngineeringEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Engineering equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EngineeringEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Engineering equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EngineeringEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Engineering Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total common stock equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After One Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SuperbWisdomLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Superb Wisdom Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SuperbWisdomLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Superb Wisdom Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SuperbWisdomLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SW</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock, common stock warrants and redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Of Options Granted Under Incentive And Share Based Compensation Plans As Percentage Of Fair Market Value Of Shares On Grant Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price of options granted under incentive and share based compensation plans as percentage of fair market value of shares on grant date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of shares on grant date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification Rights and Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payable upon the Achievement of Certain Regulatory and Commercial Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payable upon the achievement of certain regulatory and commercial milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payable upon the achievement of certain regulatory and commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestones paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value in Exchange for Extinguished Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value in exchange for extinguished preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FutureMilestonesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestones Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FutureMilestonesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future milestones accrued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FutureMilestonesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future milestones accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityFairValueExceededCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity fair value exceeded carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityFairValueExceededCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value exceeded carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockWarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockWarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockWarrantsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Collaboration and Supply Agreements with MSD [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial collaboration and supply agreements with MSD.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial Collaboration and Supply Agreements with MSD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares returned by the holders in exchange of redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B One And C One Redeemable Convertible Preferred Stock And Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 and C-1 Redeemable Convertible Preferred Stock And Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontsAndMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfronts and Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontsAndMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfronts and milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontsAndMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfronts and milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B-1 Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SimpleAgreementsForFutureEquityIssuedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simple agreements for future equity issued, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SimpleAgreementsForFutureEquityIssuedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreements for Future Equity Issued Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SimpleAgreementsForFutureEquityIssuedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple agreements for future equity issued amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in carrying amount of redeemable Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CashPaidForOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CashPaidForOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CashPaidForOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Amortized Cost, Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting rights, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FurnitureFittingsOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture, fittings &amp; office equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FurnitureFittingsOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture, fittings &amp; office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_FurnitureFittingsOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture, Fittings &amp; Office Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in net loss available to common stockholders from equity modifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Net Loss Available To Common Stockholders From Equity Modifications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in net loss available to common stockholders from equity modifications.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments Recognized as In Process Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments recognized as in-process research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments recognized as in-process research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt securities held-to-maturity current accumulated gross unrealized loss before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities held-to-maturity current accumulated gross unrealized loss before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable Securities, Unrealized Losses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock, $0.0001 par value; no shares authorized, issued and outstanding as of March 31, 2026 and 262,597,889 shares authorized, 222,658,133 shares issued and outstanding, and aggregate liquidation preference of $1,159,762 as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 50,000,000 shares authorized and no shares issued and outstanding as of March 31, 2026 and no shares authorized, issued and outstanding as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured At Fair Value On Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityCarryingValueExceededFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity carrying value exceeded fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityCarryingValueExceededFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying value exceeded fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of future lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current portion of early exercised options and restricted common stock liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of early exercised options and restricted common stock liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of early exercised options and restricted common stock liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Dividend Rate, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cumulative dividend percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestonesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestones Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestonesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestonesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestones, paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Operating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ResearchAndEngineeringExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Engineering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ResearchAndEngineeringExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and engineering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ResearchAndEngineeringExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and engineering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts and Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option, Ownership Percentage Less Than 10% Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option, Ownership Percentage Less Than Ten Percent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option, ownership percentage less than 10%.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original Issue Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Issued And Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Held-to-Maturity Current Accumulated Gross Unrealized Gain Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities held-to-maturity current accumulated gross unrealized gain before tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Unrealized Gains, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payable upon the Achievement of Certain Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payable upon the achievement of certain regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payable upon the achievement of certain regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock, hares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Shares in Exchange for Extinguished Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period shares in exchange for extinguished preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Including Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Temporary Equity, Including Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab Equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues In Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, new issues in initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use asset reduction from remeasurement of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Reduction From Remeasurement of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right of use asset reduction from remeasurement of operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Weighted-average common shares subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Weighted-average common shares subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option, Ownership Percentage More Than 10% Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option, Ownership Percentage More Than Ten Percent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option, ownership percentage more than 10%.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Six Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty six employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expenses And Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Issued and Outstanding Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred IPO costs capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Early Exercised Stock Options And Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of early exercised stock options and restricted common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options and restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Shares in Exchange for Modified Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period shares in exchange for modified preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SalesRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales royalty payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SalesRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales royalty payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Redeemed or Called During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Modified Adjusted preferred Stock Increase In Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Modified adjusted Preferred stock increase in fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modified adjusted Preferred stock increase in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions and In-Process Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SharesReservedForEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Reserved for ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SharesReservedForEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved For Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SharesReservedForEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ConversionOfRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ConversionOfRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ConversionOfRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_WeightedAverageCommonSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_WeightedAverageCommonSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Common Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_WeightedAverageCommonSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average common shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, liquidation preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Liquidation Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, cash equivalents and marketable securities - current and marketable securities - non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities current and marketable securities non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants at fair values</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments under Non-cancellable Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Vesting of Early Exercised Stock Options and Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, vesting of early exercised stock options and restricted common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options and restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of significant accounting policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option, ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share-based payment award, ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued In Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued In Process Research and Development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses related to purchase of IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Offset Fair Value Exceeded Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity offset fair value exceeded carrying value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value exceeded carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Operating lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontFeePaidInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Paid in Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontFeePaidInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee paid in cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_UpfrontFeePaidInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee paid in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series D Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Structure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_RedeemableConvertiblePreferredStockHoldersPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock holders percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_RedeemableConvertiblePreferredStockHoldersPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Holders Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_RedeemableConvertiblePreferredStockHoldersPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock holders percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PercentageOfIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PercentageOfIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of incremental borrowing rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_PercentageOfIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from the issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease in the operating lease right of use assets from the remeasurement of the lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease in the operating lease right of use assets from the remeasurement of the lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value in Exchange for Modified Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value in exchange for modified preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New issuance convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, transfers to level 3, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Payable upon the Achievement of Certain Development and Regulatory Milestones Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount payable upon the achievement of certain development and regulatory milestones milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable upon the achievement of certain development and regulatory milestones milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Deposit Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 (remainder of year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AggregatePaymentToPerformResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate payment to perform research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AggregatePaymentToPerformResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Payment To Perform Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AggregatePaymentToPerformResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate payment to perform research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions of IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Loss Per Share Attributable to Common Stockholders, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net loss per share attributable to common stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestones, paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payable upon the achievement of certain commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payable upon the Achievement of Certain Commercial Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payable upon the achievement of certain commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MidDoubleDigitPercentagePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mid double digit percentage payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MidDoubleDigitPercentagePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mid Double Digit Percentage Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MidDoubleDigitPercentagePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mid double digit percentage payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized and 54,138,555 shares issued and outstanding as of March 31, 2026 and 340,650,000 shares authorized and 3,068,490 shares issued and outstanding as of December 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Payable upon the Achievement of Certain Commercial Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount payable upon the achievement of certain commercial milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable upon the achievement of certain commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration of Credit Risk and Other Risks and Uncertainties, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk and other risks and uncertainties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued clinical expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Collaborators</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from catalyst4 for future services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Non Current Accumulated Gross Unrealized Loss Before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Debt Securities Non Current Accumulated Gross Unrealized Loss Before Tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Unrealized Losses, Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedVendorExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued vendor expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedVendorExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued vendor expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AccruedVendorExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued vendor expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Fair Value, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Fair Value, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Amortized Cost, Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross cash proceeds form sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock under stock plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and Regulatory Milestone Related Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone related expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestone related expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Payable upon the Achievement of Certain Development and Regulatory Milestones and Commercial Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount payable upon the achievement of certain development and regulatory milestones and commercial milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable upon the achievement of certain development and regulatory milestones and commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payable for a Compound that is a Conjugate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payable for a compound that is a conjugate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payable upon the achievement of certain development and regulatory milestones for a compound that is a conjugate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right-Of-Use Asset Amortization Expense (Income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right-of-use asset amortization expense (income).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payable upon Achievement of Certain Development and Regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payable upon achievement of certain development and regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payable upon achievement of certain development and regulatory milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in carrying amount of redeemable preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease In Carrying Amount Of Redeemable Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease in carrying amount of redeemable preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-1 Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options and restricted common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdjustmentNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdjustmentNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_AdjustmentNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Reserved For Future Issuance As If Converted Basis {Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock reserved for future issuance as if converted basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved for Future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Offset Carrying Value Exceeded Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity offset carrying value exceeded fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value exceeded fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, number of shares of common stock issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Accrual, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal contingencies requiring accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionsAvailableForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Available For Future Issuance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionsAvailableForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options available for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_StockOptionsAvailableForFutureIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Available for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock dividend declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C-1 Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C-1 redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C-1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Seven and Eight Collaboration Agreement and SW License and Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Seven and Eight collaboration agreement and SW license and development agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seven and Eight Collaboration Agreement and SW License and Development Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share-Based Payment Award, Granted In Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share-based payment award, granted in term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted (in term)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issued During Period Value in Exchange for Modified Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issued during period value in exchange for modified preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and marketable securities balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Six Long-Term Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty six long-term incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 Long-Term Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock" xlink:to="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:to="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock" xlink:to="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_IncreaseDecreaseInOtherAssets" xlink:to="eikn_IncreaseDecreaseInOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" xlink:to="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eikn_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" xlink:to="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DividendsDeclared" xlink:to="eikn_DividendsDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" xlink:to="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_OperatingLeaseTerminationDate" xlink:to="eikn_OperatingLeaseTerminationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TheColumnGroupAndCatalyst4AgreementMember" xlink:to="eikn_TheColumnGroupAndCatalyst4AgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" xlink:to="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ImpactAgreementMember" xlink:to="eikn_ImpactAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:to="eikn_TemporaryEquitySharesRedeemedUponConversionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate" xlink:to="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_InProcessResearchAndDevelopmentExpenses" xlink:to="eikn_InProcessResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" xlink:to="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_UpfrontPayments" xlink:to="eikn_UpfrontPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" xlink:to="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquitySharesRedeemedUponConversionShares" xlink:to="eikn_TemporaryEquitySharesRedeemedUponConversionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" xlink:to="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_CaliforniaNewYorkAndNewJerseyMember" xlink:to="eikn_CaliforniaNewYorkAndNewJerseyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" xlink:to="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_PaymentForAchievementOfCertainRegulatoryMilestone" xlink:to="eikn_PaymentForAchievementOfCertainRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ImpairmentOnMarketableSecurities" xlink:to="eikn_ImpairmentOnMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SevenAndEightMember" xlink:to="eikn_SevenAndEightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_EngineeringEquipmentMember" xlink:to="eikn_EngineeringEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SuperbWisdomLimitedMember" xlink:to="eikn_SuperbWisdomLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" xlink:to="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SalesMilestones" xlink:to="eikn_SalesMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:to="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_FutureMilestonesAccrued" xlink:to="eikn_FutureMilestonesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityFairValueExceededCarryingValue" xlink:to="eikn_TemporaryEquityFairValueExceededCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_CommonStockWarrantsMember" xlink:to="eikn_CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_CommonStockWarrantsPolicyPolicyTextBlock" xlink:to="eikn_CommonStockWarrantsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" xlink:to="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" xlink:to="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_UpfrontsAndMilestonePayments" xlink:to="eikn_UpfrontsAndMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SimpleAgreementsForFutureEquityIssuedAmount" xlink:to="eikn_SimpleAgreementsForFutureEquityIssuedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_CashPaidForOperatingLeaseLiabilities" xlink:to="eikn_CashPaidForOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="eikn_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_FurnitureFittingsOfficeEquipmentMember" xlink:to="eikn_FurnitureFittingsOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" xlink:to="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" xlink:to="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:to="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityCarryingValueExceededFairValue" xlink:to="eikn_TemporaryEquityCarryingValueExceededFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" xlink:to="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DevelopmentAndRegulatoryMilestonesPaid" xlink:to="eikn_DevelopmentAndRegulatoryMilestonesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ResearchAndEngineeringExpenses" xlink:to="eikn_ResearchAndEngineeringExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_UnderwritingDiscountsAndCommissions" xlink:to="eikn_UnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember" xlink:to="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockOptionsIssuedAndOutstandingMember" xlink:to="eikn_StockOptionsIssuedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_LabEquipmentMember" xlink:to="eikn_LabEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" xlink:to="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" xlink:to="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember" xlink:to="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember" xlink:to="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" xlink:to="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SalesRoyaltyPayable" xlink:to="eikn_SalesRoyaltyPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue" xlink:to="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SharesReservedForEmployeeStockPurchasePlanMember" xlink:to="eikn_SharesReservedForEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ConversionOfRedeemableConvertiblePreferredStockMember" xlink:to="eikn_ConversionOfRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_WeightedAverageCommonSharesOutstanding" xlink:to="eikn_WeightedAverageCommonSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" xlink:to="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" xlink:to="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="eikn_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" xlink:to="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AccruedInProcessResearchAndDevelopment" xlink:to="eikn_AccruedInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue" xlink:to="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_UpfrontFeePaidInCash" xlink:to="eikn_UpfrontFeePaidInCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="eikn_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_RedeemableConvertiblePreferredStockHoldersPercent" xlink:to="eikn_RedeemableConvertiblePreferredStockHoldersPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_PercentageOfIncrementalBorrowingRate" xlink:to="eikn_PercentageOfIncrementalBorrowingRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdditionalMilestonePayable" xlink:to="eikn_AdditionalMilestonePayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" xlink:to="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:to="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AggregatePaymentToPerformResearchAndDevelopment" xlink:to="eikn_AggregatePaymentToPerformResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock" xlink:to="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DevelopmentAndRegulatoryMilestones" xlink:to="eikn_DevelopmentAndRegulatoryMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_MidDoubleDigitPercentagePaymentsReceived" xlink:to="eikn_MidDoubleDigitPercentagePaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ClinicalExpenses" xlink:to="eikn_ClinicalExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AccruedClinicalExpenses" xlink:to="eikn_AccruedClinicalExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AccruedVendorExpenses" xlink:to="eikn_AccruedVendorExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense" xlink:to="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate" xlink:to="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" xlink:to="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:to="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_AdjustmentNetOfIssuanceCosts" xlink:to="eikn_AdjustmentNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock" xlink:to="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue" xlink:to="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_StockOptionsAvailableForFutureIssuanceMember" xlink:to="eikn_StockOptionsAvailableForFutureIssuanceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" xlink:to="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" xlink:to="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" xlink:to="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember" xlink:to="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" xlink:label="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" xlink:label="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquitySharesRedeemedUponConversionShares" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" xlink:label="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_26"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_28"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquitySharesRedeemedUponConversionAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquitySharesRedeemedUponConversionShares" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdjustmentNetOfIssuanceCosts" xlink:label="eikn_AdjustmentNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_AdjustmentNetOfIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" xlink:label="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CashPaidForOperatingLeaseLiabilities" xlink:label="eikn_CashPaidForOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" xlink:label="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInOtherAssets" xlink:label="eikn_IncreaseDecreaseInOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="eikn_CashPaidForOperatingLeaseLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eikn_IncreaseDecreaseInOtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructure1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpense" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprd" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock" xlink:label="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock" xlink:label="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:label="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CommonStockWarrantsPolicyPolicyTextBlock" xlink:label="eikn_CommonStockWarrantsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock" xlink:label="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" xlink:label="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_CommonStockWarrantsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock" xlink:label="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UnderwritingDiscountsAndCommissions" xlink:label="eikn_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" xlink:label="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_UnderwritingDiscountsAndCommissions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpairmentOnMarketableSecurities" xlink:label="eikn_ImpairmentOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eikn_ImpairmentOnMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="eikn_SummaryOfSignificantAccountingPoliciesLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eikn_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_WeightedAverageCommonSharesOutstanding" xlink:label="eikn_WeightedAverageCommonSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="eikn_WeightedAverageCommonSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" xlink:label="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_LabEquipmentMember" xlink:label="eikn_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EngineeringEquipmentMember" xlink:label="eikn_EngineeringEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FurnitureFittingsOfficeEquipmentMember" xlink:label="eikn_FurnitureFittingsOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eikn_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eikn_EngineeringEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eikn_FurnitureFittingsOfficeEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedClinicalExpenses" xlink:label="eikn_AccruedClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedInProcessResearchAndDevelopment" xlink:label="eikn_AccruedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedVendorExpenses" xlink:label="eikn_AccruedVendorExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" xlink:label="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="eikn_AccruedExpensesAndOtherCurrentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="eikn_AccruedClinicalExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="eikn_AccruedInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="eikn_AccruedVendorExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="eikn_AccruedExpensesAndOtherCurrentLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CaliforniaNewYorkAndNewJerseyMember" xlink:label="eikn_CaliforniaNewYorkAndNewJerseyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PercentageOfIncrementalBorrowingRate" xlink:label="eikn_PercentageOfIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseDepositLiability" xlink:label="us-gaap_LeaseDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseTerminationDate" xlink:label="eikn_OperatingLeaseTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" xlink:label="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" xlink:label="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" xlink:label="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="eikn_CaliforniaNewYorkAndNewJerseyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_GeographicDistributionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="stpr_CA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_PercentageOfIncrementalBorrowingRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseDepositLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_OperatingLeaseTerminationDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestones" xlink:label="eikn_DevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SalesMilestones" xlink:label="eikn_SalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPayments" xlink:label="eikn_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontsAndMilestonePayments" xlink:label="eikn_UpfrontsAndMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_DevelopmentAndRegulatoryMilestones" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_SalesMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_UpfrontPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_UpfrontsAndMilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesCRedeemableConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityFairValueExceededCarryingValue" xlink:label="eikn_TemporaryEquityFairValueExceededCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityCarryingValueExceededFairValue" xlink:label="eikn_TemporaryEquityCarryingValueExceededFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityOffsetFairValueExceededCarryingValue" xlink:label="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityOffsetCarryingValueExceededFairValue" xlink:label="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" xlink:label="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue" xlink:label="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" xlink:label="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_RedeemableConvertiblePreferredStockHoldersPercent" xlink:label="eikn_RedeemableConvertiblePreferredStockHoldersPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DividendsDeclared" xlink:label="eikn_DividendsDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesCRedeemableConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityFairValueExceededCarryingValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityCarryingValueExceededFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_RedeemableConvertiblePreferredStockHoldersPercent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_DividendsDeclared" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ConversionOfRedeemableConvertiblePreferredStockMember" xlink:label="eikn_ConversionOfRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CommonStockWarrantsMember" xlink:label="eikn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionsIssuedAndOutstandingMember" xlink:label="eikn_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionsAvailableForFutureIssuanceMember" xlink:label="eikn_StockOptionsAvailableForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SharesReservedForEmployeeStockPurchasePlanMember" xlink:label="eikn_SharesReservedForEmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_ConversionOfRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_CommonStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_StockOptionsIssuedAndOutstandingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_StockOptionsAvailableForFutureIssuanceMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SharesReservedForEmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="eikn_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixLong-TermIncentivePlanMember" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionOwnershipPercentageLessThanTenPercentMember" xlink:label="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember" xlink:label="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" xlink:label="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember" xlink:label="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SevenAndEightMember" xlink:label="eikn_SevenAndEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPayments" xlink:label="eikn_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" xlink:label="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SuperbWisdomLimitedMember" xlink:label="eikn_SuperbWisdomLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SimpleAgreementsForFutureEquityIssuedAmount" xlink:label="eikn_SimpleAgreementsForFutureEquityIssuedAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactAgreementMember" xlink:label="eikn_ImpactAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayable" xlink:label="eikn_AdditionalMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" xlink:label="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FutureMilestonesAccrued" xlink:label="eikn_FutureMilestonesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontFeePaidInCash" xlink:label="eikn_UpfrontFeePaidInCash"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestonesPaid" xlink:label="eikn_DevelopmentAndRegulatoryMilestonesPaid"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eikn_SevenAndEightMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TransactionTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_UpfrontPayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eikn_SuperbWisdomLimitedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_SimpleAgreementsForFutureEquityIssuedAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="eikn_ImpactAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_FutureMilestonesAccrued" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_UpfrontFeePaidInCash" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_DevelopmentAndRegulatoryMilestonesPaid" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TheColumnGroupAndCatalyst4AgreementMember" xlink:label="eikn_TheColumnGroupAndCatalyst4AgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AggregatePaymentToPerformResearchAndDevelopment" xlink:label="eikn_AggregatePaymentToPerformResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" xlink:label="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PaymentForAchievementOfCertainRegulatoryMilestone" xlink:label="eikn_PaymentForAchievementOfCertainRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MidDoubleDigitPercentagePaymentsReceived" xlink:label="eikn_MidDoubleDigitPercentagePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SalesRoyaltyPayable" xlink:label="eikn_SalesRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eikn_TheColumnGroupAndCatalyst4AgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_AggregatePaymentToPerformResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_PaymentForAchievementOfCertainRegulatoryMilestone" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_MidDoubleDigitPercentagePaymentsReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_SalesRoyaltyPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ResearchAndEngineeringExpenses" xlink:label="eikn_ResearchAndEngineeringExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ClinicalExpenses" xlink:label="eikn_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_InProcessResearchAndDevelopmentExpenses" xlink:label="eikn_InProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="eikn_ResearchAndEngineeringExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="eikn_ClinicalExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="eikn_InProcessResearchAndDevelopmentExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense" xlink:label="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" xlink:label="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" xlink:label="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquitySharesRedeemedUponConversionAmount" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquitySharesRedeemedUponConversionShares" xlink:label="eikn_TemporaryEquitySharesRedeemedUponConversionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" xlink:label="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" xlink:label="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" xlink:label="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquitySharesRedeemedUponConversionAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquitySharesRedeemedUponConversionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdjustmentNetOfIssuanceCosts" xlink:label="eikn_AdjustmentNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eikn_AdjustmentNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UnderwritingDiscountsAndCommissions" xlink:label="eikn_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" xlink:label="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="eikn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpairmentOnMarketableSecurities" xlink:label="eikn_ImpairmentOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eikn_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="eikn_ImpairmentOnMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eikn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" xlink:label="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_LabEquipmentMember" xlink:label="eikn_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_EngineeringEquipmentMember" xlink:label="eikn_EngineeringEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FurnitureFittingsOfficeEquipmentMember" xlink:label="eikn_FurnitureFittingsOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eikn_LabEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eikn_EngineeringEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eikn_FurnitureFittingsOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CaliforniaNewYorkAndNewJerseyMember" xlink:label="eikn_CaliforniaNewYorkAndNewJerseyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA" xlink:label="stpr_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PercentageOfIncrementalBorrowingRate" xlink:label="eikn_PercentageOfIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseDepositLiability" xlink:label="us-gaap_LeaseDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseTerminationDate" xlink:label="eikn_OperatingLeaseTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" xlink:label="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" xlink:label="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" xlink:label="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="eikn_CaliforniaNewYorkAndNewJerseyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_GeographicDistributionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_PercentageOfIncrementalBorrowingRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseDepositLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_OperatingLeaseTerminationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestones" xlink:label="eikn_DevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SalesMilestones" xlink:label="eikn_SalesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPayments" xlink:label="eikn_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontsAndMilestonePayments" xlink:label="eikn_UpfrontsAndMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:label="us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_DevelopmentAndRegulatoryMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_SalesMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_UpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="eikn_UpfrontsAndMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualCarryingValueCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="eikn_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityFairValueExceededCarryingValue" xlink:label="eikn_TemporaryEquityFairValueExceededCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityCarryingValueExceededFairValue" xlink:label="eikn_TemporaryEquityCarryingValueExceededFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityOffsetFairValueExceededCarryingValue" xlink:label="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TemporaryEquityOffsetCarryingValueExceededFairValue" xlink:label="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" xlink:label="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue" xlink:label="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" xlink:label="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_RedeemableConvertiblePreferredStockHoldersPercent" xlink:label="eikn_RedeemableConvertiblePreferredStockHoldersPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DividendsDeclared" xlink:label="eikn_DividendsDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityFairValueExceededCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityCarryingValueExceededFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_RedeemableConvertiblePreferredStockHoldersPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="eikn_DividendsDeclared" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ConversionOfRedeemableConvertiblePreferredStockMember" xlink:label="eikn_ConversionOfRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CommonStockWarrantsMember" xlink:label="eikn_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionsIssuedAndOutstandingMember" xlink:label="eikn_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionsAvailableForFutureIssuanceMember" xlink:label="eikn_StockOptionsAvailableForFutureIssuanceMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SharesReservedForEmployeeStockPurchasePlanMember" xlink:label="eikn_SharesReservedForEmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_ConversionOfRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_StockOptionsIssuedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_StockOptionsAvailableForFutureIssuanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eikn_SharesReservedForEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionOwnershipPercentageLessThanTenPercentMember" xlink:label="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="eikn_TwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember" xlink:label="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixLong-TermIncentivePlanMember" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" xlink:label="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" xlink:label="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember" xlink:label="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" xlink:label="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" xlink:label="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SevenAndEightMember" xlink:label="eikn_SevenAndEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPayments" xlink:label="eikn_UpfrontPayments"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" xlink:label="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SuperbWisdomLimitedMember" xlink:label="eikn_SuperbWisdomLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SimpleAgreementsForFutureEquityIssuedAmount" xlink:label="eikn_SimpleAgreementsForFutureEquityIssuedAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactAgreementMember" xlink:label="eikn_ImpactAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayable" xlink:label="eikn_AdditionalMilestonePayable"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" xlink:label="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate" xlink:label="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" xlink:label="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_FutureMilestonesAccrued" xlink:label="eikn_FutureMilestonesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_UpfrontFeePaidInCash" xlink:label="eikn_UpfrontFeePaidInCash"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" xlink:label="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_DevelopmentAndRegulatoryMilestonesPaid" xlink:label="eikn_DevelopmentAndRegulatoryMilestonesPaid"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eikn_SevenAndEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TransactionTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_UpfrontPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="eikn_SuperbWisdomLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_SimpleAgreementsForFutureEquityIssuedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="eikn_ImpactAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_FutureMilestonesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_UpfrontFeePaidInCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="eikn_DevelopmentAndRegulatoryMilestonesPaid" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_TheColumnGroupAndCatalyst4AgreementMember" xlink:label="eikn_TheColumnGroupAndCatalyst4AgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AggregatePaymentToPerformResearchAndDevelopment" xlink:label="eikn_AggregatePaymentToPerformResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" xlink:label="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_PaymentForAchievementOfCertainRegulatoryMilestone" xlink:label="eikn_PaymentForAchievementOfCertainRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_MidDoubleDigitPercentagePaymentsReceived" xlink:label="eikn_MidDoubleDigitPercentagePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_SalesRoyaltyPayable" xlink:label="eikn_SalesRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eikn_TheColumnGroupAndCatalyst4AgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_AggregatePaymentToPerformResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_PaymentForAchievementOfCertainRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_MidDoubleDigitPercentagePaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eikn_SalesRoyaltyPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eikn_IncreaseDecreaseInOtherAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="17" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" xlink:label="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInOtherAssets" xlink:label="eikn_IncreaseDecreaseInOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" xlink:label="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="eikn_AccruedClinicalExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="eikn_AccruedInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="eikn_AccruedVendorExpenses" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="eikn_AccruedExpensesAndOtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedClinicalExpenses" xlink:label="eikn_AccruedClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedInProcessResearchAndDevelopment" xlink:label="eikn_AccruedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_AccruedVendorExpenses" xlink:label="eikn_AccruedVendorExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" xlink:label="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails"/>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="eikn_ResearchAndEngineeringExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="eikn_ClinicalExpenses" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="eikn_InProcessResearchAndDevelopmentExpenses" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ResearchAndEngineeringExpenses" xlink:label="eikn_ResearchAndEngineeringExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_ClinicalExpenses" xlink:label="eikn_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="eikn-20260331.xsd#eikn_InProcessResearchAndDevelopmentExpenses" xlink:label="eikn_InProcessResearchAndDevelopmentExpenses"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="eikn_DevelopmentAndRegulatoryMilestonesPaid" name="DevelopmentAndRegulatoryMilestonesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_SevenAndEightMember" name="SevenAndEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_PaymentForAchievementOfCertainRegulatoryMilestone" name="PaymentForAchievementOfCertainRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_TemporaryEquitySharesRedeemedUponConversionAmount" name="TemporaryEquitySharesRedeemedUponConversionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock" name="NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" name="AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_CashPaidForOperatingLeaseLiabilities" name="CashPaidForOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" name="SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" name="TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_ResearchAndEngineeringExpenses" name="ResearchAndEngineeringExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock" name="ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_MidDoubleDigitPercentagePaymentsReceived" name="MidDoubleDigitPercentagePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" name="DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_FutureMilestonesAccrued" name="FutureMilestonesAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" name="ExtinguishmentsReductionToNetLossAvailableToCommonShareholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_InProcessResearchAndDevelopmentExpenses" name="InProcessResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" name="DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock" name="FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" name="CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_CommonStockWarrantsPolicyPolicyTextBlock" name="CommonStockWarrantsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_StockOptionOwnershipPercentageLessThanTenPercentMember" name="StockOptionOwnershipPercentageLessThanTenPercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" name="AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" name="DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_TwoThousandTwentySixLong-TermIncentivePlanMember" name="TwoThousandTwentySixLong-TermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" name="OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" name="StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_AccruedVendorExpenses" name="AccruedVendorExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_TemporaryEquitySharesRedeemedUponConversionShares" name="TemporaryEquitySharesRedeemedUponConversionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_UpfrontPayments" name="UpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" name="ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock" name="DecreaseInCarryingAmountOfRedeemablePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_OperatingLeaseTerminationDate" name="OperatingLeaseTerminationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" name="ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_ClinicalExpenses" name="ClinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_RedeemableConvertiblePreferredStockHoldersPercent" name="RedeemableConvertiblePreferredStockHoldersPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock" name="ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" name="RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_WeightedAverageCommonSharesOutstanding" name="WeightedAverageCommonSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_EngineeringEquipmentMember" name="EngineeringEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" name="StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" name="DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_AccruedClinicalExpenses" name="AccruedClinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" name="OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_SeriesB-1RedeemableConvertiblePreferredStockMember" name="SeriesB-1RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AdditionalMilestonePayable" name="AdditionalMilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate" name="AdditionalMilestonePayableForACompoundThatIsAConjugate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" name="DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" name="MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_TemporaryEquityOffsetFairValueExceededCarryingValue" name="TemporaryEquityOffsetFairValueExceededCarryingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" name="ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock" name="DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" name="SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_IncreaseDecreaseInOtherAssets" name="IncreaseDecreaseInOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember" name="TwoThousandTwentySixEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_ImpactOfPreferredStockExtinguishmentsAndModifications" name="ImpactOfPreferredStockExtinguishmentsAndModifications" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" name="AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_SimpleAgreementsForFutureEquityIssuedAmount" name="SimpleAgreementsForFutureEquityIssuedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" name="StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" name="SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_SharesReservedForEmployeeStockPurchasePlanMember" name="SharesReservedForEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" name="MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_TemporaryEquityCarryingValueExceededFairValue" name="TemporaryEquityCarryingValueExceededFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" name="StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" name="UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_ConversionOfRedeemableConvertiblePreferredStockMember" name="ConversionOfRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue" name="ModifiedAdjustedPreferredStockIncreaseInFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_SeriesDRedeemableConvertiblePreferredStockMember" name="SeriesDRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" name="ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense" name="DevelopmentAndRegulatoryMilestoneRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" name="IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_FurnitureFittingsOfficeEquipmentMember" name="FurnitureFittingsOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember" name="StockOptionOwnershipPercentageMoreThanTenPercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate" name="AdditionalMilestonePayableForACompoundThatIsNotAConjugate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_PercentageOfIncrementalBorrowingRate" name="PercentageOfIncrementalBorrowingRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_DevelopmentAndRegulatoryMilestones" name="DevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_StockOptionsAvailableForFutureIssuanceMember" name="StockOptionsAvailableForFutureIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" name="AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" name="EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_TemporaryEquityFairValueExceededCarryingValue" name="TemporaryEquityFairValueExceededCarryingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" name="TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_SalesMilestones" name="SalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_SalesRoyaltyPayable" name="SalesRoyaltyPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_UpfrontFeePaidInCash" name="UpfrontFeePaidInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" name="CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_UpfrontsAndMilestonePayments" name="UpfrontsAndMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AccruedInProcessResearchAndDevelopment" name="AccruedInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_DividendsDeclared" name="DividendsDeclared" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="eikn_SuperbWisdomLimitedMember" name="SuperbWisdomLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_StockOptionsIssuedAndOutstandingMember" name="StockOptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AggregatePaymentToPerformResearchAndDevelopment" name="AggregatePaymentToPerformResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_ImpactAgreementMember" name="ImpactAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_SeriesC-1RedeemableConvertiblePreferredStockMember" name="SeriesC-1RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_ImpairmentOnMarketableSecurities" name="ImpairmentOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_TemporaryEquityOffsetCarryingValueExceededFairValue" name="TemporaryEquityOffsetCarryingValueExceededFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock" name="CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" name="MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" name="StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" name="TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" name="VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_AdjustmentNetOfIssuanceCosts" name="AdjustmentNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock" name="PatentAndTrademarkCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_SeriesA-1RedeemableConvertiblePreferredStockMember" name="SeriesA-1RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" name="AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="eikn_TheColumnGroupAndCatalyst4AgreementMember" name="TheColumnGroupAndCatalyst4AgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" name="TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="eikn_CaliforniaNewYorkAndNewJerseyMember" name="CaliforniaNewYorkAndNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="eikn_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>May 01, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text"> 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EIKON THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EIKN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001861123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,138,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-43085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-2807586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">230 Harriet Tubman Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Millbrae<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">777-0566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 161,154<span></span>
</td>
<td class="nump">$ 104,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">351,028<span></span>
</td>
<td class="nump">231,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,919<span></span>
</td>
<td class="nump">12,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">529,501<span></span>
</td>
<td class="nump">348,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">138,067<span></span>
</td>
<td class="nump">142,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">91,066<span></span>
</td>
<td class="nump">90,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">83,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">7,808<span></span>
</td>
<td class="nump">7,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">4,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">850,826<span></span>
</td>
<td class="nump">594,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,005<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">29,319<span></span>
</td>
<td class="nump">44,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">9,740<span></span>
</td>
<td class="nump">10,028<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,064<span></span>
</td>
<td class="nump">55,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">245,091<span></span>
</td>
<td class="nump">247,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">300,155<span></span>
</td>
<td class="nump">312,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Redeemable convertible preferred stock, $0.0001 par value; no shares authorized, issued and outstanding as of March 31, 2026 and 262,597,889 shares authorized, 222,658,133 shares issued and outstanding, and aggregate liquidation preference of $1,159,762 as of December 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,161,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 50,000,000 shares authorized and no shares issued and outstanding as of March 31, 2026 and no shares authorized, issued and outstanding as of December 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized and 54,138,555 shares issued and outstanding as of March 31, 2026 and 340,650,000 shares authorized and 3,068,490 shares issued and outstanding as of December 31, 2025</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,554,133<span></span>
</td>
<td class="nump">41,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,003,467)<span></span>
</td>
<td class="num">(920,509)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">550,671<span></span>
</td>
<td class="num">(879,034)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)</a></td>
<td class="nump">$ 850,826<span></span>
</td>
<td class="nump">$ 594,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">262,597,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">222,658,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">222,658,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">340,650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">54,138,555<span></span>
</td>
<td class="nump">3,068,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">54,138,555<span></span>
</td>
<td class="nump">3,068,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 70,047<span></span>
</td>
<td class="nump">$ 56,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,290<span></span>
</td>
<td class="nump">14,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">87,337<span></span>
</td>
<td class="nump">71,383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(87,337)<span></span>
</td>
<td class="num">(71,383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">4,380<span></span>
</td>
<td class="nump">3,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(82,958)<span></span>
</td>
<td class="num">(68,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ImpactOfPreferredStockExtinguishmentsAndModifications', window );">Impact of preferred stock extinguishments and modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (82,958)<span></span>
</td>
<td class="num">$ (74,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (26.91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (26.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, Basic</a></td>
<td class="nump">33,700,550<span></span>
</td>
<td class="nump">2,770,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, Diluted</a></td>
<td class="nump">33,700,550<span></span>
</td>
<td class="nump">2,770,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ImpactOfPreferredStockExtinguishmentsAndModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of preferred stock extinguishments and modifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ImpactOfPreferredStockExtinguishmentsAndModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Redeemable Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Series D Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Series D Redeemable Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Series B-1 and C-1 Redeemable Convertible Preferred Stock And Common Stock Warrants</div></th>
<th class="th">
<div>Series B-1 and C-1 Redeemable Convertible Preferred Stock And Common Stock Warrants </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series B-1 and C-1 Redeemable Convertible Preferred Stock And Common Stock Warrants </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th">
<div>Series B-1 and C-1 Redeemable Convertible Preferred Stock And Common Stock Warrants </div>
<div>Accumulated Deficit</div>
</th>
<th class="th"><div>Series B-1 and C-1 Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Series B-1 and C-1 Redeemable Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series B-1 and C-1 Redeemable Convertible Preferred Stock </div>
<div>Additional Paid-in Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,087,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 808,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,869,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="num">$ (571,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,011<span></span>
</td>
<td class="num">$ (604,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,005,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock', window );">Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock', window );">Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock, hares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,977,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock', window );">Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock', window );">Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,587,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock', window );">Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (114)<span></span>
</td>
<td class="nump">$ 8,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock', window );">Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock', window );">Vesting of early exercised stock options and restricted common stock</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,658,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,161,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,870,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="num">(640,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,367<span></span>
</td>
<td class="num">(664,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,087,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 808,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,869,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="num">$ (571,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,011<span></span>
</td>
<td class="num">(604,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Dec. 31, 2025</a></td>
<td class="nump">222,658,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,658,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,005,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,161,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,068,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="num">$ (879,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,475<span></span>
</td>
<td class="num">(920,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering', window );">Issuance of common stock in initial public offering, net of issuance costs</a></td>
<td class="nump">348,104<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">348,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering', window );">Issuance of common stock in initial public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,177,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquitySharesRedeemedUponConversionAmount', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,161,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquitySharesRedeemedUponConversionShares', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(222,658,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">1,161,470<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,161,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,855,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock', window );">Vesting of early exercised stock options and restricted common stock</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (82,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance, shares at Mar. 31, 2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,138,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">$ 550,671<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1,554,133<span></span>
</td>
<td class="num">$ (1,003,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, new issues in initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value in exchange for extinguished preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value in exchange for modified preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, new issues in initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, vesting of early exercised stock options and restricted common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period shares in exchange for extinguished preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period shares in exchange for modified preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period value in exchange for extinguished preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issued during period value in exchange for modified preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquitySharesRedeemedUponConversionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, shares redeemed upon conversion, amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquitySharesRedeemedUponConversionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquitySharesRedeemedUponConversionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, shares redeemed upon conversion, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquitySharesRedeemedUponConversionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AdjustmentNetOfIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 33,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series D Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AdjustmentNetOfIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AdjustmentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AdjustmentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (82,958)<span></span>
</td>
<td class="num">$ (68,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">5,214<span></span>
</td>
<td class="nump">3,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,777<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="num">(101)<span></span>
</td>
<td class="nump">2,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and accretion of discounts on marketable securities</a></td>
<td class="num">(827)<span></span>
</td>
<td class="num">(1,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,377)<span></span>
</td>
<td class="num">(2,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_IncreaseDecreaseInOtherAssets', window );">Other assets</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,324<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(15,065)<span></span>
</td>
<td class="num">(9,384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,488)<span></span>
</td>
<td class="nump">16,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(89,801)<span></span>
</td>
<td class="num">(54,521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(22,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(306,955)<span></span>
</td>
<td class="num">(252,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">104,000<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(203,217)<span></span>
</td>
<td class="num">(213,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under stock plans</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">349,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">349,308<span></span>
</td>
<td class="nump">350,234<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">56,290<span></span>
</td>
<td class="nump">81,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">113,072<span></span>
</td>
<td class="nump">130,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">169,362<span></span>
</td>
<td class="nump">212,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract', window );"><strong>Cash, cash equivalents and restricted cash at end of period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">161,154<span></span>
</td>
<td class="nump">204,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">8,208<span></span>
</td>
<td class="nump">8,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">169,362<span></span>
</td>
<td class="nump">212,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_CashPaidForOperatingLeaseLiabilities', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">10,483<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">9,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock', window );">Vesting of early exercised stock options and restricted common stock</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_CashPaidForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_CashPaidForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_IncreaseDecreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_IncreaseDecreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use asset amortization expense (income).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of early exercised stock options and restricted common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (82,958)<span></span>
</td>
<td class="num">$ (68,243)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 1. Organization and Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eikon Therapeutics, Inc. (the &#8220;Company&#8221;) is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important innovative medicines to address serious unmet medical needs. The Company&#8217;s technology platform integrates custom-engineered super-resolution microscopy systems, bespoke automation, data science machine learning and artificial intelligence tools, and software engineering capable of processing petabyte-scale datasets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was incorporated in the state of Delaware on July 9, 2019. The Company is headquartered in California. It also has operations in New York and New Jersey.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2026, the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d7440967-f56a-48a1-8724-4db9ad3811ca;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1-for-7.4578</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reverse stock split of its issued and outstanding common stock</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which also resulted in a proportional adjustment to the conversion price for each series of its redeemable convertible preferred stock and warrants, and to the exercise prices and number of outstanding stock options. Accordingly, all shares of common stock, stock options, warrants, and per share information presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split for all periods presented. The per share par value and authorized numbers of shares of the Company&#8217;s common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 6, 2026, the Company closed its initial public offering (&#8220;IPO&#8221;) and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,177,600</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for approximate net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">348.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In connection with the IPO, all shares of Series A, A-1, B, B-1, C, C-1 and D redeemable convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,855,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern Assessment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced net operating losses and negative cash flows from operations since its inception. As of March 31, 2026, the Company has an accumulated deficit of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically financed its operations primarily through private placements of its redeemable convertible preferred stock, and most recently, through its IPO. The Company may seek to raise capital through private or public equity financings, debt financings, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes its cash, cash equivalents, and marketable securities balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2026 will be sufficient for the Company to continue as a going concern for at least one year from the date these condensed financial statements are issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Even if the Company is able to acquire additional financing, the financial terms may not be satisfactory to support its operations. Failure to generate sufficient cash flows from operations, raise additional capital, and reduce discretionary spending, should additional capital not become available, could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules and regulations of the Securities and Exchange Commission regarding interim reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These condensed financial statements include all adjustments necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative GAAP included in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;) issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to, useful lives of long-lived assets, the incremental borrowing rates for leases, accruals for research and development costs, the fair value of redeemable convertible preferred stock, common stock warrants, common stock and various other inputs used in estimating stock-based compensation expense, and accounting for income tax uncertainties, including a valuation allowance for deferred tax assets, in the accompanying financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and marketable securities, which may exceed federally insured limits. The Company has no financial instruments with off balance sheet risk of loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future in-process research and development of its technology, its reliance on third parties to assist in conducting its clinical trials, the need to obtain regulatory and marketing approvals, competitors advancing medicine in a field that the Company intends to enter that constrains its ability to compete effectively for market share, competitors developing technological innovations that reduce the value of the inventions that enable the Company to discover and develop new medicines, protection of its proprietary technology, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize its clinical assets, it will be unable to generate product revenue or achieve profitability.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts held in money market funds and commercial paper, which are held at amortized cost.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s marketable securities consist of United States treasury securities and commercial paper, which are held-to-maturity and reported at amortized cost. The amortization of premiums and accretion of discounts from the purchase of the securities are recognized as a component of interest income in the statements of operations and comprehensive loss. Marketable securities are classified as either current or non-current assets based on their contractual maturity dates. Marketable securities are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. As of March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there had been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment or credit losses on the Company&#8217;s marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included in long-term assets as of March 31, 2026 and December 31, 2025, restricted from withdrawal and held by a bank in the form of collateral for irrevocable standby letters of credit held as security for the Company&#8217;s leases. In addition, the Company had deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included in current assets as of March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, pledged for corporate credit cards.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are presented at cost, net of accumulated depreciation. Depreciation begins the first day of the month after the asset is placed in service. Depreciation is computed using the straight-line method over the estimated useful lives of five years for lab and engineering equipment, seven years for motor vehicles (used in the transportation of materials between sites) and furniture, fittings and office equipment, four years for computer equipment, and three years for software. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated once placed into service. Upon the sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations and comprehensive loss. Maintenance and repairs are charged to expense as incurred and costs of major replacement or improvement are capitalized.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the carrying amounts of its long-lived assets, including property and equipment and right-of-use leased assets, for potential impairment whenever events or changes in circumstances indicate that the assets may not be recoverable. Factors that the Company considers in an impairment review include, but are not limited to, significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount, and the impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined using discounted cash flows. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment of long-lived assets during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of a contract, the Company assesses whether the contract is a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is determined to exist, the commencement date of such lease is assessed based on the date on which the Company gains control over the use of the underlying assets. The Company&#8217;s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options that the Company is reasonably certain of exercising. At lease commencement, the Company also determines lease classification based on whether the arrangement is effectively a financed purchase of the underlying asset (finance lease) or not (operating lease), which governs the pattern of expense recognition and the presentation reflected in the statements of operations and comprehensive loss and statements of cash flows over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For leases with a term exceeding 12 months, a lease liability is recorded on the Company&#8217;s balance sheet at lease commencement reflecting the present value of its minimum payment obligations over the lease term. A corresponding right-of-use (&#8220;ROU&#8221;) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. Variable lease payments are included in the present value of its minimum lease payment obligations when the contingency is resolved. The lease liability is remeasured at the date the contingency is resolved and the corresponding ROU asset is adjusted. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company&#8217;s incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Company&#8217;s operating leases, fixed lease payments are recognized as lease expense on a straight-line basis over the lease term. For leases with a term of 12 months or less, any fixed lease payments are recognized on a straight-line basis over the lease term and are not recognized on the Company&#8217;s balance sheet as an accounting policy election. Leases qualifying for the short-term lease exemption were insignificant. Variable lease costs are expensed in the statements of operations and comprehensive loss as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any finance leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Holders of the redeemable convertible preferred stock can cause redemption for cash upon the occurrence of a deemed liquidation event, which is outside the Company&#8217;s control. Therefore, redeemable convertible preferred stock is classified outside of stockholders&#8217; equity (deficit) on the balance sheet. The carrying values of the redeemable convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because the stock is not mandatorily redeemable and the occurrence of a deemed liquidation event is currently not probable.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are charged to expense as incurred. These expenses consist of compensation expenses, direct research and development expenses such as software development costs related to research and development activities, laboratory supplies, costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation, other miscellaneous expenses, and allocations of facility and information technology expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of its research and development activities conducted by third-party service providers. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with the third-party service agreements. If the Company does not identify costs that have begun to be incurred or if the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from the estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed and classified as current or non-current prepaid expenses and other assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company makes payments in connection with clinical trials to contract manufacturing organizations that manufacture the materials for its product candidates and to clinical research organizations and clinical trial sites that conduct and manage the Company&#8217;s clinical trials. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in payments that do not match the periods over which materials or services are provided. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. The Company makes estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Asset Acquisitions and In-Process Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company evaluates acquisitions of assets and related liabilities and other similar transactions to assess whether or not a transaction should be accounted for as an asset acquisition or business combination by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If the screen test is met, a transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs that would meet the requirements of a business. The Company accounts for an asset acquisition by recognizing net assets based on their cost on a relative fair value basis. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-monetary identifiable assets and liabilities assumed based on relative fair values. In-process research and development (&#8220;IPR&amp;D&#8221;) acquired in an asset acquisition is expensed provided there is no alternative future use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for future payments such as those upon the achievement of certain regulatory, development, or sales milestones in an asset acquisition when achievement of the underlying milestones is deemed probable. Milestone payments made to third parties subsequent to regulatory approval may be capitalized as intangible assets, if deemed to have alternative future use, and amortized over the estimated remaining useful life of the related product. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent and Trademark Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related and trademark costs incurred in connection with filing and prosecuting patent and trademark applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses on the statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Initial Public Offering Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred IPO costs, consisting primarily of legal and accounting fees relating to the IPO, are capitalized and offset against offering proceeds following the completion of the offering. Deferred IPO costs for terminated or delayed offerings are expensed immediately as a charge to general and administrative expenses in the statement of operations and comprehensive loss. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred IPO costs capitalized as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026. The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of deferred IPO costs capitalized as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, included in other non-current assets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards issued to employees and nonemployees, the Company measures the estimated fair value of the stock-based awards on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective awards. The Company records the expense for awards with service-based vesting using the straight-line, ratable attribution method and accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#8217; vesting terms and contractual terms, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s cash compensation costs are classified.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of the common stock underlying stock options on the date of grant. This has historically been determined by management with assistance from external appraisers and approved by the Board. Due to the absence of an active market for the Company&#8217;s common stock prior to its IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s common stock valuations prior to May 31, 2025 were performed using the Option Pricing Method (&#8220;OPM&#8221;) as it is deemed the most appropriate method based on the Company&#8217;s stage of development and other relevant factors. Within the OPM framework, the backsolve method for inferring the total equity value implied by a recent financing transaction involves the construction of an allocation model that takes into account the entity&#8217;s capital structure and the rights, preferences and privileges of each class of stock, then assumes reasonable inputs for the other OPM variables (inclusive of discount for lack of marketability, volatility, the expected time to liquidity, and risk-free rate). The total equity value is then iterated in the model until the model output value for the equity class sold in a recent financing round equals the price paid in that round. The OPM is generally utilized when specific future liquidity events are difficult to forecast (i.e., the enterprise has many choices and options available), and the enterprise&#8217;s value depends on how well it follows an uncharted path through the various possible opportunities and challenges. Among other factors considered are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s common stock, common stock warrants and redeemable convertible preferred stock valuations from May 31, 2025 through the IPO date were performed using a hybrid method that combines the OPM and the probability-weighted expected return method (&#8220;PWERM&#8221;). The PWERM employs additional information not used in the OPM, including various market approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an IPO or sale of the enterprise, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#8217;s common stock and redeemable convertible preferred stock is then applied to arrive at an indication of value for the common stock and redeemable convertible preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the IPO, the fair value of the common stock underlying stock options is based on the closing market price of the common stock on the date of grant.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:4.537%;border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:8%;box-sizing:content-box;"></td>
         <td style="width:92%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets or liabilities.</span></p></td>
        </tr>
        <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td>
        </tr>
        <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></p></td>
        </tr>
       </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There are currently no components of other comprehensive loss for the Company. Thus, comprehensive loss is the same as the net loss for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The functional currency of the Company&#8217;s operation is U.S. dollars. All monetary assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Non-monetary assets and liabilities are translated using the exchange rate that was in effect when the asset or liability was initially recognized. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the statements of operations and comprehensive loss and recorded in other income (expense), net. Foreign currency transaction losses were immaterial for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.</span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax credits are presented on a gross basis in the effective tax rate reconciliation, and the tax effect of changes in unrecognized tax benefits related to such credits is presented separately within changes in uncertain tax positions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker, its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a1712c5d-8279-47e4-b1b8-8c2d8242df25;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options and warrants to purchase common stock, unvested common stock subject to repurchase and redeemable convertible preferred stock are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be antidilutive for all periods presented.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock and legally outstanding unvested common stock subject to repurchase are considered participating securities. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, (the "JOBS Act"), and may take advantage of reduced reporting requirements. These reporting requirement exemptions may not be applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s financial position or results of operations upon adoption.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2024-03 will require public business entities to disclose in the notes to the financial statements, at each interim and annual reporting period, specific information about certain costs and expenses, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each expense caption presented on the face of the income statement, and the total amount of an entity&#8217;s selling expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3. Net Loss Per Share Attributable to Common Stockholders</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025 (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impact of preferred stock extinguishments and<br/>&#160;&#160;&#160;modifications</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,701,800</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,869,926</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Weighted-average common shares subject to<br/>&#160;&#160;&#160;repurchase</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,574</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and<br/>&#160;&#160;&#160;diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,700,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,770,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic<br/>&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding common stock equivalents have been excluded from diluted net loss per share attributable to common stockholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025 because their inclusion would be anti-dilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,522,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,904,399</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercised stock options and unvested restricted<br/>&#160;&#160;&#160;common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Redeemable convertible preferred stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,855,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,262,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,563,186</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4. Fair Value Measurements</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets, which consist of cash equivalents and marketable securities, presented at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.628%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:11.91%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,234</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">381</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,609</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,747</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,903</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, non-current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,828</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,576</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.628%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:11.91%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,935</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t hold any financial assets that would be classified as Level 3 in the fair value hierarchy during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair values due to their liquid or short-term nature, such as cash, prepaid expenses, accounts payable, and accrued expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5. Balance Sheet Components</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Engineering equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,843</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,843</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture, fittings &amp; office equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,062</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,970</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">963</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">624</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,812</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,067</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,898</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2026 and 2025, respectively. Disposals of property and equipment during the three months ended March 31, 2026 and 2025 were not material.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,128</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses related to purchase of IPR&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued vendor expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of early exercised options and<br/>&#160;&#160;&#160;restricted common stock liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6. Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2022, the Company entered into an operating lease of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and laboratory space that now serves as its corporate headquarters located in Millbrae, California. The lease commenced in February 2024 and expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2513182e-84c1-42c0-8135-b3838edee5c8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 2040</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The lessor provided the Company a tenant improvement allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and the Company constructed leasehold improvements, which were concluded to be lessee assets, in the space. The lease liability at lease commencement was calculated to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is equal to the present value of the future lease payments, discounted at an incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The lease agreement also includes a renewal option allowing the Company to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend this lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at the prevailing rental rate, which the Company is not reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the lease agreement provides for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional tenant improvement allowances that may be utilized by the Company and is repayable over the term of the lease with interest. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of additional tenant improvement allowances had been drawn down as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company constructed leasehold improvements, which were concluded to be lessee assets, in the space. The Company is accounting for the repayment obligation related to these additional tenant improvement allowances as part of the lease with the amounts included in operating lease liability, current and non-current. The Company has an irrevocable standby letter of credit for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million held as security for the Millbrae lease deposit.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had leases for other office and laboratory facilities of between approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet in Hayward, California, New York, New York and Jersey City, New Jersey as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The leases will expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4891b7a9-ea44-4065-bf6f-ac1774d7b202;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2026</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fea5efb2-ee1e-4e93-a542-9a2bbd4553aa;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 2029</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless their terms are extended where allowed under the leases. In January 2026, the Company notified the landlord of one of its Hayward properties of its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intention to early terminate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the lease in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company remeasured the operating lease liabilities, which resulted in a reduction of the carrying value of the operating lease liability and a corresponding reduction in the operating lease right-of-use assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases had weighted average remaining lease terms of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, and weighted average discount rates of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2026 and December 31, 2025, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments under non-cancellable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2026 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026 (remainder of year)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,988</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,310</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,913</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">370,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">551,576</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296,745</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of future lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">254,831</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Operating lease liability, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,740</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense for operating leases was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> variable lease costs and short-term lease costs were not material for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into various agreements in the ordinary course of business, such as those with suppliers, clinical research organizations, contract manufacturing organizations, and clinical trial sites. These agreements provide for termination at the request of either party, generally with less than one-year notice and are, therefore, cancellable contracts and, if cancelled, are not anticipated to have a material effect on the Company&#8217;s financial condition, results of operations, or cash flows.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Milestone and Royalty Payments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into license agreements in the normal course of business in order to obtain rights to promising product candidates, advance product development and obtain technologies and services related to its business. The Company could be required to make development and regulatory milestones and sales milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">630.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, and tiered royalty payments to licensors based on the net sales of the licensed products. Contingent milestones are recorded when probable to be achieved. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has incurred and recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in upfront and milestone payments under these agreements (see Notes 10 and 11).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations, or cash flows. The Company may pursue or be subject to litigation and other legal actions from time to time arising in the ordinary course of business, including intellectual property, products liability, breach of contract, commercial, employment, and other similar claims which could have an adverse impact on its reputation, business and financial condition and divert the attention of its management from the operation of its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> legal contingencies requiring accrual or disclosures as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification claims. Accordingly, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any liabilities for these indemnification rights and agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Structure</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8. Capital Structure</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Redeemable Convertible Preferred Stock</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issued and outstanding redeemable convertible preferred stock consisted of the following (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.634%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.818%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.098%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.618%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.618%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.618%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Series</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares<br/>Authorized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares<br/>Issued and<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Original<br/>Issue Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Liquidation<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,916</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,268,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,268,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,538</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,271,143</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,456,768</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">297,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,756,908</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,756,908</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,979</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,200</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,884,830</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,194,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,682</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,629</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,975,110</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,975,110</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,077</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,806</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,441,007</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,005,669</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,597,889</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,658,133</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,159,762</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,161,470</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, the Company entered into a Series D preferred stock purchase and exchange agreement which provided for the issuance of Series D redeemable convertible preferred stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The transaction provided returning investors the ability to exchange their Series B and Series C redeemable convertible preferred stock for Series B-1 and Series C-1 redeemable convertible preferred stock, respectively, if their participation in the Series D financing exceeded certain qualifying amounts. Further, investors that invested more in the Series D financing than their aggregate investment in Series B and Series C received common stock warrants based on the excess investment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the transaction, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,005,669</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Series D redeemable convertible preferred stock in cash purchases at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company also issued (i) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,756,908</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series B-1 redeemable convertible preferred stock as a result of the exchange of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,814,375</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of its Series B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">redeemable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">convertible preferred stock, (ii) an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,975,110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series C-1 redeemable convertible preferred stock as a result of the exchange of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,352,470</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its Series C redeemable convertible preferred stock, and (iii) warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants shall be exercisable in whole or in part, at any time up to and including the first to occur of the consummation of a liquidation event and the fifth anniversary of the date of issue and thereafter shall terminate and be void. The warrants can be exercised either in cash or net issued. As the contract allows for physical settlement or net physical settlement, the Company concluded that the common stock warrants should be equity- classified and recorded in additional paid-in capital at their fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company assessed the impact of the transaction, on an investor-by-investor basis, using a quantitative analysis in order to determine whether it represented an extinguishment or a modification of the Series B and Series C redeemable convertible preferred stock held by each investor which were exchanged.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extinguishment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The quantitative analysis indicated the fair value before and after the transaction was substantially different for some investors. Specifically, these represented investors that participated at a level which enabled them to exchange all or nearly all of their Series B and Series C redeemable convertible preferred stock, including the investors whose participation also entitled them to common stock warrants. For each of these investors, the transaction represented an extinguishment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The extinguishments resulted in the following impacts:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derecognition of the existing carrying amount of the extinguished Series B and Series C redeemable convertible preferred stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting for the new issuance of the Series B, Series B-1, Series C and Series C-1 redeemable convertible preferred stock, and common stock warrants at fair values of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offset for each investor was recorded to either additional paid-in capital (investors for which fair value exceeded carrying value, aggregating to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) or accumulated deficit (investors for which carrying value exceeded fair value, aggregating to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), as appropriate.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate difference between the fair value of the consideration transferred and the carrying value of the extinguished shares was reflected as an adjustment to the numerator in the computation of basic earnings per share for the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Specifically, the extinguishments resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million net reduction to the net loss available to common shareholders.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modification</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The quantitative analysis indicated the fair value before and after the transaction was not substantially different for some investors. Specifically, these represented investors that participated but only at a level which enabled them to exchange a portion of their Series B and Series C redeemable convertible preferred stock. For each of these investors, the transaction represented a modification.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The modifications resulted in the following impacts:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The existing carrying amount of the modified preferred stock was adjusted by the increase in fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million comprised of a net decrease to the carrying amount of Series B and Series C redeemable convertible preferred stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and an increase to the carrying amount of Series B-1 and Series C-1 redeemable convertible preferred stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The offset for each investor was recorded to additional paid-in capital (all represented increases in fair value).</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in fair value of the modified shares was reflected as an adjustment to the numerator in the computation of basic earnings per share for the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Specifically, the modifications resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million increase to the net loss available to common shareholders. See Note 3 for the net impact of the extinguishments and modifications on the net loss per share attributable to common shareholders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the IPO, all shares of Series A, A-1, B, B-1, C, C-1 and D redeemable convertible preferred stock converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,855,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance, on an as if-converted basis, consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of redeemable convertible preferred stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,855,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,522,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,513,142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options available for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,269,981</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,449,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539,582</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,071,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,557,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stockholders are entitled to dividends if and when declared by the Board and after any dividends on redeemable convertible preferred stock are fully paid. The holder of each share of common stock is entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dividends have been declared.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans and Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9. Equity Incentive Plans and Stock-Based Compensation Expense</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2026 Long-Term Incentive Plan (the &#8220;2026 LTIP&#8221;), which became effective on February 3, 2026 and replaced the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted on September 19, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,137,117</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock have been reserved for issuance under the 2026 LTIP, in addition to any shares of common stock outstanding under the 2019 Plan or shares of common stock issuable in connection with the stock option awards granted to the Company&#8217;s Chief Executive Officer on April 2, 2025 that expire, are withheld by the Company for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to the Company due to failure to vest. The number of shares of common stock reserved for future issuance under the 2026 LTIP will also be increased pursuant to provisions for annual automatic evergreen increases, subject to any action by the Board of Directors that reduces the increase to a lesser number of shares for a given year.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2026 LTIP and 2019 Plan provide for the granting of restricted stock, incentive stock options (&#8220;ISOs&#8221;), or nonqualified stock options (&#8220;NQSOs&#8221;). Restricted stock and NQSOs may be granted to Company employees, officers, directors, and consultants. ISOs may only be granted to Company employees (including directors who are also considered employees).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options under the 2026 LTIP and 2019 Plan may be granted for terms of up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant, provided however, that with respect to an ISO granted to a person who owns stock representing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total combined voting power of all classes of stock of the Company, the term shall be for no more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise price of options granted under the 2026 LTIP and 2019 Plan must be at a price no less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the shares on the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to an employee who at the time of grant of such option owns stock representing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total combined voting power of all classes of stock of the Company, the exercise price shall not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the shares on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options granted under the 2026 LTIP and 2019 Plan generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, generally </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% after one year and monthly thereafter. Annual refresher options granted to employees generally vest monthly over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2026 Employee Stock Purchase Plan (the &#8220;2026 ESPP&#8221;), which became effective on February 4, 2026. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539,582</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock have been reserved for issuance under the 2026 ESPP. In addition, the number of shares reserved for future issuance under the 2026 ESPP will be increased for annual automatic evergreen increases, subject to any action by the Board of Director that reduces the increase to a lesser number of shares or provides that there will be no increase in the share reserve for a given year.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense includes options granted to employees and nonemployees and has been reported in the condensed statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,162</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,151</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,615</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,819</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,970</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of IPR&amp;D<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions of IPR&amp;D</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10. Acquisitions of IPR&amp;D</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seven and Eight Collaboration Agreement and SW License and Development Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 29, 2023, the Company entered into an Exclusive Collaboration Agreement (the &#8220;Seven and Eight Collaboration Agreement&#8221;), with Seven and Eight Biotherapeutics Corp. and related entities (collectively &#8220;Seven and Eight&#8221;), and an Exclusive License and Development Agreement (the &#8220;SW License Agreement&#8221;) with Seven and Eight and Superb Wisdom Limited (&#8220;SW&#8221;). Under each agreement, Seven and Eight and SW granted the Company a worldwide, exclusive license under certain of their patents, know-how, and other intellectual property rights to develop and commercialize certain toll-like receptor 7 and 8 agonist product candidates, including the Company&#8217;s product candidate, EIK1001. The license from SW is exclusive in the field of oncology, and the license from Seven and Eight is exclusive in all fields. The Company has the sole right and responsibility to conduct clinical development, perform regulatory activities and commercialize the compounds and products licensed under the agreements, and must use commercially reasonable efforts with respect to its development activities. Under the Seven and Eight Collaboration Agreement, following a transition period during which Seven and Eight transferred certain contracts, regulatory documentation, biological materials, research tools, rights and other information related to the product candidates to the Company, Seven and Eight agreed to wind down its research efforts with respect to toll-like receptor activity, including its development of the compounds licensed under the agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid Seven and Eight and SW aggregate upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Seven and Eight and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to SW), and issued two Simple Agreements for Future Equity (&#8220;SAFEs&#8221;), equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Seven and Eight and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to SW) upon entering into the applicable agreement. The SAFEs automatically converted into Series C redeemable convertible preferred stock upon the initial closing of the Series C financing round in May 2023, which then converted into common stock upon the closing of the IPO. The Company has also agreed to pay Seven and Eight additional milestone payments in the amount of up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">369.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">219.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million are payable for a compound that is not a conjugate and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for a compound that is a conjugate, in each case upon the achievement of certain development and regulatory milestones. EIK1001 is a compound that is not a conjugate. The Company has also agreed to pay SW additional milestone payments in the amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain regulatory and commercial milestones, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Seven and Eight Collaboration Agreement, the Company owns and retains all rights in intellectual property and other information discovered, developed, or otherwise made in connection with the Seven and Eight Collaboration Agreement, whether made by the Company or Seven and Eight, either solely or jointly. Under the SW License Agreement, the Company owns any improvements, enhancements, updates, or equivalents of the intellectual property developed, created, or otherwise made in relation to the compounds and products licensed under both agreements. The Company also has the right to prepare, file, prosecute, enforce, and maintain patents related to the compounds and products licensed under each agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the Seven and Eight Collaboration Agreement expires upon the latest of (i) the expiration, invalidation, or abandonment of the last patent licensed thereunder, (ii) the expiration of any data or market exclusivity program related to the product candidates, and (iii) ten years after the first commercial sale of a product candidate. If the Company notifies Seven and Eight that it is permanently discontinuing its efforts to develop and commercialize the licensed products under the agreement and does not intend to pay Seven and Eight any milestone payments contemplated thereunder, Seven and Eight may terminate the Seven and Eight Collaboration Agreement. Either party may terminate the Seven and Eight Collaboration Agreement if there has been a material breach of contract, but such termination can only be invoked if the breach cannot be reasonably remedied by the payment of money damages. The Company may also terminate the Seven and Eight Collaboration Agreement upon prior written notice for any reason.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the SW License Agreement expires upon the earliest of (i) the expiration, invalidation, or abandonment of the last patent licensed thereunder in the applicable country (and if no patent application was filed or no patent was issued in such country, ten years from the first commercial sale of the first product licensed thereunder in such country), or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) payment of the last commercial milestone payment. The SW License Agreement automatically terminates upon any termination of the Seven and Eight Collaboration Agreement. The SW License Agreement may also be terminated, without terminating the Seven and Eight Collaboration Agreement, by either party if there has been a material breach (including if the Company fails to make any milestone payment due thereunder). The Company may also terminate the SW License Agreement, without terminating the Seven and Eight Collaboration Agreement, upon prior written notice for any reason.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized the upfront payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as in-process research and development expenses within the statement of operations and comprehensive loss in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as the transaction was accounted for as an in-process research and development asset acquisition and the acquired technology did not have an alternative use. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> future milestones were accrued on the Company&#8217;s condensed balance sheets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025 as such milestones were not achieved or probable of being achieved at each date.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impact Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 10, 2023, the Company entered into a Collaboration Agreement, which was amended and restated on November 22, 2023, and further amended on December 12, 2024 (collectively, the &#8220;Impact Agreement&#8221;) with Impact Therapeutics (Shanghai) Inc. (&#8220;Impact&#8221;). Pursuant to the Impact Agreement, the Company received an exclusive license under certain of Impact&#8217;s patents, know-how, and regulatory information to develop and commercialize any selective PARP1 inhibitors owned or controlled by Impact or its affiliates, including the Company&#8217;s product candidates EIK1003 and EIK1004, and any pharmaceutical products comprised of or containing such inhibitors, on a worldwide basis excluding China, Hong Kong, Taiwan, and Macau, such excluded territories collectively known as the Impact territory. The Company also received a co-exclusive, royalty-free license under certain of Impact&#8217;s patents and know-how to develop and manufacture such product candidates within the Impact territory solely for the purposes of supporting the development or commercialization thereof outside of the Impact territory. Additionally, the Company granted to Impact a co-exclusive, royalty-free license under certain of its patents, know-how, and regulatory information for the sole purposes of Impact fulfilling its obligations related to the Impact Agreement and to develop, manufacture and make regulatory filings related to the product candidates. In addition, the Company granted an exclusive, royalty-free license under certain of its patents and know-how to Impact solely for purposes of commercialization of the product candidates in the Impact territory. The Impact Agreement further prohibits either party or their sublicensees or affiliates, as applicable, from developing, manufacturing, or commercializing any selective PARP1 inhibitors during the term of the Impact Agreement except as provided under the foregoing licenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Impact Agreement established a joint steering committee (&#8220;JSC&#8221;) to manage the collaboration. Under the Impact Agreement, Impact retains responsibility for all preclinical development activities for the product candidates. Impact is responsible for clinical development, including preparing and maintaining regulatory approvals, and commercialization of the product candidates, in the Impact territory, and the Company is responsible for these activities in all other jurisdictions worldwide. The Company also has the right to propose global clinical studies and global development plans that include clinical sites in the Impact territory for the JSC&#8217;s approval. The Company would be responsible for the conduct of any global clinical study in all territories except the Impact territory, in which Impact would be responsible for such conduct. Under a global development plan, the Company and Impact could each also propose the development of a combination product in their respective territories. Further, under the Impact Agreement, the Company must use commercially reasonable efforts to achieve regulatory approval of a product candidate for one indication in the United States, subject to Impact&#8217;s performance of its preclinical development activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The JSC consists of three Eikon representatives and three Impact representatives; the chair of the JSC is an Eikon representative. In the event that the JSC cannot reach unanimous agreement on any issue, then the Company&#8217;s Chief Medical Officer must discuss the issue with Impact&#8217;s Chief Executive Officer. If they are unable to reach agreement, then the Company has final decision-making authority over any matter related to the development and commercialization of the product candidates, including Impact&#8217;s preclinical development plan, and any Impact, global, or combination development plan. Impact has final decision-making authority over the day-to-day implementation of any development plan, manufacturing, and commercialization of the product candidates in the Impact territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cash to Impact. The Company is also required to make payments to Impact of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">775.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development and regulatory milestones and commercial milestones, respectively. In addition, tiered royalties of high single-digit to low-teen percentages of net sales per calendar year, subject to certain reductions, are also payable by the Company to Impact post-commercialization.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and Impact each own and retain all interests in any information or invention individually developed under the Impact Agreement, and they each own an equal and undivided interest in any jointly developed intellectual property. Subject to the licenses granted under the Impact Agreement and the respective exclusivity obligations therein, the Company and Impact each have the right to exploit such joint intellectual property rights and grant licenses to affiliates or other persons under such joint intellectual property rights.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impact has the right to prosecute and maintain its own and joint patents in the Impact Territory; the Company has the right to prosecute and maintain its own patents worldwide, and to prosecute and maintain Impact&#8217;s and any joint patents in any jurisdictions except for the Impact Territory. The Company and Impact each have the sole right to enforce patents in their own respective territories and have agreed to cooperate fully where the enforcing party requires documentation or other assistance from the other party.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Impact Agreement expires upon the expiration of the last royalty term for the last product candidate for which the Company is actively pursuing research, development and commercialization. The royalty term for a product candidate in a country expires upon the latest to occur of: (i) the expiration of the last-to-expire patent held by Impact or joint patent in such country that contains a valid claim that covers such product candidate or corresponding licensed compound, (ii) the tenth anniversary of the first commercial sale of such product candidate in such country, and (iii) the expiration of regulatory exclusivity for such product candidate in such country. Upon such expiration of the royalty term for a product candidate in a country, the exclusive licenses the Company received under the Impact Agreement will become non-exclusive, perpetual, fully-paid, royalty-free, irrevocable licenses for such product candidate in such country. Either party may terminate the Impact Agreement if there has been material breach, but such termination can only be invoked if the breach cannot be reasonably remedied by the payment of money damages. In addition, either party may terminate the agreement if the other party becomes insolvent. The Company has the sole right to terminate the Impact Agreement immediately upon written notice to Impact if the Company receives a clinical hold or a withdrawal notice from a regulatory authority regarding safety concerns related to the development or commercialization of a product candidate, in each case that has no reasonable likelihood of resolution. The Company also has the sole right to terminate for any or no reason upon prior written notice to Impact.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognized the upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as in-process research and development expenses within the statement of operations and comprehensive loss in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023 as the transaction was accounted for as an in-process research and development asset acquisition and the acquired technology did not have an alternative use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development and regulatory milestones, which were recorded as research and development expenses in the condensed statement of operations and comprehensive loss for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestone payments were made in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> future milestones were accrued on the Company&#8217;s condensed balance sheets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as such milestones were not achieved or probable of being achieved at each date.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 46<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-46<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 45<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-45<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479326/805-40-45-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-30/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-20/tableOfContent<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research and Development Arrangements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11. Research and Development Arrangements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Column Group and Catalyst4 Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 7, 2024, the Company entered into a collaboration agreement with The Column Group-Neuro, LP (&#8220;TCG&#8221;), an investor in the Company, and Catalyst4, Inc. (&#8220;Catalyst4&#8221;), a limited partner in TCG&#8217;s neuroscience fund.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, Catalyst4 will pay the Company an aggregate payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million over the next five years to perform upfront research and development on drug discovery or drug development programs for Parkinson&#8217;s Disease. In addition, the Company is required to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to Catalyst4 upon the achievement of a certain regulatory milestone. In the event Eikon sells or licenses programs to a third party to develop, the Company is required to pay Catalyst4 a mid-double digit percentage of all payments received, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate across all such programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Catalyst4 for future services, which was recorded in other non-current liabilities on its condensed balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreements with MSD</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into a clinical trial collaboration and supply agreement (the &#8220;MSD Agreement&#8221;) with MSD International Business GmbH (&#8220;MSD&#8221;), for three separate studies: (i) the Phase 2/3 registrational study of EIK1001 in patients with advanced melanoma (dated August 1, 2024); (ii) the Phase 1/2 clinical trial of EIK1005 in patients with advanced solid tumors (dated December 3, 2025); and (iii) the Phase 2/3 registrational study of EIK1001 in patients with non-small cell lung cancer (dated December 5, 2025). Pursuant to the MSD Agreements, the Company and MSD agreed to collaborate on these clinical trials evaluating the safety and efficacy of its compounds in combination with MSD&#8217;s compound, pembrolizumab. Under the MSD Agreements, the Company acts as the sponsor of the clinical trials at its own costs and MSD has agreed to supply to the Company, at its own cost, pembrolizumab for use in such trials. Pursuant to the MSD Agreements, the Company and MSD must each use commercially reasonable efforts to supply the Company&#8217;s applicable compounds for use in the portions of the clinical trials in which patients are intended to receive pembrolizumab either alone or in combination with one or more treatments, in accordance with the applicable study protocol. The Company recognizes costs incurred for the EIK clinical trial as research and development expenses within the statement of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and MSD will jointly own all clinical data and results generated from the portion of the clinical trials involving the combination of the Company&#8217;s compound and pembrolizumab. The Company owns all clinical data and results generated from all portions of these clinical trials that involve its compound alone or in combination with other treatments that are not pembrolizumab, and MSD owns all clinical data and results generated from the portions of the clinical trial involving pembrolizumab alone or in combination with other treatments that are not the Company&#8217;s compound (the &#8220;MSD clinical data&#8221;). The Company may use MSD clinical data solely to evaluate the safety or performance of the combination or to register its compound in the combination.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MSD Agreements will each expire upon the delivery of a results memorandum and final report of the portions of the respective trial where patients receive pembrolizumab to MSD, unless earlier terminated, or, in the case of the Phase 2/3 trials, if the Phase 3 portion of the clinical trial is not initiated. MSD may terminate the supply agreement for a particular clinical trial if the Company does not initiate the trial for the combination within one year from the effective date of the respective MSD Agreement. Further, MSD may terminate an MSD agreement and the supply of pembrolizumab immediately if (i) MSD notifies the Company that it believes that pembrolizumab is being used unsafely in the trial and (ii) either MSD believes such matter is not reasonably capable of being remedied, or if the Company fails to remedy promptly such issue to MSD&#8217;s reasonable satisfaction. Either the Company or MSD may terminate an MSD agreement for a breach of the agreement, for patient safety, or due to regulatory authority objections or actions. Further, either party may also terminate an MSD agreement if such party determines, in its sole discretion, to withdraw any applicable regulatory approval for its respective compound, or to discontinue development of its respective compound for medical, scientific, or legal reasons.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee 401(k) Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 12. Employee 401(k) Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sponsors a 401(k) defined contribution plan covering all employees. Employer contributions to the plan were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 13. Segment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_85997c2d-5760-46fb-bcd0-7b83f0349464;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment that is managed on an entity-wide basis. The Company&#8217;s chief operating decision maker is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2ea580d6-5cea-4c6a-9652-7b14b693ba76;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s chief operating decision maker uses net loss to evaluate the performance of its segment, analyze financial trends, compare the budget to the actual operating results, and make resource allocation decisions. Segment net loss represents the Company&#8217;s total net loss. All corporate costs, including allocated facilities and information technology costs, and depreciation, are included within this segment. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and engineering expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,483</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,564</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,047</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,587</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,796</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,140</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items is comprised of interest income (expense), net and other income (expense), net.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s long-lived assets as of March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were located in the United States.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules and regulations of the Securities and Exchange Commission regarding interim reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These condensed financial statements include all adjustments necessary for the fair presentation of the Company&#8217;s financial position, results of operations and cash flows for the periods presented. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative GAAP included in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;) issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to, useful lives of long-lived assets, the incremental borrowing rates for leases, accruals for research and development costs, the fair value of redeemable convertible preferred stock, common stock warrants, common stock and various other inputs used in estimating stock-based compensation expense, and accounting for income tax uncertainties, including a valuation allowance for deferred tax assets, in the accompanying financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents, and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and marketable securities, which may exceed federally insured limits. The Company has no financial instruments with off balance sheet risk of loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future in-process research and development of its technology, its reliance on third parties to assist in conducting its clinical trials, the need to obtain regulatory and marketing approvals, competitors advancing medicine in a field that the Company intends to enter that constrains its ability to compete effectively for market share, competitors developing technological innovations that reduce the value of the inventions that enable the Company to discover and develop new medicines, protection of its proprietary technology, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize its clinical assets, it will be unable to generate product revenue or achieve profitability.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts held in money market funds and commercial paper, which are held at amortized cost.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s marketable securities consist of United States treasury securities and commercial paper, which are held-to-maturity and reported at amortized cost. The amortization of premiums and accretion of discounts from the purchase of the securities are recognized as a component of interest income in the statements of operations and comprehensive loss. Marketable securities are classified as either current or non-current assets based on their contractual maturity dates. Marketable securities are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. As of March 31, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there had been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment or credit losses on the Company&#8217;s marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included in long-term assets as of March 31, 2026 and December 31, 2025, restricted from withdrawal and held by a bank in the form of collateral for irrevocable standby letters of credit held as security for the Company&#8217;s leases. In addition, the Company had deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included in current assets as of March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, pledged for corporate credit cards.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are presented at cost, net of accumulated depreciation. Depreciation begins the first day of the month after the asset is placed in service. Depreciation is computed using the straight-line method over the estimated useful lives of five years for lab and engineering equipment, seven years for motor vehicles (used in the transportation of materials between sites) and furniture, fittings and office equipment, four years for computer equipment, and three years for software. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated once placed into service. Upon the sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations and comprehensive loss. Maintenance and repairs are charged to expense as incurred and costs of major replacement or improvement are capitalized.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews the carrying amounts of its long-lived assets, including property and equipment and right-of-use leased assets, for potential impairment whenever events or changes in circumstances indicate that the assets may not be recoverable. Factors that the Company considers in an impairment review include, but are not limited to, significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount, and the impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined using discounted cash flows. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment of long-lived assets during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of a contract, the Company assesses whether the contract is a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is determined to exist, the commencement date of such lease is assessed based on the date on which the Company gains control over the use of the underlying assets. The Company&#8217;s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options that the Company is reasonably certain of exercising. At lease commencement, the Company also determines lease classification based on whether the arrangement is effectively a financed purchase of the underlying asset (finance lease) or not (operating lease), which governs the pattern of expense recognition and the presentation reflected in the statements of operations and comprehensive loss and statements of cash flows over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For leases with a term exceeding 12 months, a lease liability is recorded on the Company&#8217;s balance sheet at lease commencement reflecting the present value of its minimum payment obligations over the lease term. A corresponding right-of-use (&#8220;ROU&#8221;) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. Variable lease payments are included in the present value of its minimum lease payment obligations when the contingency is resolved. The lease liability is remeasured at the date the contingency is resolved and the corresponding ROU asset is adjusted. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company&#8217;s incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Company&#8217;s operating leases, fixed lease payments are recognized as lease expense on a straight-line basis over the lease term. For leases with a term of 12 months or less, any fixed lease payments are recognized on a straight-line basis over the lease term and are not recognized on the Company&#8217;s balance sheet as an accounting policy election. Leases qualifying for the short-term lease exemption were insignificant. Variable lease costs are expensed in the statements of operations and comprehensive loss as incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any finance leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026 and December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Holders of the redeemable convertible preferred stock can cause redemption for cash upon the occurrence of a deemed liquidation event, which is outside the Company&#8217;s control. Therefore, redeemable convertible preferred stock is classified outside of stockholders&#8217; equity (deficit) on the balance sheet. The carrying values of the redeemable convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because the stock is not mandatorily redeemable and the occurrence of a deemed liquidation event is currently not probable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock', window );">Research and Development Expenses and Accruals</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses and Accruals</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are charged to expense as incurred. These expenses consist of compensation expenses, direct research and development expenses such as software development costs related to research and development activities, laboratory supplies, costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation, other miscellaneous expenses, and allocations of facility and information technology expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of its research and development activities conducted by third-party service providers. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with the third-party service agreements. If the Company does not identify costs that have begun to be incurred or if the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from the estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed and classified as current or non-current prepaid expenses and other assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company makes payments in connection with clinical trials to contract manufacturing organizations that manufacture the materials for its product candidates and to clinical research organizations and clinical trial sites that conduct and manage the Company&#8217;s clinical trials. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in payments that do not match the periods over which materials or services are provided. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. The Company makes estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Asset Acquisitions and In-Process Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Asset Acquisitions and In-Process Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company evaluates acquisitions of assets and related liabilities and other similar transactions to assess whether or not a transaction should be accounted for as an asset acquisition or business combination by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If the screen test is met, a transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs that would meet the requirements of a business. The Company accounts for an asset acquisition by recognizing net assets based on their cost on a relative fair value basis. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-monetary identifiable assets and liabilities assumed based on relative fair values. In-process research and development (&#8220;IPR&amp;D&#8221;) acquired in an asset acquisition is expensed provided there is no alternative future use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for future payments such as those upon the achievement of certain regulatory, development, or sales milestones in an asset acquisition when achievement of the underlying milestones is deemed probable. Milestone payments made to third parties subsequent to regulatory approval may be capitalized as intangible assets, if deemed to have alternative future use, and amortized over the estimated remaining useful life of the related product. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock', window );">Patent and Trademark Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent and Trademark Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related and trademark costs incurred in connection with filing and prosecuting patent and trademark applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses on the statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock', window );">Deferred Initial Public Offering Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Initial Public Offering Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred IPO costs, consisting primarily of legal and accounting fees relating to the IPO, are capitalized and offset against offering proceeds following the completion of the offering. Deferred IPO costs for terminated or delayed offerings are expensed immediately as a charge to general and administrative expenses in the statement of operations and comprehensive loss. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred IPO costs capitalized as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2026. The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of deferred IPO costs capitalized as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, included in other non-current assets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For stock-based awards issued to employees and nonemployees, the Company measures the estimated fair value of the stock-based awards on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective awards. The Company records the expense for awards with service-based vesting using the straight-line, ratable attribution method and accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#8217; vesting terms and contractual terms, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s cash compensation costs are classified.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock', window );">Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimates the fair value of the common stock underlying stock options on the date of grant. This has historically been determined by management with assistance from external appraisers and approved by the Board. Due to the absence of an active market for the Company&#8217;s common stock prior to its IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s common stock valuations prior to May 31, 2025 were performed using the Option Pricing Method (&#8220;OPM&#8221;) as it is deemed the most appropriate method based on the Company&#8217;s stage of development and other relevant factors. Within the OPM framework, the backsolve method for inferring the total equity value implied by a recent financing transaction involves the construction of an allocation model that takes into account the entity&#8217;s capital structure and the rights, preferences and privileges of each class of stock, then assumes reasonable inputs for the other OPM variables (inclusive of discount for lack of marketability, volatility, the expected time to liquidity, and risk-free rate). The total equity value is then iterated in the model until the model output value for the equity class sold in a recent financing round equals the price paid in that round. The OPM is generally utilized when specific future liquidity events are difficult to forecast (i.e., the enterprise has many choices and options available), and the enterprise&#8217;s value depends on how well it follows an uncharted path through the various possible opportunities and challenges. Among other factors considered are the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s common stock, common stock warrants and redeemable convertible preferred stock valuations from May 31, 2025 through the IPO date were performed using a hybrid method that combines the OPM and the probability-weighted expected return method (&#8220;PWERM&#8221;). The PWERM employs additional information not used in the OPM, including various market approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an IPO or sale of the enterprise, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#8217;s common stock and redeemable convertible preferred stock is then applied to arrive at an indication of value for the common stock and redeemable convertible preferred stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the IPO, the fair value of the common stock underlying stock options is based on the closing market price of the common stock on the date of grant.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_CommonStockWarrantsPolicyPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:4.537%;border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:8%;box-sizing:content-box;"></td>
         <td style="width:92%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets or liabilities.</span></p></td>
        </tr>
        <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td>
        </tr>
        <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3:</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></p></td>
        </tr>
       </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There are currently no components of other comprehensive loss for the Company. Thus, comprehensive loss is the same as the net loss for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The functional currency of the Company&#8217;s operation is U.S. dollars. All monetary assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Non-monetary assets and liabilities are translated using the exchange rate that was in effect when the asset or liability was initially recognized. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the statements of operations and comprehensive loss and recorded in other income (expense), net. Foreign currency transaction losses were immaterial for the three months ended March 31, 2026 and 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax credits are presented on a gross basis in the effective tax rate reconciliation, and the tax effect of changes in unrecognized tax benefits related to such credits is presented separately within changes in uncertain tax positions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Segments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company&#8217;s chief operating decision maker, its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a1712c5d-8279-47e4-b1b8-8c2d8242df25;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, views the Company&#8217;s operations and manages its business as a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options and warrants to purchase common stock, unvested common stock subject to repurchase and redeemable convertible preferred stock are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be antidilutive for all periods presented.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock and legally outstanding unvested common stock subject to repurchase are considered participating securities. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, (the "JOBS Act"), and may take advantage of reduced reporting requirements. These reporting requirement exemptions may not be applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s financial position or results of operations upon adoption.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2024-03 will require public business entities to disclose in the notes to the financial statements, at each interim and annual reporting period, specific information about certain costs and expenses, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each expense caption presented on the face of the income statement, and the total amount of an entity&#8217;s selling expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_CommonStockWarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_CommonStockWarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock, common stock warrants and redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net loss per share attributable to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent and trademark costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025 (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impact of preferred stock extinguishments and<br/>&#160;&#160;&#160;modifications</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,701,800</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,869,926</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Weighted-average common shares subject to<br/>&#160;&#160;&#160;repurchase</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,574</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and<br/>&#160;&#160;&#160;diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,700,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,770,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic<br/>&#160;&#160;&#160;and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding common stock equivalents have been excluded from diluted net loss per share attributable to common stockholders for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2026 and 2025 because their inclusion would be anti-dilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,522,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,904,399</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Early exercised stock options and unvested restricted<br/>&#160;&#160;&#160;common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Redeemable convertible preferred stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,855,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,262,751</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,563,186</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured At Fair Value On Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets, which consist of cash equivalents and marketable securities, presented at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.628%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:11.91%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,234</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">381</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,609</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, non-current:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,747</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,903</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, non-current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,828</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,576</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.628%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:11.91%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.181%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.889999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities, current:</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,935</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government securities</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Engineering equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,843</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,843</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Motor vehicles</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture, fittings &amp; office equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,062</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,970</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">963</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">624</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,812</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,094</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,914</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,067</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,898</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,128</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,518</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses related to purchase of IPR&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued vendor expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of early exercised options and<br/>&#160;&#160;&#160;restricted common stock liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments under Non-cancellable Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments under non-cancellable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2026 were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.236%;box-sizing:content-box;"></td>
         <td style="width:1.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.823%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026 (remainder of year)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,988</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,310</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,913</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">370,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total future minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">551,576</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296,745</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of future lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">254,831</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Operating lease liability, current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,740</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of Issued and Outstanding Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issued and outstanding redeemable convertible preferred stock consisted of the following (in thousands, except share and per share amounts):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.634%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.818%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.098%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.618%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.618%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.618%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Series</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares<br/>Authorized</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares<br/>Issued and<br/>Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Original<br/>Issue Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Liquidation<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,916</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,268,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,268,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,538</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,271,143</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,456,768</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,786</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">297,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,756,908</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,756,908</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,979</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,200</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,884,830</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,194,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,682</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,629</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series C-1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,975,110</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,975,110</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,077</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,806</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,441,007</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,005,669</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262,597,889</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,658,133</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,159,762</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,161,470</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock', window );">Summary of Common Stock Reserved for Future issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance, on an as if-converted basis, consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of redeemable convertible preferred stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,855,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,559</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,522,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,513,142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options available for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,269,981</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,449,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares reserved for ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539,582</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,071,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,557,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock reserved for future issuance as if converted basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-based compensation expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense includes options granted to employees and nonemployees and has been reported in the condensed statements of operations and comprehensive loss as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,162</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,151</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,615</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,819</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,777</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,970</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and engineering expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,483</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,564</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,960</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,047</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,587</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,796</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">#</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,140</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,958</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other segment items is comprised of interest income (expense), net and other income (expense), net.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 06, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 27, 2026</div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,003,467)<span></span>
</td>
<td class="num">$ (920,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Company effected a 1-for-7.4578 reverse stock split of its issued and outstanding common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.134088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued | shares</a></td>
<td class="nump">21,177,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the issuance of common stock</a></td>
<td class="nump">$ 348,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Redeemable convertible preferred stock, number of shares of common stock issued upon conversion | shares</a></td>
<td class="nump">29,855,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities current and marketable securities non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ImpairmentOnMarketableSecurities', window );">Impairment on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">7,808,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,771,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred IPO costs capitalized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ImpairmentOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment on Marketable Securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ImpairmentOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (82,958)<span></span>
</td>
<td class="num">$ (68,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ImpactOfPreferredStockExtinguishmentsAndModifications', window );">Impact of preferred stock extinguishments and modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (82,958)<span></span>
</td>
<td class="num">$ (74,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_WeightedAverageCommonSharesOutstanding', window );">Weighted-average common shares outstanding</a></td>
<td class="nump">33,701,800<span></span>
</td>
<td class="nump">2,869,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Less: Weighted-average common shares subject to repurchase</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(99,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">33,700,550<span></span>
</td>
<td class="nump">2,770,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">33,700,550<span></span>
</td>
<td class="nump">2,770,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (26.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (26.91)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ImpactOfPreferredStockExtinguishmentsAndModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of preferred stock extinguishments and modifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ImpactOfPreferredStockExtinguishmentsAndModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_WeightedAverageCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_WeightedAverageCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">8,262,751<span></span>
</td>
<td class="nump">33,563,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">7,522,330<span></span>
</td>
<td class="nump">2,904,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember', window );">Early Exercised Stock Options and Unvested Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">63,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">739,559<span></span>
</td>
<td class="nump">739,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,855,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured At Fair Value On Recurring Basis (Details) - Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 148,094<span></span>
</td>
<td class="nump">$ 84,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">148,094<span></span>
</td>
<td class="nump">84,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent', window );">Marketable Securities, Amortized Cost, Current</a></td>
<td class="nump">351,028<span></span>
</td>
<td class="nump">231,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable Securities, Unrealized Gains, Current</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Losses, Current</a></td>
<td class="num">(448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Marketable Securities, Fair Value, Current</a></td>
<td class="nump">350,609<span></span>
</td>
<td class="nump">231,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent', window );">Marketable Securities, Amortized Cost, Non-current</a></td>
<td class="nump">83,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Losses, Non-current</a></td>
<td class="num">(252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Marketable Securities, Fair Value, Non-current</a></td>
<td class="nump">83,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent', window );">Marketable Securities, Amortized Cost, Current</a></td>
<td class="nump">192,794<span></span>
</td>
<td class="nump">123,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable Securities, Unrealized Gains, Current</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Losses, Current</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Marketable Securities, Fair Value, Current</a></td>
<td class="nump">192,753<span></span>
</td>
<td class="nump">123,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent', window );">Marketable Securities, Amortized Cost, Non-current</a></td>
<td class="nump">29,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Losses, Non-current</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Marketable Securities, Fair Value, Non-current</a></td>
<td class="nump">29,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent', window );">Marketable Securities, Amortized Cost, Current</a></td>
<td class="nump">158,234<span></span>
</td>
<td class="nump">107,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable Securities, Unrealized Gains, Current</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Losses, Current</a></td>
<td class="num">(381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Marketable Securities, Fair Value, Current</a></td>
<td class="nump">157,856<span></span>
</td>
<td class="nump">$ 107,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent', window );">Marketable Securities, Amortized Cost, Non-current</a></td>
<td class="nump">53,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Losses, Non-current</a></td>
<td class="num">(178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Marketable Securities, Fair Value, Non-current</a></td>
<td class="nump">$ 53,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities held-to-maturity current accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities held-to-maturity current accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities held-to-maturity non current accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value assets, transfers to level 3, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 186,161<span></span>
</td>
<td class="nump">$ 185,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(48,094)<span></span>
</td>
<td class="num">(42,914)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">138,067<span></span>
</td>
<td class="nump">142,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">25,909<span></span>
</td>
<td class="nump">25,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_EngineeringEquipmentMember', window );">Engineering Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,843<span></span>
</td>
<td class="nump">14,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">120,588<span></span>
</td>
<td class="nump">120,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_FurnitureFittingsOfficeEquipmentMember', window );">Furniture, Fittings &amp; Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,150<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13,062<span></span>
</td>
<td class="nump">12,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,627<span></span>
</td>
<td class="nump">5,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 963<span></span>
</td>
<td class="nump">$ 624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_EngineeringEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_EngineeringEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_FurnitureFittingsOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eikn_FurnitureFittingsOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 5,214<span></span>
</td>
<td class="nump">$ 3,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expenses</a></td>
<td class="nump">$ 11,207<span></span>
</td>
<td class="nump">$ 24,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AccruedClinicalExpenses', window );">Accrued clinical expenses</a></td>
<td class="nump">9,128<span></span>
</td>
<td class="nump">6,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AccruedInProcessResearchAndDevelopment', window );">Accrued expenses related to purchase of IPR&amp;D</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AccruedVendorExpenses', window );">Accrued vendor expenses</a></td>
<td class="nump">8,700<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability', window );">Current portion of early exercised options and restricted common stock liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 29,319<span></span>
</td>
<td class="nump">$ 44,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AccruedClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AccruedClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AccruedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued In Process Research and Development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AccruedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AccruedVendorExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued vendor expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AccruedVendorExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of early exercised options and restricted common stock liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,831,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseDepositLiability', window );">Lease deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,965,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of square feet | ft&#178;</a></td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">Jan. 31,  2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 64,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 159,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_PercentageOfIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease option to extend</a></td>
<td class="text">extend this lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">intention to early terminate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_OperatingLeaseTerminationDate', window );">Termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease', window );">Decrease in the lease liability from the remeasurement of the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease', window );">Decrease in the operating lease right of use assets from the remeasurement of the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Hayward, California, New York, New York and Jersey City, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Hayward, California, New York, New York and Jersey City, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in the lease liability from the remeasurement of the lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in the operating lease right of use assets from the remeasurement of the lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_OperatingLeaseTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Termination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_OperatingLeaseTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_PercentageOfIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_PercentageOfIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479341/842-30-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=eikn_CaliforniaNewYorkAndNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=eikn_CaliforniaNewYorkAndNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Future Minimum Lease Payments under Non-cancellable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2026 (remainder of year)</a></td>
<td class="nump">$ 30,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="nump">39,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="nump">38,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="nump">36,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2030</a></td>
<td class="nump">35,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">370,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">551,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(296,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">254,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Operating lease liability, current</a></td>
<td class="num">(9,740)<span></span>
</td>
<td class="num">$ (10,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 245,091<span></span>
</td>
<td class="nump">$ 247,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments Due, after Year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UpfrontsAndMilestonePayments', window );">Upfronts and milestone payments</a></td>
<td class="nump">$ 93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Legal contingencies requiring accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">300,155,000<span></span>
</td>
<td class="nump">312,298,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DevelopmentAndRegulatoryMilestones', window );">Development and regulatory milestones, paid</a></td>
<td class="nump">630,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_SalesMilestones', window );">Sales milestones paid</a></td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Rights and Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_SalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_SalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_UpfrontsAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfronts and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_UpfrontsAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Structure - Summary of Issued and Outstanding Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">262,597,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">222,658,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">222,658,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,161,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesA-1RedeemableConvertiblePreferredStockMember', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,268,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,268,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,268,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,271,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,456,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,456,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesB-1RedeemableConvertiblePreferredStockMember', window );">Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,756,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,756,908<span></span>
</td>
<td class="nump">35,756,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,756,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,884,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesC-1RedeemableConvertiblePreferredStockMember', window );">Series C-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,110<span></span>
</td>
<td class="nump">4,975,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,441,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,005,669<span></span>
</td>
<td class="nump">60,005,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,005,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesA-1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesA-1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesB-1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesB-1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesC-1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesC-1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Structure - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,658,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants at fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquityOffsetFairValueExceededCarryingValue', window );">Fair value exceeded carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_TemporaryEquityOffsetCarryingValueExceededFairValue', window );">Carrying value exceeded fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders', window );">Extinguishments reduction to net loss available to common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants to purchase exercise price per share</a></td>
<td class="nump">$ 43.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue', window );">Modified adjusted Preferred stock increase in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications', window );">Increase in net loss available to common stockholders from equity modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross cash proceeds form sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DividendsDeclared', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Redeemable convertible preferred stock, number of shares of common stock issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,855,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">739,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesA-1RedeemableConvertiblePreferredStockMember', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,268,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,456,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares returned by the holders in exchange of redeemable convertible preferred stock</a></td>
<td class="nump">11,814,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">New issuance convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Derecognition of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock', window );">Decrease in carrying amount of redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesB-1RedeemableConvertiblePreferredStockMember', window );">Series B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">35,756,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,756,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">New issuance convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Increase in carrying amount of redeemable Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares returned by the holders in exchange of redeemable convertible preferred stock</a></td>
<td class="nump">1,352,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">New issuance convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Derecognition of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock', window );">Decrease in carrying amount of redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesC-1RedeemableConvertiblePreferredStockMember', window );">Series C-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">4,975,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">New issuance convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Increase in carrying amount of redeemable Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Original issue price</a></td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares issued</a></td>
<td class="nump">60,005,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,005,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds convertible preferred stock</a></td>
<td class="nump">$ 350,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DividendsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends declared</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DividendsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishments reduction to net loss available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in net loss available to common stockholders from equity modifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modified adjusted Preferred stock increase in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquityOffsetCarryingValueExceededFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity offset carrying value exceeded fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquityOffsetCarryingValueExceededFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_TemporaryEquityOffsetFairValueExceededCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity offset fair value exceeded carrying value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_TemporaryEquityOffsetFairValueExceededCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to retained earnings for the increase in carrying amount of redeemable preferred stock that is classified as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesA-1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesA-1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesB-1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesB-1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesC-1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesC-1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Structure - Summary of Common Stock Reserved for Future issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">11,071,452<span></span>
</td>
<td class="nump">37,557,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_ConversionOfRedeemableConvertiblePreferredStockMember', window );">Conversion of Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,855,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">739,559<span></span>
</td>
<td class="nump">739,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_StockOptionsIssuedAndOutstandingMember', window );">Stock Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">7,522,330<span></span>
</td>
<td class="nump">5,513,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_StockOptionsAvailableForFutureIssuanceMember', window );">Stock Options Available for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,269,981<span></span>
</td>
<td class="nump">1,449,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eikn_SharesReservedForEmployeeStockPurchasePlanMember', window );">Shares Reserved for ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">539,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_ConversionOfRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_ConversionOfRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_StockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_StockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_StockOptionsAvailableForFutureIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_StockOptionsAvailableForFutureIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eikn_SharesReservedForEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eikn_SharesReservedForEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation Expense - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 19, 2019</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,071,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,557,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanMember', window );">2026 Long-Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,137,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember', window );">2026 LTIP and 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember', window );">2026 LTIP and 2019 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm', window );">Stock options granted (in term)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne', window );">Stock options granted (in term)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember', window );">2026 LTIP and 2019 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage', window );">Stock option, ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage', window );">Exercise price of options granted at fair market value ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember', window );">2026 LTIP and 2019 Plan | After One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember', window );">2026 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eikn_StockOptionOwnershipPercentageLessThanTenPercentMember', window );">Stock Option, Ownership Percentage Less Than 10% Percent | 2026 LTIP and 2019 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate', window );">Percentage of fair market value of shares on grant date</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember', window );">Stock Option, Ownership Percentage More Than 10% Percent | 2026 LTIP and 2019 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate', window );">Percentage of fair market value of shares on grant date</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price of options granted under incentive and share based compensation plans as percentage of fair market value of shares on grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share-based payment award, granted in term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share-based payment award, granted term one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, exercise price of options granted at fair market value ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share-based payment award, ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eikn_StockOptionOwnershipPercentageLessThanTenPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eikn_StockOptionOwnershipPercentageLessThanTenPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,777<span></span>
</td>
<td class="nump">$ 2,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,615<span></span>
</td>
<td class="nump">$ 1,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of IPR&amp;D - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember', window );">Seven and Eight Collaboration Agreement and SW License and Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_SimpleAgreementsForFutureEquityIssuedAmount', window );">Simple agreements for future equity issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses', window );">Upfront payments recognized as in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_FutureMilestonesAccrued', window );">Future milestones accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UpfrontFeePaidInCash', window );">Upfront fee paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember', window );">Seven and Eight Collaboration Agreement and SW License and Development Agreement | Seven and Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_SimpleAgreementsForFutureEquityIssuedAmount', window );">Simple agreements for future equity issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones', window );">Additional milestone payable upon achievement of certain development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate', window );">Additional milestone payable upon the achievement of certain development and regulatory milestones for a compound that is not a conjugate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate', window );">Additional milestone payable upon the achievement of certain development and regulatory milestones for a compound that is a conjugate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UpfrontFeePaidInCash', window );">Upfront fee paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember', window );">Seven and Eight Collaboration Agreement and SW License and Development Agreement | SW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_SimpleAgreementsForFutureEquityIssuedAmount', window );">Simple agreements for future equity issued, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UpfrontFeePaidInCash', window );">Upfront fee paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember', window );">Seven and Eight Collaboration Agreement and SW License and Development Agreement | SW | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones', window );">Additional milestone payable upon the achievement of certain regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones', window );">Additional milestone payable upon the achievement of certain commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eikn_ImpactAgreementMember', window );">Impact Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses', window );">Upfront payments recognized as in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_FutureMilestonesAccrued', window );">Future milestones accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_UpfrontFeePaidInCash', window );">Upfront fee paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones', window );">Maximum amount payable upon the achievement of certain commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_DevelopmentAndRegulatoryMilestonesPaid', window );">Development and regulatory milestones, paid</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eikn_ImpactAgreementMember', window );">Impact Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones', window );">Maximum amount payable upon the achievement of certain development and regulatory milestones milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payable for a compound that is a conjugate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payable for a compound that is not a conjugate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payable upon achievement of certain development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payable upon the achievement of certain commercial milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payable upon the achievement of certain regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_DevelopmentAndRegulatoryMilestonesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestones paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_DevelopmentAndRegulatoryMilestonesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_FutureMilestonesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future milestones accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_FutureMilestonesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable upon the achievement of certain commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable upon the achievement of certain development and regulatory milestones milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_SimpleAgreementsForFutureEquityIssuedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Simple agreements for future equity issued amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_SimpleAgreementsForFutureEquityIssuedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_UpfrontFeePaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_UpfrontFeePaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments recognized as in-process research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eikn_SevenAndEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eikn_SevenAndEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eikn_SuperbWisdomLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eikn_SuperbWisdomLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=eikn_ImpactAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=eikn_ImpactAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Arrangements - Additional Information (Details) - The Column Group and Catalyst4 Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_AggregatePaymentToPerformResearchAndDevelopment', window );">Aggregate payment to perform research and development</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from catalyst4 for future services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_PaymentForAchievementOfCertainRegulatoryMilestone', window );">Payment for achievement of certain regulatory milestone</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_SalesRoyaltyPayable', window );">Sales royalty payable</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_AggregatePaymentToPerformResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate payment to perform research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_AggregatePaymentToPerformResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_PaymentForAchievementOfCertainRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for achievement of certain regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_PaymentForAchievementOfCertainRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_SalesRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_SalesRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eikn_TheColumnGroupAndCatalyst4AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eikn_TheColumnGroupAndCatalyst4AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(k) Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions to the plan</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The Company&#8217;s chief operating decision maker uses net loss to evaluate the performance of its segment, analyze financial trends, compare the budget to the actual operating results, and make resource allocation decisions. Segment net loss represents the Company&#8217;s total net loss. All corporate costs, including allocated facilities and information technology costs, and depreciation, are included within this segment. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ResearchAndEngineeringExpenses', window );">Research and engineering expenses</a></td>
<td class="nump">$ 29,483<span></span>
</td>
<td class="nump">$ 33,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_ClinicalExpenses', window );">Clinical expenses</a></td>
<td class="nump">35,564<span></span>
</td>
<td class="nump">22,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eikn_InProcessResearchAndDevelopmentExpenses', window );">In-process research and development expenses</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">70,047<span></span>
</td>
<td class="nump">56,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">17,290<span></span>
</td>
<td class="nump">14,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(4,379)<span></span>
</td>
<td class="num">(3,140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 82,958<span></span>
</td>
<td class="nump">$ 68,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_InProcessResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In process research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_InProcessResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eikn_ResearchAndEngineeringExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and engineering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eikn_ResearchAndEngineeringExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eikn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>296</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingencies1</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Capital Structure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructure1</Role>
      <ShortName>Capital Structure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpense</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Acquisitions of IPR&amp;D</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprd</Role>
      <ShortName>Acquisitions of IPR&amp;D</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Research and Development Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangements</Role>
      <ShortName>Research and Development Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Employee 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlan</Role>
      <ShortName>Employee 401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Segment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegment</Role>
      <ShortName>Segment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Capital Structure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureTables</Role>
      <ShortName>Capital Structure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructure1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpense</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Segment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentTables</Role>
      <ShortName>Segment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured At Fair Value On Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured At Fair Value On Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Non-cancellable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3</Role>
      <ShortName>Operating Leases - Schedule of Future Minimum Lease Payments under Non-cancellable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Capital Structure - Summary of Issued and Outstanding Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Capital Structure - Summary of Issued and Outstanding Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Capital Structure - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails</Role>
      <ShortName>Capital Structure - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Capital Structure - Summary of Common Stock Reserved for Future issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Capital Structure - Summary of Common Stock Reserved for Future issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation Expense - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Acquisitions of IPR&amp;D - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails</Role>
      <ShortName>Acquisitions of IPR&amp;D - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Research and Development Arrangements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails</Role>
      <ShortName>Research and Development Arrangements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Employee 401(k) Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlanAdditionalInformationDetails</Role>
      <ShortName>Employee 401(k) Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Segment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails</Role>
      <ShortName>Segment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eikn-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails</Role>
      <ShortName>Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="eikn-20260331.htm">eikn-20260331.htm</File>
    <File>eikn-20260331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img119830300_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="471">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eikn-20260331.htm": {
   "nsprefix": "eikn",
   "nsuri": "http://www.eikontx.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "eikn-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "eikn-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 216,
   "keyCustom": 80,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 29,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 9
   },
   "contextCount": 147,
   "entityCount": 1,
   "segmentCount": 56,
   "elementCount": 577,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 471,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets",
     "longName": "75010 - Statement - Condensed Balance Sheets",
     "shortName": "Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Condensed Balance Sheets (Parenthetical)",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75030 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "75040 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_6efa0e52-ace6-4c24-8d0d-270fe66c03b8",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_82c0918f-98b5-404a-874a-7e2868a58706",
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "longName": "75050 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "shortName": "Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_7a831092-b41d-417e-82e2-51595df304eb",
      "name": "eikn:AdjustmentNetOfIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7a831092-b41d-417e-82e2-51595df304eb",
      "name": "eikn:AdjustmentNetOfIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows",
     "longName": "75060 - Statement - Condensed Statements of Cash Flows",
     "shortName": "Condensed Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "longName": "995455 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "longName": "995475 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponents",
     "longName": "995495 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeases",
     "longName": "995505 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingencies1",
     "longName": "995515 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructure1",
     "longName": "995525 - Disclosure - Capital Structure",
     "shortName": "Capital Structure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpense",
     "longName": "995535 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprd",
     "longName": "995545 - Disclosure - Acquisitions of IPR&D",
     "shortName": "Acquisitions of IPR&D",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangements",
     "longName": "995555 - Disclosure - Research and Development Arrangements",
     "shortName": "Research and Development Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlan",
     "longName": "995565 - Disclosure - Employee 401(k) Plan",
     "shortName": "Employee 401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegment",
     "longName": "995575 - Disclosure - Segment",
     "shortName": "Segment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995595 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "longName": "995605 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995615 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "995625 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesTables",
     "longName": "995635 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureTables",
     "longName": "995645 - Disclosure - Capital Structure (Tables)",
     "shortName": "Capital Structure (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables",
     "longName": "995655 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense (Tables)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentTables",
     "longName": "995665 - Disclosure - Segment (Tables)",
     "shortName": "Segment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
     "longName": "995675 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "eikn:CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995685 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "eikn:ImpairmentOnMarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "eikn:ImpairmentOnMarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
     "longName": "995695 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "eikn:WeightedAverageCommonSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe",
     "longName": "995705 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995715 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured At Fair Value On Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets Measured At Fair Value On Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995725 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "995735 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "longName": "995745 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995755 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "longName": "995765 - Disclosure - Operating Leases - Additional Information (Details)",
     "shortName": "Operating Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:PaymentsForProceedsFromTenantAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:PaymentsForProceedsFromTenantAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3",
     "longName": "995775 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Non-cancellable Leases (Details)",
     "shortName": "Operating Leases - Schedule of Future Minimum Lease Payments under Non-cancellable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995795 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "eikn:UpfrontsAndMilestonePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "eikn:UpfrontsAndMilestonePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
     "longName": "995805 - Disclosure - Capital Structure - Summary of Issued and Outstanding Redeemable Convertible Preferred Stock (Details)",
     "shortName": "Capital Structure - Summary of Issued and Outstanding Redeemable Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eea5e544-8a36-4e39-9071-f9fe1d484521",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Capital Structure - Additional Information (Details)",
     "shortName": "Capital Structure - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b9805475-e76d-41e7-932c-783895704433",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "995825 - Disclosure - Capital Structure - Summary of Common Stock Reserved for Future issuance (Details)",
     "shortName": "Capital Structure - Summary of Common Stock Reserved for Future issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eikn:CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_32e58006-0bc0-440a-94eb-1e6e99c57dfe",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eikn:CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Additional Information (Details)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation Expense - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_3076528d-17ef-41ea-9093-a57058ff97ec",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "eikn:CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_480832dd-e171-4ca4-b482-a03140d73654",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails",
     "longName": "995845 - Disclosure - Equity Incentive Plans and Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails",
     "longName": "995855 - Disclosure - Acquisitions of IPR&D - Additional Information (Details)",
     "shortName": "Acquisitions of IPR&D - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_4c693a1f-4ca1-464c-90fa-56debb4e78a7",
      "name": "eikn:SimpleAgreementsForFutureEquityIssuedAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4c693a1f-4ca1-464c-90fa-56debb4e78a7",
      "name": "eikn:SimpleAgreementsForFutureEquityIssuedAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails",
     "longName": "995865 - Disclosure - Research and Development Arrangements - Additional Information (Details)",
     "shortName": "Research and Development Arrangements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_1e8500d8-0dbe-4c15-adb9-cf43d49e2d09",
      "name": "eikn:AggregatePaymentToPerformResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1e8500d8-0dbe-4c15-adb9-cf43d49e2d09",
      "name": "eikn:AggregatePaymentToPerformResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlanAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Employee 401(k) Plan - Additional Information (Details)",
     "shortName": "Employee 401(k) Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails",
     "longName": "995885 - Disclosure - Segment - Additional Information (Details)",
     "shortName": "Segment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails",
     "longName": "995895 - Disclosure - Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details)",
     "shortName": "Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "eikn:ResearchAndEngineeringExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c6596ac-f14a-40c8-b62c-b693a7753c24",
      "name": "eikn:ResearchAndEngineeringExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eikn-20260331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r808"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and accretion of discounts on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "eikn_AccruedClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AccruedClinicalExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "eikn_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical expenses",
        "documentation": "Accrued clinical expenses.",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "documentation": "Accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AccruedInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AccruedInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "eikn_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued In Process Research and Development",
        "documentation": "Accrued In Process Research and Development.",
        "terseLabel": "Accrued expenses related to purchase of IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AccruedVendorExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AccruedVendorExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "eikn_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued vendor expenses",
        "documentation": "Accrued vendor expenses.",
        "terseLabel": "Accrued vendor expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r117",
      "r614"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "eikn_AdditionalMilestonePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdditionalMilestonePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone Payable",
        "documentation": "Additional milestone payable.",
        "terseLabel": "Additional milestone payable"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AdditionalMilestonePayableForACompoundThatIsAConjugate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdditionalMilestonePayableForACompoundThatIsAConjugate",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone Payable for a Compound that is a Conjugate",
        "documentation": "Additional milestone payable for a compound that is a conjugate.",
        "terseLabel": "Additional milestone payable upon the achievement of certain development and regulatory milestones for a compound that is a conjugate"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AdditionalMilestonePayableForACompoundThatIsNotAConjugate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdditionalMilestonePayableForACompoundThatIsNotAConjugate",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone Payable for a Compound that is not a Conjugate",
        "documentation": "Additional milestone payable for a compound that is not a conjugate.",
        "terseLabel": "Additional milestone payable upon the achievement of certain development and regulatory milestones for a compound that is not a conjugate"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone Payable upon Achievement of Certain Development and Regulatory milestones",
        "documentation": "Additional milestone payable upon achievement of certain development and regulatory milestones.",
        "terseLabel": "Additional milestone payable upon achievement of certain development and regulatory milestones"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payable upon the achievement of certain commercial milestones",
        "label": "Additional Milestone Payable upon the Achievement of Certain Commercial Milestones",
        "terseLabel": "Additional milestone payable upon the achievement of certain commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryAndCommercialMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone Payable upon the Achievement of Certain Regulatory and Commercial Milestones",
        "documentation": "Additional milestone payable upon the achievement of certain regulatory and commercial milestones.",
        "terseLabel": "Additional milestone payable upon the achievement of certain regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone Payable upon the Achievement of Certain Regulatory Milestones",
        "terseLabel": "Additional milestone payable upon the achievement of certain regulatory milestones",
        "documentation": "Additional milestone payable upon the achievement of certain regulatory milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r808",
      "r1054"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r944",
      "r945",
      "r946",
      "r947",
      "r1025",
      "r1056"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "eikn_AdjustmentNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AdjustmentNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment Net of Issuance Costs",
        "documentation": "Adjustment net of issuance costs.",
        "terseLabel": "Net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Common stock warrants at fair values",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r70"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AggregatePaymentToPerformResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AggregatePaymentToPerformResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate payment to perform research and development",
        "label": "Aggregate Payment To Perform Research And Development",
        "documentation": "Aggregate payment to perform research and development."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r842",
      "r852",
      "r884"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r845",
      "r855",
      "r887"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r880",
      "r888",
      "r892",
      "r900"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r385",
      "r394"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total common stock equivalents",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of square feet",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r79",
      "r119",
      "r143",
      "r144",
      "r145",
      "r179",
      "r192",
      "r204",
      "r207",
      "r248",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r479",
      "r483",
      "r533",
      "r601",
      "r602",
      "r607",
      "r677",
      "r754",
      "r755",
      "r770",
      "r808",
      "r811",
      "r812",
      "r823",
      "r972",
      "r973",
      "r1039"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r123",
      "r143",
      "r144",
      "r145",
      "r248",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r479",
      "r483",
      "r533",
      "r808",
      "r972",
      "r973",
      "r1039"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "AvailableForSaleDebtSecuritiesNonCurrentAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Debt Securities Non Current Accumulated Gross Unrealized Loss Before Tax",
        "documentation": "Available For Sale Debt Securities Non Current Accumulated Gross Unrealized Loss Before Tax.",
        "terseLabel": "Marketable Securities, Unrealized Losses, Non-current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Marketable Securities, Fair Value, Non-current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r217",
      "r256"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r631",
      "r777",
      "r778",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r631",
      "r777",
      "r778",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r411",
      "r412",
      "r413",
      "r414",
      "r420",
      "r421",
      "r422",
      "r423",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r471",
      "r781",
      "r789",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of IPR&amp;D",
        "label": "Business Combination [Text Block]",
        "documentation": "The entire disclosure for business combination."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r415",
      "r424",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r442",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r462",
      "r466",
      "r467",
      "r468",
      "r470",
      "r472",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CA",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_CaliforniaNewYorkAndNewJerseyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "CaliforniaNewYorkAndNewJerseyMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California, New York and New Jersey [Member]",
        "documentation": "California, New York and New Jersey.",
        "terseLabel": "Hayward, California, New York, New York and Jersey City, New Jersey"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent",
        "totalLabel": "Cash and Cash Equivalent, Total",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r114",
      "r733"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash at end of period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r73"
     ]
    },
    "eikn_CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, cash equivalents and marketable securities - current and marketable securities - non current.",
        "documentation": "Cash, cash equivalents and marketable securities current and marketable securities non current.",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "terseLabel": "Cash, cash equivalents, and marketable securities balance",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "totalLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r55",
      "r140"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "terseLabel": "Net increase in cash, cash equivalents and restricted cash",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_CashPaidForOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "CashPaidForOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities",
        "label": "Cash Paid For Operating Lease Liabilities",
        "documentation": "Cash paid for operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r120",
      "r121",
      "r122",
      "r143",
      "r145",
      "r168",
      "r169",
      "r172",
      "r174",
      "r181",
      "r182",
      "r248",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r303",
      "r306",
      "r307",
      "r310",
      "r313",
      "r321",
      "r533",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r665",
      "r685",
      "r703",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r911",
      "r940",
      "r941",
      "r948"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r181",
      "r296",
      "r306",
      "r307",
      "r308",
      "r310",
      "r313",
      "r319",
      "r321",
      "r489",
      "r636",
      "r637",
      "r638",
      "r639",
      "r771",
      "r911",
      "r938",
      "r940"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase exercise price per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r146",
      "r322"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "eikn_ClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ClinicalExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Expenses",
        "documentation": "Clinical expenses.",
        "terseLabel": "Clinical expenses"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ClinicalTrialCollaborationAndSupplyAgreementsWithMSDMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Collaboration and Supply Agreements with MSD [Member]",
        "documentation": "Clinical trial collaboration and supply agreements with MSD.",
        "terseLabel": "Clinical Trial Collaboration and Supply Agreements with MSD"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research and Development Arrangements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r475",
      "r476"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r278",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r75",
      "r608",
      "r664"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingencies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r270",
      "r271",
      "r727",
      "r966",
      "r968"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r728"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for future issuance",
        "totalLabel": "Total",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock dividend declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r814",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r944",
      "r945",
      "r947",
      "r1025",
      "r1053",
      "r1056"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "eikn_CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Reserved For Future Issuance As If Converted Basis {Table Text Block]",
        "documentation": "Common stock reserved for future issuance as if converted basis.",
        "terseLabel": "Summary of Common Stock Reserved for Future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r665"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock options issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock options outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r45",
      "r665",
      "r683",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized and 54,138,555 shares issued and outstanding as of March 31, 2026 and 340,650,000 shares authorized and 3,068,490 shares issued and outstanding as of December 31, 2025",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r294",
      "r302",
      "r610",
      "r808"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting right",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "eikn_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants",
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_CommonStockWarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "CommonStockWarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants",
        "label": "Common Stock Warrants, Policy [Policy Text Block]",
        "documentation": "Common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk and Other Risks and Uncertainties, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "documentation": "Concentration of credit risk and other risks and uncertainties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in Progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ConversionOfRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ConversionOfRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Conversion of redeemable convertible preferred stock.",
        "terseLabel": "Conversion of Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares returned by the holders in exchange of redeemable convertible preferred stock",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Redeemable convertible preferred stock, number of shares of common stock issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r44",
      "r68",
      "r316"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "eikn_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of early exercised options and restricted common stock liability",
        "documentation": "Current portion of early exercised options and restricted common stock liability.",
        "terseLabel": "Current portion of early exercised options and restricted common stock liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "terseLabel": "Marketable Securities, Amortized Cost, Non-current",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r958"
     ]
    },
    "eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities Held-to-Maturity Current Accumulated Gross Unrealized Gain Before Tax",
        "documentation": "Debt securities held-to-maturity current accumulated gross unrealized gain before tax.",
        "terseLabel": "Marketable Securities, Unrealized Gains, Current"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt securities held-to-maturity current accumulated gross unrealized loss before tax",
        "documentation": "Debt securities held-to-maturity current accumulated gross unrealized loss before tax.",
        "negatedLabel": "Marketable Securities, Unrealized Losses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities Held-to-Maturity Non Current Accumulated Gross Unrealized Loss Before Tax.",
        "documentation": "Debt securities held-to-maturity non current accumulated gross unrealized loss before tax.",
        "negatedLabel": "Marketable Securities, Unrealized Losses, Non-current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current",
        "totalLabel": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Current, Total",
        "terseLabel": "Marketable Securities, Amortized Cost, Current",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r598",
      "r957",
      "r959"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities, Amortized Cost, Non-current",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Noncurrent",
        "totalLabel": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Noncurrent, Total",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r598",
      "r957",
      "r959"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldToMaturityFairValueCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Current",
        "terseLabel": "Marketable Securities, Fair Value, Current",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldToMaturityFairValueNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Noncurrent",
        "terseLabel": "Marketable Securities, Fair Value, Non-current",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "eikn_DecreaseInCarryingAmountOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DecreaseInCarryingAmountOfRedeemablePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in carrying amount of redeemable preferred stock",
        "label": "Decrease In Carrying Amount Of Redeemable Preferred Stock",
        "documentation": "Decrease in carrying amount of redeemable preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in the lease liability from the remeasurement of the lease",
        "documentation": "Decrease in the lease liability from the remeasurement of the lease."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in the operating lease right of use assets from the remeasurement of the lease",
        "documentation": "Decrease in the operating lease right of use assets from the remeasurement of the lease"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Initial Public Offering Costs, Policy [Policy Text Block]",
        "terseLabel": "Deferred Initial Public Offering Costs",
        "documentation": "Deferred initial public offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred IPO costs capitalized",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions to the plan",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee 401(k) Plan",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r22",
      "r133",
      "r735",
      "r736",
      "r738",
      "r740"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r134",
      "r179",
      "r193",
      "r207",
      "r735",
      "r754",
      "r755"
     ]
    },
    "eikn_DevelopmentAndRegulatoryMilestoneRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DevelopmentAndRegulatoryMilestoneRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development and Regulatory Milestone Related Expense",
        "documentation": "Development and regulatory milestone related expense.",
        "terseLabel": "Development and regulatory milestone related expense"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DevelopmentAndRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DevelopmentAndRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development and Regulatory Milestones",
        "documentation": "Development and regulatory milestones.",
        "terseLabel": "Development and regulatory milestones, paid"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DevelopmentAndRegulatoryMilestonesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DevelopmentAndRegulatoryMilestonesPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development and Regulatory Milestones Paid",
        "documentation": "Development and regulatory milestones paid.",
        "terseLabel": "Development and regulatory milestones, paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans and Stock-Based Compensation Expense",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r350",
      "r381",
      "r382",
      "r383",
      "r780"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_DividendsDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "DividendsDeclared",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends declared",
        "documentation": "Dividends declared"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "eikn_EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Early Exercised Stock Options And Unvested Restricted Common Stock [Member]",
        "documentation": "Early exercised stock options and unvested restricted common stock.",
        "terseLabel": "Early Exercised Stock Options and Unvested Restricted Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r130",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r168",
      "r172",
      "r173",
      "r174",
      "r178",
      "r292",
      "r384",
      "r408",
      "r474",
      "r503",
      "r504",
      "r600",
      "r620",
      "r744"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r130",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r168",
      "r172",
      "r173",
      "r174",
      "r178",
      "r292",
      "r384",
      "r408",
      "r474",
      "r503",
      "r504",
      "r600",
      "r620",
      "r744"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r175",
      "r176",
      "r177"
     ]
    },
    "eikn_EmergingGrowthCompanyStatusPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "EmergingGrowthCompanyStatusPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company Status, Policy [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status",
        "documentation": "Emerging growth company status."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "eikn_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Accrued compensation expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-Based Compensation Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "eikn_EngineeringEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "EngineeringEquipmentMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Engineering equipment [Member]",
        "documentation": "Engineering equipment.",
        "terseLabel": "Engineering Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r105",
      "r106",
      "r107",
      "r127",
      "r128",
      "r129",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r161",
      "r163",
      "r180",
      "r249",
      "r250",
      "r266",
      "r291",
      "r323",
      "r384",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r473",
      "r474",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r561",
      "r618",
      "r625",
      "r626",
      "r627",
      "r642",
      "r703"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r842",
      "r852",
      "r884"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r839",
      "r849",
      "r881"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "eikn_ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Of Options Granted Under Incentive And Share Based Compensation Plans As Percentage Of Fair Market Value Of Shares On Grant Date",
        "documentation": "Exercise price of options granted under incentive and share based compensation plans as percentage of fair market value of shares on grant date.",
        "terseLabel": "Percentage of fair market value of shares on grant date"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ExtinguishmentsReductionToNetLossAvailableToCommonShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ExtinguishmentsReductionToNetLossAvailableToCommonShareholders",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishments Reduction To Net Loss Available To Common Shareholders",
        "documentation": "Extinguishments reduction to net loss available to common shareholders.",
        "terseLabel": "Extinguishments reduction to net loss available to common shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r521",
      "r794"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r521",
      "r794"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured At Fair Value On Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r522",
      "r732",
      "r797",
      "r806"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r522",
      "r732",
      "r797",
      "r806"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r339",
      "r340",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r519",
      "r521",
      "r523",
      "r529",
      "r567",
      "r568",
      "r569",
      "r732",
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r794",
      "r799",
      "r806"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r510",
      "r794",
      "r1030",
      "r1033"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r515",
      "r517",
      "r518",
      "r519",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r597",
      "r794",
      "r800"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r327",
      "r332",
      "r339",
      "r507",
      "r521",
      "r529",
      "r567",
      "r732",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r794",
      "r806"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r327",
      "r332",
      "r339",
      "r341",
      "r507",
      "r508",
      "r521",
      "r529",
      "r568",
      "r732",
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r794",
      "r806"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r510",
      "r794",
      "r1030",
      "r1033"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Fair value assets, transfers to level 3, amount",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r520",
      "r522",
      "r797"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r339",
      "r340",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r519",
      "r521",
      "r523",
      "r529",
      "r567",
      "r568",
      "r569",
      "r732",
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r794",
      "r799",
      "r806"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1033"
     ]
    },
    "eikn_FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock",
        "label": "Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock, Policy [Policy Text Block]",
        "documentation": "Fair value of common stock, common stock warrants and redeemable convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "totalLabel": "Finance Lease, Liability, Total",
        "terseLabel": "Finance leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r557"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r290",
      "r319",
      "r489",
      "r500",
      "r528",
      "r532",
      "r535",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r606",
      "r619",
      "r766",
      "r794",
      "r797",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r809",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r960",
      "r961",
      "r962",
      "r963",
      "r1026",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r888"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r888"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r888"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r888"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r888"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "eikn_FurnitureFittingsOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "FurnitureFittingsOfficeEquipmentMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture, fittings &amp; office equipment [Member]",
        "documentation": "Furniture, fittings &amp; office equipment.",
        "terseLabel": "Furniture, Fittings &amp; Office Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_FutureMilestonesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "FutureMilestonesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future Milestones Accrued",
        "documentation": "Future milestones accrued.",
        "terseLabel": "Future milestones accrued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r687"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r601",
      "r602",
      "r603",
      "r604",
      "r763",
      "r764",
      "r765"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r601",
      "r602",
      "r603",
      "r604",
      "r764",
      "r765"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ImpactAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ImpactAgreementMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact Agreement",
        "label": "Impact Agreement [Member]",
        "documentation": "Impact agreement."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ImpactOfPreferredStockExtinguishmentsAndModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ImpactOfPreferredStockExtinguishmentsAndModifications",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact Of Preferred Stock Extinguishments And Modifications",
        "documentation": "Impact of preferred stock extinguishments and modifications.",
        "terseLabel": "Impact of preferred stock extinguishments and modifications"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r21",
      "r62",
      "r132",
      "r736",
      "r795"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r60",
      "r796"
     ]
    },
    "eikn_ImpairmentOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ImpairmentOnMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment on marketable securities",
        "label": "Impairment on Marketable Securities",
        "documentation": "Impairment on Marketable Securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r63"
     ]
    },
    "eikn_InProcessResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "InProcessResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research And Development Expenses",
        "documentation": "In process research and development expenses.",
        "terseLabel": "In-process research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Asset Acquisitions and In-Process Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r485",
      "r486",
      "r487",
      "r488",
      "r512",
      "r516",
      "r522",
      "r534",
      "r535",
      "r536",
      "r622",
      "r624",
      "r688",
      "r731",
      "r732",
      "r781",
      "r785",
      "r792",
      "r793",
      "r798",
      "r806",
      "r1015",
      "r1017",
      "r1052"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r485",
      "r486",
      "r487",
      "r488",
      "r512",
      "r516",
      "r522",
      "r534",
      "r535",
      "r536",
      "r622",
      "r624",
      "r688",
      "r731",
      "r732",
      "r781",
      "r785",
      "r792",
      "r793",
      "r798",
      "r806",
      "r1015",
      "r1017",
      "r1052"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r635"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "eikn_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase Decrease In Accrued Expenses And Other Current Liabilities",
        "documentation": "Increase decrease in accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r935"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "eikn_IncreaseDecreaseInOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "IncreaseDecreaseInOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Other Assets",
        "documentation": "Increase decrease in other assets.",
        "negatedLabel": "Other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "eikn_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Prepaid Expenses And Other Current Assets",
        "documentation": "Increase decrease in prepaid expenses and other current assets.",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseInCarryingAmountOfRedeemablePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in Carrying Amount of Redeemable Preferred Stock",
        "terseLabel": "Increase in carrying amount of redeemable Convertible preferred stock",
        "documentation": "Adjustment to retained earnings for the increase in carrying amount of redeemable preferred stock that is classified as temporary equity."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985"
     ]
    },
    "eikn_IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in net loss available to common stockholders from equity modifications",
        "label": "Increase In Net Loss Available To Common Stockholders From Equity Modifications",
        "documentation": "Increase in net loss available to common stockholders from equity modifications."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Rights and Agreements",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r880",
      "r888",
      "r892",
      "r900"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r904"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r904"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r904"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Operating",
        "totalLabel": "Interest Income (Expense), Operating, Total",
        "terseLabel": "Interest income (expense), net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r739",
      "r952"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r138",
      "r139"
     ]
    },
    "eikn_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]",
        "documentation": "Lab Equipment.",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseDepositLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseDepositLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease deposit",
        "label": "Lease Deposit Liability",
        "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r558"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r559"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r559"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments under Non-cancellable Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r939",
      "r943",
      "r1049"
     ]
    },
    "eikn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, Payments Due, after Year four",
        "documentation": "Lessee, Operating Lease, Liability, Payments Due, after Year four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r939",
      "r943",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r939",
      "r943",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r939",
      "r943",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r939",
      "r943",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2026 (remainder of year)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease option to extend",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to terminate",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "terseLabel": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r143",
      "r144",
      "r145",
      "r248",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r480",
      "r483",
      "r484",
      "r533",
      "r663",
      "r746",
      "r770",
      "r823",
      "r972",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r76",
      "r612",
      "r808",
      "r811",
      "r812",
      "r938",
      "r942",
      "r964",
      "r1036"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r113",
      "r143",
      "r144",
      "r145",
      "r248",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r480",
      "r483",
      "r484",
      "r533",
      "r808",
      "r972",
      "r1039",
      "r1040"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r272",
      "r273",
      "r274",
      "r277",
      "r395",
      "r630",
      "r767",
      "r969",
      "r970"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r272",
      "r273",
      "r274",
      "r277",
      "r395",
      "r767",
      "r969",
      "r970"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r272",
      "r273",
      "r274",
      "r277",
      "r395",
      "r767",
      "r969",
      "r970"
     ]
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Accrual, Current",
        "terseLabel": "Legal contingencies requiring accrual",
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r272",
      "r273",
      "r274",
      "r277",
      "r395",
      "r630",
      "r767",
      "r969",
      "r970"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities, current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, non-current",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "eikn_MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Amount Payable upon the Achievement of Certain Commercial Milestones",
        "documentation": "Maximum amount payable upon the achievement of certain commercial milestones.",
        "terseLabel": "Maximum amount payable upon the achievement of certain commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesAndCommercialMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Amount Payable upon the Achievement of Certain Development and Regulatory Milestones and Commercial Milestones",
        "documentation": "Maximum amount payable upon the achievement of certain development and regulatory milestones and commercial milestones.",
        "terseLabel": "Maximum amount payable upon the achievement of certain development and regulatory milestones and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Amount Payable upon the Achievement of Certain Development and Regulatory Milestones Milestones",
        "documentation": "Maximum amount payable upon the achievement of certain development and regulatory milestones milestones.",
        "terseLabel": "Maximum amount payable upon the achievement of certain development and regulatory milestones milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r273",
      "r274",
      "r275",
      "r276",
      "r346",
      "r376",
      "r377",
      "r378",
      "r395",
      "r510",
      "r595",
      "r621",
      "r623",
      "r630",
      "r655",
      "r656",
      "r708",
      "r710",
      "r713",
      "r714",
      "r715",
      "r723",
      "r724",
      "r725",
      "r726",
      "r729",
      "r730",
      "r762",
      "r771",
      "r779",
      "r781",
      "r786",
      "r789",
      "r799",
      "r800",
      "r804",
      "r805",
      "r810",
      "r974",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "eikn_MidDoubleDigitPercentagePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "MidDoubleDigitPercentagePaymentsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mid double digit percentage payments received",
        "label": "Mid Double Digit Percentage Payments Received",
        "documentation": "Mid double digit percentage payments received."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r273",
      "r274",
      "r275",
      "r276",
      "r346",
      "r376",
      "r377",
      "r378",
      "r395",
      "r510",
      "r595",
      "r621",
      "r623",
      "r630",
      "r655",
      "r656",
      "r708",
      "r710",
      "r713",
      "r714",
      "r715",
      "r723",
      "r724",
      "r725",
      "r726",
      "r729",
      "r730",
      "r762",
      "r771",
      "r779",
      "r781",
      "r786",
      "r789",
      "r799",
      "r800",
      "r804",
      "r810",
      "r974",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "eikn_ModifiedAdjustedPreferredStockIncreaseInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ModifiedAdjustedPreferredStockIncreaseInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modified Adjusted preferred Stock Increase In Fair Value",
        "documentation": "Modified adjusted Preferred stock increase in fair value.",
        "terseLabel": "Modified adjusted Preferred stock increase in fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r987"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r58"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "negatedTotalLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r58",
      "r77",
      "r107",
      "r111",
      "r124",
      "r125",
      "r129",
      "r143",
      "r144",
      "r145",
      "r147",
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r170",
      "r248",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r292",
      "r295",
      "r298",
      "r304",
      "r384",
      "r408",
      "r474",
      "r504",
      "r533",
      "r617",
      "r684",
      "r701",
      "r702",
      "r737",
      "r739",
      "r741",
      "r821",
      "r972"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "terseLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r131",
      "r155",
      "r156",
      "r157",
      "r158",
      "r165",
      "r166",
      "r171",
      "r174",
      "r295",
      "r298",
      "r304",
      "r474"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "label": "Net Loss Per Share Attributable to Common Stockholders, Policy [Policy Text Block]",
        "documentation": "Net loss per share attributable to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r880",
      "r888"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r951"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r737",
      "r741",
      "r747",
      "r950",
      "r952",
      "r953",
      "r954",
      "r955"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense for operating leases",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r807"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "verboseLabel": "Present value of future lease payments",
        "totalLabel": "Present value of future lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Operating lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancellableLeasesDetails3",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liability, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "eikn_OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right-Of-Use Asset Amortization Expense (Income)",
        "documentation": "Operating lease right-of-use asset amortization expense (income).",
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "negatedLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "eikn_OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "OperatingLeaseRightOfUseAssetReductionFromRemeasurementOfOperatingLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use asset reduction from remeasurement of operating lease liabilities",
        "label": "Operating Lease Right Of Use Asset Reduction From Remeasurement of Operating Lease Liabilities",
        "documentation": "Operating lease right of use asset reduction from remeasurement of operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_OperatingLeaseTerminationDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "OperatingLeaseTerminationDate",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination date",
        "label": "Operating Lease Termination date",
        "documentation": "Operating Lease Termination date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rates",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r807"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease terms",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r807"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r108",
      "r109",
      "r110",
      "r632",
      "r633"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "eikn_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r844",
      "r854",
      "r886"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r889"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r889"
     ]
    },
    "eikn_PatentAndTrademarkCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "PatentAndTrademarkCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent and Trademark Costs",
        "label": "Patent and Trademark Costs, Policy [Policy Text Block]",
        "documentation": "Patent and trademark costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "eikn_PaymentForAchievementOfCertainRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "PaymentForAchievementOfCertainRegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for achievement of certain regulatory milestone",
        "label": "Payment For Achievement Of Certain Regulatory Milestone",
        "documentation": "Payment for achievement of certain regulatory milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowance",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r53"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEmployee401kPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee 401(k) Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r345",
      "r776"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "eikn_PercentageOfIncrementalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "PercentageOfIncrementalBorrowingRate",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of incremental borrowing rate",
        "documentation": "Percentage of incremental borrowing rate.",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Non-cumulative dividend percent",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r709",
      "r711",
      "r712",
      "r716"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r820",
      "r1053",
      "r1056"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original Issue Price",
        "verboseLabel": "Purchase price per share",
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r306"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r665"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issued",
        "verboseLabel": "Shares Issued",
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r306"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r665",
      "r683",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 50,000,000 shares authorized and no shares issued and outstanding as of March 31, 2026 and no shares authorized, issued and outstanding as of December 31, 2025",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r294",
      "r301",
      "r609",
      "r808"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from catalyst4 for future services",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross cash proceeds form sale of common stock",
        "verboseLabel": "Proceeds from issuance of common stock under stock plans",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Gross proceeds convertible preferred stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs",
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r111",
      "r124",
      "r125",
      "r136",
      "r143",
      "r144",
      "r145",
      "r147",
      "r151",
      "r159",
      "r162",
      "r163",
      "r248",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r292",
      "r384",
      "r408",
      "r474",
      "r478",
      "r481",
      "r482",
      "r504",
      "r533",
      "r601",
      "r603",
      "r616",
      "r641",
      "r684",
      "r701",
      "r702",
      "r790",
      "r791",
      "r822",
      "r934",
      "r972"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r558"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r116",
      "r615"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r558",
      "r605",
      "r615",
      "r808"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r83",
      "r84",
      "r613"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r558"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r273",
      "r274",
      "r275",
      "r276",
      "r325",
      "r346",
      "r376",
      "r377",
      "r378",
      "r383",
      "r395",
      "r510",
      "r570",
      "r579",
      "r595",
      "r621",
      "r623",
      "r630",
      "r655",
      "r656",
      "r708",
      "r710",
      "r713",
      "r714",
      "r715",
      "r723",
      "r724",
      "r725",
      "r726",
      "r729",
      "r730",
      "r762",
      "r771",
      "r779",
      "r781",
      "r786",
      "r789",
      "r799",
      "r800",
      "r804",
      "r805",
      "r810",
      "r815",
      "r967",
      "r974",
      "r1030",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r273",
      "r274",
      "r275",
      "r276",
      "r325",
      "r346",
      "r376",
      "r377",
      "r378",
      "r383",
      "r395",
      "r510",
      "r570",
      "r579",
      "r595",
      "r621",
      "r623",
      "r630",
      "r655",
      "r656",
      "r708",
      "r710",
      "r713",
      "r714",
      "r715",
      "r723",
      "r724",
      "r725",
      "r726",
      "r729",
      "r730",
      "r762",
      "r771",
      "r779",
      "r781",
      "r786",
      "r789",
      "r799",
      "r800",
      "r804",
      "r805",
      "r810",
      "r815",
      "r967",
      "r974",
      "r1030",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r839",
      "r849",
      "r881"
     ]
    },
    "eikn_RedeemableConvertiblePreferredStockHoldersPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "RedeemableConvertiblePreferredStockHoldersPercent",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock holders percent",
        "label": "Redeemable Convertible Preferred Stock Holders Percent",
        "documentation": "Redeemable convertible preferred stock holders percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Stock [Member]",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "verboseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r978"
     ]
    },
    "eikn_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "RedeemableConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock, Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Redeemable convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount",
        "terseLabel": "Carrying Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Redeemable convertible preferred stock, $0.0001 par value; no shares authorized, issued and outstanding as of March 31, 2026 and 262,597,889 shares authorized, 222,658,133 shares issued and outstanding, and aggregate liquidation preference of $1,159,762 as of December 31, 2025",
        "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r980",
      "r983"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r731",
      "r737",
      "r738",
      "r754",
      "r1047"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses and Accruals",
        "label": "Research and Development Expenses and Accruals [Policy Text Block]",
        "documentation": "Research and development expenses and accruals."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ResearchAndEngineeringExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ResearchAndEngineeringExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Engineering Expenses",
        "documentation": "Research and engineering expenses.",
        "terseLabel": "Research and engineering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r841",
      "r851",
      "r883"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r848",
      "r858",
      "r890"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r936",
      "r1048",
      "r1051"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash, current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r936"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r922",
      "r936"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r70",
      "r611",
      "r628",
      "r629",
      "r640",
      "r666",
      "r808"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r161",
      "r163",
      "r249",
      "r250",
      "r266",
      "r291",
      "r384",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r473",
      "r474",
      "r490",
      "r492",
      "r493",
      "r495",
      "r502",
      "r544",
      "r546",
      "r625",
      "r627",
      "r642",
      "r1056"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from the issuance of common stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SalesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales milestones paid",
        "label": "Sales Milestones",
        "documentation": "Sales milestones."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SalesRoyaltyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SalesRoyaltyPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales royalty payable",
        "documentation": "Sales royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Common Stock Equivalents Excluded from Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r411",
      "r412",
      "r413",
      "r414",
      "r420",
      "r421",
      "r422",
      "r423",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r471",
      "r781",
      "r789",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-based compensation expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r558"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r383"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r67",
      "r69",
      "r70",
      "r120",
      "r121",
      "r122",
      "r181",
      "r306",
      "r307",
      "r308",
      "r310",
      "r313",
      "r319",
      "r321",
      "r489",
      "r636",
      "r637",
      "r638",
      "r639",
      "r771",
      "r911",
      "r938",
      "r940"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r753",
      "r761"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r750",
      "r758"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r179",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r194",
      "r195",
      "r196",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r214",
      "r748",
      "r751",
      "r752",
      "r754",
      "r756",
      "r759",
      "r760"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSegmentScheduleOfSignificantExpenseCategoriesWithinNetLossPresentedOnTheStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "negatedLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r195",
      "r196",
      "r207",
      "r754"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r210",
      "r213",
      "r749",
      "r750",
      "r757"
     ]
    },
    "eikn_SeriesA-1RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesA-1RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-1 Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series A-1 redeemable convertible preferred stock.",
        "terseLabel": "Series A-1"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesARedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series A redeemable convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesB-1RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesB-1RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series B-1 redeemable convertible preferred stock.",
        "terseLabel": "Series B-1"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B One And C One Redeemable Convertible Preferred Stock And Common Stock Warrants [Member]",
        "documentation": "Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants.",
        "terseLabel": "Series B-1 and C-1 Redeemable Convertible Preferred Stock And Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B One and C One Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series B-1 and C-1 redeemable convertible preferred stock.",
        "terseLabel": "Series B-1 and C-1 Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesBRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series B redeemable convertible preferred stock.",
        "terseLabel": "Series B"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesC-1RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesC-1RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C-1 Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series C-1 redeemable convertible preferred stock.",
        "terseLabel": "Series C-1"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesCRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series C redeemable convertible preferred stock.",
        "terseLabel": "Series C"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SeriesDRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SeriesDRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series D redeemable convertible preferred stock.",
        "terseLabel": "Series D",
        "verboseLabel": "Series D Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seven and Eight Collaboration Agreement and SW License and Development Agreement [Member]",
        "documentation": "Seven and Eight collaboration agreement and SW license and development agreement.",
        "terseLabel": "Seven and Eight Collaboration Agreement and SW License and Development Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SevenAndEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SevenAndEightMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seven and Eight [Member]",
        "documentation": "Seven and Eight.",
        "terseLabel": "Seven and Eight"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share-Based Payment Award, Granted In Term",
        "documentation": "Share based compensation arrangement by share-based payment award, granted in term.",
        "terseLabel": "Stock options granted (in term)"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted (in term)",
        "label": "Share Based Compensation Arrangement By Share-Based Payment Award, Granted Term One",
        "documentation": "Share based compensation arrangement by share-based payment award, granted term one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Exercise Price Of Options Granted At Fair Market Value Ownership Percentage",
        "documentation": "Share based compensation arrangement by share based payment award, exercise price of options granted at fair market value ownership percentage.",
        "terseLabel": "Exercise price of options granted at fair market value ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r383"
     ]
    },
    "eikn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option, ownership percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Ownership Percentage",
        "documentation": "Share based compensation arrangement by share-based payment award, ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "After One Year",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r354",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting rights, percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SharesReservedForEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SharesReservedForEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Reserved for ESPP",
        "label": "Shares Reserved For Employee Stock Purchase Plan [Member]",
        "documentation": "Shares reserved for employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease costs",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r807"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142"
     ]
    },
    "eikn_SimpleAgreementsForFutureEquityIssuedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SimpleAgreementsForFutureEquityIssuedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Simple agreements for future equity issued, amount",
        "label": "Simple Agreements for Future Equity Issued Amount",
        "documentation": "Simple agreements for future equity issued amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r120",
      "r121",
      "r122",
      "r143",
      "r145",
      "r168",
      "r169",
      "r172",
      "r174",
      "r181",
      "r182",
      "r248",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r303",
      "r306",
      "r307",
      "r310",
      "r313",
      "r321",
      "r533",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r665",
      "r685",
      "r703",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r911",
      "r940",
      "r941",
      "r948"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r45",
      "r48",
      "r49",
      "r105",
      "r106",
      "r107",
      "r127",
      "r128",
      "r129",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r161",
      "r163",
      "r180",
      "r249",
      "r250",
      "r266",
      "r291",
      "r323",
      "r384",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r473",
      "r474",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r561",
      "r618",
      "r625",
      "r626",
      "r627",
      "r642",
      "r703"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r180",
      "r293",
      "r294",
      "r296",
      "r299",
      "r546",
      "r596",
      "r634",
      "r643",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r739",
      "r741",
      "r816",
      "r1055"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r180",
      "r215",
      "r293",
      "r294",
      "r296",
      "r299",
      "r546",
      "r596",
      "r634",
      "r643",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r739",
      "r741",
      "r816",
      "r1055"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r843",
      "r853",
      "r885"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r45",
      "r48",
      "r70",
      "r289"
     ]
    },
    "eikn_StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs, shares",
        "label": "Stock Issued During Period, Shares, New Issues In Initial Public Offering",
        "documentation": "Stock issued during period, shares, new issues in initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock upon exercise of stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r45",
      "r70",
      "r360"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r45",
      "r48",
      "r49",
      "r70"
     ]
    },
    "eikn_StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value in Exchange for Extinguished Preferred Stock",
        "documentation": "Stock issued during period value in exchange for extinguished preferred stock.",
        "terseLabel": "Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value in Exchange for Modified Preferred Stock",
        "documentation": "Stock issued during period value in exchange for modified preferred stock.",
        "terseLabel": "Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in initial public offering, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues In Initial Public Offering",
        "documentation": "Stock issued during period, value, new issues in initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total",
        "terseLabel": "Vesting of early exercised stock options and restricted common stock",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r70"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r44",
      "r45",
      "r70"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r45",
      "r48",
      "r49",
      "r70"
     ]
    },
    "eikn_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Vesting of Early Exercised Stock Options and Restricted Common Stock",
        "documentation": "Stock issued during period, value, vesting of early exercised stock options and restricted common stock.",
        "terseLabel": "Vesting of early exercised stock options and restricted common stock"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_StockOptionOwnershipPercentageLessThanTenPercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockOptionOwnershipPercentageLessThanTenPercentMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option, Ownership Percentage Less Than 10% Percent",
        "label": "Stock Option, Ownership Percentage Less Than Ten Percent [Member]",
        "documentation": "Stock option, ownership percentage less than 10%."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_StockOptionOwnershipPercentageMoreThanTenPercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockOptionOwnershipPercentageMoreThanTenPercentMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option, Ownership Percentage More Than 10% Percent",
        "label": "Stock Option, Ownership Percentage More Than Ten Percent [Member]",
        "documentation": "Stock option, ownership percentage more than 10%."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_StockOptionsAvailableForFutureIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockOptionsAvailableForFutureIssuanceMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Available For Future Issuance [Member]",
        "documentation": "Stock options available for future issuance.",
        "terseLabel": "Stock Options Available for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_StockOptionsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "StockOptionsIssuedAndOutstandingMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Issued And Outstanding [Member]",
        "documentation": "Stock options issued and outstanding.",
        "terseLabel": "Stock Options Issued and Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Redeemed or Called During Period, Value",
        "terseLabel": "Derecognition of redeemable convertible preferred stock",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common stock, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r45",
      "r70",
      "r639",
      "r703",
      "r720"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity (deficit)",
        "label": "Equity, Attributable to Parent",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r48",
      "r49",
      "r59",
      "r667",
      "r683",
      "r704",
      "r705",
      "r808",
      "r823",
      "r938",
      "r941",
      "r942",
      "r964",
      "r1036",
      "r1056"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructure1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Capital Structure",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r305",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r320",
      "r323",
      "r489",
      "r501",
      "r706",
      "r707",
      "r722"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split, description",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies [Line Items]",
        "documentation": "Summary of significant accounting policies.",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies [Table]",
        "documentation": "Summary of significant accounting policies.",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_SuperbWisdomLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "SuperbWisdomLimitedMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Superb Wisdom Limited [Member]",
        "documentation": "Superb Wisdom Limited.",
        "terseLabel": "SW"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "label": "Temporary Equity, Including Noncontrolling Interest",
        "totalLabel": "Temporary Equity, Including Noncontrolling Interest, Total",
        "periodEndLabel": "Ending balance",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r143",
      "r145",
      "r248",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r300",
      "r941",
      "r982",
      "r1036"
     ]
    },
    "eikn_TemporaryEquityCarryingValueExceededFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityCarryingValueExceededFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity carrying value exceeded fair value.",
        "label": "Carrying value exceeded fair value"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityFairValueExceededCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityFairValueExceededCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity fair value exceeded carrying value",
        "label": "Fair value exceeded carrying value"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock, hares",
        "label": "Temporary Equity Issued During Period Shares in Exchange for Extinguished Preferred Stock",
        "documentation": "Temporary equity issued during period shares in exchange for extinguished preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Issued During Period Shares in Exchange for Modified Preferred Stock",
        "documentation": "Temporary equity issued during period shares in exchange for modified preferred stock.",
        "terseLabel": "Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Issued During Period Value in Exchange for Extinguished Preferred Stock",
        "documentation": "Temporary equity issued during period value in exchange for extinguished preferred stock.",
        "terseLabel": "Issuance of Series B-1 and C-1 redeemable convertible preferred stock and common stock warrants in exchange for extinguished Series B and C redeemable convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Issued During Period Value in Exchange for Modified Preferred Stock",
        "documentation": "Temporary equity issued during period value in exchange for modified preferred stock.",
        "terseLabel": "Issuance of Series B-1 and C-1 redeemable convertible preferred stock in exchange for modified Series B and C redeemable convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, liquidation preference",
        "label": "Temporary Equity, Liquidation Preference",
        "verboseLabel": "Aggregate Liquidation Amount",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityOffsetCarryingValueExceededFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityOffsetCarryingValueExceededFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Offset Carrying Value Exceeded Fair Value",
        "documentation": "Temporary equity offset carrying value exceeded fair value.",
        "terseLabel": "Carrying value exceeded fair value"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityOffsetFairValueExceededCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityOffsetFairValueExceededCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Offset Fair Value Exceeded Carrying Value",
        "documentation": "Temporary equity offset fair value exceeded carrying value.",
        "terseLabel": "Fair value exceeded carrying value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, par value per share",
        "label": "Purchase price",
        "verboseLabel": "Original issue price",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "verboseLabel": "Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r296"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "verboseLabel": "Shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r296"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureSummaryOfIssuedAndOutstandingRedeemableConvertiblePreferredStockDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Redeemable convertible preferred stock, shares outstanding",
        "verboseLabel": "Shares Outstanding",
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r296"
     ]
    },
    "eikn_TemporaryEquitySharesRedeemedUponConversionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquitySharesRedeemedUponConversionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Redeemed Upon Conversion, Amount",
        "documentation": "Temporary equity, shares redeemed upon conversion, amount.",
        "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquitySharesRedeemedUponConversionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquitySharesRedeemedUponConversionShares",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering, shares",
        "label": "Temporary Equity, Shares Redeemed Upon Conversion, Shares",
        "documentation": "Temporary equity, shares redeemed upon conversion, shares."
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of convertible preferred stock, net of issuance costs",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "verboseLabel": "New issuance convertible preferred stock",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r979",
      "r981",
      "r982"
     ]
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Issued and Outstanding Redeemable Convertible Preferred Stock",
        "label": "Temporary Equity [Table Text Block]",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r976",
      "r978",
      "r979",
      "r981",
      "r982"
     ]
    },
    "eikn_TheColumnGroupAndCatalyst4AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TheColumnGroupAndCatalyst4AgreementMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Column Group and Catalyst4 Agreement [Member]",
        "documentation": "The column group and catalyst4 agreement.",
        "terseLabel": "The Column Group and Catalyst4 Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction [Domain]",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r1020",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r290",
      "r319",
      "r489",
      "r500",
      "r528",
      "r532",
      "r535",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r606",
      "r619",
      "r794",
      "r797",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r809",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r960",
      "r961",
      "r962",
      "r963",
      "r1026",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "eikn_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand nineteen equity incentive plan.",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TwoThousandTwentySixEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TwoThousandTwentySixEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Six Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand twenty six employee stock purchase plan.",
        "terseLabel": "2026 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Six Long-Term Incentive Plan and Two Thousand Nineteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty six long-term incentive plan and Two thousand nineteen equity incentive plan.",
        "terseLabel": "2026 LTIP and 2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_TwoThousandTwentySixLong-TermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "TwoThousandTwentySixLong-TermIncentivePlanMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Six Long-Term Incentive Plan [Member]",
        "documentation": "Two thousand twenty six long-term incentive plan.",
        "terseLabel": "2026 Long-Term Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureResearchAndDevelopmentArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743",
      "r772",
      "r774",
      "r1050"
     ]
    },
    "eikn_UnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "UnderwritingDiscountsAndCommissions",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Discounts and Commissions",
        "documentation": "Underwriting discounts and commissions.",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "eikn_UpfrontFeePaidInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "UpfrontFeePaidInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Fee Paid in Cash",
        "documentation": "Upfront fee paid in cash.",
        "terseLabel": "Upfront fee paid in cash"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_UpfrontPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "UpfrontPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payments",
        "documentation": "Upfront payments.",
        "terseLabel": "Upfront payments",
        "verboseLabel": "Upfront milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureAcquisitionsOfIprdAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payments Recognized as In Process Research and Development Expenses",
        "documentation": "Upfront payments recognized as in-process research and development expenses.",
        "terseLabel": "Upfront payments recognized as in-process research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "eikn_UpfrontsAndMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "UpfrontsAndMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfronts and Milestone Payments",
        "documentation": "Upfronts and milestone payments.",
        "terseLabel": "Upfronts and milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r183",
      "r184",
      "r185",
      "r186",
      "r601",
      "r603",
      "r745"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r807"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "terseLabel": "Motor Vehicles",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "eikn_VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Of Early Exercised Stock Options And Restricted Common Stock",
        "documentation": "Vesting of early exercised stock options and restricted common stock.",
        "terseLabel": "Vesting of early exercised stock options and restricted common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureCapitalStructureAdditionalInformationDetails",
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingCommonStockEquivalentsExcludedFromDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants to Purchase Common Stock",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r814",
      "r817",
      "r818",
      "r819",
      "r820"
     ]
    },
    "eikn_WeightedAverageCommonSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.eikontx.com/20260331",
     "localname": "WeightedAverageCommonSharesOutstanding",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding",
        "label": "Weighted Average Common Shares Outstanding",
        "documentation": "Weighted average common shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "terseLabel": "Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, Diluted",
        "verboseLabel": "Weighted-average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r174"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Weighted-average common shares subject to repurchase",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "negatedLabel": "Less: Weighted-average common shares subject to repurchase",
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.eikontx.com/20260331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockh",
      "http://www.eikontx.com/20260331/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted-average shares of common stock outstanding used in computing net loss per share attributable to common stockholders, Basic",
        "verboseLabel": "Weighted-average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r174"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-70/tableOfContent"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-10/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-20/tableOfContent"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-30/tableOfContent"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479326/805-40-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-45"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "46",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001193125-26-216791-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-216791-xbrl.zip
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M[G"9(9ZG/D^=3*7OK1E^PW80A-V_1;,Y;9,;:POEL(\ :!NJ,U(4+ !':UX
M% ;KIK?:YG-^:3S=X>#IX4-3#YIF7 ='+&!R@.3 8DIPU!:2!<4Y)E/V=;=N
MXN3Z#?#<Q6^Z_MU/7DS'KE?)D^Q[\W)M4LKH(E= FT07NB BJ #H-L=6E!PH
M-U.%SOMO==QW?ZB=M9/Z8/::D'MN);'8]5TP$)S&4Y"CF4Q#'E*7B:T+SGL+
M7CEJ1&JS0&Q>2")D)HF2-B>,&IKY4%A+MVY4;%-K#*&1!ZDT' ]>^A2+F0N'
MKBK0%YSC$0D>6#?-99'W%NSTM;;QUAKK06H%EZI4V-P1'K0"8S4-I,B%)-((
MFH:,Y;GN+84-<'K').,&G2Q.I+$%(,FE,6"T.ZS_MI84H.13^ VMQ+[2[1>%
MTZ+;5W/X09<C%$LOJOK%%+OQ'S7-%(]WW!D=)CV +ZT1:'(BN"Q(05T13ZD2
MG#,E9&];ZVW5F1_W&FX973S_A-BMZ?3,;.?'[AUHHF;BW1N/OAT+OSWTT+3+
MP!RFC!+)4XY5^IYHK.IV.<\M'J<F3&]S1+^^<=^OOFF&QGW?3?&0R[0/*9C<
MPC"'?:(XT<ZD!"C;I=8PP_N; +W3P9U-:K."YZ:0CJ0Y!@LLF&4J+QB1>:HT
ME=98T5MM]C6X U&&=[!9KP"MPFJY7<*&-SEYLV>>KLT1J .CS0A/N,;H8Z9!
MR/@\)X[F&;6<FV![:]!]59IV//H0SR\].CNOJP^M';,K).I93HT2@A0I@F(\
MM%))#!0[FNE<%(5*>Q?G_Y95*-O)KO"9R WWCG#G%1'>>1#>&6QK+C*:,^U]
MVML8S%?QQG$5)H!&_9*FW1G.0'>\48RDW(#\PL;&1= I839U/"NTM[ZWAOT-
ML?'SL_-1=>';LY9?3VM["I)L.ZAW=8_8IO8H=X%3T#&4:8S!IXZ8G!E2%)YY
MKE(C?6];[OU:-<U3F,W\W.X_7[S4Z%=Y%18?7W*9'8V=/QO#B]L4VK],-08K
M_79=,)ODJ9N<9]S3_>I?Y>6-[.F[NE_N)[G&*T'37.6$"5-@XW(\[@8/ON%Y
M:F5A4F]Z6WEY\X--GX]/RK'WZ.[>N1H_KX(1U((QXRT>?@@[5+0>N(QZ#3NV
M"T<:]_"LJ>T88UY3I263)(OM8D!M$J.-(E92+UD6;+I]2W3[_/2K-KO'1Z;P
MA;78L$E*C$ID1%MX>N!>IER#D2!VG(^&X#9L<O"%R22Q.8N.($XT9D %;\#,
M5ER'_IX4>X_=FE9V+KWYSJ6;*[SS3F5:"D$R,,K!4O<%L*?UQ*6>YL$:9ON;
M+=G[8YOOB1F]EAZW5.D4C$:?8APX9R04P3,GE)"\M\QX,XE[^("02V!:>6_@
MB5X"SJ0"+ 'K+*$V6*]R"Z*SMR;C%W<+8_,-<F#]P;L757UO#IE-H9D@\JS(
MBXP8H6"W=,:(L3X0SW(I 8(::OJ_6]]-)[Q5&EAN;G<G&LB,#X92X@3FB@I
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M5WF6 _CR&%:G> B8<9Q897*5PWX76>\TPGUZN+9>GW;99&5\(]ML,UEDVI+
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M3YM.Z@/\XFN?%6=]S=B^O"1KGGC<$MZ51W9T'K_\RD?"?E]YW UI ?XH/QW
M+*II;7W3_GGJM8NL KOWRW\DR4_P?]),+D8@%\ZUP_/TR*0Z/Z#[LAP_^3<I
MQ\Y_.N!/8//)J4<SO_OJO&HM;'C!2&/&R1-3?2)-^6]XPH&I:G@+@4^>P.C/
M9R\(P#-XB3]@]'SRY$S7)_#8^+HG\;N@S\K1Q<%;D")-\M)_3-Y49WH\N]!4
MDTEU!M<BXQ$]*D_&!R,?Y@_"W^';[J^Z'2P.H#G7X]D8/IX"=Q+XQ/J#\]J3
MCZ"_GUP:V.?&$K_[W4<K]6 ,H#HNS<?234X/0CDA42Z,)_#:__H#R^B3GQ[C
MVV'!SR\MND5Q^/.C,S![9S?%_]$,KA_-ACO; ;EFP9>7MEMQ7$N^S^7Y)''5
M%.3GD^5-9;.Y;6$/OFZ9U197>9ODAF5FOKX\65N-JOK@#S3^/+E^ZA];!C+5
MR"WOP^86X]W+H[?/GR7';P_?/C\>UB2NR?'SI^_>'+T]>GZ<'+Y\ECS_OT__
M^_#E7YXG3U_]]MO1\?'1JY<[O5!\8POU]\/C_SYZ^9>WKU[N)<^>)IQ*4:Q=
MFF5Q*^@?YR*FF_/GI<R7QKNZ?B#(GLR52;NB^RC<FFI4NE5)CR/YXF)_02RE
M]RN6V%>MS2XQX8M7;WY+9JNQ/,*O>!O,#0 ,O":"W-)&A/0BUK6E/A4D3R78
M1IF41!<L)076N' >,NW31TD'U]_X<.,3+)*Q1FO)^?+@666G"-[0\=+7)6:4
M_&U.;RL+]<O Q3L!+M;AJ+N1U^:HZX??=/U[\FKL?UQ:#8"RR4\3M-@OP5 <
M(3X2IH??DI&^J*83>.0G[YZTCV>4[L->=S=8-(_/&P^V^[D& ]:O4H6>3BH8
M!+X/7EC/WO:A;$I3CL"X/Y@]8'857.;FY!)?2/=3NOHCP(Q9,EIF(#Q:+8^O
M>TR^SXJ5GR\_Y*?'D_K*V#MC*A+/VFW]""M#3.WU[P?Q7X(?K"&7*^-<,>/0
M4NO^;LTC^"#Z5JP>=<^!ZRXS__)MG1U5CK^)*?=HC7KH'O4GL* KG[P[2HXO
MSH#0_[37Z'%#&A!QX3KE0'-J?28%23.58W8$* ?--%&4YADO0J%LL2GE\+>I
MKD%8C2[>^/.JGCQ*0E6?Z<G/C\I/'>F323W=F/ZXH0 K<I$]N8%>>#QQ#YN4
MMKO0?WMW^.;M\S>__B-Y\_SUJS=OD]?OWAR_.WSY-GG[*@$3Y"W8&0E+DU=O
M$B9_<#\FKUXD;__[>;)DG<PMD\.G;_%K5J1B[0[-Y0G\@N+U1FN9]0Q;;L[/
M\J*JD\FI3_XUX[^D==6NQ9MW&W6QL4'[L?/K1WCSMUTC\])"6LLLMG7,\01=
M(4F!D1U#C5=69S0$N2F9]SJN]/,VM+$J\1Q\0L[@+:=X&W'Z@EQX71,_WB@A
M;6Y+?L-N$DG*]K:R*T+JG!EAB=+M<18&+)1"DE!8I5V1"8<KO)E=>5$V()/_
M :O] CYI>KK>"<;(OJ29;F#(?(\R[]6; 88/,'Q+M+\-("X"2YFG*?:>L$0X
MY4&**3S?S]%<&YY;JC;FI<%\U1@KN1Z)!SUJ[@&*BUV%XALFI^TN]=LWAR^/
MCR+D[BD:EP]6,\W0^&3.A#,X'NKJ+%GS,ZDV#]0W.*%U0[Y/C^!]!K"'N?8X
M$KBYQ<"TX++!-*[D10FH$I24\?7!EP(X7QK -=! YYQ9(2FA!59V,X&Q&R.)
M55X  J JL_:NT.!Y3 '#R;1SN>7*;WJA*65$I%3)(7"SRX&;]9-=O(C?DC.$
M%9D7.B4IQ1/!G6.DH)DDQLM<!I\Q(]AF...-/\$$9CV>8'_FC<JE+T[^YKOZ
M_.BO@-L J+TY?/W\W=NCI\=[R='+I_N;\18\5&G^P_-/VDX2W-BD"LEBJQ/=
M),?GWF*"KTO*<5).FN3I:?2B_GC?HH<.@F<KF.E+AMP=IGK5#[5,+]%YU&/'
M5+J?R]MXHFYV7\^=3RUQ]2)VM\K UX1ULXRFWGL"RE$1D5%.BLPYDJ6.AT(6
MUID-0<:CL:WJ\ZZH.>;T/ZVFXTE]\;1RJP$/TGB+]2 3?UY7'_ YMXYTW(C]
MGOF1QI*O;^50VC$2R:0TC.98T)1+^$=YHC5GQ!8ASY@+E&F]&1)YJS\==74R
M;=?,.YD8-]I[)0A7-)?JB_&3M9ZJ-3(H?P B*.\GGKL92(NR):GJI)J<^CKY
MY[0N&U?&I@N VKX *.XR<U!?</<]3[]<%K-Q%>H3/2[_'?_^L8>R;*=I[6C_
MS?[Q?M+U@JU_,O7C7U9%6/*RVE^_[)\3(L4#$"*7E=273(,[N 5PN:ZQ_(,V
M!<5F P&;3XO"P/+YG!.J:6I%IIUU^6:TUZ%SV$>G^^_7<NS9-C473VGRW[JN
M2S])WDX-K&#R=WW12P/^1AOE/"LD+S1VI,R)X%H3+;PAK,A=)BGLF7<;W:BG
M\.NK^FWU<:O@\K=R-#*U_A*XO+4/=9Y%<J/1[-T@4>J:_3'66YZ#I6!2 VMM
M,D\*(0TQ7"@KA!**^8WN3]3CK^K78 . 4KM?$V'1%/&[-Q*^BFA\FJ56>4T<
MEXP(*QTPM1!$,L&ES@,0SH9LAXYH7E= %:/_OSR/5N46*:(0%)M&##;#@\!Q
M'?6@5_>\!FE3GNM1XC]Y&X\ @(^QRW<SP.<-+SOP:8*,^@6 _#7Y('U9@$W'
M'A;!AO_Z@^(L?](D$S_RYZ=P4S*.?I*]!"AW-$6R231("Y"KSJ^/-?<E<_6'
MK60(NTPIX8(D3#(L9,PS4@!T(:G XSWQG+7\SI@?T>,A+/(=],RV%S<5; NH
M<]NC_G$[N?R4&A,XI21C-B,BSP+1!D]QHR9CVC'K\^RN-/%K!9+]-7+DG1R7
MVU[A/,\)E=E-/)Y#O'(3\<HX2.P^,IX<R/TT3?_XF<6Z@YOD+OFA&Z:QQ:E)
M21TUEZ^]2\ZG=3/%>/FD2N"*Z!]C_ ?S(P(OS'4\M).#S9G$=\]8[''X60SA
MY^O"R+3@:<;F/^EM@M$PZ#RG*EW\W*JZ@NTS6>1\\7/[P:S\J-L%V&F14KGX
MN<&4/F>VJAZ;K=?KD)M:5JJ?AL7-\O;+R2CF*'EM3]L&6=_0=KUV[9,_A/A#
MTY[LPAV=0&L:D]W3RO9D/;=,U;7&.7Y!*>_R#-LRL!^^J:=IX-:!6[=!R[,T
MV:B"_"=[BEV&$T#\\"+X9&$6[&!TO,_M.6X4F%&BD*+@C(34<B*<<41S/!,P
M<RI56:[R[,Z]OCH;\()Q$_'(5@-TL?]^$GL;[R7_"8"94I: B9%\T*.IQ\JY
M)':BW9WX73'(TAV->JHT4R(5.2FLM41H/,HD2$>\276@-FB5WSF5H<-"+6#8
M)F<]/_KKRX%I!J;9-M-(+8+2J2;&*F  E6G42)I0KBQW3'O![IPJ,--(SSLT
M$DNTKN25(%;9?DK)VU.?O-2-T_]JM5:"?0'])/GUUZ>W2BNX&B3]*K?SE]R)
MN^%V/AH[S+OTB;E([*F'53W#;HL?3WW,!487<[VHVOJ!_9B<ZB8)Y<B[1(]&
M\"6VN4"?];^F)7JL)U5B?'<!/'/NM$XQM;;M>-"YKI<\WC/R0G<V?HT=#Q('
MWXY/XJ6P!-;',"WC26SLU"0_P/. $)-F"MBX.:VP=&Q6[S\YU9/+8_^H5T>)
M0VQO[N;PXUZBQR[Y@;=S-$#.\+WY)\P KX^7PDTXBNXYV/&CB8.(@]3-)"EH
MXO1%L[]2J[_1N!RWA:.Y*DAN,HD'<DC@WA10?"Z<MLQD06^H .7IM*YAAFTG
M$U2=$SVY=4NG#=/M/WRSA5#MIJ,A=THE6#N8SS; ^1K%&ILS;GY\=VIV\;+J
M^8J)(5QY*[V!\A1$Z5DYF8#P]2,0J74U1D0VND@\H+.+Y AQ$)[T^<$GS_1$
MM^T?+JF5Q3.6 Z-OIG"EH+(K,9Z.VCJ"8_(V^0$19/Z$IWR_NV!R6C8P8GV.
ME<;;UC'M>.>JPS<_;E$Q>&U4SK@GAA5H1 $HU/ K2:4WC <JF=M0/OC27N%6
M=7JB'X0Y*(9!,0R*85<4 \ABG8Q@8C[1UH)BP P'%V5EC7!\[:<)#("L^:(Y
M WT"[ZAG@!6$W1FLR,4>VA[P, #LN(0GR4E=?9R<SK[>!U/$QY$Y'\IQ[!P6
M,YLQ<933)]>-+W[-GLPN^^(%UX]O=B':']W%UXQU=F4Y;M4>XX;PF46U;$;M
M#YDXNY>)P_:%6,Y]X?R6R2]"LE0M?F[0HO3J8\0^4XH58O9SJQ85F(A3L&SY
MYW9903*]78^,#2T&W6<RSY8?<X.$H@<=DMN4X_@NNNM&,N+7]>*[;VU/=V8]
MDV'EKJ[<UC'EL- #B7Z#E3L<Q.1 @P]!3#YH['7_Z5 ^TYDR.A!-L4M(IO W
MJHD4CJ:*FL*Z.Y\ILNB<6S\%@712U1=K8L_QHBBJ;'?1=L/0+]<Y'W:DM7X?
M1, @/'LD/+,!8PXD^JU7[O@Z/^BPH@^%%K\A0+FQ:+P&R3"F"N4R2F3."B(*
M41 E&2.422.8=<$5&PJ;1KK_\[0IQ[YI-GQ&Y[:.Y'S0,'IG^/OY^F!0W[A^
MF^O9STSB[T=,:J8RA7F&!:,6##Z=$Q5 ^"F9.XP1*1"7FQ&3,V+_2Z3UIRVI
M[XBX')AO=YAO6+!AP88%^ZH"B0>?/G++U*U[08Z;3MP*GTF1PDYY:_.ZRK N
MUS=F^'J7C*N8H#MMVO0JF'=[^/B:$QJK.KYK=($O_UC"J^&UR1@F4J&GX$/9
M1%_K6(]MJ4<8SL?#,/#B9J+'3M>N2;"U;>FN:YN4_J!_7)LI]97IN+="3X:E
MG&L&<"GE1$C 43KPC'!3,,DD%8S2#:&G3XLS:-LCTC=]!NVW3*:\0:.U(<?R
M)CF6S:D?C6;<G/P /!IS'=O#MSZ?2=CEK/\#!MOW)-P=25O>K&Q1S.0FS1R1
M@:9$Y*$@!7<%L3QC081<>K8AR^P8B>@S!EFOI<J-#+GO6:H<QISGW_1%PO82
M3GFV=U6UNSN6KFS4/N^XX44L10$-W[*#U59G:5 D^)02P2RP0\@RDJL@,F\+
M[]R5MON%\:80G!.=>4.$"1F> \L)RX1TZ"#VA5Q3'QE;:,1:Y&/LE-&\FDXB
M&(&1/TJFX[)]_+OWL8]&\PA$KBW/@$=^?G3T\L4J XVG9\15$])=\N@7*?98
MJO8RKF;T.IMGKPI9VJDAX=BVH4C3-A19-!*9MQ:9-1392ZK%.JU/4_^J9JE?
M![Y76PSQ?8X]AEPU!4/GCF:)^GY.<MSJZ=>/7?D![<^?X/_9>/X=9?&G _XD
MC/PGXLJZ1?684S\]&S]Q97,^TA<'^&U\51>BH/N8-/[/:3,IP\7LK?$J I;(
MD_.J!<H'M<>BP0^8FK]X_^D\X-&M7CD> 60B0+MUE^^_^@4\LOWX7)_X-@ "
M,'_BZP,]^J@OFBXQ?'EB*QZ).-C%5*_,X^IPEQ+0YX3]Z9LXFY?+*NAJ)03M
M+37%OHZXG7#[+&$?_X>_??WH,K')]?3Q'??4?QL+:T#8/VT_:KY3&;7;549X
M[EZVJ.N!G]M4Q&3[')#14G/<VY75R)3Q.QYBBXK7:/O[25U-QXYTW-*V8MQF
M@'J?LAOXD,]*YP!;?-F-W#YNNVT->^)Z'U;NOE;NQATVO\6:WD>3S=< S6Z>
MZ;()L7(O8F0-Y?9'/_>6.X:E_,JEO'$GO2M+N>#];2YF?/L]A$[7H)0XIT&>
M;-\M>DN]</CF;7*T__W*&YV<UNBN_ .8'9/WY?MYK/5].6X]E6 (7[\EU]%P
M?)/SMCM@^P!(W]?H+>E@Q\UWZ,71R\.73X\.?TV.7KYX]>:WP[='KQ:-5O4@
MV#:;_<8&E/1=J_9A*;]O83*@I)UD@HWJ@*.)/TO8 (H>_0&6\>P]6P)%\2SU
MV #X/C'1TPI3%# U[L4\->YX/K+DAW=C/74P O?C )1Z )0&(?? -?UN+.5<
MJMF9^'AO] C$AW_?G'K?%Y'VYW9,R7$<TR# !@&VTUPW"+#-"[ %"GM?G?M6
M]C3O]=B]QU3G]Z.JZ8DL6P)E54A>S<<:6[YB2FWM3^%*['[^:]4,PFYKPHX/
MPFX0=CNUE&O0VI+8B_FVI]4(1%3SWOG01W'WQCOOSV*Z%%P2-P%_?PW3\G4=
M+\?SG% 4'B]-YT_)\W]-R\E%\L,S'TI;3@8C=FMB,1W$XB 6=VHI/R\6J_#>
MZN;T?1A5'WL) 9_"Z)(7.+I!J&U+J(E!J U";:>6<B[4QM7$-^\7HJUO@8>7
M.#XLK_]\!&*0;=N2;7*0;;L?6N5#:+4+K?+W<)L^Z=";*QL[;9I[3CC[;3XB
M/'6)Y4^:Y-E\8-%:/1SKT4531D"W$'\H$MOF)GC-&]],1Y?=?H-<W)I_;W#P
M/0#!F Z"L1.,Z?M_82>C<A+K3V-H SX8=7_?IWC\V]*XHJ3[VV)<45".JF:*
MS0$.336=S$YK?U,VOP_2;VMNO,&/]P"DG]B*]+M9,\,>B3Z!]N^DKD9M1/>\
MKJQW*%'NV9\7AQ0EWNOYD :1MC61]A5>O$&,#9Z[82D?F#09"A%VD@F^1;GF
M4*\YK]<LWU?8_+,OQ9JOWO[W\S=#H>8W 4A?$0H8!-H#U.K#4G[?TF0 2#O)
M!$.EYC8K-4?^1(]:GY''0=ZKT^A7'$SK+6H',Z"A/J"A09+U5I(=#J)L)LKT
M^[IL?G\?M)U4=?.>W:<@P^A=\J(=R2##!AFVVXPV)'=]J^2NZ;@]1L+7F*:O
M1SYFZ/M8WG.?\NS=TKB28QP7YFEU94?'WD[K<E+Z-MCWKHFMKSL4-XB_K7$/
MHT-%^@.0?T,.UR*'R_F@,0OT_?2\&K]O_+BL:OAO)E_N4P0^ZX:6O(.A@<S#
MH2V)OD',#6)NQYEQ%Y.U=F-E+^=KP4)Y@'?!3RYB#G^7 7J_-NMO>--Q'-1R
M6NH@V ;!MN/LMUW!)@?!U@DVV;/<BGC*Z]%B,(,H&T39CC/<=D59-HBR3I1E
M[_VGT]*4]UL]_KP;PR"X'KS@@H?@,'Y^Q!]]/ZS6P*=Z<M^E*L?S40Q\MCT^
M^T+%'?R"C<_ZE&.W T?X7J:H>/SM7<[UO<M!N8S?_GSWCLZ[*UH^FOUUS6FY
M7W64]P:WL5R[@\,AR,,AR,,AR"MJ]?7S> K5RU=OGR=OGO_E\,VSHY=_25Z\
M>O-W^)7\^NK57_'OX[>';Y__]OSEV^.UAR3'^>(2@]P2^S)-_WAYM!N20'>Q
ML#9^?O1IV6";@!KV=W21O/'G53U)JG'RHJK/$D;)WY(?L-<*IT\N7Q4_9D]^
M3#I2;9)0U1\UP,]15?T.;TX6C;$2'3L.3-NX?36M$UAHT!7U1?*QG)R6XV1R
MZI,SKW'$&-/'/X,'R:%'R2(JEXSTQV8O@>6QI\M/+\<?JM$'P&-3 Y^.)]CS
M!5.TVM=-QQ9 $HP0'[&/,[MNE"=^C&^$*4;.\MA.*TP1L"7^0]LGL(ZC[SZ<
M]P"+G[>]9.")\$OT!,%[]Y/#T6CY%=%O!=.+6[_<?A V8E+5".423"QK9LOJ
M71*79\T^[<$W=C1UEV91^Q.87US(Q5#K1=.;:K77]6(2,[FREYAI V]N&G@L
MGGA]<K&7G->5F]I)8N&>TL&'L!$ #]IMCP]:>@40K07=$V?33&"$7<;&_,-)
M#2^$)\ ]7M>PF_BM@T4>5><X"YA],X'O81&GN!Q  +BP^#Z\Z60*VU,!]>AS
M&->'^*A)>8;7X(-&Y>]^5)Y6E</!-%-K82Y[B6Z2CQZV _YO1QZ)T?P38<^'
M-M%DT?,H3JM;O,6*P4-PWZ\EH?WD"#:V.O.P3@TNT44UQ25+2I0K (T^QR3&
M6SUM/!+_Q6S[$[3?&IS#*8Z[X\4S?;'7\=_LHX_E:'3YL^:TFH[<E2O7?>@_
MG<,R-)<_;E?\TH?(8;8\CS1PZ2N[[MDE2AMWY5K *R=^<N6-=?7/=2.),NOL
M?+3NK09V&VCGRN<>T.C9NAN /EVY;KH5RD4@S?D70 1+ RC'4[_\%8JI,;#;
MG'[@ ]C =L]0)D1N;X R1QJN]O59_!@6&PB_B2P(H@"I'674.#)LNQ,S<EMB
MP);X*Y2=<93P_6>EV9<%2"<_/#+\)%+VN)H ]YSA 44@_/:NB/"#9=6YA%W0
ME45&(,*('\7KH\XZ7X(OR\@,U"M7?UPU,):4:P;J;:TE$2'NDZA%";ZQ.3#
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MFF4?K,0,)P#]D5]=-9#[0.X;KW18 Q4[1;#BH9FWMYE<<^#-TMDYGVDL&9.
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M^\8WD[J,QVA@FO$.R.O!;KW+ZMZR84P/UG\'H<?=%_MA@Y,L*)ZF09*<9BF
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M=HIG%9G4>0L>\_=K0WR\LL.F$DR'5-JA5FQ?CN*^1(MEG-^DD,Y\FEURGNS
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M32TDL2 -,T)XXS/=R*KH\FD[MO/#H[.6UA1^62OU#+?@J=- ;8[$R""YX)L
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M/D")T6%?[<7Y<T9$ZKFSH)(R16Y8"28Z 429$&(DSKO-QM7O)F%ZEBHR;OX
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M4NJ^-_)Q->*IJQ'GJ8S2J9NEAZQ+# >^SNMVJSZ.QHMYBAU@H*X.&.JJ?8\
MZBK45<]:JLB9&I4C:&D,"$\->!8CD&05M<E13_TFEBK>NO86FX]I]G/%XGO4
M4_FV[O^X>6H^Y%=G:5:<Z,UT/':SIKWD2EN1F]J*/51:?:&C<#!24^5 45:7
M:@0#9P(#+[G+6022%-O&\[]9<LM.+<!.Q'TGZJ+6[ (@X_(-R@R4&2@S^BDS
M: I4>Z&!1ULH,WD#UF@'U-B8F<CE%VLRXRG+-UV5&9$;+ZDJXH(P4I[?<'"!
M>[!,F9!340QI(P<7=$)FJ!-[7T,DU!E=0&3,L#G@-:W_VXY(BN"*4=QO:;FN
MU=3:DYMK68/I8M[,W:0:9+!H4AR,)FV#B$7-J_NKG_VPTD0WOTYPO0R%;.^%
M[,&G0A^W?KU?73F1C2%<02 ^%'55#U^FDD!TT5FB?! F;F(1YQ)^7RW1]_WB
MS*?9A]R*IN;#->:NJ\XE3M^44^1).K+<,Z.:>,@A<Q#14C Q<$@A:!],49E^
M(YE%7WC2E9Q<>^!G/BOGPR)GAU+>EX6-LO'(\:^KID0RW_<('* S(YE_LT,T
MYUXZEB#16,_(2 *<E 9BH)1PQY41:SLR3UDJV3^94R\,LRF Y2$7,O<:'.'E
MKG4.GB06O5B3+1M\TBV1.1MJ389<,N3R0X"_JY6?\DV-\[O$H]>?_;6/>XX9
M'O"L[!L?_Y6GO0;JIV#H(YZ^?><7HWGYV/ (>_QRF@8NU(4A-[FH:T63Z;R\
M>;OT4T"JO.RWF1L/SMVL;6\R/TU-JG@4:U?@.,BCB9N$47E%4Q>3VUK-DUM.
M%D>?JF_]M?Q[^?3_;IN]?'[!7N9Q^@QQ-$LM&+PH9EF<35[&47,^=A<OZE_7
MINR)+#.O/LUJ:7+YB_]9-/-1OKA\L/922)/X\GS:C-KWGJ6QFX\^I3+A/U>[
M5LM<S?W/#YR[]/F><+/_#;G\:04K.W"3!SD%NW<$3Z]6A5=W/9J,1Y-R1_/B
M'"_<8CY]>?L/Q?[+7Y\7REDN$(/+Q0@OW/@/=]&\_.Z'NZYQ&^WKR%X[R]J@
M;W9LGP=HCQG6?:+=K?D8QJYIZG"6RU<7M?^6G]/LN[O35=YC\"V;]GGH^<?2
M6?QT'+=CWK>CWXN2*Q!:/C(MBMYHAH-WDW#R2'IYMGE:,7D%RK]>0_&O-]?I
M?XTI=]62KZ\8Y>>KFZ]\\U.**9VUFP_E)9_2<_:NM_X017'6&[UJ9#!H:P7:
M?9&;50-M9Q[]<O#V7XO1_&+P_9N41V$T_\NNO::C5OQ^-"DR8[IHBMW*?$J?
M0ZI=#Y:[46?31?&,G9FJ8UJUU>C+K;C;3-S23DNU*]JKMU??OSQ-?3D4.35=
MK%ZR_"A*2A3SY\O7A[KW?]ZD%TTJ4J_,P-L4UE[WW=KN\*=1,_*C<?'B%Y=O
M<-^V[_(#F3D16OSY)D=?<DY+TC]\Z4*ZHVO4B=6VP_?WE&O$B:%]>Z:GC2VW
M?;.#.B&\?\^D>N>OYL1*T^'[>\HU]D33[3S3U]*0]%>SD.[CY?M3D]89_B'+
MCAO>OKH_=-);%7E[VZ\Z*-OM8:>ON'+]TW]]I[[;BA6?V$MO'S[ZY$#D00-Q
M-Z!<QFQM/MR=N&VW;O[D3F]'!2,K*UT:X,M>?! XTS'C'I3M$*/[B]'+1AN(
MP@@4!PX4;#M T1D/W"X,O"I/67>;W'@IS]PHPFC2>X?%R8Z3O8L>N.7)'L+B
M;#%V3RP>ZH%]<8;C#._S#/]E.E\Q^3V;X;WWVUW/>5Q&/\AAZY/M>@C5N$2S
M&HAEQ0 NSB!$($0@1-P?T;6Y>@@1W8,(W$5#_$7\W;^/HD1#B$"(0(A B880
M@1"!$-%%B'CMSFM-.6($8@1B!&+$O0.Q*F!%C$",0(Q C+B_5<)7BMT1+#J;
M%+"O4^L>B4L/Z\2U39S::%>\O[FQFX3:AJEM@O$FA53[M0TX'0X88;(#30P[
M.@S]:,C94>/NVHX[<-,]]M&\/6:[:)%-1%"LGNZFM0'!F0&;C 9!DJ,L!9%(
M6NLU&4@F7JORT+F>N<LL^! ]I)A]\(Y%2LC=7I._I+/SZ<S-+I:<_]CFDN_>
M__BM]I*,#94T0\H[>$PNSEVD&*288SQD#+GF1E_CX$*6-(%BQA:&$1J<31*D
M9")DKDB(>0M<\]K-9K6+Z7)CZ]TDC!=U2#Y.9_7>7MTXR^:7Z?OII'[^;#H>
MEY>\JV.3FGGS\./<O\I1=$@5'0I]WW$&./7WQ5#?S'Q""D.%T _S(DP<C)L>
MDS!0D>L<. &9:3T%U# P/FLPMAC)<RZM61,&@H<4G/2@1:9%&%@+1C("T3MN
M@W56:W97&&P^ZN1#HLQ06&3T(YZJR"C],^[1QIR;,NKVCPEJJX09>C "+0+M
MX1KW:(&V9QK>T?)VNLAW[4@ 4=6\CS)!DH%[RHP5>>UXMD <UTYRR-DJ$,XG
M,-P*2$9G)P5GWIHU#7^C3\1R?6]#BW.BKLQ)U/%(+T@O_3$NTLM>A?S5^#[<
M\M_?=YS/[NF,A>BY#$!#M"!43&!S)."RXEQ)8:36=^F,V) 4,1I<M.4:02E8
MGSA(81DGDJBLUP[4?@Z=-65XRG??X#7+R% 2B\2V9<1X4O8J,APR'#(<,MP>
M&$YRJX(*!B21)?@*413>HAIHIBI*59F+WF6XZ(31,0;009<@3Y-Z3;) (J7*
MQTA2V@/#&6V'A MDN+TPW-.;"O:B?F"KQPIN$83>-<VBUA/46H*P[*W?G@LZ
M&-43GD?S>GSS^<*/1Z%MS[GDX)M?ISFG6?F8X6"2VF.@1Y?O&*9->U#G%R[\
M4R?@+T6BO60<E.-%K.>B\CT3#'A(F>?HE=1KB<_:&4Z)9> %C2"H3F!88B"I
MM#)F3D3RE_"71K]/7KR*]0SJ>G#I^S3_D"]M_GJZN9PRSH?$;C[E&<4HBE%<
M%<3=4G3<@W5<Q-?^&;>';HKXBHZ+B?Q] V T+_);1V&B2_S6LR0@;JR-/FD@
M,1 0V3,P3%G(3&GFJ2<YV6<OJK0+RG4I)<4WB[H"]3'-1M.X3.XOQFK_U+R;
MO%NN8GUL%[$^K%:KGE]G3H=4ZZ$BF/)_Q),:N:=_QNVAFQX3]Q 2E A!0_;:
M%Q[A KRE!&2AHN@H=52M):!NBGO^Z<:+]"CJ>?J"/T/>.=X)C;S3/^/VT$V/
MB7>RDX3IQ,$3FFKA0P23(P7/'6>%6Z3-8:VK"3-"&2*AC*>I7*7!2Q)!RRPD
M55)SUCG>X<(,*4'V.>)IC>S3/^/VT$UQ1PD=]R =%_&U?\;MH9L>D[I/20K"
MB06?<P9A!07#O0$6I<I"&.\]N:ON65#2*A<@4^% D&# *Q;*%\N=UI(')KJI
M[C&'?J?3&EOO[SUS_F'G74TGQ1Y-185I'LQ23.FL]@NM\[XU5/G^"\GNY=/*
M/"V7K++KY]/;V?:+\^GD"Y?>SL(?7.;;'P!!H([IGW%1QV!UX2-T4Q16$I\#
M".Y);>U2Y$_T";2.17-D8ZGU=W638JH(*B'!DQA!>"W!VN2@1,'*)$>3DO&6
M;KKW4(&?6GA.\;\+LEX#]\^K5 \\9># RPV[!2'(=/TS+C(=,MTCF,XS[7*(
M"0BGIC =,V"B9$"))=SF'!B5NV2ZY3$'>&+!,; =5CQTAP[1O*@V4&T<V_Z
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M=A_)IO],S;R\J&::)C<;7URUKHV#VRUJ[^]DZR9Q,"MO,1N%>;D$DU61=ON
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MS\B'A/,;7I*]7XR8K<+OWA9AT7;?LEUQYOJG__I.?;<5.SZQ[] ^+/UDD?#
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M:9X2GK9'9OZM8M;K&Y"UJ6-IAEIWL/TO3M)CF*1(*.BKA^*KNSCC+/#(10A
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M6_2RZ>&R:2OP>'?)-*<W6@272R7/4$3J@D([/\H)-(&-#R^=*:K2E,4L 7G
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M$>)BB8,V:!4(PSZ4[LR+7_[GVU][ \-(5_V1C;)A&%36%C9J'-?#<-%F-&X
MUC%N?7>BREKDVCX!GIQ3?C7P_11OJI^B\/T4OI_BI?HITH?U4]"GGW+PI-')
M(S$ P"(5FZ75S\8D-[B*#OBE_D,MZ_/&I,&=+D-?#)2HVG4K.A"#^"6<<F\[
M-C'V ZK==E[V=?6]7S 9';FEO W6B^M"Y-KA1!/!Y#6OL<%WVS)8]*M4G\"?
MZ!=D$()!>5__&S&*3N_@4-YB%8]LS+N;0LZ-U*T*)ET)!I4N*%CK0:E ?-%'
MN*;^XP.?Z6W=47G+N,ZZCW,^-!Z\G7(4RT8;JM;.,V[[OCON#22_^$0 7BD:
M@[ E,6>2I"+)2*FRA)1)HA*I$BII^>B4U)[DDV_G^!R?[LT!^<3.YP #;G!4
M.Q=YJ]U1M&!X%JFC"R[/KSN#&*S6ZZ7M:F@U=,4-O]H"33VW>JOI9V_?[Y8G
M+NVWM?9I8YE]#8-;5ELXF/'\S[$@6UD\&.ZF8(]G^@U@ QH-WMWCP?6SG],/
M-TB@BF=)3D-%*$@;[+"0A(LB)24+TRAD/!3EHR10/\O'Y<5_-"\Z8()Y*72G
M+/6(;EX,[1-#!JM\? #'W6)8 [H<AXIO@K0Q-;6?_9Z.?!EH7 M/TV/N]J,Z
M6VW=@D6R(QI<W5+_E*'*YB3X;O0]= <JG;WFKJC5Q&^M:3-"/QH#_D[PC!I;
M:84!7PL8I =J] D;\V5MJ%M<SWZ4<@W+N\2)\:U-["'^,";K1L$T8QSS]?"X
MT7QDC>JBHP2F-K+/H3E$:&>I(08+/DL7&MD0]L#R)F0\)LWXEZK#$MVZ.\<-
M'-/YO%8M1N*O;<K&:1M\79UV0Z)<\$_U!>R8Z4<V0^6;$JN$1SDR+%/&B&B?
M73&1>#U7>NO:S6KG:I,'&B8W#TN$=_H<J^'LDGJ'A72Z1+/<6$-A]5S/<UB!
MN>K-WW&'(R;;--9E#Q>ZCV@+C0G;5VX9P+3UQ\;49 V9F]'KNM#ODAO,L-&W
MQF1Y]W@1]KA(TCV#19]3KH\(%OT_@?GOKZ;*?!K\TY$N)$7^IZ]LK T7B4^!
M=\(+R))?-QL;&30/+-*3L/\ZB.8EO^S4NT[!$8-#!&MPCX1G]M'&J[JKS9E]
MYRX9?Q.^*GMBZ:>P/XT#@2ZPI2.!7]YV71'?Z<*_?KEN]R[4!B<U.^S=-FS!
M-''0=R8:BA_L88"]:YR$1C'Z:7\V(4?X0+OX8#G:>\'W=H+GH\ML;+)>O4AX
M](%:^4Y\^X-&QHTF!_?+M?14O!<5_VO3&+0NG;6OMPK%+!JZ!MX3@SX8*=1Z
M:TS)9 =N/#+^F#Q,]C\T^O\6CL7S4LU+_WG)+2/]8R_]'T7%GW?<@C^;:BAP
M3E:!U;#!O\8ZXB]#!N=?=] =#BAXK^98[-["7=M[LQIQV4[AG.BBS]\<9T'H
MM['OUM]SY![H@9HK[;0T;=OH26.FXG+T)>L18F^;5W8');8]U;RR.WPQ;01Q
MXI7=HZCX^YXH6*\2<+)DTUK1#PID;73#JND+],S\L6L;4'*7C<I81PC]0ZWJ
M=A+Y!E4UU 5..L3UY,W.(>3KAL1JV7R<]MR8N%\_PT!WR?QK<V>_#'Y BHPV
M=SO4,Y^HU[.62#T_-$R2Y6DI*">I*N&/)!*$"R%)E=(PC5BA6)4^16KK_;@)
M]OL5#K%^LLS6L2:V)C0+?F@ZGUO?3QK34SU) W%;PJ_[_TT^>C+C8MPI(DV^
M@?=@*Z9X7^<@]%"K\0P6_0E".C4?L6V[:S:ML/,=6Y-P&(\=-]T0J[XS7-O^
M>QK"M[H?\78;#?:X[S7[UG&;[L)D_>0N)G=Q =0ZQQ=%4(LI,IP6SW/#SGII
M5*Q8<B[*(B,L*V*2LDB10J22%(Q72E8ES^)'P5;W6?VF!4FQ>F_FUE__-N(F
M V>]ZFQ9H\_RWPKYA%0,'!F#,1V]7!SC!FU6PC9_"$>L&\I#>Z0*%"L:0T5B
M7@N;1Q$3NY]S<T/2%4C;.#Q7W2-8V4WJGZL3L);#]9? (AT_QX&R]!E[C?<"
M-,(,,@K@?=,+;9[[I_$DGILJ%:;/'_IWIP\T%0(:?=NAQ?13/_8D[,TW7673
M4,UPTL^<VWZP?4V'$31Y>C=^7ZN+])<-3+@NE=6*Z23X;IN^XV(!#=MK*-!T
M;@UC.$+7ZW<?I!*'9]9.( UK;< %?[8P*']9H [ZS/+LHG3+5'W1#\!^"SKK
MAJJRI%*)%)PP5J'I'7)29+(B*E<)DXPKRI.G&3J)F_4;_W0_A)2[+._-(Z08
MV@9 7#]GLB=*#_Z]YI]N$\PCV)%>S'=U7VWC&F<Q#.\*H6XJ"#,A$'A<?X<;
MGFLT@%J9T;UXA1'!@^!W NE:\2U4IO&"=L'<0+1WH)7>V\YA[/R](QW&\M5V
ME6"E"0YJ;GI9NT86VYK,IV=!VI[24?N+UF8("[)O >.)5V:<E?9H;'L,?-'&
MHO1#8;6+ ?!,C[*HUW#U$@>-@7]BV@KZ%AQSW#3U7058H#0,F6DUU\O2@Q>;
MUJ[XVN1US.A#C& MEV:N(X:^1M#R-[X*7JE?QX $XSS'H8<:,28^:L/!P"3:
M KB[%!#[-M(C:B.-0M]'ZOM([]%'^I3-G/=I(KWI'O<WQMYDX]R-+3?]!"6M
M/]RN=UO#96^T+LIK]-$ZT=:EB12B B-&@1%48,0H,/C..0+F:)CCW1NYQ_78
M*./Z;!V>'*].8R%I\).QH5$J^[EVN+4!HS$B3M (Q;F_LK9@.1:FUEA7W(Y<
M-O:1?5=C\:"OYPPAO4)8-9@H4R05_((UD!"Z9#!R-JL1#;4%IE:JPC6X45JP
M:%V>X=96=Z.EN8I;, 0LPLSDWGMW[>5;$#/!DRKG)6$X726M9$EX654D9I*"
MATYEF!5/ J"OSI 7?E7:^EF=^>:?SY8+F0@&'$I+.^^&[9*FLZ2Q7E>?))DF
M)TR_ATN*H @SKH\[HJ->^EZTC=%EZA&LEKY\A.!D(2%Q0G$?=<)HEQ+&T;D
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M-'YF#;<RBL*,VEE>NU4.(FXBF:_!,1T>TE?#61>XK[!V]]WO\NZ9'*.E%79
M;=>(ZT(_30'XT<=YFJ$*./BIN5(ZIAF'<;H8F,KNX.F'W_5O2)@L]B8<GV'I
M^L[O<$Y6+>Y?TOS!%:UH3HF_ZFL2@FGOG?FZ_9)M?PB^J3M^=H8SES5#?6/0
M]O3$[S]_V)2P]Z"+XC@$/?*7=]O?!I[;7D/?5S&GW./)>%?-\;-6AK.HQLV&
M%A&SZ:$'G?$(1U;U@X;V51\M^N% >BIR?6$$T6J%P:W!]G,9@7Z0UC@W;\8U
MNVH:.S36CME&ND[:O6V@3I_^>H73MYKV>F&'RR@U&4"[0"A^'%0[JA>J<3KB
MF8X?FN89\(5AC?^V90*CCA3]5FZ6+FA^8TJ-ZY;L>*6^6=T6)O?4&54HZ6%H
MUNWNRQG&4^,ZM=0]-NZEIQN(%<*],#78H'LIC X_""4#\X^UG\$W(*[UV8^H
M:57IR:!WZ_XWR >?P)GLJ$]J8ZVW#6XQ+A.#L"BKU^./3H)O.>*(.CFM QB8
M+UGKF,.6GS,TJ[IJ#9M/&;21N9'^N.X&Y=C< L_JRZO?5GEUY,NK?7GU?<?T
M[+BEK!(A3\$JB!17X)92Q**@\*, QU0E*@FY? JW%.0C4J(O/_'^Y]Z2$K!+
M@N0D>'QIR9/&+JJRC%2F2A+%+"%I'%6DB$O8_YQ66%>7 )<\22FN.%=RLU0_
M5]OLHK.ZIRMIZRA^TU5+GV>AM^B:_S:%U#;@S1:'SZ:M3:%);_F7-Z?,AW3X
M79+GKF9D3A[#W7N<<:(PQB8W'7P"UKGZ)-3EVKV^SF;UQ- 6;_>7_7#ASZ6^
MYJ.A/H\-KDV*.R.#Y^&MR. 33:TO>R*L\"P[*8KD@8#AT4EV-\CP/9<^]+KX
MA+$D'/Y[\(W\.]]PW>= #]'TP#'N9WK,-K%BK=+_/3<8XDD8W0')S\B/.X#Y
MF=OM-[G8P:)6'A/UK#_Z\O0#ML9?_^<7V1?/0LO>\7,! U2TS;*6@;,09D/M
M!SL'=[36T#SYT9@GWT[-DY=G\5NVQ4BX,)G/QKPN^*W7 UX/'/4!F.J!V.N!
M9]4#Z(EZ>?_:[.[%A1<7AR(NJ!<7,S8/=?1MUSX40*-*W,<^?#I[\&X(_^9>
M>RRW@P;]U_D,OH8;SD0!S(# 1Z //D?:03(\)W'UTX_96O$4]13U$F"&U/44
M?7V3SH7\'FF]C4L5;AZL]5(VWCB5&YTPFOQILL#PEC**&1N!MJKAH6?J03OB
M[<('TWC5'"F%IUQ]=]+^GP/AW%=4$4\J,/[\F$*F.SW!EMM]U]J!#1;ZLE11
MG$6*Y*6B)$U$0H#B,1%AF29<Y(FHG@17 @2BZ?K 6L,O@LVJ-G?[_7]___ -
MV&O "_#MY L-X7?!E]U_?D'@)YQV!__Z(C"]#O_Y1?UI_6ZUN2"R61/[U2_^
MQN)%09DK17=O^#<O&)Y!,/S%"X996^.>>;U6\UHMR3*5E0F199*0-,\Y*15G
M)%(Q5UQD15;FVUJM8)Q615B1+!>*I&E:DI)%"8DR491A'H8LSUY4JV5L$:>)
MUVJOJ]4>F7WQKOK<7?7O^T[(;30\6 1<O:F[\Q[8ZZ]E^Z55T.,_+QJI9S+O
M3"N<L8[Q/O]CA> #2P1FL >O0>XG8.G'$_Q8#"L+R##W8W![J88_"$?H/WCQ
M[KG:B_<#]9NCG.&P(T8RAG"?-):$<9X1*67(*ZEH%>\,0KJ/WZSA/HW!_7/U
MBS.W=6/YMU-C^W0E?QP;U4_N7"^2,)RG;WW(^G0V_K=/E1^*__W3/3#S9Z*H
MYGKZCM7VBD]B%(*RV2!KS-WZ.O3DQ%/0WAMBCS/$JJI084@E*41.21J6&>%*
M)80759&D1:5X]"C<];T)C%,WWF_?D"X-B_.6$O>W'H,W:(C-2\7Z"(?7LE[+
M>BW[N#*!*,X*R2H2)@5HS)@*PA M/XWC)!0\XS2LGKQ,X.6U;)XNZ%P+";R6
M]<V>!]SL^8U:-? [W^[IF[W>AOWI*>HI.@^*>@G@^?5 *.IS6$>>P_J?[0GH
M-PYYGTGTX0U;CF^\0OY :X-FK#M>HBXG2Q2+LX2$H6(DE45%RH2GA,:%*K,D
MYWFQ$ZBZ]QA>)\1.C0RSP2DMP7X>!-@D.&7DVS@J%7XF%I4DBSR,%FRNQ3?^
MV+Z58^M5C>?90^/9%U U7,6,Y45"RDCE)$US3G@2*I(4819F29%3N5-Y<.\2
MT!=1-?&"9<6B0+!;KVE>X=3ZSLDC]WI_4%WW+OB,[]MMRG\JL0[6S0V]DZUR
M$TD/1/Y[W]AWUAR82>,[:UZ[U*1@.2]S(4DHHYBD(J]($0I.8AE'5(8A>.3J
M*0HZMRRKGS8X>/CGRMA6HWJ3#T8L_];\VHO?G]OW?"74<JD[;AYI?$6+F,[4
MQ??]-?/5K3X>X-6K5Z]>O=Y7O2:*<JZD()+FH%XYBPA/HH3D85$6D12Q5#LP
MA@^IY)R+>BV*!<U3KU_GKU]][O_(HR!WS_TOAO'7-\1"[%#LF:BUN1[28[74
M#JL!YRALM;?==[/?EDIY$9=9%))8A@784@EHH%)6)"PI5?"// N39P]5C-)
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MD.R^KU$]UCSJ@;8@O95RE!N&ZH59F;*"$9GA4+TR%Z3,RYPD85JQ-(UBGNQ
ML61EIA+0WB0O$7165)1P2G'FK2@+2GDA\W([B_K(W.GI!:B@]2-;<?(%C>-%
MDLP4Z<R?Z[=RKKTN\CQ[:#S[ KHH#GE<4% ^61G')$U K[ P922K5)EA#T/.
M=G51JB):I"5)0\E(2BM%&*<ER:(THY6@&:N*.>JB>%&$Z2(I"J^+#JF_\XF
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M*1597*2D3)*,I"JAI Q3^"/)5)IE.:C!G;JT9QME^AR!0G88(QT.2]>]=E&
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ML1O?**$N2M4&2;0(XA"' KTT8S^XY>GXF-_;'T^ZA;/K-#@HZAV5]O0"WVX
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M/<38/Q5^MI\].>:\(Y$C+ZW-<<H.618C\D0QSKF,5LA[9$^_3<;^H 2*<C'
MIJ>^HVO%L?<DZGX\3/!'+GC3)Z/_WDL#[1:?#,./MRV2]41J9/V>J53\/(UC
M(%NPQ"^77&^;3[8]A@+K6- H-%5(),\1IT0@JR)!7"CK,'6@)'>JC-^F+-NV
M1OUITEZM0K^N8KCJ>5W 58'P7K4I5P(\!N%T44GO*+(RY"PK"2.M%$.*6,(#
M9CJ0G2PK1EN1#$Y(*A\1D *'G";Y6+4W#BN,M9(/)ISZA%?A_-HV974Z/XWP
M_RS&YFR24^LV$? E["MHF6M8]JGYE^II-N5L;U=TL/\+CGMK(DT&)289XI8G
M9#UQ"&MBHP PH&(G-OXV:/ /.QMF'G7->KM896]^^V6W5#<LM>R%:N/X2EN!
M,$:4D(A8K!$WAB-MB$2@3Z24T7#C=W:7;Z,\'J(O)"A%DZ7(" GMP@2&UU*&
M:'0N:JVQ-#O5?6_3ES].)[-Y+HY^GYW11/"HN4*60^NX -/,$*P0CYS1I)P7
M7!U"R [<F?%DCRJ_Q0?]457-QZ7H+IV&'H:H+4JUS4.'YC!V6U\5+3:>S!L8
M)# %\G&^I:[N4[>.$S=.OFQQE1][:RM''B21&DG*0-4QDY#A@B#I'!6&$K<G
ME<QM5M1/D[.SX;R$^[T:AY_@>="M./;#V.;2WZ-)NYA=65:YO'\X7L3P:G[3
M1O\/N9GG@.C',2MWJG4>6BI^F\QCHTZ:C9$OTKLU]E]9LE@^T;'Z/;:QK/.N
MSCG0K\DTCUCSZ@,HA)T@U=OY+QYI\ X]5L!*LTQ!2\Z;XC%N\RFH24&$R0)D
M;#UD32F/'1N P>'8SLYA&2]F;8D#=HMV.(YM.VC:11[V-M?1AJ\^#>>G\-%T
M.AK"@P>-'PW'V>.8F7$W0Y/9!SL>_MMF2,P70+LR0 *NC!<)?EG,LB?ETE5Y
M6M>/FA?X:6&\VL*QX;4;;9[.)A^'H?/,9!2#EA<"8N>E+[/XKT5LR[98A+;&
M63.UL[Q7!@L*+,'1Z+SKPP@Z!S? =,%8HEP+,:/?T,?2%CN+@_RX6837P*^;
M]=!7/2JK== ,T^K;"'_9)8I:6,-^.+7Y#!J,_:G]" ^^P-:8$I@1\.K2YN5L
M_:__1U.B7K9-@C[!ZH?KX%UAF+M73(_%:%Z*L"\=4F7D8!2\;4^;E N>WP!H
MRL__:)J,."M)_7=9(I]?T)=I%#^C,)S%PFAR7>[%V?AE&+;3D3U_D;_=\2:?
MB.&XR.)RO[G[X)^+=CY,YRNQ++<B .R7TTE;.O1B%D<V&U*;9:[7;NG/-W0K
MDSOX')?;*9O[C'CUU]+CW9<E3?C6Q*ZF\'2]U[]L]G ,:PB:- >1[TJO;W\!
M$]!]/+4?8K?MCTINJA=V],F>M\O:XINRL;T3D:?V0EIV9OVPDWLW)_O7S.NC
M>N W%Z0?V;;-TPFWKVJ^YW_A[SA[=GF]BCT#_NROF[/W%7WH3+HED;.;!14J
MF?ORO/[2G9OY=0BX,H<+"XK\/CFWH_EY\V[/.9I*4?90E!'@[W@;[I<499RM
M]]$>@I(O*(HEP^S$Y972E%7>Y@^ +)P-VTPXX+>P ,@%K [# #B<64?XF)%[
M_5W8()9Y_I:/FT=_.H:1^@!\O#.AX^PCM+1MRJKK$'X(+URUJ;"6=0>AS:/0
MN(Z: +26R\_LGW'G?;/X80$/G  3.UL)TO*-%O[<_!!&8#'-#SH"5S_EN>P*
M80A;3D&!B(AT "T2E26&4J]TQ)=-6&ZIYEA%Y&F*B!OK<@;5@+@GFG)XCJ1R
M*P/9AE$ ]NOOZY%<K\BK2[C)ZWQ%NXY_R?#)U9&1?5A>*]?_L>P%16J)S8>6
M&<86<96R_U DI%W$BL+D4V+N+"!_Y"5T VDP6[M ^@O"0$ZNCO#HA2BX3A0Z
M$VL.1AOHG]D2EU;G.YNUZIV )G:VA6N6IDF.,.R4#VB<_,%218>5TFQ/+AP6
M\RVU-<L:SV?=')I/IW&<[W#%@H+7@3JT_G0(BS:<+'$R:]=/T-I.5?K)![ /
MX58P/;.',K^_:TAY5FZ*GWPLW5FUI+RR!8COE.GZH?ECZ&I^]4GSJO2D3U.T
M[<#L4\L&F]8IV+ 9;$N0U'*$5[-[!"J&&P"?Y"(2TN:-"5 V3IB(6! !Z*T+
M*=PI34)1,?\]3;-)YT!=*YH5]SO0KK-AQX(]0)P6W7@485EKA@NMLQ@7VG;9
MP?-=&V.3G:-M0W"YEY#O3[[2$?ID#8V_QP_ @[_L(_[6S8IA6_QPP_''R>AC
M2035Y(^G<1RZ2*X\C( </L;\0?$%PN5S0)]1AJ5VR=LO>^[ 9HC9!+GPX&7F
M?WN/W9:I<&:AA6#AY%P,LXR#[<+],[^F /1\^&'IZLRV2?%M=MWHU "T JP=
MP/BS@K#E7SOKK)^;.'I!MX\6H;MZGMV9?K[HQ@@:GSVH:YS=.(&0?4C9Z9O6
M;M'L\CT[B[,\&H,FGDU'D[+>!QO-;H<PTW:6W1W#LXSH0WC&YGB/U^,\A)&Y
M&.=9G"[FMAO>M068G[MG LKG89AC8DOG[3R+2?X"6IL?!L)E/Q2ELQRY/$*K
MB5I=M-^FL][/%IE:7(Q%<4@79_E9?M-L251 HH;M!O7)4K9,LE%B#*&M\/L%
M\SFS(79#59ZU=0W8KATYLNUD#(\#X[F%:<XFZ)$%HT2<L-:1(.J,!LY..=*Y
MT)8404E&C9#D3DFIUUF+)FU[H2O/7^5ILZ.?[&QV#A_](V<]N?+8W 4JX]N$
M0@0NM-9*(D$H-#=8C1PV'AD9'#<\8.%VXCJ"Y5J%X)'RRH,AA'G.U6T0#H0
M1PDXQIV-VP?IXLT")'K$0CK%Z#=A<NE_R0K.=H.4E6Q8;VZWV=3HM6VPW/WT
M\<R!$EU^*BHU6@[6&V [9^-A&GI[^1C<-TV+WMP _.=7>&0W>'F!KLQ0.J(
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MZQJN:[@:LU5FJ\P^!NZ(:*.CQ*!  3FX-1(9(P.*R2D?I1.>[:;]Q=I+XL$
MY@Z,6:\%&, A9"<J]H$9954/C-F*.T=HR=8-V\>Q9/_H\KY,NR.8PW(TI!S#
MF2SF.4ME'H$CT=?5L*W*J1*,WA ,IGSP-N7BP X(AM *Z>03$M@Z12WA//#+
M! ,L5^6,"(BI!,:P-P%I90@2BFF+A7>>[SGM]N $8R H'3!V=1'8NHJ_G55<
M8:<*[%$)[-.&'4R,3YA11'T"&Y5+L&MU # A0L"_B8?=RDI$!ZD4F,'&X9A+
MUL$]UGBD"/&!AY XIH\/.V(@"!L03BOL')-E6_=H^V#97F0QVG-@^4@4=V4:
M54=5IM$;IJ$X&+4\240#XXA'F;-1R(B"$REQHQWS.QYT$BW1!NYA%FQ;3IE#
M%DL'% 6'H"D++*C'9QIT0*49&%VCP>HJKK!3!?;(!/9IPX[C21-+%&))D9R2
MCN5*ZQA13;AS+!+,=V G<$:U!+!1PCG$<1 (#!6/C)>)P6^ 03TP<,F <Y-]
MJQ5VCLG K5NWCV3@=JGLMC)Q_?S'NW='HJ4KK;BK0KIEVH8>S,&1$H^[#_C3
MIB;!6T4H(2@DIA#/E<:LI0)%JIRPT>(0]4Z"4V)UC$X@$D5.[,@%LCYXA'WR
M42MOD^G!EJ_(,66ZI\3DUNE"JB:HX%;!K8IT!;>;Q#-YS45D 5%C*>*,).0$
M!:!20>.$5>(N[8";=#$YC%'@V=W+B4<.ZX283,Y:;*+5#Q\P?30))RJNW=XH
M/]"N\V:>Z_*F1[72-S,BDQ,MV/.M!N)K<G#WUXQ_/X$EWA,,Z.MJ>JJTAI[0
MK-3"9)$C$RJQ>0!B<[LA?]K4QB?!90)RP@)8Z]R6\LW)@_G+36)<\N!WSR!C
M)075 1$54]Z&L,A@PY 5"@N=DE'1/[[=3L@ *S+@XBA,]TNR^>V0G(IR%>7Z
M,@M'*M05Y;Z$<C81I7'>+K?Y<!'MRI!J,. )E=P1(^6. 1\LURH$CY17<(_"
M'-D0#<*!$.E"P#'N% %_>)1C:B"$&AC)*\KU6"%LF?+P1PY'_NMJQI8ELOYZ
MN8#THV//_5>!O%U5K2=2.G$SE=BREFV3:]["M\/YJ"M3#A(QA$$)N9Y6.9S]
MZ32.LX88V9Q%VYV7,EH_3NRL.[M=RIK";^<;=\([;EA7L13,7HQ&YZ4F^DF3
MJWEW+<LYO4M!]:XL[Z4B>LVPW6KU'0LR/MM?/$YJEARC&$D3)>(&?C.1$N2]
M2,Z'))7>T>)?4SQNCQ;_QR27+OX]JZ6V)U(#WZU7T&7]L3OJCU9M\>-D'D^:
M5Z7>8I\:]NMFT7?9IY8-CJ".:<+889HTXM)&(%**(Z=UMO\3DXDD0^U.!.+7
MN M*_<;7*\WU>JGFMBNRPZ^YJ*F=Q_9M>E5$W[[.1>IF;6%;UQ$HU$:?253V
MA;=Q_.ROXTF_BY9>:/%3^S$V+FYH_QL5/B\_]FE3XZ77@2KDM>,Y([I A@,G
M5H1QIK@7H&0/H4U?#UL_FK1 >M\FT*S3.&Y+ W_/I9MC^&G2SKMY^]&V,;RS
MYZ5(_/NXOQ!GL^QC#*_F-^W%_Y";4<<G6]KU-]#%C3EI?O[78C@_;]Z,L[4W
M!'%Z-[+Y@!SPAH)VJ$Q!LSE+S<^?\^]Q+VF[>B@?J>[IO8_DWA&\.Z%](F5B
MWXR;OUG0/[/S JZ#PDVS- $?+=O-ZF6[Y*K "EX/9]'/)YGTALD45,&@2.)P
MWEZBQ-/I;/(Q?YT?EQ_<_'T"QN+[.#N[-!/-=_F2_"J*7W97OG_SKOQ-7GX_
M /(\!/!WT8.&:F)*N6HYW IB_DMTL])PUA&#TI19G(Y@U,+RQ<3L7T&7W@J7
MY4]7;UV^])-=]S._[X\(OY5Z4\0,RK.!+ %UGMO158RI7TS IR"5E32?7P,R
M+C7..5XLLKDX>3(Q:;6S<< UUHR&D$N8$\2]Y;FV.446,\)Q4$R*'KA4^( P
M-2!$]9L97)0SW[?*MJRS"^JP%3&^.@,- Y8MO(O5!6MFT S'3?;*E"D'DRZ;
ME/LKJ&_F"]MZU'(A-/"J*^XL+<B&*+P,NC:.G81]&LY/RS/:C8/<C?T$BJ-M
M/N2,VYV9N:_C/YT.8P+4BGY1%NC;E(8^VZ_CYM5T-APUM"QP 3?;>1,_3T$+
M#8KAF]]Z&D=KHWKYY#)4TXZ6Y Y A^+G.//#-MO/\.S<OWQ-!LPVG>=1F-O/
MW>- A>6_)PYT=<'3=I O+W;V9);B<+<G35C$_%&RPU$^J0Z_?HSMO#/&05A=
M9XQ?,:+7%>?>-\_0S-&H@94Q 0&!:?"S6#C =#'+-\WSZ[/Z';;E+'U^JAV#
MBH=[%H!%T"??Q(]Q]F&6Q6MU/_2R7;A_PG2N1&>I.[;\%5L84*8#2.W"Q[9<
MLWI6>4(SBBUT;+?_I4'-!YCI<7,>[>SD[F!,GHA[Z?W6/&<\NUB294I#EQ$A
M#W995$52<^FV=@YR/5]YA;(J6,%=NY59X;LEYKWYXVU[ ;+P2&C7OT!&AFFX
M=BU=ON>W_V_CII/F]TLO+>TMUS1G]CS+YL:Z7ZV4>#8=3<YC%K=)M\SAM[ 2
MJ8Y.Y)+SB]$\9^D_:=ZLGC<9C[[XT.8[Z/=H41;P^J& YI.R?,N2*?7L84W!
M$]:W?5]%<"V";Y>3OD_Q; ODI4DN<@G\KBBXQ?3^?(HY!C)*Q1%-W" N1$+:
MQ(!<Q-@2')7A=B<7+BDG*@4*G))<?XP@QPQ#8 YC2I/CWHLMA\:%>;MI6KW*
MM2,^Q(PK/YZ72]"F"?PJP]W_[L;CS3B3W5U/1EC,UIZ,7DSX?*F&VV-P4:;9
MY*P(9;#SXM(NTC=8*<?0G$X^96P;=.!46 DHQ^D:UK(^V50AMIF""LH$!I3$
MY-.X78/R-.-RIV'/)AG43^'N_I/\0!4V0-%12J9$!P'=CTRCX&04-&";]$Y&
M+>U5 IXOD&(L(:ZD0M8SBQ260@GM7,@KZA:K8V=QO/TTAN$^'4[? 1V##^V'
M;?(/' 8^:+W- XOH5X8/79WBL0_"^WQ%_#N3$3B@&XY!"C^6#8MF"I);:)(%
M=N='%LA34:5++-ZR&3J[.FO;3*K@>M?Q@O'D<+)ZA?:E2HE@'$42!X>X$6 0
M)JZ0#(0PR:Q.;"=1Z,-KWZQ[WX[C$:C?E#G:D>O?2I^V&/QE6S.MF?0*>&Y
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M5Q@E:I('XT5-&].>$TEE&ZTPXTP$:45:N7F[GUR@Z]8ZA@)62 U-^?.NIA2
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M% LL;?AEQV8MX=3*6/BQFS+O[O!Y<9<#$$@E2[2W$TCHY@I!2))_TDZB6K9
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MAZ6F5O+-6B01P/?BUW_[D_E\%CJ1-9E-QY8WC4&FA-'8F@6^&X]=#Y0J[U2
M)+J_-SC3^W$*ZU-17>Q.)O!;^FM*>;-@).YYPFR<I%I;[96U/:]OZSFFRYK:
M0=550W2S"+EFT"X_,H(X' N[(RSHYL 6PRG6=T\<0!#;0]88L-GT5!!DQ^U6
MIXLQ#VX*L$/^,3>:CVW'M=QP#(<&^&3-?6YC QQ[QEQW$K*MA-9#R+^W>;3\
M6.2PR7_F9?F!,Q2%_Y-?_ZODT2\@!XMDA<K?B:#+'C178U('WBY!W6<VHR\#
M=_A)1H"A+):N_^+D[<^HN6A5@#97FN1-8[*W;U!'E[S)_F&B=WZ[&AE!,+MW
M!9=YC>V&P>;/0W5KF5ASV<C9=LG-G77E8+"JRBMLQ"B?'AEO,.:6%RN1Z47)
M,=T[U^2D&'1CH<K!911"ZEQ1WK;JD@.(=!F\H2UAPILI,H3D%=Q-TDS2P*\E
ME"WM\:'TTU%!#JJ#\O'8&?-H9KF3.5IXP=3R@TEDS<:S@$\GDPBLN8/08+C@
M49WRW^--:GS?'L+/:_GE'?32[S:L5\*BT'W-V@PN ['[4C3IEFC9D!+BK"2F
MML=%D^55]M.\9&_F6Q/&J(D=]:2-DK(I0*%N6G$.U'9=&J^(-O*ZA$'*'R_N
MF3+^L%2<T\FV^7\,\=_?*IG>U\V>HE0A2H^2J4JX1)P#=H2/6RE;Y[5\1$SG
MCT?CE^IQ2F]=E?Q")23WLX[HM1?-$F -3?K65:)N?KY0@W2?A$>C!G@T[W0Z
MFL_=E]WT*I4N1/E5/]WTLCV:.ON^NN][SLCWW7'[W]X#Z3WO>.]O/U7%('+)
M##WT#@0L_'I98!#.DBPSIO^&629V%A))@A<B51 _&"#NP:7W\P;'-F8'RH]$
M2AY\<,4Q8L]2.9S@'UL)IITW9?J>&&[8*^(?B'')[- [LZY]L_^J2,/OH/ #
MQ,:OR=M\#%@V::PJ_7E5R=H-I7^<#+3W]N#=4?E!%_,'X6)^UW<Q/SZ*WW L
M@L>-W=,YF..2@98$9W^$&GZ'E 2.E@1'E03=]L2:XVMV<9[PT^SB\=C%1+.+
M$U80R0.WK2&& *,XW*$,WEWY&]S;;><*[]^9/PVX'Q_;Q7G07+!>KU2>P3JX
MR-A4_M]]B6FOD[BGL#B!PWA2V=N=/,N?*83[Z'YWT/YP)IC;,NEC0I9F/RHG
M&<XJ=9DSY=-X:@7^9&YYTZEOS>=C^"?BS)\[D>?R!Q4]4(NX3F/0=RT+N_56
M,+>7,NK>UB!T;GK^[JQ13;L#M/L4C/!YDZR6-UK>G"WR/L;E;'/&Q]QVK:D_
M"RTOBAS+=]C,"OVYS[UY$(['[D.J&!Y/WKBN.75F6MX\B;S9TXI5<0YMQ3ZN
M%=LT9]16J[9:3P+"6O,]0^7!9F'DCYW B@/F@N$9X)75;&R%P9B[WM3U0N=!
M2>JD/"A>=6AU86).IKNK<S61:B+5YJG&68VS3R)8^"28^2RRF!>#D.#^U)I[
MT\B*&/=]U_$C-MVJO+BW57HDP>(XYGRZNXF_)M(3M$-U-/5I[-#WF;7"&S7*
M.W1B/A/&K$W4AS*I/7-S3N ,SE37>#C G[<V,O&8-QXS;ODS4"\\/W)!LV"^
M-?'&KL/\:#9UG >;N>^SCX(3#M_:>& E96("M$Y31]D[-TPS@&=H;&BQIK%:
MB[6CB+68N<R=>X[%PG&$8LVS M>;6N.99\\#;S[C\ZW+B>]M9!]5K,7)-QY9
M?_$B1]3S'=MYK67:R5+_T\:(NSTQ:*8G-=:[70[LD3]Q7_86.+ZA7\?I6O-?
MJ/6,-N2U(7_:$#Y3?>;[UE;FS&'<"V*+QV%@>7$TLP+'QQ3I&"QM9QQ&V[?+
M[].,Z48]Y4#6]VQLCCV=JJ:)5IO6&F<USIZ6H G'DW$\M\?6-& V")IP9OD,
MQ(?K^ [GH1W$TX/T=7\,03.9FA-?"YJSLG=U+/IIK->_T_6#XF(M%L%3\@KO
M*ZXM5VVYG@:$M4)QA@K%-)@Y@3?C5C0&7<(+P(9EH1M9TW@R];QX/ D=?@C+
M53(PT"?>]-C7854*>V8Z\Q,-'6NR_5[(5HL:C;/GAK./(&J"V2SF8S^RYGX4
M6)YK>U8P9U-KXOG1F,T"SW:]0]BNCR1J/',VGVI1<T[6JZ[H?1KK]7>ZKEA=
M6@1#+1MK=?><N"7+&TW]>?>_R:[@> N7Z6@&#ZWR,D&*O"AX2N1_C_7^UYG(
M"VU+Z[RW,U.!=-Z;.I97#[DI["$)XZ$?.<%\;KE3V[<\&W/LHGAB32+7G\S#
MR!N[XV-<WD5"X#WP_EON?KV?&N:9[FQ^FEK8.>?5[=LWZ<<383,GS$2T\'QZ
M]-;"4PO/_1*]0M<)9O;,LAGGEA=,8BN8!)$UGL\CWV53-_*W.F#NX\-X'.'I
MFK9WHMYR+3Q/)UJOL]./[B'Y3=[Z>"*"YE0IZ[GJ3L[(0087Y35>-GGJVM.Y
M-U4]!.R?BR(UK.;XP3P.8\>S9NYX:GG3V=@*8H9_>G[(;&_*G8-<+@QL[WT6
MYDN.]WG?7:G!FW3AMUNT&]\QYQ/_'-2;#10\>07G3,VG$Z9I+=A. :^U8'ON
M@FW.QCS@,\>:3SS/\IQ)8,UG6+=E^Y$]<]W9S-M*=]O'?C^J8)OZIN.=Z.45
M6K!M&^SP!]X*?TKF4COW3=,]!!S-7KO&N3>:N&"OGXZ%OH'79;T"WK>92G 8
M$/V7\1"?Y:$/;" EPTA*X'S+59&4/#+RV$A0$O 2OB969KR2I08_FD;&*ZI%
MR&F8P>]'/>(0O.JW>LF+)(2_H^1J7QRQG5N@<"1'SJ&/X,N"&V\!WBQ;4W^0
MV>O22'/DNLD5'  K2UZ5\ ./XH.Z+]O *U0)]+_PD"\#@+[\=')*Z&5< ^;
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MK%WBF* #EC@F:.0%-M O@5'E=0G4OP2&0(_ ,C+.(^!R<O%(O<':N,Z+-+*
M >77&7P2%?6EFHD#%_NE& %T+H$V/XR,CT"]R[H"(C;ASU]&IO%Q03_(0*8G
MU\;/; VKZ3U C/4J(1:>T$(#3BX,V#I5C^'^8($IL"@<&Y:UJ@O08#E!Q% 0
MP:U7!1-"54 ZS2_7;9M!XA8LN@*!Q?M7LL.<<E<P-^Z@ [B8E?"!6"6<887,
M,09.1"Z:/ MI$M,0TO-:'CU-(HYOE:PX&E'(00A^(< CB=#L-L#> HE.SX&
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M>45&85D'?Z*:!!_322;+UH4 C)49 "H&H 3%+R=5$8DW =[(!2W#>XA6M.B
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MP!R_Y=\6K"X%Q-D52U)!$G*+[1+*'$Z9<F<R.BZRJH%I1$UQ X*M;$"J:I9
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MV4-:ODC&T>V<,.ZW.QCO2_"'/L:-%'EUA(LF0B>7G638D\,J*U;(9@W]+^
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M*)5MS%[2DB8732Y')!? 5XI'"S]R#(R^<1$7.48?1423510T6W53&Y2T4Q3
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M>DV*CDOR)'5[E*@P<K?[B:@0!7+@&34[$=T7I+%!Y:6\6,I$O0I! PL5?0(
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M6C3TSZ!S9LCC6\4CT$&B@>Z"9+3#4;%(EO0Q\K0DPV\Q!N<,FXT<DWHEZ8.
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M\^W@'-*RT9K[S98':4FWQ%^) _[^4R3<@\KYK<OUFI$N[.L]56LMSMJ+FOR
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M$#WR$#\FG!MZR1-N=*PANM<SR?(P&E8A$*93+CE=X&9A;7.1EI+!8)+,YS3
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M.]'.[YD3'-":?Y\UH0"2]+)&8'D.6"S%*JM> &=)\]J)\"2>OOD S ?@_1X
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M">R%!*XLM*\N@3+'7!XHU&S(4+HLW@Q'.V#]/_9RH!LPPYL^V%=ZI+OC".4
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M:PNV+A6/P*!X1R[(-L(%Z2$(DS;=VFCRQ^6+R8ZII1II*>(S?04+^L00/D3
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M:9A5J".>$S@I>E!-8U;\L;6$-0"IT:](2GY$?DAC$J$O!JBOY17U;5R%:QG
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M;A)!2@4]T<C(3E)4+,P O0X3PF=F 9T%]-Y[[$B35OU^Q16FK4^GM+$LOYV
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M4MT(X/B,>CO $4SQK=L7@RT&^Q0&ZVUEV#MNME#$XZTTY7$G&7'>-N,XJ<H
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MOOSKRXA7JM<!/?_=IV+%9DPTBL_P'O3OWU>K"8HIR#NPPC+9)U_V)]<]0R9
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M%&#MPG^-2I'?P=#P9+=@#0HDUPUX ,RNQ3MG/0G("WBB=I+<Q=3$%B!=DH2
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MG_EL:OL[\3M!@'J#>LBSC(__8!!*K?WK$B'H![H ?DA8M+37Y62&7T<@:=V
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MHYJD(NX@^+YK/O#(:_6CV+RCDY8/%K 1'ZV]V%)J%2:DHLLRA3GC ^,-$:P
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MJXT;UN"Z)>\D#6)Q'\5K7KS'J#LMVL?V:F^5HE[6T&.U=0.M%:O^TAKLG0;
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M $/%I'I8*^2:$J94\?:$2N&XH>AT%+-_"K.W#K_AO)NWV4NC]N!.$]?&"((
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M:;&WJA>9%M[,@:[<-EJL_O+R]1(:(\9NKH:IQ18T5V\9G#&X'RA_A>@DPF)
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MYU\Q_X;#DYE F]4FLX_*$G(DDPSF1X**?[]Y>V/J1*M#33(Q0 ^Q0A]RA P
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M FX&*1&C$F+"H4C47'[/ZF@^R9%FB<3TT?S[?X?8UHJ$D_!?T*_IW0T<R^^
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M&";F?&CR)>N3D=63T\FZ+FN*\UNFG/<'*IR2XW2$/%WAY%[R'^#43LG\21I
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M3!EAV),AT-8%&[7K&JI&R0P&,#IGO'B&X Q.VCX AQ]A];%]P):\,BT(=_5
M3KN?*O X@2NV=6?2Y\AV"H&K-'7:KB,7P'KPY)WY#9&.BD !XVSD3<M@X>*[
M:21*O!,,DG#A.>:@Z&LR,:-K_N7?,DP>[D:T/VRPL7T)^S].P.ME--]>O@#O
M9S@1&6?07@A.;H4A)9:FH:CMZ*B-&QG2=U4:-*_!HP-I _*HNAQ+64)$DCGC
MD.C@N!;3-E$>_$]]4J*[[#$>Q#/X:$NL%'HVXHMQFQ^OTQ,*AI]G0\>^O7O;
M1TJ[9<+WX9>ZO[\@2&&FV4D5!+HYJNBS9#5,0/HHUG(#"I#^ZC5T;.DYZ/R+
MG&@KP33KZP.$^9_^[C-DK!>::NVR,CS.?C BSI"[^\D=UT/?^CWL6*_U7#W[
M$/PLBX!I!305PIRF1V^$G9]GH4 )HZ)!5,*>2:P>]XP8[JP8="79]X<$XGNW
M*#\FD@BPQ;[78^%1>G#'GF;Y\I#G_-O;EW]]B82+X&OJBTC::@$_/V,4>'@;
MHYSBM_T[9Q<L,V77<GHAB;@_ZC9S=LW9WD'7K$&8@>E4\4GYR870;FZ&.8M5
M-H*P_[#G]N!+C%R4P$Z@K?"M2&85ETT-Q^<'L\](;] TVJJ$[11*?8U^L-E#
MT]#*"9UZZR\)!W$L'8[ ,5(*IV1-OZ$\(O'RU+8/D_HJ4B?M 6F@BML@O0=*
M89.TR$HF:> /8.*'F^=V4QMAV//$V_#:XG7!0Y)LJ'VAN<8>GK1UDLSI0('$
M3K@N).2JYSP4Z0=">@ I]G>4TS+:@@FY:=1FE.>H#>DG#N]CXF .[5IAK4QI
MN=*_E\CO:>F]\VE4G#L3YL6][Q]^CE*W.G659II*.;].1&_ZG;Z[W@NB!T>6
M!HRXA>M;'U[*G2CU'OCUX\?;AG BR@3_ YEK>',2KP*/@Y3!VM8JZ":OWGXE
MO#&S_(C)+J=%CK95G95)3GIO/:[>7M*TRWM,%V,2@4'[6_*DQ%_UOS8CY;C7
M$*M:9(5,AG6_>$PTY3;O<W5 &2(<W8Y,I<"68%3-*# PQ/Q-(Q6J*'\H$Q7O
MLVL7!"QA%U*6P&B_6N-F3=8C.W:R#_*NS+NP)C6CN9WM^Z._Q(8ZNL,C_IQX
M!U>%%/<7#A7]XI,"%2U0T<<DQ?V5.$!T(N!&'V_*Q 9Q_WGUX3[I>.XW[T#R
M<N,2!U7.CX27UI\DQ7-5SW7W81&I?Z^6 12S[QC=LW.8Q/C-[KX(?Q[@)Z%]
MB,LWA[XGU3-.%^7#]'MHH4*4%ZSU"M)!DA776*ON<=TK#II##NP_(''],&('
M3".\"8C.;_U?6DB"@?/_>H#U?KZ\YVS]FW*V_X8L?RX+(CD>3/ R$9LI,3=V
M@D\\P;;!\(IZA;#EQ=5H^XF8I@\7#E<213$U=W=T"A1;0: )_R<I2=T[9'ID
MR/N-C)>3QP7BI*&OMQQFL,)&3R5+":AMPYF0BBT)UVHD)E2QFO#94(D-^$$J
ME=*P,$Q-9;67*S=8F'K>L>8IGU+CD,4 &,64;,O;OG])>X?O-Y,E 6T@P;E5
M\9HAM6-3M;[7#',TVK;JK2SH]RPQ.DDG! 69$D,R='*%G,)OFVX'QRGFS./N
M7\ZBAT#\MND%%;>XO-BA\E=P9X#(T1K%<Q6N,V(2!Z65B*KP+ E&^R65L5G[
M3:-I$?#$TQI8P\?EB:MQ\:Z2QI;..QXM=C #"DR$:!3#%S4+4)F;-21C7Y.J
M.BSE31E<6M+TJ 1ZM;;BUPKLL^0,_0N5]^S607W7]3NB/QQ)*LO/+,V_7ZX#
MXQ#AE[39'46 =BD-*)8,4S:=F%Z=(2:6U A1/_R*J.Q.W.+8=T ;,)X/+.&-
M#DW40<YRGMQP#LEEHX;U_4$2_CXXZC=4L*(R%+U-OG,@B:\I>=4G'Q J5YUV
MH*Z^H]YT4X>,S#Y_!=@/03XV]W5OFLB %]UHJWE&]#*W.A7&N*3@AF_R+62;
MB-D+;EU!%[,>23DK!C+1.VZTU\<CG8".=PB<LSE]F%*':3'B"WJC/-2+.VL"
M=HG15)5LLT.#]"=>C-.5/&?:SF)UJ,>0(.TN>F8VMRSW"&(%"5 .\[X@CT?M
M+<.D@"4M8>HB9^C*MH>-]F;U NE3_1(0V<&\+T/C,*)8/K0#Z*6\1!^V Y!H
M+RGHS$?-:+!>._8M6SF\I?W@MN PX+9FK28WG194?'1^.R!5<ESS>A,HH$+U
M-=@=BVH3D>=P 5Y . H(!*U%*-SW5J_IMB][C7A7W\/5*-1^_?+[*A)>L"/:
MD@*EO>;!R,@L&1 O^P6S ;BW8V+>,RAOXN:*YEDI;ZYQ,_%0H'PMG1>TJ-CO
M8>2K 8-&700\[IM50/H&IEYZ,^#"$=2Q'0$)#W J/RMR;-TVHY;J\J\O6O$Y
M3K^(SX]7I4HZ*AK/KW@JRT4V8P9 ;RL[#L0]>#>J86MG?<,ZV:(0+P9H Z.8
M<89&CC$[+;AY!O[."B<'<.1]]^SZS.#D>T-]_NG*W^I\" H%='2C/ 3_RA"$
M7K\HVBL.09OZ2.\DF@I2H.Z[]-KX2LT'B0W8X!L?_G"(M5T>0QA"G=Z5@P+L
MNN4J?-N/3 EM'+*U]1N3B(H<K5L"T(U"OT)0!;Q..%CO?XYD?,DZX6(2+F^W
MNO13J*R1M4:.#]S0D?#L]9,C0#9,")B<I20? <R\6[L9S.EKLM*(BAY]SU7Y
M6Z9O;H:@?P/>LP)63=P'QSC6V_"P2:8HG.RC/!D^$1<JV<.F A<TA,!<HJ 1
M,[V*ADI@.!/G,$P>O2 &+_FS!WG<YQNE#0J)M#8<P];359PFW>)),'"_EI3G
M=]( 5MDVNLHXR00_RX1#%;W(S>3C WAC9"05G*34:H3NT4Q!),A2S+$XL'-5
M2HSMPI@J\=CQC8HC"4Y;:%A""//8#,:IC]9M%?'PFRR,F+?RY]#QKIL?+L[<
M]9!ZQZ3OB6:;O4CFJ"9G\F;UFGT\Y9A"VO>):=9MS 0CP)X7T!Y. ]RYH$#V
M%.UT__%N*8ICHT\0*V1#61R6,AP=456<OHJ/9!I>J;5R=/6 8DJQB+34(]:D
M,4*"W.>^1SFO:R>!/[U:"-;W!VH@.E-6H<?C*\R6= WL:)!YFD^905 Q(4=(
M&RKM5Q_\4/UT/DUGEC7B;(,[GMK^XD@S6L#;D3ILI>WV(V[UT"*7?N+E&^AW
MH*X'7!DMQ.-@4EM_SO6:+IMGXY2]G7Q3:S340SEKE:3'XL.5GB5Y6W7N3 5I
M-' A*VUR^L'U_G9;VGPS2:/<RR64 @9]Q"\==_&:M1]@S;,$ @412 82FA+1
MA _DU_G7%]R&*)J2?H_0C6NOTA Z+=<Q\@\:)"Z; "@2U%P?"*KMBPV;$_P
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M"E'>^G?^U2U @,RL14T]2_$MCP@370^9T45N(DPX^L?>,CI3YR##*1R1"'W
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M**[]_>;M#9&9,.5W1-=Z15L/_7AA1:%XNS*Q]YCR$D4Q@V)\Z%VF77,)DZ9
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M0*,-D$EGQ4QYV 'E'?!"R%#4)M3)$,"?G(+(O-.Y"HR%21U7O(^TDBN%0IN
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MQ'$B+SAA9?<DY\8T42A'&^=//7^G?U,*XNN6#@XF3:^*_;T"[$[N2T([Y8&
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M,#=47[(K!//+1S=YB@69X<+!R &=:@O2N.0?%&CN(%J9JNQD7'RU9(VO9"^
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M;7Z0/&!X4W^,U) _6-?&.\[6WZEA_N_ B.B8A](HB)RD.8N>=!+S'M^1U^A
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MV<!<2F^+#CE,@>G8)9S^F4!B<\7UDB\6#N,,.-6BXH9H/HMX#X#AA%[>I 4
MN06J&[TM3\.)1M[R7H%>Q<L77SB.LW1Y"9P?=;&B%H6&[HUAF51S*.GLUCB
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M=!]YJ*#0<:V%_8.KY_XJ5V3"@L)AS$@N2=:?B8,J[+H7AE+J]WFFVP:+3>Q
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M+M))HAAXEK+OS*A,*$1O]@QE?[+N,4V6UM*)CL>^%U@]#$1N%M8)DZ%ABQH
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MAZ8TS_)(+6<H*@=-AG#N,_QK\<BHDJ)(BC5CJ9TB^ /F5!6),C:J8=8.^?:
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MU>7?5 &H2/II&(@-1EN'.E0!7U-^LR%ZK2L5YU&(R*IY?-4!!_K$#329.:*
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M'H=2CX?VF:RMH6:L8#L@[S#U6;OYMXFBNI#@T7'+PF(HS063'&L28V?.N,Y
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MP^QL_2$K.69:%LVR7T-9>6GDH$6=]\2CBYA27"TD")+8^]JX,3@R\#D<@,C
M6)++JA?70B&M/_WG".%M7#V.CM%8!VJI7;OS])E8:9LG7BH\K18<3U1K-@6G
M;?+7QT='OBX+G=@9+*9<XO,R:SN/X,PSQXFWKA&TM*1015>! )MBWZ%=VJ%E
ML*R0F4B^C+AF.(2V4XDB0LQ5O[+A\N')Z;D/F;E[C3,O.-UT=8R?%P"&YUD
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MLB17AKJ=/9>T(MT69(!QQ=K@G1:/M4$ANY#>)]\Z?)\Z(N(>*B/Q F0QV#4
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MG[VK^H0(A>[;T(F79RC?Z?$OU+'X![I@WW[(*J6O&NLFBTU6)MX[_T19;4"
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MQ=4Z1;DU&>-Y6/<1)MI.5>(4TWK*F.E(:7SG*34&'GN*LI?&<C5I95RI?V=
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M)L-$[2NC0?7DA4.K CHJGA[!T5ZL#W<30.("%3.Y1K$?&U%8.U*S= N[ %M
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MOH/YM ^=[!2618ZM7(@\I6YVBNOD2YVN#4P-:1O7&DW7; ]GCXBD3=G@R4M
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M+5S5 )>^PB#0IE78"T4>;80@&V.P&&?:=B2-WWXN\5.BK+MGQ_/A_":\T[O
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M13OOO6.E0E!O-D8 LZ:+B:%@\?(Q8V3@YQ' /V"7YAZ(XGJ]=-7((V,"("R
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M7@MVK9?*T\EQI2-2F-HLY'B8X"L? Z-R-K&=O5((\9FO5C%.)';EU><EQBY
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M9+A?S2IRC"F6\AG(-*>5'!=1NH1T---<'=2(ZCLP)6E?%@=)&SLY@"E,]@N
M^\UXFA7@?M7P!#Y'+'CI=RGI)LQ%>IOKB0K+J"%)SEI].DV,%"(H"MP8W>1;
M:)L_LTG!(Q7-0\4@/@M%%.)I\^\?L%YW:^1MB?C5TV:]<,YW&WWCYSW9(F^"
M9;C%L$_VNU/=<7#U<78Y'P&Q4+3L<?>[Y%H@.DQ518AVCO"&Z([@T+;!1]YF
M=A'&/7?%S)Q)JUJ$^=B&$V#GP$7 (TZ EM$]+ N?GZ]H56<.IAI&4?A".O)
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M0<\8#B]./,@24N-3[.A>Z@P';5C/&F7F93M9A7TYJ%J<$_2O[[YY]^[=&=E
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M9Z"BXR*.]G[@_)LM; J&ZS_/#H[&NP^@T=@)]U5G8^V4E:YNQ-E7('JR@E5
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M?G"#-2$JAPB"9!0NKU\R2)@O.%LW>P>])>E+-YC96([WC'; H_S@E'EG:R)
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MV OP8FX'_)S^9XM4N; <T&'9N<.L% J924902CF/L-I=JY1)V";-5'(A(U!
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MW#!%_U7A1S%AY6U!8F)BSU[OK6@9XO_T?HUWK&JIW98QXE09V11"TXYHO!$
M5:M6)WWEF9%/[*%&@)$+#=6FO$L/LJ (YK'.27\4ERCOMI1V??4&S"L!LFY\
MNV:J+OZFGXTP2@!]6FT_I46 BDUE$F6#RDXU1M)U(?TH$,>#=GO^6_#9[A_1
MC[H\*"[MLD4EJ-4V5^0:"@RU7T(_V$E*ZZ?/O;-B6RQA!&]GN R%MD?1>",
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M!N3?Q@&\9WAK/DT->43OY)=PZ2T]?,'Q]8Y?76>SVN)MU9E9__7&@8TR6X7
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MN?\@B#2-82L2XMI'M,\"NZH-W@+Y[=S?M.'D-W%_]/,FT+$,AUUS"))#4-.
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M\)P(U%DG@JZLX6J[=39(@L E9^JL=(!5"12(06D:K>\U\[?1.^E#AI4;OQD
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M^C)QM-9Y1")(8:N+@CR/>(1VZ&.D$)]GT$&G&A.CU"?1ZIRSCDYDN2]1$&]
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M9,5V\%5O=(QSAQL" -O[+1ZK+T8_IXKM@^_M'D"!H1;9M7^-,/\YPD.PVG+
MD9]O(H@_(=>^]X-O(2^T3FZNOA!AQP/%X@%9(7IPK%?')=TEF*"PQVK;^FVB
M$:1%ZT5A:.RQ^J(;:1C(,SI"NRC8CHV%5-MY<^S8<M=.Y$+/AR<_)$_Q*O@2
M^/%Q%1!5.(H0 L?J'0@'(>A&=UY\2 P('/"'^][D F?Z2!YY7G*;=]]DOXE
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M:1-\NYLC8H9HJ7N6$$>6[SL:=:Q/_^V@\-=)HE*H45,#<5KLE&%)_2OTQ!#
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MM_<2XDH0$0XVO2IO?_!)B7I<QC3SJ&#6-IT]S<I=9X?IAE=^OS^ A-5@"OY
MPZNI+(Q'SR=Q$@8$#A%'VU6-GFQ=].7/U0Z,I9T'9X!29KFY(1'81,$+V:8^
M_8DCG! :!:?I,C4(7-$QTB_AHL>H)$"&]:@;/_]>\U95OPT"U\RV]_R=R6@!
M(GM!O=,@H]W5SDGNXZ<P@4^"7].MH"U5?V S8F4.I?'P::E?57!@$=\'[,7B
M.)9Z,W64NCY0#>.9Z0@5MR_6ZRBMW'_UQ8N&CD/Y+P2VW7/IJ_3Q3D++YCC#
M:\G="IG:I!:E:F'2X1:?[+>QTVQB,J&AS$B,,@4/J*E,SRP/&<V9UF9:Z(0:
M^&D3NAY]RV.*VNZEJOB YUJWE H_6GL0B<.\?@HXWEY+<)?E%/1%WI+\ 2T&
M4#C#ZW30D R6T$/&%"8)<@Z,<A[]97HDL'6+X L$QMGT#M/5F_CA%<N1%P8[
M^3K0X'".Y1E8/51(<40(,RTFE2K"BPDSA4Q+EDY!.LL)HY8Z@L ?YB8BDQR9
M"?I93-A4I=,!D45?+6]B88@.PZ*]EO>>F)*&8Y-MPB81XY-M.FZ;L/&#0;+U
MC5%;WL[!$ 65D>TQR/2W,R#3V#3Z.U(:F0B_CZ)^8W5Y"./XHU !JWG&SQT8
MA018%?#I4A9&(2M6?7[4K(91*(E5JS>2!3$*Q; J]+K9%#96B/(O\7H74905
MHS47^SMIK#9PG\)@+?BZYE)3]K(R^A,(*E(-X*-7LVKLA^8K;@/8RTUM;;)"
M0N[8^;IOG=#;X9-8VFZG*Y0?"]W!A7*BIZ-W!,Y.N@^^1F%ZH'J?DSC^,4[^
MHE';HS_Y4L\\53VS*%=_"SM"?0JY>;T*GTE$KU;^9<S;[:X@SK^D\P:&>&O'
M7T6@JC8C\('[FAX._K$*&W[WDMWCZZWX- V 9ABO?(.I:TK/V\Y#ISL0TZG7
MGGL;IG"IWWI;+ZGZ[=8<3 34 6Y*LO9<TP6A#A#C)3PZ?G*45##RALUV'S+7
M'''C+V#M5&P;1B+M13S>V@SO,4P#?D:X.8T:=7Z47B*Q3&5NM,/KJK%90AMI
MHO%(Q+$DOU3MCNFIQE=O>NAKSI92ZHP*$]3L,)8([Z=]8R9FCW0JTWZ@B1*N
M?H1L]PG#>D,E[A!SRW+2C2J=>IA[F,F)1#XI%#'+$T1'94A]R]WR]-)1J<CU
M)5B>2SJVH2WQ92"(M#:<H8QDU \*Z]W_=$?GQ1[L\5V0[DEV+3YX<6(X7JIP
MPZZ\A,K3^\#UWCTW=7QZ#;\0GRV'ON*V"N^"!*C(;1O8!\*D7N8;N!XW=Y]D
MG5(&6VXVWII$0H>^;/3\.JG<[NNYD87:*B64P9,$VN Z]9W1DA;*EMXW(8 *
M@-[7CD\?&WO=$<(]6[45<;>1LTUQ?9]@(7\N-RE.]UGNPY4'R^"+Q ?/>?-\
MH! IWPW;A3[P2IS5)_'$7&U.G;$^""TE9)J8\FJ8$\^;-(IJ_MN&-VN]ICE&
M<7[AE2,M05)O^YY!@A% +-MM]DRF-1@NXA@.CF0':?XF\Z;%.TJ!=]!BZ/V>
MW("Q>/2"K5WH-DZ:]"#:QJK91G+/8'.++<&GCQREB8I>4BB@<$?0]SU)L*[+
MU9^1XZV/:?X:9_, 8D=/*6^RMX;I9?$*ZDK$/8O8D51(F>6!&03!]H$X,2D&
M'ZG!9!FB8J$#EAM@"98NJ&<T99:R,G.F/Q%[T.NEXP"RRV1'HKS\0W*E_ DY
M^LJS"HK/P?'<O-ZG1)Q[WV!'5G5F*6:U,9S#BAU#\6%M"B3V(/9R\PUVE,ZP
M!K\^&L,+<0G9TV/+W%5! K\&@[;W04(B$B?9S%+!+Y3>HKU$Y:*TA3*2TRRX
MEMH'&3NR>AM?E30496KL3?.:7F4-PDHQ_0*,''GKA# KSK;]%(LMGJK(D<O8
M$>PCMWBC*O<_:G1U!3,-=A+WSHD"$$FTF#;=TW42]Y9LO+676(.PF(&;!Y/#
MNO:B5M,$.7C]1S>\IDF<U3V'K?Q9Y30,"*G7CF*9K4M,O-IBX'Q51P+'-G?A
M@L'S503J\C8F;N9ZV;FKYHV<CU%XVEF;/QIC9ENJIJN?BX+>W)EW04K^&>DN
M<UOSJ2V9,2L:39^T<.V-8;,M6.IJYJY=-F,V-#3<R5QDU//FK&&2>(\%0E\R
M!8N:H.$;UE$@U&#FO*75+F'1K:V<.=\9D[A_^8=+/ &)H#AQ\VH(B?:<V5 9
MZ+?EHCH,)I)=/77;=I']LY\S';<L7T*J)\[(K%S_JX )>6-1J4A*V:>8-.,^
MJ'V*@DU13D3"7,J]$0Z?]VH]]12*;]63L:=9JJT\U*G35*O>6DTY&U<E+D6S
MR(#6;+(OBVJ*;_#K$<6.YK72E'>?9)/SAEM_PI#E*K@_!H05T>>C$6 [(D"F
MV+O;E%MS))T+^PWL0G4($#"?M*MJ*[J,G3+#><'"S*<A[" D6#_<9U4SN^F7
MZ)9OIY;<E?G:<13=Z3@1% O,[M@*86%C5+/>/!QJTFDU3_E)O-Q0_?2+'W[@
M4'B8-=8,;C15:=86MOY!;>1]L/93%_8&%,-#&#M^T:.$*HK,>9\2-]_ ,.#&
MT\^K#&-N:C9AX[YXYZ 5)[@WV1(NX<^QG01:K@';KHN*@[)N^8>([&@)]CMY
M"&,4E:'E#5V]C\&53.(7-:R1[T\D@6,?[C/:<] L?.K9J!R]>FF(51@NWAV/
M.6I68<WAG.?-7#NQM^;1H$4D2Q ON5B^P1QF/T7P"C>&LG/ZE00PRH=CNG#W
M7N"!Z&1=+MHG%;L?0WE2F<NUM>F<\VH5GMW.:^V=S>6FF5MV]TF)DGKQKLC%
M>0Q=;^.M"W7JE#HX>5[-!KQCWZ\P:&([NGV*179S.6Y.+4UV]XN4-LF<V5#A
M\E-KZ<TQLRU5K(IP5RT<CH/6^J)-MAL:4.8_V$H&XXV<;=E*A8&+@FK6O%%;
MB5H@#M^*)QENWM[SRFZL?  @R^SGTMV*P50&;J#K>8["=P^POCY^@]7>!R7K
M+-9P"(2UVC!MXR56656#/&S/)/)"(,\ZHJ[_6Y+]_^XS][O!'SO:>>\%-OMN
MLR%K;I%H%Y);0E0!2O?!.U!2S45Y(&P5LA?B(B+,,+;'M!50Y(L7.,%:YUR5
MW1COXSBE"2JT6>MIR;2EG*$I7V[)(2)KC_V(-08P6@G#/8Z6$-6PA.$E3EKE
M0S N7*J<;%!:WD'ZTI:J33W,&F9!>P*Y.V1)TY>!)[#&=+0_,U7BG82>O.-R
M(SV-EM)EP&&\IVU?'?\Y??.]]1)X+ (PMM-#\\9_W3D1N88#QR*+8#LU[W[L
M'4;Z(<]L7T[]S]5R<U54 "WV(<CDW]D"<DL^,^MY+2RLNK9TB-,6Q_=!LX@M
M+JK8\HS!H@HY)\U??RC2U'+W2PK\[3PI4,RF]9F$+;9V3):;VSSED+(',,S>
M2_=Q=F$Q=;"DSM_/FSK"TW.;JW?<4M!*W;/5VNY-'HDH^=E6ZZ"?+,D+GP5B
MEM=._>?S5E"X)*J7C%>$.$]E17%JJC1H+G-@[[,U"DU.NP=4!.G8H,M^@JA*
M<O[S1R.(2I[^%6/21W<JG$;!=0',V1RE#&]QD:@-L#-KO;>SRV3>>O=%8&-[
MB1-,C^UY .9C^P[Q./ZQT > ;2<E;CN]G>0!F%. J>*((KFFF#<;2LV0('?U
MC2%X3A'?RZUW@+ASD;&55@2I [OIP$-! LUXAA)U/3@H4%:$*K1WF3]_OG:M
M@N@#%Q_!8,.Y=?W# HU%#X-E.E^PIS?_%*.>D$;'I^%&U5EV?<*</11[>=&Y
MQZ,GL!FST_LYR;G(]P2&"'GE^>LT=?0#U\%/K7,<]<$AVK(31[3F?K7G(4))
MYE+NPHU\$-@0Y?F)NV#)F8\)Q4Y]C?3G8T)12^9TGX^NPJ'JN_=$F/_SF41,
M'UXD2>2]I8FHI.F5>MBC(W,F'&!8IA2P0B?6J,)/$^)JPT120?%CUJ?;5>A[
MJ1"TNOCT4GG642Y?.SYUL+SN"$FHK T#BD'5%K5PR;<:^.>M3S$(5IVG";0>
MPOT:V216NZ+=:)%<.;[A;S\SOP.W;H&K:ZMP2M:S>:A"Q:;=4,DFS>DQ,L1\
M(A^2&? 6"VIM5P0"T<VNTLZNF+HTN]L?_/!(R MANRYYTQNK'.]/@_K,&_@4
MU S_I*D3UMHK,VA3/VE(F\/RNZV@+X(Q0X5?0+R$T<G68\TG'8AT/N29RG'J
M#+AS(O]X]TFBM1?3?I5,U6[F#U5VT&D"(=8,T^&R4?6@U8A/O@K,KT%>=PM\
M[!JW$5=O4<\;9R-.;PTAV4^&CK,BI4 7+E U<YSUMD6O<'FM@8978THFGB[?
M$.29'['I^*J?_AM^V*R#$9ZU^3,&Y\YHC[P4<U_(WO$H)8!40$W'_S<($?3&
MPV3D@;E/P*FK#^*_DT?@QQU^$V-*XE!N67V$Z V.R6D"8IR@MTBFILJ7,(W0
M&R!#B,)4!]V)BTU"HA.RC&&67-[W,8*@X*[LCS(?(&XB<&_$0;M^ @X] <I;
M;Q#>!10[T,TNM.$(,SA6H)R)Y<$8,S"&[=Z>5\RIF=L/$&)#,']F^36)TC6U
M_.J)5(5Y3CTET3MQOX119AX6919%:.BG^=;_2K:4YI4!^^IM Y9*4391OW$2
ML@TC,,R_>\G."XHTL C0HL_&+8/5CI2==.L/T2 (?4E38OJ\9X&^Z8I6$_U2
M>:R-O@NV7D!8J8\UX2WM[<WY_(4<J(<MV#+7TSW :[TUB[Z-3+?M%<8KL1O.
MR@W5>R?J3^>UG0KG^]#0Y+EE)U[>+,#ZOHI SU3=1J<*I6+&?"6KJON&2VS5
M+-/AK)/;@1.8:H\Q7C.F*=).EZ8[5=M\R+^E_WD#PR3[^)\_P5K_X1P.7K )
MZ4?Y!T$09G42[#/Z$?&9!OP'S\T76%L,"]UMZ6^&T?'1\TF<A &)GQT/%/G
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M/8\D526E[O8DV@*>L(Z/9$=S!)S@^)HX22HOSNT^#^WMF25)TL^>"-Q@A3[
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M ]?.^Z7@8-@!^4"GI-FLV?/_MPYPK[.%+:AW@4I^!(8@^M, ^&8:/*T9SC[
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M/S[^@ Y$5&2$:^2@5.L\:#:GTZD;)Y0KP0I-!5=N)+(F<IS]GNEP( DVQ>@
M:X*"EM?:<;RNX_MC?R?P_:#3<5L[_MX?GA=XWG4KD<\EO4@UVHJVD6D$FCDG
MC)$Y.J0<\XABAD:US@8ZXI&+^HRA<]-,H7.BB+PBL6OZ?-%+=<;V7Z!>2G ,
MGZBGJ69D?_C9:;=<O]<L'T&@64GT)B*>(Z7GC+S=R'$<4WX1[.6S,,/R@O(
M%UJ\I%DNI,9<AU\<RF,R"[S0F9+))=6.)C/M*/J%.#C^JU Z\#UO,\R%HL;B
M0!*&#<KAAC4GIE>WE#E:Y('G=BE?=-X*,\J=E)@15E5W^YN(F5%KS)T(&1/I
M0 EHZ>6U@D3PTC(P*=?5@$IUH:U+<$;9/!C3C"AT0J;H7&28UX(3H;7(0-:.
M$#-ZP0-&DD5'YCO45D^R--888/JN;9BF5!-'Y3@B02Z),Y4X#V\9=I\MMNZ2
M2&[&R04G%IHIC74:)(!^!/5 4U#[^I6_XX6]IFFQWVOF\ =@+T"/&%;J[4:&
MH7G5R'[",Y$;M;GU#'173N#C0_N-Z#TB>(\Y5,N5VV.-!!,R>.79G_#K(Y^6
M;C$1+'X<(@UG*9U0C<H%XYL0\??^Q8I[0(E .Y%/%I7!\'Q\='@TZ(^/3D_0
MV:?ST:?^R1B-3W\5:9XX/OX>^N2.W(&+1L.!Q<AO=[T&ZH]0_^#T;#P\> ;M
M#F@U5&^\'71ZB,;OAVC4/W_7/QF.G-//'X9_HOY@;&I:GM=:B9D=JUFSN0XZ
M;K?=WKQMZ;)[MK[?/5<MSP_%\6?#=L119**DR 9<4ZI3I%."/A98PFRS.01%
M)EY!4'DH9(9\S_F(1(*&]!**QBD!RP@$5%$=3VV9YJ]?S5J>'X4#D>68S\O'
M.-Q&B9"V_YQ(*F)$N E;T#&648K:?J,,V[!""64DOC9G1*)"PAX*@\0\1L-9
ME&)^02#FRS*JE#$=?HUD;$)&L(J C3=,*<>QL 2L11&1FB;S!LH+J0H(R9 6
MZ-KYS$:V&U:^!S;A6.0:K%J6KF0,Z4"A-17+">9$.:<S$WA"7&QJ#.D:4(]U
ML,R]I6@")CQS&%7:(8R8<-E.>KX44"S'2L#/UMYF&%.5,SP/$D9F=]AI(D@8
M7CW95LA1&B8VM#QTC$H53+ BC!J*W&+L-66,-^QN/AT*=]S=;LO?W=OIO&FU
M=SN[K>YF.(7 U9G R>$RN"0D!SO9 A[*S0 =B](]J&SL;_G;]?0L1=<WNWDJ
MG@N^5SMG4C#P5#A#Y<RXR,)M)/F[H-*R21D6JLK-_?86WD;@BGYW*]Y>,/?:
MR18.5M'7?]/NA,;U%N0U\7#U_YG$3XS$K?4B,>6P*V3EB;\^1L50:DE9,QQ3
MLQF!,<J0N6&J 1P$S6 G@6,]5.3 ;M6PK9+%<1\ZC.WARVX<(%6PTA<$L-+J
M5#7_J\W*7<7QE4&" U/8>0,'].KT79/Z_LCAEY[J'O%,#*=AU--XPL@JWS:Y
MCK!*)ACS3/\P&B/N  U%48F4JGS/<[W-6A[(R'"N2*!(CF&2R,W$@&UG4R#&
M %EKOZ(*SEJ,ZGE0=U!+@5B\0*QTOJ[;V=E<3GS4!_DJ\]'4\=?:^MYW-FQ_
M9[N.[W8[#VH+W^0=8*KDC^7"!$>7%U(4/'8JET_LSVJ77UJ.['_'%*R@Y!V[
M;^2C3,IIV4-,P94)O2+,JGY*NB_$:O8OM:QR0E#R'^1.'KHZ/LB13%(S@)!W
MCOPJX+V1:%I%@V<XOPXG^NGH@=S_ [IW\^!WIMZ/)2P>A&!3-1$8<D$D.G;1
M&1R8LT*#T@8\'K@-=);"QTJ,GU?JI^\?/W]I>4;O1]#+:!PSLO;HW4F%KAD9
MJRB]?->XV\T! ,%H'"[K7[Q.6KLE_7DU7S^/6C,'>D;O-T)OW5?S]5RE!RDE
M"1K.2%28"Q7H-$EH9%;J08JIM+F^ RI)I(5<C_>C#QKUUIFD/*(Y9G>'OGW_
MQ@1?3.[MZ=T[^66W=FY=RVF%-FD>6Y:8RSDP4T7&;[Z-N.U-]O[4G0M5*[/Q
MA,?/-ZU^9,[212!5&5N] +&O.<HD\,T*0+PLSO$%*<,G!R?@DP%F4SQ7-F#J
M-<TEO?T7O::]WO</4$L#!!0    ( +6!JUQ+50+.? 8  +8G   /    96EK
M;BUE>#,R7S(N:'1M[5IM4]LX$/[>7Z'2H0-SL6/GA1<[928-8<I,"Y2D,[V/
MBBUC';+DDQ22]-??2K9#@)3CH.TDO60@+])*6CUZ5MI=J_/:<=#QR>D9ZD::
MWI!CJB(FU%@2M#/XM(L^##]]1,<B&F>$:^2@5.L\J-<GDXD;)Y0KP<::"J[<
M2&1UY#A''=-A3Q)LBM$QU@0%#:^QYWAMQ_>'_E[@^T&KY3;V6JT_/"_PO-M6
M(I])>I5JM!/M(M,(1N:<,$9FZ(1RS".*&1I48];0*8]<U&4,79IF"ET21>0-
MB5W3YZM.JC-V] IU4H)C^$0=334C1_VO3K/A-CKUXB<(U$N)SDC$,Z3TC)%W
M6SF.8\JO@H-\&F987E$>X+$6KVF6"ZDQU^$WA_*83 ,O="9D=$VUH\E4.XI^
M(PZ._QHK'?B>MQWF0E&C<2 )PP;E<,NJ$].;>X,Y6N2!Y[8IGW?>"#/*G928
M&995#_L;B:D9UJ@[$C(FTH$2&*635P,D@A>:@4JY+B=4#!?:N@1GE,V"(<V(
M0F=D@BY%AGDE.!):BPQD[0PQHU<\8"29=V2^0VWY2Q;*&@5,WY4.DY1JXJ@<
M1R3()7$F$N?A/<4>T\7671/)S3RYX,1",Z&Q3H,$T(^@'F@*P[Y]X^]Y8:=N
M6AQUZCG\ ]AST".&E7JWE6%H7C:RG_";R*U*W6H%VDL7\*=":P&\#U\DF)#!
M&\^^PN^#.2FX,A(L_CGH]J<I'5&-"BNZQ?@)B/@'_Z+%(Z!$,#J1*XM*KW\Y
M/#TY[76'I^=GZ.++Y>!+]VR(AN?_$:)GDV;%\?$/T!=WX/9<-.CW+$9^L^W5
M4'> NL?G%\/^\0:T!Z!54!UZ>^C\! T_]-&@>_F^>]8?..=?/_;_1-W>T-0T
M/&^Y+=JYFHV,ZZ#EMIO-[?N:+IIGX_GF:8^#9^+XHV$[Y2@RKD-DO9 )U2G2
M*4&?QUC":K,9> KF$$=0>2)DAGS/^8Q$@OKT&HJ&*0'-"'@94>5D[)CF;]],
M&YX?A3V1Y9C/BI]QN(L2(6W_.9%4Q(AP<Y:C3UA&*6KZM<*7P0HEE)'X5IT!
MB<82#A:8).8QZD^C%/,K HY0EE&EC.KP9R1CXT>!5@1TO*-*,8^Y)J MBHC4
M-)G54#Z6:@Q^"M("W1J?.1KWP]+V0"<<BUR#5HO2I8PA'0QH5<5RA#E1SOG4
M>&/@+)H:0[H:U&,=+')OX8B%!<\<1I5V""/&A[2+GB^<LHL.!/"S<; =QE3E
M#,^"A)'I W8:MPJF5RVV%7*4AH4-+0\=,Z0*1E@11@U%[C'VEC+&&O:W5X?"
M+7>_W?#W#_9:AXWF?FN_T=X.)^#-.2-PIZ^#:T)RT)/-X:'<3-"Q*#V"RM;1
MCK];+<^"RWFWFU6Q7+"]RCB3,0-+A< B9\9$YF8CR=]C*BV;E&&A*LW<;^[@
M702FZ+=WXMTY<V^-;&Y@)7W]PV8K-*8W)Z]Q$LOW#8E7C,2-]2(QY7 J9$48
M7,46,91:4E8,Q]0<1J",,F2NF6H !T$S.$D@UH6*'-BM:K95,H^!H</81B3V
MX "I,2ML00 K[9BJXG]Y6+G+.+[427!@"5N'$+66(6E%ZL<]AY=%D:L3*$*(
MB#H:CQA99MLF 1"6$;91S_0/LS'B#M!0C$N18B@(_ET(_TMY("/#N2*!(CF&
M12)WHV7;SN8%C *R&OV&*HBU&-6SH.J@D@*Q>(Y887QMM[6WO9@-J*+;,AU0
MU_'WVOK>,QLVG]FNY;OMUI/:PC?Y )@R(V*Y,,+1]9448QX[I<DG]K7<Y!>V
M(_ONF((EE'R@]YTDC<G#+%J(*;@QKE>$6=E/0?>Y6,7^A99EH@1*?D6NYIF[
MXY,,R63Z G!Y9\@O'=X[V9=E--C ^7TXT0]'#^3^']"]GP6_,_5>EK!X$H)U
M54==EDCP5]Z+"24U=)&ZQ^Y25#=[\^I;Q(_?3#;HO02]C,8Q(VN/WH/DYYJ1
ML?3+BT=N^^T< !",QN'B^'X5::S=)K[9P-?"B-;,9C;H_4;HK?L&OIX;<R^E
M)%FXSW*>)#0B<CT>>#YIACL7DL+<<IC<[31-HK(;17".:/-PK)SU[N-G$GPQ
MN;5?;T(K<U7EWEV41FB3XC&5Q4,/DQ0<9_SNTX;[AF0O#3VX1;0TVTYXO+E>
M])(U2^<^5*EL^8##/L8HDKQW*P#QHCC'5Z3PG!R<@(D&F$WP3%E?J5,W-]..
M7G7J]D[;/U!+ P04    " "U@:M<T$7G@_*W"@!Y-@\ $@   &EM9S$Q.3@S
M,#,P,%\P+FIP9^R[:503:=0N&D5%0(S()"#$ 41%Q(%! 4DK#8@($5$0$-(V
M(H2($0$)$%(.S(BT(-""$)%91$0F98H0AE9$9)8@9$!%)JE2"26I5&[Y?>>>
M>\]=YZYUUCW?NK\ZK%TK))6J=^]W[V<_3U6]TO=2/F[=,5M[6]RRY3C<,NP/
M)QW%6>.6_6^^?AWD?_<8RZ0O<4JK5UW%$V26;<$M5UHFH[1,VH8C8.-<^9\[
MX/[;:]ERF14K5\FNEI-7P':H68=;ODQ&9OD*F94K5ZS OHW"OL>M4%JY?O/>
MPZN4G<_);@E2V7?]3M[JK4<J6U1/]H*Z^_^\<D-.7DU]@X:FWC;][3MV&IN8
MFATX:&[]NXVMW5'[8RZG3KNZG7'W\#GO>\'/GQ(0'!)Z-8P>'G$S.B8V+CXA
M,37M;GI&YM_WLA[F%Q06%9>4/GI655U36_?\17TKIZV]H_.?5Z_[^@<&AX;?
MCW %PHF/GSY/?IF:AKY]_[$@6H1_+OWR:QE.YK^[_C_U2PGS:_F*%3(K9'_Y
MM6QYV*\=E%:LW+QWU?K#SK+G@I2W[+N^6N7(G;S*%KFM^T^"JG]>Z957TS46
MZ$&_7/L/S_[7'+OQ_\FS_^[8_^47%[=&9ADV>3)*."(.1;<_3,3]:__:O_:O
M_6O_VK_VK_UK_]J_]J_]:__:O_8_VC_#"Q)\:];:.F&*\HPF+:[11-"T]>0P
M8ETQXU:[="DE[TO$H?O<V^6/ [C)'__B4I8NW3L7&!0)1(;N<A75/G6P_*;K
M7(7G.Z#R^Z4X66>T3XK3MMKS >TB@W9LF0 ':LG,=]B:P]:<0S=V0_LGR.UC
M%^2>_$&Q6H,8#H3DT(Z_LSQ8>GA-_U2=U18P,X$16/H^W/RQJ\[*^AM4E\5%
M1&>9.(S*6R[%G6?%D"O9G+DK@?IM4EQ-+?M) 'O]Y-,[$XTI_!2.?M^V9O!'
MOXWQ?G?.!$]KQENG+LS9V"/WIH"HYI\9E.UUY#23C2K:2G$WSB.6\$JQ-CU2
M- ]UQAA+2*($28GA0E>/+!QW^IG] C&.L'QV(;L<?_A=H^GWGS>//X?CK%*"
M)AR!TY7?+IDDRYX B](N_ZYYJC1X*07OZVYES3%*WH^L"3[V]^/C3\/7GG8?
M5?1XK'=R7YOPX4#ZT1V]%5\'HJ<Z<M1^ZI^LT2=E%$R>K'A:K+]2M?LD-9+B
MJ]X[71O64/N*!\DX8:/;)\6UO"/4Y#PFK&/N1]])<<J6RI'E1[+*G\1 G:)!
M*"HW[YP21?/U.'XE<F"P,:B0?O"61_*G-^:K*]]][&L4PT;5<V8GLJCV#$!(
M3@'XGXW@S3E?$R!]X6(;+]E;']Y>WUU^9\@2@%280\2JW.+@T@]'7PFZKP0&
M>T*[R\&WCE<7BAQ\OS=KP#=/-X=_?E<C=^E"AI\41PK@-^] C&  JA)T)C<K
M(:?!HI0)5AQ!J=&DC&[7D;M^>%;8W&<RCY]Q377GO1\;?5W @(YZCPOW99J&
M.7/"*;O,3ECO<R0H!YD$M-ZF<CY8)+WVU9-_+^\>4##U[NK)I>I)U\<^)_?"
M7D<=35//9AW;VEI0(9^N,M1W9>9S>5TQ(O,-CZZND.)6EL".V)8&.SY1RAM!
M#"1%5JHC4WX3LBW0([VY]/;T:>M V38@3OG#&VY1,2AV&=3X\3-O0&D!6!TP
M3WM(#5/O]?YBOAA/O$2%K;&0_X&%O!D 7?"P_C"BRAP61</!Y8P=H!0W6P9^
M%PZG-&IR><E,O<>Y>^%^L0&<L;3H]#M)EF[ 07?O@6LG.+0\.+;_=RBP)\8P
MT&H3_4HK)53!0<LST%Z*:WC]\^V^EQ_/[.)EQ^VM#@J_8(0GJ3KE[&SFGM%,
M-YK;DZX[&A9S5Z#Q:B#Z0NFI2R&?=E".G-;#C[=W!%T-<_WL1?@YZC"KXO:]
M"7,8)\7=S +X]UE/,V\W'@:9PRX0>VX_E-V:E=,1)^2M9B@\ZZ4UFO!SKG:X
M;QX((:LS[""=RGSZA4-DQUR-QZ&.^JWZ'1Y/DLILEYR:? K&6\*U*SX:%B,Z
MO>#@PIV54ARBW-]I.J[S;<XA((-5??5ZY.,$[ZN> YIK>+(A8K7;X\,7AYZQ
ME,J\G3RX_A=]G$.&K_-W&[UY"K:?VV=YJN148L[!H=+85O._4IWV%Y/4O6/L
M6^U+;9UOWGHX\) ;)O?G]O9O]8EB"WT#J^YVX\:O/X@OZ@V@2%0N#O-M5!('
M\$OKTZ6X:\U* <V&L \T:M?[>;@&?YVG?M$XA] >491\_G3H(>I+;FU2V0Q3
M"VK.+,IPIPGZ0PV ]5-#QTT,/3D>EUC9UY?LQ*>9[YHU)6G A?ED7G7GK6K'
ML+9<%5@='&XG*S,./Z"?/T-8-Z-)BO[Q8L&AFVBK6?Z9591C^WF#I@6M=IP[
M&GZK^2+TY S]P./\_2\G)M(G]IP&W_]TRCEPCFJ=6O#)XYCQB]T__313*4<*
MSD]U%60=[]M_*[];0U_[:V,=FQKJF2NQ 2Q959/(QCHI;@4,=XIW(CZ2)\V;
M"3KH6Q[>2@E>=(#]J(*>A!-TJBN<!-EU9'7&]B0\#L''C"N!5FRA0<_Z:46_
MZU<U9F>K_7_G=L8;50-X[GC D!279K4#RX/W3#D/>@&7;B"2@XN%^!621W.R
M\0P7J*'5&P_9/[-9U<&'+>Q!]=O&=T*OC'@V[)U(4TR]]HY'3CT1^=Q[A7#6
M]ZSC1BN[Q+M@FNA,W$EZA(K )=7DT'VJ6_FQ9/<2I_5W=SA=23$^E1JHG]WF
M;&_F'/EZQG:L(C"U_N=[E.]?T0' >I.(NK5('RN@TJY'= O!JD(A*Q;09ECD
MYT1ZP:K0G_W'^A"OT(<O>SDE]+B72T4ICP+&"=!P7+7XWGJ+GR$-,\"ZJ3U=
M@>%"_)HOM9FU)S\PW[CU7-"X:K&S_53+A0,>[RU/&QSLK9"5*]2COR5>N)PZ
MI+KIDURYS[;DK=N[=]B4Z@\"'D3]$F=RCQNBTH"N=9!$$_GWQXG#3%F3BEM2
M' 7/5>#LRD!WPN'@G1]'+0_R#1V'WYCKMQG%UX]-4SQ,V2IDZ*= BEM+R=TS
M7$V-O3W<9GXA>?]U<I84MPS@?Y?B1NPZQBVJP,6Y9>+M# \8S^^V/A%I#,<(
M .TO/,VYZDA7/\] S[9<C5HPA3/'5-CST&Q@,_C&VW"@W/IY9>6@QQ[=Q:?W
M%=O_GEW_9L\+G7U%:J<DY0?9/DZ%'H'!MB&7%P(XRA[[DTX639W,*LFZ_-E1
MXW73AJ[T ?NYP<+I/@ICY*<$*PXB%N,$YAA908KC?[1(&:D3\.9\(5X+@,L4
M94IN6NYCK[8\""FW:9*OR<8U1H$]HHL#""4?K\@=*[IO+,6I!.CH02N_UES<
M_&W^JTGR$7>.R9L8=@T9WM%1 X5Q6"")-&KD#:\,GL@V2HZPFX4@LQ.P5QCX
M6MM[0JC(3BYO- O?=MWHYA_OMK \,MMV,"JU]QW:K4'S^+CINL8_JF@( )YD
M)TAQ>"9VLI;N<76X$F1UF,NVX6.EN'5$"AG>!B1::DP0%:;734>HQX<8DO@8
MN+),<B0Q'W7+#';X%]\X?7OZ[?3!V?E-=0UUN:NEN'Z"Z)$DCV$BWH9V\[38
ME!0-_ZSY!,L=H)&@(K%Y&WSS-_"?IU:;AXQ9<E/!TYE9S%LFGMU$1_/D-WN,
MK_("FVIJOVLP1B;./EWZNJ>5L]*:XQ?752()"-_M:?Z>=L[I%O1W"6>W9&C'
M%9NWA<>2^TNFBPW>GAVMVHF_)Z3ITRC&.?.^3\;M WU^YF+5YL[$:J[%'MT&
M<$(!#L>$Q^WW1#$6$NLCQ<5@+431KA"Q[V=V2PJQ]]@LR6%8NHD'/JV>P5N\
M%<O>8 NVH?]\9[ -.#RN#OF>+WN)5]$AQ<&Z%8A:"I^$J'Y'U;&?["#%D-6:
M-0#.(:#UD107G8FJI<('@5HI3G!1BFO]!^U 6[&/26W-FWM$-,3@D)N8)+:>
M!2 IKEB2.4>8LK*;!MJ!1&P0S1@[@#+;I;A;.B;@(J<BEHP/P4"%WM/1O&-@
M2[^QH8SM,X7/8]Y>QZ[T.1BT4WQ\+Z7QIB-BVHNRB[ACT^I7A_H0/]7&2_H)
M>]GNKP1I$P%=*V7OGLO7L(T>5U"0/U&HN=?Y;N6ZCQ5=J\?>5KE>:1+EORZU
M[9],)/&B0L.:1+7<V3M?3* 41"6R(W<73,-P\)ND$=U"EVWS8$=;AO*-WG>*
M'D+%-Q#W!][=13/-ZI!?3+,L/'D6G(RO=K0=2Q5RW'I-DK0..3@V7>^C>G;Y
M^R6D3YPDWDOARJ#X0Y(["%[89'=$DDOT!6Z1"2&*YA.SE?!H^_C>=TQ9_Z7/
M7>GVM!^*.VEK&4<A"\I)C\SGSP"E+[D:@T7W7+G?;?L'NUM#S=G(QB3QNE]3
M2^2S>. )]O7D0KA.=$F2UWA8O)(YLK456&NE/SZEF1G7O(E$%1]D'*[/=L H
MD/)1:I29&R3?NELWCA/Q]8X@,-CE-M?OW<708-76T:6_O5<*'^M=7$74N/-G
MWHW;^^7,WWJW%@CL1ON#TQF[=O8H.=W_8[1DNO?6.55]"ST#APK[4IM329D&
MM4L-%KIS%\2Z7^D\1--.3&,.LVMZVE)&:8Z28C8%?XN@L\L2ST^YH3Z^K@K.
MFXBBMM>B6HW#)O,)>ZCJYI8>Y6]F?$T+U]XK;@_7W>P14E7GIFO['/U@@"RQ
M^:]8/W>RP1-DL3ZOBH<6 *HSXJ]013*# /):K?2P'&K#J_CKR('$FR&.=FVY
MNZ"PQ%"JH0(G5PM$[U#UOI8^GHEX6VA2$YM=-"7ZJRLH+#S,\L3A]?L;KAF0
MUC\=* DJ\HMK/3?56_PJ<V?(GA_Y3AO[NY[>?E=X;*=E__WL:I]P>YYK>TS@
MNZ3 )M^RL%[[A:C;N8GH42(%*P1+,Q2K&3"I79,5+<5A;#.&J,$.H!AGQ]:F
M=7"O3!'EFC4#4K3?W?!Y$( :I3A#;_,V!NFU=86&@1/'*^N)Y\6*8X--;S)=
MV7OHZBC^'$PH">BUAO:+Y.%R@?::<:>T *N5\(B $)]5'1'QX>&HETT^%5T)
MD_U,/M;&VD]61D6L-OSJ;.@S<.G/.Q5;/N4+)C6&'U2N^R?H6'9BZND P7;7
M*C<WSG";2YL^[=G4#K(#^7"CXXJYN:V 0<UBP; 0H V"=8A*G.@K:(8H4T5'
MX&SQ6<9AD)S(W.+/QG\$A])]^>S59RFNYG7QEO831"5*LPHX>)?[I-+2U</T
M5FBR:Y]7F+O:4OGG>P6=86'%7SP^_7!=.CV>,KL9ZP#RD@PBOX"PJK.#-^+3
MB44J@\[L/.&%;T<UABZ2?\,FC\-6JE[^A0YT6JD^SZ F;_M&O7+)>.[(4)0=
MA_NI,?@L#'@,!C[(\L<(! TV=T 5\*"=*XB?(V&5F10G -J/HL9T/PS3JFI?
MA$'[G 5&\.E%M45- $.<E"3%2I*262+R"2O.P.H+WQE$32"PQ6KC^Y]AM!X.
MPR2Y^T"F0MJ?5Q"',PPON<D-%#*>C+\6:X!W4#>__U9U4[YFKV/K]^J)[?KY
MVAZ5,?HF>H\8*2$?^P/&=,:S H##9-":#&^O:R?!.PFS,1,IW)O"SAC+S7RO
M8S2NF=#N6N,./F_E[KS=F8**Y; ?)W=9T[N0KFZW4[G4^754BFE#24_93%][
ML4V)U]MNOP**VMY1"L:4GBV@ 0!HG0(?R!>=QUJH)[.]/F6V!PKF YU /-.@
M"1Z<J$@HK4 .D.,F.:\*Z676X(5TO^(7D-DM8T,'\9%QFJ*7?7#2UL!/'SQ_
MNOPS_F?QDLO9#Z,CHSUA89:FM1E/NX*QU\[#M$#:<N,JDF7?L\XU>SK*=9_]
M\_K.PZJ&E2N2X<FX2@VU\*1:\JZU[HGM0E<7/W6G)P3\[*FF]&+SC!OEQ[X6
M%NH;CUX2''E8ZF2U:'S7IV?,M'YI9-;1!C"0XFH[$>UB;(9^2OY&@A\SC.'-
M&/- WS=O S\M=.0\H1<+GI0^@#WY VZUJ3_5KT;HMS51Q4XS'8IKRC:EN(&9
MT28L65Y'F56Z,!L^O];J#&R"B?0"YNOF'=!55CX2)/F+:<S8!!8N0-79'=YK
MH,D8YIZ<+>.>9?&!H8Z>G#IS=<ZAW]^W7]KU=<'_AWM-DU.O;E/<\?Z:5^6&
M+B<3+64Z#MS:V7'RGZ#;T7ES6WMVJI2]5JL/:ATL7^-2'Y9XRC-SY+C.ED3&
MDP):G2L;U"V'T>-H[Y<*O.0^QLZ(UUDU[%:\'"-<<A_5A8.%=:TL+8^:MS>%
M;,6>_3:31WX/6[*M*!KG4![3@]LB;%I,(R9C&8>+I[+0!$:*WZ.IH<SMO?C+
M%6EEQ\KET[</%9],#G!)-Z]^U'IJVJ5TU<2!4]%]=_4UMA5JZ&VO[K?//]_O
MYC0UG37R9!*RPZ)P&1V0XM3F&IW%,F@KN:HB&?$3T!*):@BMC'%\*!!1$$H\
M6SW:$6YMOA\8QA]*VX5J-]8.7GK,L!$: L)C]JH<F_.9'MK9G+6%5S9.L=[[
MM1!BWR&:\%XP3:"B62YJ4&_EQ3)7PO2LKZ7AD27369/(YMP-?8@Y=ZBT9#I,
M/2(COW2ZNUC;^L2 B59#^1'1-R&U;/3>5]\,-U3#^ A6Y"XTV*+GY,"ZVDJP
M0;1F8%[OQ#5>L@Y/=+1_2^^6.WKK'*@KB."P]Z[;T/F@Y8=7%6R^(:BQIF$<
MC.<5-:Q^1..20ZO&FG,;A@O320<[:U0>63H%G1XL/%;%8RG:LK8DS^:;C.W/
M36&;#QJ%?"[M?'78H&::QU=QMF'(O<.VN/^_C,G$.K +:HCV$I<#?Q"X=L*>
MV>QBJF;=')[?LX9^95&0D?. OH%Q;&AWC2>/0'<X.I#:^7+28:@S7I>,#]!L
M2[D8TM"S13=5W$5^]K,4,<30\ O GZQ8VD;82(3(2L!W5L6/HH>%1>.IU*4%
M&>0E$U,M+1PR>-FNA3!+A+TT.ZK )'0],$>$;3&RY8=VYLJ#>$27^)X](L6-
M$MX#8#IRH ^H83\#:JHKYHA/H_)G"=P(@-M84>L9GM,9 _!?L,$K*;<;+0KH
M[!8=5:PY&\G!-[I-M&7;=50ET2&L=7"89_^G794\BN;X'?#A=\>!QQ_/_Y%I
M&K;_R*<S!JEKB=9L_H(4][,C3C).1I=R  <,NXQ^_NXWJRC%G9?A\)8N#S[:
M]?-^>&[BXG!7SQO\1SR_&%%31M<Z8_J1')VK 0US4I)=<U=#ZFV\9?[>>^M?
M2&[\T3LWUVA0!I<=ZT>L@ZR>8-QTL^/N#2%)2:_T!CS\,]I5GWB<:;.)6]K5
M2[Y-J-5'U!M0N2CQ>GJ^&QP)V8EB:S 6J;V<VN5($Q2W>,FZ8&K34=GYZ9K=
MU;1UTUGR1M<1HXK#E]>_C9)I0W?W+F13[^T-]EFS9\QQ96%78\4,UKNNBPDV
MP&XN'M$>Q)"L<,CDGG&WM:VDC&'@JSUP=49H&(F)@9C=QI2'D4'[R7:R,>@.
M>EK;\J$=Q%Y=^^KM%8XO#57O9_Q=3VPD/+.;JQ/O8HX!:\_#I>(=C M@1?O\
MZA&OP\4S<;;FL=E"(_F 3-//TSQ[*/-FXV'? KBJU2.]O;YQ**-Y4V^UB%UW
MVZ%,)C2@.8A27/5;E(L-HT?LA0X#,L1S[.NYNI)\P)^W/L!;&781''+@1#C5
ME4]9:0U;ND?1HH3=5SHY6;I!7W(W5@Z$>L8\'PS5.J.;JN#F$'(U]^K1.W\S
MM(4]L!$>479KP5J/;!P[L,EAPK32J*5'"^YOPU2_]M1?=/6V(?9ZC 5WMO1[
MM N3]5O)^(7L0P;NS^O>G?S&C2*3!U>E"W),#;)5FX<"OYHX[E00SM2C;,%+
M2<)#MC+P!PT^((/*36!158$KBQFKX?U"?&+S6KBK@CL3-JZ*31E5T+BD5BAL
M,%*<<HOXVA243\U=-XB$\@<"C6R>-@WZ50TV.A1.KS_#]2(%4LQ'SX:3\X@U
M[/\(:RMKK0\65E<$"VLK8?7X&*GXBY^[>6RAT$AU.F-(.#UA#])N-A)]R^A5
M[?7I30VZPU>;";TUJY[6I5J4?:<&C%_>71Y9MFS!415IL?X%L4"+?B&61#*C
MS '3)5<^&\SN!H.M:0K\'ET]])5LFSU"J?&QJ=^**BFBOU<^RGNQ?M1FR1["
MV(DOEBI#L+/8A'%0\F2!S#4B0:271HFY![(%[&C$#UQL9>Z#"KETX>B1 4O[
M4$&*,DRR?\=J1U</[_H1:!HYVKVUPUPM[I&'C4G2V9&V.E'@WC>L4[+3W:H3
MK*K)3E8LNT:VA19'J,:WC'E_]X;/09Z<J^.[0->J$HIFQLW(DB^95[K7J)MI
MFE;2**53?1:CKQ5KYJKWE^"J?;;4DQ+)JLV:C'6@;$+S3L8Y:#(:U6"8@9=R
M0TDJ,*]CZ2M+T*/H?]7[XF4[/;2LM(=&5<ET<SGLZW-1EUI^!/W,;>W02NKZ
M>].=Z[Q><K=^&P!;**-R>GR2$L]?<RT;HW/"[O+DCU<!\"[C &SQ$;[RW8Q"
M/328A-A!=ISN"\*W@QKSNBRQJE4_1:'V?EV_/6V%%!?&Q*3\60*L+XNH*+>Y
MYN)@+>CU(77A>%Z#V(P_WUZN]EW ;M.F^I:-VQ-B'@SFTA1A[C<M?R/]^GY+
M92%9*:#6M%;=;7C(E$N/G?9]4ULOLU#+QG@YOXP(>O5<(X..1CIT,U%$'4A+
ML-J##I#7S2*&95^:5U3?GN0P5X,I,8WDBC%ZF#U$NVT9'.YG[&)W:#RGS+Z8
M3FYUC1BOBN">O4-UTU&N8O>'>K)&R$D\E48-T$Q Q&AG,DNI1B%97S#?,A^7
M:P(73G2[]I.:!I]4]ZQB6('CQ4*>2H :US5'L2.O](.[?Y;-PAOSJ)C&Q;I4
MV]JAIUV6\<FH!QGT8HWR1'Z2%P"_"%!D4T@C/1V:G8GH>CI- +0 :P*X7\L%
M>&6ZTY*B3TNS.13[HN)E%B&^>HSHEFOA9>%6F;%#6$U_DFN7.%:0:G:B8+9Z
M[#KZ1,7M4]BL!59S]R77 /Y#EIJE-4@2G8990D 3.0*R.=V>PHRJ0BIYC644
MO\P36.6?JX=1KQKM(X?<VCW69A9_.&M3#O,XM:^*.9<7GW6&&;ZY7*V6B2=,
M)QOWOU^>N+UHF8W*B7_M7_LO,7(\L2X%V;A,+ ^TF /^"E+<2)WH>A_3\@-B
MW=]H(*C8T$WD2'%QJ#:D'Z?;B[C1@H**PLTS\B:Z5WT9VSEZ//.$?5''ECNV
MK_1LW8AU@Z@W#PQ]PHHL UK^6$@V<JI+G3\QT+R*(=\_:[@%UQ4:&4Y]/,H=
M;9/#O3+^INLOAZM:\]?!TC2*5YB,9+>5'.,"'"S^'=D"!T,] O7X.88GV"^L
MB ZA:<+[V]2N/21_R1HK"',5"L<@D]C""]UZL>6%8[O"ZIU*J>%%/&O%3X\A
M_9+AGY- 2SD9/*WM(@J!VQ]A]&T/D>)X<H:3*PNG3!B>8Z[H%G8T/'T!4Z"I
M>>_^-M;J><& :;*6(WP'"+2@>%SL.H_QXD2U?LI48- C^M)G!^#'WF+U4( ]
M@,\D!A*X\P+2+$%LC-A+RIAF+<(N5HP4)X]QP;527'0N7N:+*&(QD8 JIQ#H
M;H+F)$EF 6^Z7J]PG+<.YMA'\LQ.U7PS_M3P(N5MADI=9@>1GT, 70@C7:C\
M=;"SDZC&OM! 3%!CJL)1$QQPQIN4P-S0;VGXB!TO&_<#6)_QM*H/L1,>?8(-
M<7;NRC]110YEX59]VY)FQ3[KB>UL,%@=R2.(,$G;<%F*&ZJ%%<E99/!"'/+W
M\)R#%.?G+<4ME5AM/!GX7:^WXKL4MXGX-&O[PQ(,61[\GX8WA\N@2 'M)6]5
M $'):B_C-S"%0Y29"O;P&*?G=V1A'4NRV:A&+J8VNX@36D*2'P_@%O;K%:47
MC"0L&#I!$]5/:YX_O[.%9E/Q/5J*NUG"")^(LD/E%\16B 4;BDLT8A)@/P'Q
M)4V)'O9RT4-42HPV-EH'QPG)R>4+$L >',ATS*<L?:X++*)DU#=74'W5\DH]
MIK("RS^]&1*IW>&@*:$[QFI&26]_*9 3*YG:Z!@;O$Q#E*4X5&Y2?'B&4&76
MJ0[W/F$X@?.QR%XA28D#=KZ,("3\"%QIZ56<XV?;NW#(^C14'#N9=#;S2*;C
M\(7JQ-?^6_L6RK?Y-H3[92D [^<3R.L0/3!%,)QBM1,6N\8=!LTXI%5P=N?X
MOJ&O>S].6:F#L<F1%3/<6]?2/]1&>+-"K5Y:'[RU!7EC@!0QEZ-O6:I8/ZSC
M51LAJF11SL"LT3:(%6>UBO&'I)2QMXC+.V@JQ2EI=61AN[6RHS6I]S8G3H\#
M<1%&20R\0(J;VZOWT-/?U3',4OT&S_G&>6Y-'3 LE%VZB[[A5;MQ"-Q1OGHK
MB^O 'RH.+\/T?CM?8M%AI?9\8$Z=-#@7.&_YC]$/KZNM![\**B'9N%!JH/5O
MP[/E\T:!@:$Y^Y84/&=&Z<+Z[ \S\$-LDBR P$&(UDJ\S7YJE!1*VW\6=GQD
M#_'XDL+N-X'&[+6-?B4C&.$-\3(?*W3?VH\83(B3\6W[PB\_3\482-3WKBT7
MDSW%7D4Y?0!0LE+%^?A_9%/C3"M;O5D-GND UC5KPT9"V6B&VT1*=)6_&ENY
MT4@P%D8:,@%P9'J1MM,D9XF6%'A1/Z?:T-.EIG=!X;EQSF\MI8;W]XYU4[6;
M!@NJD#"LL?I"*4E, M"R'[C$UJ+CV]!-(/E6XW[Q'H;7(&(F[)&G:L;%(0Z"
M.8_A5H\DCP"NVHO"LQX!$;:E?OKS%Q>TK:;'O_7YNI=_3CSE1GC#1C0BPT(!
MD(?*XZ.B@H,B(R,A M]P[-.G#WUGQ[S&SGXAJA8]?_'B^;U<RE?]>^/N1>GC
M]N>OAEVXH-O%_.:U@$AQ_^!G#41)\!R?-7*33VJOX&X5'O?X.(Z#]_*)2@P;
M*-I;\VG=H.5A_3AD;W%7:8!#_M2P&S>PYNN#P#R@RM,1\-OX[)R'<$\8/A[@
M9Q- -]J( RI?+,4IY*,:MSN%[9G(]A38C0QF8VG2 \;>$9#,4+4X1!\ DX%S
M4IPOO:R-1\.TI_QW,MK_'>6(O): =!&K^I4(>,8.((^(.4 -;?835"&B0K=K
MGM"#6]D;K;3@8D%QO,F\HM8RH>+68Y#W/:O,<" _YV2?%.>$OJM-O)HZ.E?K
MYCK^9XJIAOI.X!";GR;%@;8IU]G@T7F8S (+T1W(&3A3BE-<B9V["EU/@MWG
M!*O0=DRA.6.CUQ(3Q'A4B:0( P0N&7P62IXCUDDJ4$L,N9Y)6!+]MQ%C5VN;
MV<.?96?U_EO"X-N-KA%![Y[WP:*_)"\PGOL=7#P.3^([[UF&0S<%[^HA]6LA
MBF8OK=L(*T((VO24CHL,Z\")9+L3:$\:"0ZO>))TQ7BKW@)G"NJA7:C;9T\3
M>Y*O$:I(B%:/V)CYA@PZJTAQ-U+HI E:)W$=XT2*T*Z3F.#SLGD+#<=:INTV
MT1F+;H&I;:XK*,WK*B&\B)E"@?1//>\->IS$JCY#D>(N94T3JW5Y[!_I2_/
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M9^Z EH&^;S+0#4.;6&?Z0G<<SQAR"#3IG+6;HXE/,39+$HE^I$16C6RGUX5
M=0&KE;S6M*&\YM;51<VWE9'!8=0".+*U>>.S^OIG-T] Q"2&=0F%N1%<N#6<
M\=?9Z:6<AV?'N!X_AT^(@9&#'>Y)KW>ZO9ZN__NG8*_[!8*2S4#QWQW!^>;&
M@P?LS9\^GCX9<VRG<VG _=03:?U6=$?''497IQUIVOUC(555@Y0!U('(OTX
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M:EH&FFLGZS(2T$"6/%9():QGP[.OH"14+KP<KA-.SDZ"6X6LQ'Y1 5Q5H)^
M;D6VP, $L*XHW5= C%5VGTHJIV=SN$4%]5$%PV$G1]T5[@2NR#3#JQSM/^I)
M0]?.8[5W@\X1A4C2K=28G6P%R\.A& ]78P[7C>]Z#K/**&8GN=,9P'*4\"1I
M;84@Z%"U:-'U!.($$>-_=._^ZO]F:*DXAF$T05+DM0YE#5QO"D;7H+]8.94M
MNLK:P%[ P\[DFP 88?V!,)HB.I&<Z^//?G8K17[_P3K/!"LCQF'/S 3[;VT]
M&Z_>N/J;=JK%N<T[*WU81JV<_5"DJK76#K>\FV^J-GIIJIZ?=#S-Z0W.[Y(S
MVU#BFKRS-M&^WMG1^.SH;<4#7SYLRO8PS;:7S)"L1<6HXA#FU@;F&[*L%'>>
M=I-=:S2G!\:UL#38%!)7O543WYZBB$\8W]C7Z"O JF$MXKR>REN[JU%9P%HW
MM6CN%7=KH4+A[)?F[9!^TM?'NI#:O<A2*:[5)&^<P@V-S3-M$ /B &PVMF,5
M"(QR!$;QJ!KB!\N"2QCE<>E_\B?8V4Y<0;?F>*O %>"\I^FJ3D=(-IKA6T0Y
M,;W7ONCOV8]IOPUJG02?U*G&%*;$&Q]R:ET]UP\WPT0I;@5VY)OW&FW - $M
MWDH5:#F&>.8SC(:9&^&M[C M_PL .A.X<7:]QA7+ G(U^HT8A*(O2TX)13E:
M#GV/&8>L<JC%4]S#YK[I!2=&SRA356R;M-"-^;^6ATEQ?23F)BE.^ ^;2D)=
MW:PHU\[,SBME][0U/HS=^^>C4WFOR.JR-VX%>.?J)-Y*+9;?>VSC'7N']!??
MC[F<D[O28CU=%?#*HJ39KW"TWW6<_2G0ZC(VU@CT$'+NORWD\6W>#K3L96Z'
MLQPP;"2J6NDS;."5PKF]WI.HTEVX%WQ#G0,[A<6QN_0;](^G=>[QMV[-%MIE
MN[U#_!YH!Q@D, [F=Q=*<7EA<S;0\&^2OX$+\RG$:K_$%5?\B3+-ZY C<'&)
MQU'QVH+FU6!MJ7"U,=V*SG7H#IAN5=S6NGK,]T534UU=],]G#RH$!!$)&QU&
M!OA/B7@B/X]<I3^7_NOF?D\+.3Z3C6<'$&^0-:SVP),>\"*D(,2W$]3H/BW
M.F3O8YCK7@.H(L0HAS9T\X#EYL)I<]^',YH?:/2>E?>S8JI_=U2?8R':A6(G
M]DL>K,?,!UE'!SR&?RV-\VOOD4&VK_-,S<Q_B6ID3 J+DVM6W"WYO3*\45W
ME@\(*F#Y/Z^#;KQ\^HJJ-_N7;SO];%G"\\[8J4]_?] YYVE2>)WC=_HI?O%*
MQ9&*W0;K^^S;&[<$ZC\J/B(W4M2:E+-3]>S$]A)3?F%35F\$&;H(*Z!K>+!6
M.<PZ+*D':&S"O1K:!H87S"I"=/H:;<+6G#CK[345SS1$O-BW=(_JQ;5Y;X)X
MU[S=ZN3\,YMUGM?]UL?9B<$43?4GUI)7Z$GNI<RRL#=YDF2F)GDJN1 N;B,J
MS#7OA84:K8K6Z'IV<MTB"\-$$Y+A5N<H@<2L;<DM9HVG@Z>GO]I0JD.0KF*0
MT4PZPT[CLW/W<]:!]G[*NS,OSEW^4/MQJ59^;\N[RPY'.T*^[$PP-#)=#,Q1
MV?KJ6-9,UQOQN/=W-N^/AXD&G[J/_"]<>?RO-+R @.+)F,3U!\8^27'SI<,_
M?JT<VH?!F"WS)4_TFR5&DHH5/=A9)/@0@ ;E27%AF5)<<S&YCX>LZT*=-<0R
MP @.7$3OFP3$0%W]R+5?Z^2J(-9<DH &ZQ>WCVF)E.$@B" DS"E YA-VL%>!
M(UA&>C'0Z,<W6@T_(-M/S.M0]IXYZQE0FQ7#BC$><^#4JU7D6P0L$1(0QSRJ
M^96DL@T?4WZ^P>I,#FAY09!'3H-);I(B-K^8C+,, B""%U34\!#9+\EA[N;2
M)P0?=-:!O)@*VWNA$ZQX*X6K(#L^M"FX/6M6LQZ.M(-V-(!W<]?6]C-(:MGE
M]D)'T\6C*!NXB.<N\LFS1J!,)Z&:-:<L3+ T GDOAT0S!YY6F[/B&^V?3)^4
M9!X&XZ)#3F>L&F(X"[6$M1&^:6<]W%LM)0YN \9-ZSDG!W>Q$PE:0,L0#W0&
MN+3.^N'K;'X.^:GW32"@RDCDS0KF TF$ZN%V41\"YU4-ZO=:;?""28=[+]78
M_WG7H;A;,*_"==<;I=36/\D+]<]J^_@XB^;=RP.EN$/H;\ QMA; '^?!NK2.
MGF73N?*9HM] 0NO,3+G1K"8QQ6J-PR.&.<2.I6VIR>!V>3QMZJ,YW2D/4(MU
ML6B9,%1OXSJ57D[875,T?3S>#7Z.!523V$Z"]2>1C1L GU&:BE= A&I/.X&[
M7W0*+E,LR'35)+8I*@O0) CKP*TZ!E[[[-?LK6;N!.UB&\GY#N$TP[DG:6&E
ME,M->8-//A+RKH[OQ'"' UQ\H6S[K!=Q%IO 1)<[:E*<\PMP\B5A9.B0]F^1
M02%+N6P:L?/T+<+><1XG&=AOG'#EXLC6FE3"/RQ8EQ7-W,7 LNYFLI42PQ*&
M)MR;=1F!<*3X#+.W&0>_@)8#ZZGC>P!-QE&0%&.UCT[NR-4GJ\)%W*ZVYJUQ
MGM#:M)( M:4AMJ_OXP#7[^UA)2,>7@Z&C5>XETQ=AVLJ'LF(+;"C%Q(_*1()
M&,<%8(PUEJ6UJB()&(HO!_AWL%BWG%T E . ZLXV-H'">N8VFZ!8$<LXQ"?*
M!K@NN9;]>O[&:6!!BM.8UEP5\\CKS+2IE5;?N:P/,\W$X2W]NQG.Y8<! 0D_
MQ8U)+R]_DH?QBIDJ=.U=K*R,$8Q-8BJ.CT>?D%:[O2* ?BL+'P$MQLV'R'HU
M]=X?T \\)</=1FH;AJ8C/8VND:O.#EWM/[M2V8%&,9'\J'W74'W9/O(JM-/D
M3?M8A=D(%=Y$M"'Z$.#-P'_>L4[[M:""7:O>8I"28&Z"IH.1[;GXIGZF+OUM
M3_OX.O!"<GAH/K59%VI."@YZP*4GD89N)PE&FPQ.Y"YZ#.[*M!T(/?#X\>RM
M;_> Q)2X+'PG'C[(1A7P%9T3%9IP6BMA6<@!Q%$HQ6T9P4H2+)#B?,FKJ$O,
M]#RZ2TN6[U1];SFFNJES5$Z&YI-BW?4M81,D96JN26._T8]RC6H3*<Z:".\8
MRHO$?MF"_<?/\RC*"=(KRBM".>R:C+QS84K+/3U'B=>:B<]KGL?_]5NJQL3M
MWW77:=@>WN@&M6",W,-SI*Y=BAOE3DU$\SC@*/]T4W5YW9R<7[ P);Z/;*>D
M'Y:V:R@KDG2]CF$JCM]\Q=Z@/:29%[9PF5@T)H,J+F*)3_Q"7!.(JA'>LP3-
M=86=A>W%7G =>:"17,)P&BAVL"_W&_QJI5L17XZ0_1YY'VI;?):C?JJO6AQ9
M&SU5'Y7<E,&B49!5F =T(C^C&2,6-TX@5_N8&QD'H.);C=9B K/7Q0LY!=L4
MS]3G#'#L(?)UJ_X'U/&UT/&@#<;L=7"9X"UK(E[=&J(\340G6\8MJVJ?!Y>:
M/O\./#8!M A@>#/KX2OQ)O0?C\<H"=%U)5=C9$FRJRY=E#+K11+$-@57A+M;
MFZ72JE,4?Z)G$]0@VN>"Y(_53O8>HIJ&9>+T_RF,)\W#NWKFC*#OJ,)^#*<C
MP4Y$V8Y/3+AD:+46V0</$U^29;XXA 5+<:MSL#1BR=?F^T*=$YVW+AK>LG9/
M>5E)&3>I[MN6Z&@]FXL#8P;G8W\W&S<:RA\@5F,9F(D\W"_"@O)LF6!><B!@
M$/5C5WK-(RH8 *#R)D+V!BQ>!P-K'&FBE_V6=E!/6[WJ0FPRF-^F66!N56G%
M?@A+<:>]+"8,DZ6XZQ=2)VT@U87"MCK7DV0;G;Q=6?ZW+^O:&#ZLM_ >_2'%
M[2'VZHN\L4J^PN:G$ZI8'$7]%N^MDNQ& [$U//CCS*Y&"N0S$1V&&D"RB0M7
MZ^@+BFX.H*2C4#^&L2S@N^.>ONIY64I6U!#+/^-/L=M0#95BTL":O(FNQ89[
M0P'1D:18*5<@*A:B9?T+\S>Y9 Y!@VX+)+'E$6+%S+ F^>;#H9HYBZ-@77M/
MC$?WY\(P(2!']F=:-+PS#,U9/GJROO_Q\-EJ2#V6U5K+U&A\-H!1#04#%.\H
MQ3T(2\%*9P!H.0C\3*[0A2$!";:8$&7!AR=XU]@;&2LGV!N1;7!.'CO.,DAP
MD$E 7V8MGXFP^##J+;E+]59]]X.H1+FB-U98TV96;UI1S#N\:SOXH<-N:U#
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M,V[4]0WKHK:J4K?Z!9P._N )AH( D*%T[*74QGJO;#SZA)I%TB4CO_1>;/I
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MFF@_='.S'=?8C?,9-60+&&3U0U4J<(63D+\#9$X01SHUY*6JIU%-9J>[:5L
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MIXQ*D@1P1;>&MPMH%-R?2J>RP8ZBHR.5*>Q-8-'7QT6P=7^S*$A?QDB8FM4
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M5;T9L2MEH()[DO@1BS)V3?\$$V3(>^$#1:RT*/[ H4:7!8R&;@<7>OO<ETS
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M*793*^5G8'>%+OTC3J_1$#0;8;RQP :15N$WPM72:PVA$D*22 ?1I=X8%IV
M8RA!(\PU?@X2F38/K]=5^ +TG4J,&G)VB;TQ>+(KBJ+Q]OGY,=NZ>X\0&!G
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MAD/0?35PI[YYWM\IY@FJ6M9XORQ=8:A44S6P,52!/%15H-PQO V.'ME_X6%
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M"TFZL&=+3MU-P_:[MRN?'Q;^F4'TT+Q6]:OF$;D?YZO:O&&_E*34(R,K24^
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MW&K!Y%?#GXV1J1^^ %(%<\,Y6+ ED Q$. %YM<*O8"Z_5Z>M_H</X=V\7_7
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MX/^'L;K;=B^I'U<[UQIN=WJ =% 6!1X%<LZS*R8&(V,MA$$=<VM Y-FA.M#
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M%S[BDJR+A^O/F<_735Y;OE1HL7#9*>CR!TD^<)_S7]=9D1X(3OGB.LO\B<H
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M&@X"^"E_'S9G?HEEH3QR@'G^Q5V?.8."*7*RZ253]&60[3RW,T.&Z75"-GY
MQ[8%CD#1@>E2"%L/S]!^!X(H(].O<;7S:8N*^[[;2#;3=P0''(28(HT.[O;3
MAV^JM8+ML.L ;,'T>=*H3"K8T6\1:RKBLVI>U=1+6!MK-VIUBI0+_P(K3Z^>
M_+/:XMF7%P_[5%*9ZP,^6V#/Z"]&[ZYXYKCQY,.'S'-U%]DJ6M7%T5GWF'KW
M5%4]I)Y57,:D",Q!G+W89A*#\0TRS.!55^8/5,S=](/,#HGF89W]Q<'T'0WD
M%KMN,4_ZDD:B*-]SRUUB QN1#RPE6Z,KQS+>OKH($P2ANJ+7)V:>[^O6VZ>6
MA1]XQ?_<V_*UW2P^\EHF.X(4 4Z\7K+D6/8_$2]9_H "7;(U^;D[@[\D!(^<
MN^T]<O>/\^%GGZ@@00SP"/&G;_LH\FX 66\OPSS+$3.9]_F:1S4I2?TI8?>H
M03J[WMC\]M9\[ZSYDJM%^/+^8TZ=\3(,,P/F T\]@!P>K)%]4K2$;/1L@(Q$
M:G[>X,X'(GNQ,J2V,<L\[0/0_LL$;QV\925QZ)[\9]L]XR$RC!KL;_/8^=4_
MK&R/+"W7,N11ULI PBGM!!WD;SSH0XCG->JF%M9_B1.EN*(ZJK3=M[YC:8?S
M(-V WFLDP*Z:1I0+'#W)-I7[_P"=V =]%TUVQ #/J0U=7PRR?\X+X[#RI6LZ
M[K\]+4HP4/GKB_D>DS>.!(W9/5F!;W8.N)\R],H:?K8WDSM3X2L=]*\J<C,E
M"H;(/X)E&!?HS.WQ796SPK1U6U.W)6P^>?;VYL<G,CI5@]5VI)E[_/''B:>/
M=E_'J/UHG(T#66R6-OX<JOF(* ,T#HW ;82=(:PHL"VWN%YHU+%5)'>COO>
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MBN;:5)>,*)3GVPV#WK[8,0=I%FIK@S+,]W@>%XN\Q<Y(99AR1MO06Z#- (V
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MX(<2Q*^A@Y(3(>-6H-F-^4<<6LP$;V1"J-$AP_R*ZJ8=(1H-ZE:Z1B+*K;F
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M*P&2#,,EBX]!?A)G:EQW#K">OCD8T&[]C;8-Q*7"<F#C'^!P<AD9,03?)4X
MRM^6O^3(, I&IT46\XGSBZ]BSIJ9IZ].M>R:LW&U/]W0'-JRO:"%2(0 $S'G
M\O9A@$*$;(H$Z0E^$UZI0-#_1=N;AC5U_NVBJ1,B0A $%(141;%%2%60RA25
M*B+%J)1!$%)%A!!#JH $"5D*0AC$5*U0H1*12840&4($ @'"4$5%F2)!R.3$
M)"L*84E6PE[\S_ETWGVNZYR]]_N!*Q^ E>=Y?M-]K^<W3*^/PJ%C-5OX'@^A
M2W.JD]"QAX[7L\L\[3X4QG,@SQ9Q$J_CA=$Z-O9T[F_!BM*W@4%$_!]M3\]Q
MZXL7+^&2[9$S1GR6OD!:W&S+T^1K<53L/FBI.M@K+#Y>EH3UZ*=\A$XI"QVR
MW4,\"(P6S]""B5"0DU6;'QSB<9PE4S4]HJ;)%?NJ\OU>\_W8WN3R,3%N0@"[
MV6IU$?EYK=-<!93(ET1,:ZE^VDLLD* A(2P+LU@1!46HSR!?[^3N2ENM#._)
M_L^-S$71-/+7V(SF9<K15"E>[-12L*M1VS\8C1;B#*-VAUH]4=ZMRY<13*,N
MFAD%CI":-_*5%[FV)]W9%\;O*CB.<#[B0\;F5$LU!R,Y+%<SM1>,15C'V054
M*E#;<QTF2@6I$@/M5IH#1%2:N'HJ.":?"DS YMLZ[1*#R#Q51EB,'&<H(8I/
M7CCIQ1:_&=*MO#%M;[6M,"#G@,?3!=1_;=/RN5DCX/R-"1!]:T!V(\5PG=+=
M-VG?"O1PX5DN$^DT7?7/-.L^5Y_$$O;S9#U)AF!=L79D(,Z[//"=Z1<-HR6/
M<'FR-K<^M7(R]&O["ETCB=\-@F89':,=P-2@.UAKA-)I9.E "R6#;O^$V]#,
M WG"!102&M&T</F>R8HP(TFH1R$4TQZ44V;'_N<7K[@_<M@F_#.N+S-C"!\2
MD9.>9OZ:HC78 @UC,]C3 IEEOIPY&>+^R,ZP9&3P*JOFX^1'@T?BF#W99_X6
M+I_B&VV_LORMS_H;04[#N^B?[XK^T_WV$Z*CR[HU3-HNM2Y=R*H13 [?^S38
M<*1*AF8TF)8H[3^L+ IF&M)"E':I=3SE+H+@;KQ7C*,DRWY6CV3L6N-X/2.\
M>,S02^7F/.B@;LO\<3##ON6"U@D,2'6WICIUL-"T^$*B=AN(O\YW8D,>':/F
M _=WC>4MH-)HGJ5OQ\P_9#_8O][<V\W;AU]?\\0O-F;MBZK7CX7?$*5))@"M
M];BE"RCI'4)MB&#*34801RB =A:&.(_)YF\ARL9J.<LAK.Q#B0RS?K_J11&5
M]POCB-(I?7;,X8;IC4?BD$!(L"^98!1YZ2+;D3&TIO:69OUKK^(I>OYWBY>@
M[Q=07\((U2+-W4O ^#V(26"S0 H.+BQ3F2W>IG1AYNO=K0/>L6 KP@)JJZ/:
M#A@2E6D?H=-GYQ?'*'Q=0#TS!TX!:D/7\PNH\EOR X>A]V/:O?2=]-<8,+1G
MF"F+_[];V!VAZ!-92S&JI/X%U&(/.ZG/B]$RJ25]0FX(>G9H\+(MK*PMS/8;
M5/GPD9 +/_/)%7>WPE 2>W+DW+5!I],ZQL 1A'-RKH\Z:?[&G>H1\U3I$-F4
MX<34KJ:MAE*59JU*:DZ;XC<0+O@>[+P2_Y#XL((XR!.37WPNB#ZU+X:LK_GG
M9E>]OWQG//JK5%,C>'].@@03L3<"6#7NVI=<S5N@-1SW?JT$/ JH'='76//I
M46L/\-:[3'#>Z7RI4KL K6]Q:V>80P%R9J8@$I\F06OMZ8/SHG8$S.-JNMH(
MJ4$KN%*"'I;Q'ARX.UBF(&3DQCO/9<UFQ#82#!'P3<\J@BXY#O)#'A3G6=Z*
M5"FC0JU[:5F=!- 7"[E8' ,'NJ:^(ZM=:$<@ 'PT:O&"KA#2K319KB[G2\2?
MC(;T9$DXABM)!IC1PAE"9[]T\C['I]PUR_R3O=F^_O7<[#L_8Z!=$A4>2E(R
M5(\U]P5$O"4UQENYNU"]'4++IAC"O^.R@ETF*/KP7JCG$=3I@K,@JN8VCN(,
M(YO-(:(\&WM(<'VW>:12?Z2?LN)>7BS"\8J2K(L'ON5-(=%%<!3W)P;:I -O
M8,OQPX B@B$(XPSC6IKUP(!.CGGP.(+;=)MM8=?D!=0^$&#&:8Q_Y0]0:&8*
MK.[$I=)'H^N4:46E8[S<(%/V_?&R?4K3AQ;0):P!E'@LUXL9J+V.DQ82+/D4
M]4^((7(I4VM L9T!!0.O@]8K]>38%#EB@IT/9=]<]\FRETP?[_,-[&-3:H?S
M1US?MB5_$%NH]VQA7F"WG_F,^;C8@?U7T"D5")^&]MPZ/$ W/^$ILS.GB 4J
M)VC4H4<O,'@LPEMI<ZT8\E1@+=^^Z5C[2OPVE,KLW$5E=I@=F0A?/=?\_9.Z
M)P</W/R@4+]";/$9\.P'@10)+:HHS'K<K&'_#Z53UJ./YF&!]+MO"#U=H4"<
M9(@@2@+]R()WXV"']\RV1"QT# /V$,"K0-MC,(TCPSMI31DP%@-Y 3P<E^8G
MI_ F$0>>< \XFX YK;;7>+Q0X\5A:MR4S=24FDI#;#\YAOZ2;J,IP462"4>Y
M8!TS@2A#XAHU3*A2B49W0EF*NT$63V=P2ZF[?!H;'W/Y(L=ML9K]\R<XE(K8
M%S8'^QQ#*/Y-M7T.PP_[OID@,60;[N.6!=3<699Z]O:7>-A2IISNE)@***S+
MF&JKU/@X;"K=F+855-6'R=[7_Q0TCC.E.T&WCJ5]UGYP&R/O.B"S6]J2=S'W
M_$4KGSV5LZ\IUCNB O:'Y;W"<UCE&M3,OP*I% /92^"UC*[1[;T":1ZN>H29
MS$??\[$^3%L.-H@46[FRK,0.VS*;=D(6:^T43N:WC_-KM1[;?1"G2W6S+TK;
MGW>VA$**=_% W,IR&#F#ST#K;NT6R'.Q:];?VA?^])V@N^#\NVZ*0I":AV_S
M">XPW;WSA&>%DQ"?!:RRVP01DCA#GLMX3C^QT%#S2Y':[TQ#GYV=?>T=LH"'
M?0.H]B,H9M5BRHHN<)9RM<'T5O$G .UJ6SP$I?CWG?N^AJ_\R,3XU# ["6M<
M/1W.']A=(L>:3?R$?S@Z&A(NNU(QT^A7USLSXOY,E+G8-%?;;K42^4RG=R&Z
M$<Y9;\\,2U)0T-U)H*+3O/GON!W@1WD=8P.O>8ERI/@/5_.KA"'GYF&?*+>=
MGWN_^H.E)7*, ?]#UPE^<EA.\%<7U1A]1,#ANPC>E*O^A6S5B?27&#1 G+Y\
MJ>E#D12'.?&V?"ROW505N@T$,F++TZJ4F&0^H70X)%181KTE;/CK0M#H 4I\
MPJG$Z,&\3F;2@T]Y.?D/1A90[A(P$(#V4/9JTIIWD 35-I,9(.< M(!2>T/1
M)$N+3JVU,J2S"M<F8="Q U-3'_KX:\B(NJTZ^0;*EU.R?P\>WB*:R=[<;F76
MQ\<!,0:I6ZL>46_JQW@@)K(?)\T$0"_T8I;?9KH)[7<HO%S;=YS^RCF@0[".
M&M8U.'] (#0&)1X@.F/FQ:IIH7;KDU[^M!5U=+K=B,HYDM)6QXL7V1;^?1J\
MG3:\PFGG2O>CFFLXZ3 K#5<M@-=N)0POH+J 6EX&CH@QZJJ@'8*NE$ N78)5
MM=FFXWT*SW:?(Z0Q]VVCU)HCRLK"L$>AD:0*ZB.%3V\Q^*N1A]PNP$OI6%!U
M"I!U!WX>_E!=79,X=0]S[:.J!S&+%JWUF HA_+"M&D=5M#2;%WB[A>)6M:IW
MTHS J;<Y3D=]**9_:]="O-)QPMK-O(13I.&_@[L'IZPCS4F-)+V_O\\W4X4A
M#WJP@(KF#/$4LV6+@^Q_9+8$KZ>YG6(3&S#M2?M%LHM-8)@J&3IE*=]OK;1;
M0%VQ?\<%YS*WDZ=*&0&WA']  6T-:67AVW.#=C=N<KM]=0'UEM'.1 +>26@W
M%MTQ+<9+S=H*RUYL:;Y'MZ:=AN*EI\+.ZSV_M8]*P\O=M@?[& ^_O'E@=Y=G
M<GCX"B<]+9T QC&F$M0H^AOZSYJ_7(^I;>"(Q3Y>61)TK"!S=#74Q*'AJD38
MVCXIJ5NP?!QQ+I,45[+[+;(LA.ZV.13Q3XS=3**LB>!?\"\U)8#EJW8UNW2L
M((A(N#,2VZQ.@#6H!=3!Z=74W'U*5AKLID"O&J^[-)T*!Q2.N6\!1^O+#MOT
MS=[5"7G,&W!(\N_\'977<ZSO,WO:K@2E^_T=S%)';;2@U@9F2^X!0W/TYZSY
MJ[ -YS-:NW(J,?X!T/KCXES!OM&W+^(<@&JGE@GKG 1SSV ?IY8\][MEP[8[
MK#TB3I'(1,JZ;Z=YR=O^7+Y7!_RFW@\\&YG7T;#B)Q<O\/!MEZPJT7TS2S4_
M/+B?^>K_2V\P]-<WB#!?X=Z] TX#ZDT8(]RL:Q])O0<Q\R $]^S$2?]!8L%I
M7+6-MF9.*%[,A/M_MD;]EJA:;)I3#9QC#G5+=5HD0Q-M"ZB:^,D7E1!)BFN=
M3@-6T%S8$T^5OTXT=*:"@M8@FV2'[( @9X!9,?.U/,J<SJ#$/]"DO>SMF;KE
MHR)%;APRBH@M'9X4[,7U;1+\C3 F"@&TOX- V")SI\SPOIX,V$OM"6^N@XBD
M/TZ15,K=^23YB.^)IK[[B0D?\=60N:3#GY?[9U.>AT%Q74TH4-85!L!J$@ND
MBN"UOD&9^KM:636,R2O%4;Q>QW]B0J  !3XS^EW>%+TGLL$OE=<98K+B7N[.
MS7MY.\;_Q&_]-[1S;P?AG5N % N;V6@-=*$)J<"(=@+T; ]FKAC3W\),@^.5
M>BUB5BLPE"7]F ;OSQ&).SY>+7SR>K)BMI%]6'*XSWJ U:;2[H:NR$WJP,F@
M%P,CU\Q_'2PNSJMNDL H7 D+V@5X*NV8B]?(5P?BUCGJ :LG@,4;0HR00$RX
M^>S+-!["@<D][>9I^>2-:_B4[_MBA]F'1W>9# SFS"?BK>=='P\#3CC0%Y,Y
M:@"M0; ,$M$4C':7\FX,BF:NJ1><P6>.[FGNJ[ 9<-3#Z=!<N9"Q?-HX)' L
MI["2:]&=9.;9E"=N&_IU[M;]X+;5-[=Q9O[0I"R@P@AIA,=FDR5@ENHWZ.C6
M!O"CT&Y%8!Q^C<1C;5!7-AS!EIR<:'94-G/?YW;,9;AZ/8@R>S5TIXSQ2V^^
M#ZAB;1H+.G!U!Y W#9L,2R%-(2!%6'^6!)7=/[A9P9@BJAUAC%/=]*J30>@,
MNCF$E0JX>^>L@XL'%U##H>?P>PS+[]\YM+>_.._H-$=2-JXS:7--(.6SP)-X
M:-MBN3I"DI;=TUR'?:2LR\V6_9P9]N9.%4%GLGD[M7E,[GE]J[*L'6,I3 )]
MO91K55/D<J$T9.G!AN97[VY/5B*@QFSH8-[5T36@2&N $,UD'@+,-LSTI$I
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M3&$0HXN9WAN$)Y+V2"+*QIVZ'T8-1M[HT)\)4 1>]C8HSMVU@-K 6@%([PC
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M 97K[#FU M'<0SW0SX"BIXLB+I=9-2E7=+5A:CE3F^5V9SM']1(YYMXR C/
M?>< ;:,R438SNJV^K\+1+>JKT.KG7KY/F=<CP@G[JJ+QALJ_Q:6W'H;:EYW2
MC-&?(\\].8W@I*F@!C^6D#FL(RM+@_T>3:;AEL!A#7S(3M[>'^3PY]CN08D1
MF^]20II/KL@TI.(#E/HEW14/(^(OO#JRV7LT^@LI.#A:P/23?%FJ9&AU$4/6
MV0TQ5,6:>ZX[U&;:4<$JVBXP11%_C3M&6R[%9KBOK%;J,%QW5<(^:?-)SB(9
MKQW-*/BA:="1N93:&,A/41L?Z:^8[6YR.:I,Z;AWDDH1;OTR)%(OCS_TNOC&
M[34F=T?>_+AIV_;GS]N7^Z%R3N]%&1U93E^K?44 ]V+>4%0/-753 FEAZ/=*
M9J=@%7RT8<!]'31]I*]9'^(@U#J5_]T#J$_V444>O*(T??<4_-ANKGI8&;68
M$CO^6=O3/GA1]"708NSFN'SV8P@%^KE<5:IT6IP]O.R>IA#VDI*/3^Q72CIR
MP"XD?,C(T<_DWMXOMM!_B#HK[(S/"?C)>_E(9;%@]:3K>=,;26$.\9>B.79I
M)7KH*N[Q!OR=T6'WB7EX+QS]WU1\\26Z1GT)>>X(9C5MI\2<3U+CJ-W'H,2R
M,3NY)5XH$E1_;,OVJH@E.^^A..HU 6WN*_JFFNTC_^P@)JYMN"^QW"UOZSN<
MF&;J'<Y^82T HV(%X!%@"#FP3J98I&)I2@5G>E(%M;GIK@GQ8)DLC:%L5##:
M,-]!DA9 +Q:O'YF7(Y"S5G^B.RGMF95$ *SF]AB'0O0%5#"O;M/70^"AOG/1
MBMI^QVY2SZ2WUNHV<K"(JA=?H[?AH%R@9@[!@#_^E3_P3#1D4S<*,/+&==YY
MPFOBM098B+S8TT49(IB4*-6ME] M&+'8VZ)1H#=VR:H(P G1V;K%Q"_CYK#[
M$N>9N:"Y5%I(L5@\;OX7PE&Y4[[M3F;F^M?$E=ER=E0PF7#D-0)3@Q90]A0(
MJ^6J?X+1B$@*:;L6040^R\I]!;7Z8^<\<%7K0D+65)/;+EE"G=X/VDQ92/'K
M1Q90420G'1DKW=$"BSY)?3GL W*R'%WT,K9'<R6&H]3&H-N5&/_ZN 74K\PK
M$N,*]]TT$PBGS#]\A5PKR +TFC'PD3[R3?P>\J1KHLS-IL/_C^V"+P.G>0-A
MV6>T/Q4V]F6-."6>4]]S.\BW5?VMR6]>0Q>QEKIOI+_$63GH>W=@=)NW$1OH
MN0I]O4-*?";-[ %AF.C\(5<>\M,^.7;%A+E9NIWI\,G7L=V-68&.)GVSB:2$
M6O+%GM]>Q>GCO?ES03^VP-\62W*!UIU . O:2KA*WTK=K#KY&CY5$DDPX1/#
M%( 1)]O5UR:+(VOJ<W AZ_CTUKXX+'_6JW(S:%L9/6W'YNIR+=H% ]P]01II
MGEXBI8K^(RT0"@==6JRV0@^565T%)A 1_-C:<$[,RX")"K>HKGV@EAFVY.:9
MAG[LA[3-#CUU>BX_7\O-G;O@$1Y&.1_O^I, +_<4A8&?FVQ2955/E#LC&XJ@
MBQ+?V]*^")%_Y\7>C?TVV=8W+=;'?1>=>Z'X@NL?#M<?3"YA??UW,6=)A(:V
M"]JQWW5QH(^J3LA/?13BM:E*YWZ%8N0]3()EG/II]&IC31$>1."F/?7';N'1
M\>,]V]*&9M4]R\=XACXQCJ-EI\?K1#N',ZL#-+B>/]S/+1[2 BIZD9 @D?1]
M,$<<( U@S-IB4B\1ICP4''&BOVB2C'5(KR6D6"WKCRX$7S;)T]_SOB[BB)-C
M,CLSO]Z(=)_S<JS%"/%+[47YYR_HF7><KXL7B*N!UD#7]8@)#$)]-K Q7O5$
M\R=LK':"\CMPQN?<-U!%BN:LLHD\G?9&7(8@*LE6"-)?*R%>D%(/8@BKQ\45
MCS^-_@#6L1'/MI+JY"W:W%]+T>V6Y:M'SF)F'$OT@ND-_YD*^;\T]2R!UTG(
M'#6$C,$L.;.S)]TLNPRRD)D)I]?!WLK4\82S"'Z%,,)Y1H9C&<^K.&U/]'56
MZ<NZQPX//[YU.)JV6B[HGE9M@2R5!*W!=F2W?*BO"U-KU23WQC/,LS_4*YF*
M R]O/VCLEF*2K2P'[&I92V@FH(FFXTEMG_MK^Q)9#^H33^\<+V?^E-+F^OO:
M@;@LRT,$X \D6&/;O24,#'B0,FSZU?L)B1S0T4!IXS N5FZ^W>N-W4 C07&%
M4,&H?UIDT)9ZD-R5+KU^\&SZ6Z_5,1ZNQUVQT&)163#-I8],MZ"/XDQ#;1/B
MDF*Z,,N:+8>?/S/_W.4#5J8HIHU&#^BM6[J/\FB$^JSULY_]R1"O(O'ZW].'
MA-:O[<X4?05$W<JE:CO(#O20H2<_@L-"@HYV.>P,LMH$::'H&M-0*Y"2XI"?
MM-FSZIJLK/[FSV8O!0/8#R/QY23GOT27FJN2K,5I#Y,2$EU%Z/'88_XZ2BX2
M/W% *P+%X0.0L8( ;1-,3DF3L&T8"ZUAIZNWVN.3UJ3O][Y)^D_PSAR2BQNE
MJZ&.=6YCC94K1%I/,(PJV)AIFR@PI&[%&>G3R0%'7[ON?GP)#YL3$>=IK+29
MVJS&4N=43E Y9P0!+YH;(N$MVJX!QQ]<AS7!4IU,NNC4?2KM+69G8B=T0NYF
M_W'?=?F4PK1@K1)[I=9EV4U]<U^S6:PR13:8JP1D-AW8JPURCZT92D^9*%MK
M25KS]F#U\-,2:%CHS$KC+BNPN7XFQ[2V_\.),&I)P/YGKY]LP7_+0TRI5&*(
MY5LB2XI^Y>I(=NN_*#%9I/G9[LO[3U]9(WW"ZYV<P62\8G_^)M_A83DM;"1N
MRMOV^:R9[3*KPZVN<X;"7B\.MT@M6JS"K=3\@QAF'0;$$\0L%>N6:@_DJ?3M
M, -J-UQB,&M3I,!:&E:)D L]$F8U.2YQVOR3,FK4^E6LYL<0WX/5KQS+Z[>?
M;DSX4-<[77K%^OKH0<*@^0+*@0#]:'\'!QN5:0V\P=RI/25"S15PKG,!M4YK
M0A]D.PL=B(E25J;XGU%S3?$F(OG4OBV=]7(7PK4VSV3;C-,I@=S$!QP;XH&N
M^4"WV;\N^CST2HC*NQ#$_2II:O<^D^.]Y@FILR'"T.Y1R^H7?YQ9L_+*G\VM
M#?\$Q^-C6^"KFD?(EAH1C/;K NI-HV(Z0W!V<>*S15R//BT$/$-?!YA$YN&$
MF/10V[Y:4R4]I81:] OCF AVD6D\#J;)*>B)2T?*8]##YMZVP9_,/_WR_@;P
M^ZD\V_3[!;IA!;H*K\(\LQ.;\GY8ZWJA8Y.IU^8;ZYR==P0<7^^U#-GZ>M:P
M=P=@B#@]+%/"BY^:*":*\CA"%A292-)$^*E=9;0=,GQ6Z"9EW6T0?X3_Y_Y-
MF2Z 'F30)ZRRR,W\( \^]+<U4Y7&U/@@N\@6U,8L=EKZ%?>F6['E_:33O&:Z
ME6W<TOQ3?7:WMU,V?<W;4?@'9<C[M[_2NA/9OL%@^(?'X!._'>,[?"@-O:0$
MRX,^=<V1!M.JS_^IN>A"3L6G"2T3I0,D0GI>[I7M]!_'1[]_S4<;9$L74,:0
MZ/B@/6P742HA?<G&MC5$/TRBA)5Z5(S9Q@&NND3+SI+PZ-Z,RD+/F6D(<>Z7
MR]56@##^)&GT^VI-?D]K#T0@R;.F=:AY?2% :L_]!52;)UEN#9Z9CZ(6:B6%
MM4&E=T\WG.(WU=37%8R:>:=G ;H$\+P@@^_Y?W5J2A9K7RP.+NIA!$A(#-E[
M01ONRN'M(9Q-K[6;: FB6(XY;:_2^LLY4J#=#&;)1.A29^DO3T)VT#8_:()'
M8YU,_7%O/&$32BO=8A'P+/M#PVVVI.[ZE7$ !"X#IRGI=#VPE!F]@U(,4=HD
M!B6O9NQV?M>Y\7'OI!WY]#J,M?>1Z5'QTX1I#?WR.1H*6<Z_0*O+ HJ(OBPQ
M0SX$2VGT/AH.=)+Z<\NHB?((IG9;I-4FB%#R*6^04V9?4CQV\4^HQZ>7PQWQ
M]DN5U_7&CAB(CO;'D8\D)MEXU_+[*S=R@>>$Q=**80'H]6)IAXYP_CB]K]FI
M]\# R!-E5YJ[_IAI@=F.X <_2?3PZR'D -T=U';?7,B&T-[0HB64BDG1:N Z
M&MK(@(WS.S"@'^OZ(L*B7-=NAOI:)=785N3\:LTZW7:UY?J#)TE66_O-?$!L
MV@Q9OW)JVD&-64<M?6G;Z$)8,YYW\5$!!D0@W6#OE._1_E6A ,T, *,!>,VS
MCS($]^GUJ9S D;O%#8E!78I@_ 88CS$F4[1/5=39-ZX)YQ4NV>39E1%Z#^RR
M^WGN%CE3M$;V"@4^8;NES=;:NKL$PH36XE_WYQH&HL8EA*IX>*UOVSPO Q>.
MSG;&MNOUZ'M$.%WCHX'P1U1?.2YY\%N>"Y'F)06,3HPUO#,_-[?F1011;JN7
MY-DVG_W6S'3^+"_1VBA572WH7BKC"3F60.M:Y,ER+(.U#)%V3>@B,=JB/@S;
M0,0590^[5'H<C+8'J.6'KAXIHEZQRY%X#7+)+JVX-79L+/8>-\L3LP:V,:T/
M+R/>&LL9O(CYM'CI:J6IJB6\,59M6:P^)NF'/A,%-$(!TIS\5BV&GW.(3?-6
M6K3/%[ 06V%881I)?XB\2\?INT4S/\<]G-I\4R[TT/;U^^T^\>^S_LJ[,Z0_
M]@B&4[2K&&H#1.(N#FSG"=4CZ.,]R*;]TFQ65.@ZB%PDC@K= 17*26M<ZQX^
M(!8L!SLJ2]C!D=4C^V*(F(RX?V.9JY.JQ?+7L\7U:8=RO^@=0GSQ$YSTECBG
MT>!& EE]]),Y+7N5(#,.2,G;(#9Y<OMSCF>>9!^4P8;NY R193?/ZS B+GI/
M'(O.-=HR?F(!Y20!?T&XJR1#(*T':H$NUG",ZIMR^KIK#)C?UNQ:R^RJ[JH(
M(19L@L:4P8%]BD'TY=^5IBQ7LX)5(.8*#6O#R ^L 9\1X_/H5RJHWFT%*UE[
MN2<<]8W5NY4,V-!,JZNCP#!NP4ZYJHU0@.S%GMK$[$U=[5KTK?9F2XA14OOX
M@$DS6X<Y.2N!#CM:GNX,IMJS/_,]'DR<QSL?SKO-U92HBDA4CLVCZA"L8%9S
M\?<DM7H'?1#1<L)4/C@JD4LF&Y6W6H'U_*6.;6_>CFN-F_\>_72I*-@C09,A
M[]$?OS@?G^EJ(5]>\X37>$NHW?ZZEAQE&YQNO^7QH;,9DCKHO;((@7P(Y(B7
M!W0Q,\4E@QF@2&:3$M=C!2D"JGMG]:.G?4 18WM)OV-P-WGS85Y#/W?]/6[J
MR/9)<EG]W<N'BLY^'_"M$JKL4@3 %HN]OK)>UPI60A_;1W=J\OAAZ*NP[\,3
MA!UU3(739+U"G_);KZ.=3<=\*&MMWF\"([K9^#PEDSQC%]WY<GU ^^B&*J5)
MZ9U2*+[3;'3=$^UG@90CKLRO1%3&&J#XQ!QLXO779D>H]D*<1V-!V<7)P<$:
MIV/@@??OLZ=JR[\\I<21''R%W\L4-P+_(#YT<2EW['NGPX(P6CT.X@)?0E?4
M.VFA&HX#X?I<#F$9?16UR!/$9L4)C*@ZG<WK!V>QEA#3*_\$^#&9OUX60CI0
M(X+#Y#X7.D<3*BIB72R*T_1(4Q['"KH.]SEZJ[$%@C,+*&A/C%8W2QU"(X%E
M+=B5I 64.=V*MA=*E;-WM>(,-D$/P4IO?8NN@A\'IV\=>54;8N$'[A8H/LTT
MLJ.^!))G/BAC0]<G!V=(N3<C*S]DKM B $;*6"PP!A"C;@UH=O=1_P3UR($L
MOH[Z1_A[QE%-H;O]$.0?_%L_UXUP##" T#Z]L .O+K?!1Y#-]R&MO43/E^,,
MB>(!5JKKGE)JY?2O?3;\?OM839BZ5I,'2(=[(!NGR5MJ/,U,\ZA9;P@^5:TL
M:_6>BO%[#6/E$DP0U-7J/%KS"(HX :I8G/'!(!8C]P0C".P7"U2#C-VYE2>(
MKZ)R_&^])<8;'5A[8UN]2R2[YNOPS#?*N\L:<TTM("W"5>7"QA_;YN,S$(J[
M@+KNOAXZ.S_IM(L:T+;?$M\N,.2'UE6$Y>'UJ6BA:1 OT]%B7>7NH!&2IP]C
M;]_G\$P[O%_USA]P&4*MP102?'Q9:W9G:*ZH [,=?KPA_PHR6B7@]2K2Q]H?
MZX3R>N79=SR__C>\U &?:QGFN\;W^[CA_D9(CI4N\J]UBYU 64;-%MJW"R@C
MK.L>L.^XIE#[,\VYE^;LNL_^RM8RQ(5=%A7L>-V\%EX&?DP_2Z+"3C;I4S#V
M5-BCT+&G)0@8'L"Z'M):F5.R8;_2MP<T+Q<;25@C3_?PD6T%?;6MN*4KK@W*
MWXQVE%&3T:;IG04.K[H5D",$7\S%G%WB<;'9VLSG080_\?HC'YGQ7US_PRH1
MG26:_<,]97%4CK1X 57E":_=O+<_CC.$4PA2M5L(D;O_D%#+6G<*'T$!<L^K
M4V?K=WO%(TY>:UOUFN\77M($[O:?AR^%=S$HGR]6YI>/;K_ARO*% Q=0-X.5
MMMIV]'I@W.5A 'CG'M"Z'"<ME(!X";3=)MG="6C=PU\JQZ[3/L.AM9L@O<Z<
MT)U*7(<DS<JXD24C9%:2?>6B%HGA,&ETUVN:KQSZ_34.V6:[\U7Z^OK@%_8$
M=!1/9,MY%.HT%Z$,TWI1VCEJ0]?P!=2#SR6_Y2>6.^A\JP=:[Q<X@ ""]K9%
M3-DJ!.E6/X#3R:[&,BQD(^E@)W:X8Y71-674>*'[AM<.TTR@QJ1#RZDDY7$[
M2N^4$.O^V.P=DY@8LYR_XR'1^M@+X,AB?I)T0@)9\X18L[>0[UXENHN5?7$P
MZ.98;NA/D#>8HP,F.S_=[A1_420P@D^ (K^!V.'UIS=.SY MCO'Z-U,K:YT&
MR-;!*5I  A[N>0/(=>"U!%4'Z#EY2RHQ'V>A71V5%MX#6.U.2'#$S.RG,<Q*
M5Y.84FH?X>8"ZF#F>.]PNY$/YU.H:8K0^<B#Z1*@+<[FZJSMZR7$[@22]A;&
M )"^[8$VBX22--4"RL >=\9'1VZX>T?0A)4+E*W 6$T 1H[J8K\37!)S[5B!
M]:MAX9SHU_M>OX..N5=GT@,?5_5.;3[K\4\"NX0W M<N_81[XZ+5TU=_![1Z
M4NSA/6I'6F3:5WEH?FE/111+AY]X?]Q]*<0BE03OU&LZ(MPW>.,</Z#T3<;O
M9/PQ\"!;3M+__N3P5G9,V';EP054\?R'LK)/#?:<BO$7-8=[8YL\?/LE3TG9
M#4FIQ:( MBHV($$U?."'+\<L2SH[_+=_MX#Z40#9XB>O)"&JODB[2^"=2O1D
MF;QG[0EJ4#<>Q$XY@4;JX/[1K\%@^P]R@>&GH(_"NY2@R\$OY/KV??Y@:57)
M28M/KAI"2_.FJM[9CP.59_NGL8)^3(?[UCX^$=1II^_HU=M]2]Z3(A9DU%9/
M6>SIXTXO?QN5<R#/YN;6,'+\FK,9HSLO'!LZM%4^W)#(F9@?>XRYBWF,@4WR
MM;IWU53::27":-_TM./$DK6+EGT"NL$)!MIN*/%"<L&27E=?J61U%$+2HR<*
MS%[;V:L@1J>5*5.]U:7>WN:K^YO_P=E[AS6516^CL2)2I2H(&45$1<B,4AS
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M;D:LXWEU&S4W51ZA@T,B/XS)DFYQ%.="$1UHV*0FJUP: AI+;V6F! G9=S[
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M6Z]E? _Z\S=P1*ZXFO-'X2#0HM5($/@JB"V80W(+ZI8AR\B):X(VOME(+.N
M=!=4PAF[F1ZL"VR0WJKY;R^J80*KM,?2Q;'-;^N'\"BWS\/<HP-VO@+G2&?
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M&L5R-:97-C%.&FZ'#3V1DQ[_5<"T\@3T5HTI22H@-1,F43EK>0$B(#U^RB7
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M;Z@]A/S[T]V]+9VQD;'G/J=W.+[^%=&J/ZD\!32=(HC^5F.&HEH #+*8>GB
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M9+E%RG3#KN9 HVYXK>@/VUFY37*]4=3E%ZQ;Y2C83-3&)T3\J^D%J?TYH@H
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M02HV-Y@%6=1,SIPKH'72V6V98*+$/OW9ZX$B*$H\Q#49S3>!AL6=)*79K.<
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MM]$K<>VL9&]?=G\2,U8\OE?[97>,3F[N/N)QL_7L#TZ[Y)N:'3(?Q<0%Z6;
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M4BBG8U-;L.5S\^E15$VB@<K*88&F%E'32I3WWP!>S<(&SHI]_0B>HI2J,>W
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MQNKK\%YE[.A5->:EQ<0&BS0G;Y#D*4]*Q[;B4GVO/GH^Y(]\,-O2,Y/K!F\
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M-J K7,#SL4)4M1O4Z\AY"KL$H[K[EF?KM22DU)%U'+#KKO7I=Y5OXR^#OJ8
ML>?]A2Q#^:?1G7-7B+;G9J\%UOFPQCM1Q;! B6K6)6,49TW=BA34&2()X3AH
M:W)F57%##]ZX4^XN#:Y1/'K]V-8FA8ZK/U".,F]RLD<%N_^6):IFD[-Q*X^G
M!7Z7>.R6-LV?%\3Y^_N6%X2I_@4T!1,^KQ:")P"E'?8.?3XEW& .7>$E^<@[
M$OB4(,K1DEZH*8I/;R.Q:UJX*ZDN]KO:/Y-J>.1%[@1>5W(.]=M)?Y\&Q3TI
MV2C,^C.LQ!J[QIA<V]6B-1;[CRFZ'I8'YE UBR%DR:"=:2/#Y011D7?D(JN8
M1817G^OMK?1,4B*GZ(K"K"]+BW\^?]<D=?ND>;[YKP_V,>O^7?;AD+>2H]E_
M^O]FR<Y>/HY;-H=<Q/[8ADX."EKOVG-<50^Q'V/5F&,XG8AY3<6?UVR=(0)D
MKLIC,UO^=:"4U@=H1:N.FJ^W^OSPNE9+I)?CM0KM7\H+B\\&W%B*CRQSW;,(
M]Z40T6E78RS-PG"*$X0@H6H'U8HU&8OHE"K70KF:\CX)P9HB25HT7-BI","
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MD]W1]:FP ])CD6U]KDG3D5Y87>S$Y#E)0WFRK2%BG?7^?:1_>YPXS^AL0^W
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M/L1^[GMB/V=(;"YF<OXZS:PTF/Q\#L<Q3PVI:+?!4+4D-G^U2;Q45DEV58B
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M9E=O'@J0>H<^+,16UQQ>*R=&&[6;'OYR@NP_\OP9Q7(3!H2D:YG8.!JA?7I
MK;?6C9:UKM^OE*%@M=PK*,^-HB7Q;'?K=.J>#)9A5"FEH0;Y]G;A=3V<-;EA
MF0[S<9)SM'=H'?PU1FU";N$+O[6G_^<<-0WJ=C2$7 3M+/_5(+47':PR(E\3
MZ?_G.6I#,LQY@#R\,$?M$^#C'OA5?01M^]QZVOXK ,'#PJH)B.*8-)'%>^RI
MA\*VE2RH\A=?D6:[.Q2TSSC&>BJW&5FY/H(F?^HP=&,?"!<XLL>J7-CME/#C
M[0'Q'>R?1,;W!$3%L;$,3O\P)^M+0?8(1_=9 J3NC993$E!SP J/\LU*[$T6
M+P-9WH$H>^0W=17'6G+O$C1+0E[Z)BX$2&+WH@KLGAJP69$:Z!EV_4.157OA
MX=*C=M>D<_\J:9]U$/D;J-4:6C/N>4@=?172AM- OO=CE(0T LM&U3BSO^IU
MPT9D'OD6VK'#CN<NEUTGQ4R3EFXI$H39UGEN;],]$*;@*7*,#IS.-Y9N$JUY
MP-^#K[MJ0<C-DF'LM0W;6/RM8%DTU53,?(Y&T(8O]=XO(=\3,PK0;/CVFN'\
M).8I9#&]2)K1,F4%60VDDE+4)L98-B;Q[4O@'J!F Y$WZ A=*9O8+61RS!'-
M601M?N MK*56CJ CLI8+'<6!3UA% %\'N@&RT>TC :A%\Z7 %-CV$U"1MHHK
M,9!H2=;T3N#ZB8%(3[C$<CR$VY&B<C3>?0G\&:@YMS#L" ?.XNZ2% @F !ME
M538!=;48.L)"N48+32 6M4>2^)-C83L!:Z)U@@Z=XBJRBH+0NI![3RPB%J)2
M3M@Y0>+@1G#GHV:#V-S5Q.>T%</ "F(9H5<:"V;\!*$YD=<3>Z,K'Y]<N8_O
M.-$Z#DS(5S(LFR2 V%O\M-IS$J4&'P*A(\PSQI!)>XK]7(2LY*.YF0+862S?
MUHVT=A;8RP)1(N2;0DH"X"8 1J)^_HHZ>&)A5HT\K@X;J6WQU]L_ZW"0![".
MT"<F0BCA]Y'><]]?9?D@?9(0<3&NC^M5/:>'8%&H)VBB,!T?ZY1A3LC574=J
M_>>VH;M8-6$#U1I*DJC2WB8[LNE+*)V"%7FG)<>R,\*R*7JUG*&8&04C*ZH>
M%'&!_&Q\VD!+\M#_QR KM<^??3J66+7;L-[>4\VVVUK,RC^*^YWXO!?6*@*=
MD%4>Z"89+8UA^3I&LI1-L7UEXF<60*/[1J"A9UY#9'L#T6/SR9P$(2V!?PTF
M/^KW<]M2ED4IVM]1W(+;VV$5PA\XV^K+EYJU.G93307$\0$U!X,N*@J'%>$T
M5% J6X5DCK)*B;#*CMYZ3VR[<6;1/EZ53B.PMC($X-].58]RZ B>C+F>_3 +
MVC8ZNU-CO2]A>^=T68RZ_4;2N^ RY :+]X$L#^6]0OGF(!JRVD%3L/>V%4X0
M@$<TM22.[%3]]A(<=JP\I!_P8]ZUB$OJ+XYSXW0>+99X,D)\P_S%L12DW3N8
M'*P&;8GK%T]%K"].*<<W+9FR'3\AP2+OB* C]T:YWK@,(]D!::-=G<%/+Y).
M] 1;CMUX C4VTK96Q*POP:^'OM8Q5ZL3-HFV//IMGWQ*>DEG<0N!TWR@S61
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MYG\X+,.L?R,U8 ]B<AH-S(-WVGUB]9$Q25O6[6(&S'"?><+O8[1;^Z3'W#[
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MWP_04-MQB0RS_#(:D1!:U\*!5.8@D:<W@<NF[H-R!,/!S?0UT'$N?[)^8$7
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M*%K^:HO%W83UC$D:25>,LFT^S&C\A=&#3*U8X7UZ-(&/K]PB1N4-9Q!:U''
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MA&R0EW_,$DCG),!(@)$ (P%& HP$& DP$F DP$B D0 C 48"C 08"3 28"3
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M^]:.N:O:K32=TO6RU[2E>/]F67#4-=\LMWA4C%H#7%1PF@W@%</2P0('^!,
M$M"W::^F&T36']KA.DSI=$1)-+3E!3UB$JEXO-6/\=2CPMF/5(\S>'>-'C1S
M9)IHB9E*&;4'QY)[QLIM?3#RQEK[[YTOS7[?52 ($+C#;29*(JH8Y4FC,DL6
M[M8=&B6LA!4A!F>E3_NI+J30^L-W22?9.',+F%WY"9T6CI17\E7WV.'Z&;Z
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MS_?KJ E:]*Q2G_M(Z0O[*3$17SWC^NNYDI'[3-$#HK 8N(3KF0=\Z9#^)OX
MSY&:W1C.G>[%P=*Z7%J?5TW[?EW5$G A LD^T;W4$U#Q%7^_SF'JZ1@V(5;H
MP E[=],CM8$CJ$D_54Y<Z7P\[ZP8%<H$3V#[96!5ZG)4V$6^UE&*GR*HF8)#
M3>R0^G/#&5\Z,)R0FG794 BGT,Y!]<_:,,X8&>?'S>/L!S@$3L86^WV?GC_&
MQ"%Q^X88U4!5@A;8P*0',GH&=.Q&.4:!X0=0C9QBC2USJG4/E$+!(&>F"=^*
M8VO<V>'67AN:5H?=Y).I;?17K'MY!/MP^;49"\6H6J<$)'+>P\SX,,JZ17]9
MW&;,.]<[ 5X@ [0#H",$6!HG\-:[!T6PG(2;=O)#>"&3S2#A]]GA#CTV3],6
MI"?!:@/GQ^Q.)>0.CG4[ES!+F G:/_3F>R\OT2.GMQ/3,K4=0PG@)0MA>L!4
M*:(N.5: R+'H=RE^-H>I#.$_F&SMK'3GTA5((=44^:]^4<-O.32EB=" &&/#
M+.<M'K=<??N&BJY[Y?AT-=Q\&HF_&;S>_)S'W<,+OU-LH0 D+F"0N! F]."]
M)A^&; 37*7_3Y*NVV80IT3Q8C%_@5L;:2CM.N-N,]Y3:]J]!KLKUW6E+L/I2
M7Y>EWEDL)^;WD'8-TOQ:S5(J5 <-Y@IMQ*B(9 8+"8=;@(OT34('7DMM"Z2)
MF5P)< 2  @G_8:F@KY9[S(7ME. 'JY"H=5<7/]YD"Z9CF0HF.\>=AQXA)8>2
M;Y_C$ZF(*K1W.?UQC^6+LB)L'(, ^# @O30DH>>ILBP2R!C!82&69S YR&,;
M'SU*-H):?'C)7 )U6RDO.RHOV2RC 9:'HKB,+22B+?@E/[]:@;*G'.R*>4P\
M.+80\IKD+T995L;_7;-"9.$$SB.Y1*48]<D.8+T'^*X_&/-/&=Y]@J.P[#E$
M/0G"8%%^U0HR(*(R?-^'.?&\&AD]I@TF:J ]Y0!/>X1/B]>?CJ9L2ZY769/P
MA$1SUCW?S"'(DPUY%DBQO0D*7:@K=Y)W'7?#,, [;BUYXX[E2X@I&W @L468
M;0#+="/1>&A"C'+6XB<^1D_9-=+D3#!"+; ABQL0!QN!(;74-3[2] +2N\9,
MC59C##OQ(.8HP;9;:!J>Z^-HU>]"/#]8MV'#NFHZU7@Y5?@=$=H3&JE?64U!
MTH([491Z]=T\^_(;J8>-U!,%OY.5&%5= =A"FV]*0UM/&GM/<,Y%KJAJQ<0P
MSQ -[TW15RGO >FSW0(7H%I5C/+'05I8H9*,*\] J+ [N$4&X7T/O-Y'A0NW
MP!L@@!=6LZ<*&[X#(SNZ=",-%UVB[3M1#ROP+.J/N?S.DTHR]N*&6]<&$I4H
M"N <@+Y"-LLZF:EXO[]H63*DKR(<:(Y;!S<RMI+=P79V9\OD(QZZ&I 5$C@!
MJ\BN&?Q;T#N.K 9V\ZCZUHY@8(,WK/$5UA.>YH5$SOLINW;NW]X^KZU[JJQ5
M?^(=,9_[=3[<:&%R]L0*D6_6L]C[YA.[KNVK,#IP*>C"%M<MEHZ.9Z1?[=IX
M?%6$FR6;UB?#PB:Z<%0@ VY(#4:IO,90!1,_P:;%N:WOSF#?_:A1)%//6^_C
MW-D+GH_#QI1"#XU/ZG6=TSOFOE8VQRT6]Q +Z9;S$Z%<7CF\+H/+1 E/\0X7
M<"9PO?W\V.XJ%;)N1^E[JUF[CB @>HEVB[R:JZ9;G1 8OFOVD5:MT8^WG.V/
MZ_D1:S*R?)6<91-+<S*RSIT ,FB01N.D#!<-[6T4*J;!THF"71"=*U6'CJ85
MW4*2/4TR2510N1><=H@Q[3(YQ!3N$3TVT2*%L')K>^<-7E=M/ =<$?[.2V5<
MP_K1]=[X!64\LE+=S;N1P1(1S)$\[P0V!@F!MHA;=M<#&&P-(QI7CIE,Y,EP
M[,O'LGLA=#6MA%"#DX>*[3MHWH>-=**>D2JF;;MUV/>ZAL9EU8?XUD<_][J^
M,/#]2BTN@,B('1& JXL9X.F6VQ@0'Y"(*6F9]&015(1KH%K!(=)>$TW+W8PZ
M,2H.D O"QCE+1>M,TNJ[JO:TPSM)M/IR(XV7%3*^*L/W7I T1FH/.QHU/%H5
M$GJIXOSL[O*Q::&\-2QMR^D'((.86DPY,+7WN:_),1Y^D@LZ<=L@JDN7?D)&
MRT8R'H,B6W()&Z UW?:=/YYDSN 5H7<V7X5[V5J#'K89MA6=QJ9Z5=LZIIU=
MS;]?0(E84(O @M)"*(Z.\^(0^C#<QFK:K:&M'?Z4QEPH@HNK1Z\BZ[1B7RZ8
MTSR+.\F!+[UO*#L=_1Y'CM6\&6*I,M649YSV@="OR3\IRK\_"C<#)=,?L%0[
M'WY<V/.SY!W06Q8NUJ@L\0IG(*8[")"9J$@M>/):]+S'>@/=RU,/&RAMK6*<
MEPLA4]&=@T#U/C;R<XY(V,Q@%=! )_06DH";FH 4%'%NVZ!PD,KZ3DTTMF;1
M9 ;'X"T'!B>NR9K6&+U,X^!EA ? %!@))VMC;AFC67X!-9F.N5FD-,=NG?F5
M@7(=QQIA&20JKX&$&T6W :]F1)G6R)27U@'O@3_AMN NG=-C8*"$&HH"5,"3
MJE<*9=RYV.&GQY GE=<,:4*W.70Y$K.V2@,L3,W6>/OR[$=.H74-\M*/%JNW
MEZRG\W*[X'>I!54.50'RJ%97ZZHD</%RHR8;05KTW$2A1YW;'IXY/7=47>UK
M4,:>/N*@G7/7/#'!QL"ZO7"[8^HX?VE8ADCJS#QG>US_F_/TE), 2R*P]:F-
MC$V4-MP*XZ,@UNYM9HL-U/Y2Z [=?$;6Z-"9"CXZI33>U<@Y_(2C!4@-#O03
M52YG/VM9I?+Y?FW^V$*7_+Y!9[P"T%+V7D!B(FB>9+"ZJ7UX?C9/.SN'QMM9
MARNR:$1T0B84O2I-:CR-CV=L" H/JX8/= 8U;78[JR?:65_N?-[D<&O0WY?_
M\C&RB+L2]#:;F+&W!E8"JBMPH!DSF@':XWHM:@D8@/4D4P-*X1'X-R I#A5#
M7B.ZS[CLBD-"-8BYI9>H 2BZ"IV1_.J]XT*U004F[GN O- 22G[AD^KW>'E]
MZ-F"LT81)G9:/QR+!_URXE>(QH6K1"\8GM-]-,OWW;C+M#Y-%JVQ6=?:Y4:7
MCLE&(1[TJM/\FCZFR(JH4ZI2[@H^^OZ7'V:>8I1IUX6B=V=N5.X;<)+E!<#2
MJP5KA;_P2@!9BB&E#_.:7CT=&[!+[B,K((Y9@JZAK225_>UZ[ORX4O%XICH/
M&S\WZ'3R];NRTC^<">.I93><G [UG>T?L P#/ ("81(#=*+U!#@CF"(I0[4]
MPS-#C()VI5&%UT$/@J@ 5A\?DH/"V43ZI@GUO6D?AK"\A5C_*MEQ6/UU-_E$
M<+-37>:&3AQ[-\B()>,\N'9<6;OCO,P_@UM*?>5]JM0C;."'>FA(+P%>%Q8&
M'A+4X)3;N5[UM#Z7>A6SSNE$'/&]%Q=-+:S:QB2?[-J1/GV>%_V0]??\".2E
M'9DNZNA.=28D"/=RIMRLUTY-S3,W$4.SAB9";F':NV.$QQ^3BD^T5=JP_:Z?
MY&&CYR=D_)Q,>5(Q\UK:7B>Z@IIZ4L..65MU!HW]N**O*O/&5:.LLOA-^A#I
MX:5X"_-5'&B6HXG,Y%&4S1UD/QZNT6T#%,AJWNXP'Z!,FJWKTXP0'LS9.4(<
M-Q*C8@-*IO9]="'Z$3/>W*ZN/J(O] .J,W *5=@>DC(LC14H"G_C:4_'&F\7
M;"/[+F=@:]4*IX0+7R&B/90&\!BUC(US-BLTWKQ+L *;O[P#+S;5E568TZX%
M=717FG)<G8\T_R@"0FZ.,4O+A7(,/A>QQVO$'A=*F9N ZM^<SH,,H3R5U7#O
M)6X2J4*GD5"O7+DC@;/0MAT<HN;Z7(>(OW4A53(;KT"VZRQ%;R1Q&R@&'94&
M2D5>;#S: N0WUCGKQ;'/:=_"/<%++UL:QWI(,>3]"A(BEA=5"$46<60'[<'L
MQ*28+$H'9C5]NC2C:<+NYNKR&'FTBA&4ZHX**+%@+W2D?[D41JQ>_<E8:^&^
MT<FX7?ZO+7849&6ML3!?D=+Z(,73<UO!+\=7;3RI+TQ!)$?Z[J%!.S&18I0'
M,\GD .0#CH_P3T,Q+$8TC"1Z=TQTF@6_DEUY:Y*5[P:A-_@:,6+T@$W>@ I%
MD_2N)K0LX>5XZL:QI=2'.2[>Z?.#I1V\T="J1V'\FT_?(:Y^ TEE%>##R'AT
MR6$L3%RF1B?9U4MPE-*JLE"+CPY-+<]W\PU-HH),.Q!]J](CAW30'_LL\WHV
MR<NUV_B$WN:JKQ?:@_Q^:SI>5%;2'D3<$RM%0SI#HC?K'E!L44OM*8"E'R*Y
MESP/+N!MXD<A4W1(ML\2XY9Q "^Y7CESYU<D><>O)HI1*L)UN6,,V:I5D.7
M&$6A-0@GXRO+?J-/Y'<%O]G_K7,;.-4=->='_/WK,WCY[WK)C)D$+*1!$_TI
M-8GP\F("'*XZ@>395,;W=8SR1E$RXQ=@?!SR)+@B FD"WY4(H U.< #=@X2^
M<]WL9E2X&/4_W-#68B!4;N=W=IC("?> 8M1D 2@X2T2KD*^VZY0"L0LWG&25
MGCPC[RBK2#OMNE7/<_<M\HFNPNF2=W%GS,]5'F-/R_L87-53:3L"1Q.%((Z5
MAU'!FAC!@XP2KX3=[^Y/6'TU#L\7ZH$U_P=[;QK5U-;U^>;8(2(B(" @Q(Y&
M$;"A49KD451$A @H" @YBHJ F(.(! G)$:3OC@V@($3:B $B0D!I$D,"'$5$
M"! !)0T'E<[LK1*W)MG4YGGK6]TQZL.MJO?>=Q1CK&2$#RM[K37G_/_FZJ)K
M.B[DLE<_@+;WUOB8]30-637&?R Q5KC7!G^,/1%WWW5>^I;!O:1G#+6[V_0"
M0.<YA6H!RZ3$N&;=Y[/1R>F5R7\_&L[TL'75\:Z+6*8<&7PE]@R_^FFO>X&>
MS^V\_!Q"@6=F7,(,[CY@N\X+/W?_G^3_Z9'[_Z+E$A3+<Y#>).TO(]*Y!DPX
M28)3#Q^]UOXPXGH0+_]Z_JV:*?LH_%1A<?+@H?/-;?5MB89%8>6_@ST&#@\R
MNLK**AUBJM_DG3I0N_U)GL/=Z<-[:-X/)!-[/;4\]]R4O#^O;Z9_J)%_3./[
MHB(0X>%\?!-EMEZDD;6;^0!CF[*OS1#$N3]]=RN,HMEFJ],8,':(8.S[I@_/
M?,XG!5;ZI_PU,F6\\4GC;7_31%]&,_VG#F+142R;X#"L'NQ(^JVM-;H<XK\H
MC.4IM8;]E)WL-">-FA%BK&_@0=BP-N0PF% A(*'MA%R[?_*^HB@SC]DOL!6$
MU%,$-<7ODO'U/=7Q&VX3"_<-NWC@;^?X%'NE..2L*59^<K=D^&CF\>\6W9U(
M]+E;\<^8[-&)F&V'<?$!P9$7A7V4>UZ'=*"H_](S1/_+9YQ^(F3/>2P$/*CO
MDF3S4+S\0@2:V?="8PTI?)!E2.P3L>Z+XFMC\2 K"T;7@U:IH-;,Z>8FW$JH
MG-OOV9+<E5OUT@)O,GBKZ.!:IZ,#*@LHUW#X!$4D0(*>8(Z&P.IGB"(_>Y':
MA./D0CXMM$[<>L6&(9(*$DO5],18'GIN3&/59_;:2-N?"FERB0/8SBJ0J65'
MN^>^&C[/KVJ1^\K-OVBII:1^>19M _>*@VU.[$$_NK W'1 ,YNW #T4Q\W9<
MLY2P'I=Z%U_/*#8H8,S&W=W6]R,_B]E1L>]Q?UM<65[@N'W&M6Q&N?O)RE^U
M&F_Q4"H>7HD(R^%-@!QY#&K6 DKQE=Z(^,)$6+Z#]:(T _W?>V(0K:".M/KQ
M;>0GPHPL:RY970T,=(^)"W8+.M.<L7>H(O968N*7UV[8.N;/240]SD'Z($YV
M#ZGF#_@=]C?R2@@/:^,ST>M8:V:"=0"S9&R3PE',GOMP_<LWS_QQKCRVLX65
M)*[=\SI'-7 NX$T];<3TM7-'@SD&@R^:J(\;=O6S[=U%?+SWM&#YR1.O=S'I
M/ER7F:LF 64EIC7EAS<T3FQO://;H5W4>/+Q\:PS7@<T/3J.]F=XR&M-R@1/
ML=2^%.Q7VHK*!=2%6#!Z >7'SK:8]X/5N?W?>_7@E?5R]?V5_B[G=:0W,:81
M>A$K]ST?G,_-H:ZS-3HJ"[W2MU7@%ZOU=^>]M+<5:]/FQ"E;?[:^8#\QFXLH
MIW"8>D( IW078T?8$??9%_K26*A<L;7"C*)N^D'R(5;2EZ[PJ S# B7[)[:1
M]368%Z]G%TO'QKI"CB6]D=OVSMI']5RFEK*!P^@1X83>;#%B)EW*.]A0:BZL
ML8"ZJ3*APL6J$!E'0?9-K'@CT)S!KK>>MTYGV8/J=]%C\*IAA:LXP;VO?S[;
MX5OO@&TK%")W'?EXV_%1:*)UF63UM35-;M3^\BSNR6H\[]@UA[SMIS)\BB]M
M>'+O;ZZ^Y]JBO&,VE7N[UJ?1W%ZY;6O>6G*BW,3[3E38CAUGQSQ,++H_)%#S
M/W4@:?:I/FAS0?H"ZG)?#GX9^U+NB+6L< &5XJEL9:D1KV/5(;/.6._I:P$:
M.38:ZN'7W[275;ZABWTQED!7JY@NU(WP_5%BQK]*T \,+]$=RDV>EZJ?GGIY
MQI8QJ9))N9P+[9/#JK;B2)<N85/L"]Q-=A.BW4.BO6)JY^+2H(LXL]W/ ^BM
M[*R\VTR0"&]Z0[C.<=WFFWT1,JJ^PA\RK.OH?]\;2XF)M6V?E5$?X@%?+&1*
MF>.7D<>%*[$BAA XRA?CUL,#X\N 2AI7FKF :I#FV!;O.= /6Q!]N>Y#)*QQ
M:0A%8DGA.JRH7E,M5C]&#.3!Z]D@-OG+7&JJPD)"73ZMTGGM]JUO^#D3< 9>
MLW-QSSA)!Y3.>I52.%:DY7*CSVR#-ML$H'L"VTU-1^O;(#ZE,456$<Q5#2A"
MT:EVT[O& Z?&MS8$]FHI%?L>D@*'^-Q"YGN'"U23WMXZ=MC,/T/MK*#;8I#(
MTN[;?<0KV2G&Z1?Q6+/MWQMG7DJ>/ M@Z+GOKCZZZT[U38;+C&;-Y,L-SIA3
M'(]#81Z/AI,/"RVJ*LT'^_V9/:^H;I:6$4U?R$\40<I&>#U"IA31#6$38K1
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M"85;UP<ZO)2%,>]]^1+]=$#UG^4J4S]FTT5X'9+UXC:Q"QHI)0X#"Z@GBDA
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M=N[-ZJ)J@VO<[[R]?/KPUS#)HS/5T6<C?.DW_AM[[QW5Q!JV_69O"P)B5)J
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MW<A9+ARSE3P2>1LAS7"U\KH5Q*1*46)V?<S,T^XW[OCU>S7W7B$L^BYU_!X
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MC*LLM&#)LC45O<=R@DA)5WH*'OP*5.GUZG\LW^&V[[A+O-@+6\Q]8!,PW@"
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MH$"T$ 8=^%X)+I[BUZ!\K9#1V8S60,,65^H=G4>"73QWZ'[I[*ISS+70'*T
MV_H:R&H<KHQ^>L$TO/+SB(L[E*(33W[=9Y=T)M!TR>.R"PP?;^NYCWL,W\/8
M" 2D17G^P2\0PGQ("D!S$Z3/-K&A#C1(32 @\P9')GJA$W5N<!FUA>$.-)^8
MB(33/ _V&:7XF/57\"J]3/JFTN<9OK''M:Y$W8JL_UM"XV< 1W0,HMX"33K
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MT:-S49-BF-I%_HB/@#SU]N *9"^PS%,4PEX(T$)8^<[#N4%,1R&,%"*$]5Z
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MI]/=-J)2[X68*[7TB74],DP26%H-\CHTB)5L"U*^2'!SA,?1=W41XHQGV,L
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MUJQH\AJ8/"'S>U18_%#]3PWB:B4( VE2+I6 XIMA(_I ZW+(""?"\FS#%:?
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MB/^TU$;8== ^I1:T$07D4SM@1G_KH-H2%:5!W+21<KYI$ JZ%/>#K^;,_.R
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M@[:_== *R&[3HR^L>*OU;9D&H7\"-GT'YPN;(M @P!@-(ARO3@Y2'\$**[&
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M*WS\BG-502>=K]RF;WG2<C&ZEU7RH-+/R^=JIJ&B@G.)%[ F]FPO)7R2U\X
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M)V-GR5'/NUBWGG[[49>S4\HNGC>1)AK>-P:K/E!V,L3]@]*$D<D(J#IEY0Q
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M!@@IPM8DL=C6124501%:4E9H1^'XZ::OT#K2*\QZTEKH)8109-.?-['TB=J
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MKN-C^J7M@LB0GLO?0_1, YVY5$'K\\:LQ67$-Z/?UY#5^,"Q@O^2#H259@C
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M0^#O$H414"M,O\%4)IJ#>"!4F)8.:TH.&W.3]"M 9JNEE^I!@R.6--!)KBI
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M+MM\]J[!7QV;-C]9/C29(5_/E:(.*_:37$/Q4!XH[H*WLZ:;05MI)HPMIAE
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M;ZJNK*BL3OBZ:P:_ZZO1?O.PL-_3G;_N,KV]*5'KVN9(Q_.X/P'0&P=OYB0
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MVD6(FA,$'(:'5>3K9Q#5 T(9,YT)'B49G%9?UN:_K[NT>F8MU54:7I.U;>N
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M@;;2P*KPYQ))-S%D?8KO0<O-O_$G&ZYI5^6+2^/0B]3&1$Y%Q_E)R109<&@
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M[3XO6)$^;:Y1XN1I\'YVK\#CL>&I0Z=AV1,]M[Z$=I>MNI,.^SGZ?F4VY X
M0\.0?)HX;U76V4\( P^R1"I=@A[!M$:;T22*N<99[BN=*OV ,>\8K:$CI8HT
MTF*3_?420PIYN18^.M>\MBX2.W^UV2EY/N:$;:+-U-]L'$*P!1P5^N"Q_.8D
MPD'\$<!BV9E+9%XCRBRL!X*S;XMTQ<51-0H2$Z&F2<X.<!; NN@^7QY7NYA[
M[]IZ^&V_12)H9WX\L\C\$-R-:X8&]R&6.P$A[1AIJ\UFK\<[Q.NHI VIU[EY
MP1A.AC1'BT&+-8[DPI)LM*N/"?**%("UGC98VO2>-X H8D)78*-).@7HY[T
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MNHG;M8@4Y9VLL)G'B_(L2!,8B1(Z#S[>Y<-\%PH5!>U4M+T'V0-E8;%R[:R
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M^8D]4'3#P-37OI,\A$^0$WL@DUE_;I3<;&P9<Q8GA;DZ$4RLK_]1VI[]YX1
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MYZWA!Z$P&2&RSZH> 4+(_57P0,0'G5ZL1I!Y_6W!$&=. J#^K-_=*AHNG]C
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M;0OV]-9]\S@]6-_8Z?J5YYG6T0,)$7D/ARXN#Y:6DA,Q+NPR*O1PLUULMF*
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MA,<%=[7 C78LEE6-A>//!U<Y&'8645A>SN!Y8'6^;44TA)U#-0M+Z-(#QET
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MSX_GIZV#=Y7.'Z__>*9D]W?CEYF1?=^_H<^&TSH('Q;E*E316K%B:J[1Y.,
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M7$CK9?G2K:(-\B'*<^>.WGCQHX$RZ.XC*  C*R:O(QV3%4@3GDH=H?M\%_N
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MBI$KJX+=O,D.YF:2^G#K(7]2H&BBB7?6B@KOOH):]^)]C14!O@PC+,/"W6,
M/J#I_-0Q1J^E\9^;''N+S>[?JNYB&IC\5F8P9LD!,XI<AFT^S%M<AMEX2\E
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MX"GJ-3MWU_2A9S\JVA][5>A5_?/I3M51E<>?:<2)?#/\O(N%MW&"S>V).6S
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M9QEV$<-9*W:I@Q0);=T%:&TEL8;E(@(ZYC?-M.XSW&.H+@G-S8:S$*I0SC=
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M/?>E1KRK/S"RMVIKVB</JX?E/;,?*[R\>HQ=:PR<)S(8>CY>V2/>I<5Y2=S
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M-6#,\?[29A$J.Y8+MT=3IU%;7D"%B9419+U<GY>W>BVDR AAX(X/;M$D"S,
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MZG]7S$D?-";1D]K)'B[#(K%C!PY?D34RH[@W; %M.?*#?J&!TS+L%<?@79T
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M\M5J?CV1W<W1.XNQSQC>W"W8$V5\7><%G4[:#I/4_D\]Q*0\Q7P]!-I.H=8
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MOCZ[]NN"G^[H"H,M-V2*3<Q7BE_K(1_D*L>3S(*K?"G^?DMNDW$SF;*EGU@
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MN(WXI<U,L*L5#*@4F(-Q0".[-Z9-%1>Y_H7!1762I1D@I886<\7JN!@FF?6
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M5,-Z3X$D^[@UI9L7:3/DD.SD]LTFYFSSUQJGUK<%@PO,>58M9'J44"+)='X
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M?&QL><:HRU>K1)=I$:\:?DKSR+LWDOZ& :-<94U(\\JX8UW&\8RZ[%[6+Z1
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M[=Q-<KD>%Y)Q7_.6;6=*S61F$NG=84>'A@R,ZZ#7LD;N.C*OX+EQ$E:A;8]
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MDOD!]';P]>]&;@.3"SL(E7X_LK[96,1_S"(9G//S<GS=MX%=62P@'0>R5]8
M'295R@H=SNF/G=D-&@/,TR!N3N;\TNC\1A=#]CMV2]!-#5FN46$4KF2A(4+9
MJS^^FKYZ_LO2E/T@/B!GWN'BT)7] ?7)&42O76\.@2_?*' 5K_^38FV/ECDX
M.Z)WH>Q=;G$R&#)VH]S,[<Y&>8=+[F"!*B&O%ZV5M[;FNY%N,['^0V/ AFPG
M@$)U!\J^CGTB&2)O@UV:CKI*BST$,LZ,'!@P0V.EO(E3'-M[Q2&CY:2Q+%5:
M,E(-Q'3GRPU=-= :NKJROK5M#"IS=>O:,8XMAT+<;][,%*61E,$Y()27 MYZ
M(O "9;C'.Q#*;:K$>Y<MC5/;$,3T,UQ4 BV@/O-5:ZWH_> 7H_V-P_3EOT:;
M2AY$? SQ"IAT""[SFO+IX1IP;K3T2]CF:ZID^S^EZ_]/*C?QPD.&4G3"*SYE
M-HT$25W+##F2C LKRO4K1YEMY)?;D A\#VA*)U&7:..7QGY_+JQB!(EA\:QM
M1B17]48-E?<D=(7/#,CH4CKG4YPW6EY(U&$V1(XEKQMJO/MRNJ%M],KW8_1*
ME>E+S2UQ+[WF4'_20#UW@?PR;W&D!/B\4LF_0#(%JSD+ID-5C-L7<[T!2M>!
M0;GM7XS"CR(U!+\/"'3GO"OW((\5J%:/-,086)X>-&PKXV5OM3E]H^6=AUUZ
MFF]:UJ\6-WIZ)>\23V<&-R9>$";5.1WOM\WY\+/_N'^+D?T0^Z5UD];"_Y($
M!6=2F7<?W,4_2#KZ FSEVY(P0&\G(OZF5\.#)[Y@?_>&R610UF3;"X._@\WE
M?;RG/M!#L?UJ3$+3H?2#DBTF!PE_4X(8H$&@0%Z3=W;D.UQ6$"5\*E("];O:
MM 8$9IP]QSM']3GIZF#%U$EN:@.5PD[%8H%>)DL6I/D!)=2JQ9SJ>%I@."?U
MN%WL0N,6KWM#CFFXEZ-JAF^OMR1+_-7#F;8[;RJJCJ-A)QTS8BIW1^F%?@Y[
MX'BU(/6#HOTQ3T<+=;;:-\?#];1;VKC5J+;6X]3B8?=^5AUAU9U_5#2.@ON#
ME?S#@@! IX<!RUTTK<RCM$\.>V4L6G8=8H8:)7-DS&UB/("91L7Z[OKA''-&
MZ6)3CM>'*9_ZQW<X*HAN"HX ZM)6Y/E2?L&;F%5?_CF!"6C#<7(Y@\=A %_A
M3#F'<%?9RVC1/]DSG;UV^SM#GO@A6#G4^\.41PCAL6%:800N//BB=5\?G6M;
M_@G<?%YZN_AVSX6>GO,I3\. D=*D\VFUR<P>V=K[[EV/C)J*9)W1#U_KH=Y.
MHM?&^35)H D/\W/Y%7([HE&C+H)-G<#R2D$L%]<]ZO5GSDCO[15".$:&N,'7
M^/7.LEM">[[Y( 0[O]J\NSC.3&W95PGG:_:Y$;V(G^%LR_SBZW)AR-3:Q'FT
MOMJVUW[@>[):JXO;2#VZ.1IU9O!['W(&W2RT<V8T9ZAYZZOI>P2\:&Y^D:4?
MA2,6Y03+F5Y6X5S[IV5/8'PW^_INGY/U"Y>"AI]XAI(LBMT.Y\PO$I??ASAG
MM'AE?,G!K=DLZ7/'7,6PF+_$L-G428O4W'9E2B.CXT?]2%/^6]:BFP9RC"3_
MV1OC3]!,3_32B0F')QB&#(8HK6[["I9-^)[8L]Y7W34Z>;G8L!1RV[=;(F;3
M$T4[@8TN>+SH$-";+I#D3!^1">R<,0$N-Y<0J9TSFH-&M\TW\Q-H"XWN37[E
M_N:CNZ8]?9VDC]0F?*CZ;;RE[DC[R;PS-[%I'2<;@<#DSDN'@,IB,2Q";WBV
MM*1M.3)$^ZCCTI&4G&E='8*W265!DG[LXX*D@[#_UNL%1H/XN1.QPPH^9YR(
MW4DZ50*BV[%P*UV.L3K(ZHX<YHS9 ?VQ5MI%?CB1-E>V^L8IZ6@+FP$Z?]I1
M=*/H% YO$+OG.>T;U(W?68:$AHC<*V)1ZL2P7LB9 !A, F67$>IB/\R7B,8(
MR\4PW!L6'*>!&!3<;-O+-4\N!C'LTH0Q5_K0/$"-LSK%P?69U:R:W=($8[A*
M@Z.\HRV&3XA;3G'-/B>*,N.?^Q_F7+ER"/3@J^M5VN8;'ZZJCNO4&TK9^ZCX
MH&W-_JJBPH3.DR$U^PN=TPUN+9W2J_=W-&SUS77V;B8L9+M]1W]!O9^'?(I(
MTET,.\B 1DP0PR;BR+VLS7ZL[/*JD.(WT*+_!$?6X2H5XPI!"C/'MIB&:VK]
M?D?-4-]V8&5^V,S:\:M_EUN#N=NW:1][8MKNO/1?6ZS.[F%SB2EZF14+E_38
MP_>O+%FZ:CLYG#AF.C\7KJCKQ6N>7L@;C/+560P/]4H2P_2I&J)!,:P!GDXV
M)%V .)?<HDP#9^;8[LQ^4/?S;:BN8-E=.6G/\$_@<3EVL5_"?768;?OKLN:7
M,<FG<]G5V4QL[,S>%GK2A'*7AMF+YXT>]=)\EU)*&:H3(ITT. $PV&,]J 35
M+N1>D,)UZ=!0@HQ#]8T/3Y)=@<:4,+3QSB#W=LV796.J5Y_@M>X1+L?;$A^M
MV2I^;W'J# >OYO]:Q0WC)LN5VBFNE!\U^"W@Y .IYX_:BEJ+;8X-QN_/3<5.
M\[V=*JY_O'RA4J_&04?-L[(U0#G*<=2M-3]G"MUZ5I1TD)9A+J4_GXX@3V*?
M]7=2=S7&B Z*1K%U=DR"\H''I@E 8WK;<8$A$'%WR/5B&/,,7KX+J3=4;S:\
M_5GK_I>3R1D&7^XF*WV[LD&0 AL[\RW?7[%RF:7*@U$]R-TC_L%TQB[0W6N(
M=.KQDK,F'6,83RORF0G>N%=UEULW]<&^8NFE?<!>O!5R_Z-];L52PXO#H-[9
M^VS):=\;9YV='XPV6904.%G+.U4/!N?)*+ZB=$;/8D T@XT5PSIQ;&,0@^P5
M%HIAVS$"K4B40)LU(<),(J>A/["F4 WD7AZ%):Q<\;/+Y$_SD2%?K4UX;<),
M,P;B%5!H*RRC!.*QG/ONY\;? &-GH&",0MG ]?O0?PM'"-2)J;9R,KZ;L125
M=_Q<8_PTG6U:-SYS\NZ@U[NR4_"[947LD_3AO14.G?<_%CJMGG>R^=KQ/9>.
MM57V'>6Q: 27A9R#-&60QK<705[MEZ)!#OB)NS;+Z$@,;VAP4D)![%)H@0-+
M3KYKA,PS=;Z&5MB:A57R6.3]>XN\-T':)BQ+K],:[-C+NH/E7B%YJJ&5Y[$[
M=#M=<K^GN&3^V(O7OCGH.W.7EZ0//H9XF4H^@(1R=IL*E"J[EE$R;7L;"F?[
M=PL"ZEY 1$(E]7V.MW(M0?-_%_4_M;/$!EE\#?;ZE'(/?5W*L7;:N^6&D^HS
M]VN4^DU>J$&6YTW/>_-':*L:H:?4O,<MC1X]I6U+R9<]=W_:(<K.0C;JJ\M'
MAKY39:;*-\?KC>T<6A0K1\]]"NTWU?Q%P1G;E2Y00HAD=P^+D()#X 9?&Y(:
M39+%'")5LHBDRVUKYF-$XTBE@? HPA:!)GBL:#$RA_A-M-/PY-?7+[5[RHLZ
M(HHIG9 K#JM6W1*%*R(9IW>W'>+*)E>"82^)E,,<]3^O/5>]6:KBLCESA/8B
MMGVPW,C56][+Z:3DI-\[JD4][>!SYY1/!:YZ)S-:\FL$S[ *.0O9\SQ?3V&C
M,_8. [B"%3Q>YNT7PYHSQ;#1%I#OAIIM0P%NU021Y"V^!=&2.=N6&LAA3,[Q
M[G-EH )!"13^QD<3=HXOX J1*21_[A9G8/B(=O_=C^\SNU25XM@4>,$KC>HY
M8X6@\WY>2U[(W*K@;'<CC>X1SAD[F3^\NCEE\_^\;7C@:3=^LJ!CK-JQY$"1
M3T64E'.I+3&I,K^TME0E:NAZLW61J[:;E\[V5]6K;S,=\!$W,R;7GO$?5N,V
ME>-7>IYP#'$.[Z^H_MG@O8H[7S>XTM>5M*;^Z_QFT#X3^V<O7^V,_O+LA>L^
MCV35R^4E.#>H6J67C2]-XB?K)I=4 Z9;A:FOM=+EZUNGJS*FWI8;$-1,;QSR
MW/7^[]>_BRR16Z 8T2;75G'L5FE>'$2A5^1Q%%T,ZZ%.!O9L1H(Q;@ \MFWO
M0L/,'M!;XT4@?C]1;[E+0Q]@I%YF#)MZ^-/O;#+;S6<D +_DZ,LYLLG!U0M-
MKC7E98)R?CBE0P<5M 9:L)AO(((J0V?'B(8H*O6$6(ILBTN!C^@]M8[5'7UR
MK&L3WQ^S/DTX-23O/':%I%E,=&&*83O;-%Y5-.2QQ3#Y$^4@ <UEW/F>G&K<
MK8I)^9R+'C:;5IYZPE1')7?;Z75P\7H3]0[\'9;YKGY9+HG=K(RC(<<RNUX7
M5PQO'.1HQZ3JU5YW]A-X)[@5^'PM&)9KWAC*\3K^?.(*+3QJ$S$3I_B5LF+,
MO[! :?B\D@S >160C4T(QVSW(ET&%-/OK@ETJIA6[C/*7.L'TY\3! 'LZ8W#
MWGW1@05$AMV8:9^)NSEOL7HQJR&RZ]PIQ:^V# _W;LY!U\XQ6CQ-XFR;1KVC
M8GFSQ=EJE==Y]N:Y[BES!YO-:^AXM0-%]S.;@DWY)374#PKN/P#1".M97ZE
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M;A,='5 \X1<2F?>I)J]D<;11>3+^2?1UF>('J0^*C*]'W+H5<8W;@</AMM[
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M,^E:':VUO9^KJ[,F9<;T?VDWT9\Q^_]$#J%DBD$O8#GVRW$D-!Y*)[!,]2%
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M3<<C1O[QV[KAH^M+C-!W>V@[4S:=R'WRC-&ELR/*\P/)?1[W2?$?KZI\&X>
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M9$?!I;GZ.Z%'5M][HGA;SNCPM70<'YNY>R\O6O4*,_:1\7CF5LS<&\5P-NI
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M!F(MO05UGZ\6BL;]:0(@!:0>'XE$35^ YW@7Z_8-E%0-6/Y7AF@9+<E;1A0
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M#Y_YWNK/$B@2CO9V<\G+QDP-:FN%T\.V0S[O=\T ?Y&C,'5)R=JRD(8&;:.
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M/RN^S7ZXG'I^\MD5+],950L[8YL;OY3ZET*=INO_K&S#00>=YV@B$W(G%K#
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M3'0"+,NF^F@!KS,2_3SI#/$:N!)7)A@Y /Q(XC*_X5OPNQC[22?Z)9I3DQO
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M;3,5EFP).C)M0/7AU/ZW<M=$I3RD#(3CK431L5S*[T2?/P&?"'.=_*M3&BH
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M\C/Q5+%J.:.ZW9Y<93%E*7//6L1DJ?/LIE>/L[;WR'M@7,1#,H/33 $X >X
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MY:*L[@6"\(.?R$/ES;6!.NJ*"A9.A ;*^DA_G8AFY\UI=,-0HZ0'#]IEEC,
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M-].OKEHQW;HYV"7JP1$EBY0(:VQ_?7,#R+I+:%,O=E\3N+6?Z:'T3YTL$+G
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M#K*(_4B5!8E!1_.'$OXZA$).G;4CG!V)>\"FR2S:EA==X".<^;X4I-I"]P[
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M(K/89$QT)B'RN3-W'9**AW8F:%>^6#A *8:.Q[O;4C@X H>44FRV<>PEZOA
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M?!UR!0U:_Q"42__>#>S&FX\\R0<IXBIZ9^38*Q22%AB$E4O@(%5 7PIJBMA
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MCST*F_6VB58Z7RJ?#, PM*5?\K[!.(J6@%AC"^='-.9_^/!ZZ;PO2S*E6+>
MRWL.B.^)%'N<,?K]P&&ZEO3.&MS%K,M!=(P5N?!N#%3,J:JXXH>NF^7<9U,S
M0U_'*O@AE+96'>@B0THR?8>$][)=//C@LF]4<SF!P4*-(DO4ZQ][,!F.[VZ\
M+*?M[?]LH%F]]<: NWESAF"IO%&R_"X9<D+Q1^#Q"L0=A-TZ.X$?HPI!?K#R
MVOYR.'FJG?MD@M^M>]I]V<B;!G\EF>HD,#7.?![X3ZM5;?2J'VP?;2:,6H,
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MU=E)G^/S9\-<@'L!H8#02$&TC15E4(3LZ>(CZ(W(ZGA%+L2=;E$>A#]@E'6
M;D5;+^]J?HO8R$=KI6X-?\L;RLI'VB2LM1_C+Y8 ?6(,<$3\X9PH;@GF%XS:
MYR&D,CB3GW#%D6;_$Z''0496'D&L59E !#Z3R29V5,Y27=?0UD#-U*KV,/Y
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M/PEJQ[6X:MDH/?NK8S-5&WD)1 %F<:-]!0&%8#N@!V>V%Z[T?PTO/=[2PVT
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M_(H%W*])1:@!P&=-K[OD&J]@">U8+>-8>I-SF%" "-XT@;A$\)AUC#1 0E_
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MR+,S\N?BA0-L<?6&J8.O[4;V3 F$AXWV1FDG=A0O2L_1APBUG9G.9S#G<*?
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MYJL:MU>_Z+V4N'48 Y=_<<E-\"Y6%_=LT7="]J)0?%XGBE6YH>))TOP]5_.
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M]Z@[%M/>S^Z;8B9;U\K/7JZF@GZ70ZXX9A==6'/*;R581!HNE48D(QCJ5+L
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M#SW5][9A6P!CFJ,P,T6?PLOERK>(DC]M&ZY\4=>]8:9]!<"N8X!N[7UD9TD
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M L)L\N[[KB3/+-O)#:(5S*4/SF[MSKCG<<I%/^%[DH=.KL%?Z6_W["G"U8"
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M5U>]8RI1^]8$P$9_*%$PZ;M<MKTR?Y!5PF)<B"(XT-C_-OT(Z4<EZLE)V79
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M-39X]B!4)63$#1K4W":?>>((CK;@S21U=0,UFYHELX=KG<'O0GDUK>/(.I_
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M;)+(5?LG&A8=6GJW92Z9>(L $EG]&X?X4_--MOY!J'""VXQ-NVS72T(;C'=
MA)PQ[Z\OA5DJ35*]7F,L]%#(TB"_='I,?=!RK-/2>_10=XD@Z:38V(ED%'#C
M[G%/C _ WHG_E>:@R&4)LODO*\6_2$(]R[AT4_D9139]C7R?9*34/Y?$T\W.
M%Z5J07^TN_5,6Y1%;1CL^KUK??8$R7CO7O5 B]/'M,QZ?M/YY8>#KKP 6;C+
M@*  4Q$P=1@YZO4(97[P!WYI>Z.%2@-+#2!-ZT/8@Q#KT40]"B0FE<RV6A"'
M6F+D&L\LLXJA> =6K]462UM<,?'DSPR/X9=)[KJ?-^Q])N^:4*+ T'2Y3KP4
M29C1@?1W&!1^*_Q//>ZC7'W(U1C^V K*&GEQ-8)456AB\'O#J+ RI?;@16&7
MW#<WJ-<S%" '5M.0R%L19\ZT-(UY_RWWSHG%<QY/6+?, 9XVO/(\\JEED-<Q
MQ3.6@)%1.:5$(2Z6*5*M(P>\W!79M@1)$%J-3PN$I@59^LBF3D0G6Y/Y6C03
M2/! '[^QJFN@^&PD)=98G=7UY2[;4DX4)CZ1>"7@G13W"(+A5&BK[_V69C1D
MZM5,['/\7?$($!154YHBB=$85)AXK_W'6HW'07C+KG,2B\HF(_NA#_>%Q40$
M!-]=PEQ6'*-)+]L$1!;]9JV1R!7-;RT(PF6O!?-BD W^ CW=G 2O8 6C;_'!
M*^ER[;W",E8EKB651Y">A;@@@>/-C-L,Y8"9PA_7X=63, 9<EE),O14X9_EP
MR,X&>X.H1J.LC+&L$>W%H/E0NI#96!SI2ZP@:9$'33)=NQ[7O8*K"6<P_0SA
MM)@I6T;34=2LN]TJ'(VNWT2S[*X-']IKY^.5%&4J'&$*(@<B. P]JT+6*E>-
M6Q'>V&A;HA"K1\KQJRKO@OOR2.8%G_M.6+WRV?_+#PM=.9Z$+*J7$@59H.5Z
M:=)DJ!#L@I>G(0HS#E.*FZH" [SB#R/R,8AQV\\ A$O#BYTLVCYU,FL=0X>(
M2^3'/\Y<D=S/3>./L5;2-$%&,W[71ZL+!LQ$N?W%=*ED7*Y$-6/[I^&5OR)K
M:QC$0M-- ?:AD?F.G$N7*FZ'*R)_!QG)M1$@X_>/,YG3RT[QFPL"GC8-%2\6
M8MB %A3:%+&(=W(FRD<$<%+UJ$Y-^GE#G)=0$O]$_8NJKC>$:AOS;RW2$D5-
M<#D&VJ3?0H#,B%-7A_8>[G7M4V]2HC"P"L0ZUF$E_OU$T"KJ_E&?CCB6,.6L
MN<(N/$K%/<G9O#';H.?1:[BMMTSA>*A[PR[>^YB?JQ5_LP3%!/!RNUPW4Z#/
M<54!V'MG?%=R6HA+K-K^ 'C?I5DU8.74#\$ H9FO56LO<6JQ:>$P4%1OOB@[
M6XE"AXDW<OC+1%"$HC@7VMO02<UW[U&B*IBV7I&DQT$V-&^!RIQ!!_$M3@P@
MCD!$270"LFFW$P1_ 2_#4\4.X/<W?&U$1!(KT$FVEP6(G-]-1(_-1=RHW3RX
M6N*<Q]A<)6K#"ED)%O)=0^C5GP('=T G\U(P;&]&;*W)<VIE<Y=OOPL/'3M2
M*<'>F]_\X-7[];&7)=G8_F3IKM=<PDMW1,K$!;P"?S0<MNZ _PS7!K\.DEE]
MZ_'&N\M_N3_#[8UO6?9=D/ ;:]77^Z=?GT9/-23!$8" /PUMXZ<BT<48!?%!
MEC0-NOI8;J%@LL[;A=I_Q)L'PFM+NV><U9OF#I:'BS0,NAJE=+W>K[,:K@WU
MFSH0&607P.&OLL4I<H#\<1Z[<];">J;?F8Y9.<;HT$7I>'UK0]+9*H#].RMX
M&C));\9\6CR$9;,,2(@<?85M!!*\_%8IGM(T(T$^&S:M[]Z$!#!;$U&A3!VK
M'31WL7YS9PB\7KZSN_;\4Y(DT"";8<G Q82$JSLEV^T?V1L')^+Q\D@PX@W0
MQQS2%UL7!>GIUR^##H/$%J)!"'.H&GWF.02PZ]6[Y>?7E%95:I6_FY ^T.3D
M)Q_()K^U?'3[PYZ1#+//BP<"F2(FK($DE6@QS$6VD!O 2Y/>4/Q-"'8U0C"M
M?B4W[*JWE*\.1@M_W*S' .>8-VM]SC^&IO=?AP)<NHB^P61GZ(8PV*_3PG?6
ML-67T!!1><5]T[&)5Z>BQA$7&"$\N+&0S?D)V\!_R6 3/OG[?@SC\SC2,FB4
M$$^S6YDO3%T!38B )6,/,H!8_H%XCM_FKEEG?.>/9HQF_09H6;MC;WZYUL[
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MB(A.M;R(QU I1U]7=<&KOG99IT6*@%6EDY_NDBCY2.Z-!9 I@ZX4WI!T4,$
M!,6(_ 9B,* +\_J@(=0G.T'O897I-[,60=ACDK9O_9"Z4#_>UE#VF_R A' +
M$7ZO/I '#!JD78Y=F^/,<;VV^W(#I5Y=]G9MS,2O;?$WK4'TK-435@R%IT0-
MF<J-TA$G%4-T)(JFMTSS<-(+BF?U2P.]N7$E]*UR.Q!SG;:828UX4WVE*G+9
M_3/ZMRZ&\:\3%]5>?4*]8G0DBL")F)OFI*Z9N.0S<:WN]N/"(%RR13-3?Q8)
M-TOZ%95R9+\M7:-(PB^A?Z*K=V0V]++T:G& :4*MH074/0IZI=J:BC1\V-EV
M8 [?NOP>MR+#-9E&*'1\,A%A0\^RK!*.=EH/OZR(.1ZW_9<?1CI>WS60#V0@
MB\J%/[)**6([T =634$&ZX-<A?Q;Q$IF"SEX&3QT7'*?*<V_25\][K<M[9BQ
M<9=X)K1P[ $.QE9WAJ4X-6?T,D7%+EWL[$6@0_$#5G'?)!C4E7?S%X5M!['I
MQRW6!09DV\KFZ15( &=%/>N<:T+UR,,G*0=H:LC^HVL!(1/27JX6&2VTP+I(
M J9(@NGXN^3?G<9-/2@)4IORGJK;']#Z[PN73,ZM04IC$& 'X#<AH<<3KRN_
M!#J*UPLH*R%U:8[BP>RT*E*]K4IOX%TI$ [H-]>OE21!=]L=).O!VY67KP)"
MHN[X-7ZTW/$Q-+HO3CKD7,;R-3_Z*L8AWMMYL1,*3@ED"O.EB$=BKK,$3UBE
M[7(]HO23(I:N)<=WL8(V19ESD"##.H/H>6D_FZ[7>>:EXA&-E$]3E>Q^*&(F
MT*TZT_9)\LH%2-1S/ K5/)_@!;<G;=OV-?]UY^.><+[:V(-TO#DXPRA#HEP,
MAW6>%4LW4Y3)W66'X/=(QC$2^"Z3M1 U"1>8-V%5R%F40F0;+_GH&>7?N$B)
MVM_#"D"J-2<F:1#3=7?R:,^T[6))9E/]GN -O?[!A<1]I.'F7Q1OW8A_$L #
M1&BK'5.NRY!N[%"B GU]&N:PU^%M$*'Y&K?!-:5>'9P=;OMP(Q^2<7@7XDLV
MUPBILUOR>RUJMXBF-: T>VY9H;-+Y'A99G\*D>-X@GO^HVG/- '-(F&A;4RY
MSN1\^U^:'%'NT9$ 6\V*'X]7!4??F"N\G*%VV1FY\T<YCCF^F\>(LWY+LQ89
M77CG:C!FO >,2P:[J1E[:K'"[JYZ0YJ#1(EJW#,U(O&*+9Z97L&^TH$"#LQK
M/6PJ1I=U 0-M9HKO(.\14))80A6H"LP7?*@4M:.@2AF:0S>!V5PQ-FPL&(F<
M+VC$'"B&8Y.?;M18*/4E'^R^R*#[]3T\SGS/!RD4<:C,GOX9 )T8,<0RHMA1
MH@+KQ3>[ZD+M0Y9I3*@%UG1=0C47SP&Q>#-J)J=Z*4N^D;]2;BW$JO$4,0>[
MIJ;D_18K>9%,4['^JU,#A[=-RY$*CNV.MP+8;-8+XA1!4B.(E^N,'H/6R"[2
MWQ/+,9PH=T$30ZP-NC1P77KJET!?X<%>RG)[4;&3([0/]![YVDJLZDHI;ZS?
M#2Y[6JUH/50=T;@W*GQ#1SECD %9?8>/9LIL@;X#"B3TSH93WUTG/-WZO\'Y
MY 5;L/]U5H31H>9SC)>#7\M%2I0!-74?&']3CLOW)1MOD#@F64<1?@._QCSM
M.]CE-Y'16UEXRIM4[9=%4BNK]*KD;O?Q:2[Z]BY)]9'&A/D75XB*F=)7HARK
M9!L T6$Y(DQ&.E/_[<7K^)HG]4B<B;\!LX&92,8K4W@3@\V$@\W'C4Q;Z"I<
M^1J2Q'"_)#W6FAE?.:<J<4Y-M6*L&C=(C\'2MEL8'L5O+),X9'WAF7R(WJ8Y
M[<+4^([(X7.>53+'N[EO5#P<:$U"H)\LW2%A)901EU.QTBK%7[5$4;M6T.YJ
M1!=CA4 J0ZU<B=(D\\JGH@TML X=5@S=@0GOO)R(7=L\*SQW=WW^?(B](?'3
M#;\.B8K(B\.\6:]?*V$U$3&0N9 1/3->)"Y'Z\OW23QC!>WJGSX'X=SZ2-(?
M&4I4PO3,P.9>LJSO<5EI4F39W8F)$V*!UP.'_;_P.OQTP1;I$\7#^MV3/^BZ
MT"[9 ;D:5"5*(1QZ+5F*E%KP:ODI4"6U7&:QJ/.':U=(>6L=IJ%^74^Y8?"&
M?K>>LAKUE"/DL%=Q/XYUB<]E!=16WG8-?[0H28))PI2U3_%!>\^N&70*H4R?
MC;YI\Y69#UPD>6.;T$GP8G!9<<$X@93=*G-W[:)Y,<=QZ=41_18EP?C^X!45
M?%)E-AK7EG3 D[9=D4^XT)["FV]DAE>'/S(6UUM"\4Y=&)_N&6P<1H^V=$@<
MX-*14UW^,@JI#IW /%8A\>1X8E3D^0L_?JQR#*KTNE(QXF;=>$A@/.2@^WVZ
MA<#KDGHJ_L)P-.%.?EG+E$QF>WCH?"^1G2AI'\)Q&#>9HB_@>">W$2V,E?Q(
MM,7SYL:<2P)S3@:;^:9LGS0X4;?=:'_7!]2<6I((;RAWABB25+:-2B/K)F$5
M35/B+FQ)$N?7@I6-Z#C8_"/MLH"AQ?,>'"!5>GFK),EW ,\#O9O**W+.1^:W
MX[. 4!U<1;KGJYWME&VD_H^_.%"9S5B>JS1,D355;$W@+1Z:9A-O9 3+0YW]
MG]'.0@4"8IRGUXO^OUTM<ODIX0-:ZG\);'\'_YG4%+[+Z(*<)*,"2LN %D6;
MI@JU@SE#7G'BWK>C$I4&8D+]*BCUR6\9]XZUY]ORF#'E*1<:K%EQJGFO EZ[
MA>OL?/O+G8U_H.S\DLPW$B7+;@B=]8])3)/"VS9R_(PZBDU8O=9BX-BKCAG?
MK<V:#YGA%NYNV;SFYL[U[ROUW9M6^*=?,EOLE_33ZPVA,F#*7N+3-"J<;ICN
MWRCU@-*&A)&D/,9B2$4:!SD.8?13'(]>26IX Y$Y]=CN\,>1D1MLKSS(:VVO
M"C\7ASN_+LKC/WN$ZDJDB&A?ND)QO<PU,1VSM)S1GRK%=^)W]$%-=*,!^>9N
M)8J4&MV+T;:@K\,79:A1]8;>I/M9)S=MIS;-OMW8D<[9.>Y47%$TGJ^N36W0
MEFJ@=-P<_AMV F\F<8VSU10.D)M@*XEQC!"M"E%<JGMM'42I.D%S]!O" 97#
MKU+RZGJLBRF>K\NZPNIL.G5)(4Q*R>F*RI23P_=UM'\S[/;ZAP&"A$]8.#54
MBH25QC3(6HEJR\7\VXNHJ B'/XS5H!@!-M%[)Y0LY*;(UP]-HVNSCY#KU226
M*:+B-7G?.HE;PNW4I/#;I]^>WG:._F/P5 +$FW E(DYJ@UC-?JN@2&&Q?W,V
M7D)$"EC!--K;4 $T96.Y5BP-*MG^I9:C:EVO]4#01*M3E\625TV:K^NJHS4W
MW<E3?'@DP:C!!/ER:"+C"V,)?3=M$]2"B3-T<=5B-; 2C36@F]G&4:>)N__,
M&*(ZGNSA'@YV"VL[--Y*#VX#NZ937MSS/G7UM'&E@^X_U.\B]/5Z/:J[AV2T
M<=H0LA>VW)C!OE"B0JCM+=DF';7KA<Z&,O=CI1UE?#%1DQK]PZ73:EIL1'3K
MFBG$E _:2^N.S'UHYK^OKHHV14V.,>\0A +@!5%A/#J5B%1OIB!2TF<>^=<7
M47-?D[ZSX@']>FT:L6M3+_+/42A"8G\P.2"SD+97PHRK#<YS'$GIN)H.&W3/
M[CW^77_$N3-EZ/X_S -(Q/I9VHQ4L5, V-]DP(K&;X![&*4!UVDDX<\G%=S:
M]4.NMX$5MA:B%"U1Y GLZ<J>&8W0IMT&%9E6O5Z>W,L.5TDK[GI_WG<IJ</)
ML!*+U.V+%=%*U-@/PCE7^6%"#%'..ZK"#?.*I=DHGK$N4)+G_NJ@:\$=A$7U
M9I-+LY:E@9.BT>NVP07IMS?N??0"Y"98[WWR=E'9AWI/SW7GUJVS\)M$=H07
M@D4"?A'D+N"ODCM .4/ <MIN*$IH9./LWY1M@X2J,(H*%<<Q^'U;XNX"$48;
MBOOATF'E:V-ZU^KNCV/U%14I6;JY2^^M6EG__T3@TCGZ?S65)@#):7(==ZFE
MXL8(%$"1^<JIX#3[,+SC,_2D2_BWP=?$(8L0BMYGJD7M]FRSVPV$Y51*HZN*
M="_4SE&]]&/RPFU>T_/^LL;?-X!,WC2\O!BI1>L5K\LUO!J!,M.I&R#'2S)2
MUO4YB* MUZ \IYE Z<^"=OU175(UY!IGD'IS-E67_P8*3+VU6:)1NO1;0$5&
M7_8RZ >\<@=2J!RAYL-JQ3+#0.\(]HU\G'B/S ;*/ [%@T3G'N;%F6)"BS>=
ME=<_3EQ%UVLO#G+O'^=IM"<7E0TL/O%Q-FI_8-BLA'#3RF*71VWG3)2[6T\1
M81F2])F03<T0<VJ]D+62_A:#U."?\H?J\IL(,7.>R8("O G5WSF&@]&U=7T$
MT0?YA\I[;,E@BRBK_698JB8U<::5'-DK&8VW!<X_I@[GQQ]+=GKID]=KC5I9
M*OV&E(C[;$W!4';V+D4N0?"04,9M=D713D!.3\D8K5ISL$:TN3P@/.*9+T1T
MKNKYTHDWD)\#@RNC:6X"HI:57IIIG&6M_7G1^>J><Y4ON^6''_-..16?I,<"
M[%\ 02%@I$11 ,A$1>P$2"J;(JI'Q>:R==0(D4JL*53VZJ2#B&  79$)Z?/*
M+#9[CT2E[\!>&B77C\1#I,*LT>^D#L?B)J'=QD9<1 8CH9R@Z:0_RA7[*%$J
M%Z 8:1,8D*1$G:= 2*D^Y2ISI+8.538#&A/9*N"/Y-JH1X'>Z;=L-P:(G*UG
M?,F->'W($<P\"3VI_E"56_*4_XE77SEDB%DYYK6_RY=;ICCR84T9";B(E((#
MT]"FZ21 \)#_XB!3@.$M:W>I@B2RP]2,29%7"UK%,3* .897[_HZHTY1AXA"
MI\&3M3Q\9>@3:I!A)DO?K\]ZA(%-LG5BCO&N%!2/&;C<>3Z(HKLAU=P=6!><
MPKS2%S\>@HJ"64(KB;X8$5MJDQGL$_UNM>#T37CU&(\;ORUD\]80;UZ7AX25
M;/GXY*9 7M3^\8X#V62<=+UDB(T$YSL@80C#X2?L..$J<#6B;8-N"-%KFIZ3
MV@O'F4**)N3NV8DD@TJ2VZ97$YXQ3C75I*DS*2/5MZQV;+G3[04:@I@65IFI
MW."\+)3^T6\)-  ZBBC-KI )5TP0U5@XO6'HTQ;[&[^,S-GW:&#R&(W08S5@
M[U'?1<-B&@=4./"Z:I#8B @HNFEOK>DSZ 6IVBM9ON?YJ< YEUO5_#X6>!2
M;-!O".73;]JUX18">(@?S2@+:"'R8J3WP;QRL-<NB!B;D9(LMP&9M\(RL]2;
MKN7'RO<\GLC@)MLZ2!9QG;I-RSJQ7LY=2)#?FWQ?$HX(S_)-'6D'NG^SG897
M?)&8)I:P3J.A+?$W0SJ_4''VDN'41"M]4E:Q8>/@5LB\F)1M<6B=:>OM82NF
M"M5LX/='MA*[C#WFE-7&\U?4ECD!;V/A7J(T@J)$/2<+L^A_ 6QM9/73!\V0
MK7P28)O77D7X+ZL^QR]3:39$)_ -\;M]2#B]ZI34F^$*BG"6$5^&CNOU'G@<
M&74!LP31'KQK0>D5=S^3_J"V>DHN9I@,P\D6L8KV$>!?[F 08L"+!'F>/:P>
MCS"L+<+!Y;C&H%S9*I]]$BR,-E>\KG4;NDJH".?'U2^'RD,%D37MFP^'/903
M0*[@!UNQ>>]&JS]LB6>A<";98!-P+G"S;%-7_)U'=R>VE""D(3GRVT,T9(E1
MW'--X,]U\S4+R^>[$=/;B.44N?8N6.TQR(75^V5K:*;=\ [YGJI.*\5&:344
M]:AO\+-#[MLS@@Z0TUB=GF119DYN56#>\#7QJ]E/_@_V_CT<RNV/'\:GW2Z5
MPX2BB*E4E%,'4FAF=T!($T)&3&K+86)V.4V,F;V3<\PN84=,"$E,Q5 ,TQB'
M79(RF(R8TRXYY9YBW)E[QG/[?/_X_?/\_GC^?:[GC_NZS%R7=:^UWJ_WZ_UZ
MK_5>:](=_RC<55T)ZDOH*5)9:";N.K-6IPM8J4AFB -4FBY _E\B)&BV .FK
MO2K9P!/W.UJ*&)D)Q)LLVXJ [2[$RC!C0W!6<?2KX""=N"5\RU5N2)7_2,")
MVV7;=[@]RGRP8KX@ARWZ1AM.E-#:DPZTLY\2IR<4'A!)^0*]^QQ*BVRFI,=:
MIVK;UJ7)U+QNG+2T(N.K2=X=S?/=F39'#$0'*PM#_]PV.(]:S_E5SXZ/UKKQ
M;0GA_P$-YQ[)AQKPZ10#Y5.,J+9D"_C2Q$.&_ZT%#"^#3M_[9O%M#)^>X =#
M.EN.MKG]K0&PL/*'7%<_[+UZ<=7]CGN6?Z;\?49M0;H<A&1), $U+"%@_+QF
MR^/#E_$C":&>$0)8]L^][(\T5:^N'":205M1LRJ(*I+3X6^'[53O9C#S'N13
MC$E#U=J%_^%!>PDQ7$;II2]6LO1_0]%00!P**K63PXAXGJ%PI$Y. I%)_]O^
M]5A"W'6&S7J8/?T!O6X),6E4Y4>'/R=@+M$S8'T,Z33)2\$5  '[<DAE%3@1
MI $F [/<@_W#G=99\\ODB@;XM%" O'K1G63H*3N=4DHP,+[!2+QD .; .:5$
M7&ORHO&%ZB)&E(L!HA>F^8I?*9U4).8B=J1>9#=C*L)GHYXWWGM,/M1$>T5'
MQIA_D5FE!=<2</D95025@8R?S5)C@*AN>ROZ]1"Q,M1CR%+H,1 U4W ^T,4]
M8&*NV&;E>[9HG/;S5!JT_H?JC2F7KHP@IMG"U@$2L= _^.FB)41H'#P3;;O\
MQ/'0!KS\MO(QE8@"]^A#.M'R>; 36-F)JG>9'I6ER0O 4"!+?@",EJWS39.@
MFP"%B-:-3S8V@:.,]88)CZIS224H%"E+&E2\*^U1P+VYJ19+H[G:[5/^_0WJ
MUAM)N0LN*B1LMUQU92YU^AMON4*BXPU"54N]U(L\"2P71%F2"-S%I,;<!V"B
M/!HT*?U:Z%-X/:[P\NV'T &@,[6H2M"=^USP[MV889BNZ17/Q_]);:$+RQND
MD=9G8:S!0!*5^@E2[MKY4;8 \=U)H<=+SIPJC*I&TP$\EQ<TLOZ517]8L_Q9
MU;X+W.G%E/:93SX%BK/*?/9_'^&)P"BVH=90Y_&D!';6+&BJ!M7!U+0*CG//
MXV4]2PBW-L09M;GEZLCYQJ;E\AD[*N?8Q>:FU"\[8?>HR<N1F'W)CK*8K]7Z
M_D[LY12BBQOEK!IL>+!VZXO4W9+?\VV"P2.*;5.+_%2VZ U]PV3"ZHKXAY,Z
ME+?TQG>W%O*]_@FUQV=0"0P:90O_"8OS;]K9]_.!+J>:5ZZ:(>[Z[<VYO<IQ
M^*4+U#=;J*)2JCQ*9;*$X.7?QL->QEE!60G:R<O@.0A'KZ2\0ZW/)X+'*/9D
M"V6#:B,I/_%$QNR<TKH;PU2;V2F>F(^T>*MQ-6)Q'SO0S^7%H8/-Q<45;_:S
MW%[!J$]V(>\4,[3@-C>C]0D)QO3P\!K2@M2EFZ$+=GW[-25T,%:!-#I/VO7F
MVT^IT^TOR>TEVL!8L7[)NRE"".+8]GV/59E4SE5HHQ@)4SYG&U54AK/++GM:
MX,JCAE S*;:PW1MBQ@?$M,XEA-;<9E:B:'?P#9O;(C;6D$3\S3ZN/,5C#S@R
MZ<WZ _=F"KKU/_\3/: ;L44?9U'DL\M57/!WIU6_0IZ#[,M8;?))?MM62!V$
M,=UT%+L^_ !^\N]P@7-U+6G??"O6Z0,K&!!V&<1E/21E>;ZWZ8WC=>,U'=UB
M7]C2U"-P):V)(14);&@C2J5>+*&#%@O<1!JX"P5I\^1)X)0LVAO\&?\@'+,%
MO6=J;$TN]V"S]9_!LM5YU749%9VK:R@EZX&V^NIS 1R9K@3;T4)?1Z*Z *V-
MU:4!_A'FC)XG7T5&UI .G":6[.)C1'WLD=Q3_#N?8^#8B)2+ .&-6S\<;[N*
MBVIW.P;&R<,Z:EN?R@HR6;ALC0LF@14#_UW/?8FI% )AQFD/PS& "U8+/]&<
MQ"P>AS.FL+Z<A/%TJPL>SR<%K:VPU+35*B4-HT/>)B#3&CQVXU?J%88\(?W<
MGXC/%#[-2X-T"2K-?&4E^_>S0U<<L1)\FO"9:?=,@ 23.??OCE1N!UV7%5L)
M%G25V+?R"DF1W[[9',&<YULY'A$G%BD2DXYAUWUM1HW4SGS+/^>]O)/BA/FL
MB4*RIUL@V",&RH;^/")4:<'XN7$(K%&MZP$P8JU2P$^"+O[?TE2!HX>$ 7/*
M(.1"?1(>I,VWA")1*<A;CI8UA(15K?)G8@_?[S]>E6CR':VEAIIV9Y-,S@'?
MPW\,<T)J1PD&6%$('=HPJ](J@5]P:?M7>F/\M*O=3!K0PEVOS%=( MG<7*EY
M?=GP6H_\&NLNQC#EFX*+.]87-32!KI9Y<_156U^>*_,(WLJO:"W$#PG!P^I8
MN*6'9),/[,O4D7C56J',4!HR>P,3BMPD(. ;NJ=_ (P@F5NXRA;@IY$#Q'U&
M)+\N]!X FV(*R]]N%/)"D1.?;"2C.9V+77,9<&X)/?BR\CQHQ>LL2"#FDF Q
ML2QH+D3@U\Q >.GL"A6/H@[6$TJ[K5H _&DXX)/*)EB>&\P*%C$IT#7'X'(P
MP+M?<Z&P.8HI<649)5ZM*OLT:;\ZC]Q;::8F9 -.5!!6,]/W8/8)_D#92G(7
MNW"-7&"2G 46WU@;DUU PYH>L=)MQ+/?MD41N>>'1'^Y^&8&<SRM&V?9]NQJ
M15C;KD$F+)W].NRC:JO#9!'VNY\/S!4?6UBXP4Y'@G;J<ARXH#@*^]9)3"0&
MM,1W8/Y<I$\_ QSDR4_!W'+R&C TOJ(1#I-KG[#U6+%B[*:($I/^X!:>359M
M?'N0T0>6:50S/3LRYHCY"=DXC>6>6$U*^%SP&W_N([5I$4X@8=048'[G*?SA
M=Z"6$.%%1M:G MV[Z/7SE;<5WJ0M-N'F_J-D T7L+*WNPG'#M_QHLMZ@RBQ\
M*#SB0Y_E*+1OI867.Q'S8U9QB<KQL&K;"K=3SJYW:DU+_[T-[%0<_00=4";/
M]YP\<%4R;-6VFD3WPF[ZU$,@V#"B36]1C,@&[\L'B1I^E[]T2TJ*C3H.)@P]
MBVIDC_'3(8<R$ILK6+@)N5>.$-!;9,Y9CTGQ'09.DGI<1/,NYB5TT>.))K=;
M.4/\(?T#@G>/)[MVGS/?S4%]7JO05;T6;HJU!BVJIG_ HB%$UM$\5 UXRUU@
M^]^!KH$SB17G]Q4:A7)+UGY@:4LBO3OLW[[*,O=0Z\9KL$.I:RJSM^:T>V(Z
M$D'+\BP</[AQ*ZH.I<T.S84;<X?;>$OEK"1?)ZX#"9SENNC+R)N8YZ%=+2\O
MG9S+#I4\L0\@(\%!1H1?_IV==QL+*:4RJIA&BV+5U-RNG+2/L;\Y&WMAZ*D[
M+$>R1%1P-Q4RZA9CD5?80\N*AK-;I1,N^*P8:7>&*45=GQ/W@50BF*EH#KW!
M/U\/*F2)7 .?UR?1PIISD&G>E5*%WGW!(&,0#Y#4IG\^)BTA5&NK172!=[MV
MH  <E]LI2UDK9.M0VN&@06J*B)&N:\?-CG!W76D![)7):X$J7\(_CERB,O5Y
MSYJ4H"_\MQC1!U0RY:",QL&/8%7K@F6E#P<I^RBC[ 9&1FA11_S!VR-6S >@
MN<\0RT4RJ_-U0F];_7.92Q<RO<2A?W8Z<C XA[CBXXD'+I'K'JB]P0!Q1.BA
MM6I-Z;*X#X*UH!#XA7T&%@7?V#^/NW2@%%9+B!7L>;-F1D\?Z&"G\M*'Y_C,
MLNYC4"=GP17XYT(@AL'!9J*V8$0YPBTV])LJF)&NUY%0W9BU;;NFVE# $#V^
M9HK+"=*5Q:SLM.]-O1VLV?FM%)EFHSPQM?B^,>4=73SCX#=D.A)>^<G^3\IM
M>))-J9_U\( '1K$7^5$("V.^N)>ZBPU<N7R[$I:8JRIA(X\0^C^.N#Z9:#L
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M^7,M$C_(R %0D\;]]0A:/F7@3WDGA <]4Z2X /)/#LPM(5+;-'F4]6-?T9I
M:K6]2W"DE);.7RC@%S:3\-P"OZ%%YG^^A89A"U?]7U^2H#: !]O'%5&H-T+0
MIH3?3:WG0QNXJG6YBMV4?OU& 7'&HE#S_M@!7NP1'R(3HPVVB%&=#-T)E'9L
M),KS9"<]PZ)NWCH]SF N@?FP(T)PNC2\+OS#^8GGG\Z/(!),IRL>AA<60,:Y
MBO-!^(\C@:,D*J<$/3@7D"%%6MVK[E4<A,S>A[357WIKMS],,%9;V9#UNF'
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MIW!:'Z@14R$=%[FK\DZ;'7D7&"NSX_*I:F1+*3N3CJ3L!$VY)8Y 3JT,*?&
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M)4A^#%OC'.KJ^W??G=5L+]Y7;>&37%PX6%KR;KVZ>H0*+7UN *;SZJ8Z>$/
MRNLIT;%6#J ^O,Y#7&H+.4A1]&8?]5<U(.\/F:\PV(%CHPKEB'<Z]5DI1Y61
M-!_46]=T=<XV68A3$R<S/2))SRDUZ!A .;]'%.ZX;_;&J$QGZ]] 7<5??[GE
M[MARFOV+UX%VEK9"0GM_GJV;8)L->D/6V0/G$FI(O87__-A^XVS6@]_']4M=
MAY[.?RQX4CZ?%N4U?;\??@JO%!8)Q_'OXW1H41? #@%3] 9,66ROKRT,S@]<
M"D@HDY' WFZO@86+E1D=IWM,EU'Q3:I@7%QX]MQBO^'E><.P1L)GLLBYJ$?D
M$NP^./L.T\-.(FYITJ2AH& A,PFSA>7IR\?'TA4J4MW$0%+X.5/%ZM0-)$HX
MQ3_<T?/;B.7,_+>_]5[%B;+NO%"R7.M9SO2OJTGQ3/MQ4-YXA<WG4H;C)&Y0
M(EC\FK>9_3LFFK&YFOT3-096I)V C/D\M.R F!+-"B^>J>/"JI[AV)^A8R?J
MQ1JQ3%/A/6I<RY)XP*31G>O<?\5E6#E$9$HF/@?X'Y91PVD^<A:;G[;$;.$-
M;\\6AG.;L5NA$8F'>"?$!>XJM**CN4UKP<$:08YY&QK0ZB@E- NPVX@T\Y?5
MK/NSD3EHCOK]H(/VW)&"[U4V6YM[WK)KP;_.([ _IL47_'"Z\Y='[POM5*>%
M-W(,W!74MEEKFN[4<W(+<*)&[%,+<'()W_OF\/%];[J'WO2EA5Q+*JD=#Z^_
MWT":BQSKNAZPP)N72D_2%.6E-EKG:+_+'\%[H6/C:(ZU@^M -1FW!=)W]<:?
MC"(>K3>[V?10_T%"I-?<UI8?@W5GCIFGF3;V[B2,>G5ALZ$JB4C^)VN3U(Y*
MEAP38SMX/WG2^W*Q<#M"XB/Y,36B2:9XS?=PJ5>.G<.-,&O-SC/9^!3O';U3
MQ)>9+N1#WQ#(U@+OZB?T'6U_#"00-](N0HC76L. AXC5 ,=:KYG^*]2SDE!0
MSJ2IC5,2@,K:U*=!^WS?TTTARHD$[/K X<FGB^ZBXC<":X+4 8H07XS<PB"(
MB1QR:AS=IB9EW+/G(O@1J ! "B!3<1#B;ANRPA&_2)"_0F!2.Z8.$#VKCTN:
MOR3V>^ \RU@+:U![ TT#M]?VO;T;AE:3_5;A>#"R4\DA<B<_-4Z2NPV*+!P.
M?(%1(]75^UOMS9AX:>43[G&@A+BK[<)T9VRAK9N[N7';1;71]<>W!6RSNM:Q
M[L4_V7<(6<7KW'-.K+*MGM!U/+$OGDV._-*F']3P=?00>6Q)G]&#[B .J_ I
M\VW@HBO$E!ZC>8(:S<PXB^-_CHQ!;"$F/JQ[_?2DY%-Z5>_\9'_Y]BC\.7;X
M@9EALX?:8Z5/_['*UK>,OYK^0PJ28:5\1%P/(*GX%R?("^R0"""'I]"XYX!A
MF+7*2?$)9C)=RXM<WR6[CB^>(6QH$&-;<C>"DKJG00>#U&L)4;GIST:[@6?5
M]=8%H4&U7'<D.%EA-.F:,PBR)!"APP'"%5YT=(R:V<JHJ).IL 6GF_2B!286
M17GY5'*;Q>=D$EB)5B7,"M\>TM%/U:2Y09ED7Z%2@]?=\.Z-,DM0N2C-K]23
M\%NJGW0E]P8"H6XKT#E +7Z^1$B\@T&86 !Q:%Q"@7KR2%?/TS9 B/\2Q,72
MMW8*L)M(E5L-OC'5D7  3A05"BD_!;WOC/(MAP#7FL$=MNRH"(>Z6K%V84;A
M&OPN :ORL).63;O_BX[)EP9&-F7GU^\O7?U (!:[ME@Y6H"Y.[<>Z@UA)L1L
M%30^TGWC.)#5+TGWGYQIW_;B03[)YVL(+[UL9UEOL"7C+S88P97=9T!Z&O+<
MG<NH67,_XH""2$EJ3ULK?V"S[;S,1YYOHP?Y"M <2T,O^_?EL@"A]*'(Q"&8
M>#[CI$FV8KFAZ#/A,',J65 WNL7NP:JQK0_,Q43$E!5EFE"GU IHM@+XR;A?
M<('HA"R@G9>(68<+?$E3$N(3;OIEE%Q02#*@X0I-X^XPRW<,?F:&D[Y[$=><
M$(BP7OTU2B7E-<G^B,&YIT?[B(B#>,C2$CXC'D?PI!'QYV74=[U73!=/'\R!
MUU!D6N?FV0LAGMT;^3[8#8^\[8V[7H1E[$@B'Q5/Q3P[<C:FE^1D[JCR3BA6
MJ<F*.7RM\?(/K:JZX.J ;Z'\990&E=(!;P;K4JVT2H>AZ!8=,W R7KBP;FYP
M]S&_,HC2FN577I4W*_%W2W EEY B:NMJ)\_E_\DY2#E^^2F(4X*'B95UR4#@
MPA;X[UQ5:)P?'"')A(#"CV2Z"63J&Q6BEVQUN&"8,.U1I[&4GD@HV.351A(&
M_WP]_!4P.EM[Y^=+O_K17[._7&14$.59Q'EDA,\BFFMD)?16]I>76)FJ,?QW
M0 +P?:T\LW3RVC^IZ)1,E7WII4<N/70WQ\1]^B07G38S1L?=T0\](KT?0[(_
M_^C^I'V7?G'![*%G9@Z+:4G$^_>#1_Z!<]AD"K27.:\B7>=#6L*+O*5G9,;0
M":&CZ^E@,A[TEH^5""EW-0A&,[Z)GJF"A5O?V"K4CR2-4*^/(^>"*(\-4_(C
MR.&D"PB\J!;;$24K=8<>TU]CZG2J(@2,(:*D&"**R6V#A$M9 QVWYBGA>&7J
MHE3GY]MS[G&O<\UZ9:9":9E96V&,J=:<MSK9VW2JSF$F>$RX.@U*A%S%7R5&
M\B2 7\L&71T]8*5"4&>\ S:&8L0)XS[R'!L]V1GH&*Z=%]>D  &85)8_S52H
MK/=:,R6M[/RLC[I8@T-FQ 8(V(G?T I0M#,8FPY*EE&<0?<E_[+PB,OLFD$>
MB,=!N^)6RK_6RC-QP=V0+D,4+L71WZVD$ C@J0W33HKK;B^C_!CK(8M.#RB/
M5#17O^9505T*78D ,00(B!PCE97)/ 0+&N1,-IK.'6_4:M= 8OUXD^;Q W4]
MOB\==G=>[7<W.W_$T:.3Y+M7K&:@:X7?T+V)J+C^K)75A;@\#]5IZ:GGNTKE
M%]S. E10G+]@,$!ZTT3T%^UN3+M>ZJ=O7NI N:%/&/9N1+]'0X8!\V+$[WV2
M/Y9I2_=_ )J/LTF4+7#7L,)MV-1!"$1;I-ZQ<A40E3K'@;OQA2-'X2W]NF(\
M!QOO'.2^C+KXI=@1YUC7$ZZX]6%^O[9;.R.?H84P]V744("$+%YH 6(Q.K Y
MM%. 2VFR"'KS6+;C/8T4&5J 2ZW)' RCH,UR'A,[ \-*/I?5I&X*-(OHZ8Q2
M['M75>08)8DDC]PH@'UQ_ 7F#UT<Z(256MDMH_JOO&UJ11!;(<XW&\$*.%BQ
M[#DM!+0R_Y-&E-^E>?E*CU+QYWJ*(JUOCKP>%&ICA -EL86;$W-L>/:@=(:M
M4EYN\-G@<^^<(/81>'XAR>OCM0L''YF9KWX-T3H.MKLV^W]@?55<6WRBM[,T
MBHRV3;9?Y_:Y1'C =$^GADA/W];H3+JEVMZW1@UW+DZL=OS.2B]?*)\UGZCD
M13)Z_6A=?/:(ON0\E(ST8ADE<08Q[;Q5U 9) N11\'&.O0E6"=3@:F8F6&D4
M>#H(I)%(S-[8$1PDL0@SRZ3K@Z+D;@:5N2:_=&CFR[.Q!B_F&Z 2F4]I@F54
M&S*UF'\ _((QZ_[@X&_*&A)_KLT>FO?)!<-?]T,+@MW)STD8-=KAXC<31[2(
MHPB'2F$_@:[U7!Y_U5_,ZOV]^L6-A6 1XT<#8E3[J=%"\WD>HO<.Y!,3P9E4
M^N[ ]U"<)$9>;(I-9F^6_;0[/WA7AD:&C\( S54W?=XV%),F2(Z4W!;C[YIT
MA3I6)PM3?X-""@R?IXC; LB3?.K%PO-FX5;D4CN5/_[9?T-'":UX5%\M]Z+X
MVF/PZZ-Q[.B%Z1XFH6Y?4MF\:%?VOK/AQ9T!6T_TIT7M+<A9)-3V$HV7DN1E
M /\9$B_QF _$UDW48Y*G\F>P%LU 7)U%( >\/DT[,HZ_J[YD-=@W.C3K,?8+
M=",/JFM;"L\M5JZ>LLU=1IVH326D*S?=IUS9>I%B)W_ IG1_Z)0(^\++'"1G
MD%"C2;N,P+8)L4ZJP-N/+Z;$E14_:"9',:EZYVM[:1?R275IL;<[7/NK+8-M
MEB[=UW=XF&M^%M8#^#&P'B(IO6F> LU!>@$1V!D;&[B+MX5-00^K".U2K3R$
MHY:2HH0.H4T>.&+_0DPO*9[)/ ,YM.EH#LBL+XSC-'UF%FT.U8OQ:5'/[!X'
MP9I]80[)&WJ5C[Y;[&2OY*#%KAS]/21_QO;M7JE/NBEM'-ULJ"7LOF.CU_F$
M_I[X,RY _Q4+RV=H47\2[>@O-YH"G;*+2+ :.!@O3-;L)$+ N(.A>DN?PP#1
M!YRLT$G3:2@>G>7BSD#HU:X8K^V</B%>9.',M-_:>+EI_]\'MLQ;'W9+W](Q
MM._;U?0 Q3/YR1G[GCV86)>26G6_B7CN?L+342.[MQ]5F2X'*/2N@H5.O^%%
M7$\[RUR"2#HM2)['GH^5$1"+5&A5F]<T8OHRIY><&HI.]I'JQ[)]2V>^6ET[
M^N7#K'N%#^$D^+;4P%&7U5-EM^/YW5,>9U[?&E]9BI1E>X@0\G[)7,B%']O\
MROP'?//<7=ND[US"J>)\1[?D/F]-B]SN'MCNJRX";I^3FM0&V?R[RRC-:D [
MB*N)OAU.20&JR[/'M:_UGLMKZ&'I V"58(!Y-YSL65S5?R%AW*E7E\6*]:R6
M3N??5[MA\/G,%N)W!KPV#\1*-LAS =\R/&);,A6FY \Q7J0'_M1D3!WQ84%(
M>-X,D=MN%A WAALJ-?\)I7(J9L=4H"B0>XIL;>Q8"<K_<9\3S%S9GGF&\:Z_
M/,+ C)V$S-S+4[+'& F")"MCI CEG;T/GKA!D6W4D"3V Y=2(;,I2:>\T.3D
M>'8K>XTL2NH*]36#W5?JW"NA,8Z PCG'VJ3];?.Q$*V9!>%(\M9PM)GB$Z^=
M5[^TBDOWRH_%'YRW-==H;^*H^1B=]T[_??Q6XFW.1;*OSD'5H$&6-IYDZQQ2
M-&ZJ^JP[Z^#[B6)=M:,SI*,ND[/W)^H)P]UE4DQOA\@7@8[>*^M.=$[3KSH;
MY4_99'0L;CWMLHFXU)&OF^DC[FA5LC85%374-O:S%,"IX^*(Q&\-4;9:-YSN
M[<Y_,IQ\\:S4)EW2&7LRNX_MAQV9DIC*7U8W4MSE:<NH0&8L3\N58W.,FFD/
MEC-WV>P#/YF[G%).G[IKI5$V0K+!]H1)?SS),K1TZ?_FX*5\]%Q RMO)B-@S
MC"Z\3(N".*0Z)!*;P&]6$L"= BX#L3[;Y"5L4NHP%_%4JE:$W+WRO&I#K#!)
M9QNX4MUY!Y39?#^H/B".12H.NGF1RF[WT0.1ASD^@]Y]&?YZ[E4O)<S!47WA
M=-^)V5G&56HBO-:RD(9 T=LE\#M$7V?8D-Y"?--6^(W..O!M3:K($+3DY&H-
MF/#6TIS>4RB&88S-,SJK06(,?Z7.\Q::%S\Q<?J[_F_!+,L+X]X*+4W8"G"$
MK'>V_Q)XX =.D2_>FH(WZ#,NSO+K%YN,^1(RM">V/.I<PZAIYBC;;V[O*79Y
MKA>7'Y\>Q&Z<>#3]C.*]TZ+7F;'K\&[A#U?:[$&I8\.)ZAR1WRQ]EO;_S4K'
MCP4P E8J041[#_HZ/H<H6QFX@K\3T60Z4*,?K&779W66,HZ/S;@YQHQ4>U!K
MX1_/E#F"Q7>L+)_SB$UYY( +Y,)9;B@Q*-DL-2@MJ+9NA=GH,_YWK9W XO\]
M:PL^2U;:MSCOW^8]%$#9*@E=5_^B718?MOE9K5)6'FNJ%YL<86$:Y%MZ-#OY
M\ED+TZMC;XW=!/O2/!Y8?+E"*[]_)BVY6-_^BN7(V<ZRWOH(W M#P+O7RC"/
M[+-;O%IFX1,MZ-)SX88W.DT!0]]$.T]699_I9TY]Z?GT)=B@;/)EYD7+^>3:
M?+.?9,LH,4:FQD9 BP![JQXMTA5B1O3YY3F@5UONKUR:O@"SM>ZND1%.L%^,
MCAD;Q*F0?#:"HL+DCD2KLR&"J:8J30$(QSQM*XQZ]I%W"I5UD)<(@+_A1BR%
M&J)01,<'H84\F@<WG*A*'9=<6,EW /RQB<KP:GC9'PYLI"HY0.:^XYBX.HN,
M_*N%GZ^8&&JT54*::#-R(J>(>@Q?STJ?:-BPC,K!@4$,V6:NQ%M>Q/;'8F N
MIH;!02O1>^I3XL21K>Q53>MD%E!'L9?L&$0$QUM\MKV7&8[CU<@6 9SNS4 @
M=#0JH-T'*YZ &C3+XV]FW9P^YMSG/K;0:E'-W59ZYXNL/G/30'<%]4.33M?5
M<PIXHQ@-*UI(2.M+"_RFS^\?C-NGA[OD/R+U2.Z%/7/[="+2\U2O6S]P0T'_
M+2PJBQR)]&::![OTPW7 )3RT=QDUKRBE!FG&QDOUZ'T\M(T1-=N^=R?W.WH-
M :! ^(Z,82WY0^(YX"?JX@F0F91]NCKC2^^(<V/JL<A@(\FDDK:M@]<;ES5+
MQ<*%=OR=912*CD$0$KM](5YG'>0(<EMJ9T*%F&VTW\2[TP7$]3,DDQ(*6:V]
M[/GY84)VI[1D1T6?"51P?QGEUJ]7U_=MCIP]<O?7-.A/Q,W\#;\AK@+X63C0
MHQO:J2#:+MT(_=+"J"JJ$"](;@%KJ=)FG-(W*DL/E)Y);,&HP H0D7B?V[QD
M/#1-4$Y-E:T6=YX'[1*J 27D1O!8JG\:AT)Y-NH=9!R%1$Z%*Y[0U,G^E0>H
M-NV E-H!5?;ON%@<)MPZ5%("8J.1*5,S^!D0[(1^7_*/$P;;*E35]%!D)/ S
M3TB)INO,<6^F%UC0*TK)DJ+/+0MN?5V3#R [@XY)FO&V!NVDPO20W1@MG_OM
M'6B#EICSM=2L<X^V>9O;*1%J;KX$?*-+I$_?AOMV*QL:CSCM?S:QY55O"#Z]
MR;WP;7]]]?WT3S65>%=)<0MFY=C-)DX[C-59VX.CX.]<'QXA>LUTA@ISC(4:
MMZP,%LU/K++%:4/CS71MT"KCU;WC=3/"W2]NU1DL'E"]RGZA;CY(*$S/+2[R
M(<Q:7,DG4_XO*]PMF>J9&1'7%W9IN->=.;5-LKCQ)-BE5'"O8:<^YI,!M)+F
M\#JBB#RX*W>[/,M&\R/<@:OL3O[.6Q?4I T%/(?R^8P[.']L(D/1*K1DY&V3
MIE@CQLKY.8F!KE[8%G0&NF4R2O$$BVZ)];W[FGY]@Y:8)^1^)O](MUZ4_)TI
MC)-MS(:5OXI3.8P87C4FGGZ8NM@LN0XHT-?*@A$@B5\?U+2I!S:GSN17LWJ#
MRUC'A-6QN#@=E4'92=Z&S\(!IF_?YV K?=*J_3,WPYP[NE($SU?-\0_*FC(B
MTZ>V_/,NUJ?RW7;.GOKJBFT5*38I!V.UT+8F)6XAR03C.T7C+L:%+@47/]X=
MN._R(.=PR_YK4P42\OS+5Z=&YP+H607T?+B7"'HB3'1A/E6LX (YBZ62-Y 7
MGQ=OH3M1FR/$KB;MA^J$>G>M#$N\SWN.V!53&_!0@("YI5-@?=08((=&^ H/
M%(Z>(Y4OU7PS6SJOH7$ORE=J2A]<1E7A1(E\DLTNN).G!>O0*&!P3?]->O$S
M"-VJ7E^PM*;0@!B8:"^V36K7CFBI9]5^>)5J+];)+IP]2*@\7UAQJ]<6MEA&
M\5.N(<'^%:\*F \!.:VX&FP;[P-G7$$4+$YM4<=M;+*>8U3[Q#VAG1-C[EC9
MC><<FC5GK#<IQ6RCVA$JP (;M;YP'&3'\MZ0J4*$$EOCF:/DFTUE)",&Q?>K
M>H7T.+T9]R)"IN$KV0>]05SD?:B;KTV6A,A?6!T3,&\#-1ZO>=%9[Y@X#EMI
ME#K746]WJQPK &6#I<&%T\VRLP@^O MO MLS5;RFFW1!IU?DQW8%@?6LFV[T
M,B?%U]R2O_P^K+-R7,_Y*:YM(/\O_ZVTP$\_TL\K'W9CVC_PM3>]ZMQJ^VAL
M7=EEIQVFUG_WGWD@?/3L2[6NWJEVI[WM!UF"KB<4]T+_[Z=VL^:!O %59^)?
M.?^/+^L06YBRC7;MFG:RS<7PNJF5A!G(]':576?5@+J,=MS6&023SX^64>]P
M"@)S]P&K@G2,!F#MF7K;O#"Q+9>G;K-!=J3/-$=GD/0Y^%T=/YZFZW>U2;<A
MA>,&SY:*I^!UQ2NE7N6(.^.7WL3%A3,3[%H!I29K2.$TW '=D!ZEF9N%0!VG
M>C9_F7.-;J'OZZU9%:S?#J^O&\1>"4\TW/>C6DXYVG\E7%&V5TC9D$QIW5LJ
M]U#V?[G>T("GUS5!R#W+N!!XAAG/Z9,,7#W'T@Z/?^U[5JN-6WRT-*O,=G/R
MJ=X2(]OAB8RS%W8+#GF^RP[>/5]04+:GKG<NH"=?HLE^2!D)@)6\Q.P6-NC!
M'K*$%=.EJZ@1_.[V48_6I:Z5D[Y!(ZEJYZ"XUJLTFWJNZ8CE:! /SZ5I"T>5
M699"S.UEU'J9M3!5FSHY]J6SU5W,*1L.C""X4J-/9[5P)Z8!_BT>Z"G7XRCP
M:Q-7BMA#KVW6IC,<O;*3]84?=0Y%'SDP2F@K)IC+#.7'SM?T:;X]63;"N<Y3
M_;6GK.Q3Y"%:)]DR!#N'E6W.A]=2I'N!9GW\7=H-?A>^#:<%D/#:I%"2CH4\
MKVFW;A9T._B@1&+HX/:>IBR8,WM5!>+B:G)LA[DN@^-1^%8?/2XE6 "/BOV+
M?0.*SLW ,>NQBI\>B/]Z^Z-6*[[B(.?BGHF'5[1^2<V+.SO7%S8S;KSNY=MS
MX4Z'_/1<#MTT*O0\>R8HQ'ER>WU?2$)T0?FC3Q/J\UE7#DQ<61P6$;CO92<A
MT3-/^!T;I,:]QMS%J!ME<VS6R9_8*$XW:4(A0L<S947Q$>54!A^71%>F1M@E
M+ G/WO8J"Q "L1HM&8.UGSX"P=14NP2'\)3O1KO@ ://(A.I0ZE46AJIKZ5_
MHWR!<F4R9;BWMW?8+$LX.ROT/QDL$@GL,DB%82E[>@KNI;O=^Q&,B'AEK>\D
M_1T&/,N,@;>"Q6T-C8!@H0T;&\&]6=?,3H%7>5$@1UB'&'3P7&<I242^WC-$
M36W)^I3EGV-4)I .E?E[E2I9.QP?J+9V7\W&I5I,R39&PNM&Q!$M>I)0^6-D
M-M<S5%@7I'NZ BB(36\,S$*WB&R[A?A4FL;ZZZ W1&S3'.6F]+DVU X:7(RR
M680WL[?1CO;IF!^<K3=CK\]45_'976[72C5(*,=:YM\?/YC$1*?Y/KWX@CI_
MM"RVV>TI"+%6O0C3;RDC/"@]Y,;A9FQ]]J(^N^A'\[X'A<[[KH0\^BCL?_+\
MT_V@4S67LD:)3CGH?Q41*4H=3Y6IEL)*T=*+U.U&1O!ZFM-*E=H;++3PV!4.
MGCL.%8J_CF/:M/<:7/D42" GXUH2\XF\D8X@T2J=[;V%]>1CH61M[A/$C9;P
MOIQE\ZN641)JE@9<P-"96SHIOX.[@!X:AQ6[I594BH0LSY*9W\BG8FU9#=P:
M4:1/0]Q9,;,5JSG[8OA(&;30<?.3>L;&V3'=@;P7+ZIW]W*<>L/*])QZORG_
MXM!;;:COV!>\\GKJ;=>5<LTXP0=87UXE0]2GM AK1,A,I]KUT8FX"\NH&,]E
MU+H16&WA0PU69Q;S 4-"[J6.+T .5CS(R8HA(E9!Y  )\:$\:QD5/$3JRQ(;
M>?[5,VYJ'[['[D >YR^KW.2@T/0@B);;N"XTQ[/OSHS+T^DS2ZWIA#\]&%71
MC_+]\^S/A%&8V.I04JF>:919L/<(Q8QNC/2KF_<E"@ I#'E.<2M.?I[X0@2<
MY?VORPWO,"O@4;;9%=8Y)AZ!%;^*F; &<F,O [J 3?39 14NH]9R9?N8T#D&
M6+V,JF/Y@I9MC _$$1Q8::6TDI=\""<X#00LHY#!^5'9W<NH.VDBXA "O'WE
MV6YR#XC!9T.>&&6;[3)+N/=?NWN+K\<,0:*DX\,RJAJH9 OVOC=51DL=I#B1
M.^Z*%#W2-"#!U0[)2]]^L1F@L-_A-3 /^:6?/FK=*21F;WK ,?&,P040<![4
M1Y/E1@E3Z:;K6- -V^+/?JX9LK2)K!"3I$O%GC4%'V^$$X:S$N>*G@V/?,8]
M9$+&4MCY</DR:FB8=G$9U8\3G*#B9)HU8KOF@S0?1)U-,C6+G.>8364XLLA+
MF!#8=VJ5QS#S=CA&!9F++==F;U[6;>L2E=\JG[DZ3':Q35Z3:1X?MOIAKZ,/
M:AGU$J'2=@O0;D!FD2AQ9,LSV8)PY%]+4DH;<XO,!1GU%*S6(=O'TX<W=V%:
MLO 2#=E.')A+.\&3,Q Q=@SC$/$*?L771#6\A;MKI>8/0V1!B")_9?,?ZNC)
M7]H<0CZ<ALUDJ^3/FO;0VW$U=?,\*9%,B&@!DC'H\32OGG+: ;%6*V:+KY@1
M30OABY]-NY MG)Y;X8H3(Q,=@P8M+QA^(6OBXX-WU5962S6\]G;K"7WV3F(\
M.D->)CVIU3I O7Q\IKG;.'-@UITC/21,W]H_4>R1D53J<F?T9.]3?IZ!X:&H
ML]?&G)/2DGN'%4UR1.&]G[O)9=W34_"&2N@5OSN.!]IADG-_%F_(*^8(*2F(
MDZ&OD>' -=DA-]9;),,5 D;BF#+46':>-.BXK6K,[H* &+OTOND^;H?6<=8?
MW6%,T\:R*4&=3+U84)?0M!%H_A7@\XBQ8X=>I)T4I]ZI2;U],R*^^L9XAE:9
M!@&(SE5G]9MX31>=_)3HW//9B'BZ_Z)^K>6<UQU;:DL#O96FA7B72)N],D]Y
M'JQ-[T-TY$$98;>SP3,X59E6?S#"O!D*&BTS?.;M+-U)!K"AF!(N5-9E%E9S
M3>9$MERG_O#4]8$V*N#9E(;0_!E)[H%^FE_>C:S]4@0D2!&0\&@9%?<<<I5<
M!3MD6!YTA@=V\[9D"[M'V )WH*5G)='*]>P-#/DM"04ZMXS:P'X1\ND';Y@=
M.-BTF"G/;O_:^2#@AOH18MS!O_V=VR^\.%SN]\A_J-# [, %W_BVB41L7ER+
M2\G10V_[9UH>G24PE5?O2W/:],GE?FBQ2W%U=IS^@PMKC[P<>QOD6,O8QSX1
M.4TW1:;)9.ZZP1KBAVZ)@YC?8^KM^AI>*R^>ZK,*N5%PL".T\)@0Z74]V)OE
MD%G=%.V8ZFR#Z0^;"W:7])*5HGRBC'H#IQAG:FI>+FD((F1:F5)-FC\4S$?H
M@3*;7X0!W9FJ-!ST4(!&4^>:<W?TX<A(<Q'N%MVQ--="PIR%61[%FOWZ5)[?
MRPI6S)"+QY=/6!7MZ=? ,<3<I^9[P !)"Z0FUI!<E3^VPI#'5TZ5JYH<>0)E
M'WV9X>5UAQS9$(RW&_P6;/^Q;"Q5B%.>NVYQG2T8]>_JG;,?#)O3_W J\'K=
M5U/$K?RJ(5/E2NQ>-$$G$%T@^KC=1SL)N4KW$V<).9]3P1&A!^><U2DFS:IF
MD.(^[E(+CN632GVF-_.\_^$2VB9+^'*TP$"COFMT@$-27\S,K"_K-G)LW<38
MP*^\Z2FCAFIG7!37[/38%,N\V^R_Y?3E$O>@L_L_G/<C;'ED2 C]E/2T/8<0
MOEF2<CWI_,QP0=&,]%S7"9,LE\24K-V]I.*QF?(.:ZGQ2G5Y?@JQ<E&F;L=?
M1G'*M"0+\@;8!&BV:T)_&(7R6S#KFPY SSC"A=B OG!T#/W0X$(8L!5::$$8
MAG9NNN#O, QJUJ(X84TB4X8'W5Y\G-/1=M@.W"AK*QQ#J /H[) =280L(V'%
M X;_@".VO,J46Y<K\?N.)H?<$%)&GO3VKKZQU:TK/,+*;+#G9Y_(^">QNJ1=
M)W#E.-">">TP;V9"NXOCZ3MHH6*]-IPF/,"NQ;9O60B&=Z[4M%(UU.PF9.('
M:M::)D<Z@+GQX650Z9F>?+%9!9GTC%KJR;7R%#(W0[<_O^WR'PRNGK;-/J\A
M4_\%7GOOZ<HB)JQ/0\F+Z.OI SX'Y/=6TG<,]>$M-*+A[8&:1B7,8>_ "FJR
M#)_OZ&L6,XY>!<4UY^X%FZJ>DK-B,X7!*FXL\O1WC=X:;9."ZX24G$:C7]\6
MM[HL#4:DMO&#K@Y:;L\(3>&\:3GTR'\S2Y>H?)LC$,3G9>[[#H3;%NP3[IBP
M2-^5;W1.YUU05LVA=OOG0?M"HE3S\].N7ZML(!7V!-&O(GWD$;_8 _Q'1 DU
M=1GU=#3]!E.V3>OI"&TU,J4^ LTJ;,03QX>^>2Q;WVOEQ4]=3XUNS_SCR&-J
M$/ ++?(%ET4L"1I.ZM4MS&E*%73?S;)MI.L>.#WLE U8OZPWJ[1#SRB(D*"\
M:A_4(_6%VS$O%A'7?70EISH2(S1E1/E]V(A:)^0FX0(9JC2M 5H4D^:?W9JK
M)UY35P@A&G8<A,U)A(S8)M4>TRCS%C/-[QWQIH*(HD!UEQ./2?OK28/L9\"_
MEG(9\W,(EL3*<[XSAD8D2>\7BGL*FE);Z6O%S#B]VQPD_*ZGA0?XW? MHG8W
M#R=W-8X^(WH-\\8^S&KZ%P< 3^:RSDZ,Y3P[A]]V[]0J/]F)M D3*$#)P*VB
M?_]FX3]LXUSUF)NA*4J'2M9MH?EK7RQQG@HMA <TB6U)%V?<DRWN.RNZ/FHL
MK=//K'C@2I*^/_6RP;RJ5QKN8??QZ<R.7??JWVQ+*$])VJJ]98V'K<O9] >W
MGRNNVGCD5Z[XE%0IR Q772?3;D,&L Z: ^L!T4(L8RV\D0>9MS;M[6OQ"4P4
MIJZBF4"KI8=G+2QFR;O<EU&!#>*Z.[+S2X%U4L_&:G"LV+32D42Q_H8[2L*!
M1[&0/O<V2P,]/P NP$J-8N/?Y _*JKG@N[0 ;$O9>9D+R+WMJ5==!Y8G/Q^1
MG?"FCW6<[KV4:%\99P<Q!%U&EF[G+ILD[VA1"K;!#C.@W1H(Y93X(;/"C:8]
MV+15MJJ.R[(3,G2"W!$>W]:=Y&.1U?Y5J-#:2#D=.ZNM:[JW>L[!$'<2[(C;
MV6^ZAZ8O\-XW;*FM&V[H!'^.\FJU>/>J?#8W>-TK[ :_'W,M 6&ASZ^'9G3O
M:7%I^5W\X6;8_K\>V>K4[E1+SC"+6>U45\5I5WWQ36=[>P'#ZH?UA*-;Z;Z(
MZ.(MIQQ?V1N^VM6;=,.KS^/Z?-DD?27QYE[V1  6,C27IXTLR)U@1>Z,N6S;
MS#)JCX6\#O@\@OO.M/G)HX+^%@!/=4/^.&AOMPBAO:NW(1@5\:2*;!D22>**
MWP,"1P3'/$<B&1E6F\HIA_2\I$29 0XZMX3@1-T&0+!!:GYO!0C&1@"!/\:N
M2C'IX=\8,M4YR7:D@128P]9B^V(A3QY8A "<:T!+S3(J<>4/_VK%#B?PH?F
M"FW$'RK(UP:@N:1#PI;]RON ^V(R PPMHX89PXP9]D7X70/UT9Q!21OKP$..
M"FV#]P:5<V_ACHV-B9U[^;XI/F]ZSSZ+5+!](A\X+'4B?I0>'[]F,OET,-'G
M6\Z5L^%,TQ_AC>D+ Z7A%5,\$(D6/XY/R50ZX"XLOQO.6PJ/HDC/47<2H6RI
M =S+5I;M54V#BH7HU^BDW+5@__ZD3C.VL#O.9^?[,.J3GX2[3YEJ22_]MBMU
M<N<4GK5_&87@R:%.>*N2Q%&>B_-;@$X#@@M RQW(@=\=PP81D-!BC0R8(=,%
MP+O3DB6\9 $!?R.YN^$6^+T4-XRKP@E^';1YPWX+OW\U,FG>%_[EY?QYW4>^
M!SZ0]CV8>'CQ0-BN\5W%"@DY02XA64GW[X=<.9AT*:WZ?H3M"T?7))_D(WJ?
MYM.^X.YC(>-B(3'&E CIQ;6S;\?3:QDJ39OH S8'!JPH_+G>VJ7/]YY0%YM]
M5A&5R!XWR2]8U14#IGA%J.-H3+G@-EY$5)QSGSP@N=KU'2?3]A '- -H-C\9
MIT-3%EH3!KM;&=JT"'"G8(HS>O!4#\4T!^ P-*V4Q='G',B73:J.75@IH$K?
MT5#_U^K8T9A*AWV=(1156;?(8QFU9I&L =38)2ZCKF"AW>:BM'$&TDF1DGB#
MH^L9*#./2N;T4HL%V%;M .]ZAHM86=X>'UP^71EX &)X4DUY&Z>78G/&@;4?
MR1F=STFYJKWA>S6G0XCK<?Q1_%VBEHT554F2M(+BZ6.,C0 _SX+7,O*!(OL)
M=):96&T"'4Z_O/W%\L>OW&]O3+WFHLB<X4)1;4YD&=6+8Z,.1?DQ.PN&/D#U
MBVU9OW0_8?/ZV\'VG?$EX@=?V7[VA_ZQ"7'=N91QT//9/_L_IT?<+C[K#'?G
M* I)114N;7T)^7I;CPW;^42>=6N,JVJ8N"IYU/-IXF8H0<8])3.[,L6 ^QC*
M,D<P#5;>%/>:?N!%?2_+L1!N95>UYS\GF4L0.L;NO<)R%NL+@,0UZ4"07[IH
MH?KO\+^?4WY/OT\M#YYP2(ST;,WHH=< S8K Q$8<B%^0FG=O &8ZW)D%./X3
M7,4P?8SWW\C[LJ@FLJ_?=-N*@!"024"(BHJ*0*L@RE0JK8B($9%YB+0#DY!6
M!**$E(K, BT*M"!$14!DB$Q&$1(A#*V(R!@!(9.*#)&*0BA)I;C%_S[=M;[O
M6^L^W8?[$!>&E>)DGWU^0]4Y>U>3.D@?%H!D$R@+2+=?^YYJ7P@05^+7&B?<
M=I#D)E)]F(J"Y1*K>!U/;RZGR,4W4.B_<9]9V_L<5[+4>X'XP5GJA\W>%OG?
M .;FAIQ1#3KL#4(/4<.)L=^67!NJ3H<=0,%6M/OYR^?H /:6+[H:KX5E_V5>
MZ)"4 !^N!\T[1Z4=H_6T2(-[@NI&JV3.NX<99U.%T^<BW937N%](U->XF@ $
M/VD(33O"MK3$AXC/ORBPU'X4MF9/?]K8CH</XJQ.B&/%#/*N*6N4L(CC/Z7C
M&Y=+?%'5'&QJW1$;N(B?N9+J!(/"[J&7@MVY0OJOL(SC8W63:B#TW\':@7YP
M>U8@Q*^"$SM=>RSSM?/6G-N=EY[>]2)GRZ<=,^F'4;Z)A+3T=/HZ '*.@,W>
MP!D2O$T'L0"0]2#T9A&'IV[B$V%7'E0&"HRPKSB#JI-UD-/8AQC(]F[8NT$'
MV8"E, :2]5+\4VQALR4Z0Z" (/,<,0/J:5TEXRU["S6V=H@D:QK_>/JFZN"]
MP-_GC)3Z;K<)_\HJ3;P1=\-XSQ%WGR-%KC<(37O;3#+JSNYI.Q@PL&ZX)[@X
MIJGADGTMAIKN&'Z;+^(F,/_RU!-=/S\]MXA[]XWU'+ZPU!FBN5ME/[_[!DD%
M608QFJ4U%H-CFO %;.GA*02.Q_>:#19/@P/6]-4UF>GJ&J7KBNH]MB0_^ON)
M0NQ!JOQ\M)6&UJI#N[0"%$<//-M0Z552YW(H,NO8< #7PC5U>.N5C6PC>.8_
MLN<-#>!?!Z7'ZP"Y/VLM8_K 4C6L\&YXXSBRVU'\4_8;^I$-L4$!EC4<-4IB
M!^:A$TB+.*5:=/4B#L/[/R6L?)%Y#=@2OHA3)F!:%DKXR<8 ?6@,1#;8;Q\:
MCZM]#9I/,V3J 5]B_CDEN4M4#GPZUU1,?6G2%BAY*HT*G X[^59"27;(>V2D
M=*\_M(7:7WQ".3_[M=.>"H&.KGNX]Y&0#O<GGU+9.67?0"T"%&R>,<M(H$-'
MNT<8PNB7RP?>I4#CHIDT)*9BY,.3)G%[M@!_U7"Y9,6#Y7DVV^SZG^51>T;*
M:\J/_JM[=6.FD?Q:(Y9SRP',-*9-TRS00;H&R"^FZ[#_I _%<^BZ]=T)AJKR
M0O;9.$=/:/9UY$,XIH6V,W<_FPWQ4AM71]3)E1TE[,1']L9PBDY&XWZA?^",
M66!OG8'9R&$O\ $ &^4BZK*E?GRNM'=T/2 H+E(41Q?O?8@$P=F@J(ETO)^F
M?A#J(#)[YX!?8?#50M(-1J,5T$I.@:9R8G+R-O:-^G>5>1^TU8O_X%2R\T"$
M,=(.S2/ZU;(S:#N@8;]ID@<Y\>!MY+2E\G_7>3J67^O9:E0]"39#^<3D9RS]
MK*TE8>Y]ELXCHXY_2#8.'WS$<>J)BEW$*7RU-_57&N,>X5(]&74725WS6K5(
MDE:!A&:E\ __+R^$HWZM+"O(.\>;I).8J)=MN39JBVO9M=;!9FYY\'=NH=*)
M"_$WSKJ\/N(ELT[5_%.T]="V(X_6;RR8_1Q>=M#)]!(Q;J8/RD153; O?Q1]
MS89<2$-LOG&R[5Y)IS0>_BGS0D[#;\^;(V=E!Q#OIY*(!AH>WO6*ML5^<SP'
M5>^SM2RJ?)9.2)T#D]2>59>'^C1]*[!0+O7V=PI_\I$3)/\;6S .+"NP>9>M
M@FP-HKG4 F&Y0U-/=S-[V.T Y'D-,7D05HB'TRM'0@M->RW,5?PZ'G^@= C0
MM$L\Y7KZJJJR\(HAF.LF,8\G':M/.TXG#AJ$SP@(=PD$D#_8:3[<(8A)J6<,
M@ZB2CN2EB"[F"-.#6B[NEWE0#T&NW$8#OOEOE.C8(09+#[&6%\YB?L'>H/<2
M 1]6Y)KG/,3KZ',,>]*\@O%PPAH8L1P%O.1WY14@_Q_22G9$]P>@F5=-%'LS
M BB\XQ YOG'9BEL2=DO>'B@S]1*05O@KE H'X-/&--[/^9]N=PWFZCU_/IA[
M$BIA5%$*WTWMEZPHOS\ZR<QZK<K0V1Q&_P1/VAH[Z-._>*?[E>]\&W3WRYIM
MEI#7D^.M%6N?/J^HY'(>=Z@D%FBM<<C*V'8DW<D1GQ05\EJM=,^;\O0];<=V
M?+J9E]70U#\]'\MSKYIQ@VR$ *+G6THUE6 JIHT$;W9$- %IBCP+N?3&K"X=
M\!VP-#TVYAZB'7PI%D@%E"P9B886[^L.^S?*PM*='>%KE!.6US_Y-XKC=-[0
M:PGBE[(HV@@=<B;#9IG3>-G)20^V 6J'MH**B/?#$% +L=N46%U)F2*^CP*3
M?<@W&\WC'G_5BTNG9T34Z=-O6&<OXJXAWF&!9FQ1@94'Q7)7S&,?;_]) NTK
M /U!P"0O!Y,;7F@W3Q7@-]G;]()!^2H6<*3SBP;X8+EQ&UZ%XA\^UL(]#*$U
M5/ Q7-.B8N*2^J[;B=E+,_WJL7 ^L*@W\>Y:]8WT6@ ZBH<W.4XO51BNAHV%
MY 32RHA&1]$B3HMZ;) O(;:SL:6FAMGT;XU!$L=6[4&F1\Z.T-\_C#A@!LMM
M?Y+KP$.(FR"4A4YPO ?)40;./ES+RB"O_NAVR6[##)+5/^/_J)J^?7SZXMMC
MC@'8XE*YV>RX/+TTF>&FF]G*?YI]Y\*:*V3\]EV%.ZD_3D2Z7O^[R.E%;-WG
M0V:[W#6R[ISYK&_F56;G-HA.]E5U?&=@HS1=.F&&OJ9#QY<T(,?\YE/T(P]R
M)2>.V;]'G"7*KT!ME@:B)"^Q5180DDAXVZ!'<+=W_[2IA?G*4>I:B6K1?5^X
MO/E*=P(U9KM/8OEET\$'PC!9=N'QSTFU8+,#P$]C0P<SAY2/P0[%-!X&ZFYX
M>)M!U5V);YMU6Q)'95D;H&T!9%CE-DCC2];W1[D S89J\BS6.DK62KX>J^!^
M06@GI_=00V9RW>A.Y^3V^VVT?O@:-F&?D9-R.FI-W?>?8@V_4;$O<I4R+_TE
M5U@L'*5,\=VY"9A!V W;V>A/D/GQG![.DQ'?#W#L_N?/^S=C049\^=V&3@\6
M<>=#HPT-),9)EW17W!Q+DVW#H*$I;Y0I]N;/C-Q&E2)E091Q5$E?M@^QONW4
M3].%8UMI^F1EJC&DRGS@I^*PG^6RX4< ]PQ7C.RJ^"912)SU-SD*Z22$4_>)
M*T)9NH.,S )_2H9Q"_'WMB UT=%PVP;FX(Z3.\]O5BI>^SUG \;HI[0W//OU
MF?^1 KU>UP51J^?-KP<^9I5M[G]RXO--@Y4_RHWW.EE'^[XNWK1Y>.)LU4M"
M+Y!8%P:HPI'[(+1P_L2'8)_-V45>K^.8XAKOB9S?O7WMOGPP]1035ZWDZH=7
M<M^9)Z]?DQ[]^"%[;?BSD9CP9[SHN?/?;&5"+I+%2&%+B8V8@GO\I9C4B4=T
ML=6RA;U$Z4%3$H=%G/>4U(\QB:WC!CRRR5Y38I5H/["DW1"[RF @XCOV'T <
MMWN<*/,<:IP"ZS!^,HRY)4VV'2TD%6B+IWX&8G.S9("]0<Y#C&46<8:T+A[4
M! KN_V=VYH69Z5A2W,64436F!USEV$^*QAQ> FL9IJ9.H^H\V(NTFC4B-8<]
MV,/L$=+(,WH(.BS#2X\2AGCGV0M^*P+CBUH^.N0,5':F=YRN.?+!Q_Y=15.E
M[=KJ;G7SD#76QZ6A]7;;3MXH[9+5FQP9.F(Z4+RQZ4/[PX@I1S/?D)=-A;Q=
M/_)15<4[:#^OCHFL=D 5224O25YH+[W^$F$M:CFAMH%(O\[^M>[GHT%QO>_N
M<.9"1+6@*TAXK#K\[(6U#=2\I*M97^8[=T>_!1_Q4@D:C;] GH+N=-04<9<$
MW.*3$WFJMCLJ*)WMJ#DW*"S.F#.F]WY[2;^E_S&)R"GH5KCX5*169865#O/V
M/Y7;PZLBQA,5@5WA /\>:\\@IFEKK$L139$0:&6LHJ2]*E25YYS&7",V8PF[
M\P(8A!3JLC+>V,1P9HJM_Y/0^6/#MN6/7S.HGM49?2X)9GJ=;5<B_?QJ?8B_
MS))@$_ST<B$(;Z5/QPJ!(2S,=9OFIWFE<'<[38F+!(J4S9.^4YV)ZO#IYN$;
MP]^7NBMS=L R0;O,P*'UV9@^-T""[-_XEQ_EXK!57\0-]"SK>=[/@,UKM]XA
MKGU\]L-1Z_*\T^N/U#LFM9VCO/9\NTG/M7A;]K; IW^W!&:5'KM0<-0^P[7?
MR24VY/'8"=HG7R?+-<4&5_Q'9[@/D->AK/7R>C9_@IVNQTQH5'D,=TL=EXY^
M(YLD#1,!6R1ZVYI%F<. '_3Y"_U)\<W!$V]S"HTD_IR#9Q]/7+&M)E%M81/R
MY< J2A:@!T_R#O76@]-N4G]Y+DV!UDY?UJ@LLZ&]&UO>1R,@IC!84IF16?2!
MD1_[>*PS)8JT&LYU_SN.V6IO(E&9N5M&B6_5NW.;-!GSP[:FH;WZH,[W(#X9
MME26/H4#!>E6S005@-_ JP,XW2N">:'HOU#F-=8JJA.4FVC!8 80'V/2]MQ7
M/05Q9>F$!W"^WZR*4<7J#-$9-C<+>I%/[3LLGLV<GL P["MMB/<;$ Q< _1L
MW3 %\D9>RC*%@P3X=F(B0=/6$2HE0<9MOG;*PH@$/EX_F&8R@!+"8JYDBM.%
M<?;<PY)"^J./E,@3SUD0-_D\O[:_)&?*8>"^Y]/G"U2T=-67-913%[^9-Y^Z
MZ/?KO>](8893(2JM26#5IK<2E0F5IR7:GPLW,U\Z.6?EW=C[L:;D2=N+(S>+
M3_@<B2BVTQJ\Y=EK$FMZ:8!%'_BLZ4K**0C\OZD<0LJE0[[F/_\@(YI!:)>&
MR!-],)Q.>\#]/(YH=Z*NF%-9KHOQX!\P9@P?1Q?M(WS>CR&%O_RZO0'8[,SF
MWP>4EVISIK)V2AA7J3HBAC)RG!N%UZ#:6ZM)#A9T7*/^4@6_)":^A3.=!NOH
MF[_/.R4._^CN^WQ[NN;U)]L3XEO@,P)\W5>*7::H9JDBQ@P[GH1,3\$8SES?
M@(Z15H+\O*4-K4LVI)[9052E'I:0.)G+*&["DH3R8+;B++@JC+7[^4M)!V<4
M;/$YFA>=+\*OH6@<R!OFN0Z$C_<'C+?F9''.W'8*5_DXF=,+7B1)]# $Z423
M">(E4DJLE48MXKX^N:]*X@#06?JTL0!<38EM'03K@\1A%V($HY%.W/#P;R3^
MS-#X\UYS\=S*]<^_L_0=S6]O?S:9]?/BQGS=9];/UH#NO'IS))\@QB)VQD@X
MCY;/J'&__UC$J9>#S=O97Z^A&+'"84 0"4U](N=#9'$DQ)-"V/<\!;.ESV"'
MAQ0>AZYJ;X%!KX$E3SF8O=IB5.&PI#ZA)+V((FOQ=)U:("?:.HM4E :_N#AR
MYFM?Y<6D6'KEO?'UWIBW=<PW>!_PFHZNS%_$;;V(7342'!I=JEO=WW&,,1N)
MV1_,V'Y69&/&[PYQ"!,[GI[Q88@(X*>PO^>:P\96\@)>,TE^]!)&(XX ;(-?
M:B*$4<O0'QB.S451=E\%.@&IASR;98T.@P94!=D>])W]LGYT/>(.)Y55)J87
M>9EGGRWU/I@21=:@Y'O<B4OBL%9#XLR[97!2J_6]OS^$1*N]WEYCD;YJYR+N
M$#:IO@1X-\]M*0"T-EXM0VP"=;<OS+<[5Z[88ZLH"PZ5#*VAVCR@_&B[<H=9
MJ"*9OU[W8S5O E!!>12:]D>#P'319#2Z<C!B->^X)+$LL'A! ='%+K?5!?Z)
M+>U?),1%G(^)U)TQ6P*/+X&]V  B"V->D=)8AL\DGASSM+&5$@(F*_6#/=<K
MC%S":X3DZIV=\GXG^7=0KS+OG?FLO\^HQ[SC@/A\E*]B8%,M\RX.N)8)6QBC
M2IAU7PFF++7B\:!2)&OC.?:[^J-X.K1_\[Z5FH77X=?XI?'4*3(^Y^/KS2/^
M-FW3>9D9C>J*&5O<VHK:]7S]_"8-S=Z?+UK$.;S!I&;W"%=Z .9B2ZM$WF2_
M'EDV8-D5Z2AAOF(D^Q!OHBK(R=Z#[Y+BA$1%Q\>^,$.@T$9?-;;OI-=DC/:.
MD)CYTT<;&DBK*'TN@XWVYB7L]Q%^X)-%'*(V@BK1!6QX6_>TLX"8.IP]EKUD
MQ"S1=W"DS(4"$%/'FBVZDY_E4;)&VO,.96K^<#[+[TYIN&0N)*L:E(>=I;&,
MH.)&;B1\0AJ-D]]A?'^%9=&_X&<S'[P\S[B9+C]*,_5<H'-_G@*;/P'?<TT5
M, SA=Z,E@/;C9;*$_[+F=G<N0C 0.%R&IE#%UZ+,;?)<#LM27H)L";II+#T3
MU.ZCTVS@=Y!RU'0=^Q^*.MU%^<)J?8KE">CC[^EB]GW>?]'<ZOL\8A DTZ+4
M2AN6% PEK0U4M;5[#.<*"=,/)!H.\@>5%NG:NA%SZ6X"-/<!G-0":&T7GR_*
M(-7[!J-:$@?J@7ZCE---,O.K__@<_5S\E(V#3=!56?V5F^1)[+!1 X/TN4RQ
M=V"9WR'7ZZ8EY5!:L_:S8S7JU4-?>A@#/4[!K<'O<-F[?C 0@C%#GM\"8C98
M67X;E'8DL\,,0/$8C5<+MEB5H.^&8X;L.S\Q"Z0\^ @R XC5X_*G#4FW@6'F
M" T FZL!R)MQE0<Y,U*6>CIPR,.=)S'%:_\+^GXAZ%I4/F 8;*\W2 TB<-C)
M/-5QB4I!TSN&@*[BPX/S1!S4#!I/,P^O#Y,O.\*MM[%SYMCK)=H93'^;4QX!
M-+"YN(VIE J> O;O$Z">S;$C2LGV&YJ6]BD$\1(]:8I0;JJMZ\. I6Z.W3=M
MO1G.0OQ:"I,(H27K!V;)JJ]#0@0$?(C'%7%Z8KT%NK8_ROFE;VS<D3>]'Y;-
M6Z$JM7#<8YB+JF"8>OUU<.99T.RN1)T=1DX:-"]V.K]0\*7H@DP=/M9WHJ8O
M?"BBV!FN1-P?Y>\UVW[F6:'PNT5"1)[RX]-H&, ?M3O2=P2[R #M58QGU>M5
M;$W$I:1H@\6-T2E R7[=5^E*]U_6GV&QF.D?D6HCBXP#1NKHWW1H'_#!^:0\
MD\V_15I&6X[\"7T:#-@#LQ_ '4)>.WGEY-_*^OG*O/2:SABRP,!G;/#@R[K^
M67)B:4N KF25QJB^+#R4XW:C_N\,?1/@!U["B+=?.JRAP^:71WL$K(/0)V.6
M\E1VJ+D*980SV,"Z] G.AV0MACMJ),"-^F"R1^^63]!,&SLI[.Q.WO!PN\XQ
MB:;DIS;S+^=PG,+"-[#Y* 89\$& G\^#CA,UXVYC<8+2T592?31;2@"FV>%H
M!XP7C3I.TT._1]"ZI/3:R_;@T/CWF)^%1U]&6_WTQ$93WW#L02783 9.O;3;
MR1-;_0YW"PLK-]+.JXG[9@E#,N'@RW(_\O.L+=U#%I76WZ?>>.SJ_O13NZ<K
M<N-Q]NP\QN88E\87LD^1AXFHXEW):;[.=(H0GSQF#G^6$2DV+G!L)1S3BBEA
M9WXG&,]2YT;9Z&<F![7GO:LGDP5BT+,!JBPL%_AO[A9(7PB[;">OR*O*(\NP
M%)I@[IX'<&#S/V U.96V#OU 6@-$F 8YO63"9V7VU+V#+"W8V2=K3*MNT'X7
MU2WSJ/.4BOWDG]V[*)Z"FU>FAQ'M"]L'TT6@DEW;Q]WSO+-LW =LJ"U+E77&
M]L*W9(<QG/ZM&=H_0-T!E4MC,-NA+U1H?W%BTID,^]"U&B_S[10ZT)5]WP*O
M'\BEK8)C^*0U7^<7HIHX-_IMR4*#@&^+.&((U4B0OI]6AV774JDT+X!_@P Y
MS7S@'8"CRJ@T242YS EQ]S?I .O&,V9Y0_.B@[/6N>GHZVTAM&60M&1,(3&D
M405J;Y&*]K^G'+8,#Q"UCNWP#=-M=+=,9WSE(9H=J(H7?!D+] 8YT]X2';:>
M$>>*@ 0]1CL9]EC$A4(K;D.G'23GZ/?!EI>P$]\\02V.WJI#5YLUP7A;[$S^
ME5/I_"7$@WV6[IKUVA86YWPAWP"%"J0;O-F_%W')=#AC3&\1-UZ_C] &Q-/V
M4*U[V/QB5%/^B#$7]AQ=/4%B'DJ2M,S[N9BXYORT-_!"XNHEXO:*/#W? A_G
M>JB?2&DXX6-P\,NO7>%=K]6YLE_ 9H#-+R-58_9EZA"<ST [Q@")0J9%]PUK
M>J(%:.#"H"QK#U@6MWL1UZ[=,/ M0:O.WKS7XF[4IA?,]Y96.;Y:A3:GE39.
MIUL$LCL4.$!M0@9;]A<<*_WC=EM,]' $4^81 M3&PP*+?\ZPF-7]++,19 =9
MJ^0&MY.\Z:/'#P/_2[?+*DQWINVBJLGO@Q5)B/II=&6U@ 0;D1-H (6$Y0"A
M<;]$"&0:KH-!1D! & \_._,+D,A[Y1.36@>'5S[H0]R%"?VY)TB:3MMK.C?=
M?;8[./FVXMTBG+SQ8>H6W'_W^F^::K&/3WW_@2IC+G@+YGJOW\2XYB$U%!-2
M-J[W\3\BL+=,P6;515PP1JV\ENYT@CI+"1U8P$]+'B';X&L/8!.?GJ@P<P-_
M%Z&IHP?$YP8.;" K3N9%U3B&G6]YGU:?<W%H2^<:'-K#1G3+9']-!B]$,+&4
MV0F=7-A]O_)T^2M4%W[Y9./PV0^_DUH7SO+23"LMM;)ZG5PK(JK"Q=^:=_\@
M:EZT2)N;0735%W&;\V7AX% K!1/K[A7N\H;C"I(1V2]8>A> -83I(8DR%D!M
M,(QP$]T@K\:4KF+H[BO2-*B?LH$K\&QVJ/3J7#X:3^'L(VK W#:"VOFZEU]7
M"^UV_FAE&4+OGI=+ 4V*IU?OYH;>*N O@%_'>]9*@HAT>'.F>*]LWX1>43!;
M+1"R6,2IV"O9W<TR^9=E3G51X?.6A>K]Q0Q^QHS_%J6+Q%Q\&'L^)$"#K?;&
MS#;YD_P$XT<'MKS;V:&@)C5&7@J>(<";YIMGFR1FU8*1 @UA3!K5]%'==V<A
M(9VM.W,&CH-(+9M[D.?T@![;K1<J0K5/_%'K:%K:-N+E(=B<,?D;#EFJR+8:
M; YF85:BV8#,#B;JP4RICX0L7B[Q%%'M5:'/26F7V"D+P#4QHL\'E+O*0X<S
M$L+"07ZWAC_)'V:V7BG(**T:=8I:>[10&_H4#75L],SRH]6@/!X439J6R&+1
M=G:=^72:B 0;CV?6%9B+@CBCCIP\4G(I/"-P\;<U$CDKIY'4$#O)_3YCF+B&
M35:@3#E",RD'[WEJQU@Y..^6<J4:G0:?"!_GIT-DRE0M>19PUGSHAS2DCZK
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M^B;?0WU?'*2WK ]?)830!GB0Z]+&-*D%7";;A2C#W:)8F&9!XP+:J"'5$"9
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M9Y(?[R^?>!964'ZVA)++L=*K* H.C!4.>=6FN/^)9DZA5ZAG^;J40&',&NA
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MTYJ74&^N$'K%I;"X_$.;A4],RJ71<V\0CF[?-_(BSH;-?P!J(^NQ]%S:(;Z
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MW6[.,-3/_-+(<$!WP#/V?C1Y_F)7I270!7FX5Y@(-HFYE2+/86P(Q6*A>=%
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MJ8DT?\\B+#ZD'KNL].:FJH]F;X/LES%3!QFA7UY!S"7HSJ_LC?G])C/,]92
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MS'_OWQ12KTI>PON! H=JD-],'_X^3K72'RQE&<M>,4L*%=7.*T#8-BU+J%S
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M%7#-9$PU )_>ZWR_L-KZ(\O9Z&Q\OZ,B\4?9Q,^93@C;DZ?L_HD.JR2+O5
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M%E0/*L5X3"&2XXZ'OBKJ:99/I<!54+\*,WB"/PQ^:P24LZ&FG&R7/KQJNZ"
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M/__X&;:W>2Q.^1J $.N<$!E^!./Y1'UX)(%9R%4>"':YO9J."V87R^I+J0+
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M/.\G8?ZLJ4CHV*<H*Y?K(33A9DG=]]&9+.$Q<*OH/*KHCQ ()@N_4SK.:%%
M77WYXCT.S9D-]P7"<[\?=YQG6P[,%59@>;32??26SLX4]ZQN1R9S/M8U+!;9
M:%X$$)*@$&"-5A2>U+69@U#"0OH<#6,&RK'^O;\T"SGD72B5X.!10HS!X[+/
MK:V!8<GQ6@Q__^9*4KV[W>S;-=5M12C]CD"P8[S:;#+L]*X2[?,U9N<_6:%\
MJO[]N/=3M<V]P*Q\2N0"PRO[S'BE3K.OV>"3 W[/<LU*3JE7V^GV^)J:&.EV
MFJ")@VMB?:I -U @G[HN=PDY[=2'OUY-$I\%B3QD.AU[:^X<.9H48:\C3\.D
M%7.OGD?%N5,S\#9-3?FI^^W7,@.V5,=7REA7&:OI97.+3B[?3G2V]:GE4ZV1
M*WA-H^*0!%=A08NK%/+:,4A[[9%F>(*?Y5V7\"W$9"J[=D,$3!F4Q?P9R:,6
M<C9D=]=Q-B8)_L*"V"PV<))QO8848G)L,5F>@,;3&3?7&'((C;=%LXQ,J!/'
MJ?(,TSWKV[84B].)?B<DL(N$WFMP]L/6]X@8$_XP<+R\+=7UWZ#;H7Z=)0\,
M4=I_4BAC\QWMCVKOZW>W'!FUX>?L^?=^/F+:MZ[XTW2(>]KP@:RLFI2Z>_T(
MY9.^ZG-F;<?WC-3&N/85N5KJ5Y!CQ[[&+H9A5T:/DA\-*QDA5-P53FHLGR;N
MIWF?J^4^83,?KMVJJRH\3SA, ,XI@_N5!Y"@(77E!PD_0VA<X'<+YIFRP# $
MYIJXA!TALRX<#^\96LA^P=5"SF<9"[L I-95?O[%$H8TU44T88E]OQC)#;9D
MU8CX0-(L_514J'%6#<&?"+@CF+R C4>%?Q*FAX5% @]22FYV5P+GN(^[0-):
M]$_O%5D&(7"["1Q&%L7) R9_/[98605=JM$EL,^OL&E>9'HV7XJ:/YN>YRKN
MD=7.<"K[1:DL4=S- DU.R6YHV?_LNN \.%/!!US8V P; "X,,AU2H!YE+MR#
M8CNNI5,_$_*W6/XIF.4Y!CV1L&7NP%BL)&809L.X9HM0_/QK5_+<V5]5]VLB
M ]]E_8H7.>/?V\,!#$:L0F4K]UEN\] :A+2<A>D4RPA1L.-G]P3.,/E>Z>%.
M!MY('"#X\:DESR4^D8W8@BWL9TJKT9$Z]I/75[L./+U(" ]:MIF]X E+A>L7
MAK4<_C[17!]RR2[%U[2OP&3)X T=F[]GT"N3C#+Q,W-3N3%]I-&W\0(4?REH
MJX->N=*=K/XW:B47X0S?/[B-7[P?/)R%Q-7>0+T>M.]T^7X[/C'\DC(3T\"O
M)XF7T038%RRI[-NJU>7FEJ21QV/0Y;IV-J4U]^;/+U<SM^=7WM>H9WS5$!TA
M],KAT**;X&8:B^(BUF )'TO*>_;AT""I<@9+=P8#.&3MQ5M6CX%F&MZXN74B
MEJ0F@P_)232# VWCE-%&5Y3=0E*72B463BM5+I8:>F@V':]H=GDE-FT%>;+D
MO4=FD.?XM\0F2ML0)AVB0V 3D:V4+[D<2%J/#DBL57+Q!J.Y+%7T5,@F^J=F
MM+O";:T_&&)KWFWG/FMR)$QC7!8E!#6L[L!APK7/PL#6^^CGBP;^0IAF.=EY
MQV.:1@YMO,[OO*9.[&<_H<H-DJ*]L2^$\O" ]M%O7M4ZF98#,_Z+]0PU#R]R
MYG!E:B^CQNT)&OJ'26!AZX-L4^ZA)87I0>^'Y]LC)_+M^0=9SB*;9]3'5- Q
MCR>L 0JE.Q;8JVEXG4E,"UD%%P.*V)+?$DOLI:MGNY+Z8-O&?JS+&2P[^*WY
M>0\<OH]SK< :#_"GD[V#(AV.-*?=M<WK7Y>[N@H:CO)WR.K!8<G#_\I.[L:S
MJ"VY0\IW",U3)0":PTKKV80?I#9+VRNQUSUT.>]2./JZ9X&V?DC.W$$!,46,
M".>-9LY!FU]D#?Q:1L\I=DU\?VWW.*6GG#-M9[ZZ,^*QUQO4\":7PP.AEY++
M KL#S:SNU4X^J"A?]4XV+G$]=LQ$:X6SO?>-;T+E=G>W]I)3.:2_:7\N9)#<
MLLT:W.I1/EG//U4&O+'TN7?Y&?WBM^(BK\J(-^Z_7E,Z*#V4UNX7[7>_OONZ
M_3K)BG\UASNU-,6U*U(H1J<'<$MW<&,+M)_=S+DP':R=?\>& ?Q7Y>$S -G8
MBO^("OR%W^A;.0UJ"PA<DW[EZ<2A$)4IC%CF4KI+]CK)'9&NHF,AXAM 3QOY
M0T2K8WPJ6]"0PC4/MJ%E<$F0$\#;7VUIXC_>CX0J]518ZGZ'2Q4VCC\:2RJ^
M$W)96PEL&4("$$H>+40FE2?NV"<8[0_2+F^;P.MB8P92OQY7^&,L+E1I!AMT
MH7VLGF*M#PX/FD;\2KN+VQIZJ>;S'8I2.)]IGW_$C!I"X_SU(3.NYG+C^6][
M+M>>XG 0\G;'W%KW*XV,"R-5Y]V\NWE186'JWVH)/N2,_G,E9B^O701L:#X/
MT>^JS*P.GW_N>M"LZTODNS%*Y>W]TQ+;X_PG_G["(\$S+K?CE48&*HM'58.#
M3UR96DXXWMUYM"@B2N?+V/4KV=I[T<71YON*#DVA?P:_)[ G,=-U_3 %Q[4A
M K-:6 .FB<XMVQ<4D=/Q#JBY0\"*XVURSMX+U[6\Q[XCU$"?_E*3B=CAH \%
M-B;IN*CX!E;0OE*&SWNK?]-6-A9<T^$49;XK>UV.Z2^489N[)Z13+(TX3"9$
MA7!5R<2/T:.$^W/R"]D.J>K.MM3U>P^UC+D>IY1@;?VCQ&@%&@U\&YS;^D)@
M4)90_[GH:F5]1,PPH1PUY??+*NY(EP4 %H&* Z%&2?<B+YLB%'P4)?>J=:Y3
MMBWY"ELXQZSP$>-%N=W#M:?H;Z,/D=/*<UY)O"Y_.GBN1O'L807F<\?,["LU
M=&',PU"K$']O*]>A8L_0*MD0Q=)98@NYCYJY+M?DOZ(B,A&?Z@8#>+DSY@,H
M#C4]Q &H[&X36XQ :/A#@M4DF#96D_;JULS;M1"U=D9<2>C@$22Z(XQ4F.X7
MI>"616-*'V<'7)4^JK>(:AG6M;0?N>+N 1MG#DX:E7*7SK>VI.R]<Z6]HR"Q
M[K'FP0GHFHU'M,UFP_'7!VR(W_X>V]!PA^_JL2#TWA"?D+GQ/$ >RLWM.0 &
M &E]:_A]@H5!4F@(("T7N)_NI,-44:7'N@P@5,<C$<*_+HC/"@@I8JWHA46E
M:/71^HN#XVY1UQ'?'\O<UP!,X.2"1LKBW4$\_U?4E+FC@H6L+_/TW+Y59>SJ
M4-'X*(^J@H88P"PJYLPG[()#79(\4G5+M'H=5S/XW\_35_CE[A#E17N?;?$=
M702?0\.-D:7.!9S#.R\\.5GI[7%)_YA?:I@WT#]5_)P9>VG[25O#CP\A#K8^
MX<5WWAZ^7A7SZ'+CESVW#,9WW$:=SS9EFS*QM[S.N;G5?SKVIL4[B]B)LB5)
M]-TMSITR_/9:[Q!-=]AVO&-(W>MTY;\/7/62SXQM"K^YS_?$U;V_1;I)]639
M7!:#9ZE,LG1GIV@';OLXS$DZ!E&!7R5_B-_HS!?GH<:!].7NU!:[\ BY4H>7
M@M%TG+]@,X_1OTRZ\678H_CWEX)W;0V?(4HMLX'T@$2"$I9P-N],X_C^5(0F
M]ML7Q(P\&R)6/R TWSB%$[HN!QJ%BU5I?>MR>^Q :(!Q>:B +*338Q/Y>MC3
MK($>NW9EQ1ZSIHXI%B<VOI Y2"*!N<'T52T?P.$.%,Z9->EK^_KZ^4>[MJT7
MBY44W7J=[<J@%Z,U3*?N+;H5&*3LC+R1'_GRL0>->;#7]-)B;?9Y8K.OT<'F
MCM*H$"R!-&Q)UK-][E-S^ER-#F5YZOGB\_'JM'OJD_8+)CH_]-22CWT\H'W@
M%[% .J@P[ %#SYS!K/(Z"@8'@QZ%=G5G_N<DYDI+:[S:19<(*\L1>E].*Q=[
MMG)+3<<LX> O%[$.2F2*-M!+"@3;10%XAH$M*+A]27\AH\<09; 7Q%2!,5Z"
MW.GRV?I>#E4-YR@HO%?:ISNAZA+U''>V8]*X->?HNR;,(=7J#86MWR1/U^50
MN:FL-@2_5_:Z >P59/436N"TW.F"4>ZN.D#$E0'3.,O3ZW*T-AE%A5E@@S@W
MR\H6"V]U2RFU*$?(/8NN@*CZ 79G=Z(/O<NT%AMZ/NE$5%M']\A'A%G?>=IE
M@38^[$?[GV4ZE,7S?>?[YAY6/5WR>E)[WL<K*L3F_/Q43<B8F7:!6>D!)6?]
M0HG?T==O2G;^,^"L$IFIMZ01JO-7] U7T5A,9N3(S!R\(?+N_-+4.[NB+_,*
M%TH3@\X7S$>PLQO(#64O7K3ZY^<')@X/IUM:7MKR.CH.:@_4#9L=(*@2@1 6
MTX7[8U6LB1!N \T!K3X&40V* 4)=0#27M0-WR'&.5 DF#K)TI/MP'EU370Y/
MP7&Z9]%13)<&2CX)IA<Y9^K^V**L!Y@=3;==EKB?;E2NZUU;S8&S/[9)&NNM
M\":$WC^H&#@SAJ?%-R5/(P@6,@(:!]^"Q;#]:;>O2D<RP9A7R%U=7FR$ZIN>
M7>\Q@0=#TW[O F/M1.B$+_^.?S_NXE,48?HO>&L/;I>)_J,A!<4HK4!U7FK)
MK<5$ESW,)V:G'*_OM#/ROE%=/V$Z6.<3C612EOT'+P$7Y#-*=[VH-!U6T5$/
M^O=>9<*;)T5%>0\/>*K4X%U,WQ3]-2\M0?]\\/]4UA1 0+L8'G7(.H.XE7IM
M='IF"*XB@SM[0'DA5A!/Z[9F5\O >1O#&%B![R;AS0*P:6> R?F*-9; $^5O
ML 58RVCQV+IZ_?O($5Z_?]74'M(/>37\P0A9NG EIB$UX>QV_%[9X&.P_KRA
M(9:*V )TYB12=X/?>'Y-9"S!"ZPL#UXD[K =U9M35F:5:-LF'K7 &V.I?5*%
ME]^^I[[,#)^R"D49V;>9T(=O/+&7=WAKRJNCU^A5*T&#2PU\47[59CO/U1U\
MXWKZ?,DMM6SY4=.)KOT,$YMOS8ITE:PW@$WON2=&1?ZI.LN[:R8JO>W:P]V.
M>'65^WJ3Y -NG%9G0 M[GE%;(: Y8D54C4O84 3%,UC;HUK6Y5I'J\7;!%KW
MH/KAQXCG.F$FX+$P^7ZR?%#0;+"[W3)K#FV@2/_>FVC77ZB:]=IC(J^"H6"=
M*D/:LI"<10C+99\5+!UEKF;$':,0=,1&:8'@9IZ"J+BUN_-E!Q@<HY26O-#3
MGO]O1[%7!X@BL-&SIQ,'T77%R\59-0:^)<9Y2ZR_(4UK=PB7R1_0/I)'N -<
MC#;N%,!(P2D+;@2Q-,5N5,JD&,GMS-4>X9)5EKS!N_-OQ@?[3K5Y7(FX>8@9
M$'1*,[OJPXG]PXXCT0[L<+&.6L.2 ^2% ]^'4W/UZG@LD>GDQKA&>IN7G^4E
MT*)9*R[^JN@S?DRZ7]T*]/R3;7CN%/39K!\7Q<N<M!2#/M4^!T8.[.AH?#5_
M(?"[N=NN)]5Z;G6I3]KU*CC\ YY//LF;!@PZ1-65C#]97#AVK7*K&_8M5>TT
MY>!KST,%^N/D/=^>#R"FVR?N/G"UG<U_+(GV.J7Q;:CC_SAP][]?&CQJB_PK
M2#*<XM!+3$<V+PQ1M\W@3H!P@<\)6?GXULL(K.HN&VB(6(V+PC5:43BW?9P%
M!GDQ6W^45/)+*Y^A=:Y7A\9';1TI^5>M/^=X9J;<3W/A$4D*-0P!FE#[HIS9
MF)7;0!&=O=HG00YV#/4'^]-N2LT%K.RK$UUH,BIP5UHM>'==KA^N(O;B*:O-
MSG[\+-4"A(_NCY)<4>C0BH"@@)F9 4TZC]7"$JN&2G?P15?P[ZF*ZW*19"9"
M&$N'&8NQX(E+;+[U*YA#AV!=;H"H1*M:[-DDR*GCL79\6)K;#6!R<4YL@E8@
M"F\Z]<-=F#0(TV'P)J+(AF,_?'O&-(\?@Y]Z_O2W'A7)(P+[,:L)LH(2Y/%R
M^9M$]F)U6>&-%L0([T_$60;Q7+((G"NX($&:V/A6*HE;XC[8D3(D5,[%)7)S
M%<%XOH'QY \EQ!N@*JOLA!83-K0E&B4X@=*:G3@G/[_ 7Y05CW\D?Q/8E6T&
M*I-4].K?4Y#=T""V^8Y8PG90](? Y1X, JZZO@_O+O0JI#T BU\QO]RYW8"]
MA@Q&A@1&&!QP',RK9"W=JJJL"$3]*BB/3S"/(K#OLQIM"8U5,@2_Y<-$C^)2
MQ[K<2G1%)*F!B3.;@EGB0AW,ZZC]NM3,!\'5.2TL@\4>>',. L*: ^]_GW7H
MGW)T#@Z^V"LA"LTS^!42HV=_0[/8)J\(*?!FY=[1-*(<;!OH+]U-2";LQ#E%
M<>!RH+LHIK_42-K[WM*P")VHS%_56C;8*["O^?0ZVOQV7>!4G"Z#E=8>YJOP
M+7[C4<B6=Y+T=;GKF'3"%JF9=(*U%<Z) $7"N(GK=IBD6VMBB]PLO(S4)3N=
MZV! X=QC7^ OI/K8M3Y'ZW2'Y1#-]V0H67V1^:^"$-)<@4;%)6P=DLWG-I=T
M*/PIMOGD%-2:2U(^(W!(Q9VJ0D:4[@56TVUG+,-/,F*C/)GNQ]W/3-EFGU8H
M@?O0[11<JR@]C=UMI5-?F %[7V:>*9'1R.,L-1D^G:2"^U?[1W58V&EX.%Q#
M[%1XOCOOW$3788#&D^]'*(!FB8^KU#PM<';VE-H \,:;L[;1BR'JCKORPA4>
M?1?I_M[T4)IY\*GR/]10\@<3X>^2OWL@'W%VDOOX+5AS]E":G?&+XG[_(OWN
M^6KNNIQV\.+8J'[*:H[,<<Q'0@=[;#J;@NHH]'\%QMTU5H\*"\\M9H1CH/<A
M7I(RZM5UN3M(2FY?KBINEZ1<JH5UY\GWY6J2VH0+=\6AU9(VSZ+YP;!V.L5)
M-_U*VT1+<(Q[NV_'>)Q$=<USJJ7N'RO;95% ZB_AFX.;?[+ Z'6Y;4T;O;GQ
MNN+3+\ LC,@>FS5(F+Z5M70+>0=_0!P$9O#@:?;-J^&M=]=H.J4RWJEA7X)Z
MN1^%/]PCT"S!IM?5SD1"#F,F()L)O3)V=)F:NB'RG;4NAX%OPNUN!-KX/CRJ
MW&>60I>[X(";@-B?WC),E,,F]H5L :PR.-D.G"1P$)%<:M X+C8!1E_]LBS&
MQK\J\IWP^Z5X(RN7$K(4,R>AGI+#N8IDH^UUA(<2P(.K-+X"A\Q/ Y!G0'(9
MZ.[3/=6E4:N/[ ]1$^3>C8LZ/3<WX]T)5&=#]>L^PXS'+TU>;J8/ME6XU,"2
MN)NK4,@9IE^%[;#*==8')^D.ELAL8V5+J@[FL:DKV>R2Q%=(97$P;WA=+@._
M;SQN% (N#)$(/ _WD^^A-@GU P[9=GR,Z(CK=X@"-M&C2'^?A>672^-1AAV9
MB8_$/"%?7<Z?JSQ !!V4I=N'!$-<8C\UFZ!.#<6 ;K(,]2=XAV>=B53!>:S+
M*2F)?#\3@?O85:Y\^@]K36QGL'006!VR/$#[Y2*DIMO==CXG??N^A63CTBAR
MF8X=@;UY<]#RF:3GV=_PW^IEKLJ@@OO"LF=)*_#&[N:1\)BM$ZX)(A<\0R>E
M?!AC-JPS>P$I3FQO[&D-_]VDN;OU94M[>HO#(7>%KJA?))$U?@#Y(G[%EV,^
MN@7_AM"\1E.^$V(P:9RS<#'W58AV,YV"40W^O2>XFY79Y7&H?6/%E?],,D)B
MI%-N>R9&R-V=.\,YE[3XZ^!FF1O/H#?:,$)D,WD:NI4#3X6W^O=!P(LA\H!#
MUE NU+)L0XI(X,Q9%2(S![-K0&PDE8G<*4:S;X>L28UT!LM10GV7<YUTPCA^
M3 BG.&\1W [C8!0_XW<"0VE074ZQ]<JH$NA^8AQJPY$X\!WBB=._#)*J9Q8#
M/0IG[!2R.D74%Q<"@WJ%Q3-UQ>UBJOT\%U7R;]32P<W?DH1K,FC@CG_% KQG
M+%6H:,S?OURR<4$<M+S,Z03.-&9K&QN1&:)'-^"BRRJ"L(P^_U\AE?58O&YQ
MW4PG4@%;)U555IAF16HQ2ZJR=E7&67)^(H1^ZW))T7#V/^MR+QQRKN&-02UA
M\ N9<?D&GZS$Q[G*.3WF I,!$7+7Q0'#F)FYB+E= M_O4KDDW^;V5%V2$Y+8
M%P_;-]YP.2"V.W"D2.8-[;'GY'NIV^#LQ_ FY95O(E\Q4M**5\1IY+U"ME"'
M1D%WQ,"Z'&01J88_]%'&BPGZV%P/ 2'+>!*FNT3<;2W5/!%3CZUV;6)\:J?C
MU$*C,76&:ZW>,XC$6VNJ6&?ICA*1"J@L?"^H%JM;]Q&WPE]0KRFGWXH3YO&4
MLUC "Y@EBX!>_%5PYQDV1,B2[E9R'VHC*GQ?EW,Z"7S)#IU?Q.]\40IODE29
M'NAZV?&2^$4VN1Q(!@0XN_HAE[O 3P%FA#_!%,!'-EO,4<ZNDK)%^"ZI^898
M)-A6(;L=KP:CNG[_94D5[^V Y,:R4CO:/A0/."Y^BQO=MA3S4=*I=</3\MH
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M:3_!T* 3<3=V]<TX%VAXC*[%8S:VU]NN9B"!OV2X!C$(:=9:46 3MF*+^PB
M)R2)JHD<)!I\>8N*$MAP]5*LKH#H,NR;-PK%3B76%P2,-$NI/NX@?=6*U#+B
MWN_,#>_?.E$!7-M\+NN7S-62$N#L\M*MDE89M9&AU7W=P%P*4"W,DN3$6BN)
M%<%1 .,YOB(VLQ4A=J!XM%(U@3"%_?G9B\(_WG?YH\H1:-*B>Q5*@ T=8B(S
M<=""^ZBI7W;ORE;" :PGI'_AP\6>5-UTFWO&P>X999[G/WZ]9F^O]E?_6-^@
MJ<S]1&:^YNV)8+CUY?9(_X7]Q?//:]H=W'9YYB5Z#!6>7ETUBT?%$LPAQ2S
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M+<=+RIIH YI?4; 3CZHFGCRI>.=D-YV'?=J2^U;MJ$G5\#FU!N?F/QK&35^
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MAL($V#O3L5R."N5CX=!IH35%N'F^8]:EH953YZ,_Z7' A]OJM7%H^CVZP:9
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M^'QP+&W\\M&V+JIH#9V,!GR6P2.S:41>,46%N0^WH:B6'C.]B3#"JBVCER_
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M*=O++'0E";!R@%@G#/)@7AY@Q+P$?HNEPBK8#"9/]SO ._X-H).[>>64$7*
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M=P">E$A3?"AC;@TUCYVCJ?Y C.)A;*G( C,'U 1E8;DT)FC;#45WQV$#T%N
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MH7V3#W@I3+DN7J+8@<=)QU9?31!$MPS9>X84#,S!)I^@<6Q*06O6>!A[K^#
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MZ_<O++ #0T(8IV*XI1D9-V$TY?Q#L^-T*<:#XN0K=S+8^.H11!3.V!!FG%=
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MJC[NN7Y[7?O85*3<:WAXI/ROEP_(Y<]$=?57=4SG=-Q^./#YK_2?"4$+]'-
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MO#WI_G (7-1F8$.$A1WZCL+4]_VU(>Z=R]NZN,P30\X>DI\&V\#C%5+E8>4
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M]\)V/&S<+_9)[3]E/1D^'W:.'UAUP.]6B?^!H7_RK@5\;H,\K*<G!#&?Z(%
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M2=+E!W8P=KB=P336,R=0:<B?LA$)852,386 ?K)=H#\'>VV:K4LR> JI\7X
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MEDZ+E':U6!R#6Z&BCHX.[_4TC\':C,"*+V],&8<:&OJ0G:)I#*JPP72JT\%
MJ]HK_:Q/=9JN(4-U1@$A_8!OU#WLAWREAB&:Y<%C:%3P)$1Q4@GUA.<S@O)V
M7#5^&B\B:GP,7=5/\RJ!3_I UKD2*T);8T$Y(/;6(CFFIM(B1=ZZL'ZGX\J$
M]U\OD^<CRLN#)O*\<M)^R?//B@L_4SZ:.%J$QAVW;C8!:-W<O/!HKU?1I,)$
M$=<J>^DV<%(YG-JN-%"45WR9G':2Y%R49K ,J2/MQEJ0;NVH"X3GE;><H&C
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M6_FQ*:OFR*3BC\9;07P:8@)]+SW D)O[0,Q+S2$/'I1KN)1(L*O(\_WS*84
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M=UR%X:7"NL)K*@RTL5"%>5U-?Q8L9\)8!+=0KO\W+K4&^+]>Z,G\>\HG0$0
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M)4GY?KV?K$Y+/-:<RK/+[2K8T7.08;B#>54B'(:>4_\V"P0#UIZQ=KN]Q>%
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MA&S^@P;5Q+=W_WW.71:\>0S1OXG"24%T$V5_*++8&O#)Y[W*#HXZ)]);%_&
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M$/4$<?L>N8>R+!)(,#)2%G^'(R0,(]H>Y0O4OW!O\DR@8!E/;,%(J O.A_\
M)>"'0DDLH&Z;8M&PB0@M/N7O<10,YK&UJ72!>X_5<$1C57;P;1KAV00&U\.
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MT'ZY<0?M=/XX'PBCDCPKN\NN02>/.RTZ5P<6E@Y!5[\,'TL-M\SLF[!J6_5
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MFJ!=5AE+OGV%>I.L!47PYUU%1.BB<$+OBO''3")'!)Y&4]LV,KP&U>,/%)N
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M$P%.C'JRRG+14(=P+#I(TR+X5!'8"IRC9,8N862F#-@%'==!=%Q$J=J ")^
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M)Y?U&^MR:2 <L1USH=6)I0PFT$9R9<PO#Y!L#J,U#0RA,F#PKCHJ10R:MHY
M<1NG0*#8QS<!73<\,>8)^E)4A; ^,>_*Q$JVM.4NXM*@^U:D]'^;VH3@UW+A
MZN9N]F6(@/'9 $U*6]*D?VSG6&\:V>[5^9WUN^5BA56PZTNCT_Q14)^+&V7Q
M7X!!91AO$,;=*%)=\P7RRRO1R6<>S&IJ#D7$U*JY#V"<.!H(VJ0!,%E]%1>R
M-\L#^-Y1.BL79K#XQ.!#X<T27%@4%_=J34R#^6*5E(3Z FY"'(79V+WA8N]D
M@LI4B==^/I4H(SHAB ()S\+'B/CGE):!562B%)?13=684=6LRV]+X<>VM>+G
MFSJ</!LRNQB>;93F@96_:R&P-#$"YEDBSV AA;HHPJV6D8T1,Y*()ZS&7H&\
MN4AR9D,7RPR B:WG-RR#"MS%?F8IPC@V8EX\QS42&.!R1+JBKV(2_9R+1.Q#
MSXETH:H81Q[TK@EC@;%W=#P<QM,!>HC"Q]^$>?8B1GV<@>]*VI^P%"IHJ2^2
M/,.5.;E$HP*7X:.6\$&,.>\P)ZV$+1Y?V&N!U(XA0OH+335*?1:'L*#_TG_&
MSK+//^&M>7Z\3HH 6>V[V-;ZB0W ,WJ_;&W.B7!#]9- XT!Z_)+8'MDD1+/.
M/2O7!&$9%[4?VXU0(WMQ#>S_;FW9P+9SC<:B^(BAU016HP]=II8ZUBS5ER'(
M"KW6FO7A)R?SU-!%7!E#+ @Y)$VT5_>D!*\8_Q)-[!2=!$2-'+@2B/1MPE_\
M3+;ED/:&C5C8M3^?Y:OL!@)F"EL*XF*NXL).FIB;M<K3#C58;OO5N;'ULG@_
ME?T$"KBP,N,W(3W4+W-\E!@Q&,^<#I5;1:2V+650.;<P\>!=_M+O2.QA@)1E
M:BVUH<8MH$/5T-CQ!9L# #S-5&[!TEJ/=1F_83S?LI[BZ=66VOQ%8D;X/[#K
M4].5B_J3M0V#K'8FH?O8O5T$Y;F"W?)3/CQS&FD7<JSI1]U//>>*V3;KB7^J
M2,?N*7V_HFE_Y>0\O'QT="R,G]^BK-PR;*9L]LE[U-N[4ZFYK*BLR4FFN;:V
M2>^O\7'?K@S%/><R%%T/]:I6'?V=_G_9;=U-!%P7C/A-0[AK<F-:L*MPY0E0
MG]\R0%9"<4E)JOWW\M@+=WXNTP.D>9IX[AQ!TC<,NB<:*@\:7WS2NRZ;48.6
MMT3M^;&F+#MY6*W.9.:<3Q%Q//JB!"]#K+Y6Q2'RE<WO:%]VFV"K2DHK@X=B
M,Q;*@&H_GDZ:2'O. %#SP)_AE=X'DT01JNYBG@V9.>P)0+.B_543G.7HFNI#
M9+4782_G')T#_Q@T)'H1G0<V(19;M7V;S<578,^@QEA\+V$6CDUD26*/CF_U
M(-]F%1([!;\':T+=LSHA@:]I"K7R:[-Y6 >VK?HW^\)WAP7L >X4D7Q J.UP
MS%&,JWCBU[^V86SV)6D<AK]Y(_J%U<;VPQH)/;5GQ[W =QLP@0+87#5*TV@N
M+N<9<[SN6L55^(S3O__RY(]0=#_%^#XZF,5XTI>IZVFR7#96\@&S1MD))K*-
MTC0U&@$\#;$=;<N93ED1KVP H-XEFY:@G6@ML/9,Z(JUPK\:F"OCJ*^=TH@W
M+? )FGSBET\0V61'YC$39V/GSTWM,4U,DRPI:V.7)KO[ \-=79.6OI;1<0$.
M_E=:,T\]++W_SY5G[8WRSNM'G_V>^=\.Z06$_0#FS$M$:!N_H!P9;U8>H55<
M5CK+]QS+?USA\X=9'S+Q:ISB<.N= 5+?$96]#@KW]E^H$W,^61%48-'XADF!
MHE4Z)[<SEX)]G_1!=X(AYP!ZT427_B$_O[$?^6;'X2>K3]8TE/Q=]6$;Y$)=
M3R;DZ(O_=BS[V[-[.Q<0W3-3$;X<&,W?O2>R7^,#UG 0(\E)8"F4=9_^>5,!
M\6:@;,@SM-6\X&B[O+;+\'[3F4O_=3VHLS+):APYC1F#9R"KJUB-EY^V;'][
MW2BSR=JHV\+IZ[E<>R5:V%A'[;<GSJK.>O:Z*7]G',NLV?;*E QE0W\76#._
M#5AM8Y,DT5#'XL HL\=BLY(-%>UG?G]]NK^[Q<>@Z&%3GOK3][S]LBZ^>?X1
M_WW2Z 78BH-U,?A; F#$YX%E%>>O\45*X#!_$Z)J913]ZD'2=Y2*5=_4A3^J
MK/)B45/C1O+.QW9/1M_Q:HOX\"/IYZ%-R.0J%H[K#(!==2*.V_*C-U!WHW\L
M4DX)5//<>2A:Z'W7FQC7<G_?LQ1#,+[1_'T#F#O0U;-QCM7LVSVFG1.B12^Z
M][SBJ]'*TF=]NA\TM=C@RHG]P]JG E2Y-5HN*A]Y'M=+;'];?;^B_^UQ68C^
M6<57<?F:J58><>]/T(+ FH@[8WC]Z6YFC*ZE_GNC0GUJS+)7P^P +"E3CSY1
M-DF,%3M'9&108E"D:=G"PZ\G??W'_,<O?/KJ,^'[H=*T@T[^F^<L79%[_I#)
M;;V&O_1'-DH+<]VRW+)S(W/#7A:VA=6J(B\-YVB>$H/U]O\X_?\K''H)OKY/
MYJJ1^OIQ2T9&.FG# P/#NH:&-^MN'KG\K+4U22LNN#C._U#:T<^EN7:7S@=?
MD5;:Z-^J0R=,,H41H*I;.5Y17-FL0QA54*.NLP)]!3'^JH7'HM=:OB=_FI]_
M."A5I/\VSYJ4L9I5AM+?"#>2G;'Q_VINT>8M,,JPPN6BKW9ZKZE.KSZ7UH0G
M5[JE[1_,U@^.RSG'*?AV^=SB=$8OM\AB3T/X@R#WO5ZYJ:K-!Z/9LR['?5M)
MN;.L%[ JZA<"VUW4#VN(?4M(BG6UEZUGDR S6=QTCM0W.57D3S]T2<^DN^ZA
M"U3.L>'5^]*EB_D'[GTY]J_UXDQ]4:PQF:71O?\CBA@<8]T25/0=+6 =K\ES
MK#,_2??HN59U9#S,I2,\UZ$5.3:_)N_JJ!]:6O#"\\QY1:]'Q_]'$X?_?WYL
M6U8029W>,,/1O'&=AM0(>++R<"0+N4;=$;,)T03-)EXL:Q-[81+?&\%F]IR:
MP[;#XW[AH@. 1UH&/^56Y<YR"Y=&GW?69&J/BD"A<4J#(5#";U7%2/H-LXM"
M)O.@2>)8]I38\+*9!^4.O7SQ?1Y,X$IT0C5 TEG@47MCZK!4^FH"/ 77D)*1
M$'O[>H$S[Q("U?RZ\*.3LY-0HTC^'/J?\[FGE>Y_'CQI<5SO[]FWU?JZ!Q\D
M[3JRYPRIAP5JKPGV,/@F6ZD[F""PD]?+OSV"-45BCX&]G$J,6D78)D21[,36
M2*")I(!2D5XK#[,N\>>"0 ?HZU1M*2IG5(:MF\B_;*\!,QV.-6EHJ;I';1_Q
M@L;2GCHEO6^0GMZ1GH-8V#['/:GW%]XD[%KC,4J+.^'I]";$\,VMQC+/)QON
MI7ECC.):79?2([5]+RI)%SX:$^HJ28_YK0N;D WS<=$(J]Y\P6'#I$^^+X&'
M9Q,)&!U.RYUS3G UIQ=^++2$6Z#1(G\FP+3AD^G).@\_'\60;#,QO;!&@#JX
M;L:_RT>(=+?RO8B RT0,:35"AW\4O+OQ+T$@R"P/\)EX!*51MH.D&LP?@&?&
MU/9"K:1)#>-.<6 PL-D?-GSW:O$8@S[<4O"'8?-E+=C,9P0!5M\KV"O!-Q7B
MJ1&P>ZQ6K\X)^-3.$E[(5)? &>\*].8([-F)[IP"6A\\2TR)EM(IVHU@X/-0
MF"S&F*NAJI9HZ]3\*=K;Z@R7H>C_!>U=UU3^YDW^SUF^1Y? *>7=SZ=SDID>
MFKJ54R=USZI_+GD\W%<_ZA'^$#I*&*JOKRC^"J)O_CHK1BQZK-5@H()X6;<G
MS+>N'OE=3%8[[U"_[8$!%Z$;YEN-!&=Z'4C66YO)-B'?I*BO\,*\)?5-R.PT
M^!!1BF@NF&>RX>-J_%M@YX:1P'F([/L<+3$5DDS"[.76(MX6K-L\GI*!.5(+
M)^/JK& 58C7$L\M"5NB/VQTN< 5$U3<47R/MM1RG1#W0!A2-]"60?PUTWCB*
MT1HF([E&>-S.E43?<T!/(T_%]5,S2A4QAM34&;'RBM+NJ-CJ5+WWTV+=X<&8
MC;^O),)HA7[((*6FV^>/S1A\F+3X %!G'S0D,.9(Z<\?5_R$A:Q>_O;P>.V&
MTSAQ[)VA$Z)@\@V&,*Y7>'M#1\YRN;P5>?@7=FN'_R;D_5<$X$#<,.DXO F!
MLUHCXG +C=Q$%;Z,&(6Z34@08XPTU3]HLQ>4W/@#<_@5@"W@&5U^<Z^O2P0=
M,1(IH+/8V_NJPG-?>,_P*1J\;.P.,B]BLBP2%<AA28/O1[K;<N95,==U5C)X
M!2+)JQLVF$CQ=3-%#!C@CE!&]TYI$WG3_# P%@4PWU+D@:5TC$(80/#\5%LG
M.C;9&\N=D' #XZK18C+J=5(0R+,@K\,(T6K&&O>2E#M]1BXFN@_#;E)!G9'Y
M>C''4 =/L;9O0L()^/M@+ZTE'L]GI0CLRP)LDJ>6\),'O]2;=; 1RF.]6HL9
M<9&_U]:5!\_$O4"VA.?[\/.J?.S5I58>877[C@Z]J_1,TZZ3$L*[;U&BYJ^4
MI+^H1V?[.SY\]?3GQ6H]PY>:I7%/ ]WSHQ>+7]Y\4%A44[8P=!D1\KXD2#^<
M%-)Z?Q6:(SJ(5N&0[F(<>):](D-@+5FDB8;11B:/\>QS,&>J1F>*53^135]Z
M=PCYK16S(R?+BBA%J. <2S^3=@VS]+7&%ZT\YB9DY^LOX=0FE86M-U,$,6[I
M,SZ&9:6"P\)GU%#B'A^!91LUHS:MK *]S*5V$W,H!P9RVNGZ64N2Z%@Z3H[:
M=&G2:)35#9P-;+O]TT=H7"ZV]PI<X\-?G\D*/'/^5F7I/P67A$\%QG'E7W]
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M9L3"K/4ZXR4:[SBT4AE<GP>8R8$F:^P=0T4D&D$)UWF&RGX><$Q8V-27Y3F
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M^\Z>25\G@WME8>JQ^;'*;75YD14_UEHL<AAB@=%Y>A-R#9I"K$?,&P/N_*L
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M=75?BQZ.C;OSQ8)V56Q&XV(#2A3;JKT@(19(8$]G6T4!<U-EM<4E.)5..4+
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MX10BK6 2-A"MX;C6';]8 /PTL'1BKBRE4G3 NQR4/%C0;=SZ16!DDTN)-@N
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M$[5<+IZ_J9=*^O<O0-+Y)/"2SOH.[D$!C(R&"V#:&FS[!"3#$R<N@!4X?!#
MH*O"P]+;U172]#=AF(]$#@G/Y &T5ZB?,I"9 !;3C^!?L1/ X"L"6-0#X+,+
M78ZO>![X%8Q*>"9\6FJ9%L13R-TJ?-$6X2$]MK9" $.J"+?R)_XKPTK]-Z,R
M;@[Z]0O)W8XG J  AH)4Y7B;(R4!>G6L ):Y&_AW#KHP"G<#[4V0H@!F7OQ
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M#: U$$F;7!P=HXVPOC/P8\O\[01Z]N*HZ6H\+Y5U'9HNG2'MY-HQ/$Z0351
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MT6Z.G!,6NBX'Y;W2I7_QH3X!;*LMT*K&E\:=8\N123LQ^'T"F-\]W(%@ )Z
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M@]Q6U0)@6]=X9@",]':2JU1<AA$F!)PQ;1)2M6"-TH*V8:7;Y5;# O/8^-6
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M!LA,@NA%;@Z**V?-_P2G$?CEP)ASE0!V#?7KBAQ_A[P =OT$!;G^*+)[*$\
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M*LD7SSE V@ZL_ ;R@.,H\!Z!FR^ T2QX>$*; ,;S)5!3FE-I=[E[!3!A).^
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M7;H_DQIOR]G2%G[]2:%IC_OFYHK'H)H:\+EDG350]ZLBMXNC9])8<&.87KZ
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M0G! 3#M<G">S7%1^BGP4/- ("8E%(777^53IVDKS+S<H)IF;$RG^@:G!@4?
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M-ASX)HL!;+_[BEH]--TO9'>4G1H..IG.-\0!7 ;9XE:''YA:5*FZT>_NURJ
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M(TN;>AK.RXC8J&'CBU3CLV(Y07L"%P;>2.4? "WNGK_^5E-K:D!I?KLG,9D
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M:"U=>4ZLQMQYGH)9*=](>Z$AQ!@C:#0.$0-IZ\D*G=>"[NJ:>?T:FF2NQ=M
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MK1_?1\89P]5*]R;;99- >R,1M,:N<%YCP@88S?TET2[_)T<EGLC@[U_$WMO
MR:QRSV WG@)5*^!,&Y()SCH$.[2T#"Z&J@???-\O)&[E!7 ^?('Z? 4%B@Z,
M-CGF#G7.=>0/HC*1O\2+76ZC=86^<Q(G-]?FA:Q"]2YUKU1KI''WJ%\S)P)8
M"V<=A_H3JT*W_ALBR/>L@WC)TQRW0SG!=T"DPN_>2='%<W*,+<!_S<-)CXP
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M<5U+4CWTYO2U)/IH\GTH0\KIR?=_D1FNF$D3_4/C:?5E\ZLD^E)5.$(0HN4
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M(BT^.%P W&)M9AR<LO^ %S#VK!NXGC3Q$E&3/65J*"I&;ZOUF* 0P;)4!DF
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M/*4;)-[;F6ES-A"KT=BN7JL7>.Q772B2QOJ,!G6Q7!6!#EX;I@*!S(]3WHT
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M(Y[L2+<2)H@1!:TK:2Y3"9 39+?\R17S+4.,D'NSNE>-&-%7*MR^^C(<4_C
M[I_NSCM)DZ5]2YS,H,$$?^IYC&WI3U@W[A(C=@B_ZY(7[,2(A#/$%C3QVP D
M3V0E8Z$319#F;?AJD1A1Y +:P"AZM.5]&> S3#QSX=B53N:?8L3/CU9%[LMP
ME\@BWH.B%+U68+E"?XYFD6@+,!?<0 -LS& ,UW\SRE/&=.S*]H.3\W\3E^=0
MKF5"N!^_I?TM1E@DZXODX6[Z$06X,%=@F7,7 V[/AU%T_VF4NU78#2+YK5>6
M/J.%?.2S00A'_,S\3'S4K@0EPASO/WOU/O$?1Z@D XQ!B>D'!3]04+348"C1
M$OT#^P/=PTF&.P01O"XE5%B"TM!L%6A#B1CQ^1WZ'T>7' >&P_]OMS5F&2E&
M'(Z=,447H);-EE%35_X_A_T^\3\%O651G=2+%.8+,WZ^?$+K0_US7/YUA)Q"
M@@:Q3[X31; 6(WK/_+]2QZL(OP\\PG.?M$LL!$BM+@D!)F 6QSZ5R-,!, FF
M&/F (ULSGOL'5#\(N]P8D[RU;FFI%QN(56]N4)$_ECX+Q<*Z4"&#+P<LOO>Z
M&367!6RW9X?S'F'8W^,XJMDK\0>@W^H'N1_+OIBUC:FN=WJZ%N.-P[1J*0!6
M]Z02A"ILHAQH?80B1F2$*[2N[,IGB[8SMYU:5K^4%1X2A'Q73FN*PWEH(L@/
M.2C&CDQK&3=+/79/6%+'.T.WJK9#5(6U<84'7C.R]XR&&[36[]9C+)Q+:7FE
M4XSS]4E?QV0^R^0JCA'-PF+>0S[HLQG@;W*TR+)@ICPM?$S@KV]'R9R 1E@P
MV_EKGA+N\:$R)9PGU7'3DGNV^.,EMUQSG5CLHO[LMT"W"=V^P'A?>UK9O"R(
MI4_(?3#!2N-<CO4WF[))R)#A/*M8MDBN=<RQ;R%F=ZM20\WJE]\]!\,OSG'/
M'$N6P6T_/FFSYI3GN))0EE.:*B1.:H6[F$R>&!O[T-I(&KVQ:_V6UO/>QW:/
M,>S6W.)GHRC/[I_STDBI2.X<OGO6N=ZHV/Q4H1SC6J&]CTQ S<VW*[0^[QOK
M%%TQV7G_W1]*2.Q_+4/=H?WKFJ6 1W"', 6S@%G[56%.>+-RJ6)R?ET(S 3?
M(.7H46>?X2J.UKRFW ]5+]OKQ_C$[+3<@CBB9Q#Z9O/Q%J4E'>ZH0 UO#%\:
M"[VCP13Z/"IU92D#OQ]876"Q#05DAI$VF;H@@ZF'8/UR5XIC=M=*YYL8\?%F
M;K+0<-+IES'NZA*9A28G1RZD-MC,W3YYLH$BT)RK9\21?[X0(S8'$EO@VW]K
M@B9HX#5T$!F*>R=X2%:C?RQ0@NC=/RT#?!-+VY1^^D30OY!1:GUEN6<O7TFM
M2J0_<RQX9(^^Z:1;=?CSL$*:C2_CJ+3]P,G:7,.\_*QO*ZC!):$A.0ZSX&Z%
M(K*#V+V0M]=7%Z&*BE<_A0GNR.4NEG_+*R!53D=A:J>2H-459O"0XGKO54S7
M#]Q0R<GLQIIE7=GTW/'+WQ-^??8*[+[[!$=8@JAA5E\I7C$2(QK(D"9R=%:,
M*+Q*"\;+P&Y^*'H$@[7L)=-8]WW,TJQ,_:">)4@.3&(E-0>5@1EO!O#!_OJ<
MH#:F@M!CI'H[3XE,3S%>:U08PD$IS1RX>:P*^,)]W'>VIJ&YCD9-C[&=RG9G
MP[ZX/UDCG-?\JU<V_TS8'\'#;R<V6F^T)==7^2A9O4KD9V^?;I5_\OC5\A>C
MR+<AZ(F>_:F%JA-;[,M^1G=[ZU^M,!R'[)*)+8UBQ(\XYD=KZ.U2.G$Q0NA
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MGPNX"R/4$ DTX"34@RQQ#?QX40%!&QJPVL<K3:7*SS+7FSH93Z)3J<JXA%8
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MEIVP(Q(PM4N)Z%#O:BN-;ZC:J3F8RBM9&4WW^U9U-!6")$Y&$H68U)A[^_&
M=]66GYUF!69@FLH= Q./1UN6.KQR5DY%_3#H@O.T-^H-.4Z,4(=O^24CO9'(
MC1$0\"<&8'X/[M)II:G-\$FU8L3<@R+\D>? 5QK/;>I8DW)4;M[#?K^62.VJ
M3_7<8N$QD'SM7IA95MJY-Z0-;*#]X<V$1$L+40B<]C;P?0O$B UH5@FM]B&S
M%MEIK([W ]#T,9H&B.F,6H)9CJ4U&\ZG(C<:D#GC5#RMLE2P#[#+6/!]M.;[
MHN)@=67^$17C9]-Y'N]5ACN&<K!OQ @P5A_:"'=?&R9_48R@%PH.$Q>,/#X?
MFK!V*,#FG:LUL/5N6ZY&*WFJKJCYU:+FYHQV.1='W?[:]N'4E;^2LT,[3I?J
M#14=N>IV\N$7UVR]P4N;4T]-']WK;!1JR?7YQ+!H]PZIO=E4?&X%"WH8SW&!
MVA;">M "B#H%NK#FUX(6Q_LMU5A(!&Z_']!=D/LTY'J(9OR]PF\W;>)X!N\=
M[+9>>=H0U7"UKJ9N*>+M3E(G3:CL[@S 7G05(Z248:_L0[,>BQ&J?=?F1QLX
MRO?8I+5@1:=/JI,HCD56 X]BU<&U 4.4BMSX[S*:^ULF-,!<X&?G_)[3\[MJ
M!_!'K!ZM=7EJ'X&Y*43 D]P)(NLA+ HR.C/N$.O,;D,F! :#G&:U%N\'8GFD
M5G5,,K0#+T,%J,6<C+B)?7W-5]@"Y!;O$%1M?$)%0+!*7GU""+;29_KF1,:S
M3R']?NV!Y2%+QDJ?T,TD"CQDK, <&F?^:FDG. P-T.1@P9!(DK.TWJG"\^TV
M[7E AIO6]8W[IK6,@:#$A>7?AIKW<QYM_>1<GU?PZ/*=KSU?X2 -52T:KO48
MJJN8-UO[X/R#]5=?J/IU[NFI$7:MS>CZ^6"P)<9:35HMSLRA$H &E!(]*EK>
M'8S3ZY&.*)W[HMW+57JWOTS&8>_=0MUW,OEYAIV^%MKG%WUTPA;KJ=V<WB0:
MTE(&F H :3!74 ?#?@?]V1D; \"? 3RHL&*TD^UDT9)'R%D9&DDJ&<[QJHE1
M,[EOQIN@&[SP\U6,OI[[/M7LAS:<A/FX*"_>5#J15<6L]TQY,A.@!>H)[*$!
MJF8=Z!$2$9JS)\ LOMF>1^-HU:[UC4D^V(4+L@;[6%7[U@]4*_?(5(Q?>!<=
M85B)#EK: .?\ &FT>MK 2@O,XG\7T?"N@CW3ZE7UI<50]PJI'26;L:%%,TUH
MQK]Y,5,GSI?>-_KTGNK3E_V6\D4S,ZFU'T/S8H0A-]'%QJ,"/AXT%>@+M0"S
M-VAX9GMCKD-'WZ7)F=PNPCFVK$A_,JU*:W(Q_0+_+ J7\JHI53,K:=T3561<
MK ]UT+0[^O3KUT.4M*-+KDTO7V7M_O@^0_?OGWCR[O=[U:@ZA\MNQX4.[=G_
MYF3+F>>JI&I;R^PPCT<7_6_R2M6N&I]S>!C4Y>:6^54QU/FISL%GNT,]'1R<
MW3*_8(]5*=;/1HSJ/DD&:R\_2=9%2$QB$I.8Q"0F,8E)3&(2^V^T5\BM.!4Z
M1KX9C8X3^H8]"PAN,%-NV'^D) S:!G2/.07I%HQG>0(=944S?=O_?MSLBMGI
M7GWNT<[4;*L=8L2F*$ &^K\_%&!/@V-B1.^6ICU UY?UO-.5@>H/NW7/ B9[
M]URNJ7OD\"!]BX/33QW4^7Y[4[/K3U#.?9B]1+JF\!<QHI#800-O$E9W(F@K
M@E3G62HB&<@4ENL#O 8QHD ;.U>#74&N[K,U &--??C_<ZU6URXQXK&P5XR0
M/8B!8M8L<)5^J@CW,M\8KZ@(P\2(A-))K!AAZ8!FIT-KB!]HDQCA8;0&<9GC
M*@&5@$I ): 24 FH!%0"*@&5@$I ): 24 FH!%0"*@&5@$I ): 24 FH!%0"
M*@&5@$I ): 24 FH!%0"*@&5@$I ): 24 FH!%0"*@&5@$I ): 24 FH!%0"
M*@&5@$I ):#_M:!D#S "R'U#DS9<=,3\>CKLP)[9_3Z?0F4J<?2. *,;VK7V
M10U['">1F\/Z/Y8__9&0WLXM>I@=TF^;ON^!9VE.Q\,"E$IZA;=OCE*-T$HK
MW\OOTU#(5]P#V[XF>]?<_0Z&[5;GM>[9*'IM^._>&E-B$I.8Q"3VOZMY]: H
M9"X&<.3O$)&@;5 _LTXGF0/DTM$)ZO:TP:"T':^&*5S/+^W5<6SDQFD7TZ99
M@B'/MDR;>N_QM&NWM-.-R[M>OWHQ$#Z/Y486V=;OHAA8:3V<]2*[*3[K+U4Q
MSPX=S$S5:]WK],X]RS79@=NT-F376(U//=^QZ7!^Q\1! $-WV8B+[63*XWW9
MY#6@1NO-P X*)T,5[/0;L#1E$^6FE5.HLZ=&3+D7OO8Z]L\9CJP/:QI[]MN)
M6ST;$6*$'JJ^5ZBY*)#%2PV98M=#[S!R>*S@#[#V1(ZOO:7_^B(Q0CJ%]>R5
M;7"@.38E4B03P",GI=V?>=]=@C>G /PJZ<Y=]SBCW._*W]&38@0D?4B,6'=*
M](K&>HFNNQ0+T%L9R+1<=O6+2:5^=!#YXSP[BE_2]&M#ST^[XC KW9K^PG1,
M(FW+SN?>U12TPLQPD2,P5!M:P6Y"R08[E<44K2B)$7<BQ(B61S?].Q(>"QW@
M7W.$;L-GALEGZP?MYD8!,Z\![MF^V U?_<TXZ/9E0PJ&Z]B1-C'B^8&J$<)7
M'E;94\GP:NL.4),NG3M-V,!.5VKYT,G[;N6Q-YM5[OKW<P_MGI'3SJ=O[%[\
MHO*]I\K\Y47M0S^MQX::=X&/;E*>3B9D-#:4:2]C;*9##E!JT%:$U?,!/J,
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M-[7H"F+$$20/:B3$C$(X-$\E2*C4!1'0%[#"?2,DX5B?&"%_G=CB1YN:Y%^
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MB5)VG+)^^BJ:<S$ V$K-5WO_/Q:"@5(WGNJ0B%_<!+LV1->?RTD0PL:S&>>
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M>G3R:ZP9/@[[2%(*)].%V(G7K$8J5\5K]3G8H#HFKL1B6]X'*O?-0H2!3'8
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MT7LX:?#M%8'24$E(K.-+<HSZA-[7[X&)P_>:]0R7ZBR?FOP:$_JGC4 20:<
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MG_[N1>GWIPJ]4\:94[D4?W"]+\_P=[)Z4U%IJ/_)<;[6J[6CC7>KA3;CU0=
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M.7RAYD3C\1AXXB$!C6G.0:29"-2KHP4WUWKQS!/UHZ43>IYCSAXQDE4A$5Z
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M*_[:%U]:LP>);>BR-:/0V8V/GW/@.L,;7AM0%]"++M0!EI+O7+^B,PC$&'J
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M="N)9_/EJN;6.Q4XI@_"+.TK;JNZ8B0'#M<-'GN=X^LW,V]KG;M=U.T0%92
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M!KXS0T0+'MX;_;,WAWP<O81^(KECQ*UT2W$Q>B2ONJ8RX%YZB<RX7N;SP7\
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M(+(C2ZDWT-"<,MS-)8%8#J85Z^NG/C])O6_H(-8NA$E4#S>\\?P8CZP>)!P
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M9FDBC+\W5>180D'%7+21$:*<$66I,6N&/ZJ^&D\P >/;&/*AQ%U>ISBTT94
MQ5:/KUF_5:=C#QEF==.;I#Z'A)T\D'C,JFN( DSQ%8TA*38'SI?38:V2A+
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M=YZ%FO]-^XS@*Q9 DNY,!J@NUGP"3D?L+#5 *D%?X,I572>A73C[BS'^EJH
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M&4+WN Z F%<)R*<'!AX9/0W(K65%L076G_\Z*\44PJ+']3GDF 7UF1'O1\3
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M61$^GKT&X3>F^D,9T1Y0]G%_PC$@*6W?2/ZC(MMPEA"V_0O*?V@$BF21ES^
M7AQW9D'[PB8<AD5I7E %[5E8.EEINF>F29%#N[\R9MZ:I3QT^* Z?E;*T_Y-
M7=6S[-1KM?61'Q45W(,<_,+D%,_92Q U:("'-&C8^0Y>/15CX<ESA)I7F^1
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M9$/^YPM"./R_ %!+ 0(4 Q0    ( +6!JUS6\><3#+ # /!5)P 1
M      "  0    !E:6MN+3(P,C8P,S,Q+FAT;5!+ 0(4 Q0    ( +6!JUR+
M"BA'9QL!  EJ$  1              "  3NP P!E:6MN+3(P,C8P,S,Q+GAS
M9%!+ 0(4 Q0    ( +6!JUPBJLE/L@D  &)$   /              "  ='+
M! !E:6MN+65X,S%?,2YH=&U02P$"% ,4    " "U@:M<EI8'\*8)   V1
M#P              @ &PU00 96EK;BUE>#,Q7S(N:'1M4$L! A0#%     @
MM8&K7%M_E)*/!@  P2@   \              ( !@]\$ &5I:VXM97@S,E\Q
M+FAT;5!+ 0(4 Q0    ( +6!JUQ+50+.? 8  +8G   /              "
M 3_F! !E:6MN+65X,S)?,BYH=&U02P$"% ,4    " "U@:M<T$7G@_*W"@!Y
M-@\ $@              @ 'H[ 0 :6UG,3$Y.#,P,S P7S N:G!G4$L%!@
0   '  < L@$   JE#P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>eikn-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:eikn="http://www.eikontx.com/20260331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eikn-20260331.xsd" xlink:type="simple"/>
    <context id="C_82c0918f-98b5-404a-874a-7e2868a58706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_83013968-b516-4963-8f78-e02e28e21aac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:FurnitureFittingsOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_855d3fb8-6bf1-4d46-a30f-cd01135bf333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_88eddc74-25a3-4aa5-b892-0c78cef4f38f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_8ad16874-961a-4ba2-b824-435ee9b04091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_8c7f8085-733f-4767-ac3a-7065758bbd4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-19</endDate>
        </period>
    </context>
    <context id="C_8f4e15ac-2c2d-4f6b-9d70-e69adc4f166c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_8f9cf841-a084-4a0b-8321-a9f82ffed0e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="C_908c61c4-64bd-4c85-a9dd-94e0cd397a73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_912863b5-d421-42f1-b393-0c8022fb4cc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-19</endDate>
        </period>
    </context>
    <context id="C_92846805-1608-4137-b50d-75f45165732b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_92fa46f0-fe5c-4ebc-817d-ec6bec9a5f5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eikn:StockOptionOwnershipPercentageMoreThanTenPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-19</endDate>
        </period>
    </context>
    <context id="C_95010d63-09ef-4c23-8c49-40323fc46cd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9552213d-49d0-4396-a5da-0277b129dc28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_95fce60b-f21c-4670-9602-3e7e50701ea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9608e9ac-9845-4074-830c-41f067773cfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_968ee666-b8c6-47b0-97be-66417cf66128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_98a5f90f-67ce-444b-b813-16c9b0700876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9b34b095-baf1-4e92-bd9f-785cb99e7d43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_9b60e528-d867-4710-996d-aa10971fdb80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_9beb9422-a6eb-4bf6-9cb2-1645d1189e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <instant>2026-05-01</instant>
        </period>
    </context>
    <context id="C_9c0f0b76-fafb-4f29-bcdb-edfbcba2d100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9de7842e-b8a1-481e-8377-402c9062d31e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_a0702cde-f66e-4486-b5d3-9b3aee1b98c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-27</startDate>
            <endDate>2026-01-27</endDate>
        </period>
    </context>
    <context id="C_a147cd78-029b-4abc-9fd4-bc8f281f4101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a58a5eaf-b724-4201-9cb2-92d031377e5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-19</endDate>
        </period>
    </context>
    <context id="C_a72dfdfc-a580-488a-9676-5c50bffd695e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-06</startDate>
            <endDate>2026-02-06</endDate>
        </period>
    </context>
    <context id="C_a949f785-fff1-46ba-9714-cd224ef31489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_aa0ce56e-57e3-4af8-a0ed-914475550a24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_aa54d368-814e-495c-b6b0-69aa5b033eff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_aa9bb9d8-99cd-44a2-b558-5d96aab73df6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="C_b66b40a9-6ffa-4592-8e55-0cc8d9219267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b9805475-e76d-41e7-932c-783895704433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bc59c656-e863-43bb-acfa-25a6bfeba2a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_c0a37a53-ff96-4abe-8394-e87fa5432b98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c1976207-b5cc-489d-b211-526e50ce39ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_c1981874-bd18-46b8-8717-745097f2f3bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="C_c3beda52-07b7-41e0-a055-08c63663c5d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesC-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c7bcc98d-42fc-40a6-991f-28a29433e55e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_ca062afd-ce86-4311-8424-bd51f8222d31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ca978d31-a9a9-4f8f-b576-a32d51689a78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d2fe5e36-b89d-4ab6-a220-01ee0d375971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d3834c7d-2fa8-4b3f-9745-5b403f6177a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_d432863b-75bb-40d5-bacc-9c6f3baca062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsAvailableForFutureIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d5e0b4aa-c652-4259-90d9-48a14221845b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eikn:EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d632d010-5232-471e-abf6-d727c87dd4b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eikn:StockOptionOwnershipPercentageLessThanTenPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-19</endDate>
        </period>
    </context>
    <context id="C_d6aef30d-4b1d-4072-adb3-7c8d3cb1b224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d927b95d-37fc-4c9d-8791-5738a05cbc4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_dd617b4e-2a11-46a2-ae77-d0760c22bfc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_e170b844-9352-4f6f-8503-8d06a7499836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="C_e647b2ed-2de8-4ede-8766-0746071aee38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_e6ef9b81-32b1-4c49-9fa3-1c3d269aece2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="C_e7df204e-01a6-433d-b71b-99e1e283b5e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_e8020709-4b5b-468b-8ef7-0060d74c84ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_e8403787-14b9-4395-a9bd-4273c59b3ebf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:EngineeringEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_e8fb40c9-0eca-4b95-9025-0360ea439706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ea08a515-6580-47df-bab8-c50e516fc3e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_eb9e9cc2-9255-4256-ac03-f2e532a2ed46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ebfe9b65-c71c-4702-a2c5-feb06a82af91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed86a544-6aee-4ee9-acce-d3e07fcb1c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_eea5e544-8a36-4e39-9071-f9fe1d484521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f1a8eeb5-1e5a-4045-acdc-0cfce87caf9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SharesReservedForEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_f4769796-b48a-4a61-bcef-e175508ab0bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-06</instant>
        </period>
    </context>
    <context id="C_f6befb00-d49d-441c-b08f-36fbaa09ea83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SharesReservedForEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_fb91cb81-7c4b-448a-988e-9ead42c05b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesC-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="C_020258b1-9d04-4044-a458-aad5f3a473ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0395c051-54e6-4697-8ef1-dbef23445ddb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_06851da8-c034-45e1-a93f-8136cb20bbc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_09ce6087-ad99-4411-9be3-549230506f74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0eb6f30c-2652-4bc8-8657-bc2aac3eb2ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-07</instant>
        </period>
    </context>
    <context id="C_0ec3c10e-a93c-4886-a100-9f5b244f7eee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_10b77abe-4227-414e-a522-1ea2c59579c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_15155790-267d-4a2b-aaa0-e438238b971c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_16c203e7-dbb4-4d54-a213-cd806db24194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_170bbbfc-0868-43ef-95ca-29607794121a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_187793de-c269-4ef7-bb05-41fa5133f848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_18d67718-9b0e-4fc6-9a9c-711cd4ddf402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1946717c-8e31-4a84-ab14-fa2fc8fe3174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eikn:SuperbWisdomLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="C_19ce2956-fe58-4b8f-9894-55d51e63a6f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesC-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1a50a933-7364-4862-966f-2cce973d2edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1c487c21-7dd9-4244-95e3-68a278433e25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1c77db10-7d9d-4dcb-8c50-adc69f65d083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1e8500d8-0dbe-4c15-adb9-cf43d49e2d09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-07</startDate>
            <endDate>2024-06-07</endDate>
        </period>
    </context>
    <context id="C_1ea189f6-3a9d-423b-a06b-980dd823d3d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:StockOptionsAvailableForFutureIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_1fef2348-70de-4794-94d6-9e3dca9ad9dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockAndCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_21e45ff9-b261-46ab-ac86-9eca533d24f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_28287679-ce3c-40bb-abd2-c8b78786196d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-12</instant>
        </period>
    </context>
    <context id="C_2c6596ac-f14a-40c8-b62c-b693a7753c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_2eca1e62-aa09-48af-834d-34f067e0bf98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eikn:EarlyExercisedStockOptionsAndUnvestedRestrictedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_3076528d-17ef-41ea-9093-a57058ff97ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_307b49d7-4a22-4c20-90d0-a57dab4d74f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-12</instant>
        </period>
    </context>
    <context id="C_31e76bc3-5aba-4a5f-9818-f4b753bd92ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_32e58006-0bc0-440a-94eb-1e6e99c57dfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:ConversionOfRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_346f6ee4-54e2-4fbe-b3f1-de86b076b6d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3989eb12-e5ab-4eaa-81f3-cfefea545c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3cf22cef-9013-42e6-8cf3-e35b755febc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:ImpactAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_3deb9837-54c7-4413-864c-a18fd9e51818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_43059c80-0146-49ba-8b0b-010e3648880e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_43ceca5b-74f1-4f99-8520-dba39c9a9772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_480832dd-e171-4ca4-b482-a03140d73654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4a28407e-c2fe-49ab-87fd-4c1824a42626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_4b9ef807-4b9c-4eeb-b8bc-e8285f9f168c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_4c693a1f-4ca1-464c-90fa-56debb4e78a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="C_4d578cb3-2d47-417a-989d-844acb9f3cbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4db66fff-bc05-4074-8e36-aeef64b327a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="C_4f7b2433-ea8a-4286-bb00-c2633ee0aa88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_4fc1b14d-49f9-46f4-b17e-b2678287a627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eikn:SevenAndEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="C_50271040-0f62-455e-8383-928757d00db6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesB-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_60427b0d-3053-455a-a653-545c63de803d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eikn:TwoThousandTwentySixLong-TermIncentivePlanAndTwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-19</startDate>
            <endDate>2019-09-19</endDate>
        </period>
    </context>
    <context id="C_6244dd7b-fa8c-4429-a004-33462cc5b476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesBOneAndCOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_62648b45-b0dd-4b75-99ea-21268ea1e65d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_645f2052-193d-45d6-894c-a8d3a45a5203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:ConversionOfRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_64e1594b-40d8-45fe-8a5b-61465fc568f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_654d525f-1b50-489a-916a-b5b3453bca96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_660ec3d2-b609-4bfb-b1b1-c4305903c960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:EngineeringEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_662558f3-ac07-4fe3-b87b-689c90cf7fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6b6e3025-7be7-4cf5-a556-aecb955a9d7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_6efa0e52-ace6-4c24-8d0d-270fe66c03b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6f295888-378b-4391-a021-9bca631286e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eikn:FurnitureFittingsOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_6f92e515-198c-41f2-9ae2-33fc324dbf18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesB-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_72c9554b-3432-4aba-ad4e-feadbc19e644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_734a9e98-beab-4d4c-b47e-a15b69419607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">eikn:CaliforniaNewYorkAndNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_760222b0-6d13-4c82-a9ee-2f2a276df9e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eikn:TheColumnGroupAndCatalyst4AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-07</startDate>
            <endDate>2024-06-07</endDate>
        </period>
    </context>
    <context id="C_76484ee6-c514-405c-9fcf-875c160c471b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesA-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7756d92c-fabb-4333-b946-71468f2cd618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7793f816-84ea-4007-b84f-955f26f60859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eikn:SuperbWisdomLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eikn:SevenAndEightCollaborationAgreementAndSWLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="C_7930da5b-8c34-4bde-9df0-f3a4e63faa1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_79517728-0638-49d0-b5e2-18ddacc50546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="C_7a831092-b41d-417e-82e2-51595df304eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_7c4a7bfd-264d-45e7-bcf8-d63ea24ce46b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7cfa5dbb-75bd-4c08-84f9-248de234217e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_7d79440a-32b9-4e44-9930-5f1dcba2901b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_7f0bc01b-6dce-402c-b6f6-7f08c14a5096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861123</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eikn:SeriesB-1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>eikn:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_e9d4c374-3c57-454f-9c1b-4e04018b2483">0001861123</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_73e76b8d-0092-49a4-8dee-9b25ac5251cf">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_f6e8d3dc-888a-4fdc-90c5-0f2ebc9fad8b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_3680dffe-fb9e-4e37-962a-89878e0aac8c">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      id="F_406021d1-f696-4dc5-823b-2dbb02101b41"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      id="F_d5172da2-0e18-422f-9dd6-381742ad61d9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_a0702cde-f66e-4486-b5d3-9b3aee1b98c2"
      decimals="6"
      id="F_d7440967-f56a-48a1-8724-4db9ad3811ca"
      unitRef="U_pure">0.134088</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_a1712c5d-8279-47e4-b1b8-8c2d8242df25">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194"
      id="F_2513182e-84c1-42c0-8135-b3838edee5c8">2040-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_e8020709-4b5b-468b-8ef7-0060d74c84ab"
      id="F_4891b7a9-ea44-4065-bf6f-ac1774d7b202">2026-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_aa0ce56e-57e3-4af8-a0ed-914475550a24"
      id="F_fea5efb2-ee1e-4e93-a542-9a2bbd4553aa">2029-07-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="INF"
      id="F_85997c2d-5760-46fb-bcd0-7b83f0349464"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_2ea580d6-5cea-4c6a-9652-7b14b693ba76">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_62d03e34-735e-4655-a913-9c56822f6ae3">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_070ce654-3687-4335-aa1a-8007629f98c9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_395cc1c3-2d7d-4245-92b9-b0be8ca60ff5">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_45a71b4c-8a13-42eb-9c95-f9c8ad964d24">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_4f131e03-916c-4d8e-b680-a5d07ab27c08">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_a721c450-0993-4143-9cb5-c8e4c65086cc">001-43085</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_4c46e4a3-30ef-4dd1-9065-be575fe61b41">EIKON THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_06603eee-4a38-4602-96dd-63d2f959cdbc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_655b1079-4e75-4e8e-aa21-c9f761df01aa">84-2807586</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_fab902e2-f8f3-49bd-be72-0a03c46adcd7">230 Harriet Tubman Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_de19529a-4ec7-42aa-a4eb-197d650e72ed">Millbrae</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_bcec27ee-b3ba-4b6e-945b-b248c448481e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_e363c8ea-d251-4c5d-a444-51425a7fc44a">94030</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_d6884df5-151e-4676-927e-34c5b43a4577">341</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_00bbf200-61c6-476f-ab5b-60b61ad1ce76">777-0566</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_84954921-f3c2-4dbd-a2e3-56d838678763">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_83684347-9ccc-4ad0-bf5d-eb3af0cfa87d">EIKN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_5a4f8a3a-bc8a-486a-a2ea-028c2d1ae41a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_2c9d0789-7b65-4025-b63d-b74dac1b6fac">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_eab8712e-b19c-4a8a-ab19-35eb12f051dd">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_e6a68baf-a0f3-468f-a00a-54d0380b9cd4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_11898d60-5719-4949-8511-015b41cdfd9d">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_a186863d-910c-46a7-8f4a-857d9444815b">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_ab1322a1-8532-453d-af26-2b9151504100">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_81b7b36d-5f03-47f9-92d9-c261f4f75e1b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9beb9422-a6eb-4bf6-9cb2-1645d1189e95"
      decimals="INF"
      id="F_caca63f8-fe30-41c9-9f66-78f46ec9edde"
      unitRef="U_shares">54138628</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_1298ade4-c379-44b9-bc04-082e559bbc77"
      unitRef="U_USD">161154000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_4c646c2b-9cb6-438a-9cb6-63a041fb259c"
      unitRef="U_USD">104901000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_430b1ae1-ca5a-45fb-bd88-ed5eb54455cf"
      unitRef="U_USD">351028000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_7a0e3e9c-02b9-4c3b-b180-84e799e23c2d"
      unitRef="U_USD">231074000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_6588e086-03ef-46c7-be43-ef30ffb50b2f"
      unitRef="U_USD">16919000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_2ca7b8b4-57ed-43d0-adc2-de561d617f64"
      unitRef="U_USD">12542000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_6f8233f5-7063-436a-a25d-ba5d17e42f58"
      unitRef="U_USD">400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_4e97eba3-03e7-40c5-88c2-b4d685f8318b"
      unitRef="U_USD">400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_b89eed7d-cb69-4957-bb9e-0630574fdbe9"
      unitRef="U_USD">529501000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_00771179-853f-482b-8267-8579a87bc79b"
      unitRef="U_USD">348917000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_79405566-5ee4-4905-81ea-bc9b535b59c8"
      unitRef="U_USD">138067000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_fc116891-ec80-42fe-9ba7-9af5cee39770"
      unitRef="U_USD">142898000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_9d279727-2106-4eb5-8eec-96e8b3dbbf93"
      unitRef="U_USD">91066000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_54e74ead-e02d-477f-ac2c-524c5feb3a65"
      unitRef="U_USD">90965000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_15a8942d-5a64-40dd-8d17-da1b2e994f26"
      unitRef="U_USD">83828000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_269906fe-6c43-4dee-856b-6e7fe83ca644"
      unitRef="U_USD">7808000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_5461bbdb-e376-4dbd-8ea3-910d575ddf80"
      unitRef="U_USD">7771000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_8ae67b7e-37e2-43ec-ac60-5dedaacf8bc5"
      unitRef="U_USD">556000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_9b620e04-d456-4f4e-bd52-f16ffc173798"
      unitRef="U_USD">4183000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_8a506e2f-a09a-42bd-8e70-75a581a85a9a"
      unitRef="U_USD">850826000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_b773e6d4-ef16-401e-973a-2d7453b81e8d"
      unitRef="U_USD">594734000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_5671e417-e2b7-48e9-b602-23f5d41e2416"
      unitRef="U_USD">6005000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_6c0c51fb-c871-4959-97c5-dc34a6a9747b"
      unitRef="U_USD">681000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_b1de2385-d9c4-4a5b-b933-9c241df104a6"
      unitRef="U_USD">29319000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_350160c5-9848-43fb-9f46-cd46c76be10e"
      unitRef="U_USD">44298000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_396215bc-73d6-4754-9553-ba2d88fde0d9"
      unitRef="U_USD">9740000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_e2eaadf4-f598-4bb6-9507-b39ba1e632d3"
      unitRef="U_USD">10028000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_644f4356-a49f-453a-af9a-71727ed1417e"
      unitRef="U_USD">45064000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_f421ef1a-c1bc-45dd-a4d8-7442859a225a"
      unitRef="U_USD">55007000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_b30610bc-4685-4089-945e-ebf4e4ab6090"
      unitRef="U_USD">245091000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_6663b200-2173-4f0c-8e56-87ccf17aecb1"
      unitRef="U_USD">247291000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_d57ef116-8bcb-425e-83ee-0285f55829a1"
      unitRef="U_USD">10000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_e6b060f4-d3c6-4c61-bd8f-070da36e8f60"
      unitRef="U_USD">10000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_4347ef0b-b530-43d5-b732-e4d5d924ce4e"
      unitRef="U_USD">300155000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_cd58afc1-a5b5-4b89-8190-5958179b49e4"
      unitRef="U_USD">312298000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_06bb60a7-e6ec-4003-9ea1-ec40c5774995"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_78397c62-8fc7-4ac3-8ad6-8bd6bfe804ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_4530fe1f-48ff-4c51-8c1c-0d0036d74b5a"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_c467e3a1-e09b-4c2c-99bb-677fa0a2c56a"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_10757568-7fe7-4f56-a7d4-45f81b59599d"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_c9f58b6f-3fec-496d-b0ef-8f3d750b7cf7"
      unitRef="U_shares">262597889</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_92d9bbf5-baaf-493f-979a-dcd0e4b34336"
      unitRef="U_shares">222658133</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_46112bcb-ff52-4aa7-86fd-f5970eee8f04"
      unitRef="U_shares">222658133</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_d51f3553-f894-47aa-8733-c7a63f6d257f"
      unitRef="U_USD">1159762000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_d54b30d8-f810-4df0-b7cf-06a153c4100e"
      unitRef="U_USD">0</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_b06870aa-5a19-460a-9aba-b853b1818afd"
      unitRef="U_USD">1161470000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_d566b202-01c3-4a06-94c7-b5ba2fba2bec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_18471c44-3030-45d9-9178-d1beba0168c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_fb3c2758-5fb1-4f1b-96a1-cf99ba233935"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_6b040ab7-05b9-4da7-90b2-d62f485955c1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_d1e26192-1f23-4b8a-9dc7-be8ac104488d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_b4cdca40-e3a3-4d53-afdf-1909e726136f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_7b0bdbd2-2bd7-4b4d-a127-e7cf5e603478"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_35854f55-5aed-4c2f-94a1-02156e7b8fd6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_8ac40109-661c-4915-a097-4505716a1735"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_f8026e45-1b60-4990-ae60-40dd11977fb9"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_7465953d-8c16-4d7a-9a0d-492844b8bf11"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_3da991f0-b552-4839-b1a7-19fd085c5343"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_c4a8d0b4-102c-4ae1-be4a-255299d8af0f"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_23c53375-aab6-4798-adee-de9283fa59d0"
      unitRef="U_shares">54138555</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_2f34306b-0235-4e45-9ab8-f89051bf7e2b"
      unitRef="U_shares">54138555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_8b693cd6-8a1c-46ff-8d87-d7a4eda453ef"
      unitRef="U_shares">340650000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_cb96cfa5-65a8-4b29-8d51-c55144ffe45d"
      unitRef="U_shares">3068490</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_53ec40f6-8a6e-4f6c-8570-6d8e6c226b46"
      unitRef="U_shares">3068490</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_a5e3d8fe-66c1-4e68-98a9-b45eaca9d0f1"
      unitRef="U_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_74cd5f75-7290-4368-93b0-12f41ce4d605"
      unitRef="U_USD">1554133000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_3b930e43-d639-4e65-8ac1-bac41ec27b0c"
      unitRef="U_USD">41475000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_e91b8b8d-6148-46bd-87a5-37a5cead01b4"
      unitRef="U_USD">-1003467000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_9f9e5a9e-8d89-466a-a89f-4c67acffd38b"
      unitRef="U_USD">-920509000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_4b137ad9-bbed-432d-9244-30eb9f62ad68"
      unitRef="U_USD">550671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_46de2d73-1a60-448d-b358-9f4eaaaf4876"
      unitRef="U_USD">-879034000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_b77cfc14-db57-4ce0-ba63-b4db6aa2d3a5"
      unitRef="U_USD">850826000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_ab3011be-573c-4966-8887-3b86e86cef2c"
      unitRef="U_USD">594734000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_83407a55-df4a-4a2f-8842-13dbd614d2fd"
      unitRef="U_USD">70047000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_9a4abc7a-92da-42bf-bc62-a1bafb6ca942"
      unitRef="U_USD">56587000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_8ea5591b-a798-4d1c-9880-953ad9a3c063"
      unitRef="U_USD">17290000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_7c438408-c9b6-45e2-ade9-48d24e45f100"
      unitRef="U_USD">14796000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_3b583b4b-213a-48e6-9506-fd9df4ef9ab6"
      unitRef="U_USD">87337000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_dd598f64-33e7-4047-9942-03ebffdd97b5"
      unitRef="U_USD">71383000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_84d1b3a9-6e68-4495-8da4-068ccdd0aba6"
      unitRef="U_USD">-87337000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_80132ec7-e68e-40aa-954e-c23a2642f8d1"
      unitRef="U_USD">-71383000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_552fce07-6981-462c-ba19-f56de6b3ea43"
      unitRef="U_USD">4380000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_6d7528e7-dc04-47d9-b49c-b3dd84de96ae"
      unitRef="U_USD">3160000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_7760b2a5-24a0-4a61-ade7-3f201839fd75"
      unitRef="U_USD">-1000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_cd5f5c9e-ae8b-4bee-b01f-748fffef244f"
      unitRef="U_USD">-20000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_2214ca20-9d5e-4842-8390-b0c38132610f"
      unitRef="U_USD">-82958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_40b611ff-f23c-46ef-b5ca-644f7c43e5b8"
      unitRef="U_USD">-68243000</us-gaap:NetIncomeLoss>
    <eikn:ImpactOfPreferredStockExtinguishmentsAndModifications
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_08d221ed-c51f-40fc-8efc-b2483da98eb8"
      unitRef="U_USD">-6300000</eikn:ImpactOfPreferredStockExtinguishmentsAndModifications>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_e1947356-4961-418a-bc1a-ce92a7ad32d3"
      unitRef="U_USD">-82958000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_14f9dd25-6d1b-4f40-9c02-c5daa2eba0e5"
      unitRef="U_USD">-74543000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="2"
      id="F_eff186fd-7588-4b18-b2dd-0e9619ea1b1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="2"
      id="F_8c85716a-6121-4142-a8c2-b53aff4c0e62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="2"
      id="F_1ec17b47-3d9a-4eb8-987a-189df24feb8b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-26.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="2"
      id="F_d38b5162-a020-4e83-ac3b-9268cfe3c2e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-26.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_a4f88036-c0bc-4e47-9150-dada906bc48d"
      unitRef="U_shares">33700550</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_6592170b-fcf3-4d91-8dc3-ecc7bc838bb3"
      unitRef="U_shares">33700550</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_733b5a2e-e1d4-47e4-a558-dc1103a36842"
      unitRef="U_shares">2770352</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_1b4829ec-93cf-4db7-a033-17fcb0e2db4d"
      unitRef="U_shares">2770352</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9c0f0b76-fafb-4f29-bcdb-edfbcba2d100"
      decimals="INF"
      id="F_a04c6218-b778-4328-9e87-40ea12ec4e0e"
      unitRef="U_shares">222658133</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_9c0f0b76-fafb-4f29-bcdb-edfbcba2d100"
      decimals="-3"
      id="F_1cacf51e-6289-4047-a9e5-5524cf360cdf"
      unitRef="U_USD">1161470000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_43ceca5b-74f1-4f99-8520-dba39c9a9772"
      decimals="INF"
      id="F_6d37fc30-5f1a-4e82-8bf7-89addb33598f"
      unitRef="U_shares">3068490</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c0a37a53-ff96-4abe-8394-e87fa5432b98"
      decimals="-3"
      id="F_a1ace71a-7a0c-4c30-bd5e-e5c3b12894f2"
      unitRef="U_USD">41475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_09ce6087-ad99-4411-9be3-549230506f74"
      decimals="-3"
      id="F_a2cdb35c-1cd9-46de-9fd0-af6336548577"
      unitRef="U_USD">-920509000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_5396c6c8-5056-4cd4-ad17-1f16d569be31"
      unitRef="U_USD">-879034000</us-gaap:StockholdersEquity>
    <eikn:AdjustmentNetOfIssuanceCosts
      contextRef="C_7a831092-b41d-417e-82e2-51595df304eb"
      decimals="-3"
      id="F_ed07b523-6a39-4fd9-b242-3cef3fdb657e"
      unitRef="U_USD">33093000</eikn:AdjustmentNetOfIssuanceCosts>
    <eikn:StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering
      contextRef="C_7a831092-b41d-417e-82e2-51595df304eb"
      decimals="INF"
      id="F_3899dbe7-0dc0-4fb2-8269-f2672b1b0fe9"
      unitRef="U_shares">21177600</eikn:StockIssuedDuringPeriodSharesNewIssuesInInitialPublicOffering>
    <eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering
      contextRef="C_7a831092-b41d-417e-82e2-51595df304eb"
      decimals="-3"
      id="F_00c64cc7-fb7b-4134-b910-5dc0da11a162"
      unitRef="U_USD">2000</eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering>
    <eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering
      contextRef="C_92846805-1608-4137-b50d-75f45165732b"
      decimals="-3"
      id="F_fa5027e3-b01e-4c3d-8fd1-b3a3209259fc"
      unitRef="U_USD">348102000</eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering>
    <eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_ee540309-bfff-4941-83b8-2d56f448bbb0"
      unitRef="U_USD">348104000</eikn:StockIssuedDuringPeriodValueNewIssuesInInitialPublicOffering>
    <eikn:TemporaryEquitySharesRedeemedUponConversionShares
      contextRef="C_62648b45-b0dd-4b75-99ea-21268ea1e65d"
      decimals="INF"
      id="F_d4950bfc-43b0-4abc-bdbe-77ddecf8919b"
      unitRef="U_shares">222658133</eikn:TemporaryEquitySharesRedeemedUponConversionShares>
    <eikn:TemporaryEquitySharesRedeemedUponConversionAmount
      contextRef="C_62648b45-b0dd-4b75-99ea-21268ea1e65d"
      decimals="-3"
      id="F_b27afcde-0318-4a28-8d52-109039ffc215"
      unitRef="U_USD">1161470000</eikn:TemporaryEquitySharesRedeemedUponConversionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_7a831092-b41d-417e-82e2-51595df304eb"
      decimals="INF"
      id="F_5f958e87-2770-49da-a3bb-6a70b1e8ef5c"
      unitRef="U_shares">29855741</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_7a831092-b41d-417e-82e2-51595df304eb"
      decimals="-3"
      id="F_0a4955cb-52a3-4ba5-aa54-f7abf5cc3929"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_92846805-1608-4137-b50d-75f45165732b"
      decimals="-3"
      id="F_91537f2b-f72b-4e1c-83e6-55adf8afac52"
      unitRef="U_USD">1161467000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_34cd23b6-b1b0-4b35-9cb2-6ec3970a076b"
      unitRef="U_USD">1161470000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7a831092-b41d-417e-82e2-51595df304eb"
      decimals="INF"
      id="F_6d585c9b-5494-4b1b-a1c6-c073c24d6b81"
      unitRef="U_shares">36724</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_92846805-1608-4137-b50d-75f45165732b"
      decimals="-3"
      id="F_82784b26-9e2e-42b3-9265-8c9997504a9b"
      unitRef="U_USD">277000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_bc4fe2cf-c3d4-4597-9ac9-defd9b0f059e"
      unitRef="U_USD">277000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock
      contextRef="C_92846805-1608-4137-b50d-75f45165732b"
      decimals="-3"
      id="F_80bc589f-3b96-47ec-93f9-34496edbfe20"
      unitRef="U_USD">35000</eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock>
    <eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_1e38b1e1-08e2-43c0-99b9-837683e61848"
      unitRef="U_USD">35000</eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_92846805-1608-4137-b50d-75f45165732b"
      decimals="-3"
      id="F_8fbaf4dc-64fe-4a52-9558-5ffc7651dd58"
      unitRef="U_USD">2777000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_c0303193-f35c-41f1-8ee1-23ee1ed95ef1"
      unitRef="U_USD">2777000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_8ad16874-961a-4ba2-b824-435ee9b04091"
      decimals="-3"
      id="F_98558b5c-63d6-45a9-b978-785fdde94b1a"
      unitRef="U_USD">-82958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_c6759add-a193-4d67-b961-dc0fae273cfd"
      unitRef="U_USD">-82958000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9b34b095-baf1-4e92-bd9f-785cb99e7d43"
      decimals="INF"
      id="F_77ff738b-2c4c-41f4-acbf-3c2345c138bd"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_9b34b095-baf1-4e92-bd9f-785cb99e7d43"
      decimals="-3"
      id="F_f61e54d8-75d7-4f39-814c-65181054ad9e"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_4b9ef807-4b9c-4eeb-b8bc-e8285f9f168c"
      decimals="INF"
      id="F_f4fd9b9b-5069-42d5-bf42-fc34dd5f7c13"
      unitRef="U_shares">54138555</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4b9ef807-4b9c-4eeb-b8bc-e8285f9f168c"
      decimals="-3"
      id="F_37caa142-f522-4c01-8a65-f102fd8e81e7"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4f7b2433-ea8a-4286-bb00-c2633ee0aa88"
      decimals="-3"
      id="F_41833894-3f3d-4719-a823-08e6612a41af"
      unitRef="U_USD">1554133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7930da5b-8c34-4bde-9df0-f3a4e63faa1e"
      decimals="-3"
      id="F_ccc81f08-4d0d-4fa4-8c4e-e197dd27e774"
      unitRef="U_USD">-1003467000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_6c1f0a8d-93c8-4ce0-87f4-fc7403b734d6"
      unitRef="U_USD">550671000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_6efa0e52-ace6-4c24-8d0d-270fe66c03b8"
      decimals="INF"
      id="F_1cec1854-c8b1-4a44-886c-cb3b0437fa4d"
      unitRef="U_shares">135087291</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_6efa0e52-ace6-4c24-8d0d-270fe66c03b8"
      decimals="-3"
      id="F_73fe79f6-9753-4c72-a81f-980d5b0e5e58"
      unitRef="U_USD">808221000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_43059c80-0146-49ba-8b0b-010e3648880e"
      decimals="INF"
      id="F_acc95c7e-1f24-4b44-997e-b354759feeda"
      unitRef="U_shares">2869760</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1a50a933-7364-4862-966f-2cce973d2edd"
      decimals="-3"
      id="F_e2b4f83e-1c20-4670-a7a7-f67c75c416e6"
      unitRef="U_USD">33011000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_654d525f-1b50-489a-916a-b5b3453bca96"
      decimals="-3"
      id="F_739c440d-a7ad-4dfc-aae8-aa75b4398a09"
      unitRef="U_USD">-604941000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_170bbbfc-0868-43ef-95ca-29607794121a"
      decimals="-3"
      id="F_362218dd-08f1-46e9-bb55-f88b9bd05b2f"
      unitRef="U_USD">-571930000</us-gaap:StockholdersEquity>
    <eikn:AdjustmentNetOfIssuanceCosts
      contextRef="C_82c0918f-98b5-404a-874a-7e2868a58706"
      decimals="-3"
      id="F_668f27c4-5ca1-4072-b380-0c38de02f74f"
      unitRef="U_USD">547000</eikn:AdjustmentNetOfIssuanceCosts>
    <eikn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_82c0918f-98b5-404a-874a-7e2868a58706"
      decimals="INF"
      id="F_c730454e-0a44-4016-9aa1-377d679f6f10"
      unitRef="U_shares">60005669</eikn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_82c0918f-98b5-404a-874a-7e2868a58706"
      decimals="-3"
      id="F_5a290fbd-a8d7-427a-ade8-fd8e3e009ae9"
      unitRef="U_USD">350153000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <eikn:TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock
      contextRef="C_8f4e15ac-2c2d-4f6b-9d70-e69adc4f166c"
      decimals="INF"
      id="F_4f33f83b-2b14-403c-854d-a246738345a6"
      unitRef="U_shares">19977824</eikn:TemporaryEquityIssuedDuringPeriodSharesInExchangeForExtinguishedPreferredStock>
    <eikn:TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock
      contextRef="C_8f4e15ac-2c2d-4f6b-9d70-e69adc4f166c"
      decimals="-3"
      id="F_8b700dc6-6b68-4512-b863-3fb0569aecdd"
      unitRef="U_USD">-8566000</eikn:TemporaryEquityIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock>
    <eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock
      contextRef="C_ca978d31-a9a9-4f8f-b576-a32d51689a78"
      decimals="-3"
      id="F_bd7be9a6-6b6f-418a-aa43-9cca842f308f"
      unitRef="U_USD">-114000</eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock>
    <eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock
      contextRef="C_187793de-c269-4ef7-bb05-41fa5133f848"
      decimals="-3"
      id="F_6227bcfc-604d-4fce-8367-1b6765b8eefa"
      unitRef="U_USD">8680000</eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock>
    <eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock
      contextRef="C_1fef2348-70de-4794-94d6-9e3dca9ad9dd"
      decimals="-3"
      id="F_280fb900-231b-4aaa-a4cb-5be74103f20a"
      unitRef="U_USD">8566000</eikn:StockIssuedDuringPeriodValueInExchangeForExtinguishedPreferredStock>
    <eikn:TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock
      contextRef="C_d2fe5e36-b89d-4ab6-a220-01ee0d375971"
      decimals="INF"
      id="F_17339fb8-e1af-47c8-8377-494e455e20e6"
      unitRef="U_shares">7587349</eikn:TemporaryEquityIssuedDuringPeriodSharesInExchangeForModifiedPreferredStock>
    <eikn:TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock
      contextRef="C_d2fe5e36-b89d-4ab6-a220-01ee0d375971"
      decimals="-3"
      id="F_05bc3a11-6c3f-4c4e-a4be-56a406cb38b5"
      unitRef="U_USD">-11662000</eikn:TemporaryEquityIssuedDuringPeriodValueInExchangeForModifiedPreferredStock>
    <eikn:StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock
      contextRef="C_6244dd7b-fa8c-4429-a004-33462cc5b476"
      decimals="-3"
      id="F_dcdeb78c-9cda-451c-ae71-fbb5d4aeaecc"
      unitRef="U_USD">-11662000</eikn:StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock>
    <eikn:StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock
      contextRef="C_eb9e9cc2-9255-4256-ac03-f2e532a2ed46"
      decimals="-3"
      id="F_d1de83c1-3a30-4457-8ec4-b90c6fe48aaa"
      unitRef="U_USD">-11662000</eikn:StockIssuedDuringPeriodValueInExchangeForModifiedPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b66b40a9-6ffa-4592-8e55-0cc8d9219267"
      decimals="INF"
      id="F_a2588e1b-743c-4db0-ae53-86239b244a6e"
      unitRef="U_shares">1197</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3deb9837-54c7-4413-864c-a18fd9e51818"
      decimals="-3"
      id="F_f96ce468-8ef2-4dd0-a98b-de8ddead8d84"
      unitRef="U_USD">25000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_8bdab32d-74ec-40e4-8111-9306997c2633"
      unitRef="U_USD">25000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_b66b40a9-6ffa-4592-8e55-0cc8d9219267"
      decimals="INF"
      id="F_ae7ae7c4-11bc-40c0-83a0-d90b4f6b8b02"
      unitRef="U_shares">201</us-gaap:StockRepurchasedDuringPeriodShares>
    <eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock
      contextRef="C_3deb9837-54c7-4413-864c-a18fd9e51818"
      decimals="-3"
      id="F_1231c48a-01a6-44b5-ba37-626ef92bdbba"
      unitRef="U_USD">137000</eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock>
    <eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_70fc7320-2c79-4ffe-b1ee-07bc159fa05b"
      unitRef="U_USD">137000</eikn:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_3deb9837-54c7-4413-864c-a18fd9e51818"
      decimals="-3"
      id="F_a4fb5ddc-f535-48e1-b3a1-ecdf66d1e058"
      unitRef="U_USD">2970000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_4114263f-6445-4e06-a2e4-3404e4969699"
      unitRef="U_USD">2970000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_95fce60b-f21c-4670-9602-3e7e50701ea5"
      decimals="-3"
      id="F_98ed9f51-fd2a-4660-926d-87165f474523"
      unitRef="U_USD">-68243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_e36337ec-ad08-4d3c-86ae-37419bf15aec"
      unitRef="U_USD">-68243000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9552213d-49d0-4396-a5da-0277b129dc28"
      decimals="INF"
      id="F_0d2e0308-ea65-4a73-8126-eb8727e66026"
      unitRef="U_shares">222658133</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_9552213d-49d0-4396-a5da-0277b129dc28"
      decimals="-3"
      id="F_400e1dd9-68a4-43dc-9bfa-6ab59836c933"
      unitRef="U_USD">1161470000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="C_aa54d368-814e-495c-b6b0-69aa5b033eff"
      decimals="INF"
      id="F_762f1d72-67d4-420a-8cbf-4cd4f04f7f0e"
      unitRef="U_shares">2870756</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4d578cb3-2d47-417a-989d-844acb9f3cbd"
      decimals="-3"
      id="F_250ffd97-5db8-4ef1-b8ec-383a3eb3a0fa"
      unitRef="U_USD">24367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a147cd78-029b-4abc-9fd4-bc8f281f4101"
      decimals="-3"
      id="F_418b58d9-8a1f-45e2-a109-5ad2fa850107"
      unitRef="U_USD">-664504000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641"
      decimals="-3"
      id="F_0e4f69c6-d54e-4ddc-9862-457698f95211"
      unitRef="U_USD">-640137000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_46f32449-1268-48bb-872b-d5b338f75429"
      unitRef="U_USD">-82958000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_4b34b96d-a978-4ce2-b8ce-f8f989a51c8b"
      unitRef="U_USD">-68243000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_1bbde1e5-f207-47ad-806a-91fc67154c38"
      unitRef="U_USD">5214000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_5eb53223-0233-4344-877d-7fdafd89bace"
      unitRef="U_USD">3789000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_f65128b5-9b1c-4ea1-beb2-63bc73f204fa"
      unitRef="U_USD">2777000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_2c3d34cc-0b73-48a2-98d3-d1792218e341"
      unitRef="U_USD">2970000</us-gaap:ShareBasedCompensation>
    <eikn:OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_c72f2a38-8d5a-45b1-b8f7-763f8e155273"
      unitRef="U_USD">101000</eikn:OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome>
    <eikn:OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_19d02bd1-0519-4d64-93b2-ed3c06c49309"
      unitRef="U_USD">-2677000</eikn:OperatingLeaseRight-Of-UseAssetAmortizationExpenseIncome>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_1bbc899f-02fd-4f48-9df9-70d7904e9514"
      unitRef="U_USD">827000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_1ad1324c-ee47-4923-a975-e4f2227bcd68"
      unitRef="U_USD">1234000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <eikn:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_0c132468-6df7-4344-add0-e4fbb5851e6a"
      unitRef="U_USD">4377000</eikn:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <eikn:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_86b9fbb1-5051-4dd5-b86a-1cb52d9c85bb"
      unitRef="U_USD">2686000</eikn:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <eikn:IncreaseDecreaseInOtherAssets
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_38ac9cb4-a00e-4529-9f17-7696fd29dd24"
      unitRef="U_USD">-2700000</eikn:IncreaseDecreaseInOtherAssets>
    <eikn:IncreaseDecreaseInOtherAssets
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_7c6babbe-b013-4599-9179-8667deaccab9"
      unitRef="U_USD">399000</eikn:IncreaseDecreaseInOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_18c2ab90-f16c-4f0b-9b5b-26108aac5f8f"
      unitRef="U_USD">5324000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_5491d9c5-6608-4b57-b1d1-25852f07d162"
      unitRef="U_USD">2277000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <eikn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_f472f9cb-4624-4707-b614-8a3fafb6cbac"
      unitRef="U_USD">-15065000</eikn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <eikn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_f22c6139-0049-4234-82a1-7923bed35700"
      unitRef="U_USD">-9384000</eikn:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_a593c996-de0e-4da6-a7fb-83e6a10bb598"
      unitRef="U_USD">-2488000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_94c952b9-03ce-47a8-a586-dc9228cc0533"
      unitRef="U_USD">16023000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_dae9165e-d7ad-4622-95f8-59735dd939ba"
      unitRef="U_USD">-311000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_3cf7310e-d497-42a5-a53b-f5de80a738a2"
      unitRef="U_USD">-89801000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_be6f2f92-9a69-48b3-bc2a-499f1e357478"
      unitRef="U_USD">-54521000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_7dee2f25-9371-457b-b4d7-80f5bff79234"
      unitRef="U_USD">262000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_6e51e37d-ee15-4b91-95bc-d0829b4c04bc"
      unitRef="U_USD">22358000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_30716680-d5e6-4c2f-923f-d05b00e0fbbe"
      unitRef="U_USD">306955000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_46d3e51e-3282-4421-a9d9-4d8aeda5819f"
      unitRef="U_USD">252496000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_6c86d80b-bd72-4598-9a98-109c0944dc00"
      unitRef="U_USD">104000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_4e6f3655-90cd-4206-8f9d-496541adfb2d"
      unitRef="U_USD">61000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_fb304823-72be-441c-ac99-841ccbe0d80c"
      unitRef="U_USD">-203217000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_fd8aa235-f670-4891-93a2-4ea43efdb808"
      unitRef="U_USD">-213854000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_ad298e01-7069-4024-a1ab-912384bc912d"
      unitRef="U_USD">277000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_7e6e8f78-9597-46cf-9ad7-e5deebfbcc9b"
      unitRef="U_USD">21000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_9ac74a33-fe41-418f-84ce-31ed7cc5ad7d"
      unitRef="U_USD">350213000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_2d6df483-0ac5-4c22-b201-7933b17c2817"
      unitRef="U_USD">349031000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_d40d52fe-5332-4bfe-8293-a8b73b5355a1"
      unitRef="U_USD">349308000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_e163e53a-4cac-4db0-8d7a-aa2e689c3fab"
      unitRef="U_USD">350234000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_b9d9e1eb-bce5-4770-8f7a-1307627cef60"
      unitRef="U_USD">56290000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_53c22f54-903a-420d-93f9-e055584ad34d"
      unitRef="U_USD">81859000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_e99376ff-953e-4b25-a1c6-f6086f0394e4"
      unitRef="U_USD">113072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_170bbbfc-0868-43ef-95ca-29607794121a"
      decimals="-3"
      id="F_0ca606a7-4627-4892-95ee-31455ffde629"
      unitRef="U_USD">130878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_4164670e-d82e-41cf-8452-8802d6e418f7"
      unitRef="U_USD">169362000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641"
      decimals="-3"
      id="F_202473ca-dc29-4756-8acd-f25f193bf37a"
      unitRef="U_USD">212737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_0a514a15-9045-43e3-8c38-61c140c265b1"
      unitRef="U_USD">161154000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641"
      decimals="-3"
      id="F_ad5c5857-f0fb-463d-9e8e-63cc087e200a"
      unitRef="U_USD">204582000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_7a1c4e57-4c18-4e69-b205-340e4e4bb489"
      unitRef="U_USD">8208000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641"
      decimals="-3"
      id="F_c21c4ace-6f08-4d72-8b23-54b74040ec1d"
      unitRef="U_USD">8155000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_0e552fa0-a93f-4571-be4f-9221940228ef"
      unitRef="U_USD">169362000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cbf7e2c5-c2c0-4111-be0d-c653f7f3d641"
      decimals="-3"
      id="F_a2f7579e-3867-4222-bfa1-88a0a4a6e866"
      unitRef="U_USD">212737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_1dd9882c-d859-4a1a-8f98-602245da2525"
      unitRef="U_USD">4000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_aaad2668-b186-4a75-b118-981e072fb28b"
      unitRef="U_USD">6000</us-gaap:InterestPaidNet>
    <eikn:CashPaidForOperatingLeaseLiabilities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_360c08eb-5817-4759-8ebe-91a2fa13668d"
      unitRef="U_USD">10483000</eikn:CashPaidForOperatingLeaseLiabilities>
    <eikn:CashPaidForOperatingLeaseLiabilities
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_5349d9f9-c9c1-4503-b365-83b6d9c56709"
      unitRef="U_USD">2555000</eikn:CashPaidForOperatingLeaseLiabilities>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_35b7f864-d1f7-45fd-95b9-708612149f8f"
      unitRef="U_USD">221000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_4947f691-31c7-46b1-ad96-639e2db7df04"
      unitRef="U_USD">9346000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <eikn:VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_cfac1ae0-0496-4f2f-a47b-50839f7fda41"
      unitRef="U_USD">35000</eikn:VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock>
    <eikn:VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_7cca946f-5eb4-4e4c-b84d-c7d21ee33de2"
      unitRef="U_USD">137000</eikn:VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_3490e21c-dfa3-430f-a4bc-43a14c245ee4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 1. Organization and Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Eikon Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important innovative medicines to address serious unmet medical needs. The Company&#x2019;s technology platform integrates custom-engineered super-resolution microscopy systems, bespoke automation, data science machine learning and artificial intelligence tools, and software engineering capable of processing petabyte-scale datasets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company was incorporated in the state of Delaware on July 9, 2019. The Company is headquartered in California. It also has operations in New York and New Jersey.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 27, 2026, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d7440967-f56a-48a1-8724-4db9ad3811ca;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1-for-7.4578&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reverse stock split of its issued and outstanding common stock&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which also resulted in a proportional adjustment to the conversion price for each series of its redeemable convertible preferred stock and warrants, and to the exercise prices and number of outstanding stock options. Accordingly, all shares of common stock, stock options, warrants, and per share information presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split for all periods presented. The per share par value and authorized numbers of shares of the Company&#x2019;s common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 6, 2026, the Company closed its initial public offering (&#x201c;IPO&#x201d;) and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,177,600&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for approximate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;348.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In connection with the IPO, all shares of Series A, A-1, B, B-1, C, C-1 and D redeemable convertible preferred stock converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,855,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Going Concern Assessment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced net operating losses and negative cash flows from operations since its inception. As of March 31, 2026, the Company has an accumulated deficit of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has historically financed its operations primarily through private placements of its redeemable convertible preferred stock, and most recently, through its IPO. The Company may seek to raise capital through private or public equity financings, debt financings, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company believes its cash, cash equivalents, and marketable securities balance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;596.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of March 31, 2026 will be sufficient for the Company to continue as a going concern for at least one year from the date these condensed financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There can be no assurance that in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Even if the Company is able to acquire additional financing, the financial terms may not be satisfactory to support its operations. Failure to generate sufficient cash flows from operations, raise additional capital, and reduce discretionary spending, should additional capital not become available, could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_7a831092-b41d-417e-82e2-51595df304eb"
      id="F_f8edf35b-cf9c-479f-939c-234e68696c22">Company effected a 1-for-7.4578 reverse stock split of its issued and outstanding common stock</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2"
      decimals="INF"
      id="F_3e4019c1-5da1-4260-8523-3a51da064b3a"
      unitRef="U_shares">21177600</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_f4769796-b48a-4a61-bcef-e175508ab0bb"
      decimals="INF"
      id="F_5c306c4e-7a8e-4e85-b65b-a865980c1f72"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2"
      decimals="-5"
      id="F_8693ecac-95e0-4dc1-9d8d-eb797eb89b89"
      unitRef="U_USD">348100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <eikn:UnderwritingDiscountsAndCommissions
      contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2"
      decimals="-5"
      id="F_0fb3f51e-d221-4464-9c94-9f4da6536bc1"
      unitRef="U_USD">26700000</eikn:UnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_a842e7bd-9bec-48dd-a574-efaeade2a2b2"
      decimals="-5"
      id="F_474633bb-ff42-4ae4-aff3-b3bee5ecec02"
      unitRef="U_USD">6400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_f4769796-b48a-4a61-bcef-e175508ab0bb"
      decimals="INF"
      id="F_e864d6b3-4ee8-4b39-abbb-fbd2d79a315a"
      unitRef="U_shares">29855741</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-8"
      id="F_c978ca01-d3dd-42ef-a3c6-8aa21da05b68"
      unitRef="U_USD">-1000000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <eikn:CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-5"
      id="F_6f69cc32-ee13-4641-8eb3-48ec69954326"
      unitRef="U_USD">596000000</eikn:CashCashEquivalentsAndMarketableSecurities-CurrentAndMarketableSecurities-NonCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_b7e3cba2-72eb-4d33-8962-3e6ee0315099">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and the applicable rules and regulations of the Securities and Exchange Commission regarding interim reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These condensed financial statements include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position, results of operations and cash flows for the periods presented. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative GAAP included in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;) issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to, useful lives of long-lived assets, the incremental borrowing rates for leases, accruals for research and development costs, the fair value of redeemable convertible preferred stock, common stock warrants, common stock and various other inputs used in estimating stock-based compensation expense, and accounting for income tax uncertainties, including a valuation allowance for deferred tax assets, in the accompanying financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents, and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and marketable securities, which may exceed federally insured limits. The Company has no financial instruments with off balance sheet risk of loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future in-process research and development of its technology, its reliance on third parties to assist in conducting its clinical trials, the need to obtain regulatory and marketing approvals, competitors advancing medicine in a field that the Company intends to enter that constrains its ability to compete effectively for market share, competitors developing technological innovations that reduce the value of the inventions that enable the Company to discover and develop new medicines, protection of its proprietary technology, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize its clinical assets, it will be unable to generate product revenue or achieve profitability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts held in money market funds and commercial paper, which are held at amortized cost.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities consist of United States treasury securities and commercial paper, which are held-to-maturity and reported at amortized cost. The amortization of premiums and accretion of discounts from the purchase of the securities are recognized as a component of interest income in the statements of operations and comprehensive loss. Marketable securities are classified as either current or non-current assets based on their contractual maturity dates. Marketable securities are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. As of March 31, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there had been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment or credit losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had deposits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; included in long-term assets as of March 31, 2026 and December 31, 2025, restricted from withdrawal and held by a bank in the form of collateral for irrevocable standby letters of credit held as security for the Company&#x2019;s leases. In addition, the Company had deposits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; included in current assets as of March 31, 2026 and December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, pledged for corporate credit cards.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are presented at cost, net of accumulated depreciation. Depreciation begins the first day of the month after the asset is placed in service. Depreciation is computed using the straight-line method over the estimated useful lives of five years for lab and engineering equipment, seven years for motor vehicles (used in the transportation of materials between sites) and furniture, fittings and office equipment, four years for computer equipment, and three years for software. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated once placed into service. Upon the sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations and comprehensive loss. Maintenance and repairs are charged to expense as incurred and costs of major replacement or improvement are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews the carrying amounts of its long-lived assets, including property and equipment and right-of-use leased assets, for potential impairment whenever events or changes in circumstances indicate that the assets may not be recoverable. Factors that the Company considers in an impairment review include, but are not limited to, significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount, and the impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined using discounted cash flows. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment of long-lived assets during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of a contract, the Company assesses whether the contract is a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is determined to exist, the commencement date of such lease is assessed based on the date on which the Company gains control over the use of the underlying assets. The Company&#x2019;s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options that the Company is reasonably certain of exercising. At lease commencement, the Company also determines lease classification based on whether the arrangement is effectively a financed purchase of the underlying asset (finance lease) or not (operating lease), which governs the pattern of expense recognition and the presentation reflected in the statements of operations and comprehensive loss and statements of cash flows over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For leases with a term exceeding 12 months, a lease liability is recorded on the Company&#x2019;s balance sheet at lease commencement reflecting the present value of its minimum payment obligations over the lease term. A corresponding right-of-use (&#x201c;ROU&#x201d;) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. Variable lease payments are included in the present value of its minimum lease payment obligations when the contingency is resolved. The lease liability is remeasured at the date the contingency is resolved and the corresponding ROU asset is adjusted. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company&#x2019;s incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Company&#x2019;s operating leases, fixed lease payments are recognized as lease expense on a straight-line basis over the lease term. For leases with a term of 12 months or less, any fixed lease payments are recognized on a straight-line basis over the lease term and are not recognized on the Company&#x2019;s balance sheet as an accounting policy election. Leases qualifying for the short-term lease exemption were insignificant. Variable lease costs are expensed in the statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any finance leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026 and December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Holders of the redeemable convertible preferred stock can cause redemption for cash upon the occurrence of a deemed liquidation event, which is outside the Company&#x2019;s control. Therefore, redeemable convertible preferred stock is classified outside of stockholders&#x2019; equity (deficit) on the balance sheet. The carrying values of the redeemable convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because the stock is not mandatorily redeemable and the occurrence of a deemed liquidation event is currently not probable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses are charged to expense as incurred. These expenses consist of compensation expenses, direct research and development expenses such as software development costs related to research and development activities, laboratory supplies, costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation, other miscellaneous expenses, and allocations of facility and information technology expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of its research and development activities conducted by third-party service providers. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with the third-party service agreements. If the Company does not identify costs that have begun to be incurred or if the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from the estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed and classified as current or non-current prepaid expenses and other assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company makes payments in connection with clinical trials to contract manufacturing organizations that manufacture the materials for its product candidates and to clinical research organizations and clinical trial sites that conduct and manage the Company&#x2019;s clinical trials. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in payments that do not match the periods over which materials or services are provided. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. The Company makes estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Asset Acquisitions and In-Process Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company evaluates acquisitions of assets and related liabilities and other similar transactions to assess whether or not a transaction should be accounted for as an asset acquisition or business combination by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If the screen test is met, a transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs that would meet the requirements of a business. The Company accounts for an asset acquisition by recognizing net assets based on their cost on a relative fair value basis. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-monetary identifiable assets and liabilities assumed based on relative fair values. In-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired in an asset acquisition is expensed provided there is no alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for future payments such as those upon the achievement of certain regulatory, development, or sales milestones in an asset acquisition when achievement of the underlying milestones is deemed probable. Milestone payments made to third parties subsequent to regulatory approval may be capitalized as intangible assets, if deemed to have alternative future use, and amortized over the estimated remaining useful life of the related product. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Patent and Trademark Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related and trademark costs incurred in connection with filing and prosecuting patent and trademark applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Initial Public Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred IPO costs, consisting primarily of legal and accounting fees relating to the IPO, are capitalized and offset against offering proceeds following the completion of the offering. Deferred IPO costs for terminated or delayed offerings are expensed immediately as a charge to general and administrative expenses in the statement of operations and comprehensive loss. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; deferred IPO costs capitalized as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026. The Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of deferred IPO costs capitalized as of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, included in other non-current assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For stock-based awards issued to employees and nonemployees, the Company measures the estimated fair value of the stock-based awards on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective awards. The Company records the expense for awards with service-based vesting using the straight-line, ratable attribution method and accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#x2019; vesting terms and contractual terms, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s cash compensation costs are classified.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates the fair value of the common stock underlying stock options on the date of grant. This has historically been determined by management with assistance from external appraisers and approved by the Board. Due to the absence of an active market for the Company&#x2019;s common stock prior to its IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s common stock valuations prior to May 31, 2025 were performed using the Option Pricing Method (&#x201c;OPM&#x201d;) as it is deemed the most appropriate method based on the Company&#x2019;s stage of development and other relevant factors. Within the OPM framework, the backsolve method for inferring the total equity value implied by a recent financing transaction involves the construction of an allocation model that takes into account the entity&#x2019;s capital structure and the rights, preferences and privileges of each class of stock, then assumes reasonable inputs for the other OPM variables (inclusive of discount for lack of marketability, volatility, the expected time to liquidity, and risk-free rate). The total equity value is then iterated in the model until the model output value for the equity class sold in a recent financing round equals the price paid in that round. The OPM is generally utilized when specific future liquidity events are difficult to forecast (i.e., the enterprise has many choices and options available), and the enterprise&#x2019;s value depends on how well it follows an uncharted path through the various possible opportunities and challenges. Among other factors considered are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s common stock, common stock warrants and redeemable convertible preferred stock valuations from May 31, 2025 through the IPO date were performed using a hybrid method that combines the OPM and the probability-weighted expected return method (&#x201c;PWERM&#x201d;). The PWERM employs additional information not used in the OPM, including various market approach&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an IPO or sale of the enterprise, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#x2019;s common stock and redeemable convertible preferred stock is then applied to arrive at an indication of value for the common stock and redeemable convertible preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the IPO, the fair value of the common stock underlying stock options is based on the closing market price of the common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:4.537%;border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There are currently no components of other comprehensive loss for the Company. Thus, comprehensive loss is the same as the net loss for the three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The functional currency of the Company&#x2019;s operation is U.S. dollars. All monetary assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Non-monetary assets and liabilities are translated using the exchange rate that was in effect when the asset or liability was initially recognized. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the statements of operations and comprehensive loss and recorded in other income (expense), net. Foreign currency transaction losses were immaterial for the three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax credits are presented on a gross basis in the effective tax rate reconciliation, and the tax effect of changes in unrecognized tax benefits related to such credits is presented separately within changes in uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company&#x2019;s chief operating decision maker, its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a1712c5d-8279-47e4-b1b8-8c2d8242df25;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, views the Company&#x2019;s operations and manages its business as a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options and warrants to purchase common stock, unvested common stock subject to repurchase and redeemable convertible preferred stock are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be antidilutive for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock and legally outstanding unvested common stock subject to repurchase are considered participating securities. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss is attributed entirely to common stockholders.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, (the "JOBS Act"), and may take advantage of reduced reporting requirements. These reporting requirement exemptions may not be applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASU 2024-03 will require public business entities to disclose in the notes to the financial statements, at each interim and annual reporting period, specific information about certain costs and expenses, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each expense caption presented on the face of the income statement, and the total amount of an entity&#x2019;s selling expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_c3ac895b-0ea5-4f82-971d-f6fe6e7b7c7b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and the applicable rules and regulations of the Securities and Exchange Commission regarding interim reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These condensed financial statements include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position, results of operations and cash flows for the periods presented. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative GAAP included in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;) issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_58c1c101-9a45-4809-b2ff-43edb628bca7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting period. Areas where management uses subjective judgments include, but are not limited to, useful lives of long-lived assets, the incremental borrowing rates for leases, accruals for research and development costs, the fair value of redeemable convertible preferred stock, common stock warrants, common stock and various other inputs used in estimating stock-based compensation expense, and accounting for income tax uncertainties, including a valuation allowance for deferred tax assets, in the accompanying financial statements. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <eikn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_9925596a-3355-4f65-bfbc-3d5956632d0a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents, and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and marketable securities, which may exceed federally insured limits. The Company has no financial instruments with off balance sheet risk of loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future in-process research and development of its technology, its reliance on third parties to assist in conducting its clinical trials, the need to obtain regulatory and marketing approvals, competitors advancing medicine in a field that the Company intends to enter that constrains its ability to compete effectively for market share, competitors developing technological innovations that reduce the value of the inventions that enable the Company to discover and develop new medicines, protection of its proprietary technology, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize its clinical assets, it will be unable to generate product revenue or achieve profitability.&lt;/span&gt;&lt;/p&gt;</eikn:ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_9b7bbfb9-3fc6-4a9d-9ca4-2821380e5bff">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash and cash equivalents. Cash equivalents consist primarily of amounts held in money market funds and commercial paper, which are held at amortized cost.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_a8794a30-1361-4646-a8b6-f65102ba413b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities consist of United States treasury securities and commercial paper, which are held-to-maturity and reported at amortized cost. The amortization of premiums and accretion of discounts from the purchase of the securities are recognized as a component of interest income in the statements of operations and comprehensive loss. Marketable securities are classified as either current or non-current assets based on their contractual maturity dates. Marketable securities are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. As of March 31, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there had been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment or credit losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <eikn:ImpairmentOnMarketableSecurities
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="INF"
      id="F_4ada991b-2683-436a-8739-5fec29a8f28c"
      unitRef="U_USD">0</eikn:ImpairmentOnMarketableSecurities>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_5a4604f6-ffd7-4b15-9e0d-12910307b148">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had deposits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; included in long-term assets as of March 31, 2026 and December 31, 2025, restricted from withdrawal and held by a bank in the form of collateral for irrevocable standby letters of credit held as security for the Company&#x2019;s leases. In addition, the Company had deposits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; included in current assets as of March 31, 2026 and December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, pledged for corporate credit cards.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-5"
      id="F_f95f1bcf-d351-4e1b-bb62-bf7ba1cbc89b"
      unitRef="U_USD">7800000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-5"
      id="F_425276d3-9166-4318-a6b3-e6d9c94f4538"
      unitRef="U_USD">7800000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-5"
      id="F_fc638199-801f-4f94-99ba-40ff4a2b7534"
      unitRef="U_USD">400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-5"
      id="F_1f6e9302-314d-46ff-9242-205fe3cefb0e"
      unitRef="U_USD">400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_f448283f-4a12-4669-9765-d13769a52784">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are presented at cost, net of accumulated depreciation. Depreciation begins the first day of the month after the asset is placed in service. Depreciation is computed using the straight-line method over the estimated useful lives of five years for lab and engineering equipment, seven years for motor vehicles (used in the transportation of materials between sites) and furniture, fittings and office equipment, four years for computer equipment, and three years for software. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Costs for capital assets not yet placed into service are capitalized as construction in progress and depreciated once placed into service. Upon the sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations and comprehensive loss. Maintenance and repairs are charged to expense as incurred and costs of major replacement or improvement are capitalized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_fceb6ff9-8d8a-4c29-aa89-87198f403348">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews the carrying amounts of its long-lived assets, including property and equipment and right-of-use leased assets, for potential impairment whenever events or changes in circumstances indicate that the assets may not be recoverable. Factors that the Company considers in an impairment review include, but are not limited to, significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount, and the impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined using discounted cash flows. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment of long-lived assets during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="INF"
      id="F_20c1b660-b57d-42b7-bdf0-1cb08efb1e59"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="INF"
      id="F_8ff70eac-1809-4497-8576-2834e9685029"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_e2351cf5-b8e3-4664-8dd7-95a2501ffc0d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of a contract, the Company assesses whether the contract is a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is determined to exist, the commencement date of such lease is assessed based on the date on which the Company gains control over the use of the underlying assets. The Company&#x2019;s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options that the Company is reasonably certain of exercising. At lease commencement, the Company also determines lease classification based on whether the arrangement is effectively a financed purchase of the underlying asset (finance lease) or not (operating lease), which governs the pattern of expense recognition and the presentation reflected in the statements of operations and comprehensive loss and statements of cash flows over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For leases with a term exceeding 12 months, a lease liability is recorded on the Company&#x2019;s balance sheet at lease commencement reflecting the present value of its minimum payment obligations over the lease term. A corresponding right-of-use (&#x201c;ROU&#x201d;) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. Variable lease payments are included in the present value of its minimum lease payment obligations when the contingency is resolved. The lease liability is remeasured at the date the contingency is resolved and the corresponding ROU asset is adjusted. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company&#x2019;s incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Company&#x2019;s operating leases, fixed lease payments are recognized as lease expense on a straight-line basis over the lease term. For leases with a term of 12 months or less, any fixed lease payments are recognized on a straight-line basis over the lease term and are not recognized on the Company&#x2019;s balance sheet as an accounting policy election. Leases qualifying for the short-term lease exemption were insignificant. Variable lease costs are expensed in the statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any finance leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026 and December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_9baf0df5-5f55-4d94-a94b-7a54f1740c85"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_26e15826-8d2b-4cea-8e81-470360d62c08"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiability>
    <eikn:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_6c9e18c9-cf18-4156-8b90-ff8509618434">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Holders of the redeemable convertible preferred stock can cause redemption for cash upon the occurrence of a deemed liquidation event, which is outside the Company&#x2019;s control. Therefore, redeemable convertible preferred stock is classified outside of stockholders&#x2019; equity (deficit) on the balance sheet. The carrying values of the redeemable convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because the stock is not mandatorily redeemable and the occurrence of a deemed liquidation event is currently not probable.&lt;/span&gt;&lt;/p&gt;</eikn:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock>
    <eikn:ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_d194dd37-d7f9-417b-b19a-6ea9713225f0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses and Accruals&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses are charged to expense as incurred. These expenses consist of compensation expenses, direct research and development expenses such as software development costs related to research and development activities, laboratory supplies, costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation, other miscellaneous expenses, and allocations of facility and information technology expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of its research and development activities conducted by third-party service providers. The Company accrues these costs based on factors such as estimates of the work completed and in accordance with the third-party service agreements. If the Company does not identify costs that have begun to be incurred or if the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from the estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed and classified as current or non-current prepaid expenses and other assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company makes payments in connection with clinical trials to contract manufacturing organizations that manufacture the materials for its product candidates and to clinical research organizations and clinical trial sites that conduct and manage the Company&#x2019;s clinical trials. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in payments that do not match the periods over which materials or services are provided. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. The Company makes estimates of accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/p&gt;</eikn:ResearchAndDevelopmentExpensesAndAccrualsPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_05dc25c5-7f9e-4bf3-85f1-53e422887a38">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Asset Acquisitions and In-Process Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company evaluates acquisitions of assets and related liabilities and other similar transactions to assess whether or not a transaction should be accounted for as an asset acquisition or business combination by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If the screen test is met, a transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs that would meet the requirements of a business. The Company accounts for an asset acquisition by recognizing net assets based on their cost on a relative fair value basis. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the non-monetary identifiable assets and liabilities assumed based on relative fair values. In-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired in an asset acquisition is expensed provided there is no alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for future payments such as those upon the achievement of certain regulatory, development, or sales milestones in an asset acquisition when achievement of the underlying milestones is deemed probable. Milestone payments made to third parties subsequent to regulatory approval may be capitalized as intangible assets, if deemed to have alternative future use, and amortized over the estimated remaining useful life of the related product. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable.&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <eikn:PatentAndTrademarkCostsPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_b40f6945-c960-480f-883a-a32f59359a8a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Patent and Trademark Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related and trademark costs incurred in connection with filing and prosecuting patent and trademark applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</eikn:PatentAndTrademarkCostsPolicyPolicyTextBlock>
    <eikn:DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_5ae67fe6-c0df-4b69-be86-f805ee181348">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Initial Public Offering Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred IPO costs, consisting primarily of legal and accounting fees relating to the IPO, are capitalized and offset against offering proceeds following the completion of the offering. Deferred IPO costs for terminated or delayed offerings are expensed immediately as a charge to general and administrative expenses in the statement of operations and comprehensive loss. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; deferred IPO costs capitalized as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026. The Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of deferred IPO costs capitalized as of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, included in other non-current assets.&lt;/span&gt;&lt;/p&gt;</eikn:DeferredInitialPublicOfferingCostsPolicyPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_192de495-12e8-4ff5-8c9c-5d40bfe5edea"
      unitRef="U_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-5"
      id="F_058bdab3-350f-4bd8-971a-ab972f3f26ac"
      unitRef="U_USD">3600000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_78a11302-01da-4c6b-bb47-012406d136ac">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For stock-based awards issued to employees and nonemployees, the Company measures the estimated fair value of the stock-based awards on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective awards. The Company records the expense for awards with service-based vesting using the straight-line, ratable attribution method and accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies, and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options&#x2019; vesting terms and contractual terms, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s cash compensation costs are classified.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <eikn:FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_1149f673-112a-4a12-871e-87aa17d0ab6f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Common Stock, Common Stock Warrants and Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimates the fair value of the common stock underlying stock options on the date of grant. This has historically been determined by management with assistance from external appraisers and approved by the Board. Due to the absence of an active market for the Company&#x2019;s common stock prior to its IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s common stock valuations prior to May 31, 2025 were performed using the Option Pricing Method (&#x201c;OPM&#x201d;) as it is deemed the most appropriate method based on the Company&#x2019;s stage of development and other relevant factors. Within the OPM framework, the backsolve method for inferring the total equity value implied by a recent financing transaction involves the construction of an allocation model that takes into account the entity&#x2019;s capital structure and the rights, preferences and privileges of each class of stock, then assumes reasonable inputs for the other OPM variables (inclusive of discount for lack of marketability, volatility, the expected time to liquidity, and risk-free rate). The total equity value is then iterated in the model until the model output value for the equity class sold in a recent financing round equals the price paid in that round. The OPM is generally utilized when specific future liquidity events are difficult to forecast (i.e., the enterprise has many choices and options available), and the enterprise&#x2019;s value depends on how well it follows an uncharted path through the various possible opportunities and challenges. Among other factors considered are the Company&#x2019;s financial position and historical financial performance, the status of technological developments within the Company&#x2019;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#x2019;s competition, and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s common stock, common stock warrants and redeemable convertible preferred stock valuations from May 31, 2025 through the IPO date were performed using a hybrid method that combines the OPM and the probability-weighted expected return method (&#x201c;PWERM&#x201d;). The PWERM employs additional information not used in the OPM, including various market approach&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an IPO or sale of the enterprise, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#x2019;s common stock and redeemable convertible preferred stock is then applied to arrive at an indication of value for the common stock and redeemable convertible preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the IPO, the fair value of the common stock underlying stock options is based on the closing market price of the common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;</eikn:FairValueOfCommonStockCommonStockWarrantsAndRedeemableConvertiblePreferredStockPolicyPolicyTextBlock>
    <eikn:CommonStockWarrantsPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_afe52031-2a8d-4c36-be63-b33e3de35d5b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.&lt;/span&gt;&lt;/p&gt;</eikn:CommonStockWarrantsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_fa63750e-5e35-4ffd-ac94-b804108a0cbb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurement establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:4.537%;border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:92%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_3674bc5a-4eba-431c-accd-f4504189e8f4">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There are currently no components of other comprehensive loss for the Company. Thus, comprehensive loss is the same as the net loss for the three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_2daacb96-8692-481e-9c4d-98afedfba62a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The functional currency of the Company&#x2019;s operation is U.S. dollars. All monetary assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Non-monetary assets and liabilities are translated using the exchange rate that was in effect when the asset or liability was initially recognized. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the statements of operations and comprehensive loss and recorded in other income (expense), net. Foreign currency transaction losses were immaterial for the three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_f3fe3dca-88fa-430a-96df-e7e38d8ae5a3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax credits are presented on a gross basis in the effective tax rate reconciliation, and the tax effect of changes in unrecognized tax benefits related to such credits is presented separately within changes in uncertain tax positions.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_6ca3f7ab-8ff5-4fdb-abff-28d5cab5d069">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company&#x2019;s chief operating decision maker, its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a1712c5d-8279-47e4-b1b8-8c2d8242df25;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, views the Company&#x2019;s operations and manages its business as a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <eikn:NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_57ab0668-5514-4e68-9c30-d07c9adcc96c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of options and warrants to purchase common stock, unvested common stock subject to repurchase and redeemable convertible preferred stock are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be antidilutive for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock and legally outstanding unvested common stock subject to repurchase are considered participating securities. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss is attributed entirely to common stockholders.&lt;/span&gt;&lt;/p&gt;</eikn:NetLossPerShareAttributableToCommonStockholdersPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_5f5fa97c-7fd3-43ab-bd50-855fdf3ebb66">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <eikn:EmergingGrowthCompanyStatusPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_daa1fb42-e46e-4b51-828d-ba1c581d5dcb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, (the "JOBS Act"), and may take advantage of reduced reporting requirements. These reporting requirement exemptions may not be applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards.&lt;/span&gt;&lt;/p&gt;</eikn:EmergingGrowthCompanyStatusPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_59956d62-9874-4c0d-ab6c-81ad831e9a24">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASU 2024-03 will require public business entities to disclose in the notes to the financial statements, at each interim and annual reporting period, specific information about certain costs and expenses, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each expense caption presented on the face of the income statement, and the total amount of an entity&#x2019;s selling expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_8fc0a420-1eae-4c5c-ac50-1c81ae3e30ad">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3. Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impact of preferred stock extinguishments and&lt;br/&gt;&#160;&#160;&#160;modifications&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,701,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,869,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Weighted-average common shares subject to&lt;br/&gt;&#160;&#160;&#160;repurchase&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and&lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,700,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,770,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic&lt;br/&gt;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding common stock equivalents have been excluded from diluted net loss per share attributable to common stockholders for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025 because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,522,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,904,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Early exercised stock options and unvested restricted&lt;br/&gt;&#160;&#160;&#160;common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,855,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,262,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,563,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_fbb1e6eb-1283-421f-92bc-f75fb1b8330a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Impact of preferred stock extinguishments and&lt;br/&gt;&#160;&#160;&#160;modifications&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,701,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,869,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Weighted-average common shares subject to&lt;br/&gt;&#160;&#160;&#160;repurchase&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding, basic and&lt;br/&gt;&#160;&#160;&#160;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,700,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,770,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders, basic&lt;br/&gt;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_6be1261e-7be5-43c3-add2-c0b43ac73cf6"
      unitRef="U_USD">-82958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_6366e6b3-db33-477a-bea8-1e2aeac696b7"
      unitRef="U_USD">-68243000</us-gaap:NetIncomeLoss>
    <eikn:ImpactOfPreferredStockExtinguishmentsAndModifications
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_1785d068-686e-452d-8aa6-ddd0afde5f29"
      unitRef="U_USD">-6300000</eikn:ImpactOfPreferredStockExtinguishmentsAndModifications>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_ff9e005d-9c75-40b6-aee3-a9f9349fea1b"
      unitRef="U_USD">-82958000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_61269d8f-039a-425c-8c0d-42230ca6a50f"
      unitRef="U_USD">-74543000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <eikn:WeightedAverageCommonSharesOutstanding
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_163e8263-00e8-4d9f-b3a4-529eb637a79f"
      unitRef="U_shares">33701800</eikn:WeightedAverageCommonSharesOutstanding>
    <eikn:WeightedAverageCommonSharesOutstanding
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_ae288793-b1e7-447a-a30e-3906063975db"
      unitRef="U_shares">2869926</eikn:WeightedAverageCommonSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_987ab7cd-0d12-4c7f-90ca-2d215d00a77e"
      unitRef="U_shares">1250</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_3e5aaedc-d572-4a81-a313-709b91dc2de6"
      unitRef="U_shares">99574</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_4a92b610-2d09-4a3d-bbdf-0b55ebdf7603"
      unitRef="U_shares">33700550</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_ae763516-31fc-4b9b-ad80-a0d8037f5b68"
      unitRef="U_shares">33700550</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_945f6c4c-c909-4d70-96d1-3c8b6cf44a52"
      unitRef="U_shares">2770352</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_d11ac3bc-643a-42f1-a27e-96aa54d5fe97"
      unitRef="U_shares">2770352</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="2"
      id="F_836f822e-411a-4d5c-a58e-e1fbd4c6e85c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="2"
      id="F_49da7903-5528-44d7-8980-d30d6d9c9103"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="2"
      id="F_dc2fbf50-7975-4ede-951e-d2029af60a18"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-26.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="2"
      id="F_2951e757-a569-4043-a629-c5b44ce4cb73"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-26.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_9995c632-9cc5-4f82-a61f-4ade0388cb71">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding common stock equivalents have been excluded from diluted net loss per share attributable to common stockholders for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025 because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,522,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,904,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Early exercised stock options and unvested restricted&lt;br/&gt;&#160;&#160;&#160;common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,855,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,262,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,563,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6b6e3025-7be7-4cf5-a556-aecb955a9d7b"
      decimals="0"
      id="F_606b4898-d69a-4b7c-b7b7-304f84412a36"
      unitRef="U_shares">7522330</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_64e1594b-40d8-45fe-8a5b-61465fc568f9"
      decimals="0"
      id="F_20a295b7-6b22-43f5-8048-6feb6c6e8786"
      unitRef="U_shares">2904399</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2eca1e62-aa09-48af-834d-34f067e0bf98"
      decimals="0"
      id="F_ffd87672-2458-4614-978e-35a17469f3e4"
      unitRef="U_shares">862</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d5e0b4aa-c652-4259-90d9-48a14221845b"
      decimals="0"
      id="F_dacf49c8-0a6c-449a-a07f-e030e939e933"
      unitRef="U_shares">63487</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c1976207-b5cc-489d-b211-526e50ce39ae"
      decimals="0"
      id="F_71e53620-7967-4de1-b424-bdb8ff6c8ae4"
      unitRef="U_shares">739559</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_855d3fb8-6bf1-4d46-a30f-cd01135bf333"
      decimals="0"
      id="F_417934e3-df0e-4caf-83b6-e0d37cce4317"
      unitRef="U_shares">739559</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_62648b45-b0dd-4b75-99ea-21268ea1e65d"
      decimals="0"
      id="F_aa98b5f7-a866-462a-b820-1909340818d5"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0ec3c10e-a93c-4886-a100-9f5b244f7eee"
      decimals="0"
      id="F_9267e3d8-2376-41ce-b57f-810dd8195ae7"
      unitRef="U_shares">29855741</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_1bbce7cb-5b44-4d0e-864b-b31422eefaf8"
      unitRef="U_shares">8262751</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_68c1f9da-847b-45a9-bc71-091aec381fa4"
      unitRef="U_shares">33563186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_5350677d-4114-468f-9e6a-7b2498f654a2">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets, which consist of cash equivalents and marketable securities, presented at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.628%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.628%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t hold any financial assets that would be classified as Level 3 in the fair value hierarchy during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair values due to their liquid or short-term nature, such as cash, prepaid expenses, accounts payable, and accrued expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_b12ad585-066b-4c7a-a994-36d6abcf1f81">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets, which consist of cash equivalents and marketable securities, presented at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.628%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, non-current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities, non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.628%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.91%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.889999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities, current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d3834c7d-2fa8-4b3f-9745-5b403f6177a1"
      decimals="-3"
      id="F_58ec3791-72c2-4ce1-a182-0cf27d88e4df"
      unitRef="U_USD">148094000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d3834c7d-2fa8-4b3f-9745-5b403f6177a1"
      decimals="-3"
      id="F_4162694c-4570-408a-9f7a-cadbb149e8c1"
      unitRef="U_USD">148094000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256"
      decimals="-3"
      id="F_dd5c4688-1150-4f25-a02c-1b0b74c3b8d4"
      unitRef="U_USD">148094000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_62d0ea5f-195d-4d23-a2f1-c8d0f5238256"
      decimals="-3"
      id="F_7823aaec-52e6-4c74-86ab-feb07634fa16"
      unitRef="U_USD">148094000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"
      decimals="-3"
      id="F_25ab3cfa-691b-479e-9f42-3524482ebd6b"
      unitRef="U_USD">158234000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"
      decimals="-3"
      id="F_244a0f34-3aab-40ed-992d-7b116b07b3e6"
      unitRef="U_USD">3000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"
      decimals="-3"
      id="F_bae92fb2-b57f-4567-a4c6-db4c1c75211a"
      unitRef="U_USD">381000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"
      decimals="-3"
      id="F_528d8e03-226b-42fe-af4f-1c05bbffa223"
      unitRef="U_USD">157856000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e"
      decimals="-3"
      id="F_6bc3e12b-83d7-493a-9981-108d90e5c953"
      unitRef="U_USD">192794000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e"
      decimals="-3"
      id="F_00f8c655-ad58-4eed-bc9c-2fe74a5d598a"
      unitRef="U_USD">26000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e"
      decimals="-3"
      id="F_f636b164-545f-4c72-a347-a894584216b9"
      unitRef="U_USD">67000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e"
      decimals="-3"
      id="F_14b880bc-6f73-4e50-84e2-ef692fd95b18"
      unitRef="U_USD">192753000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8"
      decimals="-3"
      id="F_7ca03030-f48c-4c78-8957-991fce813da2"
      unitRef="U_USD">351028000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8"
      decimals="-3"
      id="F_1bb2c494-e701-45dc-aa38-1bb5e5ddff68"
      unitRef="U_USD">29000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8"
      decimals="-3"
      id="F_e1f7357f-ed0d-4a73-a324-6592fbea51e6"
      unitRef="U_USD">448000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8"
      decimals="-3"
      id="F_0f1b6507-f223-4443-830e-4d758d407d06"
      unitRef="U_USD">350609000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
      contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"
      decimals="-3"
      id="F_2dd6b255-4950-4cbb-adb7-96fdcc4a3e7a"
      unitRef="U_USD">53925000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"
      decimals="-3"
      id="F_31d8b2e6-2a9c-415f-a350-8330251e69e2"
      unitRef="U_USD">178000</eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="C_af6351f6-a905-47be-bc5b-2b5e6b1080fc"
      decimals="-3"
      id="F_1a9f1d29-b1f7-40e7-871e-dfe4d210c76f"
      unitRef="U_USD">53747000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
      contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e"
      decimals="-3"
      id="F_a6c48ba4-1df4-4081-a2b5-8e5c8c799023"
      unitRef="U_USD">29903000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e"
      decimals="-3"
      id="F_fed17eeb-84a9-47d4-8a7c-9cc2c97fbbfe"
      unitRef="U_USD">74000</eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="C_9de7842e-b8a1-481e-8377-402c9062d31e"
      decimals="-3"
      id="F_b55c6294-b336-4e35-b045-b36e46677fb2"
      unitRef="U_USD">29829000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent
      contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8"
      decimals="-3"
      id="F_012f4d07-5aae-43df-bdf9-eaef869207a1"
      unitRef="U_USD">83828000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8"
      decimals="-3"
      id="F_2e77954f-1a53-45a9-aada-98d3d8e7ac02"
      unitRef="U_USD">252000</eikn:DebtSecuritiesHeld-To-MaturityNonCurrentAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="C_10b77abe-4227-414e-a522-1ea2c59579c8"
      decimals="-3"
      id="F_c43da301-c5b5-4a80-80bb-a9d18a76a9f6"
      unitRef="U_USD">83576000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ca062afd-ce86-4311-8424-bd51f8222d31"
      decimals="-3"
      id="F_2776fc47-297d-4dd5-9be8-b70c4598918c"
      unitRef="U_USD">84960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ca062afd-ce86-4311-8424-bd51f8222d31"
      decimals="-3"
      id="F_907d93ef-e897-4268-873b-b40fd30b76bd"
      unitRef="U_USD">84960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_21e45ff9-b261-46ab-ac86-9eca533d24f1"
      decimals="-3"
      id="F_b265e74b-eb98-4515-8e81-cd9bd5a012be"
      unitRef="U_USD">84960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_21e45ff9-b261-46ab-ac86-9eca533d24f1"
      decimals="-3"
      id="F_3dff485d-552a-4557-9996-0db14bd6f48e"
      unitRef="U_USD">84960000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d"
      decimals="-3"
      id="F_1c465c0f-81ea-4322-a507-d5b950d915a7"
      unitRef="U_USD">107870000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d"
      decimals="-3"
      id="F_2a68dc31-6949-4c35-a513-bb90223f5528"
      unitRef="U_USD">65000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="C_d0b43c6f-c795-4565-85c7-10b06ef9cc0d"
      decimals="-3"
      id="F_dc6228a4-f839-4d85-a3ff-0f1e7497a069"
      unitRef="U_USD">107935000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="C_968ee666-b8c6-47b0-97be-66417cf66128"
      decimals="-3"
      id="F_1642487e-5883-4730-bea0-9d7d6ae632fa"
      unitRef="U_USD">123204000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_968ee666-b8c6-47b0-97be-66417cf66128"
      decimals="-3"
      id="F_c44a17d6-8615-4905-9d62-a0b050642368"
      unitRef="U_USD">154000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="C_968ee666-b8c6-47b0-97be-66417cf66128"
      decimals="-3"
      id="F_3fd70016-2ea7-4f0d-b8b9-1b79211a64d7"
      unitRef="U_USD">123358000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent
      contextRef="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154"
      decimals="-3"
      id="F_6563ff5b-3f5b-48d0-a4c8-130eeff798fc"
      unitRef="U_USD">231074000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent>
    <eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154"
      decimals="-3"
      id="F_948976a5-5f5d-4ddc-9304-3767254a4f44"
      unitRef="U_USD">219000</eikn:DebtSecuritiesHeld-To-MaturityCurrentAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="C_48fac971-61a4-47b6-9d0d-ab87ed9cf154"
      decimals="-3"
      id="F_7771ecf2-a7f4-4695-abde-5e9246b0785f"
      unitRef="U_USD">231293000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="0"
      id="F_ae4a63f6-2eec-427a-9a43-791e399df5dc"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="0"
      id="F_11a67bfa-8331-4aab-b06d-a34c6b27e6eb"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_7bc83aab-3af3-4067-8474-6f4c2a3fcccb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 5. Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Engineering equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture, fittings &amp;amp; office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2026 and 2025, respectively. Disposals of property and equipment during the three months ended March 31, 2026 and 2025 were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses related to purchase of IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued vendor expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of early exercised options and&lt;br/&gt;&#160;&#160;&#160;restricted common stock liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_7f7cb1e3-38dc-42bf-b8d6-bb42527c47bf">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Engineering equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Motor vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture, fittings &amp;amp; office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ea08a515-6580-47df-bab8-c50e516fc3e4"
      decimals="-3"
      id="F_82ad0d92-6f74-4c3a-bb40-8c430aafa486"
      unitRef="U_USD">25909000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1c77db10-7d9d-4dcb-8c50-adc69f65d083"
      decimals="-3"
      id="F_ce1e303b-5fca-42c5-bb01-0ed5af45a0d1"
      unitRef="U_USD">25909000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e8403787-14b9-4395-a9bd-4273c59b3ebf"
      decimals="-3"
      id="F_b705c853-67ea-487b-b7bd-2afcbe2e3acc"
      unitRef="U_USD">14843000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_660ec3d2-b609-4bfb-b1b1-c4305903c960"
      decimals="-3"
      id="F_1979b5d9-e358-41d4-8f68-23c7f02ad0d4"
      unitRef="U_USD">14843000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dd617b4e-2a11-46a2-ae77-d0760c22bfc1"
      decimals="-3"
      id="F_4721da35-79f6-4dda-90c6-7398e34f85a5"
      unitRef="U_USD">120588000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1c487c21-7dd9-4244-95e3-68a278433e25"
      decimals="-3"
      id="F_670cc9b0-de7c-46f0-989a-cc33d4d42bda"
      unitRef="U_USD">120588000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_15155790-267d-4a2b-aaa0-e438238b971c"
      decimals="-3"
      id="F_432ae07a-60f4-406c-92d6-2ca35720daa8"
      unitRef="U_USD">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_020258b1-9d04-4044-a458-aad5f3a473ac"
      decimals="-3"
      id="F_87f718a0-f634-495d-bd3f-201eef6a9008"
      unitRef="U_USD">101000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6f295888-378b-4391-a021-9bca631286e6"
      decimals="-3"
      id="F_4638bb5f-abac-4db9-811f-51dfd760049a"
      unitRef="U_USD">5150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_83013968-b516-4963-8f78-e02e28e21aac"
      decimals="-3"
      id="F_964050a4-145d-42b7-84fe-e43efccaa94a"
      unitRef="U_USD">5150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_aa9bb9d8-99cd-44a2-b558-5d96aab73df6"
      decimals="-3"
      id="F_a5ee6359-8ad3-4309-8d73-fa6cf85bd3c2"
      unitRef="U_USD">13062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_95010d63-09ef-4c23-8c49-40323fc46cd9"
      decimals="-3"
      id="F_ee94a6b6-52bc-4159-ac1c-3a583dd4d629"
      unitRef="U_USD">12970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e647b2ed-2de8-4ede-8766-0746071aee38"
      decimals="-3"
      id="F_050a9d6d-abdc-4930-baf7-4496d81105e9"
      unitRef="U_USD">5627000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7c4a7bfd-264d-45e7-bcf8-d63ea24ce46b"
      decimals="-3"
      id="F_3b0e1acb-11e1-48d5-bcdc-c273dde208ba"
      unitRef="U_USD">5627000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_06851da8-c034-45e1-a93f-8136cb20bbc9"
      decimals="-3"
      id="F_7e55d2cd-cc55-457c-95a6-882012da7031"
      unitRef="U_USD">963000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7756d92c-fabb-4333-b946-71468f2cd618"
      decimals="-3"
      id="F_9b95c6c8-0e53-4c9a-838c-a88657a217cb"
      unitRef="U_USD">624000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_38208a10-dbec-489a-8a5c-3eded675db91"
      unitRef="U_USD">186161000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_506eb8ce-7144-4a7f-bf4c-e176c7502e3b"
      unitRef="U_USD">185812000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_20f2ce54-973d-436c-8b5f-fd24aff17704"
      unitRef="U_USD">48094000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_599e89e7-974b-4cf2-ad18-fffd7469f033"
      unitRef="U_USD">42914000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_a4d9f723-bf6d-4c8f-bc51-17609de61d6f"
      unitRef="U_USD">138067000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_a9275a90-cf55-4710-bab8-eb9a37068599"
      unitRef="U_USD">142898000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-5"
      id="F_6f043000-296d-4662-b142-e2827ec25beb"
      unitRef="U_USD">5200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-5"
      id="F_26dbea41-de40-403b-bffd-45f685431a01"
      unitRef="U_USD">3800000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_0ff4a6dc-7993-4c84-b1f7-5e536aae80da">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses related to purchase of IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued vendor expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of early exercised options and&lt;br/&gt;&#160;&#160;&#160;restricted common stock liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_415a400c-ab10-49a2-bc84-8c5593f45913"
      unitRef="U_USD">11207000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_aa575ebe-5d06-49cc-9c92-1efb492bcf48"
      unitRef="U_USD">24868000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <eikn:AccruedClinicalExpenses
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_c7b6c620-cb9b-4f98-a838-00fabefe42a8"
      unitRef="U_USD">9128000</eikn:AccruedClinicalExpenses>
    <eikn:AccruedClinicalExpenses
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_3642aa8f-2fd4-4731-87ea-d014cbe8f656"
      unitRef="U_USD">6518000</eikn:AccruedClinicalExpenses>
    <eikn:AccruedInProcessResearchAndDevelopment
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_561b3eea-0732-472f-b4ca-3e95c4ac130e"
      unitRef="U_USD">102000</eikn:AccruedInProcessResearchAndDevelopment>
    <eikn:AccruedInProcessResearchAndDevelopment
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_596bd91d-11a4-4723-ad53-255f0db97e92"
      unitRef="U_USD">102000</eikn:AccruedInProcessResearchAndDevelopment>
    <eikn:AccruedVendorExpenses
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_b83478d7-6df1-46ac-bb3f-37a28a749177"
      unitRef="U_USD">8700000</eikn:AccruedVendorExpenses>
    <eikn:AccruedVendorExpenses
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_ecb1f5cb-d632-4087-bf79-f8b7e6699098"
      unitRef="U_USD">11300000</eikn:AccruedVendorExpenses>
    <eikn:CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_7f67846e-dd07-48e7-9d25-e24105246109"
      unitRef="U_USD">0</eikn:CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability>
    <eikn:CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_73193497-b5c0-4084-8e22-c9b72b739fcb"
      unitRef="U_USD">35000</eikn:CurrentPortionOfEarlyExercisedOptionsAndRestrictedCommonStockLiability>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_fd87776f-90ee-45fc-935c-649f87f511b7"
      unitRef="U_USD">182000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_965ea90e-b7a2-4172-9477-264194e9116b"
      unitRef="U_USD">1475000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <eikn:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_8b7bc364-3a2a-45a5-8f06-058851dcde3b"
      unitRef="U_USD">29319000</eikn:AccruedExpensesAndOtherCurrentLiabilities>
    <eikn:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_7ce1e87e-4cb2-44ae-acb1-8272c9f0dddc"
      unitRef="U_USD">44298000</eikn:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_de02886e-20bd-4bee-b6ee-76a63173ebd3">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 6. Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2022, the Company entered into an operating lease of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office and laboratory space that now serves as its corporate headquarters located in Millbrae, California. The lease commenced in February 2024 and expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_2513182e-84c1-42c0-8135-b3838edee5c8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 2040&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The lessor provided the Company a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and the Company constructed leasehold improvements, which were concluded to be lessee assets, in the space. The lease liability at lease commencement was calculated to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is equal to the present value of the future lease payments, discounted at an incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The lease agreement also includes a renewal option allowing the Company to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extend this lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; at the prevailing rental rate, which the Company is not reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the lease agreement provides for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in additional tenant improvement allowances that may be utilized by the Company and is repayable over the term of the lease with interest. $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of additional tenant improvement allowances had been drawn down as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the Company constructed leasehold improvements, which were concluded to be lessee assets, in the space. The Company is accounting for the repayment obligation related to these additional tenant improvement allowances as part of the lease with the amounts included in operating lease liability, current and non-current. The Company has an irrevocable standby letter of credit for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million held as security for the Millbrae lease deposit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had leases for other office and laboratory facilities of between approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet in Hayward, California, New York, New York and Jersey City, New Jersey as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The leases will expire between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4891b7a9-ea44-4065-bf6f-ac1774d7b202;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_fea5efb2-ee1e-4e93-a542-9a2bbd4553aa;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unless their terms are extended where allowed under the leases. In January 2026, the Company notified the landlord of one of its Hayward properties of its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;intention to early terminate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the lease in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company remeasured the operating lease liabilities, which resulted in a reduction of the carrying value of the operating lease liability and a corresponding reduction in the operating lease right-of-use assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s leases had weighted average remaining lease terms of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, and weighted average discount rates of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of March 31, 2026 and December 31, 2025, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments under non-cancellable leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2026 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026 (remainder of year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;370,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;551,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of future lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;254,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Operating lease liability, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rent expense for operating leases was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; variable lease costs and short-term lease costs were not material for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_7cfa5dbb-75bd-4c08-84f9-248de234217e"
      decimals="0"
      id="F_f70a7d48-ab1b-40a4-bbbc-1c8ac330e62b"
      unitRef="U_sqft">285000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194"
      decimals="-5"
      id="F_3c24c43a-ed2f-479d-b37c-30bcb02dcbc9"
      unitRef="U_USD">64200000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7cfa5dbb-75bd-4c08-84f9-248de234217e"
      decimals="-5"
      id="F_450737af-cb21-41b4-9d3f-65ae4d400865"
      unitRef="U_USD">159500000</us-gaap:OperatingLeaseLiability>
    <eikn:PercentageOfIncrementalBorrowingRate
      contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194"
      decimals="3"
      id="F_b714af14-5023-4ea6-9752-0149fd244c4c"
      unitRef="U_pure">0.13</eikn:PercentageOfIncrementalBorrowingRate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_16c203e7-dbb4-4d54-a213-cd806db24194"
      id="F_e73ed994-3094-4696-8bcf-61623f970edf">extend this lease</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_7cfa5dbb-75bd-4c08-84f9-248de234217e"
      id="F_cd463777-8822-4d47-946b-b0ee2580a743">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_7d79440a-32b9-4e44-9930-5f1dcba2901b"
      decimals="INF"
      id="F_120252e0-9cd8-4d13-ba2b-b465c8a6a0c2"
      unitRef="U_USD">57000000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-5"
      id="F_1aad7f8f-bd64-4e03-b88c-92fb708afd62"
      unitRef="U_USD">49700000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:LeaseDepositLiability
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-5"
      id="F_7d4802a1-1e0d-48c2-be5d-f2a6d6f9c0f8"
      unitRef="U_USD">6600000</us-gaap:LeaseDepositLiability>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_6f92e515-198c-41f2-9ae2-33fc324dbf18"
      decimals="INF"
      id="F_aba3036f-edb4-4b33-aab6-a9c82ff4f217"
      unitRef="U_sqft">25000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_734a9e98-beab-4d4c-b47e-a15b69419607"
      decimals="INF"
      id="F_84b9f22a-7715-4950-9daf-f5c49ef2d607"
      unitRef="U_sqft">72000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_c7bcc98d-42fc-40a6-991f-28a29433e55e"
      id="F_ecb1b47f-b825-442e-8606-522aa1b491fa">intention to early terminate</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <eikn:OperatingLeaseTerminationDate
      contextRef="C_c7bcc98d-42fc-40a6-991f-28a29433e55e"
      id="F_44f844c8-fc05-46bd-81e1-930bc0a3e310">2026-10</eikn:OperatingLeaseTerminationDate>
    <eikn:DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease
      contextRef="C_346f6ee4-54e2-4fbe-b3f1-de86b076b6d1"
      decimals="-5"
      id="F_59f237cd-b911-49ea-85e0-918ad9900df0"
      unitRef="U_USD">5600000</eikn:DecreaseInTheLeaseLiabilityFromTheRemeasurementOfTheLease>
    <eikn:DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease
      contextRef="C_346f6ee4-54e2-4fbe-b3f1-de86b076b6d1"
      decimals="-5"
      id="F_45a9a613-867f-4e51-ac42-65d7ce3943bf"
      unitRef="U_USD">5600000</eikn:DecreaseInTheOperatingLeaseRightOfUseAssetsFromTheRemeasurementOfTheLease>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      id="F_d5ce9d3f-2a83-4653-9f26-271b2b1a52f7">P13Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      id="F_0d39f021-ac95-47b6-9296-447004df3384">P13Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="3"
      id="F_666c822d-549b-4233-b083-0f1dcad4f43d"
      unitRef="U_pure">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="3"
      id="F_88a5c077-681f-48f5-b0bd-d2ee5b0bcd01"
      unitRef="U_pure">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_786ac81f-3164-407b-8dd8-1435110c9c6c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments under non-cancellable leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2026 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026 (remainder of year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;370,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;551,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of future lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;254,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Operating lease liability, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_4a4090b8-e912-4918-b22f-7f017ec110a8"
      unitRef="U_USD">30988000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_fae49951-72d1-4f3e-aa33-d90865bb951c"
      unitRef="U_USD">39310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_7d122dba-0b7d-44c9-85fb-a6e8970e7635"
      unitRef="U_USD">38286000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_f8cce0b3-0225-4525-9dde-e3a1a4ca0a4b"
      unitRef="U_USD">36777000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_00881499-ede0-44c5-87f3-16f4e1cddc84"
      unitRef="U_USD">35913000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <eikn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_fe384188-2ea6-4bda-ade8-ed3279da385a"
      unitRef="U_USD">370302000</eikn:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_a1444d22-38cd-4a61-8468-3da203039a78"
      unitRef="U_USD">551576000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_08c4b917-5230-4e6a-9fa0-28ab3f71697d"
      unitRef="U_USD">296745000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_fafb6262-6ebc-4b95-84ba-8b75d03a0cb4"
      unitRef="U_USD">254831000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_380b6625-3496-44a1-be54-ea83f12e3413"
      unitRef="U_USD">9740000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-3"
      id="F_b3bcb1e4-c6aa-4bdb-a3ee-c1734446ea56"
      unitRef="U_USD">245091000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-5"
      id="F_052e5827-5fc4-4215-a7e1-457ab02b570f"
      unitRef="U_USD">7800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-5"
      id="F_0be76cb2-a6d5-45f0-8773-71a14d038d1b"
      unitRef="U_USD">8400000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="INF"
      id="F_4ca9e2f9-f363-4a4f-ac1b-081ae5b57258"
      unitRef="U_USD">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="INF"
      id="F_b1331756-1a08-4994-8916-cb2666e949c4"
      unitRef="U_USD">0</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="INF"
      id="F_1d772fa2-956e-401c-ba23-2ebbe8880691"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="INF"
      id="F_8154e847-a40f-458d-9107-4e432f7bc547"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_7e4d6168-6238-439f-9451-6bb25921bc84">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 7. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into various agreements in the ordinary course of business, such as those with suppliers, clinical research organizations, contract manufacturing organizations, and clinical trial sites. These agreements provide for termination at the request of either party, generally with less than one-year notice and are, therefore, cancellable contracts and, if cancelled, are not anticipated to have a material effect on the Company&#x2019;s financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future Milestone and Royalty Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into license agreements in the normal course of business in order to obtain rights to promising product candidates, advance product development and obtain technologies and services related to its business. The Company could be required to make development and regulatory milestones and sales milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;630.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion, and tiered royalty payments to licensors based on the net sales of the licensed products. Contingent milestones are recorded when probable to be achieved. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has incurred and recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in upfront and milestone payments under these agreements (see Notes 10 and 11).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Legal Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its financial condition, results of operations, or cash flows. The Company may pursue or be subject to litigation and other legal actions from time to time arising in the ordinary course of business, including intellectual property, products liability, breach of contract, commercial, employment, and other similar claims which could have an adverse impact on its reputation, business and financial condition and divert the attention of its management from the operation of its business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; legal contingencies requiring accrual or disclosures as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026 and December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification claims. Accordingly, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any liabilities for these indemnification rights and agreements as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026 and December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <eikn:DevelopmentAndRegulatoryMilestones
      contextRef="C_4a28407e-c2fe-49ab-87fd-4c1824a42626"
      decimals="INF"
      id="F_2470e713-0a42-435e-8d9f-e7a1922c78e0"
      unitRef="U_USD">630000000</eikn:DevelopmentAndRegulatoryMilestones>
    <eikn:SalesMilestones
      contextRef="C_4a28407e-c2fe-49ab-87fd-4c1824a42626"
      decimals="-8"
      id="F_e2a1afa0-300a-47f7-a45f-8be07249a219"
      unitRef="U_USD">1100000000</eikn:SalesMilestones>
    <eikn:UpfrontsAndMilestonePayments
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="-5"
      id="F_490a4fbe-56af-45a0-b59e-3d5d4d6bdfdd"
      unitRef="U_USD">93000000</eikn:UpfrontsAndMilestonePayments>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="0"
      id="F_e0f088e1-2b98-4c24-8525-65d76329561a"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="0"
      id="F_d4588876-512f-4da8-b09c-96db494d05b1"
      unitRef="U_USD">0</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:Liabilities
      contextRef="C_e7df204e-01a6-433d-b71b-99e1e283b5e3"
      decimals="INF"
      id="F_a736155a-d983-4883-a106-ca38f5929597"
      unitRef="U_USD">0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_662558f3-ac07-4fe3-b87b-689c90cf7fae"
      decimals="INF"
      id="F_678eafaf-f6c9-42ec-a1a7-728f2f6a7d26"
      unitRef="U_USD">0</us-gaap:Liabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_1fdda789-7e13-41eb-8f75-9233130c7454">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8. Capital Structure&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Issued and outstanding redeemable convertible preferred stock consisted of the following (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30.634%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.818%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.098%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.618%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.618%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.618%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Series&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Original&lt;br/&gt;Issue Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Liquidation&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,268,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,268,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,271,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,456,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;297,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,756,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,756,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series C&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,884,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,194,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series C-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,975,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,975,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,441,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,005,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,597,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,658,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,159,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,161,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2025, the Company entered into a Series D preferred stock purchase and exchange agreement which provided for the issuance of Series D redeemable convertible preferred stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The transaction provided returning investors the ability to exchange their Series B and Series C redeemable convertible preferred stock for Series B-1 and Series C-1 redeemable convertible preferred stock, respectively, if their participation in the Series D financing exceeded certain qualifying amounts. Further, investors that invested more in the Series D financing than their aggregate investment in Series B and Series C received common stock warrants based on the excess investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result of the transaction, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,005,669&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Series D redeemable convertible preferred stock in cash purchases at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company also issued (i) an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,756,908&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its Series B-1 redeemable convertible preferred stock as a result of the exchange of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,814,375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of its Series B&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;redeemable &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;convertible preferred stock, (ii) an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,975,110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its Series C-1 redeemable convertible preferred stock as a result of the exchange of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,352,470&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its Series C redeemable convertible preferred stock, and (iii) warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The warrants shall be exercisable in whole or in part, at any time up to and including the first to occur of the consummation of a liquidation event and the fifth anniversary of the date of issue and thereafter shall terminate and be void. The warrants can be exercised either in cash or net issued. As the contract allows for physical settlement or net physical settlement, the Company concluded that the common stock warrants should be equity- classified and recorded in additional paid-in capital at their fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company assessed the impact of the transaction, on an investor-by-investor basis, using a quantitative analysis in order to determine whether it represented an extinguishment or a modification of the Series B and Series C redeemable convertible preferred stock held by each investor which were exchanged.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Extinguishment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The quantitative analysis indicated the fair value before and after the transaction was substantially different for some investors. Specifically, these represented investors that participated at a level which enabled them to exchange all or nearly all of their Series B and Series C redeemable convertible preferred stock, including the investors whose participation also entitled them to common stock warrants. For each of these investors, the transaction represented an extinguishment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The extinguishments resulted in the following impacts:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Derecognition of the existing carrying amount of the extinguished Series B and Series C redeemable convertible preferred stock of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting for the new issuance of the Series B, Series B-1, Series C and Series C-1 redeemable convertible preferred stock, and common stock warrants at fair values of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;149.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The offset for each investor was recorded to either additional paid-in capital (investors for which fair value exceeded carrying value, aggregating to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) or accumulated deficit (investors for which carrying value exceeded fair value, aggregating to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate difference between the fair value of the consideration transferred and the carrying value of the extinguished shares was reflected as an adjustment to the numerator in the computation of basic earnings per share for the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Specifically, the extinguishments resulted in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million net reduction to the net loss available to common shareholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Modification&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The quantitative analysis indicated the fair value before and after the transaction was not substantially different for some investors. Specifically, these represented investors that participated but only at a level which enabled them to exchange a portion of their Series B and Series C redeemable convertible preferred stock. For each of these investors, the transaction represented a modification.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The modifications resulted in the following impacts:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The existing carrying amount of the modified preferred stock was adjusted by the increase in fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million comprised of a net decrease to the carrying amount of Series B and Series C redeemable convertible preferred stock of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and an increase to the carrying amount of Series B-1 and Series C-1 redeemable convertible preferred stock of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The offset for each investor was recorded to additional paid-in capital (all represented increases in fair value).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The increase in fair value of the modified shares was reflected as an adjustment to the numerator in the computation of basic earnings per share for the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Specifically, the modifications resulted in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million increase to the net loss available to common shareholders. See Note 3 for the net impact of the extinguishments and modifications on the net loss per share attributable to common shareholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the IPO, all shares of Series A, A-1, B, B-1, C, C-1 and D redeemable convertible preferred stock converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,855,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance, on an as if-converted basis, consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Conversion of redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,855,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,522,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,513,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options available for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,269,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,449,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,071,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,557,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stockholders are entitled to dividends if and when declared by the Board and after any dividends on redeemable convertible preferred stock are fully paid. The holder of each share of common stock is entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dividends have been declared.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_1543c30b-0262-4be9-99ee-22a405751153">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Issued and outstanding redeemable convertible preferred stock consisted of the following (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30.634%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.818%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.098%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.618%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.618%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.618%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Series&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;br/&gt;Issued and&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Original&lt;br/&gt;Issue Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Liquidation&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series A-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,268,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,268,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,271,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,456,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;297,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series B-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,756,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,756,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series C&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,884,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,194,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series C-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,975,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,975,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Series D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,441,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,005,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262,597,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,658,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,159,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,161,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521"
      decimals="INF"
      id="F_d3e9110c-8f14-4b97-9d0b-6f31070379c2"
      unitRef="U_shares">48000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521"
      decimals="INF"
      id="F_29c77500-5f55-4a9b-aa9f-cc44d11070fa"
      unitRef="U_shares">48000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521"
      decimals="INF"
      id="F_9459b305-c44f-44f7-ace2-6f2a84018467"
      unitRef="U_shares">48000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521"
      decimals="INF"
      id="F_c74d6c7d-0cdd-4c99-8cfc-7594cb14a61e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521"
      decimals="-3"
      id="F_b5000920-7805-4f68-81c6-2ec7bb7353b7"
      unitRef="U_USD">48000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_eea5e544-8a36-4e39-9071-f9fe1d484521"
      decimals="-3"
      id="F_5434ca69-7218-44f8-915c-2c269133c8fb"
      unitRef="U_USD">47916000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b"
      decimals="INF"
      id="F_a5a8d63d-ae45-4512-9c35-5cad7212df88"
      unitRef="U_shares">51268891</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b"
      decimals="INF"
      id="F_171f5e71-2703-4482-88d5-c713622e10c4"
      unitRef="U_shares">51268891</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b"
      decimals="INF"
      id="F_06bde316-d35c-4fc0-99e8-a684b4981001"
      unitRef="U_shares">51268891</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b"
      decimals="INF"
      id="F_99b86313-e7be-436b-8bdc-b9b926f6895d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b"
      decimals="-3"
      id="F_d8137126-41c5-4b87-b017-44eba4b49500"
      unitRef="U_USD">102538000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_76484ee6-c514-405c-9fcf-875c160c471b"
      decimals="-3"
      id="F_0afb69a7-4e68-4ab5-8668-14f4f952923f"
      unitRef="U_USD">102472000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1"
      decimals="INF"
      id="F_6c96681f-4297-448e-845e-9982a1cc2e97"
      unitRef="U_shares">29271143</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1"
      decimals="INF"
      id="F_ba66a150-5ea2-4620-a842-11b6c163aa6a"
      unitRef="U_shares">17456768</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1"
      decimals="INF"
      id="F_f01550be-bff8-4a48-a3ce-0ed9603bbeb1"
      unitRef="U_shares">17456768</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1"
      decimals="INF"
      id="F_bfd33ffa-8d6d-4cdc-9675-dbf83d093097"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.69</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1"
      decimals="-3"
      id="F_7c4ae21c-6207-4754-b05e-def72524f836"
      unitRef="U_USD">308786000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_a4b87d2d-41ab-4b6a-a113-7185c4724ce1"
      decimals="-3"
      id="F_7f96d98e-f236-4bda-9bf4-ccb0409e7ae6"
      unitRef="U_USD">297294000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623"
      decimals="INF"
      id="F_ecd7e70e-bb0d-4107-8fde-70890f18adcb"
      unitRef="U_shares">35756908</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623"
      decimals="INF"
      id="F_9d4ad982-c624-4767-ba59-a7838dd39177"
      unitRef="U_shares">35756908</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623"
      decimals="INF"
      id="F_0d0e02fd-e7c4-463c-a71b-d98ab280107a"
      unitRef="U_shares">35756908</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623"
      decimals="INF"
      id="F_9de91909-3ff0-4b8a-884c-e0041c74c8e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.84</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623"
      decimals="-3"
      id="F_343df225-df62-4ecc-bd6b-3c19120cccef"
      unitRef="U_USD">208979000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_709f11e3-5a93-4ecc-a34e-9fce4fb92623"
      decimals="-3"
      id="F_de2651ec-57ab-4025-b223-1745ee99147c"
      unitRef="U_USD">224200000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706"
      decimals="INF"
      id="F_e4f48db6-1fc5-4980-a598-a784325defff"
      unitRef="U_shares">24884830</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706"
      decimals="INF"
      id="F_31db0da3-e961-4c4b-8639-a228ff35ec2a"
      unitRef="U_shares">5194787</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706"
      decimals="INF"
      id="F_9798746d-5c97-42bf-a23f-63dc94e40323"
      unitRef="U_shares">5194787</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706"
      decimals="INF"
      id="F_fb99fea5-06df-4671-a194-eab0245e6342"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.5</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706"
      decimals="-3"
      id="F_5f3257f4-1079-4ed4-a1ff-c782e5841a0a"
      unitRef="U_USD">111682000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_e8fb40c9-0eca-4b95-9025-0360ea439706"
      decimals="-3"
      id="F_b47432e6-b01c-4797-b985-0c474c767811"
      unitRef="U_USD">108629000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec"
      decimals="INF"
      id="F_07fd8da0-737a-4444-b1de-391fee2a29b6"
      unitRef="U_shares">4975110</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec"
      decimals="INF"
      id="F_ffb4f73a-a1f0-4fd9-ab4c-3b99466a93fe"
      unitRef="U_shares">4975110</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec"
      decimals="INF"
      id="F_d961901e-4fef-45a3-aeeb-348e31bc4886"
      unitRef="U_shares">4975110</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec"
      decimals="INF"
      id="F_a23e6899-0a38-405f-b42c-3165b0ee0322"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.84</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec"
      decimals="-3"
      id="F_421015ae-981f-4514-8a05-3bfbe2cf43a7"
      unitRef="U_USD">29077000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_c51b427c-8f11-4b03-8f6b-e23e73d535ec"
      decimals="-3"
      id="F_e87777ab-2bc7-4bff-9f69-c993989a23fa"
      unitRef="U_USD">30806000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44"
      decimals="INF"
      id="F_e33e22c9-8630-4d3b-a761-e862836f35e2"
      unitRef="U_shares">68441007</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44"
      decimals="INF"
      id="F_d1acfa50-8095-44f0-9700-3ca0ef36b314"
      unitRef="U_shares">60005669</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44"
      decimals="INF"
      id="F_a2732424-ee99-4db1-a432-3a72d6c7bbf3"
      unitRef="U_shares">60005669</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44"
      decimals="INF"
      id="F_578c8491-2b6b-4f07-bfd6-80be6c2ffa7b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.84</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44"
      decimals="-3"
      id="F_c529fe55-77e8-4b2b-9183-ae2f630d8646"
      unitRef="U_USD">350700000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_a99f27e3-aa4b-4f23-b22e-eba0e1288c44"
      decimals="-3"
      id="F_d61460af-69ae-4e67-8140-26ba0196d572"
      unitRef="U_USD">350153000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_ee7e153d-9b2b-45e6-afa7-d1c1adbc1377"
      unitRef="U_shares">262597889</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_899d1660-7c50-4175-8aa9-2de7ea78bdf2"
      unitRef="U_shares">222658133</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_b14084d7-1b4f-4558-963b-2261d2461738"
      unitRef="U_shares">222658133</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_f92c9658-9f28-4916-8577-c7cce8fe4d5b"
      unitRef="U_USD">1159762000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="-3"
      id="F_156691eb-7cec-44e0-bb69-d383dd68bee1"
      unitRef="U_USD">1161470000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredCarryingAmount>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289"
      decimals="INF"
      id="F_d871e0fc-8682-4f57-9176-9dcbbfbd9f3e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.84</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289"
      decimals="0"
      id="F_fc016e64-d0a1-4c4e-a51e-8904eb0f3f29"
      unitRef="U_shares">60005669</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_b1d57b0c-741e-4bdb-8c15-b3196aad4289"
      decimals="INF"
      id="F_76436e43-d23a-4b9d-919b-b9746e28dc4f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.84</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_79517728-0638-49d0-b5e2-18ddacc50546"
      decimals="-5"
      id="F_46e53835-8031-472e-99f9-8a8e4b16a361"
      unitRef="U_USD">350700000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_7f0bc01b-6dce-402c-b6f6-7f08c14a5096"
      decimals="0"
      id="F_f06a1542-cfb7-4182-b0ab-c7c8526705b2"
      unitRef="U_shares">35756908</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_4db66fff-bc05-4074-8e36-aeef64b327a4"
      decimals="0"
      id="F_01c36811-ee1a-46ce-bb6f-5ea059d97f49"
      unitRef="U_shares">11814375</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_fb91cb81-7c4b-448a-988e-9ead42c05b5a"
      decimals="0"
      id="F_f2d02f0a-ada1-4df9-b974-1dca5fb2b92f"
      unitRef="U_shares">4975110</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_8f9cf841-a084-4a0b-8321-a9f82ffed0e1"
      decimals="0"
      id="F_5c763650-c97d-4bda-a6ce-8a77a2dd9eb1"
      unitRef="U_shares">1352470</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_e170b844-9352-4f6f-8503-8d06a7499836"
      decimals="INF"
      id="F_01565543-0004-4a98-8ab8-c6cb367683ee"
      unitRef="U_shares">739559</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c1981874-bd18-46b8-8717-745097f2f3bd"
      decimals="INF"
      id="F_606b9a69-6839-4c25-b233-9aedafb75788"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">43.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_72c9554b-3432-4aba-ad4e-feadbc19e644"
      decimals="-5"
      id="F_5ecca716-be5d-4aa8-b797-49314c323abe"
      unitRef="U_USD">6300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0"
      decimals="-5"
      id="F_b3a750ac-69d0-4bd4-8154-401b005e1040"
      unitRef="U_USD">172800000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44"
      decimals="-5"
      id="F_11f93170-c946-4c71-8d0b-50137b2f7aef"
      unitRef="U_USD">30000000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0"
      decimals="-5"
      id="F_c6fd6ab3-0dc5-4f31-b534-1580e523c080"
      unitRef="U_USD">16700000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_50271040-0f62-455e-8383-928757d00db6"
      decimals="-5"
      id="F_74a7e0c3-a88c-422b-b327-57def106976b"
      unitRef="U_USD">149600000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44"
      decimals="-5"
      id="F_5fe8ee84-24ef-4e37-af0e-e583e068a1a1"
      unitRef="U_USD">4800000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_19ce2956-fe58-4b8f-9894-55d51e63a6f4"
      decimals="-5"
      id="F_d46bc6f3-cae9-4652-933f-f8725a43db0e"
      unitRef="U_USD">23100000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_b9805475-e76d-41e7-932c-783895704433"
      decimals="-5"
      id="F_679d40b6-8c45-4fc7-bbde-1fe3302b13dc"
      unitRef="U_USD">6300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <eikn:TemporaryEquityOffsetFairValueExceededCarryingValue
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-5"
      id="F_8f534f93-ef4d-4a1e-b2e6-51274a7aa06d"
      unitRef="U_USD">6400000</eikn:TemporaryEquityOffsetFairValueExceededCarryingValue>
    <eikn:TemporaryEquityOffsetCarryingValueExceededFairValue
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-5"
      id="F_0e182d18-db93-4013-b3ee-a339d443852c"
      unitRef="U_USD">8700000</eikn:TemporaryEquityOffsetCarryingValueExceededFairValue>
    <eikn:ExtinguishmentsReductionToNetLossAvailableToCommonShareholders
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-5"
      id="F_a71bd741-23cc-43fb-9bde-18559f17f459"
      unitRef="U_USD">2300000</eikn:ExtinguishmentsReductionToNetLossAvailableToCommonShareholders>
    <eikn:ModifiedAdjustedPreferredStockIncreaseInFairValue
      contextRef="C_b9805475-e76d-41e7-932c-783895704433"
      decimals="-5"
      id="F_a0330dd1-fb73-4ff1-ade3-4105173fe4b5"
      unitRef="U_USD">11700000</eikn:ModifiedAdjustedPreferredStockIncreaseInFairValue>
    <eikn:DecreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_fa02dff5-46ec-4f60-ac80-e25b1ea444b0"
      decimals="-5"
      id="F_56d81b63-e16e-4e3e-a4e4-e5931d68ef9e"
      unitRef="U_USD">64100000</eikn:DecreaseInCarryingAmountOfRedeemablePreferredStock>
    <eikn:DecreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_21c475ec-ccd5-4f72-b0cc-a6a435466d44"
      decimals="-5"
      id="F_b3fc673a-3691-4a3f-9d24-fbc377a71567"
      unitRef="U_USD">6500000</eikn:DecreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:IncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_50271040-0f62-455e-8383-928757d00db6"
      decimals="-5"
      id="F_7fa45286-9b85-477d-8a8e-a81a91154a27"
      unitRef="U_USD">74600000</us-gaap:IncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:IncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_19ce2956-fe58-4b8f-9894-55d51e63a6f4"
      decimals="-5"
      id="F_c0635fc8-9e69-44d0-bcba-fb6a0a710382"
      unitRef="U_USD">7700000</us-gaap:IncreaseInCarryingAmountOfRedeemablePreferredStock>
    <eikn:IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-5"
      id="F_420849d7-a12d-4046-8612-118bb99db5cd"
      unitRef="U_USD">11700000</eikn:IncreaseInNetLossAvailableToCommonStockholdersFromEquityModifications>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_f4769796-b48a-4a61-bcef-e175508ab0bb"
      decimals="INF"
      id="F_dc406e7d-31cb-47f7-ac27-2470d293c89c"
      unitRef="U_shares">29855741</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <eikn:CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_ec6132da-41ab-4c33-906c-371adc3fa80e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance, on an as if-converted basis, consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Conversion of redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,855,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;739,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,522,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,513,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options available for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,269,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,449,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares reserved for ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,071,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,557,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</eikn:CommonStockReservedForFutureIssuanceAsIfConvertedBasisTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_32e58006-0bc0-440a-94eb-1e6e99c57dfe"
      decimals="INF"
      id="F_75b5f648-dfb5-42f4-8816-45a3882fdbae"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_645f2052-193d-45d6-894c-a8d3a45a5203"
      decimals="INF"
      id="F_84eed224-61e1-43e9-a99f-4b07de7ed10b"
      unitRef="U_shares">29855741</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_31e76bc3-5aba-4a5f-9818-f4b753bd92ef"
      decimals="INF"
      id="F_d131f769-b6ec-40b0-b8de-c7d82cf6c4ae"
      unitRef="U_shares">739559</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_908c61c4-64bd-4c85-a9dd-94e0cd397a73"
      decimals="INF"
      id="F_5eaeb219-d218-4a96-996d-efb7ce6b5c3c"
      unitRef="U_shares">739559</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d927b95d-37fc-4c9d-8791-5738a05cbc4b"
      decimals="INF"
      id="F_37cdcaf0-4bb8-4587-8fcf-50ab72a144d4"
      unitRef="U_shares">7522330</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_18d67718-9b0e-4fc6-9a9c-711cd4ddf402"
      decimals="INF"
      id="F_019cf032-2cfd-4466-98dc-41558dcf4d6d"
      unitRef="U_shares">5513142</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1ea189f6-3a9d-423b-a06b-980dd823d3d7"
      decimals="INF"
      id="F_744584f6-2d34-4e6c-b66e-db5ff498b3cc"
      unitRef="U_shares">2269981</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d432863b-75bb-40d5-bacc-9c6f3baca062"
      decimals="INF"
      id="F_b4f81a17-3f71-41e3-8c40-2814bb3e104c"
      unitRef="U_shares">1449522</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f1a8eeb5-1e5a-4045-acdc-0cfce87caf9b"
      decimals="INF"
      id="F_dca71211-df37-44e4-aa25-e27b5aea0de8"
      unitRef="U_shares">539582</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f6befb00-d49d-441c-b08f-36fbaa09ea83"
      decimals="INF"
      id="F_3c845e3d-29a2-431f-b52c-07d80f07f4bf"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_cf546f1c-3d25-4acc-a6fc-de49f3464dce"
      unitRef="U_shares">11071452</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_da487ddc-7c7c-4704-ade9-0d116bdd0ee4"
      decimals="INF"
      id="F_af1780e3-8afc-42d7-a128-071264b1966f"
      unitRef="U_shares">37557964</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockVotingRights
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_683fb320-69e6-4920-9e21-cc5fbcdf678f">one</us-gaap:CommonStockVotingRights>
    <eikn:DividendsDeclared
      contextRef="C_3076528d-17ef-41ea-9093-a57058ff97ec"
      decimals="INF"
      id="F_f00b02f8-46ae-4274-b88a-90f36f1f92ac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</eikn:DividendsDeclared>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_9c6c8d27-c8b4-4405-9428-7134374c59e6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 9. Equity Incentive Plans and Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2026, the Company&#x2019;s Board of Directors adopted, and its stockholders approved, the 2026 Long-Term Incentive Plan (the &#x201c;2026 LTIP&#x201d;), which became effective on February 3, 2026 and replaced the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted on September 19, 2019. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,137,117&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock have been reserved for issuance under the 2026 LTIP, in addition to any shares of common stock outstanding under the 2019 Plan or shares of common stock issuable in connection with the stock option awards granted to the Company&#x2019;s Chief Executive Officer on April 2, 2025 that expire, are withheld by the Company for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to the Company due to failure to vest. The number of shares of common stock reserved for future issuance under the 2026 LTIP will also be increased pursuant to provisions for annual automatic evergreen increases, subject to any action by the Board of Directors that reduces the increase to a lesser number of shares for a given year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2026 LTIP and 2019 Plan provide for the granting of restricted stock, incentive stock options (&#x201c;ISOs&#x201d;), or nonqualified stock options (&#x201c;NQSOs&#x201d;). Restricted stock and NQSOs may be granted to Company employees, officers, directors, and consultants. ISOs may only be granted to Company employees (including directors who are also considered employees).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Options under the 2026 LTIP and 2019 Plan may be granted for terms of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant, provided however, that with respect to an ISO granted to a person who owns stock representing more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total combined voting power of all classes of stock of the Company, the term shall be for no more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The exercise price of options granted under the 2026 LTIP and 2019 Plan must be at a price no less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of the shares on the date of grant, as determined by the Board of Directors, provided however, that with respect to an ISO granted to an employee who at the time of grant of such option owns stock representing more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total combined voting power of all classes of stock of the Company, the exercise price shall not be less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of the shares on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Options granted under the 2026 LTIP and 2019 Plan generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% after one year and monthly thereafter. Annual refresher options granted to employees generally vest monthly over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2026, the Company&#x2019;s Board of Directors adopted, and its stockholders approved, the 2026 Employee Stock Purchase Plan (the &#x201c;2026 ESPP&#x201d;), which became effective on February 4, 2026. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539,582&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock have been reserved for issuance under the 2026 ESPP. In addition, the number of shares reserved for future issuance under the 2026 ESPP will be increased for annual automatic evergreen increases, subject to any action by the Board of Director that reduces the increase to a lesser number of shares or provides that there will be no increase in the share reserve for a given year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense includes options granted to employees and nonemployees and has been reported in the condensed statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_480832dd-e171-4ca4-b482-a03140d73654"
      decimals="INF"
      id="F_cfd67a62-9806-4680-8fca-a7550f9ef87e"
      unitRef="U_shares">4137117</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <eikn:ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm
      contextRef="C_912863b5-d421-42f1-b393-0c8022fb4cc5"
      id="F_8212e674-2f49-455f-89ed-be00a10e794a">P10Y</eikn:ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedInTerm>
    <eikn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage
      contextRef="C_8c7f8085-733f-4767-ac3a-7065758bbd4a"
      decimals="INF"
      id="F_d2709b48-ff95-4ac2-9e38-db6e52d0af8d"
      unitRef="U_pure">0.10</eikn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentage>
    <eikn:ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne
      contextRef="C_912863b5-d421-42f1-b393-0c8022fb4cc5"
      id="F_2775d9b2-60db-4954-bf47-6d11363a8f34">P5Y</eikn:ShareBasedCompensationArrangementByShare-BasedPaymentAwardGrantedTermOne>
    <eikn:ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate
      contextRef="C_d632d010-5232-471e-abf6-d727c87dd4b4"
      decimals="INF"
      id="F_1550a6db-120d-4b4a-8c87-963753f34258"
      unitRef="U_pure">1</eikn:ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate>
    <eikn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage
      contextRef="C_8c7f8085-733f-4767-ac3a-7065758bbd4a"
      decimals="INF"
      id="F_6163863e-d104-47f0-b7da-2f9dab66159e"
      unitRef="U_pure">0.10</eikn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceOfOptionsGrantedAtFairMarketValueOwnershipPercentage>
    <eikn:ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate
      contextRef="C_92fa46f0-fe5c-4ebc-817d-ec6bec9a5f5a"
      decimals="INF"
      id="F_d4046894-b97e-49d6-a8b8-e86f576ab025"
      unitRef="U_pure">1.10</eikn:ExercisePriceOfOptionsGrantedUnderIncentiveAndShareBasedCompensationPlansAsPercentageOfFairMarketValueOfSharesOnGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a58a5eaf-b724-4201-9cb2-92d031377e5f"
      id="F_68b1550a-1032-4e68-ab46-b07cbac3ce75">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_60427b0d-3053-455a-a653-545c63de803d"
      decimals="2"
      id="F_490ee96a-8b14-4bd2-a341-4b8bde79a27b"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a58a5eaf-b724-4201-9cb2-92d031377e5f"
      id="F_e64dcd16-9ac1-4289-b1d3-ecf293455008">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e6ef9b81-32b1-4c49-9fa3-1c3d269aece2"
      decimals="0"
      id="F_3ac5cf92-db93-4df2-81e3-e70fc01f2d4d"
      unitRef="U_shares">539582</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_b6658163-7733-4606-8b6c-949b55ab5ba8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense includes options granted to employees and nonemployees and has been reported in the condensed statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88eddc74-25a3-4aa5-b892-0c78cef4f38f"
      decimals="-3"
      id="F_35fd9c95-eca4-4f42-90ba-83d6adaaa8f1"
      unitRef="U_USD">1162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ed86a544-6aee-4ee9-acce-d3e07fcb1c78"
      decimals="-3"
      id="F_ed879f1a-4ec8-4ec5-8a34-e4c0414737c4"
      unitRef="U_USD">1151000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9b60e528-d867-4710-996d-aa10971fdb80"
      decimals="-3"
      id="F_a828569d-e3d1-4134-ac03-42d3e975d9f7"
      unitRef="U_USD">1615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bc59c656-e863-43bb-acfa-25a6bfeba2a7"
      decimals="-3"
      id="F_3ca56ffc-c230-4659-9030-9ae348225831"
      unitRef="U_USD">1819000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_9b60487a-0b3e-46cd-931a-6ceb9423ebd5"
      unitRef="U_USD">2777000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_4642d0b7-e1a8-4f25-bae0-cefaf07c6e47"
      unitRef="U_USD">2970000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_a1e82350-035f-490e-8cfd-e8f848c36e6a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 10. Acquisitions of IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Seven and Eight Collaboration Agreement and SW License and Development Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 29, 2023, the Company entered into an Exclusive Collaboration Agreement (the &#x201c;Seven and Eight Collaboration Agreement&#x201d;), with Seven and Eight Biotherapeutics Corp. and related entities (collectively &#x201c;Seven and Eight&#x201d;), and an Exclusive License and Development Agreement (the &#x201c;SW License Agreement&#x201d;) with Seven and Eight and Superb Wisdom Limited (&#x201c;SW&#x201d;). Under each agreement, Seven and Eight and SW granted the Company a worldwide, exclusive license under certain of their patents, know-how, and other intellectual property rights to develop and commercialize certain toll-like receptor 7 and 8 agonist product candidates, including the Company&#x2019;s product candidate, EIK1001. The license from SW is exclusive in the field of oncology, and the license from Seven and Eight is exclusive in all fields. The Company has the sole right and responsibility to conduct clinical development, perform regulatory activities and commercialize the compounds and products licensed under the agreements, and must use commercially reasonable efforts with respect to its development activities. Under the Seven and Eight Collaboration Agreement, following a transition period during which Seven and Eight transferred certain contracts, regulatory documentation, biological materials, research tools, rights and other information related to the product candidates to the Company, Seven and Eight agreed to wind down its research efforts with respect to toll-like receptor activity, including its development of the compounds licensed under the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid Seven and Eight and SW aggregate upfront payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in cash ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Seven and Eight and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to SW), and issued two Simple Agreements for Future Equity (&#x201c;SAFEs&#x201d;), equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Seven and Eight and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to SW) upon entering into the applicable agreement. The SAFEs automatically converted into Series C redeemable convertible preferred stock upon the initial closing of the Series C financing round in May 2023, which then converted into common stock upon the closing of the IPO. The Company has also agreed to pay Seven and Eight additional milestone payments in the amount of up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;369.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;219.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million are payable for a compound that is not a conjugate and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for a compound that is a conjugate, in each case upon the achievement of certain development and regulatory milestones. EIK1001 is a compound that is not a conjugate. The Company has also agreed to pay SW additional milestone payments in the amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of certain regulatory and commercial milestones, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Seven and Eight Collaboration Agreement, the Company owns and retains all rights in intellectual property and other information discovered, developed, or otherwise made in connection with the Seven and Eight Collaboration Agreement, whether made by the Company or Seven and Eight, either solely or jointly. Under the SW License Agreement, the Company owns any improvements, enhancements, updates, or equivalents of the intellectual property developed, created, or otherwise made in relation to the compounds and products licensed under both agreements. The Company also has the right to prepare, file, prosecute, enforce, and maintain patents related to the compounds and products licensed under each agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unless earlier terminated, the Seven and Eight Collaboration Agreement expires upon the latest of (i) the expiration, invalidation, or abandonment of the last patent licensed thereunder, (ii) the expiration of any data or market exclusivity program related to the product candidates, and (iii) ten years after the first commercial sale of a product candidate. If the Company notifies Seven and Eight that it is permanently discontinuing its efforts to develop and commercialize the licensed products under the agreement and does not intend to pay Seven and Eight any milestone payments contemplated thereunder, Seven and Eight may terminate the Seven and Eight Collaboration Agreement. Either party may terminate the Seven and Eight Collaboration Agreement if there has been a material breach of contract, but such termination can only be invoked if the breach cannot be reasonably remedied by the payment of money damages. The Company may also terminate the Seven and Eight Collaboration Agreement upon prior written notice for any reason.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unless earlier terminated, the SW License Agreement expires upon the earliest of (i) the expiration, invalidation, or abandonment of the last patent licensed thereunder in the applicable country (and if no patent application was filed or no patent was issued in such country, ten years from the first commercial sale of the first product licensed thereunder in such country), or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(ii) payment of the last commercial milestone payment. The SW License Agreement automatically terminates upon any termination of the Seven and Eight Collaboration Agreement. The SW License Agreement may also be terminated, without terminating the Seven and Eight Collaboration Agreement, by either party if there has been a material breach (including if the Company fails to make any milestone payment due thereunder). The Company may also terminate the SW License Agreement, without terminating the Seven and Eight Collaboration Agreement, upon prior written notice for any reason.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized the upfront payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as in-process research and development expenses within the statement of operations and comprehensive loss in the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as the transaction was accounted for as an in-process research and development asset acquisition and the acquired technology did not have an alternative use. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; future milestones were accrued on the Company&#x2019;s condensed balance sheets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026 and December 31, 2025 as such milestones were not achieved or probable of being achieved at each date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impact Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 10, 2023, the Company entered into a Collaboration Agreement, which was amended and restated on November 22, 2023, and further amended on December 12, 2024 (collectively, the &#x201c;Impact Agreement&#x201d;) with Impact Therapeutics (Shanghai) Inc. (&#x201c;Impact&#x201d;). Pursuant to the Impact Agreement, the Company received an exclusive license under certain of Impact&#x2019;s patents, know-how, and regulatory information to develop and commercialize any selective PARP1 inhibitors owned or controlled by Impact or its affiliates, including the Company&#x2019;s product candidates EIK1003 and EIK1004, and any pharmaceutical products comprised of or containing such inhibitors, on a worldwide basis excluding China, Hong Kong, Taiwan, and Macau, such excluded territories collectively known as the Impact territory. The Company also received a co-exclusive, royalty-free license under certain of Impact&#x2019;s patents and know-how to develop and manufacture such product candidates within the Impact territory solely for the purposes of supporting the development or commercialization thereof outside of the Impact territory. Additionally, the Company granted to Impact a co-exclusive, royalty-free license under certain of its patents, know-how, and regulatory information for the sole purposes of Impact fulfilling its obligations related to the Impact Agreement and to develop, manufacture and make regulatory filings related to the product candidates. In addition, the Company granted an exclusive, royalty-free license under certain of its patents and know-how to Impact solely for purposes of commercialization of the product candidates in the Impact territory. The Impact Agreement further prohibits either party or their sublicensees or affiliates, as applicable, from developing, manufacturing, or commercializing any selective PARP1 inhibitors during the term of the Impact Agreement except as provided under the foregoing licenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Impact Agreement established a joint steering committee (&#x201c;JSC&#x201d;) to manage the collaboration. Under the Impact Agreement, Impact retains responsibility for all preclinical development activities for the product candidates. Impact is responsible for clinical development, including preparing and maintaining regulatory approvals, and commercialization of the product candidates, in the Impact territory, and the Company is responsible for these activities in all other jurisdictions worldwide. The Company also has the right to propose global clinical studies and global development plans that include clinical sites in the Impact territory for the JSC&#x2019;s approval. The Company would be responsible for the conduct of any global clinical study in all territories except the Impact territory, in which Impact would be responsible for such conduct. Under a global development plan, the Company and Impact could each also propose the development of a combination product in their respective territories. Further, under the Impact Agreement, the Company must use commercially reasonable efforts to achieve regulatory approval of a product candidate for one indication in the United States, subject to Impact&#x2019;s performance of its preclinical development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The JSC consists of three Eikon representatives and three Impact representatives; the chair of the JSC is an Eikon representative. In the event that the JSC cannot reach unanimous agreement on any issue, then the Company&#x2019;s Chief Medical Officer must discuss the issue with Impact&#x2019;s Chief Executive Officer. If they are unable to reach agreement, then the Company has final decision-making authority over any matter related to the development and commercialization of the product candidates, including Impact&#x2019;s preclinical development plan, and any Impact, global, or combination development plan. Impact has final decision-making authority over the day-to-day implementation of any development plan, manufacturing, and commercialization of the product candidates in the Impact territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in cash to Impact. The Company is also required to make payments to Impact of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;775.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of certain development and regulatory milestones and commercial milestones, respectively. In addition, tiered royalties of high single-digit to low-teen percentages of net sales per calendar year, subject to certain reductions, are also payable by the Company to Impact post-commercialization.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company and Impact each own and retain all interests in any information or invention individually developed under the Impact Agreement, and they each own an equal and undivided interest in any jointly developed intellectual property. Subject to the licenses granted under the Impact Agreement and the respective exclusivity obligations therein, the Company and Impact each have the right to exploit such joint intellectual property rights and grant licenses to affiliates or other persons under such joint intellectual property rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impact has the right to prosecute and maintain its own and joint patents in the Impact Territory; the Company has the right to prosecute and maintain its own patents worldwide, and to prosecute and maintain Impact&#x2019;s and any joint patents in any jurisdictions except for the Impact Territory. The Company and Impact each have the sole right to enforce patents in their own respective territories and have agreed to cooperate fully where the enforcing party requires documentation or other assistance from the other party.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Impact Agreement expires upon the expiration of the last royalty term for the last product candidate for which the Company is actively pursuing research, development and commercialization. The royalty term for a product candidate in a country expires upon the latest to occur of: (i) the expiration of the last-to-expire patent held by Impact or joint patent in such country that contains a valid claim that covers such product candidate or corresponding licensed compound, (ii) the tenth anniversary of the first commercial sale of such product candidate in such country, and (iii) the expiration of regulatory exclusivity for such product candidate in such country. Upon such expiration of the royalty term for a product candidate in a country, the exclusive licenses the Company received under the Impact Agreement will become non-exclusive, perpetual, fully-paid, royalty-free, irrevocable licenses for such product candidate in such country. Either party may terminate the Impact Agreement if there has been material breach, but such termination can only be invoked if the breach cannot be reasonably remedied by the payment of money damages. In addition, either party may terminate the agreement if the other party becomes insolvent. The Company has the sole right to terminate the Impact Agreement immediately upon written notice to Impact if the Company receives a clinical hold or a withdrawal notice from a regulatory authority regarding safety concerns related to the development or commercialization of a product candidate, in each case that has no reasonable likelihood of resolution. The Company also has the sole right to terminate for any or no reason upon prior written notice to Impact.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognized the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as in-process research and development expenses within the statement of operations and comprehensive loss in the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023 as the transaction was accounted for as an in-process research and development asset acquisition and the acquired technology did not have an alternative use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in development and regulatory milestones, which were recorded as research and development expenses in the condensed statement of operations and comprehensive loss for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milestone payments were made in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; future milestones were accrued on the Company&#x2019;s condensed balance sheets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026 and December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as such milestones were not achieved or probable of being achieved at each date.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <eikn:UpfrontFeePaidInCash
      contextRef="C_4c693a1f-4ca1-464c-90fa-56debb4e78a7"
      decimals="-5"
      id="F_cc79dcba-202a-4986-bf17-23ebeda4193d"
      unitRef="U_USD">11000000</eikn:UpfrontFeePaidInCash>
    <eikn:UpfrontFeePaidInCash
      contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627"
      decimals="-5"
      id="F_6ddc2e53-e135-40c9-bacb-bbaa39e79d51"
      unitRef="U_USD">10500000</eikn:UpfrontFeePaidInCash>
    <eikn:UpfrontFeePaidInCash
      contextRef="C_7793f816-84ea-4007-b84f-955f26f60859"
      decimals="-5"
      id="F_f9e571df-7f10-4df8-9427-d32abd93faae"
      unitRef="U_USD">500000</eikn:UpfrontFeePaidInCash>
    <eikn:SimpleAgreementsForFutureEquityIssuedAmount
      contextRef="C_4c693a1f-4ca1-464c-90fa-56debb4e78a7"
      decimals="-5"
      id="F_d5bb753a-292a-4711-974c-1423ac3a83d6"
      unitRef="U_USD">35000000</eikn:SimpleAgreementsForFutureEquityIssuedAmount>
    <eikn:SimpleAgreementsForFutureEquityIssuedAmount
      contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627"
      decimals="-5"
      id="F_0126f086-2810-4fff-bfcc-6a344c7a1536"
      unitRef="U_USD">31500000</eikn:SimpleAgreementsForFutureEquityIssuedAmount>
    <eikn:SimpleAgreementsForFutureEquityIssuedAmount
      contextRef="C_7793f816-84ea-4007-b84f-955f26f60859"
      decimals="-5"
      id="F_703e011e-faf5-4b03-96d0-da3279ac5b09"
      unitRef="U_USD">3500000</eikn:SimpleAgreementsForFutureEquityIssuedAmount>
    <eikn:AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
      contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627"
      decimals="-5"
      id="F_2405276a-87e7-493f-847e-32df627d4ac9"
      unitRef="U_USD">369600000</eikn:AdditionalMilestonePayableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones>
    <eikn:AdditionalMilestonePayableForACompoundThatIsNotAConjugate
      contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627"
      decimals="-5"
      id="F_7d261dba-d9d9-4230-888a-3af3c3edf597"
      unitRef="U_USD">219600000</eikn:AdditionalMilestonePayableForACompoundThatIsNotAConjugate>
    <eikn:AdditionalMilestonePayableForACompoundThatIsAConjugate
      contextRef="C_4fc1b14d-49f9-46f4-b17e-b2678287a627"
      decimals="-5"
      id="F_8ea1853e-b5f8-4a6f-b08b-7e7f9cd84929"
      unitRef="U_USD">150000000</eikn:AdditionalMilestonePayableForACompoundThatIsAConjugate>
    <eikn:AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones
      contextRef="C_1946717c-8e31-4a84-ab14-fa2fc8fe3174"
      decimals="-5"
      id="F_4f7379cb-ed94-464b-b42a-ead1b02db7e0"
      unitRef="U_USD">29400000</eikn:AdditionalMilestonePayableUponTheAchievementOfCertainRegulatoryMilestones>
    <eikn:AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones
      contextRef="C_1946717c-8e31-4a84-ab14-fa2fc8fe3174"
      decimals="-5"
      id="F_c9b3f71f-dcc6-4a02-a82e-05cbe3daf9d3"
      unitRef="U_USD">350000000</eikn:AdditionalMilestonePayableUponTheAchievementOfCertainCommercialMilestones>
    <eikn:UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses
      contextRef="C_0395c051-54e6-4697-8ef1-dbef23445ddb"
      decimals="-5"
      id="F_2584b476-924e-4708-8122-2ab1891a59c9"
      unitRef="U_USD">46000000</eikn:UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses>
    <eikn:FutureMilestonesAccrued
      contextRef="C_c3beda52-07b7-41e0-a055-08c63663c5d6"
      decimals="INF"
      id="F_63b57687-cecb-47d0-a0e4-27474d5c4489"
      unitRef="U_USD">0</eikn:FutureMilestonesAccrued>
    <eikn:FutureMilestonesAccrued
      contextRef="C_d6aef30d-4b1d-4072-adb3-7c8d3cb1b224"
      decimals="INF"
      id="F_51b52b3f-3184-4ecc-8dab-e5492508e0f6"
      unitRef="U_USD">0</eikn:FutureMilestonesAccrued>
    <eikn:UpfrontFeePaidInCash
      contextRef="C_307b49d7-4a22-4c20-90d0-a57dab4d74f7"
      decimals="-5"
      id="F_0a8f1d37-451f-45b2-8078-adf13011c4a9"
      unitRef="U_USD">31500000</eikn:UpfrontFeePaidInCash>
    <eikn:MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones
      contextRef="C_28287679-ce3c-40bb-abd2-c8b78786196d"
      decimals="-5"
      id="F_f8c6659c-91b3-4d56-b8be-f1b9249eebf6"
      unitRef="U_USD">181000000</eikn:MaximumAmountPayableUponTheAchievementOfCertainDevelopmentAndRegulatoryMilestonesMilestones>
    <eikn:MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones
      contextRef="C_307b49d7-4a22-4c20-90d0-a57dab4d74f7"
      decimals="INF"
      id="F_ce30ea08-3352-4e1e-8dda-da0c34d3e2cf"
      unitRef="U_USD">775000000</eikn:MaximumAmountPayableUponTheAchievementOfCertainCommercialMilestones>
    <eikn:UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses
      contextRef="C_ebfe9b65-c71c-4702-a2c5-feb06a82af91"
      decimals="-5"
      id="F_6f1f3939-73ad-454d-abf3-dc4a93735a4d"
      unitRef="U_USD">31500000</eikn:UpfrontPaymentsRecognizedAsInProcessResearchAndDevelopmentExpenses>
    <eikn:DevelopmentAndRegulatoryMilestonesPaid
      contextRef="C_3cf22cef-9013-42e6-8cf3-e35b755febc6"
      decimals="-5"
      id="F_934a7605-bfbf-4fa5-8902-ec021adb75ac"
      unitRef="U_USD">5000000</eikn:DevelopmentAndRegulatoryMilestonesPaid>
    <eikn:DevelopmentAndRegulatoryMilestonesPaid
      contextRef="C_3989eb12-e5ab-4eaa-81f3-cfefea545c70"
      decimals="INF"
      id="F_1c567530-278a-473d-b181-369e7178607f"
      unitRef="U_USD">0</eikn:DevelopmentAndRegulatoryMilestonesPaid>
    <eikn:FutureMilestonesAccrued
      contextRef="C_a72dfdfc-a580-488a-9676-5c50bffd695e"
      decimals="INF"
      id="F_b4fdda17-278c-4307-806a-d963652a6de9"
      unitRef="U_USD">0</eikn:FutureMilestonesAccrued>
    <eikn:FutureMilestonesAccrued
      contextRef="C_9608e9ac-9845-4074-830c-41f067773cfa"
      decimals="INF"
      id="F_adf52e64-0bad-4f5d-b541-f66b4c639d71"
      unitRef="U_USD">0</eikn:FutureMilestonesAccrued>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_2f71c769-bbf6-42f9-87e6-cd6cd477d174">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 11. Research and Development Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Column Group and Catalyst4 Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 7, 2024, the Company entered into a collaboration agreement with The Column Group-Neuro, LP (&#x201c;TCG&#x201d;), an investor in the Company, and Catalyst4, Inc. (&#x201c;Catalyst4&#x201d;), a limited partner in TCG&#x2019;s neuroscience fund.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the agreement, Catalyst4 will pay the Company an aggregate payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million over the next five years to perform upfront research and development on drug discovery or drug development programs for Parkinson&#x2019;s Disease. In addition, the Company is required to pay up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to Catalyst4 upon the achievement of a certain regulatory milestone. In the event Eikon sells or licenses programs to a third party to develop, the Company is required to pay Catalyst4 a mid-double digit percentage of all payments received, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the aggregate across all such programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from Catalyst4 for future services, which was recorded in other non-current liabilities on its condensed balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Clinical Trial Collaboration and Supply Agreements with MSD&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into a clinical trial collaboration and supply agreement (the &#x201c;MSD Agreement&#x201d;) with MSD International Business GmbH (&#x201c;MSD&#x201d;), for three separate studies: (i) the Phase 2/3 registrational study of EIK1001 in patients with advanced melanoma (dated August 1, 2024); (ii) the Phase 1/2 clinical trial of EIK1005 in patients with advanced solid tumors (dated December 3, 2025); and (iii) the Phase 2/3 registrational study of EIK1001 in patients with non-small cell lung cancer (dated December 5, 2025). Pursuant to the MSD Agreements, the Company and MSD agreed to collaborate on these clinical trials evaluating the safety and efficacy of its compounds in combination with MSD&#x2019;s compound, pembrolizumab. Under the MSD Agreements, the Company acts as the sponsor of the clinical trials at its own costs and MSD has agreed to supply to the Company, at its own cost, pembrolizumab for use in such trials. Pursuant to the MSD Agreements, the Company and MSD must each use commercially reasonable efforts to supply the Company&#x2019;s applicable compounds for use in the portions of the clinical trials in which patients are intended to receive pembrolizumab either alone or in combination with one or more treatments, in accordance with the applicable study protocol. The Company recognizes costs incurred for the EIK clinical trial as research and development expenses within the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company and MSD will jointly own all clinical data and results generated from the portion of the clinical trials involving the combination of the Company&#x2019;s compound and pembrolizumab. The Company owns all clinical data and results generated from all portions of these clinical trials that involve its compound alone or in combination with other treatments that are not pembrolizumab, and MSD owns all clinical data and results generated from the portions of the clinical trial involving pembrolizumab alone or in combination with other treatments that are not the Company&#x2019;s compound (the &#x201c;MSD clinical data&#x201d;). The Company may use MSD clinical data solely to evaluate the safety or performance of the combination or to register its compound in the combination.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The MSD Agreements will each expire upon the delivery of a results memorandum and final report of the portions of the respective trial where patients receive pembrolizumab to MSD, unless earlier terminated, or, in the case of the Phase 2/3 trials, if the Phase 3 portion of the clinical trial is not initiated. MSD may terminate the supply agreement for a particular clinical trial if the Company does not initiate the trial for the combination within one year from the effective date of the respective MSD Agreement. Further, MSD may terminate an MSD agreement and the supply of pembrolizumab immediately if (i) MSD notifies the Company that it believes that pembrolizumab is being used unsafely in the trial and (ii) either MSD believes such matter is not reasonably capable of being remedied, or if the Company fails to remedy promptly such issue to MSD&#x2019;s reasonable satisfaction. Either the Company or MSD may terminate an MSD agreement for a breach of the agreement, for patient safety, or due to regulatory authority objections or actions. Further, either party may also terminate an MSD agreement if such party determines, in its sole discretion, to withdraw any applicable regulatory approval for its respective compound, or to discontinue development of its respective compound for medical, scientific, or legal reasons.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <eikn:AggregatePaymentToPerformResearchAndDevelopment
      contextRef="C_1e8500d8-0dbe-4c15-adb9-cf43d49e2d09"
      decimals="-5"
      id="F_50423364-8d68-4b44-9b20-bd3aacdbe316"
      unitRef="U_USD">25000000</eikn:AggregatePaymentToPerformResearchAndDevelopment>
    <eikn:PaymentForAchievementOfCertainRegulatoryMilestone
      contextRef="C_760222b0-6d13-4c82-a9ee-2f2a276df9e9"
      decimals="INF"
      id="F_b4464876-74b1-432d-83c5-2e05448ae82d"
      unitRef="U_USD">50000000</eikn:PaymentForAchievementOfCertainRegulatoryMilestone>
    <eikn:SalesRoyaltyPayable
      contextRef="C_0eb6f30c-2652-4bc8-8657-bc2aac3eb2ba"
      decimals="INF"
      id="F_665311ce-feec-4093-82b3-0313cdb79c70"
      unitRef="U_USD">50000000</eikn:SalesRoyaltyPayable>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_a949f785-fff1-46ba-9714-cd224ef31489"
      decimals="-5"
      id="F_8f0e8ee3-54d7-4dbd-8db9-a34d1ea50467"
      unitRef="U_USD">10000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_31a18fb9-bb8d-4258-94d9-627312994c9f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 12. Employee 401(k) Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company sponsors a 401(k) defined contribution plan covering all employees. Employer contributions to the plan were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the three months ended March 31, 2026 and 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-5"
      id="F_af8d26ed-bb08-4455-a6dd-83269463c2a8"
      unitRef="U_USD">1400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-5"
      id="F_40868b8f-ee37-4fe3-9a90-66417531d5ab"
      unitRef="U_USD">1300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_4b41a36a-6f62-47b3-8436-99bff7cc4a81">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 13. Segment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_85997c2d-5760-46fb-bcd0-7b83f0349464;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment that is managed on an entity-wide basis. The Company&#x2019;s chief operating decision maker is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_2ea580d6-5cea-4c6a-9652-7b14b693ba76;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s chief operating decision maker uses net loss to evaluate the performance of its segment, analyze financial trends, compare the budget to the actual operating results, and make resource allocation decisions. Segment net loss represents the Company&#x2019;s total net loss. All corporate costs, including allocated facilities and information technology costs, and depreciation, are included within this segment. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and engineering expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;In-process research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;#&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;# &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items is comprised of interest income (expense), net and other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s long-lived assets as of March 31, 2026 and December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were located in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_a3d90123-3c0a-4821-98e1-e3517a335ca7">The Company&#x2019;s chief operating decision maker uses net loss to evaluate the performance of its segment, analyze financial trends, compare the budget to the actual operating results, and make resource allocation decisions. Segment net loss represents the Company&#x2019;s total net loss. All corporate costs, including allocated facilities and information technology costs, and depreciation, are included within this segment. </us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_e0020ed7-3597-4fb6-8b5d-707be655d8a5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant expense categories within net loss are presented on the statements of operations. The research and development expenses have been disaggregated as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and engineering expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;In-process research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;#&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;# &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other segment items is comprised of interest income (expense), net and other income (expense), net.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <eikn:ResearchAndEngineeringExpenses
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_3a26e6f6-b859-4668-9908-9dea892d43ef"
      unitRef="U_USD">29483000</eikn:ResearchAndEngineeringExpenses>
    <eikn:ResearchAndEngineeringExpenses
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_99ae0e13-687c-4dd2-82a7-c898e49bc003"
      unitRef="U_USD">33627000</eikn:ResearchAndEngineeringExpenses>
    <eikn:ClinicalExpenses
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_1acd802b-fba3-40b2-a2a0-cb0e34634c27"
      unitRef="U_USD">35564000</eikn:ClinicalExpenses>
    <eikn:ClinicalExpenses
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_1e5b78ad-a4fa-4e86-946d-dae88328da65"
      unitRef="U_USD">22960000</eikn:ClinicalExpenses>
    <eikn:InProcessResearchAndDevelopmentExpenses
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_54a400ae-870f-48d3-b8a8-54032a8d7622"
      unitRef="U_USD">5000000</eikn:InProcessResearchAndDevelopmentExpenses>
    <eikn:InProcessResearchAndDevelopmentExpenses
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_fa3a3942-ac0d-48d4-b346-07419b497e96"
      unitRef="U_USD">0</eikn:InProcessResearchAndDevelopmentExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_9a2ae4bf-efcb-4fd7-b289-46f65920cd2d"
      unitRef="U_USD">70047000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_c050f910-6ba1-4fc7-8a4a-3282eec1bf6b"
      unitRef="U_USD">56587000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_6b72b47e-d0c7-4bbf-ac3d-6f5644f05c2e"
      unitRef="U_USD">17290000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_b77fe08d-98db-4314-b9a6-548d0a7b4134"
      unitRef="U_USD">14796000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_5c8d2b99-3618-4142-adf5-5d3859cd4030"
      unitRef="U_USD">4379000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_9c32b717-1aee-4b5f-b5bd-099d83a63d8f"
      unitRef="U_USD">3140000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      decimals="-3"
      id="F_8b9fcf24-7306-4670-bfa4-7348ca146e25"
      unitRef="U_USD">-82958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98a5f90f-67ce-444b-b813-16c9b0700876"
      decimals="-3"
      id="F_9a0ebe72-9544-425b-97bf-e18d1733774e"
      unitRef="U_USD">-68243000</us-gaap:NetIncomeLoss>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_be18b8a3-5136-49c4-bfc1-3a9f4f3b59bd">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_d1014c2e-2e9e-4a97-86f1-fbba77473d8d">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_f33337d9-c342-413d-a45e-6c59b60ff873">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_2c6596ac-f14a-40c8-b62c-b693a7753c24"
      id="F_751e0830-d438-4e35-b24c-3998741e1394">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
